Comparison	O
of	O
the	O
backbone	O
dynamics	O
of	O
the	O
apo	O
-	O
and	O
holo	O
-	O
carboxy	O
-	O
terminal	O
domain	O
of	O
the	O
biotin	O
carboxyl	O
carrier	O
subunit	O
of	O
Escherichia	O
coli	O
acetyl	B-Complex
-	I-Complex
CoA	I-Complex
carboxylase	I-Complex
.	O

The	O
biotin	O
carboxyl	O
carrier	O
protein	O
(	O
BCCP	O
)	O
is	O
a	O
subunit	O
of	O
acetyl	B-Complex
-	I-Complex
CoA	I-Complex
carboxylase	I-Complex
,	O
a	O
biotin	O
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
first	O
committed	O
step	O
of	O
fatty	O
acid	O
biosynthesis	O
.	O

In	O
its	O
functional	O
cycle	O
,	O
this	O
protein	O
engages	O
in	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
with	O
three	O
distinct	O
partners	O
,	O
depending	O
on	O
its	O
state	O
of	O
post	O
-	O
translational	O
modification	O
.	O

Apo	O
-	O
BCCP	O
interacts	O
specifically	O
with	O
the	O
biotin	O
holoenzyme	O
synthetase	O
,	O
BirA	O
,	O
which	O
results	O
in	O
the	O
post	O
-	O
translational	O
attachment	O
of	O
biotin	O
to	O
a	O
single	O
lysine	O
residue	O
on	O
BCCP	O
.	O

Holo	O
-	O
BCCP	O
then	O
interacts	O
with	O
the	O
biotin	O
carboxylase	O
subunit	O
of	O
acetyl	B-Complex
-	I-Complex
CoA	I-Complex
carboxylase	I-Complex
,	O
which	O
leads	O
to	O
the	O
addition	O
of	O
the	O
carboxylate	O
group	O
of	O
bicarbonate	O
to	O
biotin	O
.	O

Finally	O
,	O
the	O
carboxy	O
-	O
biotinylated	O
form	O
of	O
BCCP	O
interacts	O
with	O
transcarboxylase	O
in	O
the	O
transfer	O
of	O
the	O
carboxylate	O
to	O
acetyl	O
-	O
CoA	O
to	O
form	O
malonyl	O
-	O
CoA	O
.	O

The	O
determinants	O
of	O
protein	O
-	O
protein	O
interaction	O
specificity	O
in	O
this	O
system	O
are	O
unknown	O
.	O

The	O
NMR	O
solution	O
structure	O
of	O
the	O
unbiotinylated	O
form	O
of	O
an	O
87	O
residue	O
C	O
-	O
terminal	O
domain	O
fragment	O
(	O
residue	O
70	O
-	O
156	O
)	O
of	O
BCCP	O
(	O
holoBCCP87	O
)	O
and	O
the	O
crystal	O
structure	O
of	O
the	O
biotinylated	O
form	O
of	O
a	O
C	O
-	O
terminal	O
fragment	O
(	O
residue	O
77	O
-	O
156	O
)	O
of	O
BCCP	O
from	O
Escherichia	O
coli	O
acetyl	B-Complex
-	I-Complex
CoA	I-Complex
carboxylase	I-Complex
have	O
previously	O
been	O
determined	O
.	O

Comparative	O
analysis	O
of	O
these	O
structures	O
provided	O
evidence	O
for	O
small	O
,	O
localized	O
conformational	O
changes	O
in	O
the	O
biotin	O
-	O
binding	O
region	O
upon	O
biotinylation	O
of	O
the	O
protein	O
.	O

These	O
structural	O
changes	O
may	O
be	O
important	O
for	O
regulating	O
specific	O
protein	O
-	O
protein	O
interactions	O
.	O

Since	O
the	O
dynamic	O
properties	O
of	O
proteins	O
are	O
correlated	O
with	O
local	O
structural	O
environments	O
,	O
we	O
have	O
determined	O
the	O
relaxation	O
parameters	O
of	O
the	O
backbone	O
15N	O
nuclear	O
spins	O
of	O
holoBCCP87	O
,	O
and	O
compared	O
these	O
with	O
the	O
data	O
obtained	O
for	O
the	O
apo	O
protein	O
.	O

The	O
results	O
indicate	O
that	O
upon	O
biotinylation	O
,	O
the	O
inherent	O
mobility	O
of	O
the	O
biotin	O
-	O
binding	O
region	O
and	O
the	O
protruding	O
thumb	O
,	O
with	O
which	O
the	O
biotin	O
group	O
interacts	O
in	O
the	O
holo	O
protein	O
,	O
are	O
significantly	O
reduced	O
.	O

Stimulation	O
of	O
CD40	O
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-	O
mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	O
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	O
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O

CD40	O
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	O
negative	O
.	O

CD40	O
expression	O
could	O
be	O
enhanced	O
in	O
CD40	O
-	O
positive	O
MM	O
by	O
stimulation	O
with	O
IFN	O
-	O
gamma	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
but	O
not	O
by	O
interleukin	O
(	O
IL	O
)	O
-	O
1beta	O
or	O
CD40	O
triggering	O
.	O

CD40	O
ligation	O
on	O
MM	O
by	O
CD40L	O
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	O
fusion	O
protein	O
up	O
-	O
regulated	O
their	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
MHC	B-Complex
class	I-Complex
I	I-Complex
and	O
class	B-Complex
II	I-Complex
molecules	O
and	O
their	O
secretion	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
tumor	O
necrosis	O
factor	O
-	O
a	O
,	O
and	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	B-Complex
factor	I-Complex
kappaB	I-Complex
.	O

Furthermore	O
,	O
CD40	O
ligation	O
of	O
a	O
HLA	O
-	O
A2	O
+	O
,	O
MelanA	O
/	O
MART1	O
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	O
-	O
A2	O
-	O
restricted	O
,	O
MelanA	O
/	O
MART	O
-	O
1	O
-	O
specific	O
CTL	O
clone	O
.	O

Finally	O
,	O
CD40	O
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	O
-	O
CD40L	O
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	O
-	O
positive	O
immunogenic	O
human	O
MMs	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
characterization	O
of	O
a	O
novel	O
UDP	O
-	O
galactose	O
:	O
beta	O
-	O
N	O
-	O
acetylglucosamine	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
(	O
beta3Gal	O
-	O
T5	O
)	O
responsible	O
for	O
synthesis	O
of	O
type	O
1	O
chain	O
in	O
colorectal	O
and	O
pancreatic	O
epithelia	O
and	O
tumor	O
cells	O
derived	O
therefrom	O
.	O

The	O
sialyl	O
Lewis	O
a	O
antigen	O
is	O
a	O
well	O
known	O
tumor	O
marker	O
,	O
CA19	O
-	O
9	O
,	O
which	O
is	O
frequently	O
elevated	O
in	O
the	O
serum	O
in	O
gastrointestinal	O
and	O
pancreatic	O
cancers	O
.	O

UDP	O
-	O
galactose	O
:	O
N	O
-	O
acetylglucosamine	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
(	O
s	O
)	O
(	O
beta3Gal	O
-	O
Ts	O
)	O
are	O
required	O
for	O
the	O
synthesis	O
of	O
the	O
sialyl	O
Lewis	O
a	O
epitope	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
beta3Gal	O
-	O
T	O
,	O
named	O
beta3Gal	O
-	O
T5	O
,	O
was	O
isolated	O
from	O
a	O
Colo205	O
cDNA	O
library	O
using	O
a	O
degenerate	O
primer	O
strategy	O
based	O
on	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
four	O
human	O
beta3Gal	O
-	O
T	O
genes	O
cloned	O
to	O
date	O
.	O

Transfection	O
experiments	O
demonstrated	O
that	O
HCT	O
-	O
15	O
cells	O
transfected	O
with	O
the	O
beta3Gal	O
-	O
T5	O
gene	O
expressed	O
all	O
the	O
type	O
1	O
Lewis	O
antigens	O
.	O

In	O
gastrointestinal	O
and	O
pancreatic	O
cancer	O
cell	O
lines	O
,	O
the	O
amounts	O
of	O
beta3Gal	O
-	O
T5	O
transcripts	O
were	O
quite	O
well	O
correlated	O
with	O
the	O
amounts	O
of	O
the	O
sialyl	O
Lewis	O
a	O
antigens	O
.	O

The	O
beta1	O
,	O
3Gal	O
-	O
T	O
activity	O
toward	O
agalacto	O
-	O
lacto	O
-	O
N	O
-	O
neotetraose	O
was	O
also	O
well	O
correlated	O
with	O
the	O
amounts	O
of	O
beta3Gal	O
-	O
T5	O
transcripts	O
in	O
a	O
series	O
of	O
cultured	O
cancer	O
cells	O
,	O
and	O
in	O
Namalwa	O
and	O
HCT	O
-	O
15	O
cells	O
transfected	O
with	O
the	O
beta3Gal	O
-	O
T5	O
gene	O
.	O

Thus	O
,	O
the	O
beta3Gal	O
-	O
T5	O
gene	O
is	O
the	O
most	O
probable	O
candidate	O
responsible	O
for	O
the	O
synthesis	O
of	O
the	O
type	O
1	O
Lewis	O
antigens	O
in	O
gastrointestinal	O
and	O
pancreatic	O
epithelia	O
and	O
tumor	O
cells	O
derived	O
therefrom	O
.	O

In	O
addition	O
,	O
beta3Gal	O
-	O
T5	O
is	O
a	O
key	O
enzyme	O
that	O
determines	O
the	O
amounts	O
of	O
the	O
type	O
1	O
Lewis	O
antigens	O
including	O
the	O
sialyl	O
Lewis	O
a	O
antigen	O
.	O

Regulation	O
of	O
Fas	O
ligand	O
expression	O
and	O
cell	O
death	O
by	O
apoptosis	O
-	O
linked	O
gene	O
4	O
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	O
/	O
Fas	O
ligand	O
(	O
FasL	O
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	B-Complex
cell	I-Complex
-	I-Complex
receptor	I-Complex
engagement	O
,	O
we	O
identified	O
ALG	O
-	O
4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	B-Complex
cell	I-Complex
-	I-Complex
receptor	I-Complex
-	O
induced	O
FasL	O
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
ALG	O
-	O
4	O
induced	O
transcription	O
of	O
FasL	O
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG	O
-	O
4	O
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	O
expression	O
.	O

Fas	O
/	O
FasL	O
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	O
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

Biochemical	O
analysis	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
SEC18	O
gene	O
product	O
:	O
implications	O
for	O
the	O
molecular	O
mechanism	O
of	O
membrane	O
fusion	O
.	O

The	O
SEC18	O
gene	O
product	O
is	O
48	O
%	O
identical	O
to	O
mammalian	O
NSF	O
(	O
N	O
-	O
ethylmaleimide	O
-	O
sensitive	O
fusion	O
protein	O
)	O
,	O
and	O
both	O
proteins	O
encode	O
cytoplasmic	O
ATPases	O
which	O
are	O
essential	O
for	O
membrane	O
traffic	O
in	O
yeast	O
and	O
mammalian	O
cells	O
,	O
respectively	O
.	O

A	O
wealth	O
of	O
biochemical	O
analysis	O
has	O
led	O
to	O
the	O
description	O
of	O
a	O
model	O
for	O
the	O
action	O
of	O
NSF	O
;	O
through	O
its	O
interaction	O
with	O
SNAPs	O
(	O
soluble	O
NSF	O
attachment	O
proteins	O
)	O
,	O
NSF	O
can	O
associate	O
with	O
SNAP	O
receptors	O
(	O
SNAREs	O
)	O
on	O
intracellular	O
membranes	O
,	O
forming	O
20S	B-Complex
complexes	O
.	O

SNAPs	O
then	O
stimulate	O
the	O
intrinsic	O
ATPase	O
activity	O
of	O
NSF	O
,	O
leading	O
to	O
the	O
disassembly	O
of	O
the	O
20S	B-Complex
complex	O
,	O
which	O
is	O
essential	O
for	O
subsequent	O
membrane	O
fusion	O
.	O

Although	O
this	O
model	O
is	O
based	O
almost	O
entirely	O
on	O
in	O
vitro	O
studies	O
of	O
the	O
original	O
clones	O
of	O
NSF	O
and	O
alpha	O
-	O
SNAP	O
,	O
it	O
is	O
nevertheless	O
widely	O
assumed	O
that	O
this	O
mechanism	O
of	O
membrane	O
fusion	O
is	O
conserved	O
in	O
all	O
eukaryotic	O
cells	O
.	O

If	O
so	O
,	O
the	O
crucial	O
biochemical	O
properties	O
of	O
NSF	O
and	O
SNAPs	O
should	O
be	O
shared	O
by	O
their	O
yeast	O
homologues	O
,	O
Sec18p	O
and	O
Sec17p	O
.	O

Using	O
purified	O
recombinant	O
proteins	O
,	O
we	O
report	O
here	O
that	O
Sec18p	O
can	O
specifically	O
interact	O
not	O
only	O
with	O
Sec17p	O
but	O
also	O
with	O
its	O
mammalian	O
homologue	O
,	O
alpha	O
-	O
SNAP	O
.	O

This	O
interaction	O
leads	O
to	O
a	O
stimulation	O
of	O
Sec18p	O
D1	O
domain	O
ATPase	O
activity	O
,	O
with	O
kinetics	O
similar	O
to	O
those	O
of	O
alpha	O
-	O
SNAP	O
stimulation	O
of	O
NSF	O
,	O
although	O
differences	O
in	O
temperature	O
and	O
N	O
-	O
ethylmaleimide	O
sensitivity	O
were	O
observed	O
between	O
NSF	O
and	O
Sec18p	O
.	O

Furthermore	O
,	O
Sec18p	O
can	O
interact	O
with	O
synaptic	O
SNARE	O
proteins	O
and	O
can	O
synergize	O
with	O
alpha	O
-	O
SNAP	O
to	O
stimulate	O
regulated	O
exocytosis	O
in	O
mammalian	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
mechanistic	O
properties	O
of	O
NSF	O
and	O
SNAPs	O
are	O
shared	O
by	O
Sec18p	O
and	O
Sec17p	O
,	O
thus	O
demonstrating	O
that	O
the	O
biochemistry	O
of	O
membrane	O
fusion	O
is	O
conserved	O
from	O
yeast	O
to	O
mammals	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	O
toll	O
-	O
like	O
receptor	O
2	O
.	O

Human	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	O
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	O
associates	O
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	O
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	O
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	O
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	O
-	O
type	O
TLR2	O
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	O
-	O
mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
6	O
,	O
and	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
,	O
when	O
coexpressed	O
with	O
TLR2	O
,	O
abrogate	O
TLR2	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	O
and	O
IL	O
-	O
1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	O
by	O
DN	O
variants	O
.	O

Activation	O
of	O
the	O
Janus	O
kinase	O
3	O
-	O
STAT5a	O
pathway	O
after	O
CD40	O
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O

CD40	O
/	O
CD40	O
ligand	O
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	O
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	O
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	O
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O

After	O
CD40	O
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
(	O
but	O
not	O
of	O
the	O
AP	B-Complex
-	I-Complex
1	I-Complex
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	O
is	O
part	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
complex	O
induced	O
by	O
CD40	O
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	O
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	O
kinase	O
3	O
tyrosine	O
kinase	O
was	O
associated	O
with	O
CD40	O
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	O
kinase	O
3	O
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40	O
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	O
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	O
-	O
induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	O
ligand	O
+	O
hyper	O
IgM	B-Complex
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	O
-	O
induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Suppression	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB	B-Complex
-	O
binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA	O
/	O
NFkappaB1	O
-	O
binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	O
-	O
binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	O
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	O
and	O
NF	O
-	O
kappaB1	O
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	O
/	O
NF	O
-	O
kappaB1	O
binding	O
complexes	O
.	O

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	O
membrane	O
protein	O
1	O
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	O
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
that	O
constitutively	O
associates	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
-	O
associated	O
death	O
domain	O
protein	O
TRADD	O
to	O
mediate	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	O
signaling	O
through	O
TRADD	O
differs	O
from	O
TNFR1	O
signaling	O
through	O
TRADD	O
.	O

LMP1	O
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
or	O
synergize	O
with	O
TRADD	O
in	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
while	O
TNFR1	O
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	O
does	O
not	O
require	O
TRADD	O
residues	O
294	O
to	O
312	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
while	O
TNFR1	O
requires	O
TRADD	O
residues	O
296	O
to	O
302	O
.	O

LMP1	O
is	O
partially	O
blocked	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
a	O
TRADD	O
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	O
,	O
LMP1	O
can	O
interact	O
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
LMP1	O
does	O
not	O
require	O
RIP	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	O
or	O
RIP	O
,	O
LMP1	O
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	O
,	O
TRADD	O
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

The	O
Emp24	B-Complex
complex	O
in	O
yeast	O
comprises	O
Emp24p	O
,	O
Erv25p	O
,	O
and	O
most	O
likely	O
Erp1p	O
and	O
Erp2p	O
.	O

Deletion	O
of	O
EMP24	O
causes	O
a	O
strong	O
reduction	O
in	O
the	O
levels	O
of	O
the	O
other	O
three	O
proteins	O
of	O
the	O
complex	O
(	O
Belden	O
and	O
Barlowe	O
1996	O
;	O
Marzioch	O
et	O
al	O
.	O
1999	O
)	O
.	O

In	O
this	O
study	O
we	O
provide	O
evidence	O
that	O
the	O
Emp24	B-Complex
complex	O
is	O
directly	O
required	O
for	O
efficient	O
packaging	O
of	O
Gas1p	O
into	O
ER	O
-	O
derived	O
vesicles	O
.	O

Two	O
subunits	O
of	O
this	O
complex	O
can	O
be	O
directly	O
cross	O
-	O
linked	O
to	O
the	O
cargo	O
protein	O
in	O
purified	O
ER	O
-	O
derived	O
vesicles	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
Emp24	B-Complex
complex	O
plays	O
a	O
role	O
as	O
a	O
cargo	O
receptor	O
in	O
ER	O
to	O
Golgi	O
transport	O
.	O

Isoprenylation	O
/	O
methylation	O
and	O
transducin	B-OOS
function	O
.	O

Freshly	O
prepared	O
proteolyzed	O
(	O
deprenylated	O
)	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
and	O
material	O
isolated	O
from	O
retina	O
are	O
inert	O
with	O
respect	O
to	O
activating	O
T	O
alpha	O
in	O
the	O
presence	O
of	O
R	O
*	O
in	O
detergent	O
and	O
in	O
disk	O
membranes	O
.	O

In	O
addition	O
,	O
proteolyzed	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
is	O
also	O
incapable	O
of	O
supporting	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
T	O
alpha	O
-	O
GDP	O
.	O

These	O
experiments	O
show	O
that	O
isoprenylation	O
/	O
methylation	O
is	O
essential	O
for	O
the	O
fruitful	O
interactions	O
between	O
T	O
alpha	O
and	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
at	O
the	O
membrane	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
support	O
GTP	O
-	O
for	O
-	O
GDP	O
exchange	O
catalyzed	O
by	O
R	O
*	O
,	O
demethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
proved	O
to	O
be	O
approximately	O
50	O
%	O
as	O
active	O
as	O
methylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
in	O
photoreceptor	O
disk	O
membranes	O
(	O
Fig	O
.	O
3	O
)	O
and	O
in	O
reconstituted	O
liposomes	O
containing	O
rhodopsin	O
.	O

In	O
detergent	O
,	O
no	O
difference	O
was	O
observed	O
between	O
methylated	O
and	O
demethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
,	O
suggesting	O
no	O
role	O
at	O
all	O
for	O
the	O
methyl	O
group	O
in	O
functional	O
interactions	O
between	O
T	O
alpha	O
,	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
,	O
and	O
R	O
*	O
.	O

The	O
twofold	O
activity	O
difference	O
observed	O
in	O
membranes	O
can	O
be	O
accounted	O
for	O
by	O
the	O
twofold	O
lessened	O
affinity	O
of	O
the	O
demethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
,	O
compared	O
with	O
its	O
methylated	O
counterpart	O
,	O
for	O
membranes	O
in	O
the	O
presence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
a	O
substantially	O
larger	O
difference	O
(	O
>	O
10	O
-	O
fold	O
)	O
in	O
the	O
relative	O
binding	O
of	O
methylated	O
versus	O
demethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
to	O
membranes	O
is	O
observed	O
in	O
the	O
absence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

However	O
,	O
R	O
*	O
has	O
a	O
substantial	O
affinity	O
for	O
T	B-OOS
alpha	I-OOS
beta	I-OOS
gamma	I-OOS
,	O
and	O
the	O
influence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
greatly	O
reduces	O
any	O
differences	O
resulting	O
from	O
the	O
presence	O
or	O
absence	O
of	O
a	O
methyl	O
group	O
on	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
.	O

The	O
results	O
from	O
studies	O
of	O
demethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
demonstrate	O
that	O
specific	O
lipid	O
-	O
receptor	O
interactions	O
are	O
unlikely	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
rhodopsin	O
-	O
transducin	B-OOS
system	O
,	O
and	O
further	O
show	O
that	O
the	O
effect	O
of	O
methylation	O
is	O
probably	O
due	O
to	O
the	O
increased	O
hydrophobicity	O
of	O
methylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
versus	O
its	O
unmethylated	O
counterpart	O
.	O

These	O
studies	O
are	O
,	O
of	O
course	O
,	O
relevant	O
to	O
heterotrimeric	O
G	O
proteins	O
,	O
and	O
specifically	O
to	O
the	O
interactions	O
of	O
receptor	O
(	O
R	O
*	O
)	O
with	O
T	O
alpha	O
and	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
.	O

If	O
a	O
hydrophobic	O
lipid	O
-	O
lipid	O
mechanism	O
is	O
operative	O
,	O
the	O
state	O
of	O
methylation	O
would	O
be	O
expected	O
to	O
have	O
a	O
more	O
profound	O
effect	O
on	O
the	O
membrane	O
-	O
associative	O
properties	O
of	O
farnesylated	O
proteins	O
,	O
but	O
not	O
on	O
those	O
of	O
geranylgeranylated	O
proteins	O
.	O

The	O
increased	O
hydrophobicity	O
of	O
the	O
C20	O
geranylgeranyl	O
group	O
relative	O
to	O
the	O
C15	O
farnesyl	O
group	O
will	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
methyl	O
substituent	O
.	O

The	O
results	O
obtained	O
in	O
the	O
transducin	B-OOS
-	O
rhodopsin	O
system	O
can	O
be	O
contrasted	O
with	O
the	O
effect	O
of	O
gamma	O
-	O
subunit	O
methylation	O
on	O
effector	O
enzyme	O
activation	O
.	O

In	O
the	O
case	O
of	O
the	O
geranylgeranylated	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
,	O
methylation	O
proved	O
to	O
have	O
only	O
a	O
small	O
effect	O
on	O
PIPLC	O
beta	O
activation	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

An	O
approximately	O
25	O
%	O
diminution	O
in	O
efficacy	O
,	O
but	O
not	O
potency	O
,	O
was	O
observed	O
for	O
the	O
demethylated	O
geranylgeranylated	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
versus	O
its	O
methylated	O
counterpart	O
.	O

This	O
again	O
shows	O
that	O
specific	O
lipid	O
-	O
protein	O
interactions	O
are	O
unimportant	O
.	O

The	O
effect	O
of	O
methylation	O
on	O
membrane	O
binding	O
would	O
be	O
expected	O
to	O
be	O
small	O
,	O
given	O
that	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
is	O
geranylgeranylated	O
.	O

It	O
is	O
of	O
interest	O
to	O
compare	O
these	O
results	O
with	O
those	O
found	O
with	O
methylated	O
and	O
unmethylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
as	O
activators	O
of	O
PIPLC	O
beta	O
.	O

In	O
this	O
instance	O
there	O
was	O
a	O
large	O
effect	O
noted	O
,	O
with	O
methylated	O
T	B-OOS
beta	I-OOS
gamma	I-OOS
being	O
at	O
least	O
10	O
-	O
fold	O
more	O
potent	O
than	O
its	O
unmethylated	O
counterpart	O
with	O
respect	O
to	O
activating	O
either	O
enzyme	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

This	O
result	O
is	O
readily	O
understandable	O
in	O
light	O
of	O
the	O
role	O
of	O
methylation	O
in	O
selectively	O
enhancing	O
hydrophobicity	O
of	O
farnesylated	O
proteins	O
as	O
opposed	O
to	O
geranyl	O
-	O
geranylated	O
proteins	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
activation	O
of	O
PI3K	O
,	O
further	O
strengthening	O
the	O
conclusion	O
that	O
it	O
is	O
lipid	O
-	O
lipid	O
interactions	O
that	O
direct	O
beta	B-OOS
gamma	I-OOS
subunit	O
membrane	O
association	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

Regulated	O
cleavage	O
of	O
a	O
contact	O
-	O
mediated	O
axon	O
repellent	O
.	O

Contact	O
-	O
mediated	O
axon	O
repulsion	O
by	O
ephrins	O
raises	O
an	O
unresolved	O
question	O
:	O
these	O
cell	O
surface	O
ligands	O
form	O
a	O
high	O
-	O
affinity	O
multivalent	O
complex	O
with	O
their	O
receptors	O
present	O
on	O
axons	O
,	O
yet	O
rather	O
than	O
being	O
bound	O
,	O
axons	O
can	O
be	O
rapidly	O
repelled	O
.	O

We	O
show	O
here	O
that	O
ephrin	O
-	O
A2	O
forms	O
a	O
stable	O
complex	O
with	O
the	O
metalloprotease	O
Kuzbanian	O
,	O
involving	O
interactions	O
outside	O
the	O
cleavage	O
region	O
and	O
the	O
protease	O
domain	O
.	O

Eph	O
receptor	O
binding	O
triggered	O
ephrin	O
-	O
A2	O
cleavage	O
in	O
a	O
localized	O
reaction	O
specific	O
to	O
the	O
cognate	O
ligand	O
.	O

A	O
cleavage	O
-	O
inhibiting	O
mutation	O
in	O
ephrin	O
-	O
A2	O
delayed	O
axon	O
withdrawal	O
.	O

These	O
studies	O
reveal	O
mechanisms	O
for	O
protease	O
recognition	O
and	O
control	O
of	O
cell	O
surface	O
proteins	O
,	O
and	O
,	O
for	O
ephrin	O
-	O
A2	O
,	O
they	O
may	O
provide	O
a	O
means	O
for	O
efficient	O
axon	O
detachment	O
and	O
termination	O
of	O
signaling	O
.	O

Regulation	O
of	O
STAT1	O
nuclear	O
export	O
by	O
Jak1	O
.	O

Signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
mediates	O
gene	O
expression	O
in	O
response	O
to	O
cytokines	O
and	O
growth	O
factors	O
.	O

Activation	O
of	O
STAT1	O
is	O
achieved	O
through	O
its	O
tyrosine	O
phosphorylation	O
,	O
a	O
process	O
that	O
involves	O
Jak	O
tyrosine	O
kinases	O
.	O

Here	O
we	O
show	O
that	O
STAT1	O
,	O
although	O
phosphorylated	O
on	O
Y701	O
,	O
is	O
unable	O
to	O
localize	O
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
Jak1	O
or	O
Jak1	O
kinase	O
activity	O
.	O

In	O
contrast	O
,	O
the	O
nuclear	O
accumulation	O
of	O
STAT1	O
in	O
Tyk2	O
-	O
deficient	O
cells	O
remains	O
intact	O
.	O

Nuclear	O
presence	O
of	O
tyrosine	O
-	O
phosphorylated	O
STAT1	O
could	O
be	O
restored	O
in	O
Jak1	O
-	O
deficient	O
cells	O
by	O
leptomycin	O
B	O
,	O
an	O
inhibitor	O
of	O
nuclear	O
export	O
.	O

Amino	O
acids	O
197	O
to	O
205	O
of	O
STAT1	O
were	O
found	O
to	O
encode	O
a	O
leucine	O
-	O
rich	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
.	O

An	O
L	O
-	O
-	O
>	O
A	O
mutation	O
within	O
the	O
NES	O
restored	O
nuclear	O
retention	O
of	O
STAT1	O
in	O
Jak1	O
-	O
deficient	O
cells	O
.	O

Impaired	O
binding	O
of	O
the	O
transcriptional	O
coactivator	O
CBP	O
to	O
tyrosine	O
-	O
phosphorylated	O
STAT1	O
derived	O
from	O
Jak1	O
-	O
deficient	O
cells	O
offers	O
a	O
model	O
for	O
the	O
intermolecular	O
regulation	O
of	O
the	O
nuclear	O
export	O
sequence	O
.	O

Downregulation	O
of	O
cyclin	O
D1	O
alters	O
cdk	O
4	O
-	O
and	O
cdk	O
2	O
-	O
specific	O
phosphorylation	O
of	O
retinoblastoma	O
protein	O
.	O

Progression	O
of	O
cells	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
requires	O
the	O
assembly	O
and	O
activation	O
of	O
specific	O
cyclin	O
:	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
cdk	O
)	O
complexes	O
in	O
a	O
tightly	O
regulated	O
,	O
sequential	O
fashion	O
.	O

To	O
more	O
clearly	O
define	O
the	O
temporal	O
events	O
leading	O
to	O
the	O
G1	O
/	O
S	O
transition	O
,	O
sequential	O
changes	O
in	O
the	O
expression	O
of	O
cyclin	O
E	O
and	O
cdks	O
2	O
,	O
4	O
,	O
and	O
6	O
,	O
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
(	O
pRb	O
)	O
,	O
were	O
assayed	O
in	O
RA28	O
cells	O
,	O
a	O
variant	O
of	O
human	O
colon	O
cancer	O
RKO	O
cells	O
which	O
were	O
modified	O
by	O
transfection	O
of	O
an	O
ecdysone	O
-	O
inducible	O
antisense	O
(	O
AS	O
)	O
CD1	O
expression	O
system	O
.	O

Induction	O
of	O
cyclin	O
D1	O
antisense	O
mRNA	O
by	O
the	O
ecdysteroid	O
,	O
ponasterone	O
A	O
,	O
resulted	O
in	O
a	O
55	O
%	O
decrease	O
in	O
cyclin	O
D1	O
mRNA	O
and	O
a	O
58	O
%	O
decrease	O
in	O
CD1	O
protein	O
levels	O
.	O

There	O
was	O
a	O
2	O
.	O
4	O
-	O
fold	O
decrease	O
in	O
the	O
ratio	O
of	O
hyperphosphorylated	O
pRb	O
(	O
ppRb	O
)	O
to	O
hypophosphorylated	O
pRb	O
,	O
as	O
well	O
as	O
a	O
60	O
-	O
75	O
%	O
decrease	O
in	O
cdk	O
2	O
-	O
and	O
cdk	O
4	O
-	O
specific	O
phosphorylated	O
pRb	O
proteins	O
.	O

Of	O
interest	O
,	O
cyclin	O
E	O
-	O
dependent	O
phosphorylation	O
(	O
cdk2	O
)	O
decreased	O
2	O
.	O
5	O
-	O
fold	O
at	O
3	O
h	O
despite	O
only	O
a	O
30	O
%	O
decrease	O
in	O
cyclin	O
E	O
protein	O
level	O
.	O

Levels	O
of	O
cdk	O
2	O
,	O
cdk	O
4	O
,	O
and	O
cdk	O
6	O
decreased	O
40	O
-	O
70	O
%	O
,	O
while	O
levels	O
of	O
cyclin	O
A	O
and	O
B	O
were	O
unaffected	O
by	O
induction	O
of	O
CD1	O
antisense	O
.	O

Induction	O
of	O
a	O
CD1	O
antisense	O
gene	O
in	O
a	O
human	O
colon	O
cancer	O
cell	O
line	O
resulted	O
in	O
rapid	O
,	O
concomitant	O
changes	O
in	O
CD1	O
mRNA	O
and	O
protein	O
,	O
cyclin	O
E	O
,	O
cdk2	O
,	O
cdk4	O
,	O
and	O
cdk6	O
,	O
as	O
well	O
as	O
the	O
ratio	O
of	O
ppRb	O
to	O
pRb	O
.	O

In	O
this	O
system	O
,	O
growth	O
regulatory	O
events	O
are	O
tightly	O
regulated	O
and	O
the	O
perturbed	O
expression	O
of	O
a	O
single	O
protein	O
,	O
CD1	O
,	O
rapidly	O
alters	O
expression	O
of	O
multiple	O
regulatory	O
proteins	O
involved	O
in	O
the	O
G1	O
/	O
S	O
transition	O
phase	O
of	O
cell	O
cycle	O
progression	O
.	O

TAP	O
(	O
NXF1	O
)	O
belongs	O
to	O
a	O
multigene	O
family	O
of	O
putative	O
RNA	O
export	O
factors	O
with	O
a	O
conserved	O
modular	O
architecture	O
.	O

Vertebrate	O
TAP	O
(	O
also	O
called	O
NXF1	O
)	O
and	O
its	O
yeast	O
orthologue	O
,	O
Mex67p	O
,	O
have	O
been	O
implicated	O
in	O
the	O
export	O
of	O
mRNAs	O
from	O
the	O
nucleus	O
.	O

The	O
TAP	O
protein	O
includes	O
a	O
noncanonical	O
RNP	O
-	O
type	O
RNA	O
binding	O
domain	O
,	O
four	O
leucine	O
-	O
rich	O
repeats	O
,	O
an	O
NTF2	O
-	O
like	O
domain	O
that	O
allows	O
heterodimerization	O
with	O
p15	O
(	O
also	O
called	O
NXT1	O
)	O
,	O
and	O
a	O
ubiquitin	O
-	O
associated	O
domain	O
that	O
mediates	O
the	O
interaction	O
with	O
nucleoporins	O
.	O

Here	O
we	O
show	O
that	O
TAP	O
belongs	O
to	O
an	O
evolutionarily	O
conserved	O
family	O
of	O
proteins	O
that	O
has	O
more	O
than	O
one	O
member	O
in	O
higher	O
eukaryotes	O
.	O

Not	O
only	O
the	O
overall	O
domain	O
organization	O
but	O
also	O
residues	O
important	O
for	O
p15	O
and	O
nucleoporin	O
interaction	O
are	O
conserved	O
in	O
most	O
family	O
members	O
.	O

We	O
characterize	O
two	O
of	O
four	O
human	O
TAP	O
homologues	O
and	O
show	O
that	O
one	O
of	O
them	O
,	O
NXF2	O
,	O
binds	O
RNA	O
,	O
localizes	O
to	O
the	O
nuclear	O
envelope	O
,	O
and	O
exhibits	O
RNA	O
export	O
activity	O
.	O

NXF3	O
,	O
which	O
does	O
not	O
bind	O
RNA	O
or	O
localize	O
to	O
the	O
nuclear	O
rim	O
,	O
has	O
no	O
RNA	O
export	O
activity	O
.	O

Database	O
searches	O
revealed	O
that	O
although	O
only	O
one	O
p15	O
(	O
nxt	O
)	O
gene	O
is	O
present	O
in	O
the	O
Drosophila	O
melanogaster	O
and	O
Caenorhabditis	O
elegans	O
genomes	O
,	O
there	O
is	O
at	O
least	O
one	O
additional	O
p15	O
homologue	O
(	O
p15	O
-	O
2	O
[	O
also	O
called	O
NXT2	O
]	O
)	O
encoded	O
by	O
the	O
human	O
genome	O
.	O

Both	O
human	O
p15	O
homologues	O
bind	O
TAP	O
,	O
NXF2	O
,	O
and	O
NXF3	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
TAP	O
-	O
p15	O
mRNA	O
export	O
pathway	O
has	O
diversified	O
in	O
higher	O
eukaryotes	O
compared	O
to	O
yeast	O
,	O
perhaps	O
reflecting	O
a	O
greater	O
substrate	O
complexity	O
.	O

Influenza	O
B	O
virus	O
NS1	O
protein	O
inhibits	O
conjugation	O
of	O
the	O
interferon	O
(	O
IFN	O
)	O
-	O
induced	O
ubiquitin	O
-	O
like	O
ISG15	O
protein	O
.	O

Of	O
the	O
several	O
hundred	O
proteins	O
induced	O
by	O
interferon	O
(	O
IFN	O
)	O
alpha	O
/	O
beta	O
,	O
the	O
ubiquitin	O
-	O
like	O
ISG15	O
protein	O
is	O
one	O
of	O
the	O
most	O
predominant	O
.	O

We	O
demonstrate	O
the	O
novel	O
way	O
in	O
which	O
the	O
function	O
of	O
the	O
ISG15	O
protein	O
is	O
inhibited	O
by	O
influenza	O
B	O
virus	O
,	O
which	O
strongly	O
induces	O
the	O
ISG15	O
protein	O
:	O
a	O
specific	O
region	O
of	O
the	O
influenza	O
B	O
virus	O
NS1	O
protein	O
,	O
which	O
includes	O
part	O
of	O
its	O
effector	O
domain	O
,	O
blocks	O
the	O
covalent	O
linkage	O
of	O
ISG15	O
to	O
its	O
target	O
proteins	O
both	O
in	O
vitro	O
and	O
in	O
infected	O
cells	O
.	O

We	O
identify	O
UBE1L	O
as	O
the	O
E1	O
enzyme	O
that	O
catalyzes	O
the	O
first	O
activation	O
step	O
in	O
the	O
conjugation	O
of	O
ISG15	O
,	O
and	O
show	O
that	O
the	O
NS1B	O
protein	O
inhibits	O
this	O
activation	O
step	O
in	O
vitro	O
.	O

Influenza	O
A	O
virus	O
employs	O
a	O
different	O
strategy	O
:	O
its	O
NS1	O
protein	O
does	O
not	O
bind	O
the	O
ISG15	O
protein	O
,	O
but	O
little	O
or	O
no	O
ISG15	O
protein	O
is	O
produced	O
during	O
infection	O
.	O

We	O
discuss	O
the	O
likely	O
basis	O
for	O
these	O
different	O
strategies	O
.	O

Synechocystis	O
HSP17	O
is	O
an	O
amphitropic	O
protein	O
that	O
stabilizes	O
heat	O
-	O
stressed	O
membranes	O
and	O
binds	O
denatured	O
proteins	O
for	O
subsequent	O
chaperone	O
-	O
mediated	O
refolding	O
.	O

The	O
small	O
heat	O
shock	O
proteins	O
(	O
sHSPs	O
)	O
are	O
ubiquitous	O
stress	O
proteins	O
proposed	O
to	O
act	O
as	O
molecular	O
chaperones	O
to	O
prevent	O
irreversible	O
protein	O
denaturation	O
.	O

We	O
characterized	O
the	O
chaperone	O
activity	O
of	O
Synechocystis	O
HSP17	O
and	O
found	O
that	O
it	O
has	O
not	O
only	O
protein	O
-	O
protective	O
activity	O
,	O
but	O
also	O
a	O
previously	O
unrecognized	O
ability	O
to	O
stabilize	O
lipid	O
membranes	O
.	O

Like	O
other	O
sHSPs	O
,	O
recombinant	O
Synechocystis	O
HSP17	O
formed	O
stable	O
complexes	O
with	O
denatured	O
malate	B-OOS
dehydrogenase	I-OOS
and	O
served	O
as	O
a	O
reservoir	O
for	O
the	O
unfolded	O
substrate	O
,	O
transferring	O
it	O
to	O
the	O
DnaK	O
/	O
DnaJ	O
/	O
GrpE	O
and	O
GroEL	O
/	O
ES	O
chaperone	O
network	O
for	O
subsequent	O
refolding	O
.	O

Large	O
unilamellar	O
vesicles	O
made	O
of	O
synthetic	O
and	O
cyanobacterial	O
lipids	O
were	O
found	O
to	O
modulate	O
this	O
refolding	O
process	O
.	O

Investigation	O
of	O
HSP17	O
-	O
lipid	O
interactions	O
revealed	O
a	O
preference	O
for	O
the	O
liquid	O
crystalline	O
phase	O
and	O
resulted	O
in	O
an	O
elevated	O
physical	O
order	O
in	O
model	O
lipid	O
membranes	O
.	O

Direct	O
evidence	O
for	O
the	O
participation	O
of	O
HSP17	O
in	O
the	O
control	O
of	O
thylakoid	O
membrane	O
physical	O
state	O
in	O
vivo	O
was	O
gained	O
by	O
examining	O
an	O
hsp17	O
(	O
-	O
)	O
deletion	O
mutant	O
compared	O
with	O
the	O
isogenic	O
wild	O
-	O
type	O
hsp17	O
(	O
+	O
)	O
revertant	O
Synechocystis	O
cells	O
.	O

We	O
suggest	O
that	O
,	O
together	O
with	O
GroEL	O
,	O
HSP17	O
behaves	O
as	O
an	O
amphitropic	O
protein	O
and	O
plays	O
a	O
dual	O
role	O
.	O

Depending	O
on	O
its	O
membrane	O
or	O
cytosolic	O
location	O
,	O
it	O
may	O
function	O
as	O
a	O
"	O
membrane	O
stabilizing	O
factor	O
"	O
as	O
well	O
as	O
a	O
member	O
of	O
a	O
multichaperone	O
protein	O
-	O
folding	O
network	O
.	O

Membrane	O
association	O
of	O
sHSPs	O
could	O
antagonize	O
the	O
heat	O
-	O
induced	O
hyperfluidization	O
of	O
specific	O
membrane	O
domains	O
and	O
thereby	O
serve	O
to	O
preserve	O
structural	O
and	O
functional	O
integrity	O
of	O
biomembranes	O
.	O

Identification	O
,	O
retinoid	O
binding	O
,	O
and	O
x	O
-	O
ray	O
analysis	O
of	O
a	O
human	O
retinol	O
-	O
binding	O
protein	O
.	O

Two	O
cellular	O
retinol	O
-	O
binding	O
proteins	O
(	O
CRBP	O
I	O
and	O
II	O
)	O
with	O
distinct	O
tissue	O
distributions	O
and	O
retinoid	O
-	O
binding	O
properties	O
have	O
been	O
recognized	O
thus	O
far	O
in	O
mammals	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
human	O
retinol	O
-	O
binding	O
protein	O
resembling	O
type	O
I	O
(	O
55	O
.	O
6	O
%	O
identity	O
)	O
and	O
type	O
II	O
(	O
49	O
.	O
6	O
%	O
identity	O
)	O
CRBPs	O
,	O
but	O
with	O
a	O
unique	O
H	O
residue	O
in	O
the	O
retinoid	O
-	O
binding	O
site	O
and	O
a	O
distinctively	O
different	O
tissue	O
distribution	O
.	O

Additionally	O
,	O
this	O
binding	O
protein	O
(	O
CRBP	O
III	O
)	O
exhibits	O
a	O
remarkable	O
sequence	O
identity	O
(	O
62	O
.	O
2	O
%	O
)	O
with	O
the	O
recently	O
identified	O
iota	O
-	O
crystallin	O
/	O
CRBP	O
of	O
the	O
diurnal	O
gecko	O
Lygodactylus	O
picturatus	O
[	O
Werten	O
,	O
P	O
.	O
J	O
.	O
L	O
.	O
,	O
Roell	O
,	O
B	O
.	O
,	O
van	O
Alten	O
,	O
D	O
.	O
M	O
.	O
F	O
.	O
&	O
de	O
Jong	O
,	O
W	O
.	O
W	O
.	O
(	O
2000	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
97	O
,	O
3282	O
-	O
3287	O
(	O
First	O
Published	O
March	O
21	O
,	O
2000	O
;	O
10	O
.	O
1073	O
/	O
pnas	O
.	O
050500597	O
)	O
]	O
.	O

CRBP	O
III	O
and	O
all	O
-	O
trans	O
-	O
retinol	O
form	O
a	O
complex	O
(	O
K	O
(	O
d	O
)	O
approximately	O
60	O
nM	O
)	O
,	O
the	O
absorption	O
spectrum	O
of	O
which	O
is	O
characterized	O
by	O
the	O
peculiar	O
fine	O
structure	O
typical	O
of	O
the	O
spectra	O
of	O
holo	O
-	O
CRBP	O
I	O
and	O
II	O
.	O

As	O
revealed	O
by	O
a	O
2	O
.	O
3	O
-	O
A	O
x	O
-	O
ray	O
molecular	O
model	O
of	O
apo	O
-	O
CRBP	O
III	O
,	O
the	O
amino	O
acid	O
residues	O
that	O
line	O
the	O
retinol	O
-	O
binding	O
site	O
in	O
CRBP	O
I	O
and	O
II	O
are	O
positioned	O
nearly	O
identically	O
in	O
the	O
structure	O
of	O
CRBP	O
III	O
.	O

At	O
variance	O
with	O
the	O
human	O
CRBP	O
I	O
and	O
II	O
mRNAs	O
,	O
which	O
are	O
most	O
abundant	O
in	O
ovary	O
and	O
intestine	O
,	O
respectively	O
,	O
the	O
CRBP	O
III	O
mRNA	O
is	O
expressed	O
at	O
the	O
highest	O
levels	O
in	O
kidney	O
and	O
liver	O
thus	O
suggesting	O
a	O
prominent	O
role	O
for	O
human	O
CRBP	O
III	O
as	O
an	O
intracellular	O
mediator	O
of	O
retinol	O
metabolism	O
in	O
these	O
tissues	O
.	O

Smurf1	O
interacts	O
with	O
transforming	O
growth	O
factor	O
-	O
beta	O
type	O
I	O
receptor	O
through	O
Smad7	O
and	O
induces	O
receptor	O
degradation	O
.	O

Smad7	O
is	O
an	O
inhibitory	O
Smad	O
that	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
signaling	O
by	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
proteins	O
.	O

Smad7	O
is	O
induced	O
by	O
TGF	O
-	O
beta	O
,	O
stably	O
interacts	O
with	O
activated	O
TGF	O
-	O
beta	O
type	O
I	O
receptor	O
(	O
TbetaR	O
-	O
I	O
)	O
,	O
and	O
interferes	O
with	O
the	O
phosphorylation	O
of	O
receptor	O
-	O
regulated	O
Smads	O
.	O

Here	O
we	O
show	O
that	O
Smurf1	O
,	O
an	O
E3	O
ubiquitin	O
ligase	O
for	O
bone	O
morphogenetic	O
protein	O
-	O
specific	O
Smads	O
,	O
also	O
interacts	O
with	O
Smad7	O
and	O
induces	O
Smad7	O
ubiquitination	O
and	O
translocation	O
into	O
the	O
cytoplasm	O
.	O

In	O
addition	O
,	O
Smurf1	O
associates	O
with	O
TbetaR	O
-	O
I	O
via	O
Smad7	O
,	O
with	O
subsequent	O
enhancement	O
of	O
turnover	O
of	O
TbetaR	O
-	O
I	O
and	O
Smad7	O
.	O

These	O
results	O
thus	O
reveal	O
a	O
novel	O
function	O
of	O
Smad7	O
,	O
i	O
.	O
e	O
.	O
induction	O
of	O
degradation	O
of	O
TbetaR	O
-	O
I	O
through	O
recruitment	O
of	O
an	O
E3	O
ligase	O
to	O
the	O
receptor	O
.	O

Novel	O
role	O
for	O
a	O
Saccharomyces	O
cerevisiae	O
nucleoporin	O
,	O
Nup170p	O
,	O
in	O
chromosome	O
segregation	O
.	O

We	O
determined	O
that	O
a	O
mutation	O
in	O
the	O
nucleoporin	O
gene	O
NUP170	O
leads	O
to	O
defects	O
in	O
chromosome	O
transmission	O
fidelity	O
(	O
ctf	O
)	O
and	O
kinetochore	O
integrity	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
ctf	O
mutant	O
strain	O
,	O
termed	O
s141	O
,	O
shows	O
a	O
transcription	O
readthrough	O
phenotype	O
and	O
stabilizes	O
a	O
dicentric	O
chromosome	O
fragment	O
in	O
two	O
assays	O
for	O
kinetochore	O
integrity	O
.	O

Previously	O
,	O
these	O
assays	O
led	O
to	O
the	O
identification	O
of	O
two	O
essential	O
kinetochore	O
components	O
,	O
Ctf13p	O
and	O
Ctf14p	O
.	O

Thus	O
,	O
s141	O
represents	O
another	O
ctf	O
mutant	O
involved	O
in	O
the	O
maintenance	O
of	O
kinetochore	O
integrity	O
.	O

We	O
cloned	O
and	O
mapped	O
the	O
gene	O
complementing	O
the	O
ctf	O
mutation	O
of	O
s141	O
and	O
showed	O
that	O
it	O
is	O
identical	O
to	O
the	O
S	O
.	O
cerevisiae	O
NUP170	O
gene	O
.	O

A	O
deletion	O
strain	O
of	O
NUP170	O
(	O
nup170	O
Delta	O
:	O
:	O
HIS3	O
)	O
has	O
a	O
Ctf	O
(	O
-	O
)	O
phenotype	O
similar	O
to	O
the	O
s141	O
mutant	O
(	O
nup170	O
-	O
141	O
)	O
and	O
also	O
exhibits	O
a	O
kinetochore	O
integrity	O
defect	O
.	O

We	O
identified	O
a	O
second	O
nucleoporin	O
,	O
NUP157	O
,	O
a	O
homologue	O
of	O
NUP170	O
,	O
as	O
a	O
suppressor	O
of	O
the	O
Ctf	O
(	O
-	O
)	O
phenotype	O
of	O
nup170	O
-	O
141	O
and	O
nup170	O
Delta	O
:	O
:	O
HIS3	O
strains	O
.	O

However	O
,	O
a	O
deletion	O
of	O
NUP157	O
or	O
several	O
other	O
nucleoporins	O
did	O
not	O
affect	O
chromosome	O
segregation	O
.	O

Our	O
data	O
suggest	O
that	O
NUP170	O
encodes	O
a	O
specialized	O
nucleoporin	O
with	O
a	O
unique	O
role	O
in	O
chromosome	O
segregation	O
and	O
possibly	O
kinetochore	O
function	O
.	O

A	O
role	O
for	O
Sds3p	O
,	O
a	O
component	O
of	O
the	O
Rpd3p	O
/	O
Sin3p	O
deacetylase	B-OOS
complex	O
,	O
in	O
maintaining	O
cellular	O
integrity	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
SDS3	O
gene	O
was	O
identified	O
in	O
a	O
suppressor	O
screen	O
for	O
mutations	O
that	O
enhance	O
position	O
-	O
effect	O
silencing	O
in	O
yeast	O
.	O

Cells	O
that	O
are	O
defective	O
in	O
SDS3	O
have	O
pleiotropic	O
phenotypes	O
,	O
similar	O
to	O
those	O
seen	O
in	O
the	O
absence	O
of	O
the	O
histone	B-OOS
deacetylase	I-OOS
components	O
Rpd3p	O
and	O
Sin3p	O
,	O
including	O
meiotic	O
defects	O
and	O
improper	O
regulation	O
of	O
the	O
HO	O
gene	O
.	O

To	O
gain	O
further	O
insight	O
into	O
SDS3	O
function	O
we	O
undertook	O
an	O
epistasis	O
analysis	O
with	O
other	O
SDS	O
genes	O
.	O

We	O
found	O
that	O
sds3	O
is	O
synthetically	O
lethal	O
in	O
combination	O
with	O
a	O
deletion	O
of	O
the	O
SWI6	O
(	O
SDS11	O
)	O
gene	O
,	O
which	O
encodes	O
a	O
cell	O
-	O
cycle	O
regulator	O
.	O

sds3	O
swi6	O
double	O
mutants	O
do	O
not	O
display	O
a	O
specific	O
cell	O
-	O
cycle	O
arrest	O
phenotype	O
,	O
but	O
instead	O
die	O
due	O
to	O
cell	O
lysis	O
.	O

Constitutive	O
expression	O
of	O
the	O
G1	O
cyclin	O
gene	O
CLN2	O
restores	O
viability	O
to	O
an	O
sds3	O
swi6	O
strain	O
,	O
as	O
does	O
overexpression	O
of	O
SKT5	O
/	O
CHS4	O
,	O
which	O
encodes	O
a	O
regulatory	O
subunit	O
of	O
chitin	B-OOS
synthase	I-OOS
III	I-OOS
,	O
and	O
SSD1	O
,	O
a	O
gene	O
previously	O
implicated	O
in	O
ensuring	O
cell	O
-	O
cycle	O
progression	O
and	O
cellular	O
integrity	O
.	O

Significantly	O
,	O
growth	O
in	O
the	O
presence	O
of	O
1	O
M	O
sorbitol	O
or	O
overexpression	O
of	O
PKC1	O
also	O
partially	O
suppresses	O
the	O
lethal	O
phenotype	O
of	O
the	O
sds3	O
swi6	O
strain	O
.	O

This	O
lethality	O
in	O
the	O
absence	O
of	O
SWI6	O
function	O
most	O
probably	O
reflects	O
an	O
important	O
or	O
essential	O
role	O
for	O
Sds3p	O
in	O
the	O
Rpd3p	O
/	O
Sin3p	O
histone	B-OOS
deacetylase	I-OOS
complex	O
,	O
since	O
RPD3	O
and	O
SIN3	O
mutations	O
are	O
also	O
synthetically	O
lethal	O
in	O
combination	O
with	O
swi6	O
and	O
these	O
phenotypes	O
are	O
also	O
rescued	O
by	O
elevated	O
dosage	O
of	O
SKT5	O
/	O
CHS4	O
,	O
SSD1	O
,	O
or	O
PCK1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
transcription	O
factor	O
Swi6p	O
and	O
the	O
Rpd3p	O
-	O
based	O
deacetylase	B-OOS
complex	O
act	O
in	O
parallel	O
pathways	O
to	O
activate	O
genes	O
required	O
for	O
cell	O
wall	O
biosynthesis	O
.	O

Solution	O
structure	O
of	O
the	O
lipoyl	O
domain	O
of	O
the	O
chimeric	O
dihydrolipoyl	B-Complex
dehydrogenase	I-Complex
P64K	O
from	O
Neisseria	O
meningitidis	O
.	O

The	O
antigenic	O
P64K	O
protein	O
from	O
the	O
pathogenic	O
bacterium	O
Neisseria	O
meningitidis	O
is	O
found	O
in	O
the	O
outer	O
membrane	O
of	O
the	O
cell	O
,	O
and	O
consists	O
of	O
two	O
parts	O
:	O
an	O
81	O
-	O
residue	O
N	O
-	O
terminal	O
region	O
and	O
a	O
482	O
-	O
residue	O
C	O
-	O
terminal	O
region	O
.	O

The	O
amino	O
-	O
acid	O
sequence	O
of	O
the	O
N	O
-	O
terminal	O
region	O
is	O
homologous	O
with	O
the	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	B-OOS
acyltransferase	I-OOS
(	O
E2	B-OOS
)	O
components	O
,	O
and	O
that	O
of	O
the	O
C	O
-	O
terminal	O
region	O
with	O
the	O
dihydrolipoyl	B-Complex
dehydrogenase	I-Complex
(	O
E3	B-Complex
)	O
components	O
,	O
of	O
2	B-Complex
-	I-Complex
oxo	I-Complex
acid	I-Complex
dehydrogenase	I-Complex
multienzyme	O
complexes	O
.	O

The	O
two	O
parts	O
are	O
separated	O
by	O
a	O
long	O
linker	O
region	O
,	O
similar	O
to	O
the	O
linker	O
regions	O
in	O
the	O
E2	B-OOS
chains	O
of	O
2	B-Complex
-	I-Complex
oxo	I-Complex
acid	I-Complex
dehydrogenase	I-Complex
complexes	O
,	O
and	O
it	O
is	O
likely	O
this	O
region	O
is	O
conformationally	O
flexible	O
.	O

A	O
subgene	O
encoding	O
the	O
P64K	O
lipoyl	O
domain	O
was	O
created	O
and	O
over	O
-	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
product	O
was	O
capable	O
of	O
post	O
-	O
translational	O
modification	O
by	O
the	O
lipoate	O
protein	O
ligase	O
but	O
not	O
aberrant	O
modification	O
by	O
the	O
biotin	O
protein	O
ligase	O
of	O
E	O
.	O
coli	O
.	O

The	O
solution	O
structure	O
of	O
the	O
apo	O
-	O
domain	O
was	O
determined	O
by	O
means	O
of	O
heteronuclear	O
NMR	O
spectroscopy	O
and	O
found	O
to	O
be	O
a	O
flattened	O
beta	O
barrel	O
composed	O
of	O
two	O
four	O
-	O
stranded	O
antiparallel	O
beta	O
sheets	O
.	O

The	O
lysine	O
residue	O
that	O
becomes	O
lipoylated	O
is	O
in	O
an	O
exposed	O
beta	O
turn	O
that	O
,	O
from	O
a	O
[	O
1H	O
]	O
-	O
15N	O
heteronuclear	O
Overhauser	O
effect	O
experiment	O
,	O
appears	O
to	O
enjoy	O
substantial	O
local	O
motion	O
.	O

This	O
structure	O
of	O
a	O
lipoyl	O
domain	O
derived	O
from	O
a	O
dihydrolipoyl	B-Complex
dehydrogenase	I-Complex
resembles	O
that	O
of	O
lipoyl	O
domains	O
normally	O
found	O
as	O
part	O
of	O
the	O
dihydrolipoyl	B-OOS
acyltransferase	I-OOS
component	O
of	O
2	B-Complex
-	I-Complex
oxo	I-Complex
acid	I-Complex
dehydrogenase	I-Complex
complexes	O
and	O
will	O
assist	O
in	O
furthering	O
the	O
understanding	O
of	O
its	O
function	O
in	O
a	O
multienzyme	O
complex	O
and	O
in	O
the	O
membrane	O
-	O
bound	O
P64K	O
protein	O
itself	O
.	O

Site	O
-	O
specific	O
incorporation	O
of	O
a	O
phosphotyrosine	O
mimetic	O
reveals	O
a	O
role	O
for	O
tyrosine	O
phosphorylation	O
of	O
SHP	O
-	O
2	O
in	O
cell	O
signaling	O
.	O

The	O
regulation	O
of	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTPase	O
)	O
SHP	O
-	O
2	O
is	O
proposed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
on	O
two	O
tail	O
tyrosine	O
residues	O
.	O

Using	O
"	O
expressed	O
protein	O
ligation	O
"	O
,	O
nonhydrolyzable	O
phosphotyrosine	O
analogs	O
were	O
introduced	O
at	O
known	O
phosphorylation	O
sites	O
in	O
SHP	O
-	O
2	O
.	O

Biochemical	O
analysis	O
suggests	O
that	O
a	O
phosphonate	O
at	O
Tyr542	O
interacts	O
intramolecularly	O
with	O
the	O
N	O
-	O
terminal	O
SH2	O
domain	O
to	O
relieve	O
basal	O
inhibition	O
of	O
the	O
PTPase	O
,	O
whereas	O
a	O
phosphonate	O
at	O
Tyr	O
-	O
580	O
stimulates	O
the	O
PTPase	O
activity	O
by	O
interaction	O
with	O
the	O
C	O
-	O
terminal	O
SH2	O
domain	O
.	O

Microinjection	O
experiments	O
indicate	O
that	O
a	O
single	O
phosphorylation	O
of	O
Tyr	O
-	O
542	O
of	O
SHP	O
-	O
2	O
is	O
sufficient	O
to	O
activate	O
the	O
MAP	O
kinase	O
pathway	O
in	O
living	O
cells	O
.	O

These	O
studies	O
support	O
a	O
novel	O
mechanism	O
explaining	O
how	O
tyrosine	O
phosphorylation	O
of	O
a	O
PTPase	O
is	O
important	O
in	O
signal	O
transduction	O
.	O

The	O
site	O
of	O
Kes1p	O
proteolysis	O
that	O
generates	O
Kes1pW317A	O
*	O
was	O
determined	O
.	O

Matrix	O
-	O
assisted	O
laser	O
ionization	O
coupled	O
with	O
time	O
-	O
of	O
-	O
flight	O
mass	O
analysis	O
(	O
MALDI	O
-	O
TOF	O
)	O
analyses	O
yield	O
a	O
mass	O
of	O
50	O
.	O
663	O
kD	O
for	O
Kes1p	O
and	O
36	O
.	O
838	O
kD	O
for	O
Kes1pW317A	O
*	O
(	O
Fig	O
.	O
4	O
B	O
)	O
.	O

These	O
data	O
assigned	O
the	O
Kes1pW317A	O
*	O
cleavage	O
site	O
to	O
the	O
amide	O
bond	O
of	O
a	O
dibasic	O
motif	O
comprised	O
of	O
Kes1p	O
residues	O
R314	O
and	O
K315	O
,	O
indicating	O
that	O
Kes1pW317A	O
*	O
is	O
devoid	O
of	O
the	O
COOH	O
-	O
terminal	O
120	O
residues	O
(	O
Fig	O
.	O
4	O
B	O
)	O
.	O

Interestingly	O
,	O
this	O
cleavage	O
site	O
lies	O
upstream	O
of	O
the	O
W317A	O
substitution	O
.	O

Thus	O
,	O
Kes1pW317A	O
*	O
represents	O
a	O
proteolytic	O
fragment	O
consisting	O
solely	O
of	O
wild	O
-	O
type	O
Kes1p	O
primary	O
sequence	O
.	O

SETDB1	O
:	O
a	O
novel	O
KAP	O
-	O
1	O
-	O
associated	O
histone	O
H3	O
,	O
lysine	O
9	O
-	O
specific	O
methyltransferase	O
that	O
contributes	O
to	O
HP1	O
-	O
mediated	O
silencing	O
of	O
euchromatic	O
genes	O
by	O
KRAB	O
zinc	O
-	O
finger	O
proteins	O
.	O

Posttranslational	O
modification	O
of	O
histones	O
has	O
emerged	O
as	O
a	O
key	O
regulatory	O
signal	O
in	O
eukaryotic	O
gene	O
expression	O
.	O

Recent	O
genetic	O
and	O
biochemical	O
studies	O
link	O
H3	O
-	O
lysine	O
9	O
(	O
H3	O
-	O
K9	O
)	O
methylation	O
to	O
HP1	O
-	O
mediated	O
heterochromatin	O
formation	O
and	O
gene	O
silencing	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
target	O
and	O
coordinate	O
these	O
activities	O
to	O
specific	O
genes	O
is	O
poorly	O
understood	O
.	O

Here	O
we	O
report	O
that	O
the	O
KAP	O
-	O
1	O
corepressor	O
for	O
the	O
KRAB	O
-	O
ZFP	O
superfamily	O
of	O
transcriptional	O
silencers	O
binds	O
to	O
SETDB1	O
,	O
a	O
novel	O
SET	O
domain	O
protein	O
with	O
histone	O
H3	O
-	O
K9	O
-	O
specific	O
methyltransferase	O
activity	O
.	O

Although	O
acetylation	O
and	O
phosphorylation	O
of	O
the	O
H3	O
N	O
-	O
terminal	O
tail	O
profoundly	O
affect	O
the	O
efficiency	O
of	O
H3	O
-	O
K9	O
methylation	O
by	O
SETDB1	O
,	O
we	O
found	O
that	O
methylation	O
of	O
H3	O
-	O
K4	O
does	O
not	O
affect	O
SETDB1	O
-	O
mediated	O
methylation	O
of	O
H3	O
-	O
K9	O
.	O

In	O
vitro	O
methylation	O
of	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	O
H3	O
by	O
SETDB1	O
is	O
sufficient	O
to	O
enhance	O
the	O
binding	O
of	O
HP1	O
proteins	O
,	O
which	O
requires	O
both	O
an	O
intact	O
chromodomain	O
and	O
chromoshadow	O
domain	O
.	O

Indirect	O
immunofluoresence	O
staining	O
of	O
interphase	O
nuclei	O
localized	O
SETDB1	O
predominantly	O
in	O
euchromatic	O
regions	O
that	O
overlap	O
with	O
HP1	O
staining	O
in	O
nonpericentromeric	O
regions	O
of	O
chromatin	O
.	O

Moreover	O
,	O
KAP	O
-	O
1	O
,	O
SETDB1	O
,	O
H3	O
-	O
MeK9	O
,	O
and	O
HP1	O
are	O
enriched	O
at	O
promoter	O
sequences	O
of	O
a	O
euchromatic	O
gene	O
silenced	O
by	O
the	O
KRAB	O
-	O
KAP	O
-	O
1	O
repression	O
system	O
.	O

Thus	O
,	O
KAP	O
-	O
1	O
is	O
a	O
molecular	O
scaffold	O
that	O
is	O
targeted	O
by	O
KRAB	O
-	O
ZFPs	O
to	O
specific	O
loci	O
and	O
coordinates	O
both	O
histone	O
methylation	O
and	O
the	O
deposition	O
of	O
HP1	O
proteins	O
to	O
silence	O
gene	O
expression	O
.	O

Components	O
of	O
the	O
SAGA	B-Complex
histone	I-Complex
acetyltransferase	I-Complex
complex	O
are	O
required	O
for	O
repressed	O
transcription	O
of	O
ARG1	O
in	O
rich	O
medium	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
ARG1	O
gene	O
is	O
controlled	O
by	O
positive	O
and	O
negative	O
elements	O
.	O

The	O
transactivator	O
Gcn4p	O
is	O
required	O
for	O
activation	O
in	O
minimal	O
medium	O
,	O
while	O
arginine	O
repression	O
requires	O
the	O
ArgR	O
/	O
Mcm1	O
regulatory	O
complex	O
,	O
which	O
binds	O
to	O
two	O
upstream	O
arginine	O
control	O
elements	O
.	O

We	O
have	O
found	O
that	O
the	O
coordinated	O
regulation	O
of	O
ARG1	O
requires	O
components	O
of	O
the	O
SAGA	B-Complex
chromatin	O
-	O
remodeling	O
complex	O
.	O

Using	O
gcn5	O
deletion	O
strains	O
and	O
a	O
Gcn5	O
protein	O
carrying	O
the	O
E173Q	O
mutation	O
in	O
the	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
region	O
,	O
we	O
show	O
that	O
the	O
HAT	O
activity	O
of	O
Gcn5p	O
is	O
required	O
for	O
repression	O
of	O
ARG1	O
in	O
rich	O
medium	O
.	O

Similar	O
increases	O
in	O
expression	O
were	O
seen	O
upon	O
deletion	O
of	O
other	O
SAGA	B-Complex
components	O
but	O
not	O
upon	O
deletion	O
of	O
the	O
ADA	O
-	O
specific	O
component	O
,	O
Ahc1p	O
.	O

Chromatin	O
immunoprecipitations	O
using	O
antibodies	O
to	O
acetylated	O
H3	O
confirmed	O
that	O
a	O
decrease	O
in	O
the	O
level	O
of	O
acetylated	O
histones	O
at	O
the	O
ARG1	O
promoter	O
correlated	O
with	O
increased	O
ARG1	O
expression	O
.	O

Up	O
-	O
regulation	O
of	O
ARG1	O
in	O
the	O
absence	O
of	O
Gcn5p	O
also	O
correlated	O
with	O
increased	O
binding	O
of	O
TATA	O
-	O
binding	O
protein	O
to	O
the	O
promoter	O
.	O

The	O
analysis	O
of	O
promoter	O
deletions	O
showed	O
that	O
Gcn5	O
/	O
Ada	O
repression	O
of	O
ARG1	O
was	O
mediated	O
through	O
the	O
action	O
of	O
the	O
ArgR	O
/	O
Mcm1	O
regulatory	O
complex	O
.	O

In	O
addition	O
,	O
studies	O
with	O
minimal	O
medium	O
demonstrated	O
a	O
requirement	O
for	O
the	O
Ada	O
proteins	O
in	O
activation	O
of	O
ARG1	O
.	O

This	O
suggests	O
that	O
SAGA	B-Complex
has	O
a	O
dual	O
role	O
at	O
ARG1	O
,	O
acting	O
to	O
repress	O
transcription	O
in	O
rich	O
medium	O
and	O
activate	O
transcription	O
in	O
minimal	O
medium	O
.	O

Involvement	O
of	O
Fes	O
/	O
Fps	O
tyrosine	O
kinase	O
in	O
semaphorin3A	O
signaling	O
.	O

Collapsin	O
response	O
mediator	O
proteins	O
(	O
CRMPs	O
)	O
/	O
TOAD64	O
/	O
Ulips	O
/	O
DRPs	O
and	O
CRAM	O
have	O
emerged	O
as	O
strong	O
candidates	O
for	O
a	O
role	O
in	O
semaphorin	O
signaling	O
.	O

In	O
this	O
study	O
we	O
identified	O
Fes	O
/	O
Fps	O
(	O
Fes	O
)	O
tyrosine	O
kinase	O
in	O
the	O
CRMP	O
-	O
CRAM	O
complex	O
and	O
investigated	O
whether	O
Fes	O
was	O
involved	O
in	O
semaphorin3A	O
(	O
Sema3A	O
)	O
signaling	O
.	O

In	O
COS	O
-	O
7	O
cells	O
,	O
the	O
interaction	O
between	O
Fes	O
and	O
plexinA1	O
(	O
PlexA1	O
)	O
and	O
the	O
tyrosine	O
phosphorylation	O
of	O
PlexA1	O
by	O
Fes	O
were	O
observed	O
;	O
however	O
,	O
these	O
events	O
were	O
significantly	O
attenuated	O
by	O
co	O
-	O
expression	O
of	O
neuropilin	O
-	O
1	O
(	O
NP	O
-	O
1	O
)	O
.	O

Even	O
with	O
NP	O
-	O
1	O
co	O
-	O
expression	O
,	O
Sema3A	O
was	O
able	O
to	O
enhance	O
the	O
association	O
of	O
Fes	O
with	O
PlexA1	O
and	O
Fes	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
of	O
PlexA1	O
,	O
CRAM	O
and	O
CRMP2	O
.	O

Co	O
-	O
expression	O
of	O
Fes	O
with	O
PlexA1	O
exhibited	O
COS	O
-	O
7	O
cell	O
contraction	O
activity	O
,	O
indicating	O
that	O
Fes	O
can	O
convert	O
inactive	O
PlexA1	O
to	O
its	O
active	O
form	O
,	O
whereas	O
combination	O
of	O
Fes	O
/	O
NP	O
-	O
1	O
/	O
PlexA1	O
or	O
Fes	O
kinase	O
-	O
negative	O
mutants	O
/	O
PlexA1	O
did	O
not	O
alter	O
cell	O
morphology	O
.	O

Finally	O
,	O
Sema3A	O
-	O
induced	O
growth	O
cone	O
collapse	O
of	O
dorsal	O
root	O
ganglion	O
neurons	O
was	O
suppressed	O
by	O
expression	O
of	O
Fes	O
kinase	O
-	O
negative	O
mutants	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
Fes	O
links	O
Sema3A	O
signals	O
to	O
CRMP	O
-	O
CRAM	O
,	O
and	O
that	O
NP	O
-	O
1	O
negatively	O
regulates	O
PlexA1	O
activation	O
by	O
Fes	O
in	O
resting	O
condition	O
.	O

Molecular	O
structure	O
of	O
a	O
novel	O
cholesterol	O
-	O
responsive	O
A	O
subclass	O
ABC	O
transporter	O
,	O
ABCA9	O
.	O

We	O
recently	O
identified	O
a	O
novel	O
ABC	O
A	O
subclass	O
transporter	O
,	O
ABCA6	O
,	O
in	O
human	O
macrophages	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
an	O
additional	O
ABC	O
A	O
subfamily	O
transporter	O
from	O
macrophages	O
denoted	O
ABCA9	O
.	O

The	O
identified	O
coding	O
sequence	O
is	O
4	O
.	O
9	O
kb	O
in	O
size	O
and	O
codes	O
for	O
a	O
1624	O
amino	O
acid	O
protein	O
product	O
.	O

In	O
accordance	O
with	O
the	O
proposed	O
nomenclature	O
,	O
the	O
novel	O
transporter	O
was	O
designated	O
ABCA9	O
.	O

The	O
putative	O
full	O
-	O
length	O
ABC	O
transporter	O
polypeptide	O
consists	O
of	O
two	O
transmembrane	O
domains	O
and	O
two	O
nucleotide	O
binding	O
folds	O
and	O
thus	O
conforms	O
to	O
the	O
group	O
of	O
full	O
-	O
size	O
ABC	O
transporters	O
.	O

We	O
identified	O
alternative	O
ABCA9	O
mRNA	O
variants	O
in	O
human	O
macrophages	O
that	O
predict	O
the	O
existence	O
of	O
three	O
truncated	O
forms	O
of	O
the	O
novel	O
transporter	O
.	O

Among	O
the	O
human	O
ABC	O
A	O
subfamily	O
transporters	O
,	O
ABCA9	O
exhibits	O
the	O
highest	O
amino	O
acid	O
sequence	O
homology	O
with	O
ABCA8	O
(	O
72	O
%	O
)	O
and	O
ABCA6	O
(	O
60	O
%	O
)	O
,	O
respectively	O
.	O

The	O
striking	O
amino	O
acid	O
sequence	O
similarity	O
between	O
these	O
transporter	O
molecules	O
supports	O
the	O
notion	O
that	O
they	O
represent	O
an	O
evolutionary	O
more	O
recently	O
emerged	O
subgroup	O
within	O
the	O
family	O
of	O
ABC	O
A	O
transporters	O
,	O
which	O
we	O
refer	O
to	O
as	O
"	O
ABCA6	O
-	O
like	O
transporters	O
.	O
"	O
ABCA9	O
mRNA	O
is	O
ubiquitously	O
expressed	O
with	O
the	O
highest	O
mRNA	O
levels	O
in	O
heart	O
,	O
brain	O
,	O
and	O
fetal	O
tissues	O
.	O

Analysis	O
of	O
the	O
genomic	O
structure	O
revealed	O
that	O
the	O
ABCA9	O
gene	O
consists	O
of	O
39	O
exons	O
that	O
are	O
located	O
within	O
a	O
genomic	O
region	O
of	O
approximately	O
85	O
kb	O
size	O
on	O
chromosome	O
17q24	O
.	O
2	O
.	O

In	O
human	O
macrophages	O
,	O
ABCA9	O
mRNA	O
is	O
induced	O
during	O
monocyte	O
differentiation	O
into	O
macrophages	O
and	O
suppressed	O
by	O
cholesterol	O
import	O
indicating	O
that	O
ABCA9	O
,	O
like	O
other	O
known	O
ABC	O
A	O
subfamily	O
transporters	O
,	O
is	O
a	O
cholesterol	O
-	O
responsive	O
gene	O
.	O

Based	O
on	O
this	O
information	O
,	O
ABCA9	O
is	O
likely	O
involved	O
in	O
monocyte	O
differentiation	O
and	O
macrophage	O
lipid	O
homeostasis	O
.	O

Farnesylation	O
of	O
Cenp	O
-	O
F	O
is	O
required	O
for	O
G2	O
/	O
M	O
progression	O
and	O
degradation	O
after	O
mitosis	O
.	O

Farnesyl	B-OOS
transferase	I-OOS
inhibitors	O
induce	O
G2	O
/	O
M	O
cell	O
cycle	O
delays	O
that	O
cannot	O
be	O
explained	O
by	O
inhibition	O
of	O
the	O
Ras	O
GTPase	O
.	O

Recently	O
,	O
the	O
kinetochore	O
protein	O
Cenp	O
-	O
F	O
has	O
been	O
shown	O
to	O
be	O
farnesylated	O
.	O

Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
kinetochore	O
targeting	O
domain	O
of	O
Cenp	O
-	O
F	O
delays	O
progression	O
through	O
G2	O
/	O
M	O
.	O

Significantly	O
,	O
this	O
is	O
dependent	O
on	O
the	O
CAAX	O
farnesylation	O
motif	O
.	O

We	O
also	O
show	O
that	O
localisation	O
of	O
Cenp	O
-	O
F	O
to	O
the	O
nuclear	O
envelope	O
at	O
G2	O
/	O
M	O
and	O
kinetochores	O
in	O
prometaphase	O
is	O
dependent	O
both	O
on	O
its	O
CAAX	O
motif	O
and	O
farnesyl	B-OOS
transferase	I-OOS
activity	O
.	O

Strikingly	O
,	O
farnesyl	B-OOS
transferase	I-OOS
activity	O
is	O
also	O
required	O
for	O
Cenp	O
-	O
F	O
degradation	O
after	O
mitosis	O
.	O

Thus	O
,	O
these	O
observations	O
suggest	O
that	O
farnesylation	O
of	O
Cenp	O
-	O
F	O
is	O
required	O
not	O
only	O
for	O
its	O
localisation	O
to	O
the	O
nuclear	O
envelope	O
and	O
kinetochores	O
but	O
also	O
for	O
timely	O
progression	O
through	O
G2	O
/	O
M	O
and	O
its	O
degradation	O
after	O
mitosis	O
.	O

In	O
addition	O
,	O
these	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
proliferative	O
effects	O
induced	O
by	O
farnesyl	B-OOS
transferase	I-OOS
inhibitors	O
may	O
be	O
due	O
to	O
inhibition	O
of	O
Cenp	O
-	O
F	O
function	O
and	O
/	O
or	O
turnover	O
.	O

Ubiquitin	O
-	O
protein	O
ligase	O
WWP2	O
binds	O
to	O
and	O
downregulates	O
the	O
epithelial	O
Na	O
(	O
+	O
)	O
channel	O
.	O

The	O
epithelial	O
Na	O
(	O
+	O
)	O
channel	O
(	O
ENaC	O
)	O
is	O
a	O
critical	O
component	O
of	O
the	O
pathway	O
maintaining	O
salt	O
and	O
water	O
balance	O
.	O

The	O
channel	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Nedd4	O
family	O
of	O
ubiquitin	O
-	O
protein	O
ligases	O
,	O
which	O
bind	O
to	O
channel	O
subunits	O
and	O
catalyze	O
channel	O
internalization	O
and	O
degradation	O
.	O

ENaC	O
mutations	O
that	O
abolish	O
this	O
interaction	O
cause	O
Liddle	O
'	O
s	O
syndrome	O
,	O
a	O
genetic	O
form	O
of	O
hypertension	O
.	O

Here	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
WW	O
domain	O
-	O
containing	O
protein	O
2	O
(	O
WWP2	O
)	O
,	O
a	O
member	O
of	O
the	O
Nedd4	O
family	O
of	O
ubiquitin	O
-	O
protein	O
ligases	O
,	O
is	O
a	O
candidate	O
to	O
regulate	O
ENaC	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
we	O
found	O
that	O
WWP2	O
is	O
expressed	O
in	O
epithelial	O
tissues	O
that	O
express	O
ENaC	O
,	O
as	O
well	O
as	O
in	O
a	O
wide	O
variety	O
of	O
other	O
tissues	O
.	O

WWP2	O
contains	O
four	O
WW	O
domains	O
,	O
three	O
of	O
which	O
bound	O
differentially	O
to	O
ENaC	O
subunits	O
.	O

In	O
contrast	O
,	O
all	O
four	O
human	O
Nedd4	O
-	O
2	O
WW	O
domains	O
bound	O
to	O
ENaC	O
.	O

WWP2	O
inhibited	O
ENaC	O
when	O
coexpressed	O
in	O
epithelia	O
,	O
requiring	O
a	O
direct	O
interaction	O
between	O
the	O
proteins	O
;	O
mutation	O
of	O
the	O
ENaC	O
PY	O
motifs	O
abolished	O
inhibition	O
.	O

Thus	O
expression	O
,	O
binding	O
,	O
and	O
functional	O
data	O
all	O
suggest	O
that	O
WWP2	O
is	O
a	O
candidate	O
to	O
regulate	O
ENaC	O
-	O
mediated	O
Na	O
(	O
+	O
)	O
transport	O
in	O
epithelia	O
.	O

The	O
junctional	O
adhesion	O
molecule	O
3	O
(	O
JAM	O
-	O
3	O
)	O
on	O
human	O
platelets	O
is	O
a	O
counterreceptor	O
for	O
the	O
leukocyte	O
integrin	O
Mac	O
-	O
1	O
.	O

The	O
recently	O
described	O
junctional	O
adhesion	O
molecules	O
(	O
JAMs	O
)	O
in	O
man	O
and	O
mice	O
are	O
involved	O
in	O
homotypic	O
and	O
heterotypic	O
intercellular	O
interactions	O
.	O

Here	O
,	O
a	O
third	O
member	O
of	O
this	O
family	O
,	O
human	O
JAM	O
-	O
3	O
,	O
was	O
identified	O
and	O
described	O
as	O
a	O
novel	O
counterreceptor	O
on	O
platelets	O
for	O
the	O
leukocyte	O
beta2	O
-	O
integrin	O
Mac	O
-	O
1	O
(	O
alphaMbeta2	O
,	O
CD11b	O
/	O
CD18	O
)	O
.	O

With	O
the	O
help	O
of	O
two	O
monoclonal	O
antibodies	O
,	O
Gi11	O
and	O
Gi13	O
,	O
against	O
a	O
43	O
-	O
kD	O
surface	O
glycoprotein	O
on	O
human	O
platelets	O
,	O
a	O
full	O
-	O
length	O
cDNA	O
encoding	O
JAM	O
-	O
3	O
was	O
identified	O
.	O

JAM	O
-	O
3	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
containing	O
two	O
Ig	O
-	O
like	O
domains	O
.	O

Although	O
JAM	O
-	O
3	O
did	O
not	O
undergo	O
homophilic	O
interactions	O
,	O
myelo	O
-	O
monocytic	O
cells	O
adhered	O
to	O
immobilized	O
JAM	O
-	O
3	O
or	O
to	O
JAM	O
-	O
3	O
-	O
transfected	O
cells	O
.	O

This	O
heterophilic	O
interaction	O
was	O
specifically	O
attributed	O
to	O
a	O
direct	O
interaction	O
of	O
JAM	O
-	O
3	O
with	O
the	O
beta2	O
-	O
integrin	O
Mac	O
-	O
1	O
and	O
to	O
a	O
lower	O
extent	O
with	O
p150	O
.	O
95	O
(	O
alphaXbeta2	O
,	O
CD11c	O
/	O
CD18	O
)	O
but	O
not	O
with	O
LFA	O
-	O
1	O
(	O
alphaLbeta2	O
,	O
CD11a	O
/	O
CD18	O
)	O
or	O
with	O
beta1	O
-	O
integrins	O
.	O

These	O
results	O
were	O
corroborated	O
by	O
analysis	O
of	O
K562	O
erythroleukemic	O
cells	O
transfected	O
with	O
different	O
heterodimeric	O
beta2	O
-	O
integrins	O
and	O
by	O
using	O
purified	O
proteins	O
.	O

Moreover	O
,	O
purified	O
JAM	O
-	O
3	O
or	O
antibodies	O
against	O
JAM	O
-	O
3	O
blocked	O
the	O
platelet	O
-	O
neutrophil	O
interaction	O
,	O
indicating	O
that	O
platelet	O
JAM	O
-	O
3	O
serves	O
as	O
a	O
counterreceptor	O
for	O
Mac	O
-	O
1	O
mediating	O
leukocyte	O
-	O
platelet	O
interactions	O
.	O

JAM	O
-	O
3	O
thereby	O
provides	O
a	O
novel	O
molecular	O
target	O
for	O
antagonizing	O
interactions	O
between	O
vascular	O
cells	O
that	O
promote	O
inflammatory	O
vascular	O
pathologies	O
such	O
as	O
in	O
atherothrombosis	O
.	O

EphB1	O
associates	O
with	O
Grb7	O
and	O
regulates	O
cell	O
migration	O
.	O

EphB1	O
is	O
a	O
member	O
of	O
the	O
Eph	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
that	O
play	O
important	O
roles	O
in	O
diverse	O
biological	O
processes	O
including	O
nervous	O
system	O
development	O
,	O
angiogenesis	O
,	O
and	O
neural	O
synapsis	O
formation	O
and	O
maturation	O
.	O

Grb7	O
is	O
an	O
adaptor	O
molecule	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
migration	O
.	O

Here	O
we	O
report	O
identification	O
of	O
an	O
interaction	O
between	O
Grb7	O
and	O
the	O
cytoplasmic	O
domain	O
of	O
EphB1	O
by	O
using	O
Grb7	O
as	O
a	O
"	O
bait	O
"	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

Co	O
-	O
immunoprecipitation	O
was	O
used	O
to	O
confirm	O
the	O
interaction	O
of	O
Grb7	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
EphB1	O
as	O
well	O
as	O
the	O
full	O
-	O
length	O
receptor	O
in	O
intact	O
cells	O
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
SH2	O
domain	O
of	O
Grb7	O
and	O
requires	O
tyrosine	O
autophosphorylation	O
of	O
EphB1	O
.	O

Furthermore	O
,	O
Tyr	O
-	O
928	O
of	O
EphB1	O
was	O
identified	O
as	O
the	O
primary	O
binding	O
site	O
for	O
Grb7	O
.	O

Stimulation	O
of	O
endogenous	O
EphB1	O
in	O
embryonal	O
carcinoma	O
P19	O
cells	O
with	O
its	O
ligand	O
ephrinB1	O
increased	O
its	O
association	O
with	O
Grb7	O
,	O
which	O
is	O
consistent	O
with	O
a	O
role	O
for	O
the	O
autophosphorylation	O
of	O
EphB1	O
.	O

We	O
also	O
found	O
that	O
EphB1	O
could	O
phosphorylate	O
Grb7	O
and	O
mutation	O
of	O
either	O
Tyr	O
-	O
928	O
or	O
Tyr	O
-	O
594	O
to	O
Phe	O
decreased	O
this	O
activity	O
.	O

Finally	O
,	O
we	O
show	O
that	O
EphB1	O
could	O
stimulate	O
fibroblast	O
motility	O
on	O
extracellular	O
matrix	O
in	O
a	O
kinase	O
-	O
dependent	O
manner	O
,	O
which	O
also	O
correlated	O
with	O
its	O
association	O
with	O
Grb7	O
.	O

Consistent	O
with	O
this	O
,	O
co	O
-	O
expression	O
of	O
Grb7	O
with	O
EphB1	O
further	O
enhanced	O
cell	O
motility	O
,	O
whereas	O
co	O
-	O
expression	O
of	O
the	O
Grb7	O
SH2	O
domain	O
abolished	O
EphB1	O
-	O
stimulated	O
cell	O
migration	O
.	O

Together	O
,	O
our	O
results	O
identified	O
a	O
novel	O
interaction	O
between	O
EphB1	O
with	O
the	O
adaptor	O
molecule	O
Grb7	O
and	O
suggested	O
that	O
this	O
interaction	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
migration	O
by	O
EphB1	O
.	O

The	O
FKBP12	O
-	O
rapamycin	O
-	O
associated	O
protein	O
(	O
FRAP	O
)	O
is	O
a	O
CLIP	O
-	O
170	O
kinase	O
.	O

CLIP	O
-	O
170	O
/	O
Restin	O
belongs	O
to	O
a	O
family	O
of	O
conserved	O
microtubule	O
(	O
MT	O
)	O
-	O
associated	O
proteins	O
,	O
which	O
are	O
important	O
for	O
MT	O
organization	O
and	O
functions	O
.	O

CLIP	O
-	O
170	O
is	O
a	O
phosphoprotein	O
and	O
phosphorylation	O
is	O
thought	O
to	O
regulate	O
the	O
binding	O
of	O
CLIP	O
-	O
170	O
to	O
MTs	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
kinase	O
(	O
s	O
)	O
involved	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
FKBP12	O
-	O
rapamycin	O
-	O
associated	O
protein	O
(	O
FRAP	O
,	O
also	O
called	O
mTOR	O
/	O
RAFT	O
)	O
interacts	O
with	O
CLIP	O
-	O
170	O
.	O

CLIP	O
-	O
170	O
is	O
phosphorylated	O
in	O
vivo	O
at	O
multiple	O
sites	O
,	O
including	O
rapamycin	O
-	O
sensitive	O
and	O
-	O
insensitive	O
sites	O
,	O
and	O
is	O
phosphorylated	O
by	O
FRAP	O
in	O
vitro	O
at	O
the	O
rapamycin	O
-	O
sensitive	O
sites	O
.	O

In	O
addition	O
,	O
rapamycin	O
inhibited	O
the	O
ability	O
of	O
CLIP	O
-	O
170	O
to	O
bind	O
to	O
MTs	O
.	O

Our	O
observations	O
suggest	O
that	O
multiple	O
CLIP	O
-	O
170	O
kinases	O
are	O
involved	O
in	O
positive	O
and	O
negative	O
control	O
of	O
CLIP	O
-	O
170	O
,	O
and	O
FRAP	O
is	O
a	O
CLIP	O
-	O
170	O
kinase	O
positively	O
regulating	O
the	O
MT	O
-	O
binding	O
behavior	O
of	O
CLIP	O
-	O
170	O
.	O

Disabled	O
-	O
2	O
exhibits	O
the	O
properties	O
of	O
a	O
cargo	O
-	O
selective	O
endocytic	O
clathrin	B-Complex
adaptor	O
.	O

Clathrin	B-Complex
-	O
coated	O
pits	O
at	O
the	O
cell	O
surface	O
select	O
material	O
for	O
transportation	O
into	O
the	O
cell	O
interior	O
.	O

A	O
major	O
mode	O
of	O
cargo	O
selection	O
at	O
the	O
bud	O
site	O
is	O
via	O
the	O
micro	O
2	O
subunit	O
of	O
the	O
AP	B-Complex
-	I-Complex
2	I-Complex
adaptor	O
complex	O
,	O
which	O
recognizes	O
tyrosine	O
-	O
based	O
internalization	O
signals	O
.	O

Other	O
internalization	O
motifs	O
and	O
signals	O
,	O
including	O
phosphorylation	O
and	O
ubiquitylation	O
,	O
also	O
tag	O
certain	O
proteins	O
for	O
incorporation	O
into	O
a	O
coated	O
vesicle	O
,	O
but	O
the	O
mechanism	O
of	O
selection	O
is	O
unclear	O
.	O

Disabled	O
-	O
2	O
(	O
Dab2	O
)	O
recognizes	O
the	O
FXNPXY	O
internalization	O
motif	O
in	O
LDL	O
-	O
receptor	O
family	O
members	O
via	O
an	O
N	O
-	O
terminal	O
phosphotyrosine	O
-	O
binding	O
(	O
PTB	O
)	O
domain	O
.	O

Here	O
,	O
we	O
show	O
that	O
in	O
addition	O
to	O
binding	O
AP	B-Complex
-	I-Complex
2	I-Complex
,	O
Dab2	O
also	O
binds	O
directly	O
to	O
phosphoinositides	O
and	O
to	O
clathrin	B-Complex
,	O
assembling	O
triskelia	O
into	O
regular	O
polyhedral	O
coats	O
.	O

The	O
FXNPXY	O
motif	O
and	O
phosphoinositides	O
contact	O
different	O
regions	O
of	O
the	O
PTB	O
domain	O
,	O
but	O
can	O
stably	O
anchor	O
Dab2	O
to	O
the	O
membrane	O
surface	O
,	O
while	O
the	O
distal	O
AP	B-Complex
-	I-Complex
2	I-Complex
and	O
clathrin	B-Complex
-	O
binding	O
determinants	O
regulate	O
clathrin	B-Complex
lattice	O
assembly	O
.	O

We	O
propose	O
that	O
Dab2	O
is	O
a	O
typical	O
member	O
of	O
a	O
growing	O
family	O
of	O
cargo	O
-	O
specific	O
adaptor	O
proteins	O
,	O
including	O
beta	O
-	O
arrestin	O
,	O
AP180	O
,	O
epsin	O
,	O
HIP1	O
and	O
numb	O
,	O
which	O
regulate	O
clathrin	B-Complex
-	O
coat	O
assembly	O
at	O
the	O
plasma	O
membrane	O
by	O
synchronizing	O
cargo	O
selection	O
and	O
lattice	O
polymerization	O
events	O
.	O

The	O
metabolic	O
activation	O
of	O
abacavir	O
by	O
human	O
liver	O
cytosol	O
and	O
expressed	O
human	O
alcohol	O
dehydrogenase	O
isozymes	O
.	O

Abacavir	O
(	O
ZIAGEN	O
)	O
is	O
a	O
reverse	O
transcriptase	O
inhibitor	O
marketed	O
for	O
the	O
treatment	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

A	O
small	O
percentage	O
of	O
patients	O
experience	O
a	O
hypersensitivity	O
reaction	O
indicating	O
immune	O
system	O
involvement	O
and	O
bioactivation	O
.	O

A	O
major	O
route	O
of	O
metabolism	O
for	O
abacavir	O
is	O
oxidation	O
of	O
a	O
primary	O
betagamma	O
unsaturated	O
alcohol	O
to	O
a	O
carboxylic	O
acid	O
via	O
an	O
aldehyde	O
intermediate	O
.	O

This	O
process	O
was	O
shown	O
to	O
be	O
mediated	O
in	O
vitro	O
by	O
human	O
cytosol	O
and	O
NAD	O
,	O
and	O
subsequently	O
the	O
alphaalpha	O
and	O
gamma2gamma2	O
human	O
isoforms	O
of	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
.	O

The	O
alphaalpha	O
isoform	O
effected	O
two	O
sequential	O
oxidation	O
steps	O
to	O
form	O
the	O
acid	O
metabolite	O
and	O
two	O
isomers	O
,	O
qualitatively	O
reflective	O
of	O
in	O
vitro	O
cytosolic	O
profiles	O
.	O

The	O
gamma2gamma2	O
isozyme	O
generated	O
primarily	O
an	O
isomer	O
of	O
abacavir	O
,	O
which	O
was	O
minor	O
in	O
the	O
alphaalpha	O
profiles	O
.	O

The	O
aldehyde	O
intermediate	O
could	O
be	O
trapped	O
in	O
incubations	O
with	O
both	O
isozymes	O
as	O
an	O
oxime	O
derivative	O
.	O

These	O
metabolites	O
can	O
be	O
rationalized	O
as	O
arising	O
via	O
the	O
aldehyde	O
which	O
undergoes	O
isomerization	O
and	O
further	O
oxidation	O
by	O
the	O
alphaalpha	O
enzyme	O
or	O
reduction	O
by	O
the	O
gamma2gamma2	O
isozyme	O
.	O

Non	O
-	O
extractable	O
abacavir	O
protein	O
residues	O
were	O
generated	O
in	O
cytosol	O
,	O
and	O
with	O
alphaalpha	O
and	O
gamma2gamma2	O
incubations	O
in	O
the	O
presence	O
of	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
.	O

Metabolism	O
and	O
residue	O
formation	O
were	O
blocked	O
by	O
the	O
ADH	O
inhibitor	O
4	O
-	O
methyl	O
pyrazole	O
(	O
4	O
-	O
MP	O
)	O
.	O

The	O
residues	O
generated	O
by	O
the	O
alphaalpha	O
and	O
gamma2gamma2	O
incubations	O
were	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
with	O
immunochemical	O
detection	O
.	O

The	O
binding	O
of	O
rabbit	O
anti	O
-	O
abacavir	O
antibody	O
to	O
abacavir	O
-	O
HSA	O
was	O
shown	O
to	O
be	O
dependent	O
on	O
metabolism	O
(	O
i	O
.	O
e	O
.	O
NAD	O
-	O
dependent	O
and	O
4	O
-	O
MP	O
sensitive	O
)	O
.	O

The	O
mechanism	O
of	O
covalent	O
binding	O
remains	O
to	O
be	O
established	O
,	O
but	O
significantly	O
less	O
abacavir	O
-	O
protein	O
residue	O
was	O
detected	O
with	O
an	O
analog	O
of	O
abacavir	O
in	O
which	O
the	O
double	O
bond	O
was	O
removed	O
,	O
suggestive	O
of	O
a	O
double	O
bond	O
migration	O
and	O
1	O
,	O
4	O
addition	O
process	O
.	O

Shift	O
of	O
serum	O
osteocalcin	O
components	O
between	O
cord	O
blood	O
and	O
blood	O
at	O
day	O
5	O
of	O
life	O
.	O

Vitamin	O
K	O
deficiency	O
is	O
a	O
relatively	O
common	O
condition	O
in	O
neonates	O
.	O

However	O
,	O
the	O
role	O
of	O
vitamin	O
K	O
in	O
neonatal	O
bone	O
metabolism	O
remains	O
to	O
be	O
determined	O
.	O

Osteocalcin	O
(	O
OC	O
)	O
is	O
the	O
most	O
abundant	O
noncollagenous	O
protein	O
in	O
bone	O
,	O
and	O
is	O
regulated	O
to	O
be	O
gamma	O
-	O
carboxylated	O
by	O
vitamin	O
K	O
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
gamma	O
-	O
carboxylated	O
osteocalcin	O
(	O
Gla	O
-	O
OC	O
)	O
and	O
non	O
-	O
or	O
undercarboxylated	O
osteocalcin	O
(	O
Glu	O
-	O
OC	O
)	O
separately	O
,	O
and	O
examined	O
the	O
effects	O
of	O
vitamin	O
K	O
on	O
osteocalcin	O
metabolism	O
.	O

Eighteen	O
full	O
-	O
term	O
healthy	O
neonates	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

In	O
the	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
the	O
OC	O
levels	O
were	O
determined	O
by	O
three	O
different	O
methods	O
to	O
examine	O
the	O
intact	O
OC	O
by	O
immunoradiometric	O
assay	O
(	O
IRMA	O
)	O
,	O
Gla	O
-	O
OC	O
,	O
and	O
Glu	O
-	O
OC	O
.	O

Serum	O
vitamin	O
K	O
fractions	O
,	O
hepaplastin	O
test	O
,	O
and	O
type	O
1	O
procollagen	O
carboxyl	O
extension	O
peptide	O
were	O
also	O
determined	O
.	O

Urine	O
samples	O
were	O
also	O
collected	O
from	O
the	O
first	O
voiding	O
and	O
on	O
d	O
5	O
to	O
determine	O
urinary	O
pyridinoline	O
,	O
deoxypyridinoline	O
,	O
and	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
.	O

Serum	O
levels	O
of	O
phylloquinone	O
(	O
PK	O
)	O
and	O
menaquinone	O
(	O
MK	O
)	O
-	O
4	O
increased	O
on	O
d	O
5	O
following	O
vitamin	O
K	O
administration	O
and	O
increased	O
intake	O
in	O
breast	O
milk	O
and	O
/	O
or	O
formula	O
.	O

The	O
OC	O
levels	O
determined	O
by	O
IRMA	O
did	O
not	O
change	O
between	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
but	O
the	O
Gla	O
-	O
OC	O
level	O
increased	O
remarkably	O
and	O
Glu	O
-	O
OC	O
reduced	O
to	O
a	O
negligible	O
level	O
.	O

OC	O
in	O
cord	O
blood	O
is	O
mainly	O
Glu	O
-	O
OC	O
,	O
and	O
Glu	O
-	O
OC	O
is	O
replaced	O
with	O
Gla	O
-	O
OC	O
within	O
5	O
d	O
of	O
life	O
after	O
vitamin	O
K	O
supplement	O
.	O

The	O
IRMA	O
assay	O
fails	O
to	O
distinguish	O
Gla	O
-	O
OC	O
from	O
Glu	O
-	O
OC	O
and	O
caution	O
is	O
needed	O
to	O
estimate	O
bone	O
turnover	O
with	O
this	O
method	O
in	O
the	O
perinatal	O
period	O
.	O

The	O
PAAD	O
/	O
PYRIN	O
-	O
family	O
protein	O
ASC	O
is	O
a	O
dual	O
regulator	O
of	O
a	O
conserved	O
step	O
in	O
nuclear	B-Complex
factor	I-Complex
kappaB	I-Complex
activation	O
pathways	O
.	O

Apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
Caspase	O
recruitment	O
domain	O
(	O
ASC	O
)	O
belongs	O
to	O
a	O
large	O
family	O
of	O
proteins	O
that	O
contain	O
a	O
Pyrin	O
,	O
AIM	O
,	O
ASC	O
,	O
and	O
death	O
domain	O
-	O
like	O
(	O
PAAD	O
)	O
domain	O
(	O
also	O
known	O
as	O
PYRIN	O
,	O
DAPIN	O
,	O
Pyk	O
)	O
.	O

Recent	O
data	O
have	O
suggested	O
that	O
ASC	O
functions	O
as	O
an	O
adaptor	O
protein	O
linking	O
various	O
PAAD	O
-	O
family	O
proteins	O
to	O
pathways	O
involved	O
in	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappaB	I-Complex
and	O
pro	O
-	O
Caspase	O
-	O
1	O
activation	O
.	O

We	O
present	O
evidence	O
here	O
that	O
the	O
role	O
of	O
ASC	O
in	O
modulating	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
pathways	O
is	O
much	O
broader	O
than	O
previously	O
suspected	O
,	O
as	O
it	O
can	O
either	O
inhibit	O
or	O
activate	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
depending	O
on	O
cellular	O
context	O
.	O

While	O
coexpression	O
of	O
ASC	O
with	O
certain	O
PAAD	O
-	O
family	O
proteins	O
such	O
as	O
Pyrin	O
and	O
Cryopyrin	O
increases	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activity	O
,	O
ASC	O
has	O
an	O
inhibitory	O
influence	O
on	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
various	O
proinflammatory	O
stimuli	O
,	O
including	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
,	O
interleukin	O
1beta	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Elevations	O
in	O
ASC	O
protein	O
levels	O
or	O
of	O
the	O
PAAD	O
domain	O
of	O
ASC	O
suppressed	O
activation	O
of	O
IkappaB	B-Complex
kinases	O
in	O
cells	O
exposed	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
.	O

Conversely	O
,	O
reducing	O
endogenous	O
levels	O
of	O
ASC	O
using	O
siRNA	O
enhanced	O
TNF	O
-	O
and	O
LPS	O
-	O
induced	O
degradation	O
of	O
the	O
IKK	B-Complex
substrate	O
,	O
IkappaBalpha	O
.	O

Our	O
findings	O
suggest	O
that	O
ASC	O
modulates	O
diverse	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
induction	O
pathways	O
by	O
acting	O
upon	O
the	O
IKK	B-Complex
complex	O
,	O
implying	O
a	O
broad	O
role	O
for	O
this	O
and	O
similar	O
proteins	O
containing	O
PAAD	O
domains	O
in	O
regulation	O
of	O
inflammatory	O
responses	O
.	O

Multiple	O
splice	O
variants	O
of	O
the	O
human	O
HIF	O
-	O
3	O
alpha	O
locus	O
are	O
targets	O
of	O
the	O
von	B-Complex
Hippel	I-Complex
-	I-Complex
Lindau	I-Complex
E3	I-Complex
ubiquitin	I-Complex
ligase	I-Complex
complex	O
.	O

Functional	O
inactivation	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	O
suppressor	O
protein	O
is	O
the	O
cause	O
of	O
familial	O
VHL	O
disease	O
and	O
sporadic	O
kidney	O
cancer	O
.	O

The	O
VHL	O
gene	O
product	O
(	O
pVHL	O
)	O
is	O
a	O
component	O
of	O
an	O
E3	O
ubiquitin	O
ligase	O
complex	O
that	O
targets	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
1	O
and	O
2	O
alpha	O
subunits	O
for	O
polyubiquitylation	O
.	O

This	O
process	O
is	O
dependent	O
on	O
the	O
hydroxylation	O
of	O
conserved	O
proline	O
residues	O
on	O
the	O
alpha	O
subunits	O
of	O
HIF	O
-	O
1	O
/	O
2	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

In	O
our	O
effort	O
to	O
identify	O
orphan	O
HIF	O
-	O
like	O
proteins	O
in	O
the	O
data	O
base	O
that	O
are	O
potential	O
targets	O
of	O
the	O
pVHL	B-Complex
complex	O
,	O
we	O
report	O
multiple	O
splice	O
variants	O
of	O
the	O
human	O
HIF	O
-	O
3	O
alpha	O
locus	O
as	O
follows	O
:	O
hHIF	O
-	O
3	O
alpha	O
1	O
,	O
hHIF	O
-	O
3	O
alpha	O
2	O
(	O
also	O
referred	O
to	O
as	O
hIPAS	O
;	O
human	O
inhibitory	O
PAS	O
domain	O
protein	O
)	O
,	O
hHIF	O
-	O
3	O
alpha	O
3	O
,	O
hHIF	O
-	O
3	O
alpha	O
4	O
,	O
hHIF	O
-	O
3	O
alpha	O
5	O
,	O
and	O
hHIF	O
-	O
3	O
alpha	O
6	O
.	O

We	O
demonstrate	O
that	O
the	O
common	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
of	O
hHIF	O
-	O
3	O
alpha	O
1	O
-	O
3	O
splice	O
variants	O
is	O
targeted	O
for	O
ubiquitylation	O
by	O
the	O
pVHL	B-Complex
complex	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

This	O
activity	O
is	O
enhanced	O
in	O
the	O
presence	O
of	O
prolyl	O
hydroxylase	O
and	O
is	O
dependent	O
on	O
a	O
proline	O
residue	O
at	O
position	O
490	O
.	O

Furthermore	O
,	O
the	O
ubiquitin	O
conjugation	O
occurs	O
on	O
lysine	O
residues	O
at	O
position	O
465	O
and	O
568	O
within	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
.	O

These	O
results	O
demonstrate	O
additional	O
targets	O
of	O
the	O
pVHL	B-Complex
complex	O
and	O
suggest	O
a	O
growing	O
complexity	O
in	O
the	O
regulation	O
of	O
hypoxia	O
-	O
inducible	O
genes	O
by	O
the	O
HIF	O
family	O
of	O
transcription	O
factors	O
.	O

Characterization	O
of	O
human	O
Smg5	O
/	O
7a	O
:	O
a	O
protein	O
with	O
similarities	O
to	O
Caenorhabditis	O
elegans	O
SMG5	O
and	O
SMG7	O
that	O
functions	O
in	O
the	O
dephosphorylation	O
of	O
Upf1	O
.	O

Nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
in	O
mammalian	O
cells	O
depends	O
on	O
phosphorylation	O
of	O
Upf1	O
,	O
an	O
RNA	O
-	O
dependent	O
ATPase	O
and	O
5	O
'	O
-	O
to	O
-	O
3	O
'	O
helicase	O
.	O

Upf1	O
phosphorylation	O
is	O
mediated	O
by	O
Smg1	O
,	O
a	O
phosphoinositol	O
3	O
-	O
kinase	O
-	O
related	O
protein	O
kinase	O
.	O

Here	O
,	O
we	O
describe	O
a	O
human	O
protein	O
,	O
which	O
we	O
call	O
hSmg5	O
/	O
7a	O
,	O
that	O
manifests	O
similarity	O
to	O
Caenorhabditis	O
elegans	O
NMD	O
factors	O
CeSMG5	O
and	O
CeSMG7	O
,	O
as	O
well	O
as	O
two	O
Drosophila	O
melanogaster	O
proteins	O
that	O
are	O
also	O
similar	O
to	O
the	O
C	O
.	O
elegans	O
NMD	O
factors	O
.	O

Results	O
indicate	O
that	O
hSmg5	O
/	O
7a	O
functions	O
in	O
the	O
dephosphorylation	O
of	O
Upf1	O
.	O

Furthermore	O
,	O
hSmg5	O
/	O
7a	O
copurifies	O
with	O
Upf1	O
,	O
Upf2	O
,	O
Upf3X	O
,	O
Smg1	O
,	O
and	O
the	O
catalytic	O
subunit	O
of	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
.	O

We	O
also	O
demonstrate	O
that	O
Upf2	O
,	O
another	O
factor	O
involved	O
in	O
NMD	O
,	O
is	O
a	O
phosphoprotein	O
.	O

However	O
,	O
hSmg5	O
/	O
7a	O
plays	O
no	O
role	O
in	O
the	O
dephosphorylation	O
of	O
Upf2	O
.	O

These	O
data	O
indicate	O
that	O
hSmg5	O
/	O
7a	O
targets	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
to	O
Upf1	O
but	O
not	O
Upf2	O
.	O

Results	O
of	O
Western	O
blotting	O
reveal	O
that	O
hSmg5	O
/	O
7a	O
is	O
mostly	O
cytoplasmic	O
in	O
HEK293T	O
cells	O
.	O

Structure	O
and	O
ubiquitin	O
interactions	O
of	O
the	O
conserved	O
zinc	O
finger	O
domain	O
of	O
Npl4	O
.	O

Ubiquitylated	O
proteins	O
are	O
directed	O
into	O
a	O
large	O
number	O
of	O
different	O
cellular	O
pathways	O
through	O
interactions	O
with	O
effector	O
proteins	O
that	O
contain	O
conserved	O
ubiquitin	O
binding	O
motifs	O
.	O

Here	O
,	O
we	O
report	O
the	O
solution	O
structure	O
and	O
ubiquitin	O
binding	O
properties	O
of	O
one	O
such	O
motif	O
,	O
the	O
Npl4	O
zinc	O
finger	O
or	O
RanBP2	O
/	O
Nup358	O
zinc	O
finger	O
(	O
NZF	O
)	O
domain	O
.	O

Npl4	O
NZF	O
forms	O
a	O
compact	O
module	O
composed	O
of	O
four	O
antiparallel	O
beta	O
-	O
strands	O
linked	O
by	O
three	O
ordered	O
loops	O
.	O

A	O
single	O
zinc	O
ion	O
is	O
coordinated	O
by	O
four	O
conserved	O
cysteines	O
from	O
the	O
first	O
and	O
third	O
loops	O
,	O
which	O
form	O
two	O
rubredoxin	O
knuckles	O
.	O

Npl4	O
NZF	O
binds	O
specifically	O
,	O
but	O
weakly	O
,	O
to	O
free	O
ubiquitin	O
using	O
a	O
conserved	O
13TF14	O
dipeptide	O
to	O
interact	O
with	O
the	O
"	O
Ile	O
-	O
44	O
"	O
surface	O
of	O
ubiquitin	O
.	O

Our	O
studies	O
reveal	O
the	O
structure	O
of	O
this	O
versatile	O
class	O
of	O
protein	O
binding	O
domains	O
and	O
provide	O
a	O
means	O
for	O
identifying	O
the	O
subset	O
of	O
NZF	O
domains	O
likely	O
to	O
bind	O
ubiquitin	O
.	O

BMAL1	O
-	O
dependent	O
circadian	O
oscillation	O
of	O
nuclear	O
CLOCK	O
:	O
posttranslational	O
events	O
induced	O
by	O
dimerization	O
of	O
transcriptional	O
activators	O
of	O
the	O
mammalian	O
clock	O
system	O
.	O

Mammalian	O
CLOCK	O
and	O
BMAL1	O
are	O
two	O
members	O
of	O
bHLH	O
-	O
PAS	O
-	O
containing	O
family	O
of	O
transcription	O
factors	O
that	O
represent	O
the	O
positive	O
elements	O
of	O
circadian	O
autoregulatory	O
feedback	O
loop	O
.	O

In	O
the	O
form	O
of	O
a	O
heterodimer	O
,	O
they	O
drive	O
transcription	O
from	O
E	O
-	O
box	O
enhancer	O
elements	O
in	O
the	O
promoters	O
of	O
responsive	O
genes	O
.	O

We	O
have	O
examined	O
abundance	O
,	O
posttranslational	O
modifications	O
,	O
cellular	O
localization	O
of	O
endogenous	O
and	O
ectopically	O
expressed	O
CLOCK	O
and	O
BMAL1	O
proteins	O
.	O

Nuclear	O
/	O
cytoplasm	O
distribution	O
of	O
CLOCK	O
was	O
found	O
to	O
be	O
under	O
circadian	O
regulation	O
.	O

Analysis	O
of	O
subcellular	O
localization	O
of	O
CLOCK	O
in	O
embryo	O
fibroblasts	O
of	O
mice	O
carrying	O
different	O
germ	O
-	O
line	O
circadian	O
mutations	O
showed	O
that	O
circadian	O
regulation	O
of	O
nuclear	O
accumulation	O
of	O
CLOCK	O
is	O
BMAL1	O
-	O
dependent	O
.	O

Formation	O
of	O
CLOCK	O
/	O
BMAL1	O
complex	O
following	O
ectopic	O
coexpression	O
of	O
both	O
proteins	O
is	O
followed	O
by	O
their	O
codependent	O
phosphorylation	O
,	O
which	O
is	O
tightly	O
coupled	O
to	O
CLOCK	O
nuclear	O
translocation	O
and	O
degradation	O
.	O

This	O
binding	O
-	O
dependent	O
coregulation	O
is	O
specific	O
for	O
CLOCK	O
/	O
BMAL1	O
interaction	O
,	O
as	O
no	O
other	O
PAS	O
domain	O
protein	O
that	O
can	O
form	O
a	O
complex	O
with	O
either	O
CLOCK	O
or	O
BMAL1	O
was	O
able	O
to	O
induce	O
similar	O
effects	O
.	O

Importantly	O
,	O
all	O
posttranslational	O
events	O
described	O
in	O
our	O
study	O
are	O
coupled	O
with	O
active	O
transactivation	O
complex	O
formation	O
,	O
which	O
argues	O
for	O
their	O
significant	O
functional	O
role	O
.	O

Altogether	O
,	O
these	O
results	O
provide	O
evidence	O
for	O
an	O
additional	O
level	O
of	O
circadian	O
system	O
control	O
,	O
which	O
is	O
based	O
on	O
regulation	O
of	O
transcriptional	O
activity	O
or	O
/	O
and	O
availability	O
of	O
CLOCK	O
/	O
BMAL1	O
complex	O
.	O

A	O
ubiquitous	O
splice	O
variant	O
and	O
a	O
common	O
polymorphism	O
affect	O
heterologous	O
expression	O
of	O
recombinant	O
human	O
SCN5A	O
heart	O
sodium	O
channels	O
.	O

Amino	O
acid	O
sequence	O
variations	O
in	O
SCN5A	O
are	O
known	O
to	O
affect	O
function	O
of	O
wild	O
-	O
type	O
channels	O
and	O
also	O
those	O
with	O
coexisting	O
mutations	O
;	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
the	O
exact	O
sequence	O
and	O
function	O
of	O
channels	O
most	O
commonly	O
present	O
in	O
human	O
myocardium	O
.	O

SCN5A	O
was	O
analyzed	O
in	O
control	O
panels	O
of	O
human	O
alleles	O
,	O
demonstrating	O
that	O
the	O
existing	O
clones	O
(	O
hH1	O
,	O
hH1a	O
,	O
hH1b	O
)	O
each	O
contained	O
a	O
rare	O
variant	O
and	O
thus	O
none	O
represented	O
the	O
common	O
sequence	O
.	O

Confirming	O
prior	O
work	O
,	O
the	O
H558R	O
polymorphism	O
was	O
present	O
in	O
approximately	O
30	O
%	O
of	O
subjects	O
.	O

Quantitative	O
mRNA	O
analysis	O
from	O
human	O
hearts	O
showed	O
that	O
a	O
shorter	O
2015	O
amino	O
acid	O
splice	O
variant	O
lacking	O
glutamine	O
at	O
position	O
1077	O
(	O
Q1077del	O
)	O
made	O
up	O
65	O
%	O
of	O
the	O
transcript	O
in	O
every	O
heart	O
examined	O
.	O

Age	O
,	O
sex	O
,	O
race	O
,	O
or	O
structural	O
heart	O
disease	O
did	O
not	O
affect	O
this	O
proportion	O
of	O
Q1077del	O
.	O

Estimated	O
population	O
frequencies	O
for	O
the	O
four	O
common	O
variants	O
were	O
25	O
%	O
SCN5A	O
,	O
10	O
%	O
[	O
H558R	O
]	O
,	O
45	O
%	O
[	O
Q1077del	O
]	O
,	O
and	O
20	O
%	O
[	O
H558R	O
;	O
Q1077del	O
]	O
,	O
where	O
the	O
reference	O
sequence	O
SCN5A	O
is	O
GenBank	O
AC137587	O
.	O

When	O
expressed	O
in	O
HEK	O
-	O
293	O
cells	O
,	O
these	O
common	O
variants	O
had	O
a	O
more	O
positive	O
mid	O
-	O
point	O
of	O
the	O
voltage	O
dependence	O
of	O
inactivation	O
than	O
the	O
standard	O
clone	O
hH1	O
.	O

Also	O
,	O
channels	O
containing	O
Q1077	O
expressed	O
smaller	O
currents	O
.	O

When	O
H558R	O
was	O
present	O
with	O
Q1077	O
(	O
[	O
H558R	O
]	O
)	O
,	O
current	O
expression	O
was	O
profoundly	O
reduced	O
despite	O
normal	O
trafficking	O
to	O
the	O
cell	O
surface	O
.	O

Thus	O
,	O
four	O
variant	O
sequences	O
for	O
SCN5A	O
are	O
commonly	O
present	O
in	O
human	O
myocardium	O
and	O
they	O
exhibit	O
functional	O
differences	O
among	O
themselves	O
and	O
with	O
the	O
previous	O
standard	O
clone	O
.	O

These	O
results	O
have	O
implications	O
for	O
the	O
choice	O
of	O
background	O
sequence	O
for	O
experiments	O
with	O
heterologous	O
expression	O
systems	O
,	O
and	O
possibly	O
implications	O
for	O
electrophysiological	O
function	O
in	O
vivo	O
.	O

Pse1p	O
mediates	O
the	O
nuclear	O
import	O
of	O
the	O
iron	O
-	O
responsive	O
transcription	O
factor	O
Aft1p	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
iron	O
-	O
responsive	O
transcription	O
factor	O
Aft1p	O
plays	O
a	O
critical	O
role	O
in	O
maintaining	O
iron	O
homeostasis	O
.	O

The	O
activity	O
of	O
Aft1p	O
is	O
induced	O
in	O
response	O
to	O
iron	O
starvation	O
and	O
as	O
a	O
consequence	O
the	O
expression	O
of	O
the	O
iron	O
-	O
regulon	O
is	O
increased	O
.	O

We	O
have	O
shown	O
previously	O
that	O
Aft1p	O
is	O
localized	O
to	O
the	O
cytoplasm	O
under	O
iron	O
-	O
replete	O
conditions	O
but	O
that	O
it	O
is	O
localized	O
to	O
the	O
nucleus	O
under	O
iron	O
-	O
depleted	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
the	O
transport	O
receptor	O
that	O
mediates	O
the	O
import	O
of	O
Aft1p	O
into	O
the	O
nucleus	O
,	O
located	O
the	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
sequences	O
of	O
Aft1p	O
,	O
and	O
examined	O
whether	O
the	O
nuclear	O
import	O
of	O
Aft1p	O
is	O
affected	O
by	O
iron	O
status	O
.	O

In	O
pse1	O
-	O
1	O
cells	O
,	O
which	O
bear	O
a	O
temperature	O
-	O
sensitive	O
mutation	O
of	O
PSE1	O
,	O
Aft1p	O
was	O
misdirected	O
to	O
the	O
cytoplasm	O
during	O
iron	O
starvation	O
at	O
the	O
restrictive	O
temperature	O
.	O

Aft1p	O
could	O
also	O
directly	O
bind	O
to	O
Pse1p	O
and	O
was	O
dissociated	O
from	O
the	O
complex	O
by	O
Ran	O
-	O
GTP	O
in	O
vitro	O
.	O

These	O
results	O
indicate	O
that	O
Aft1p	O
is	O
imported	O
into	O
the	O
nucleus	O
by	O
Pse1p	O
.	O

Supporting	O
this	O
is	O
that	O
the	O
induction	O
of	O
an	O
Aft1p	O
target	O
gene	O
,	O
FTR1	O
,	O
in	O
response	O
to	O
iron	O
starvation	O
was	O
greatly	O
reduced	O
in	O
pse1	O
-	O
1	O
cells	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
nuclear	O
localization	O
of	O
a	O
mutant	O
Aft1	O
protein	O
that	O
contains	O
an	O
NLS	O
derived	O
from	O
SV40	O
was	O
regulated	O
by	O
iron	O
status	O
regardless	O
of	O
whether	O
Pse1p	O
could	O
interact	O
with	O
Aft1p	O
.	O

This	O
suggests	O
that	O
the	O
interaction	O
between	O
Aft1p	O
and	O
Pse1p	O
is	O
not	O
a	O
critical	O
step	O
that	O
controls	O
the	O
iron	O
-	O
regulated	O
nucleo	O
-	O
cytoplasmic	O
transport	O
of	O
Aft1p	O
.	O

The	O
redox	O
domain	O
of	O
the	O
Yap1p	O
transcription	O
factor	O
contains	O
two	O
disulfide	O
bonds	O
.	O

The	O
subcellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
transcription	O
factor	O
Yap1p	O
is	O
regulated	O
by	O
oxidation	O
and	O
reduction	O
.	O

We	O
purified	O
Yap1p	O
from	O
yeast	O
and	O
characterized	O
its	O
properties	O
in	O
vitro	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
purified	O
protein	O
can	O
specifically	O
bind	O
the	O
TRX2	O
target	O
promoter	O
.	O

Yap1p	O
was	O
purified	O
under	O
reducing	O
conditions	O
,	O
but	O
removal	O
of	O
reducing	O
agents	O
resulted	O
in	O
the	O
formation	O
of	O
an	O
oxidized	O
Yap1p	O
species	O
with	O
properties	O
similar	O
to	O
in	O
vivo	O
oxidized	O
Yap1p	O
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
the	O
oxidized	O
form	O
of	O
Yap1p	O
contains	O
two	O
disulfide	O
bonds	O
between	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
.	O

A	O
stable	O
domain	O
of	O
approximately	O
15	O
kDa	O
was	O
detected	O
upon	O
limited	O
proteolysis	O
of	O
oxidized	O
but	O
not	O
reduced	O
Yap1p	O
.	O

This	O
Yap1p	O
protease	O
resistant	O
domain	O
was	O
purified	O
,	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
showed	O
that	O
it	O
was	O
comprised	O
of	O
two	O
separate	O
cysteine	O
-	O
containing	O
peptides	O
of	O
Yap1p	O
.	O

These	O
peptides	O
are	O
separated	O
by	O
250	O
amino	O
acids	O
and	O
are	O
joined	O
by	O
the	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
disulfide	O
bonds	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
domain	O
that	O
controls	O
Yap1p	O
subcellular	O
localization	O
is	O
modular	O
and	O
contains	O
a	O
redox	O
center	O
comprised	O
of	O
four	O
cysteine	O
residues	O
.	O

Characterization	O
of	O
OSR1	O
,	O
a	O
member	O
of	O
the	O
mammalian	O
Ste20p	O
/	O
germinal	O
center	O
kinase	O
subfamily	O
.	O

In	O
examining	O
the	O
protein	O
kinase	O
components	O
of	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
(	O
MAPK	O
)	O
cascades	O
that	O
regulate	O
the	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
in	O
Drosophila	O
S2	O
cells	O
,	O
we	O
previously	O
found	O
that	O
distinct	O
upstream	O
kinases	O
were	O
involved	O
in	O
responses	O
to	O
sorbitol	O
and	O
lipopolysaccharide	O
.	O

Here	O
we	O
have	O
extended	O
that	O
analysis	O
to	O
the	O
possible	O
MAPK	O
kinase	O
kinase	O
kinases	O
(	O
MAP4Ks	O
)	O
in	O
the	O
JNK	O
pathway	O
.	O

Fray	O
,	O
a	O
putative	O
Drosophila	O
MAP4K	O
,	O
provided	O
a	O
major	O
contribution	O
to	O
JNK	O
activation	O
by	O
sorbitol	O
.	O

To	O
explore	O
the	O
possible	O
link	O
to	O
JNK	O
in	O
mammalian	O
cells	O
,	O
we	O
isolated	O
and	O
characterized	O
OSR1	O
(	O
oxidative	O
stress	O
-	O
responsive	O
1	O
)	O
,	O
one	O
of	O
two	O
human	O
Fray	O
homologs	O
.	O

OSR1	O
is	O
a	O
58	O
-	O
kDa	O
protein	O
of	O
527	O
amino	O
acids	O
that	O
is	O
widely	O
expressed	O
in	O
mammalian	O
tissues	O
and	O
cell	O
lines	O
.	O

Of	O
potential	O
regulators	O
surveyed	O
,	O
endogenous	O
OSR1	O
is	O
activated	O
only	O
by	O
osmotic	O
stresses	O
,	O
notably	O
sorbitol	O
and	O
to	O
a	O
lesser	O
extent	O
NaCl	O
.	O

However	O
,	O
OSR1	O
did	O
not	O
increase	O
the	O
activity	O
of	O
coexpressed	O
JNK	O
,	O
nor	O
did	O
it	O
activate	O
three	O
other	O
MAPKs	O
,	O
p38	O
,	O
ERK2	O
,	O
and	O
ERK5	O
.	O

A	O
two	O
-	O
hybrid	O
screen	O
implicated	O
another	O
Ste20p	O
family	O
member	O
,	O
the	O
p21	O
-	O
activated	O
protein	O
kinase	O
PAK1	O
,	O
as	O
an	O
OSR1	O
target	O
.	O

OSR1	O
phosphorylated	O
threonine	O
84	O
in	O
the	O
N	O
-	O
terminal	O
regulatory	O
domain	O
of	O
PAK1	O
.	O

Replacement	O
of	O
threonine	O
84	O
with	O
glutamate	O
reduced	O
the	O
activation	O
of	O
PAK1	O
by	O
an	O
active	O
form	O
of	O
the	O
small	O
G	O
protein	O
Cdc42	O
,	O
suggesting	O
that	O
phosphorylation	O
by	O
OSR1	O
modulates	O
the	O
G	O
protein	O
sensitivity	O
of	O
PAK	O
isoforms	O
.	O

(	O
A	O
and	O
B	O
)	O
Lefty1	O
interacts	O
with	O
Cripto	O
.	O

RNAs	O
(	O
1	O
ng	O
each	O
)	O
encoding	O
ActRIIB	O
(	O
KR	O
)	O
/	O
Myc	O
,	O
Alk4	O
(	O
KR	O
)	O
/	O
Flag	O
,	O
Cripto	O
/	O
Flag	O
,	O
Lefty1	O
/	O
HA	O
,	O
or	O
Sqt	O
/	O
HA	O
were	O
injected	O
into	O
Xenopus	O
embryos	O
.	O

After	O
chemical	O
cross	O
-	O
linking	O
,	O
lysates	O
were	O
immunoprecipitated	O
for	O
either	O
Lefty1	O
/	O
HA	O
or	O
Sqt	O
/	O
HA	O
(	O
A	O
)	O
with	O
anti	O
-	O
HA	O
antibody	O
,	O
or	O
ActRIIB	O
(	O
KR	O
)	O
/	O
Myc	O
,	O
Alk4	O
(	O
KR	O
)	O
/	O
HA	O
,	O
Cripto	O
/	O
Flag	O
(	O
B	O
)	O
with	O
,	O
respectively	O
,	O
anti	O
-	O
Myc	O
,	O
anti	O
-	O
HA	O
,	O
or	O
anti	O
-	O
Flag	O
antibodies	O
.	O

Note	O
that	O
Lefty1	O
specifically	O
interacts	O
with	O
Cripto	O
(	O
A	O
and	O
B	O
)	O
,	O
and	O
these	O
Lefty	O
/	O
Cripto	O
complexes	O
do	O
not	O
contain	O
Alk4	O
(	O
A	O
)	O
.	O

Moreover	O
,	O
processed	O
Lefty1	O
binds	O
much	O
more	O
efficiently	O
to	O
Cripto	O
than	O
full	O
-	O
length	O
Lefty1	O
precursor	O
(	O
B	O
)	O
.	O

In	O
contrast	O
,	O
Sqt	O
can	O
bind	O
to	O
ActRIIB	O
,	O
Alk4	O
,	O
and	O
Cripto	O
(	O
A	O
)	O
.	O

The	O
55	O
kDa	O
protein	O
marker	O
in	O
(	O
B	O
)	O
is	O
estimated	O
based	O
on	O
molecular	O
weight	O
markers	O
.	O

HtrA1	O
serine	O
protease	O
inhibits	O
signaling	O
mediated	O
by	O
Tgfbeta	O
family	O
proteins	O
.	O

HtrA1	O
,	O
a	O
member	O
of	O
the	O
mammalian	O
HtrA	O
serine	O
protease	O
family	O
,	O
has	O
a	O
highly	O
conserved	O
protease	O
domain	O
followed	O
by	O
a	O
PDZ	O
domain	O
.	O

Because	O
HtrA1	O
is	O
a	O
secretory	O
protein	O
and	O
has	O
another	O
functional	O
domain	O
with	O
homology	O
to	O
follistatin	O
,	O
we	O
examined	O
whether	O
HtrA1	O
functions	O
as	O
an	O
antagonist	O
of	O
Tgfbeta	O
family	O
proteins	O
.	O

During	O
embryo	O
development	O
,	O
mouse	O
HtrA1	O
was	O
expressed	O
in	O
specific	O
areas	O
where	O
signaling	O
by	O
Tgfbeta	O
family	O
proteins	O
plays	O
important	O
regulatory	O
roles	O
.	O

The	O
GST	O
-	O
pulldown	O
assay	O
showed	O
that	O
HtrA1	O
binds	O
to	O
a	O
broad	O
range	O
of	O
Tgfbeta	O
family	O
proteins	O
,	O
including	O
Bmp4	O
,	O
Gdf5	O
,	O
Tgfbetas	O
and	O
activin	O
.	O

HtrA1	O
inhibited	O
signaling	O
by	O
Bmp4	O
,	O
Bmp2	O
,	O
and	O
Tgfbeta1	O
in	O
C2C12	O
cells	O
,	O
presumably	O
by	O
preventing	O
receptor	O
activation	O
.	O

Experiments	O
using	O
a	O
series	O
of	O
deletion	O
mutants	O
indicated	O
that	O
the	O
binding	O
activity	O
of	O
HtrA1	O
required	O
the	O
protease	O
domain	O
and	O
a	O
small	O
linker	O
region	O
preceding	O
it	O
,	O
and	O
that	O
inhibition	O
of	O
Tgfbeta	O
signaling	O
is	O
dependent	O
on	O
the	O
proteolytic	O
activity	O
of	O
HtrA1	O
.	O

Misexpression	O
of	O
HtrA1	O
near	O
the	O
developing	O
chick	O
eye	O
led	O
to	O
suppression	O
of	O
eye	O
development	O
that	O
was	O
indistinguishable	O
from	O
the	O
effects	O
of	O
noggin	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
HtrA1	O
protease	O
is	O
a	O
novel	O
inhibitor	O
of	O
Tgfbeta	O
family	O
members	O
.	O

Suv39h	O
histone	B-OOS
methyltransferases	I-OOS
interact	O
with	O
Smads	O
and	O
cooperate	O
in	O
BMP	O
-	O
induced	O
repression	O
.	O

Smad	O
proteins	O
transduce	O
signals	O
from	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
superfamily	O
ligands	O
to	O
regulate	O
the	O
expression	O
of	O
target	O
genes	O
.	O

In	O
order	O
to	O
identify	O
novel	O
partners	O
of	O
Smad	O
proteins	O
in	O
transcriptional	O
regulation	O
,	O
we	O
performed	O
a	O
two	O
-	O
hybrid	O
screen	O
using	O
Smad5	O
,	O
a	O
protein	O
that	O
is	O
activated	O
predominantly	O
by	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
signaling	O
.	O

We	O
identified	O
an	O
interaction	O
between	O
Smad5	O
and	O
suppressor	O
of	O
variegation	O
3	O
-	O
9	O
homolog	O
2	O
(	O
Suv39h2	O
)	O
,	O
a	O
chromatin	O
modifier	O
enzyme	O
.	O

Suv39h	O
proteins	O
are	O
histone	B-OOS
methyltransferases	I-OOS
that	O
methylate	O
histone	O
H3	O
on	O
lysine	O
9	O
,	O
resulting	O
in	O
transcriptional	O
repression	O
or	O
silencing	O
of	O
target	O
genes	O
.	O

Biochemical	O
studies	O
in	O
mammalian	O
cells	O
demonstrated	O
that	O
Smad5	O
binds	O
to	O
both	O
known	O
mammalian	O
isoforms	O
of	O
Suv39h	O
proteins	O
,	O
and	O
that	O
Smad	O
proteins	O
activated	O
by	O
the	O
TGF	O
-	O
beta	O
signaling	O
pathway	O
,	O
Smad2	O
and	O
Smad3	O
,	O
do	O
not	O
bind	O
with	O
significant	O
affinity	O
.	O

Functional	O
studies	O
using	O
the	O
muscle	O
creatine	O
kinase	O
(	O
MCK	O
)	O
promoter	O
,	O
which	O
is	O
suppressed	O
by	O
BMP	O
signaling	O
,	O
demonstrate	O
that	O
Suv39h	O
proteins	O
and	O
Smads	O
cooperate	O
to	O
repress	O
promoter	O
activity	O
.	O

These	O
data	O
suggest	O
a	O
model	O
where	O
association	O
of	O
Smad	O
proteins	O
with	O
Suv39h	O
methyltransferases	O
can	O
repress	O
or	O
silence	O
genes	O
involved	O
in	O
developmental	O
processes	O
,	O
and	O
argues	O
that	O
inefficient	O
gene	O
repression	O
may	O
result	O
in	O
the	O
alteration	O
of	O
the	O
differentiated	O
phenotype	O
.	O

Thus	O
,	O
examination	O
of	O
the	O
Smad	O
-	O
Suv	O
interaction	O
may	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
phenotypic	O
determination	O
mediated	O
by	O
BMP	O
signaling	O
.	O

Role	O
of	O
the	O
isoprenyl	O
pocket	O
of	O
the	O
G	B-OOS
protein	I-OOS
beta	I-OOS
gamma	I-OOS
subunit	O
complex	O
in	O
the	O
binding	O
of	O
phosducin	O
and	O
phosducin	O
-	O
like	O
protein	O
.	O

Phosducin	O
(	O
Pdc	O
)	O
and	O
phosducin	O
-	O
like	O
protein	O
(	O
PhLP	O
)	O
regulate	O
G	O
protein	O
-	O
mediated	O
signaling	O
by	O
binding	O
to	O
the	O
betagamma	B-OOS
subunit	O
complex	O
of	O
heterotrimeric	O
G	O
proteins	O
(	O
Gbetagamma	B-Complex
)	O
and	O
removing	O
the	O
dimer	O
from	O
cell	O
membranes	O
.	O

The	O
binding	O
of	O
Pdc	O
induces	O
a	O
conformational	O
change	O
in	O
the	O
beta	O
-	O
propeller	O
structure	O
of	O
Gbetagamma	B-OOS
,	O
creating	O
a	O
pocket	O
between	O
blades	O
6	O
and	O
7	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
isoprenyl	O
group	O
of	O
Gbetagamma	B-OOS
inserts	O
into	O
this	O
pocket	O
,	O
stabilizing	O
the	O
Pdc	O
.	O
Gbetagamma	B-OOS
structure	O
and	O
decreasing	O
the	O
affinity	O
of	O
the	O
complex	O
for	O
the	O
lipid	O
bilayer	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
binding	O
of	O
Pdc	O
and	O
PhLP	O
to	O
several	O
Gbetagamma	B-OOS
dimers	O
containing	O
variants	O
of	O
the	O
beta	O
or	O
gamma	O
subunit	O
was	O
measured	O
.	O

These	O
variants	O
included	O
modifications	O
of	O
the	O
isoprenyl	O
group	O
(	O
gamma	O
)	O
,	O
residues	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
beta	O
)	O
,	O
and	O
residues	O
lining	O
the	O
proposed	O
prenyl	O
pocket	O
(	O
beta	O
)	O
.	O

Switching	O
prenyl	O
groups	O
from	O
farnesyl	O
to	O
geranylgeranyl	O
or	O
vice	O
versa	O
had	O
little	O
effect	O
on	O
binding	O
.	O

However	O
,	O
alanine	O
substitution	O
of	O
one	O
residue	O
in	O
the	O
beta	O
subunit	O
involved	O
in	O
the	O
conformational	O
change	O
(	O
W332	O
)	O
decreased	O
binding	O
5	O
-	O
fold	O
.	O

Alanine	O
substitution	O
of	O
certain	O
residues	O
within	O
the	O
prenyl	O
pocket	O
caused	O
only	O
minor	O
decreases	O
in	O
binding	O
,	O
while	O
a	O
lysine	O
substitution	O
of	O
T329	O
within	O
the	O
pocket	O
inhibited	O
binding	O
10	O
-	O
fold	O
.	O

Molecular	O
modeling	O
of	O
the	O
binding	O
energy	O
of	O
the	O
Pdc	O
.	O
Gbeta	B-OOS
(	I-OOS
1	I-OOS
)	I-OOS
gamma	I-OOS
(	I-OOS
2	I-OOS
)	I-OOS
complex	O
required	O
insertion	O
of	O
the	O
geranylgeranyl	O
group	O
into	O
the	O
prenyl	O
pocket	O
in	O
order	O
to	O
accurately	O
predict	O
the	O
effects	O
of	O
prenyl	O
pocket	O
amino	O
acid	O
substitutions	O
.	O

Finally	O
,	O
a	O
dimer	O
containing	O
a	O
gamma	O
subunit	O
with	O
no	O
prenyl	O
group	O
(	O
gamma	O
(	O
2	O
)	O
-	O
C68S	O
)	O
decreased	O
binding	O
by	O
nearly	O
20	O
-	O
fold	O
.	O

These	O
results	O
support	O
the	O
structural	O
model	O
in	O
which	O
the	O
prenyl	O
group	O
escapes	O
contact	O
with	O
the	O
aqueous	O
milieu	O
by	O
inserting	O
into	O
the	O
prenyl	O
pocket	O
and	O
stabilizing	O
the	O
Pdc	O
-	O
binding	O
conformation	O
of	O
Gbetagamma	B-OOS
.	O

Menin	O
is	O
required	O
for	O
bone	O
morphogenetic	O
protein	O
2	O
-	O
and	O
transforming	O
growth	O
factor	O
beta	O
-	O
regulated	O
osteoblastic	O
differentiation	O
through	O
interaction	O
with	O
Smads	O
and	O
Runx2	O
.	O

Menin	O
,	O
the	O
product	O
of	O
the	O
multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	O
)	O
gene	O
,	O
is	O
required	O
for	O
commitment	O
of	O
multipotential	O
mesenchymal	O
stem	O
cells	O
to	O
the	O
osteoblast	O
lineage	O
,	O
however	O
,	O
it	O
inhibits	O
their	O
later	O
differentiation	O
(	O
Sowa	O
,	O
H	O
.	O
,	O
Kaji	O
,	O
H	O
.	O
,	O
Canaff	O
,	O
L	O
.	O
,	O
Hendy	O
,	O
G	O
.	O
N	O
.	O
,	O
Tsukamoto	O
,	O
T	O
.	O
,	O
Yamaguchi	O
,	O
T	O
.	O
,	O
Miyazono	O
,	O
K	O
.	O
,	O
Sugimoto	O
,	O
T	O
.	O
,	O
and	O
Chihara	O
,	O
K	O
.	O
(	O
2003	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
278	O
,	O
21058	O
-	O
21069	O
)	O
.	O

Here	O
,	O
we	O
have	O
examined	O
the	O
mechanism	O
of	O
action	O
of	O
menin	O
in	O
regulating	O
osteoblast	O
differentiation	O
using	O
the	O
mouse	O
bone	O
marrow	O
stromal	O
ST2	O
and	O
osteoblast	O
MC3T3	O
-	O
E1	O
cell	O
lines	O
.	O

In	O
ST2	O
cells	O
,	O
reduced	O
menin	O
expression	O
achieved	O
by	O
transfection	O
of	O
menin	O
antisense	O
DNA	O
(	O
AS	O
)	O
antagonized	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
-	O
2	O
-	O
induced	O
alkaline	O
phosphatase	O
activity	O
and	O
osteocalcin	O
and	O
Runx2	O
mRNA	O
expression	O
.	O

Menin	O
was	O
co	O
-	O
immunoprecipitated	O
with	O
Smad1	O
/	O
5	O
in	O
ST2	O
and	O
MC3T3	O
-	O
E1	O
cells	O
,	O
and	O
inactivation	O
of	O
menin	O
antagonized	O
BMP	O
-	O
2	O
-	O
induced	O
transcriptional	O
activity	O
of	O
Smad1	O
/	O
5	O
in	O
ST2	O
cells	O
,	O
but	O
not	O
MC3T3	O
-	O
E1	O
cells	O
.	O

Menin	O
was	O
co	O
-	O
immunoprecipitated	O
with	O
the	O
key	O
osteoblast	O
regulator	O
,	O
Runx2	O
,	O
and	O
AS	O
antagonized	O
Runx2	O
transcriptional	O
activity	O
and	O
the	O
ability	O
of	O
Runx2	O
to	O
stimulate	O
alkaline	O
phosphatase	O
activity	O
only	O
in	O
ST2	O
cells	O
but	O
not	O
in	O
MC3T3	O
-	O
E1	O
cells	O
.	O

In	O
the	O
osteoblast	O
MC3T3	O
-	O
E1	O
cells	O
,	O
transforming	O
growth	O
factor	O
-	O
beta	O
and	O
its	O
signaling	O
molecule	O
,	O
Smad3	O
,	O
negatively	O
regulated	O
Runx2	O
transcriptional	O
activity	O
.	O

Menin	O
and	O
Smad3	O
were	O
co	O
-	O
immunoprecipitated	O
,	O
and	O
combined	O
menin	O
and	O
Smad3	O
overexpression	O
antagonized	O
,	O
whereas	O
menin	O
and	O
the	O
dominant	O
-	O
negative	O
Smad3DeltaC	O
together	O
enhanced	O
BMP	O
-	O
2	O
-	O
induced	O
transcriptional	O
activity	O
of	O
Smad1	O
/	O
5	O
and	O
Runx2	O
.	O

Smad3	O
alone	O
had	O
no	O
effect	O
.	O

Therefore	O
,	O
menin	O
interacts	O
physically	O
and	O
functionally	O
with	O
Runx2	O
in	O
uncommitted	O
mesenchymal	O
stem	O
cells	O
,	O
but	O
not	O
in	O
well	O
differentiated	O
osteoblasts	O
.	O

In	O
osteoblasts	O
the	O
interaction	O
of	O
menin	O
and	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
/	O
Smad3	O
pathway	O
negatively	O
regulates	O
the	O
BMP	O
-	O
2	O
/	O
Smad1	O
/	O
5	O
-	O
and	O
Runx2	O
-	O
induced	O
transcriptional	O
activities	O
leading	O
to	O
inhibition	O
of	O
late	O
-	O
stage	O
differentiation	O
.	O

3D	O
structure	O
of	O
human	O
FK506	O
-	O
binding	O
protein	O
52	O
:	O
implications	O
for	O
the	O
assembly	O
of	O
the	O
glucocorticoid	O
receptor	O
/	O
Hsp90	O
/	O
immunophilin	O
heterocomplex	O
.	O

FK506	O
-	O
binding	O
protein	O
52	O
(	O
FKBP52	O
)	O
,	O
which	O
binds	O
FK506	O
and	O
possesses	O
peptidylprolyl	O
isomerase	O
activity	O
,	O
is	O
an	O
important	O
immunophilin	O
involved	O
in	O
the	O
heterocomplex	O
of	O
steroid	O
receptors	O
with	O
heat	O
-	O
shock	O
protein	O
90	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structures	O
of	O
two	O
overlapped	O
fragments	O
[	O
N	O
(	O
1	O
-	O
260	O
)	O
and	O
C	O
(	O
145	O
-	O
459	O
)	O
]	O
of	O
FKBP52	O
and	O
the	O
complex	O
with	O
a	O
C	O
-	O
terminal	O
pentapeptide	O
from	O
heat	O
-	O
shock	O
protein	O
90	O
.	O

Based	O
on	O
the	O
structures	O
of	O
these	O
two	O
overlapped	O
fragments	O
,	O
the	O
complete	O
putative	O
structure	O
of	O
FKBP52	O
can	O
be	O
defined	O
.	O

The	O
structure	O
of	O
FKBP52	O
is	O
composed	O
of	O
two	O
consecutive	O
FKBP	O
domains	O
,	O
a	O
tetratricopeptide	O
repeat	O
domain	O
and	O
a	O
short	O
helical	O
domain	O
beyond	O
the	O
final	O
tetratricopeptide	O
repeat	O
motif	O
.	O

Key	O
structural	O
differences	O
between	O
FKBP52	O
and	O
FKBP51	O
,	O
including	O
the	O
relative	O
orientations	O
of	O
the	O
four	O
domains	O
and	O
some	O
important	O
residue	O
substitutions	O
,	O
could	O
account	O
for	O
the	O
differential	O
functions	O
of	O
FKBPs	O
.	O

The	O
MKK2	O
pathway	O
mediates	O
cold	O
and	O
salt	O
stress	O
signaling	O
in	O
Arabidopsis	O
.	O

The	O
Arabidopsis	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
kinase	O
2	O
(	O
MKK2	O
)	O
and	O
the	O
downstream	O
MAPKs	O
MPK4	O
and	O
MPK6	O
were	O
isolated	O
by	O
functional	O
complementation	O
of	O
osmosensitive	O
yeast	O
mutants	O
.	O

In	O
Arabidopsis	O
protoplasts	O
,	O
MKK2	O
was	O
specifically	O
activated	O
by	O
cold	O
and	O
salt	O
stress	O
and	O
by	O
the	O
stress	O
-	O
induced	O
MAPK	O
kinase	O
kinase	O
MEKK1	O
.	O

Yeast	O
two	O
-	O
hybrid	O
,	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
protein	O
kinase	O
assays	O
revealed	O
that	O
MKK2	O
directly	O
targets	O
MPK4	O
and	O
MPK6	O
.	O

Accordingly	O
,	O
plants	O
overexpressing	O
MKK2	O
exhibited	O
constitutive	O
MPK4	O
and	O
MPK6	O
activity	O
,	O
constitutively	O
upregulated	O
expression	O
of	O
stress	O
-	O
induced	O
marker	O
genes	O
,	O
and	O
increased	O
freezing	O
and	O
salt	O
tolerance	O
.	O

In	O
contrast	O
,	O
mkk2	O
null	O
plants	O
were	O
impaired	O
in	O
MPK4	O
and	O
MPK6	O
activation	O
and	O
were	O
hypersensitive	O
to	O
salt	O
and	O
cold	O
stress	O
.	O

Full	O
genome	O
transcriptome	O
analysis	O
of	O
MKK2	O
-	O
overexpressing	O
plants	O
demonstrated	O
altered	O
expression	O
of	O
152	O
genes	O
involved	O
in	O
transcriptional	O
regulation	O
,	O
signal	O
transduction	O
,	O
cellular	O
defense	O
,	O
and	O
stress	O
metabolism	O
.	O

These	O
data	O
identify	O
a	O
MAP	O
kinase	O
signaling	O
cascade	O
mediating	O
cold	O
and	O
salt	O
stress	O
tolerance	O
in	O
plants	O
.	O

A	O
histone	B-OOS
methyltransferase	I-OOS
is	O
required	O
for	O
maximal	O
response	O
to	O
female	O
sex	O
hormones	O
.	O

RIZ1	O
is	O
an	O
estrogen	O
receptor	O
(	O
ER	O
)	O
coactivator	O
but	O
is	O
also	O
a	O
histone	O
lysine	O
methyltransferase	O
that	O
methylates	O
lysine	O
9	O
of	O
histone	O
H3	O
,	O
an	O
activity	O
known	O
to	O
repress	O
transcription	O
.	O

We	O
show	O
here	O
that	O
target	O
organs	O
of	O
mice	O
deficient	O
in	O
RIZ1	O
exhibit	O
decreased	O
response	O
to	O
female	O
sex	O
hormones	O
.	O

RIZ1	O
interacted	O
with	O
SRC1	O
and	O
p300	O
,	O
suggesting	O
that	O
the	O
coactivator	O
function	O
of	O
RIZ1	O
may	O
be	O
mediated	O
by	O
its	O
interaction	O
with	O
other	O
transcriptional	O
coactivators	O
.	O

In	O
the	O
presence	O
of	O
estrogen	O
,	O
RIZ1	O
binding	O
to	O
estrogen	O
target	O
genes	O
became	O
less	O
direct	O
and	O
followed	O
the	O
binding	O
of	O
ER	O
to	O
DNA	O
and	O
RIZ1	O
methyltransferase	O
activity	O
on	O
H3	O
-	O
Lys	O
9	O
was	O
inhibited	O
,	O
indicating	O
derepression	O
may	O
play	O
a	O
role	O
in	O
estrogen	O
induction	O
of	O
gene	O
transcription	O
.	O

Reducing	O
RIZ1	O
level	O
correlated	O
with	O
decreased	O
induction	O
of	O
pS2	O
gene	O
by	O
estrogen	O
in	O
MCF7	O
cells	O
.	O

The	O
data	O
suggest	O
that	O
a	O
histone	B-OOS
methyltransferase	I-OOS
is	O
required	O
for	O
optimal	O
estrogen	O
response	O
in	O
female	O
reproductive	O
tissues	O
and	O
that	O
estrogen	O
-	O
bound	O
ER	O
may	O
turn	O
a	O
transcriptional	O
repressor	O
into	O
a	O
coactivator	O
.	O

Ubiquitination	O
and	O
proteolysis	O
of	O
cancer	O
-	O
derived	O
Smad4	O
mutants	O
by	O
SCFSkp2	B-Complex
.	O

Smad4	O
/	O
DPC4	O
,	O
a	O
common	O
signal	O
transducer	O
in	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
signaling	O
,	O
is	O
frequently	O
inactivated	O
in	O
human	O
cancer	O
.	O

Although	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
has	O
been	O
established	O
as	O
one	O
mechanism	O
of	O
inactivating	O
Smad4	O
in	O
cancer	O
,	O
the	O
specific	O
ubiquitin	O
E3	O
ligase	O
for	O
ubiquitination	O
-	O
mediated	O
proteolysis	O
of	O
Smad4	O
cancer	O
mutants	O
remains	O
unclear	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
the	O
SCFSkp2	B-Complex
complex	O
as	O
candidate	O
Smad4	O
-	O
interacting	O
proteins	O
in	O
an	O
antibody	O
array	O
-	O
based	O
screen	O
and	O
further	O
elucidated	O
the	O
functions	O
of	O
SCFSkp2	B-Complex
in	O
mediating	O
the	O
metabolic	O
instability	O
of	O
cancer	O
-	O
derived	O
Smad4	O
mutants	O
.	O

We	O
found	O
that	O
Skp2	O
,	O
the	O
F	O
-	O
box	O
component	O
of	O
SCFSkp2	B-Complex
,	O
physically	O
interacted	O
with	O
Smad4	O
at	O
the	O
physiological	O
levels	O
.	O

Several	O
cancer	O
-	O
derived	O
unstable	O
mutants	O
exhibited	O
significantly	O
increased	O
binding	O
to	O
Skp2	O
,	O
which	O
led	O
to	O
their	O
increased	O
ubiquitination	O
and	O
accelerated	O
proteolysis	O
.	O

These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
the	O
SCFSkp2	B-Complex
complex	O
in	O
switching	O
cancer	O
mutants	O
of	O
Smad4	O
to	O
undergo	O
polyubiquitination	O
-	O
dependent	O
degradation	O
.	O

Drosophila	O
T	O
box	O
proteins	O
break	O
the	O
symmetry	O
of	O
hedgehog	O
-	O
dependent	O
activation	O
of	O
wingless	O
.	O

BACKGROUND	O
:	O
Segmentation	O
of	O
the	O
Drosophila	O
embryo	O
is	O
a	O
classic	O
paradigm	O
for	O
pattern	O
formation	O
during	O
development	O
.	O

The	O
Wnt	O
-	O
1	O
homolog	O
Wingless	O
(	O
Wg	O
)	O
is	O
a	O
key	O
player	O
in	O
the	O
establishment	O
of	O
a	O
segmentally	O
reiterated	O
pattern	O
of	O
cell	O
type	O
specification	O
.	O

The	O
intrasegmental	O
polarity	O
of	O
this	O
pattern	O
depends	O
on	O
the	O
precise	O
positioning	O
of	O
the	O
Wg	O
signaling	O
source	O
anterior	O
to	O
the	O
Engrailed	O
(	O
En	O
)	O
/	O
Hedgehog	O
(	O
Hh	O
)	O
domain	O
.	O

Proper	O
polarity	O
of	O
epidermal	O
segments	O
requires	O
an	O
asymmetric	O
response	O
to	O
the	O
bidirectional	O
Hh	O
signal	O
:	O
wg	O
is	O
activated	O
in	O
cells	O
anterior	O
to	O
the	O
Hh	O
signaling	O
source	O
and	O
is	O
restricted	O
from	O
cells	O
posterior	O
to	O
this	O
signaling	O
source	O
.	O

RESULTS	O
:	O
Here	O
we	O
report	O
that	O
Midline	O
(	O
Mid	O
)	O
and	O
H15	O
,	O
two	O
highly	O
related	O
T	O
box	O
proteins	O
representing	O
the	O
orthologs	O
of	O
zebrafish	O
hrT	O
and	O
mouse	O
Tbx20	O
,	O
are	O
novel	O
negative	O
regulators	O
of	O
wg	O
transcription	O
and	O
act	O
to	O
break	O
the	O
symmetry	O
of	O
Hh	O
signaling	O
.	O

Loss	O
of	O
mid	O
and	O
H15	O
results	O
in	O
the	O
symmetric	O
outcome	O
of	O
Hh	O
signaling	O
:	O
the	O
establishment	O
of	O
wg	O
domains	O
anterior	O
and	O
posterior	O
to	O
the	O
signaling	O
source	O
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
odd	O
-	O
numbered	O
segments	O
.	O

Accordingly	O
,	O
loss	O
of	O
mid	O
and	O
H15	O
produces	O
defects	O
that	O
mimic	O
a	O
wg	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Misexpression	O
of	O
mid	O
represses	O
wg	O
and	O
produces	O
a	O
weak	O
/	O
moderate	O
wg	O
loss	O
-	O
of	O
-	O
function	O
phenocopy	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
loss	O
of	O
mid	O
and	O
H15	O
results	O
in	O
an	O
anterior	O
expansion	O
of	O
the	O
expression	O
of	O
serrate	O
(	O
ser	O
)	O
in	O
every	O
segment	O
,	O
representing	O
a	O
second	O
instance	O
of	O
target	O
gene	O
repression	O
downstream	O
of	O
Hh	O
signaling	O
in	O
the	O
establishment	O
of	O
segment	O
polarity	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
we	O
present	O
here	O
indicate	O
that	O
mid	O
and	O
H15	O
are	O
important	O
components	O
in	O
pattern	O
formation	O
in	O
the	O
ventral	O
epidermis	O
.	O

In	O
odd	O
-	O
numbered	O
abdominal	O
segments	O
,	O
Mid	O
/	O
H15	O
activity	O
plays	O
an	O
important	O
role	O
in	O
restricting	O
the	O
expression	O
of	O
Wg	O
to	O
a	O
single	O
domain	O
.	O

Formins	O
:	O
processive	O
cappers	O
of	O
growing	O
actin	O
filaments	O
.	O

Taking	O
the	O
advantage	O
of	O
single	O
-	O
molecule	O
imaging	O
,	O
our	O
recent	O
study	O
has	O
revealed	O
surprisingly	O
long	O
processive	O
movement	O
of	O
a	O
Formin	O
protein	O
,	O
mDia1	O
,	O
surfing	O
along	O
with	O
the	O
growing	O
end	O
of	O
actin	O
filaments	O
in	O
living	O
cells	O
.	O

This	O
finding	O
provides	O
direct	O
evidence	O
for	O
the	O
ability	O
of	O
Formins	O
to	O
function	O
as	O
processive	O
cappers	O
that	O
has	O
been	O
postulated	O
from	O
several	O
lines	O
of	O
evidence	O
in	O
biochemical	O
studies	O
.	O

With	O
nucleating	O
filaments	O
from	O
the	O
profilin	O
-	O
actin	O
pool	O
,	O
Formins	O
may	O
effectively	O
generate	O
long	O
actin	O
filaments	O
,	O
and	O
contribute	O
to	O
the	O
generation	O
of	O
the	O
specific	O
actin	O
-	O
based	O
structures	O
,	O
that	O
is	O
,	O
the	O
contractile	O
ring	O
in	O
cytokinesis	O
,	O
actin	O
stress	O
fibers	O
in	O
animal	O
cells	O
,	O
and	O
yeast	O
actin	O
cables	O
.	O

Furthermore	O
,	O
Formins	O
have	O
the	O
potential	O
to	O
function	O
as	O
actin	O
polymerization	O
-	O
driven	O
molecular	O
motors	O
.	O

Although	O
much	O
remains	O
to	O
be	O
tested	O
about	O
the	O
role	O
of	O
this	O
novel	O
molecular	O
mobilization	O
mechanism	O
,	O
cells	O
might	O
utilize	O
actin	O
polymerization	O
energy	O
for	O
cell	O
shape	O
change	O
and	O
/	O
or	O
trafficking	O
via	O
Formin	O
motors	O
.	O

The	O
Crohn	O
'	O
s	O
disease	O
protein	O
,	O
NOD2	O
,	O
requires	O
RIP2	O
in	O
order	O
to	O
induce	O
ubiquitinylation	O
of	O
a	O
novel	O
site	O
on	O
NEMO	O
.	O

BACKGROUND	O
:	O
Crohn	O
'	O
s	O
disease	O
is	O
an	O
autoimmune	O
inflammatory	O
disorder	O
of	O
the	O
gastrointestinal	O
tract	O
and	O
is	O
characterized	O
clinically	O
by	O
dysregulation	O
of	O
both	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokine	O
signaling	O
networks	O
.	O

The	O
function	O
of	O
the	O
Crohn	O
'	O
s	O
disease	O
protein	O
,	O
NOD2	O
,	O
highlights	O
the	O
biphasic	O
nature	O
of	O
the	O
pathology	O
of	O
Crohn	O
'	O
s	O
disease	O
.	O

NOD2	O
can	O
both	O
strongly	O
activate	O
and	O
negatively	O
attenuate	O
NF	B-Complex
-	I-Complex
kB	I-Complex
signaling	O
.	O

The	O
biochemical	O
mechanism	O
for	O
this	O
dual	O
function	O
of	O
NOD2	O
is	O
unknown	O
.	O

RESULTS	O
:	O
We	O
demonstrate	O
that	O
NOD2	O
activation	O
leads	O
to	O
ubiquitinylation	O
of	O
NEMO	O
,	O
a	O
key	O
component	O
of	O
the	O
NF	B-Complex
-	I-Complex
kB	I-Complex
signaling	O
complex	O
.	O

This	O
ubiquitinylation	O
is	O
agonist	O
dependant	O
,	O
and	O
it	O
does	O
not	O
regulate	O
proteosomal	O
destruction	O
of	O
NEMO	O
.	O

We	O
show	O
the	O
NOD2	O
-	O
dependent	O
ubiquitinylation	O
of	O
NEMO	O
is	O
dependent	O
on	O
the	O
scaffolding	O
protein	O
kinase	O
RIP2	O
.	O

Crohn	O
'	O
s	O
disease	O
-	O
associated	O
polymorphisms	O
of	O
NOD2	O
show	O
a	O
decreased	O
ability	O
to	O
bind	O
RIP2	O
,	O
and	O
this	O
decreased	O
ability	O
to	O
bind	O
RIP2	O
correlates	O
with	O
a	O
decreased	O
ability	O
to	O
ubiquitinylate	O
NEMO	O
.	O

We	O
map	O
the	O
site	O
of	O
NEMO	O
ubiquitinylation	O
to	O
a	O
novel	O
NEMO	O
ubiquitinylation	O
site	O
(	O
Lysine	O
285	O
)	O
and	O
show	O
that	O
this	O
ubiquityinylation	O
occurs	O
in	O
vivo	O
.	O

Lastly	O
,	O
we	O
show	O
functionally	O
that	O
RIP2	O
-	O
induced	O
ubiquitinylation	O
of	O
NEMO	O
is	O
at	O
least	O
in	O
part	O
responsible	O
for	O
RIP2	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kB	I-Complex
activation	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
this	O
novel	O
mode	O
of	O
regulation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kB	I-Complex
signaling	O
pathway	O
could	O
be	O
a	O
factor	O
underlying	O
the	O
pathogenesis	O
of	O
Crohn	O
'	O
s	O
disease	O
.	O

Crystal	O
structure	O
of	O
the	O
pyridoxal	O
-	O
5	O
'	O
-	O
phosphate	O
-	O
dependent	O
serine	O
dehydratase	O
from	O
human	O
liver	O
.	O

L	O
-	O
serine	O
dehydratase	O
(	O
SDH	O
)	O
,	O
a	O
member	O
of	O
the	O
beta	O
-	O
family	O
of	O
pyridoxal	O
phosphate	O
-	O
dependent	O
(	O
PLP	O
)	O
enzymes	O
,	O
catalyzes	O
the	O
deamination	O
of	O
L	O
-	O
serine	O
and	O
L	O
-	O
threonine	O
to	O
yield	O
pyruvate	O
or	O
2	O
-	O
oxobutyrate	O
.	O

The	O
crystal	O
structure	O
of	O
L	O
-	O
serine	O
dehydratase	O
from	O
human	O
liver	O
(	O
hSDH	O
)	O
has	O
been	O
solved	O
at	O
2	O
.	O
5	O
A	O
-	O
resolution	O
by	O
molecular	O
replacement	O
.	O

The	O
structure	O
is	O
a	O
homodimer	O
and	O
reveals	O
a	O
fold	O
typical	O
for	O
beta	O
-	O
family	O
PLP	O
-	O
dependent	O
enzymes	O
.	O

Each	O
monomer	O
serves	O
as	O
an	O
active	O
unit	O
and	O
is	O
subdivided	O
into	O
two	O
distinct	O
domains	O
:	O
a	O
small	O
domain	O
and	O
a	O
PLP	O
-	O
binding	O
domain	O
that	O
covalently	O
anchors	O
the	O
cofactor	O
.	O

Both	O
domains	O
show	O
the	O
typical	O
open	O
alpha	O
/	O
beta	O
architecture	O
of	O
PLP	O
enzymes	O
.	O

Comparison	O
with	O
the	O
rSDH	O
-	O
(	O
PLP	O
-	O
OMS	O
)	O
holo	O
-	O
enzyme	O
reveals	O
a	O
large	O
structural	O
difference	O
in	O
active	O
sites	O
caused	O
by	O
the	O
artifical	O
O	O
-	O
methylserine	O
.	O

Furthermore	O
,	O
the	O
activity	O
of	O
hSDH	O
-	O
PLP	O
was	O
assayed	O
and	O
it	O
proved	O
to	O
show	O
catalytic	O
activity	O
.	O

That	O
suggests	O
that	O
the	O
structure	O
of	O
hSDH	O
-	O
PLP	O
is	O
the	O
first	O
structure	O
of	O
the	O
active	O
natural	O
holo	O
-	O
SDH	O
.	O

The	O
transcriptional	O
coactivator	O
Yes	O
-	O
associated	O
protein	O
drives	O
p73	O
gene	O
-	O
target	O
specificity	O
in	O
response	O
to	O
DNA	O
Damage	O
.	O

The	O
transcriptional	O
coactivator	O
Yes	O
-	O
associated	O
protein	O
(	O
YAP	O
)	O
has	O
been	O
shown	O
to	O
interact	O
with	O
and	O
to	O
enhance	O
p73	O
-	O
dependent	O
apoptosis	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Here	O
,	O
we	O
show	O
that	O
YAP	O
requires	O
the	O
promyelocytic	O
leukemia	O
gene	O
(	O
PML	O
)	O
and	O
nuclear	O
body	O
localization	O
to	O
coactivate	O
p73	O
.	O

YAP	O
imparts	O
selectivity	O
to	O
p73	O
by	O
promoting	O
the	O
activation	O
of	O
a	O
subset	O
of	O
p53	O
and	O
/	O
or	O
p73	O
target	O
promoters	O
.	O

Endogenous	O
p73	O
,	O
YAP	O
,	O
and	O
p300	O
proteins	O
are	O
concomitantly	O
recruited	O
onto	O
the	O
regulatory	O
regions	O
of	O
the	O
apoptotic	O
target	O
gene	O
p53AIP1	O
only	O
when	O
cells	O
are	O
exposed	O
to	O
apoptotic	O
conditions	O
.	O

Silencing	O
of	O
YAP	O
by	O
specific	O
siRNA	O
impairs	O
p300	O
recruitment	O
and	O
reduces	O
histone	O
acetylation	O
on	O
the	O
p53AIP1	O
target	O
gene	O
,	O
resulting	O
in	O
delayed	O
or	O
reduced	O
apoptosis	O
mediated	O
by	O
p73	O
.	O

We	O
also	O
found	O
that	O
YAP	O
contributes	O
to	O
the	O
DNA	O
damage	O
-	O
induced	O
accumulation	O
of	O
p73	O
and	O
potentiates	O
the	O
p300	O
-	O
mediated	O
acetylation	O
of	O
p73	O
.	O

Altogether	O
,	O
our	O
findings	O
identify	O
YAP	O
as	O
a	O
key	O
determinant	O
of	O
p73	O
gene	O
targeting	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Sprouty2	O
acts	O
at	O
the	O
Cbl	O
/	O
CIN85	O
interface	O
to	O
inhibit	O
epidermal	O
growth	O
factor	O
receptor	O
downregulation	O
.	O

The	O
ubiquitin	O
ligase	O
Cbl	O
mediates	O
ubiquitination	O
of	O
activated	O
receptor	O
tyrosine	O
kinases	O
(	O
RTKs	O
)	O
and	O
interacts	O
with	O
endocytic	O
scaffold	O
complexes	O
,	O
including	O
CIN85	O
/	O
endophilins	O
,	O
to	O
facilitate	O
RTK	O
endocytosis	O
and	O
degradation	O
.	O

Several	O
mechanisms	O
regulate	O
the	O
functions	O
of	O
Cbl	O
to	O
ensure	O
the	O
fine	O
-	O
tuning	O
of	O
RTK	O
signalling	O
and	O
cellular	O
homeostasis	O
.	O

One	O
regulatory	O
mechanism	O
involves	O
the	O
binding	O
of	O
Cbl	O
to	O
Sprouty2	O
,	O
which	O
sequesters	O
Cbl	O
away	O
from	O
activated	O
epidermal	O
growth	O
factor	O
receptors	O
(	O
EGFRs	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
Sprouty2	O
associates	O
with	O
CIN85	O
and	O
acts	O
at	O
the	O
interface	O
between	O
Cbl	O
and	O
CIN85	O
to	O
inhibit	O
EGFR	O
downregulation	O
.	O

The	O
CIN85	O
SH3	O
domains	O
A	O
and	O
C	O
bind	O
specifically	O
to	O
proline	O
-	O
arginine	O
motifs	O
present	O
in	O
Sprouty2	O
.	O

Intact	O
association	O
between	O
Sprouty2	O
,	O
Cbl	O
and	O
CIN85	O
is	O
required	O
for	O
inhibition	O
of	O
EGFR	O
endocytosis	O
as	O
well	O
as	O
EGF	O
-	O
induced	O
differentiation	O
of	O
PC12	O
cells	O
.	O

Moreover	O
,	O
Sprouty4	O
,	O
which	O
lacks	O
CIN85	O
-	O
binding	O
sites	O
,	O
does	O
not	O
inhibit	O
EGFR	O
downregulation	O
,	O
providing	O
a	O
molecular	O
explanation	O
for	O
functional	O
differences	O
between	O
Sprouty	O
isoforms	O
.	O

Sprouty2	O
therefore	O
acts	O
as	O
an	O
inducible	O
inhibitor	O
of	O
EGFR	O
downregulation	O
by	O
targeting	O
both	O
the	O
Cbl	O
and	O
CIN85	O
pathways	O
.	O

Rex1p	O
is	O
a	O
unique	O
exonuclease	O
for	O
5S	O
rRNA	O
trimming	O
.	O

However	O
,	O
both	O
the	O
rex1Delta	O
strain	O
and	O
the	O
rex1	O
-	O
1	O
strain	O
are	O
indistinguishable	O
from	O
wild	O
type	O
in	O
growth	O
in	O
spite	O
of	O
accumulating	O
3	O
'	O
-	O
extended	O
5S	O
rRNA	O
.	O

This	O
indicates	O
that	O
3	O
'	O
-	O
extended	O
5S	O
rRNA	O
can	O
be	O
normally	O
assembled	O
into	O
the	O
60S	B-Complex
ribosomal	O
subunits	O
.	O

Nevertheless	O
,	O
3	O
'	O
-	O
extended	O
5S	O
rRNA	O
causes	O
significant	O
growth	O
defect	O
under	O
the	O
rrs1	O
-	O
5	O
background	O
.	O

The	O
result	O
suggests	O
that	O
normal	O
function	O
of	O
Rrs1p	O
is	O
required	O
for	O
the	O
assembly	O
of	O
5S	O
rRNA	O
into	O
the	O
60S	B-Complex
ribosomal	O
subunit	O
as	O
well	O
as	O
for	O
the	O
assembly	O
of	O
L11	O
.	O

RPL5	O
encoding	O
a	O
ribosomal	O
protein	O
L5	O
was	O
cloned	O
as	O
a	O
weak	O
suppressor	O
of	O
rrs1	O
-	O
5	O
rex1	O
-	O
1	O
.	O

It	O
was	O
suggested	O
that	O
L5	O
protects	O
nascent	O
5S	O
rRNA	O
and	O
recruits	O
5S	O
rRNA	O
to	O
ribosomal	O
particles	O
.	O

Since	O
it	O
appears	O
that	O
extended	O
5S	O
rRNA	O
is	O
not	O
degraded	O
in	O
rex1	O
-	O
1	O
or	O
rex1Delta	O
strains	O
,	O
it	O
is	O
likely	O
that	O
excess	O
L5	O
suppresses	O
the	O
rex1	O
-	O
1	O
mutation	O
by	O
recruiting	O
5S	O
rRNA	O
.	O

Either	O
rpl11aDelta	O
or	O
rpl11bDelta	O
,	O
which	O
results	O
in	O
a	O
decreased	O
level	O
of	O
L11	O
,	O
did	O
not	O
cause	O
a	O
synthetic	O
growth	O
defect	O
with	O
rrs1	O
-	O
5	O
,	O
suggesting	O
that	O
a	O
decreased	O
level	O
of	O
a	O
component	O
of	O
ribosome	B-OOS
does	O
not	O
cause	O
a	O
synthetic	O
defect	O
with	O
rrs1	O
(	O
T	O
.	O
Okada	O
and	O
K	O
.	O
Mizuta	O
,	O
unpublished	O
data	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
recruitment	O
of	O
L11	O
and	O
that	O
of	O
L5	O
/	O
5S	O
rRNA	O
are	O
highly	O
coordinated	O
and	O
that	O
leucine	O
at	O
65	O
in	O
Rrs1p	O
is	O
critical	O
for	O
Rrs1p	O
-	O
L5	O
and	O
Rrs1p	O
-	O
L11	O
interactions	O
.	O

We	O
performed	O
tandem	O
affinity	O
purification	O
and	O
detected	O
both	O
L11	O
and	O
L5	O
in	O
the	O
fraction	O
purified	O
with	O
Rrs1p	O
-	O
TAP	O
(	O
K	O
.	O
Ehara	O
and	O
K	O
.	O
Mizuta	O
,	O
unpublished	O
data	O
)	O
.	O

It	O
remains	O
to	O
be	O
elucidated	O
if	O
both	O
L5	O
/	O
5S	O
rRNA	O
and	O
L11	O
are	O
recruited	O
into	O
pre	O
-	O
ribosomal	O
particles	O
at	O
the	O
same	O
time	O
,	O
or	O
if	O
assembly	O
of	O
one	O
component	O
followed	O
by	O
conformational	O
rearrangement	O
of	O
the	O
particle	O
is	O
required	O
for	O
assembly	O
of	O
the	O
other	O
component	O
.	O

Characterization	O
of	O
FBX25	O
,	O
encoding	O
a	O
novel	O
brain	O
-	O
expressed	O
F	O
-	O
box	O
protein	O
.	O

F	O
-	O
box	O
proteins	O
(	O
FBPs	O
)	O
confer	O
substrate	O
specificity	O
to	O
the	O
SCF	B-Complex
-	O
type	O
(	O
Skp1	O
/	O
Cul1	O
/	O
FBP	O
)	O
of	O
ubiquitin	O
ligase	O
complexes	O
through	O
their	O
F	O
-	O
box	O
.	O

Multiple	O
FBPs	O
have	O
been	O
predicted	O
,	O
but	O
experimental	O
evidence	O
is	O
lagging	O
.	O

We	O
report	O
on	O
the	O
predicted	O
human	O
FBP	O
hFBX25	O
which	O
we	O
found	O
to	O
be	O
disrupted	O
in	O
a	O
mentally	O
retarded	O
translocation	O
carrier	O
suffering	O
from	O
epileptic	O
seizures	O
.	O

We	O
investigated	O
hFBX25	O
'	O
s	O
genomic	O
organization	O
and	O
established	O
hFBX25	O
as	O
an	O
FBP	O
by	O
verifying	O
its	O
interaction	O
with	O
Skp1	O
and	O
Cul1	O
.	O

In	O
the	O
process	O
,	O
we	O
identified	O
an	O
atypical	O
serine	O
residue	O
in	O
the	O
F	O
-	O
box	O
which	O
is	O
crucial	O
for	O
the	O
hFBX25	O
-	O
Skp1	O
binding	O
.	O

We	O
determined	O
hFBX25	O
'	O
s	O
subcellular	O
localization	O
.	O

We	O
found	O
strong	O
transcription	O
in	O
human	O
brain	O
.	O

In	O
mouse	O
embryonic	O
sections	O
,	O
mFbx25	O
shows	O
predominantly	O
neuronal	O
expression	O
and	O
in	O
adult	O
mouse	O
brain	O
,	O
expression	O
is	O
confined	O
to	O
the	O
hippocampus	O
,	O
the	O
cerebral	O
cortex	O
and	O
the	O
Purkinje	O
cell	O
layer	O
.	O

Interestingly	O
,	O
aberrations	O
in	O
the	O
ubiquitin	O
pathway	O
have	O
been	O
linked	O
to	O
neurological	O
conditions	O
.	O

The	O
human	O
heat	O
shock	O
protein	O
hsp70	O
interacts	O
with	O
HSF	O
,	O
the	O
transcription	O
factor	O
that	O
regulates	O
heat	O
shock	O
gene	O
expression	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	O
hsp70	O
gene	O
in	O
response	O
to	O
heat	O
shock	O
and	O
other	O
forms	O
of	O
physiological	O
stress	O
occurs	O
through	O
the	O
activation	O
of	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF	O
)	O
.	O

Exposure	O
of	O
cells	O
to	O
a	O
heat	O
shock	O
temperature	O
of	O
42	O
degrees	O
C	O
results	O
in	O
transient	O
activation	O
of	O
HSF	O
;	O
its	O
DNA	O
-	O
binding	O
activity	O
increases	O
rapidly	O
,	O
plateaus	O
,	O
and	O
attenuates	O
,	O
during	O
which	O
the	O
intracellular	O
levels	O
of	O
hsp70	O
increase	O
.	O

In	O
an	O
effort	O
to	O
understand	O
whether	O
HSF	O
is	O
regulated	O
negatively	O
by	O
hsp70	O
,	O
we	O
have	O
examined	O
whether	O
HSF	O
associates	O
with	O
hsp70	O
.	O

We	O
show	O
that	O
activated	O
HSF	O
associates	O
with	O
hsp70	O
and	O
that	O
the	O
interaction	O
is	O
detected	O
as	O
the	O
levels	O
of	O
hsp70	O
increase	O
in	O
the	O
cell	O
.	O

Addition	O
of	O
ATP	O
and	O
other	O
hydrolyzable	O
nucleotides	O
results	O
in	O
the	O
dissociation	O
of	O
hsp70	O
from	O
HSF	O
while	O
nonhydrolyzable	O
nucleotide	O
analogs	O
do	O
not	O
disrupt	O
the	O
complex	O
.	O

We	O
demonstrate	O
that	O
exogenous	O
recombinant	O
wild	O
-	O
type	O
hsp70	O
can	O
associate	O
with	O
activated	O
HSF	O
,	O
whereas	O
no	O
association	O
is	O
observed	O
with	O
an	O
amino	O
-	O
terminal	O
or	O
a	O
carboxy	O
-	O
terminal	O
deletion	O
mutant	O
of	O
hsp70	O
.	O

We	O
also	O
show	O
that	O
hsp70	O
blocks	O
the	O
in	O
vitro	O
activation	O
of	O
HSF	O
from	O
its	O
cryptic	O
non	O
-	O
DNA	O
-	O
binding	O
state	O
to	O
a	O
DNA	O
-	O
binding	O
form	O
;	O
this	O
inhibitory	O
effect	O
of	O
hsp70	O
is	O
abolished	O
by	O
ATP	O
.	O

We	O
suggest	O
that	O
hsp70	O
may	O
negatively	O
regulate	O
the	O
activation	O
of	O
HSF	O
.	O

Point	O
mutations	O
in	O
the	O
aromatic	O
/	O
arginine	O
region	O
in	O
aquaporin	O
1	O
allow	O
passage	O
of	O
urea	O
,	O
glycerol	O
,	O
ammonia	O
,	O
and	O
protons	O
.	O

Water	O
-	O
specific	O
aquaporins	O
(	O
AQP	O
)	O
,	O
such	O
as	O
the	O
prototypical	O
mammalian	O
AQP1	O
,	O
stringently	O
exclude	O
the	O
passage	O
of	O
solutes	O
,	O
ions	O
,	O
and	O
even	O
protons	O
.	O

Supposedly	O
,	O
this	O
is	O
accomplished	O
by	O
two	O
conserved	O
regions	O
within	O
the	O
pore	O
,	O
a	O
pair	O
of	O
canonical	O
asparagine	O
-	O
proline	O
-	O
alanine	O
(	O
NPA	O
)	O
motifs	O
,	O
the	O
central	O
constriction	O
,	O
and	O
an	O
aromatic	O
/	O
arginine	O
(	O
ar	O
/	O
R	O
)	O
constriction	O
,	O
the	O
outer	O
constriction	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
function	O
of	O
three	O
residues	O
in	O
the	O
ar	O
/	O
R	O
constriction	O
(	O
Phe	O
-	O
56	O
,	O
His	O
-	O
180	O
,	O
and	O
Arg	O
-	O
195	O
)	O
in	O
rat	O
AQP1	O
.	O

Individual	O
or	O
joint	O
replacement	O
of	O
His	O
-	O
180	O
and	O
Arg	O
-	O
195	O
by	O
alanine	O
and	O
valine	O
residues	O
,	O
respectively	O
(	O
AQP1	O
-	O
H180A	O
,	O
AQP1	O
-	O
R195V	O
,	O
and	O
AQP1	O
-	O
H180A	O
/	O
R195V	O
)	O
,	O
did	O
not	O
affect	O
water	O
permeability	O
.	O

The	O
double	O
mutant	O
AQP1	O
-	O
H180A	O
/	O
R195V	O
allowed	O
urea	O
to	O
pass	O
.	O

In	O
line	O
with	O
the	O
predicted	O
solute	O
discrimination	O
by	O
size	O
,	O
replacement	O
of	O
both	O
Phe	O
-	O
56	O
and	O
His	O
-	O
180	O
(	O
AQP1	O
-	O
F56A	O
/	O
H180A	O
)	O
enlarged	O
the	O
maximal	O
diameter	O
of	O
the	O
ar	O
/	O
R	O
constriction	O
3	O
-	O
fold	O
and	O
enabled	O
glycerol	O
and	O
urea	O
to	O
pass	O
.	O

We	O
further	O
show	O
that	O
ammonia	O
passes	O
through	O
all	O
four	O
AQP1	O
mutants	O
,	O
as	O
determined	O
(	O
i	O
)	O
by	O
growth	O
complementation	O
of	O
yeast	O
deletion	O
strains	O
with	O
ammonia	O
,	O
(	O
ii	O
)	O
by	O
ammonia	O
uptake	O
from	O
the	O
external	O
solution	O
into	O
oocytes	O
,	O
and	O
(	O
iii	O
)	O
by	O
direct	O
recordings	O
of	O
ammonia	O
induced	O
proton	O
currents	O
in	O
oocytes	O
.	O

Unexpectedly	O
,	O
removal	O
of	O
the	O
positive	O
charge	O
in	O
the	O
ar	O
/	O
R	O
constriction	O
in	O
AQP1	O
-	O
R195V	O
and	O
AQP1	O
-	O
H180A	O
/	O
R195V	O
appeared	O
to	O
allow	O
the	O
passage	O
of	O
protons	O
through	O
AQP1	O
.	O

The	O
data	O
indicate	O
that	O
the	O
ar	O
/	O
R	O
constriction	O
is	O
a	O
major	O
checkpoint	O
for	O
solute	O
permeability	O
,	O
and	O
that	O
the	O
exquisite	O
electrostatic	O
proton	O
barrier	O
in	O
AQPs	O
comprises	O
both	O
the	O
NPA	O
constriction	O
as	O
well	O
as	O
the	O
ar	O
/	O
R	O
constriction	O
.	O

To	O
elucidate	O
the	O
mechanism	O
by	O
which	O
Vta1	O
impacts	O
Vps4	O
function	O
,	O
biochemical	O
characterization	O
of	O
Vta1	O
was	O
initiated	O
.	O

Consistent	O
with	O
published	O
data	O
,	O
we	O
found	O
that	O
both	O
Vta1	O
from	O
yeast	O
cell	O
extract	O
and	O
bacterially	O
expressed	O
Vta1	O
elute	O
from	O
a	O
gel	O
filtration	O
column	O
in	O
the	O
range	O
of	O
300	O
kD	O
,	O
in	O
spite	O
of	O
a	O
predicted	O
molecular	O
mass	O
of	O
~	O
40	O
kD	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

Together	O
,	O
these	O
observations	O
suggest	O
that	O
Vta1	O
forms	O
a	O
homomeric	O
complex	O
.	O

The	O
subtle	O
difference	O
in	O
size	O
observed	O
between	O
bacterially	O
produced	O
Vta1	O
and	O
yeast	O
Vta1	O
may	O
be	O
due	O
to	O
the	O
sizes	O
of	O
the	O
epitopes	O
used	O
in	O
each	O
case	O
(	O
His6	O
for	O
bacteria	O
vs	O
.	O
3x	O
HA	O
for	O
yeast	O
)	O
;	O
alternatively	O
,	O
Vta1	O
homooligomers	O
may	O
be	O
associated	O
with	O
other	O
factors	O
in	O
yeast	O
extracts	O
.	O

Genome	O
-	O
wide	O
identification	O
of	O
mRNAs	O
associated	O
with	O
the	O
translational	O
regulator	O
PUMILIO	O
in	O
Drosophila	O
melanogaster	O
.	O

Genome	O
-	O
wide	O
identification	O
of	O
RNAs	O
associated	O
with	O
RNA	O
-	O
binding	O
proteins	O
is	O
crucial	O
for	O
deciphering	O
posttranscriptional	O
regulatory	O
systems	O
.	O

PUMILIO	O
is	O
a	O
member	O
of	O
the	O
evolutionary	O
conserved	O
Puf	O
-	O
family	O
of	O
RNA	O
-	O
binding	O
proteins	O
that	O
repress	O
gene	O
expression	O
posttranscriptionally	O
.	O

We	O
generated	O
transgenic	O
flies	O
expressing	O
affinity	O
-	O
tagged	O
PUMILIO	O
under	O
the	O
control	O
of	O
an	O
ovary	O
-	O
specific	O
promoter	O
,	O
and	O
we	O
purified	O
PUMILIO	O
from	O
whole	O
adult	O
flies	O
and	O
embryos	O
and	O
analyzed	O
associated	O
mRNAs	O
by	O
using	O
DNA	O
microarrays	O
.	O

Distinct	O
sets	O
comprising	O
hundreds	O
of	O
mRNAs	O
were	O
associated	O
with	O
PUMILIO	O
at	O
the	O
two	O
developmental	O
stages	O
.	O

Many	O
of	O
these	O
mRNAs	O
encode	O
functionally	O
related	O
proteins	O
,	O
supporting	O
a	O
model	O
for	O
coordinated	O
regulation	O
of	O
posttranscriptional	O
modules	O
by	O
specific	O
RNA	O
-	O
binding	O
proteins	O
.	O

We	O
identified	O
a	O
characteristic	O
sequence	O
motif	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
regions	O
of	O
mRNAs	O
associated	O
with	O
PUMILIO	O
,	O
and	O
the	O
sufficiency	O
of	O
this	O
motif	O
for	O
interaction	O
with	O
PUMILIO	O
was	O
confirmed	O
by	O
RNA	O
pull	O
-	O
down	O
experiments	O
with	O
biotinylated	O
synthetic	O
RNAs	O
.	O

The	O
RNA	O
motif	O
strikingly	O
resembles	O
the	O
one	O
previously	O
identified	O
for	O
Puf3p	O
,	O
one	O
of	O
five	O
Saccharomyces	O
cerevisiae	O
Puf	O
proteins	O
;	O
however	O
,	O
proteins	O
encoded	O
by	O
the	O
associated	O
mRNAs	O
in	O
yeast	O
and	O
Drosophila	O
do	O
not	O
appear	O
to	O
be	O
related	O
.	O

The	O
results	O
suggest	O
extensive	O
posttranscriptional	O
regulation	O
by	O
PUMILIO	O
and	O
uncover	O
evolutionary	O
features	O
of	O
this	O
conserved	O
family	O
of	O
RNA	O
-	O
binding	O
proteins	O
.	O

Structural	O
characterization	O
of	O
autoinhibited	O
c	O
-	O
Met	O
kinase	O
produced	O
by	O
coexpression	O
in	O
bacteria	O
with	O
phosphatase	O
.	O

Protein	O
kinases	O
are	O
a	O
large	O
family	O
of	O
cell	O
signaling	O
mediators	O
undergoing	O
intensive	O
research	O
to	O
identify	O
inhibitors	O
or	O
modulators	O
useful	O
for	O
medicine	O
.	O

As	O
one	O
strategy	O
,	O
small	O
-	O
molecule	O
compounds	O
that	O
bind	O
the	O
active	O
site	O
with	O
high	O
affinity	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
enzyme	O
activity	O
.	O

X	O
-	O
ray	O
crystallography	O
is	O
a	O
powerful	O
method	O
to	O
reveal	O
the	O
structures	O
of	O
the	O
kinase	O
active	O
sites	O
,	O
and	O
thus	O
aid	O
in	O
the	O
design	O
of	O
high	O
-	O
affinity	O
,	O
selective	O
inhibitors	O
.	O

However	O
,	O
a	O
limitation	O
still	O
exists	O
in	O
the	O
ability	O
to	O
produce	O
purified	O
kinases	O
in	O
amounts	O
sufficient	O
for	O
crystallography	O
.	O

Furthermore	O
,	O
kinases	O
exist	O
in	O
different	O
conformation	O
states	O
as	O
part	O
of	O
their	O
normal	O
regulation	O
,	O
and	O
the	O
ability	O
to	O
prepare	O
crystals	O
of	O
kinases	O
in	O
these	O
various	O
states	O
also	O
remains	O
a	O
limitation	O
.	O

In	O
this	O
study	O
,	O
the	O
c	O
-	O
Abl	O
,	O
c	O
-	O
Src	O
,	O
and	O
c	O
-	O
Met	O
kinases	O
are	O
produced	O
in	O
high	O
yields	O
in	O
Escherichia	O
coli	O
by	O
using	O
a	O
bicistronic	O
vector	O
encoding	O
the	O
PTP1B	O
tyrosine	O
phosphatase	O
.	O

A	O
100	O
-	O
fold	O
lower	O
dose	O
of	O
the	O
inhibitor	O
,	O
Imatinib	O
,	O
was	O
observed	O
to	O
inhibit	O
the	O
unphosphorylated	O
form	O
of	O
c	O
-	O
Abl	O
kinase	O
prepared	O
by	O
using	O
this	O
vector	O
,	O
compared	O
to	O
the	O
phosphorylated	O
form	O
produced	O
without	O
PTP1B	O
,	O
consistent	O
with	O
the	O
known	O
selectivity	O
of	O
this	O
inhibitor	O
for	O
the	O
unactivated	O
conformation	O
of	O
the	O
enzyme	O
.	O

Unphosphorylated	O
c	O
-	O
Met	O
kinase	O
produced	O
with	O
this	O
vector	O
was	O
used	O
to	O
obtain	O
the	O
crystal	O
structure	O
,	O
at	O
2	O
.	O
15	O
-	O
A	O
resolution	O
,	O
of	O
the	O
autoinhibited	O
form	O
of	O
the	O
kinase	O
domain	O
,	O
revealing	O
an	O
intricate	O
network	O
of	O
interactions	O
involving	O
c	O
-	O
Met	O
residues	O
documented	O
previously	O
to	O
cause	O
dysregulation	O
when	O
mutated	O
in	O
several	O
cancers	O
.	O

ATR	O
homolog	O
Mec1	O
controls	O
association	O
of	O
DNA	B-Complex
polymerase	I-Complex
zeta	I-Complex
-	O
Rev1	O
complex	O
with	O
regions	O
near	O
a	O
double	O
-	O
strand	O
break	O
.	O

DNA	B-Complex
polymerase	I-Complex
zeta	I-Complex
(	O
Polzeta	B-Complex
)	O
and	O
Rev1	O
contribute	O
to	O
the	O
bypassing	O
of	O
DNA	O
lesions	O
,	O
termed	O
translesion	O
DNA	O
synthesis	O
(	O
TLS	O
)	O
.	O

Polzeta	B-Complex
consists	O
of	O
two	O
subunits	O
,	O
one	O
encoded	O
by	O
REV3	O
(	O
the	O
catalytic	O
subunit	O
)	O
and	O
the	O
other	O
encoded	O
by	O
REV7	O
.	O

Rev1	O
acts	O
as	O
a	O
deoxycytidyl	O
transferase	O
,	O
inserting	O
dCMP	O
opposite	O
lesions	O
.	O

Polzeta	B-Complex
and	O
Rev1	O
have	O
been	O
shown	O
to	O
operate	O
in	O
the	O
same	O
TLS	O
pathway	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Here	O
,	O
we	O
show	O
that	O
budding	O
yeast	O
Polzeta	B-Complex
and	O
Rev1	O
form	O
a	O
complex	O
and	O
associate	O
together	O
with	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

As	O
a	O
component	O
of	O
the	O
Polzeta	B-Complex
-	O
Rev1	O
complex	O
,	O
Rev1	O
plays	O
a	O
noncatalytic	O
role	O
in	O
the	O
association	O
with	O
DSBs	O
.	O

In	O
budding	O
yeast	O
,	O
the	O
ATR	O
-	O
homolog	O
Mec1	O
plays	O
a	O
central	O
role	O
in	O
the	O
DNA	O
-	O
damage	O
checkpoint	O
response	O
.	O

We	O
further	O
show	O
that	O
Mec1	O
-	O
dependent	O
phosphorylation	O
promotes	O
the	O
Polzeta	B-Complex
-	O
Rev1	O
association	O
with	O
DSBs	O
.	O

Rev1	O
association	O
with	O
DSBs	O
requires	O
neither	O
the	O
function	O
of	O
the	O
Rad24	O
checkpoint	O
-	O
clamp	O
loader	O
nor	O
the	O
Rad6	O
-	O
Rad18	O
-	O
mediated	O
ubiquitination	O
of	O
PCNA	B-OOS
.	O

Our	O
results	O
reveal	O
a	O
novel	O
role	O
of	O
Mec1	O
in	O
the	O
localization	O
of	O
the	O
Polzeta	B-Complex
-	O
Rev1	O
complex	O
to	O
DNA	O
lesions	O
and	O
highlight	O
a	O
linkage	O
of	O
TLS	O
polymerases	O
to	O
the	O
checkpoint	O
response	O
.	O

Drosophila	O
homolog	O
of	O
APP	O
-	O
BP1	O
(	O
dAPP	O
-	O
BP1	O
)	O
interacts	O
antagonistically	O
with	O
APPL	O
during	O
Drosophila	O
development	O
.	O

beta	O
-	O
Amyloid	O
precursor	O
protein	O
binding	O
protein	O
1	O
(	O
APP	O
-	O
BP1	O
)	O
was	O
previously	O
identified	O
based	O
on	O
its	O
binding	O
to	O
the	O
carboxyl	O
terminal	O
of	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
discovered	O
that	O
a	O
mutation	O
of	O
dAPP	O
-	O
BP1	O
(	O
Drosophila	O
ortholog	O
of	O
APP	O
-	O
BP1	O
)	O
hinders	O
tissue	O
development	O
,	O
causes	O
apoptosis	O
in	O
imaginal	O
disc	O
cells	O
,	O
and	O
blocks	O
the	O
NEDD8	O
conjugation	O
pathway	O
.	O

We	O
show	O
that	O
dAPP	O
-	O
BP1	O
specifically	O
binds	O
the	O
intracellular	O
domain	O
of	O
APP	O
-	O
like	O
protein	O
(	O
APPL	O
)	O
.	O

The	O
dAPP	O
-	O
BP1	O
mutation	O
partially	O
suppresses	O
the	O
abnormal	O
macrochaete	O
phenotype	O
of	O
Appl	O
(	O
d	O
)	O
,	O
while	O
overexpression	O
of	O
dAPP	O
-	O
BP1	O
causes	O
abnormal	O
macrochaetes	O
.	O

When	O
APPL	O
is	O
overexpressed	O
,	O
the	O
normal	O
bristle	O
pattern	O
in	O
the	O
fly	O
thorax	O
is	O
disturbed	O
and	O
apoptosis	O
is	O
induced	O
in	O
wing	O
imaginal	O
discs	O
.	O

APPL	O
overexpression	O
phenotypes	O
are	O
enhanced	O
by	O
reducing	O
the	O
level	O
of	O
dAPP	O
-	O
BP1	O
.	O

APPL	O
overexpression	O
is	O
shown	O
to	O
inhibit	O
the	O
NEDD8	O
conjugation	O
pathway	O
.	O

APPL	O
-	O
induced	O
apoptosis	O
is	O
rescued	O
by	O
overexpression	O
of	O
dAPP	O
-	O
BP1	O
.	O

Our	O
data	O
suggest	O
that	O
APPL	O
and	O
dAPP	O
-	O
BP1	O
interact	O
antagonistically	O
during	O
Drosophila	O
development	O
.	O

ADP	O
-	O
ribosylation	O
of	O
membrane	O
proteins	O
:	O
unveiling	O
the	O
secrets	O
of	O
a	O
crucial	O
regulatory	O
mechanism	O
in	O
mammalian	O
cells	O
.	O

Many	O
bacterial	O
toxins	O
kill	O
animal	O
cells	O
by	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
-	O
ribosylating	O
intracellular	O
target	O
proteins	O
.	O

Mammalian	O
cells	O
express	O
toxin	O
-	O
related	O
cell	O
surface	O
ADP	O
-	O
ribosyltransferases	O
(	O
ARTs	O
)	O
that	O
transfer	O
ADP	O
-	O
ribose	O
from	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
onto	O
arginine	O
residues	O
of	O
other	O
membrane	O
proteins	O
.	O

The	O
association	O
of	O
these	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
ectoenzymes	O
with	O
glycolipid	O
rafts	O
focuses	O
them	O
onto	O
components	O
of	O
the	O
signal	O
transduction	O
machinery	O
.	O

Exposing	O
murine	O
T	O
cells	O
to	O
NAD	O
,	O
the	O
ART	O
substrate	O
,	O
induces	O
a	O
cascade	O
of	O
reactions	O
that	O
culminates	O
in	O
cell	O
death	O
by	O
apoptosis	O
.	O

This	O
mechanism	O
,	O
dubbed	O
'	O
NAD	O
-	O
induced	O
cell	O
death	O
'	O
or	O
NICD	O
,	O
is	O
initiated	O
when	O
ART2	O
ADP	O
-	O
ribosylates	O
the	O
cytolytic	O
P2X7	O
purinergic	O
receptor	O
,	O
inducing	O
formation	O
of	O
a	O
cation	O
channel	O
,	O
opening	O
of	O
a	O
nonselective	O
pore	O
,	O
shedding	O
of	O
CD62L	O
from	O
the	O
cell	O
surface	O
,	O
exposure	O
of	O
phosphatidylserine	O
on	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
,	O
breakdown	O
of	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
DNA	O
-	O
fragmentation	O
.	O

The	O
ART	O
substrate	O
NAD	O
is	O
produced	O
in	O
large	O
amounts	O
inside	O
the	O
cell	O
and	O
can	O
be	O
released	O
from	O
damaged	O
cells	O
during	O
inflammation	O
and	O
tissue	O
injury	O
.	O

In	O
the	O
extracellular	O
environment	O
,	O
the	O
signaling	O
function	O
of	O
NAD	O
is	O
terminated	O
by	O
NAD	O
-	O
degrading	O
ectoenzymes	O
such	O
as	O
CD38	O
.	O

We	O
propose	O
that	O
ART2	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
P2X7	O
represents	O
the	O
paradigm	O
of	O
a	O
regulatory	O
mechanism	O
by	O
which	O
ART	O
-	O
expressing	O
cells	O
can	O
sense	O
and	O
respond	O
to	O
the	O
release	O
of	O
NAD	O
from	O
damaged	O
cells	O
.	O

SUMO	O
modification	O
enhances	O
p66	O
-	O
mediated	O
transcriptional	O
repression	O
of	O
the	O
Mi	B-Complex
-	I-Complex
2	I-Complex
/	O
NuRD	B-Complex
complex	O
.	O

Human	O
p66alpha	O
and	O
p66beta	O
are	O
two	O
potent	O
transcriptional	O
repressors	O
that	O
interact	O
with	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
proteins	O
MBD2	O
and	O
MBD3	O
.	O

An	O
analysis	O
of	O
the	O
molecular	O
mechanisms	O
mediating	O
repression	O
resulted	O
in	O
the	O
identification	O
of	O
two	O
major	O
repression	O
domains	O
in	O
p66alpha	O
and	O
one	O
in	O
p66beta	O
.	O

Both	O
p66alpha	O
and	O
p66beta	O
are	O
SUMO	O
-	O
modified	O
in	O
vivo	O
:	O
p66alpha	O
at	O
two	O
sites	O
(	O
Lys	O
-	O
30	O
and	O
Lys	O
-	O
487	O
)	O
and	O
p66beta	O
at	O
one	O
site	O
(	O
Lys	O
-	O
33	O
)	O
.	O

Expression	O
of	O
SUMO1	O
enhanced	O
the	O
transcriptional	O
repression	O
activity	O
of	O
Gal	O
-	O
p66alpha	O
and	O
Gal	O
-	O
p66beta	O
.	O

Mutation	O
of	O
the	O
SUMO	O
modification	O
sites	O
or	O
using	O
a	O
SUMO1	O
mutant	O
or	O
a	O
dominant	O
negative	O
Ubc9	O
ligase	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
transcriptional	O
repression	O
of	O
p66alpha	O
and	O
p66beta	O
.	O

The	O
Mi	B-Complex
-	I-Complex
2	I-Complex
/	O
NuRD	B-Complex
components	O
MBD3	O
,	O
RbAp46	O
,	O
RbAp48	O
,	O
and	O
HDAC1	O
were	O
found	O
to	O
bind	O
to	O
both	O
p66alpha	O
and	O
p66beta	O
in	O
vivo	O
.	O

Most	O
of	O
the	O
interactions	O
were	O
not	O
affected	O
by	O
the	O
SUMO	O
site	O
mutations	O
in	O
p66alpha	O
or	O
p66beta	O
,	O
with	O
two	O
exceptions	O
.	O

HDAC1	O
binding	O
to	O
p66alpha	O
was	O
lost	O
in	O
the	O
case	O
of	O
a	O
p66alphaK30R	O
mutant	O
,	O
and	O
RbAp46	O
binding	O
was	O
reduced	O
in	O
the	O
case	O
of	O
a	O
p66betaK33R	O
mutant	O
.	O

These	O
results	O
suggest	O
that	O
interactions	O
within	O
the	O
Mi	B-Complex
-	I-Complex
2	I-Complex
/	O
NuRD	B-Complex
complex	O
as	O
well	O
as	O
optimal	O
repression	O
are	O
mediated	O
by	O
SUMOylation	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	B-Complex
/	I-Complex
NF	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	O
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	B-Complex
class	I-Complex
I	I-Complex
gene	O
H	O
-	O
2Kb	O
,	O
is	O
indistinguishable	O
from	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	O
/	O
p50	O
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	O
-	O
rel	O
and	O
v	O
-	O
rel	O
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	O
/	O
p50	O
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1	O
/	O
p50	O
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild	O
-	O
type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	O
/	O
p50	O
,	O
c	O
-	O
and	O
v	O
-	O
rel	O
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	O
+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1	O
-	O
induced	O
activity	O
of	O
the	O
MHC	B-Complex
class	I-Complex
I	I-Complex
H	O
-	O
2Kb	O
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	B-Complex
/	I-Complex
NF	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
family	O
.	O

Protein	O
-	O
protein	O
and	O
protein	O
-	O
RNA	O
contacts	O
both	O
contribute	O
to	O
the	O
15	O
.	O
5K	O
-	O
mediated	O
assembly	O
of	O
the	O
U4	B-Complex
/	I-Complex
U6	I-Complex
snRNP	I-Complex
and	O
the	O
box	B-Complex
C	I-Complex
/	I-Complex
D	I-Complex
snoRNPs	I-Complex
.	O

The	O
k	O
-	O
turn	O
-	O
binding	O
protein	O
15	O
.	O
5K	O
is	O
unique	O
in	O
that	O
it	O
is	O
essential	O
for	O
the	O
hierarchical	O
assembly	O
of	O
three	O
RNP	B-Complex
complexes	O
distinct	O
in	O
both	O
composition	O
and	O
function	O
,	O
namely	O
,	O
the	O
U4	B-Complex
/	I-Complex
U6	I-Complex
snRNP	I-Complex
,	O
the	O
box	B-Complex
C	I-Complex
/	I-Complex
D	I-Complex
snoRNP	I-Complex
,	O
and	O
the	O
RNP	B-Complex
complex	O
assembled	O
on	O
the	O
U3	O
box	O
B	O
/	O
C	O
motif	O
.	O

15	O
.	O
5K	O
interacts	O
with	O
the	O
cognate	O
RNAs	O
via	O
an	O
induced	O
fit	O
mechanism	O
,	O
which	O
results	O
in	O
the	O
folding	O
of	O
the	O
surrounding	O
RNA	O
to	O
create	O
a	O
binding	O
site	O
(	O
s	O
)	O
for	O
the	O
RNP	B-Complex
-	O
specific	O
proteins	O
.	O

However	O
,	O
it	O
is	O
possible	O
that	O
15	O
.	O
5K	O
also	O
mediates	O
RNP	B-Complex
formation	O
via	O
protein	O
-	O
protein	O
interactions	O
with	O
the	O
complex	O
-	O
specific	O
proteins	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
created	O
a	O
series	O
of	O
15	O
.	O
5K	O
mutations	O
in	O
which	O
the	O
surface	O
properties	O
of	O
the	O
protein	O
had	O
been	O
changed	O
.	O

We	O
assessed	O
their	O
ability	O
to	O
support	O
the	O
formation	O
of	O
the	O
three	O
distinct	O
RNP	B-Complex
complexes	O
and	O
found	O
that	O
the	O
formation	O
of	O
each	O
RNP	B-Complex
requires	O
a	O
distinct	O
set	O
of	O
regions	O
on	O
the	O
surface	O
of	O
15	O
.	O
5K	O
.	O

This	O
implies	O
that	O
protein	O
-	O
protein	O
contacts	O
are	O
essential	O
for	O
RNP	B-Complex
formation	O
in	O
each	O
complex	O
.	O

Further	O
supporting	O
this	O
idea	O
,	O
direct	O
protein	O
-	O
protein	O
interaction	O
could	O
be	O
observed	O
between	O
hU3	O
-	O
55K	O
and	O
15	O
.	O
5K	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
formation	O
of	O
each	O
RNP	B-Complex
involves	O
the	O
direct	O
recognition	O
of	O
specific	O
elements	O
in	O
both	O
15	O
.	O
5K	O
protein	O
and	O
the	O
specific	O
RNA	O
.	O

Calsenilin	O
interacts	O
with	O
transcriptional	O
co	O
-	O
repressor	O
C	O
-	O
terminal	O
binding	O
protein	O
(	O
s	O
)	O
.	O

Calsenilin	O
/	O
potassium	O
channel	O
-	O
interacting	O
protein	O
(	O
KChIP	O
)	O
3	O
/	O
downstream	O
regulatory	O
element	O
sequence	O
antagonist	O
modulator	O
(	O
DREAM	O
)	O
is	O
a	O
neuronal	O
calcium	O
-	O
binding	O
protein	O
that	O
has	O
been	O
shown	O
to	O
have	O
multiple	O
functions	O
in	O
the	O
cell	O
,	O
including	O
the	O
regulation	O
of	O
presenilin	O
processing	O
,	O
repression	O
of	O
transcription	O
and	O
modulation	O
of	O
A	O
-	O
type	O
potassium	O
channels	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
precise	O
role	O
of	O
calsenilin	O
in	O
specific	O
cellular	O
compartments	O
,	O
an	O
interactor	O
hunt	O
for	O
proteins	O
that	O
bind	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
calsenilin	O
was	O
carried	O
out	O
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
system	O
and	O
co	O
-	O
immunoprecipitation	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcriptional	O
co	O
-	O
repressor	O
C	O
-	O
terminal	O
binding	O
protein	O
(	O
CtBP	O
)	O
2	O
as	O
an	O
interactor	O
for	O
calsenilin	O
and	O
have	O
shown	O
that	O
the	O
two	O
proteins	O
can	O
interact	O
in	O
vivo	O
.	O

In	O
co	O
-	O
immunoprecipitation	O
studies	O
,	O
calsenilin	O
also	O
interacted	O
with	O
CtBP1	O
,	O
a	O
CtBP2	O
homolog	O
.	O

Our	O
data	O
also	O
showed	O
a	O
calsenilin	O
-	O
dependent	O
increase	O
in	O
c	O
-	O
fos	O
protein	O
levels	O
in	O
CtBP	O
knockout	O
fibroblasts	O
,	O
suggesting	O
that	O
CtBP	O
may	O
modulate	O
the	O
transcriptional	O
repression	O
of	O
c	O
-	O
fos	O
by	O
calsenilin	O
.	O

Furthermore	O
,	O
the	O
finding	O
that	O
histone	O
deacetylase	O
protein	O
and	O
activity	O
were	O
associated	O
with	O
the	O
calsenilin	O
-	O
CtBP	O
immunocomplex	O
suggests	O
a	O
mechanism	O
by	O
which	O
calsenilin	O
-	O
CtBP	O
may	O
act	O
to	O
repress	O
transcription	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
calsenilin	O
and	O
CtBP	O
are	O
present	O
in	O
synaptic	O
vesicles	O
and	O
can	O
interact	O
in	O
vivo	O
.	O

Anti	O
-	O
CD2	O
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	O
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	O
-	O
CD2	O
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	O
-	O
CD2	O
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	O
-	O
CD2	O
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	O
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
enhancer	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	O
with	O
its	O
natural	O
ligand	O
,	O
LFA	O
-	O
3	O
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

v	O
-	O
erbA	O
overexpression	O
is	O
required	O
to	O
extinguish	O
c	O
-	O
erbA	O
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	O
.	O

The	O
v	O
-	O
erbA	O
oncoprotein	O
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3	O
/	O
T4	O
)	O
receptor	O
c	O
-	O
erbA	O
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v	O
-	O
erbA	O
and	O
c	O
-	O
erbA	O
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	O
-	O
specific	O
carbonic	O
anhydrase	O
II	O
(	O
CAII	O
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v	O
-	O
erbA	O
.	O

This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	O
transcription	O
by	O
the	O
v	O
-	O
erbA	O
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v	O
-	O
erbA	O
oncoprotein	O
and	O
the	O
c	O
-	O
erbA	O
/	O
T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	O
-	O
erbA	O
activity	O
is	O
dominant	O
over	O
v	O
-	O
erbA	O
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v	O
-	O
erbA	O
-	O
mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	O
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	O
-	O
responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	O
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O

The	O
c	O
-	O
erbA	O
-	O
dependent	O
activation	O
of	O
this	O
CAII	O
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	O
-	O
erbA	O
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v	O
-	O
erbA	O
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

Antiretroviral	O
potential	O
of	O
human	O
tripartite	O
motif	O
-	O
5	O
and	O
related	O
proteins	O
.	O

TRIM5alpha	O
is	O
a	O
potent	O
inhibitor	O
of	O
infection	O
by	O
diverse	O
retroviruses	O
and	O
is	O
encoded	O
by	O
one	O
of	O
a	O
large	O
family	O
of	O
TRIM	O
genes	O
.	O

We	O
found	O
that	O
several	O
TRIM	O
motifs	O
among	O
a	O
panel	O
of	O
selected	O
human	O
TRIM	O
proteins	O
(	O
TRIM1	O
,	O
5	O
,	O
6	O
,	O
18	O
,	O
19	O
,	O
21	O
22	O
,	O
34	O
)	O
could	O
inhibit	O
infection	O
when	O
artificially	O
targeted	O
to	O
an	O
incoming	O
HIV	O
-	O
1	O
capsid	O
.	O

Conversely	O
,	O
when	O
ectopically	O
expressed	O
as	O
authentic	O
full	O
-	O
length	O
proteins	O
,	O
most	O
lacked	O
activity	O
against	O
a	O
panel	O
of	O
retroviruses	O
.	O

The	O
exceptions	O
were	O
TRIM1	O
,	O
TRIM5	O
and	O
TRIM34	O
proteins	O
.	O

Weak	O
but	O
specific	O
inhibition	O
of	O
HIV	O
-	O
2	O
/	O
SIV	O
(	O
MAC	O
)	O
and	O
EIAV	O
by	O
TRIM34	O
was	O
noted	O
,	O
and	O
human	O
TRIM5alpha	O
modestly	O
,	O
but	O
specifically	O
,	O
inhibited	O
an	O
HIV	O
-	O
1	O
strain	O
carrying	O
a	O
mutation	O
in	O
the	O
cyclophilin	O
binding	O
loop	O
(	O
G89V	O
)	O
.	O

Restriction	O
activity	O
observed	O
in	O
ectopic	O
expression	O
assays	O
was	O
sometimes	O
not	O
detectable	O
in	O
corresponding	O
RNAi	O
-	O
based	O
knockdown	O
experiments	O
.	O

However	O
,	O
endogenous	O
owl	O
monkey	O
TRIMCyp	O
potently	O
inhibited	O
an	O
SIV	O
(	O
AGM	O
)	O
strain	O
.	O

Overall	O
,	O
sporadic	O
examples	O
of	O
intrinsic	O
antiretroviral	O
activity	O
exist	O
in	O
this	O
panel	O
of	O
TRIM	O
proteins	O
.	O

Dynamic	O
and	O
functional	O
assembly	O
of	O
the	O
AAA	O
peroxins	O
,	O
Pex1p	O
and	O
Pex6p	O
,	O
and	O
their	O
membrane	O
receptor	O
Pex26p	O
.	O

Two	O
AAA	O
peroxins	O
,	O
Pex1p	O
and	O
Pex6p	O
,	O
are	O
encoded	O
by	O
PEX1	O
and	O
PEX6	O
,	O
the	O
causal	O
genes	O
for	O
peroxisome	O
biogenesis	O
disorders	O
of	O
complementation	O
group	O
1	O
(	O
CG1	O
)	O
and	O
CG4	O
,	O
respectively	O
.	O

PEX26	O
responsible	O
for	O
peroxisome	O
biogenesis	O
disorders	O
of	O
CG8	O
encodes	O
Pex26p	O
,	O
the	O
recruiter	O
of	O
Pex1p	O
.	O
Pex6p	O
complexes	O
to	O
peroxisomes	O
.	O

We	O
herein	O
assigned	O
the	O
binding	O
regions	O
between	O
human	O
Pex1p	O
and	O
Pex6p	O
and	O
elucidated	O
pivotal	O
roles	O
of	O
the	O
AAA	O
cassettes	O
,	O
called	O
D1	O
and	O
D2	O
domains	O
,	O
in	O
Pex1p	O
-	O
Pex6p	O
interaction	O
and	O
peroxisome	O
biogenesis	O
.	O

ATP	O
binding	O
in	O
both	O
AAA	O
cassettes	O
but	O
not	O
ATP	O
hydrolysis	O
in	O
D2	O
of	O
both	O
Pex1p	O
and	O
Pex6p	O
was	O
prerequisite	O
for	O
Pex1p	O
-	O
Pex6p	O
interaction	O
and	O
their	O
peroxisomal	O
localization	O
.	O

The	O
AAA	O
cassettes	O
,	O
D1	O
and	O
D2	O
,	O
were	O
essential	O
for	O
peroxisome	O
-	O
restoring	O
activity	O
of	O
Pex1p	O
and	O
Pex6p	O
.	O

In	O
HEK293	O
cells	O
,	O
endogenous	O
Pex1p	O
was	O
partly	O
localized	O
likely	O
as	O
a	O
homo	O
-	O
oligomer	O
in	O
the	O
cytoplasm	O
,	O
while	O
Pex6p	O
and	O
Pex26p	O
were	O
predominantly	O
localized	O
on	O
peroxisomes	O
.	O

Interaction	O
of	O
Pex1p	O
with	O
Pex6p	O
conferred	O
a	O
conformational	O
change	O
and	O
dissociation	O
of	O
the	O
Pex1p	O
oligomer	O
.	O

These	O
results	O
suggested	O
that	O
Pex1p	O
possesses	O
two	O
distinct	O
oligomeric	O
forms	O
,	O
a	O
homo	O
-	O
oligomer	O
in	O
the	O
cytosol	O
and	O
a	O
hetero	O
-	O
oligomer	O
on	O
peroxisome	O
membranes	O
,	O
possibly	O
playing	O
distinct	O
functions	O
in	O
peroxisome	O
biogenesis	O
.	O

Genetic	O
analysis	O
of	O
slipper	O
/	O
mixed	O
lineage	O
kinase	O
reveals	O
requirements	O
in	O
multiple	O
Jun	O
-	O
N	O
-	O
terminal	O
kinase	O
-	O
dependent	O
morphogenetic	O
events	O
during	O
Drosophila	O
development	O
.	O

Mixed	O
lineage	O
kinases	O
(	O
MLKs	O
)	O
function	O
as	O
Jun	O
-	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
kinase	O
kinases	O
to	O
transduce	O
extracellular	O
signals	O
during	O
development	O
and	O
homeostasis	O
in	O
adults	O
.	O
slipper	O
(	O
slpr	O
)	O
,	O
which	O
encodes	O
the	O
Drosophila	O
homolog	O
of	O
mammalian	O
MLKs	O
,	O
has	O
previously	O
been	O
implicated	O
in	O
activation	O
of	O
the	O
JNK	O
pathway	O
during	O
embryonic	O
dorsal	O
epidermal	O
closure	O
.	O

To	O
further	O
define	O
the	O
specific	O
functions	O
of	O
SLPR	O
,	O
we	O
analyzed	O
the	O
phenotypic	O
consequences	O
of	O
slpr	O
loss	O
and	O
gain	O
of	O
function	O
throughout	O
development	O
,	O
using	O
a	O
semiviable	O
maternal	O
-	O
effect	O
allele	O
and	O
wild	O
-	O
type	O
or	O
dominant	O
-	O
negative	O
transgenes	O
.	O

From	O
these	O
analyses	O
we	O
confirm	O
that	O
failure	O
of	O
dorsal	O
closure	O
is	O
the	O
null	O
phenotype	O
in	O
slpr	O
germline	O
clones	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
functional	O
maternal	O
contribution	O
,	O
which	O
can	O
suffice	O
for	O
embryogenesis	O
in	O
the	O
zygotic	O
null	O
mutant	O
,	O
but	O
rarely	O
suffices	O
for	O
pupal	O
metamorphosis	O
,	O
revealing	O
later	O
functions	O
for	O
slpr	O
as	O
the	O
maternal	O
contribution	O
is	O
depleted	O
.	O

Zygotic	O
null	O
mutants	O
that	O
eclose	O
as	O
adults	O
display	O
an	O
array	O
of	O
morphological	O
defects	O
,	O
many	O
of	O
which	O
are	O
shared	O
by	O
hep	O
mutant	O
animals	O
,	O
deficient	O
in	O
the	O
JNK	O
kinase	O
(	O
JNKK	O
/	O
MKK7	O
)	O
substrate	O
for	O
SLPR	O
,	O
suggesting	O
that	O
the	O
defects	O
observed	O
in	O
slpr	O
mutants	O
primarily	O
reflect	O
loss	O
of	O
hep	O
-	O
dependent	O
JNK	O
activation	O
.	O

Consistent	O
with	O
this	O
,	O
the	O
maternal	O
slpr	O
contribution	O
is	O
sensitive	O
to	O
the	O
dosage	O
of	O
positive	O
and	O
negative	O
JNK	O
pathway	O
regulators	O
,	O
which	O
attenuate	O
or	O
potentiate	O
SLPR	O
-	O
dependent	O
signaling	O
in	O
development	O
.	O

Although	O
SLPR	O
and	O
TAK1	O
,	O
another	O
JNKKK	O
family	O
member	O
,	O
are	O
differentially	O
used	O
in	O
dorsal	O
closure	O
and	O
TNF	O
/	O
Eiger	O
-	O
stimulated	O
apoptosis	O
,	O
respectively	O
,	O
a	O
Tak1	O
mutant	O
shows	O
dominant	O
genetic	O
interactions	O
with	O
slpr	O
,	O
suggesting	O
potential	O
redundant	O
or	O
combinatorial	O
functions	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
SLPR	O
overexpression	O
can	O
induce	O
ectopic	O
JNK	O
signaling	O
and	O
that	O
the	O
SLPR	O
protein	O
is	O
enriched	O
at	O
the	O
epithelial	O
cell	O
cortex	O
.	O

Chemical	O
characterization	O
of	O
the	O
parasitophorous	O
vacuole	O
membrane	O
antigen	O
QF	O
116	O
from	O
Plasmodium	O
falciparum	O
.	O

On	O
the	O
basis	O
of	O
amino	O
acid	O
sequencing	O
and	O
immunological	O
cross	O
-	O
reactivity	O
,	O
the	O
Plasmodium	O
falciparum	O
parasitophorous	O
vacuole	O
antigens	O
QF116	O
and	O
exp	O
-	O
1	O
/	O
CRA	O
are	O
apparently	O
identical	O
.	O

The	O
epitope	O
recognized	O
by	O
an	O
inhibitory	O
monoclonal	O
antibody	O
directed	O
against	O
QF116	O
is	O
located	O
proximal	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
QF116	O
protein	O
is	O
processed	O
during	O
maturation	O
by	O
the	O
cleavage	O
of	O
a	O
22	O
-	O
amino	O
-	O
acid	O
signal	O
peptide	O
and	O
acylated	O
as	O
measured	O
by	O
labeling	O
with	O
myristic	O
acid	O
.	O

Ubiquitin	O
and	O
ubiquitin	O
-	O
like	O
modifications	O
of	O
the	O
p53	O
family	O
.	O

Regulation	O
of	O
p53	O
by	O
the	O
ubiquitin	O
-	O
proteasomal	O
pathway	O
has	O
been	O
studied	O
considerably	O
.	O

Studies	O
have	O
also	O
demonstrated	O
that	O
the	O
ubiquitin	O
-	O
like	O
proteins	O
SUMO	O
-	O
1	O
and	O
NEDD8	O
modify	O
p53	O
.	O

Similarly	O
,	O
p63	O
and	O
p73	O
are	O
subject	O
to	O
regulation	O
by	O
ubiquitin	O
and	O
ubiquitin	O
-	O
like	O
modifications	O
,	O
and	O
perturbations	O
of	O
these	O
pathways	O
in	O
the	O
regulation	O
of	O
the	O
p53	O
family	O
have	O
been	O
implicated	O
in	O
tumorigenesis	O
and	O
developmental	O
abnormalities	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
the	O
p53	O
family	O
by	O
covalent	O
modification	O
by	O
ubiquitin	O
,	O
SUMO	O
-	O
1	O
,	O
and	O
NEDD8	O
.	O

Insulin	O
secretion	O
:	O
SIRT4	O
gets	O
in	O
on	O
the	O
act	O
.	O

Despite	O
their	O
initial	O
characterization	O
as	O
histone	O
deacetylases	O
controlling	O
transcription	O
,	O
sirtuins	O
also	O
turn	O
out	O
to	O
be	O
critical	O
regulators	O
of	O
metabolism	O
.	O

In	O
this	O
issue	O
of	O
Cell	O
,	O
Haigis	O
et	O
al	O
.	O

(	O
2006	O
)	O
demonstrate	O
that	O
the	O
mammalian	O
Sir2	O
homolog	O
SIRT4	O
acts	O
in	O
the	O
mitochondria	O
of	O
pancreatic	O
beta	O
cells	O
to	O
repress	O
the	O
activity	O
of	O
glutamate	O
dehydrogenase	O
through	O
ADP	O
-	O
ribosylation	O
.	O

In	O
this	O
way	O
,	O
SIRT4	O
downregulates	O
insulin	O
secretion	O
by	O
beta	O
cells	O
in	O
response	O
to	O
amino	O
acids	O
.	O

Simple	O
histone	O
acetylation	O
plays	O
a	O
complex	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Eukaryotic	O
DNA	O
is	O
packaged	O
into	O
chromatin	O
by	O
histone	O
proteins	O
,	O
which	O
assemble	O
the	O
DNA	O
into	O
an	O
organized	O
,	O
higher	O
-	O
order	O
structure	O
.	O

The	O
precise	O
organization	O
of	O
chromatin	O
is	O
essential	O
for	O
faithful	O
execution	O
of	O
DNA	O
-	O
mediated	O
reactions	O
such	O
as	O
transcription	O
,	O
DNA	O
replication	O
,	O
DNA	O
repair	O
and	O
DNA	O
recombination	O
.	O

The	O
organization	O
of	O
chromatin	O
is	O
considered	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
histones	O
,	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
SUMOylation	O
and	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O

The	O
relationship	O
between	O
histone	O
acetylation	O
and	O
gene	O
expression	O
was	O
first	O
observed	O
in	O
1964	O
.	O

Since	O
then	O
,	O
a	O
great	O
deal	O
of	O
evidence	O
has	O
accumulated	O
showing	O
that	O
not	O
only	O
transcription	O
but	O
other	O
DNA	O
-	O
mediated	O
reactions	O
also	O
are	O
regulated	O
by	O
histone	O
acetylation	O
.	O

With	O
regard	O
to	O
the	O
putative	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
histone	O
acetylation	O
regulates	O
the	O
flow	O
of	O
genetic	O
information	O
,	O
site	O
-	O
specific	O
modification	O
and	O
recognition	O
of	O
acetylated	O
histone	O
/	O
DNA	O
complexes	O
have	O
been	O
postulated	O
.	O

Elucidation	O
of	O
the	O
downstream	O
effects	O
of	O
histone	O
modification	O
,	O
as	O
well	O
as	O
the	O
identification	O
,	O
isolation	O
and	O
characterization	O
of	O
the	O
relevant	O
factors	O
involved	O
,	O
have	O
aided	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
regulation	O
of	O
DNA	O
activity	O
by	O
histones	O
.	O

Currently	O
,	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
technologies	O
that	O
enable	O
genome	O
-	O
wide	O
analysis	O
are	O
allowing	O
insight	O
into	O
a	O
critical	O
and	O
interesting	O
question	O
in	O
eukaryotic	O
transcription	O
:	O
are	O
the	O
principles	O
that	O
govern	O
transcription	O
of	O
individual	O
gene	O
loci	O
applicable	O
to	O
the	O
genome	O
as	O
a	O
whole	O
?	O

Here	O
,	O
we	O
review	O
the	O
recent	O
progress	O
on	O
histone	O
modifications	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
role	O
of	O
histone	O
acetylation	O
in	O
gene	O
expression	O
.	O

NF	B-OOS
-	I-OOS
X2	I-OOS
that	O
binds	O
to	O
the	O
DRA	O
X2	O
-	O
box	O
is	O
activator	B-Complex
protein	I-Complex
1	I-Complex
.	O

Expression	O
cloning	O
of	O
c	O
-	O
Jun	O
.	O

Human	O
class	B-Complex
II	I-Complex
MHC	I-Complex
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	O
-	O
gamma	O
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	B-Complex
II	I-Complex
genes	O
.	O

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2	O
-	O
box	O
to	O
which	O
nuclear	B-OOS
factor	I-OOS
X2	I-OOS
(	O
NF	B-OOS
-	I-OOS
X2	I-OOS
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	B-OOS
-	I-OOS
X2	I-OOS
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c	O
-	O
Jun	O
protein	O
,	O
which	O
together	O
with	O
c	O
-	O
Fos	O
forms	O
the	O
heterodimeric	O
activator	B-Complex
protein	I-Complex
-	I-Complex
1	I-Complex
transcription	O
complex	O
.	O

Whereas	O
c	O
-	O
Fos	O
/	O
c	O
-	O
Jun	O
heterodimers	O
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2	O
-	O
box	O
in	O
class	B-Complex
II	I-Complex
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c	O
-	O
Fos	O
/	O
c	O
-	O
Jun	O
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	O
gene	O
expression	O
.	O

Processing	O
of	O
the	O
gastrin	O
precursor	O
.	O

Modulation	O
of	O
phosphorylated	O
,	O
sulfated	O
,	O
and	O
amidated	O
products	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
the	O
precursor	O
for	O
rat	O
gastrin	O
yields	O
products	O
that	O
include	O
peptides	O
phosphorylated	O
at	O
Ser96	O
,	O
amidated	O
at	O
Phe92	O
,	O
and	O
sulfated	O
at	O
Tyr87	O
or	O
Tyr103	O
.	O

The	O
phosphorylation	O
site	O
is	O
immediately	O
adjacent	O
to	O
the	O
processing	O
point	O
that	O
gives	O
rise	O
to	O
the	O
biologically	O
active	O
amidated	O
gastrins	O
.	O

We	O
have	O
examined	O
changes	O
in	O
post	O
-	O
translational	O
processing	O
which	O
occur	O
in	O
gastrin	O
cells	O
from	O
rats	O
that	O
are	O
physiologically	O
stimulated	O
(	O
by	O
feeding	O
)	O
or	O
unstimulated	O
(	O
by	O
fasting	O
)	O
.	O

Peptides	O
were	O
identified	O
using	O
site	O
-	O
directed	O
radioimmunoassays	O
and	O
chromatographic	O
systems	O
that	O
resolve	O
phosphorylated	O
,	O
amidated	O
,	O
and	O
sulfated	O
progastrin	O
products	O
,	O
including	O
intermediates	O
generated	O
prior	O
to	O
amidation	O
(	O
i	O
.	O
e	O
.	O
C	O
-	O
terminal	O
glycine	O
-	O
extended	O
variants	O
)	O
.	O

Assays	O
for	O
Phe92	O
-	O
amidated	O
peptides	O
and	O
for	O
the	O
C	O
-	O
terminal	O
tryptic	O
fragment	O
of	O
progastrin	O
indicated	O
decreases	O
in	O
the	O
total	O
tissue	O
concentrations	O
of	O
immunoreactive	O
peptide	O
with	O
fasting	O
;	O
in	O
contrast	O
,	O
the	O
tissue	O
concentrations	O
of	O
glycine	O
-	O
extended	O
biosynthetic	O
intermediates	O
were	O
similar	O
in	O
fasted	O
and	O
fed	O
rats	O
.	O

Taken	O
together	O
the	O
data	O
suggest	O
a	O
relative	O
failure	O
in	O
amidation	O
mechanisms	O
in	O
unstimulated	O
cells	O
.	O

The	O
endopeptidase	O
cleavage	O
of	O
progastrin	O
was	O
not	O
influenced	O
significantly	O
by	O
fasting	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
peptide	O
products	O
containing	O
Ser96	O
was	O
depressed	O
significantly	O
in	O
fasted	O
rats	O
.	O

The	O
proportions	O
of	O
amidated	O
peptides	O
sulfated	O
at	O
Tyr87	O
were	O
generally	O
lower	O
than	O
their	O
corresponding	O
glycine	O
-	O
extended	O
biosynthetic	O
precursors	O
,	O
but	O
in	O
both	O
cases	O
the	O
proportion	O
of	O
peptide	O
in	O
the	O
sulfated	O
form	O
was	O
lower	O
than	O
for	O
peptides	O
sulfated	O
at	O
Tyr103	O
.	O

Feeding	O
did	O
not	O
change	O
the	O
sulfation	O
of	O
amidated	O
heptadecapeptide	O
gastrin	O
or	O
its	O
glycine	O
-	O
extended	O
variant	O
.	O

The	O
results	O
suggest	O
that	O
the	O
mechanisms	O
determining	O
phosphorylation	O
and	O
amidation	O
of	O
progastrin	O
-	O
related	O
peptides	O
depend	O
on	O
the	O
patterns	O
of	O
stimulation	O
of	O
gastrin	O
cells	O
.	O

The	O
observation	O
that	O
decreased	O
phosphorylation	O
is	O
associated	O
with	O
a	O
failure	O
to	O
produce	O
active	O
amidated	O
products	O
is	O
consistent	O
with	O
a	O
regulatory	O
function	O
for	O
phosphorylation	O
in	O
gastrin	O
production	O
.	O

KIT	O
and	O
PDGFRA	O
mutations	O
in	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
.	O

Mutually	O
exclusive	O
KIT	O
and	O
PDGFRA	O
mutations	O
are	O
central	O
events	O
in	O
GIST	O
pathogenesis	O
,	O
and	O
their	O
understanding	O
is	O
becoming	O
increasingly	O
important	O
,	O
because	O
specific	O
treatment	O
targeting	O
oncogenic	O
KIT	O
and	O
PDGFRA	O
activation	O
(	O
especially	O
imatinib	O
mesylate	O
)	O
has	O
become	O
available	O
.	O

KIT	O
mutations	O
in	O
GIST	O
are	O
clustered	O
in	O
four	O
exons	O
.	O

Most	O
common	O
are	O
exon	O
11	O
(	O
juxtamembrane	O
domain	O
)	O
mutations	O
that	O
include	O
deletions	O
,	O
point	O
mutations	O
(	O
affecting	O
a	O
few	O
codons	O
)	O
,	O
and	O
duplications	O
(	O
mostly	O
in	O
the	O
3	O
'	O
region	O
)	O
.	O

The	O
latter	O
mutations	O
most	O
often	O
occur	O
in	O
gastric	O
GISTs	O
.	O

Among	O
gastric	O
GISTs	O
,	O
tumors	O
with	O
deletions	O
are	O
more	O
aggressive	O
than	O
those	O
with	O
point	O
mutations	O
;	O
this	O
does	O
not	O
seem	O
to	O
hold	O
true	O
in	O
small	O
intestinal	O
GISTs	O
.	O

Exon	O
9	O
mutations	O
(	O
5	O
-	O
10	O
%	O
)	O
usually	O
are	O
2	O
-	O
codon	O
502	O
-	O
503	O
duplications	O
,	O
and	O
these	O
occur	O
predominantly	O
in	O
intestinal	O
versus	O
gastric	O
GISTs	O
.	O

Lesser	O
imatinib	O
sensitivity	O
of	O
these	O
tumors	O
has	O
been	O
noted	O
.	O

Kinase	O
domain	O
mutations	O
are	O
very	O
rare	O
;	O
GISTs	O
with	O
such	O
mutations	O
are	O
variably	O
sensitive	O
to	O
imatinib	O
.	O

PDGFRA	O
mutations	O
usually	O
occur	O
in	O
gastric	O
GISTs	O
,	O
especially	O
in	O
the	O
epithelioid	O
variants	O
;	O
their	O
overall	O
frequency	O
is	O
approximately	O
30	O
%	O
to	O
40	O
%	O
of	O
KIT	O
mutation	O
negative	O
GISTs	O
.	O

Most	O
common	O
is	O
exon	O
18	O
mutation	O
leading	O
Asp842Val	O
at	O
the	O
protein	O
level	O
.	O

This	O
mutation	O
causes	O
imatinib	O
resistance	O
.	O

Exon	O
12	O
and	O
14	O
mutations	O
are	O
rare	O
.	O

Most	O
mutations	O
are	O
somatic	O
(	O
in	O
tumor	O
tissue	O
only	O
)	O
,	O
but	O
patients	O
with	O
familial	O
GIST	O
syndrome	O
have	O
consitutitonal	O
KIT	O
/	O
PDGFRA	O
mutations	O
;	O
>	O
10	O
families	O
have	O
been	O
reported	O
worldwide	O
with	O
mutations	O
generally	O
similar	O
to	O
those	O
in	O
sporadic	O
GISTs	O
.	O

GISTs	O
in	O
neurofibromatosis	O
1	O
patients	O
,	O
children	O
,	O
and	O
Carney	O
triad	O
seem	O
to	O
lack	O
GIST	O
-	O
specific	O
KIT	O
and	O
PDGFRA	O
mutations	O
and	O
may	O
have	O
a	O
different	O
disease	O
mechanism	O
.	O

Secondary	O
mutations	O
usually	O
occur	O
in	O
KIT	O
kinase	O
domains	O
in	O
patients	O
after	O
imatinib	O
treatment	O
resulting	O
in	O
resistance	O
to	O
this	O
drug	O
.	O

Mutation	O
genotyping	O
is	O
a	O
tool	O
in	O
GIST	O
diagnosis	O
and	O
in	O
assessment	O
of	O
sensitivity	O
to	O
kinase	O
inhibitors	O
.	O

This	O
is	O
a	O
US	O
government	O
work	O
.	O

There	O
are	O
no	O
restrictions	O
on	O
its	O
use	O
.	O

Expression	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
human	O
acetyl	O
-	O
CoA	O
carboxylase	O
2	O
.	O

The	O
full	O
-	O
length	O
human	O
acetyl	O
-	O
CoA	O
carboxylase	O
1	O
(	O
ACC1	O
)	O
was	O
expressed	O
and	O
purified	O
to	O
homogeneity	O
by	O
two	O
separate	O
groups	O
(	O
Y	O
.	O
G	O
.	O

Gu	O
,	O
M	O
.	O

Weitzberg	O
,	O
R	O
.	O
F	O
.	O

Clark	O
,	O
X	O
.	O

Xu	O
,	O
Q	O
.	O

Li	O
,	O
T	O
.	O

Zhang	O
,	O
T	O
.	O
M	O
.	O

Hansen	O
,	O
G	O
.	O

Liu	O
,	O
Z	O
.	O

Xin	O
,	O
X	O
.	O

Wang	O
,	O
T	O
.	O

McNally	O
,	O
H	O
.	O

Camp	O
,	O
B	O
.	O
A	O
.	O

Beutel	O
,	O
H	O
.	O
I	O
.	O

Sham	O
,	O
Synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
N	O
-	O
{	O
3	O
-	O
[	O
2	O
-	O
(	O
4	O
-	O
alkoxyphenoxy	O
)	O
thiazol	O
-	O
5	O
-	O
yl	O
]	O
-	O
1	O
-	O
methylprop	O
-	O
2	O
-	O
ynyl	O
}	O
carboxy	O
derivatives	O
as	O
selective	O
acetyl	O
-	O
CoA	O
carboxylase	O
2	O
inhibitors	O
,	O
J	O
.	O

Med	O
.	O

Chem	O
.	O

49	O
(	O
2006	O
)	O
3770	O
-	O
3773	O
;	O
D	O
.	O

Cheng	O
,	O
C	O
.	O
H	O
.	O

Chu	O
,	O
L	O
.	O

Chen	O
,	O
J	O
.	O
N	O
.	O

Feder	O
,	O
G	O
.	O
A	O
.	O

Mintier	O
,	O
Y	O
.	O

Wu	O
,	O
J	O
.	O
W	O
.	O

Cook	O
,	O
M	O
.	O
R	O
.	O

Harpel	O
,	O
G	O
.	O
A	O
.	O

Locke	O
,	O
Y	O
.	O

An	O
,	O
J	O
.	O
K	O
.	O

Tamura	O
,	O
Expression	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
human	O
and	O
rat	O
acetyl	B-Complex
coenzyme	I-Complex
A	I-Complex
carboxylase	I-Complex
(	O
ACC	B-Complex
)	O
isozymes	O
,	O
Protein	O
Expr	O
.	O

Purif	O
.	O
,	O
in	O
press	O
)	O
.	O

However	O
,	O
neither	O
group	O
was	O
successful	O
in	O
expressing	O
the	O
full	O
-	O
length	O
ACC2	O
due	O
to	O
issues	O
of	O
solubility	O
and	O
expression	O
levels	O
.	O

The	O
two	O
versions	O
of	O
recombinant	O
human	O
ACC2	O
in	O
these	O
reports	O
are	O
either	O
truncated	O
(	O
lacking	O
1	O
-	O
148	O
aa	O
)	O
or	O
have	O
the	O
N	O
-	O
terminal	O
275	O
aa	O
replaced	O
with	O
the	O
corresponding	O
ACC1	O
region	O
(	O
1	O
-	O
133	O
aa	O
)	O
.	O

Despite	O
the	O
fact	O
that	O
ACC	B-Complex
activity	O
was	O
observed	O
in	O
both	O
cases	O
,	O
these	O
constructs	O
are	O
not	O
ideal	O
because	O
the	O
N	O
-	O
terminal	O
region	O
of	O
ACC2	O
could	O
be	O
important	O
for	O
the	O
correct	O
folding	O
of	O
the	O
catalytic	O
domains	O
.	O

Here	O
,	O
we	O
report	O
the	O
high	O
level	O
expression	O
and	O
purification	O
of	O
full	O
-	O
length	O
human	O
ACC2	O
that	O
lacks	O
only	O
the	O
N	O
-	O
terminal	O
membrane	O
attachment	O
sequence	O
(	O
1	O
-	O
20	O
and	O
1	O
-	O
26	O
aa	O
,	O
respectively	O
)	O
in	O
Trichoplusia	O
ni	O
cells	O
.	O

In	O
addition	O
,	O
we	O
developed	O
a	O
sensitive	O
HPLC	O
assay	O
to	O
analyze	O
the	O
kinetic	O
parameters	O
of	O
the	O
recombinant	O
enzyme	O
.	O

The	O
recombinant	O
enzyme	O
is	O
a	O
soluble	O
protein	O
and	O
has	O
a	O
K	O
(	O
m	O
)	O
value	O
of	O
2	O
microM	O
for	O
acetyl	O
-	O
CoA	O
,	O
almost	O
30	O
-	O
fold	O
lower	O
than	O
that	O
reported	O
for	O
the	O
truncated	O
human	O
ACC2	O
.	O

Our	O
recombinant	O
enzyme	O
also	O
has	O
a	O
lower	O
K	O
(	O
m	O
)	O
value	O
for	O
ATP	O
(	O
K	O
(	O
m	O
)	O
=	O
52	O
microM	O
)	O
.	O

Although	O
this	O
difference	O
could	O
be	O
ascribed	O
to	O
different	O
assay	O
conditions	O
,	O
our	O
data	O
suggest	O
that	O
the	O
longer	O
human	O
ACC2	O
produced	O
in	O
our	O
system	O
may	O
have	O
higher	O
affinities	O
for	O
the	O
substrates	O
and	O
could	O
be	O
more	O
similar	O
to	O
the	O
native	O
enzyme	O
.	O

Human	O
and	O
murine	O
granzyme	O
B	O
exhibit	O
divergent	O
substrate	O
preferences	O
.	O

The	O
cytotoxic	O
lymphocyte	O
protease	O
granzyme	O
B	O
(	O
GzmB	O
)	O
can	O
promote	O
apoptosis	O
through	O
direct	O
processing	O
and	O
activation	O
of	O
members	O
of	O
the	O
caspase	O
family	O
.	O

GzmB	O
can	O
also	O
cleave	O
the	O
BH3	O
-	O
only	O
protein	O
,	O
BID	O
,	O
to	O
promote	O
caspase	O
-	O
independent	O
mitochondrial	O
permeabilization	O
.	O

Although	O
human	O
and	O
mouse	O
forms	O
of	O
GzmB	O
exhibit	O
extensive	O
homology	O
,	O
these	O
proteases	O
diverge	O
at	O
residues	O
predicted	O
to	O
influence	O
substrate	O
binding	O
.	O

We	O
show	O
that	O
human	O
and	O
mouse	O
GzmB	O
exhibit	O
radical	O
differences	O
in	O
their	O
ability	O
to	O
cleave	O
BID	O
,	O
as	O
well	O
as	O
several	O
other	O
key	O
substrates	O
,	O
such	O
as	O
ICAD	O
and	O
caspase	O
-	O
8	O
.	O

Moreover	O
,	O
pharmacological	O
inhibition	O
of	O
caspases	O
clonogenically	O
rescued	O
human	O
and	O
mouse	O
target	O
cells	O
from	O
apoptosis	O
initiated	O
by	O
mouse	O
GzmB	O
,	O
but	O
failed	O
to	O
do	O
so	O
in	O
response	O
to	O
human	O
GzmB	O
.	O

These	O
data	O
demonstrate	O
that	O
human	O
and	O
murine	O
GzmB	O
are	O
distinct	O
enzymes	O
with	O
different	O
substrate	O
preferences	O
.	O

Our	O
observations	O
also	O
illustrate	O
how	O
subtle	O
differences	O
in	O
enzyme	O
structure	O
can	O
radically	O
affect	O
substrate	O
selection	O
.	O

Activation	O
of	O
a	O
novel	O
pathway	O
involving	O
Mms1	O
and	O
Rad59	O
in	O
sgs1	O
cells	O
.	O

Unequal	O
sister	O
chromatid	O
recombination	O
(	O
uSCR	O
)	O
is	O
elevated	O
in	O
budding	O
yeast	O
sgs1	O
mutants	O
,	O
which	O
lack	O
a	O
homolog	O
of	O
the	O
human	O
BLM	O
gene	O
that	O
causes	O
Bloom	O
syndrome	O
.	O

Examination	O
of	O
the	O
mechanism	O
responsible	O
for	O
elevated	O
uSCR	O
in	O
sgs1	O
mutants	O
showed	O
that	O
mutation	O
of	O
RAD51	O
also	O
resulted	O
in	O
hyper	O
-	O
uSCR	O
.	O

Data	O
from	O
this	O
study	O
show	O
that	O
defects	O
in	O
the	O
Rad51	O
-	O
Sgs1	O
-	O
dependent	O
and	O
Sgs1	O
-	O
dependent	O
lesion	O
-	O
bypass	O
pathways	O
activate	O
Rad59	O
-	O
Rad1	O
-	O
and	O
Rad59	O
-	O
dependent	O
pathways	O
,	O
respectively	O
,	O
resulting	O
in	O
uSCR	O
.	O

Moreover	O
,	O
the	O
elevation	O
of	O
uSCR	O
in	O
sgs1	O
and	O
rad51	O
mutants	O
was	O
dependent	O
on	O
MMS1	O
,	O
which	O
encodes	O
one	O
of	O
the	O
components	O
of	O
the	O
Mms22	O
module	O
.	O

Lastly	O
,	O
a	O
putative	O
role	O
of	O
Mms1	O
in	O
the	O
elevation	O
of	O
uSCR	O
and	O
a	O
possible	O
mechanism	O
by	O
which	O
uSCR	O
is	O
elevated	O
as	O
a	O
result	O
of	O
defective	O
Sgs1	O
and	O
Rad51	O
are	O
discussed	O
.	O

Potential	O
interface	O
between	O
ribosomal	O
protein	O
production	O
and	O
pre	O
-	O
rRNA	O
processing	O
.	O

It	O
has	O
become	O
clear	O
that	O
in	O
Saccharomyces	O
cerevisiae	O
the	O
transcription	O
of	O
ribosomal	O
protein	O
genes	O
,	O
which	O
makes	O
up	O
a	O
major	O
proportion	O
of	O
the	O
total	O
transcription	O
by	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
,	O
is	O
controlled	O
by	O
the	O
interaction	O
of	O
three	O
transcription	O
factors	O
,	O
Rap1	O
,	O
Fhl1	O
,	O
and	O
Ifh1	O
.	O

Of	O
these	O
,	O
only	O
Rap1	O
binds	O
directly	O
to	O
DNA	O
and	O
only	O
Ifh1	O
is	O
absent	O
when	O
transcription	O
is	O
repressed	O
.	O

We	O
have	O
examined	O
further	O
the	O
nature	O
of	O
this	O
interaction	O
and	O
find	O
that	O
Ifh1	O
is	O
actually	O
associated	O
with	O
at	O
least	O
two	O
complexes	O
.	O

In	O
addition	O
to	O
its	O
association	O
with	O
Rap1	O
and	O
Fhl1	O
,	O
Ifh1	O
forms	O
a	O
complex	O
(	O
CURI	B-Complex
)	O
with	O
casein	B-Complex
kinase	I-Complex
2	I-Complex
(	O
CK2	B-Complex
)	O
,	O
Utp22	O
,	O
and	O
Rrp7	O
.	O

Fhl1	O
is	O
loosely	O
associated	O
with	O
the	O
CURI	B-Complex
complex	O
;	O
its	O
absence	O
partially	O
destabilizes	O
the	O
complex	O
.	O

The	O
CK2	B-Complex
within	O
the	O
complex	O
phosphorylates	O
Ifh1	O
in	O
vitro	O
but	O
no	O
other	O
members	O
of	O
the	O
complex	O
.	O

Two	O
major	O
components	O
of	O
this	O
complex	O
,	O
Utp22	O
and	O
Rrp7	O
,	O
are	O
essential	O
participants	O
in	O
the	O
processing	O
of	O
pre	O
-	O
rRNA	O
.	O

Depletion	O
of	O
either	O
protein	O
,	O
but	O
not	O
of	O
other	O
proteins	O
in	O
the	O
early	O
processing	O
steps	O
,	O
brings	O
about	O
a	O
substantial	O
increase	O
in	O
ribosomal	O
protein	O
mRNA	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
the	O
CURI	B-Complex
complex	O
is	O
a	O
key	O
mediator	O
between	O
the	O
two	O
parallel	O
pathways	O
necessary	O
for	O
ribosome	B-OOS
synthesis	O
:	O
the	O
transcription	O
and	O
processing	O
of	O
pre	O
-	O
rRNA	O
and	O
the	O
transcription	O
of	O
ribosomal	O
protein	O
genes	O
.	O

Post	O
-	O
translational	O
regulation	O
of	O
the	O
Drosophila	O
circadian	O
clock	O
requires	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
.	O

Phosphorylation	O
is	O
an	O
important	O
timekeeping	O
mechanism	O
in	O
the	O
circadian	O
clock	O
that	O
has	O
been	O
closely	O
studied	O
at	O
the	O
level	O
of	O
the	O
kinases	O
involved	O
but	O
may	O
also	O
be	O
tightly	O
controlled	O
by	O
phosphatase	O
action	O
.	O

Here	O
we	O
demonstrate	O
a	O
role	O
for	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
in	O
the	O
regulation	O
of	O
the	O
major	O
timekeeping	O
molecules	O
in	O
the	O
Drosophila	O
clock	O
,	O
TIMELESS	O
(	O
TIM	O
)	O
and	O
PERIOD	O
(	O
PER	O
)	O
.	O

Flies	O
with	O
reduced	O
PP1	B-Complex
activity	O
exhibit	O
a	O
lengthened	O
circadian	O
period	O
,	O
reduced	O
amplitude	O
of	O
behavioral	O
rhythms	O
,	O
and	O
an	O
altered	O
response	O
to	O
light	O
that	O
suggests	O
a	O
defect	O
in	O
the	O
rising	O
phase	O
of	O
clock	O
protein	O
expression	O
.	O

On	O
a	O
molecular	O
level	O
,	O
PP1	B-Complex
directly	O
dephosphorylates	O
TIM	O
and	O
stabilizes	O
it	O
in	O
both	O
S2R	O
(	O
+	O
)	O
cells	O
and	O
clock	O
neurons	O
.	O

However	O
,	O
PP1	B-Complex
does	O
not	O
act	O
in	O
a	O
simple	O
antagonistic	O
manner	O
to	O
SHAGGY	O
(	O
SGG	O
)	O
,	O
the	O
kinase	O
that	O
phosphorylates	O
TIM	O
,	O
because	O
the	O
behavioral	O
phenotypes	O
produced	O
by	O
inhibiting	O
PP1	B-Complex
in	O
flies	O
are	O
different	O
from	O
those	O
achieved	O
by	O
overexpressing	O
SGG	O
.	O

PP1	B-Complex
also	O
acts	O
on	O
PER	O
,	O
and	O
TIM	O
regulates	O
the	O
control	O
of	O
PER	O
by	O
PP1	B-Complex
,	O
although	O
it	O
does	O
not	O
affect	O
PP2A	B-Complex
action	O
on	O
PER	O
.	O

We	O
propose	O
a	O
modified	O
model	O
for	O
post	O
-	O
translational	O
regulation	O
of	O
the	O
Drosophila	O
clock	O
,	O
in	O
which	O
PP1	B-Complex
is	O
critical	O
for	O
the	O
rhythmic	O
abundance	O
of	O
TIM	O
/	O
PER	O
while	O
PP2A	B-Complex
also	O
regulates	O
the	O
nuclear	O
translocation	O
of	O
TIM	O
/	O
PER	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	O
nuclear	O
factor	O
-	O
1	O
alpha	O
(	O
HNF	O
-	O
1	O
alpha	O
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	O
cofactor	O
of	O
HNF	O
-	O
1	O
alpha	O
(	O
DCoH	O
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF	O
-	O
1	O
alpha	O
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH	O
-	O
HNF	O
-	O
1	O
alpha	O
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF	O
-	O
1	O
alpha	O
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF	O
-	O
1	O
alpha	O
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	O
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	O
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Ubiquitination	O
of	O
beta	O
-	O
arrestin	O
links	O
seven	O
-	O
transmembrane	O
receptor	O
endocytosis	O
and	O
ERK	O
activation	O
.	O

Beta	O
-	O
arrestin2	O
and	O
its	O
ubiquitination	O
play	O
crucial	O
roles	O
in	O
both	O
internalization	O
and	O
signaling	O
of	O
seven	O
-	O
transmembrane	O
receptors	O
(	O
7TMRs	O
)	O
.	O

To	O
understand	O
the	O
connection	O
between	O
ubiquitination	O
and	O
the	O
endocytic	O
and	O
signaling	O
functions	O
of	O
beta	O
-	O
arrestin	O
,	O
we	O
generated	O
a	O
beta	O
-	O
arrestin2	O
mutant	O
that	O
is	O
defective	O
in	O
ubiquitination	O
(	O
beta	O
-	O
arrestin2	O
(	O
0K	O
)	O
)	O
,	O
by	O
mutating	O
all	O
of	O
the	O
ubiquitin	O
acceptor	O
lysines	O
to	O
arginines	O
and	O
compared	O
its	O
properties	O
with	O
the	O
wild	O
type	O
and	O
a	O
stably	O
ubiquitinated	O
beta	O
-	O
arrestin2	O
-	O
ubiquitin	O
(	O
Ub	O
)	O
chimera	O
.	O

In	O
vitro	O
translated	O
beta	O
-	O
arrestin2	O
and	O
beta	O
-	O
arrestin2	O
(	O
0K	O
)	O
displayed	O
equivalent	O
binding	O
to	O
recombinant	O
beta	O
(	O
2	O
)	O
-	O
adrenergic	O
receptor	O
(	O
beta	O
(	O
2	O
)	O
AR	O
)	O
reconstituted	O
in	O
vesicles	O
,	O
whereas	O
beta	O
-	O
arrestin2	O
-	O
Ub	O
bound	O
approximately	O
4	O
-	O
fold	O
more	O
.	O

In	O
cellular	O
coimmunoprecipitation	O
assays	O
,	O
beta	O
-	O
arrestin2	O
(	O
0K	O
)	O
bound	O
nonreceptor	O
partners	O
,	O
such	O
as	O
AP	B-Complex
-	I-Complex
2	I-Complex
and	O
c	O
-	O
Raf	O
and	O
scaffolded	O
phosphorylated	O
ERK	O
robustly	O
but	O
displayed	O
weak	O
binding	O
to	O
clathrin	B-Complex
.	O

Moreover	O
,	O
beta	O
-	O
arrestin2	O
(	O
0K	O
)	O
was	O
recruited	O
only	O
transiently	O
to	O
activated	O
receptors	O
at	O
the	O
membrane	O
,	O
did	O
not	O
enhance	O
receptor	O
internalization	O
,	O
and	O
decreased	O
the	O
amount	O
of	O
phosphorylated	O
ERK	O
assimilated	O
into	O
isolated	O
beta	O
(	O
2	O
)	O
AR	O
complexes	O
.	O

Although	O
the	O
wild	O
type	O
beta	O
-	O
arrestin2	O
formed	O
ERK	O
signaling	O
complexes	O
with	O
the	O
beta	O
(	O
2	O
)	O
AR	O
at	O
the	O
membrane	O
,	O
a	O
stably	O
ubiquitinated	O
beta	O
-	O
arrestin2	O
-	O
Ub	O
chimera	O
not	O
only	O
stabilized	O
the	O
ERK	O
signalosomes	O
but	O
also	O
led	O
to	O
their	O
endosomal	O
targeting	O
.	O

Interestingly	O
,	O
in	O
cellular	O
fractionation	O
assays	O
,	O
the	O
ubiquitination	O
state	O
of	O
beta	O
-	O
arrestin2	O
favors	O
its	O
distribution	O
in	O
membrane	O
fractions	O
,	O
suggesting	O
that	O
ubiquitination	O
increases	O
the	O
propensity	O
of	O
beta	O
-	O
arrestin	O
for	O
membrane	O
association	O
.	O

Our	O
findings	O
suggest	O
that	O
although	O
beta	O
-	O
arrestin	O
ubiquitination	O
is	O
dispensable	O
for	O
beta	O
-	O
arrestin	O
cytosol	O
to	O
membrane	O
translocation	O
and	O
its	O
"	O
constitutive	O
"	O
interactions	O
with	O
some	O
cytosolic	O
proteins	O
,	O
it	O
nevertheless	O
is	O
a	O
prerequisite	O
both	O
for	O
the	O
formation	O
of	O
tight	O
complexes	O
with	O
7TMRs	O
in	O
vivo	O
and	O
for	O
membrane	O
compartment	O
interactions	O
that	O
are	O
crucial	O
for	O
downstream	O
endocytic	O
and	O
signaling	O
processes	O
.	O

Not	O
insulin	O
but	O
insulin	O
sensitivity	O
,	O
leptin	O
,	O
and	O
cortisol	O
are	O
major	O
factors	O
regulating	O
serum	O
acylated	O
ghrelin	O
level	O
in	O
healthy	O
women	O
.	O

It	O
has	O
been	O
suggested	O
that	O
insulin	O
and	O
glucose	O
are	O
the	O
most	O
important	O
factors	O
for	O
ghrelin	O
secretion	O
.	O

Most	O
of	O
these	O
studies	O
were	O
performed	O
using	O
total	O
ghrelin	O
assays	O
,	O
detecting	O
two	O
forms	O
of	O
ghrelin	O
(	O
acylated	O
and	O
desacyl	O
)	O
,	O
derived	O
from	O
the	O
same	O
peptide	O
precursor	O
but	O
having	O
different	O
biological	O
effects	O
.	O

This	O
study	O
was	O
therefore	O
designed	O
to	O
characterize	O
associations	O
between	O
serum	O
acylated	O
ghrelin	O
levels	O
(	O
Ghr	O
)	O
,	O
selected	O
adipocytokines	O
,	O
hormones	O
,	O
and	O
carbohydrate	O
metabolism	O
parameters	O
in	O
healthy	O
women	O
in	O
stable	O
energy	O
metabolism	O
.	O

The	O
study	O
was	O
performed	O
on	O
32	O
healthy	O
,	O
normal	O
-	O
weight	O
,	O
non	O
-	O
pregnant	O
women	O
with	O
normal	O
[	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
18	O
.	O
9	O
-	O
24	O
.	O
2	O
kg	O
/	O
m2	O
]	O
and	O
stable	O
(	O
the	O
difference	O
between	O
two	O
measurements	O
performed	O
within	O
1	O
month	O
being	O
less	O
than	O
0	O
.	O
5	O
kg	O
)	O
body	O
weight	O
,	O
aged	O
22	O
-	O
47	O
yr	O
.	O

Leptin	O
,	O
Ghr	O
,	O
GH	O
,	O
IGF	O
-	O
I	O
,	O
cortisol	O
,	O
insulin	O
,	O
and	O
glucose	O
were	O
measured	O
in	O
the	O
early	O
follicular	O
phase	O
of	O
the	O
menstruation	O
cycle	O
.	O

Insulin	O
sensitivity	O
was	O
measured	O
using	O
quantitative	O
insulin	O
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
.	O

Body	O
composition	O
was	O
assessed	O
by	O
bioimpedance	O
.	O

We	O
found	O
a	O
positive	O
linear	O
correlation	O
between	O
leptin	O
and	O
Ghr	O
(	O
r	O
=	O
0	O
.	O
375	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
negative	O
correlation	O
between	O
insulin	O
and	O
Ghr	O
(	O
r	O
=	O
-	O
0	O
.	O
374	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
.	O

GH	O
,	O
IGF	O
-	O
I	O
,	O
adiponectin	O
,	O
and	O
body	O
composition	O
parameters	O
did	O
not	O
correlate	O
with	O
Ghr	O
.	O

In	O
multiple	O
regression	O
analysis	O
only	O
QUICKI	O
,	O
leptin	O
,	O
glucose	O
,	O
and	O
cortisol	O
(	O
positively	O
)	O
and	O
age	O
(	O
negatively	O
)	O
accounted	O
for	O
50	O
%	O
variation	O
of	O
Ghr	O
.	O

Insulin	O
and	O
BMI	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
model	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
healthy	O
women	O
basal	O
Ghr	O
level	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
mainly	O
by	O
insulin	O
sensitivity	O
,	O
leptin	O
,	O
and	O
adrenal	O
glands	O
activity	O
.	O

However	O
,	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
physiological	O
mechanisms	O
involved	O
in	O
acylated	O
Ghr	O
secretion	O
.	O

Involvement	O
of	O
Ymer	O
in	O
suppression	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
regulated	O
interaction	O
with	O
lysine	O
-	O
63	O
-	O
linked	O
polyubiquitin	O
chain	O
.	O

It	O
is	O
known	O
that	O
the	O
cytoplasmic	O
zinc	O
finger	O
protein	O
A20	O
functionally	O
dampens	O
inflammatory	O
signals	O
and	O
apoptosis	O
via	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
and	O
biochemically	O
acts	O
as	O
a	O
unique	O
ubiquitin	O
-	O
modifying	O
protein	O
with	O
deubiquitinating	O
activity	O
and	O
ubiquitin	O
ligase	O
activity	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
A20	O
-	O
modulated	O
signal	O
transduction	O
that	O
influence	O
normal	O
immune	O
responses	O
or	O
tumor	O
immunity	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
search	O
for	O
proteins	O
interacting	O
with	O
A20	O
,	O
we	O
identified	O
one	O
novel	O
binding	O
protein	O
,	O
Ymer	O
.	O

Ymer	O
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
highly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
via	O
EGF	O
stimulation	O
,	O
bound	O
to	O
lysine	O
(	O
K	O
)	O
-	O
63	O
-	O
linked	O
polyubiquitin	O
chain	O
on	O
receptor	O
-	O
interacting	O
serine	O
/	O
threonine	O
-	O
protein	O
kinase	O
1	O
(	O
RIP1	O
)	O
,	O
which	O
is	O
essential	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
in	O
collaboration	O
with	O
A20	O
.	O

A	O
luciferase	O
assay	O
showed	O
that	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
was	O
down	O
-	O
regulated	O
by	O
overexpression	O
of	O
Ymer	O
,	O
whereas	O
knock	O
-	O
down	O
of	O
Ymer	O
up	O
-	O
regulated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
even	O
without	O
stimulation	O
.	O

These	O
findings	O
demonstrate	O
that	O
Ymer	O
is	O
likely	O
to	O
be	O
a	O
negative	O
regulator	O
for	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
pathway	O
.	O

Monoubiquitylation	O
of	O
alpha	O
-	O
synuclein	O
by	O
seven	O
in	O
absentia	O
homolog	O
(	O
SIAH	O
)	O
promotes	O
its	O
aggregation	O
in	O
dopaminergic	O
cells	O
.	O

alpha	O
-	O
Synuclein	O
plays	O
a	O
major	O
role	O
in	O
Parkinson	O
disease	O
.	O

Unraveling	O
the	O
mechanisms	O
of	O
alpha	O
-	O
synuclein	O
aggregation	O
is	O
essential	O
to	O
understand	O
the	O
formation	O
of	O
Lewy	O
bodies	O
and	O
their	O
involvement	O
in	O
dopaminergic	O
cell	O
death	O
.	O

alpha	O
-	O
Synuclein	O
is	O
ubiquitylated	O
in	O
Lewy	O
bodies	O
,	O
but	O
the	O
role	O
of	O
alpha	O
-	O
synuclein	O
ubiquitylation	O
has	O
been	O
mysterious	O
.	O

We	O
now	O
report	O
that	O
the	O
ubiquitin	O
-	O
protein	O
isopeptide	O
ligase	O
seven	O
in	O
absentia	O
homolog	O
(	O
SIAH	O
)	O
directly	O
interacts	O
with	O
and	O
monoubiquitylates	O
alpha	O
-	O
synuclein	O
and	O
promotes	O
its	O
aggregation	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
is	O
toxic	O
to	O
cells	O
.	O

Mass	O
spectrometry	O
analysis	O
demonstrates	O
that	O
SIAH	O
monoubiquitylates	O
alpha	O
-	O
synuclein	O
at	O
lysines	O
12	O
,	O
21	O
,	O
and	O
23	O
,	O
which	O
were	O
previously	O
shown	O
to	O
be	O
ubiquitylated	O
in	O
Lewy	O
bodies	O
.	O

SIAH	O
ubiquitylates	O
lysines	O
10	O
,	O
34	O
,	O
43	O
,	O
and	O
96	O
as	O
well	O
.	O

Suppression	O
of	O
SIAH	O
expression	O
by	O
short	O
hairpin	O
RNA	O
to	O
SIAH	O
-	O
1	O
and	O
SIAH	O
-	O
2	O
abolished	O
alpha	O
-	O
synuclein	O
monoubiquitylation	O
in	O
dopaminergic	O
cells	O
,	O
indicating	O
that	O
endogenous	O
SIAH	O
ubiquitylates	O
alpha	O
-	O
synuclein	O
.	O

Moreover	O
,	O
SIAH	O
co	O
-	O
immunoprecipitated	O
with	O
alpha	O
-	O
synuclein	O
from	O
brain	O
extracts	O
.	O

Inhibition	O
of	O
proteasomal	O
,	O
lysosomal	O
,	O
and	O
autophagic	O
pathways	O
,	O
as	O
well	O
as	O
overexpression	O
of	O
a	O
ubiquitin	O
mutant	O
less	O
prone	O
to	O
deubiquitylation	O
,	O
G76A	O
,	O
increased	O
monoubiquitylation	O
of	O
alpha	O
-	O
synuclein	O
by	O
SIAH	O
.	O

Monoubiquitylation	O
increased	O
the	O
aggregation	O
of	O
alpha	O
-	O
synuclein	O
in	O
vitro	O
.	O

At	O
the	O
electron	O
microscopy	O
level	O
,	O
monoubiquitylated	O
alpha	O
-	O
synuclein	O
promoted	O
the	O
formation	O
of	O
massive	O
amounts	O
of	O
amorphous	O
aggregates	O
.	O

Monoubiquitylation	O
also	O
increased	O
alpha	O
-	O
synuclein	O
aggregation	O
in	O
vivo	O
as	O
observed	O
by	O
increased	O
formation	O
of	O
alpha	O
-	O
synuclein	O
inclusion	O
bodies	O
within	O
dopaminergic	O
cells	O
.	O

These	O
inclusions	O
are	O
toxic	O
to	O
cells	O
,	O
and	O
their	O
formation	O
was	O
prevented	O
when	O
endogenous	O
SIAH	O
expression	O
was	O
suppressed	O
.	O

Our	O
data	O
suggest	O
that	O
monoubiquitylation	O
represents	O
a	O
possible	O
trigger	O
event	O
for	O
alpha	O
-	O
synuclein	O
aggregation	O
and	O
Lewy	O
body	O
formation	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
chondrolectin	O
interacts	O
with	O
the	O
beta	O
-	O
subunit	O
of	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
.	O

Mouse	O
chondrolectin	O
(	O
chodl	O
)	O
was	O
isolated	O
out	O
of	O
the	O
tail	O
tip	O
of	O
four	O
-	O
day	O
old	O
129	O
/	O
SvJ	O
mice	O
as	O
a	O
by	O
-	O
product	O
of	O
a	O
PCR	O
-	O
based	O
subtractive	O
cDNA	O
library	O
screening	O
.	O

The	O
gene	O
is	O
predominantly	O
expressed	O
in	O
adult	O
skeletal	O
muscle	O
,	O
heart	O
,	O
testes	O
and	O
lungs	O
and	O
in	O
embryonic	O
stadia	O
.	O

Chodl	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
chondrolectin	O
(	O
CHODL	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
for	O
a	O
type	O
Ia	O
transmembrane	O
protein	O
and	O
that	O
is	O
expressed	O
in	O
human	O
testis	O
,	O
prostate	O
,	O
heart	O
and	O
skeletal	O
muscle	O
tissue	O
.	O

CHODL	O
-	O
splice	O
variants	O
(	O
CHODL	O
(	O
f	O
)	O
,	O
CHODL	O
(	O
f	O
Delta	O
E	O
)	O
,	O
CHODL	O
(	O
Delta	O
E	O
)	O
)	O
are	O
detected	O
in	O
human	O
leukocytes	O
.	O

The	O
proteins	O
of	O
the	O
chondrolectin	O
family	O
belong	O
to	O
the	O
family	O
of	O
C	O
-	O
type	O
lectins	O
.	O

As	O
the	O
members	O
of	O
this	O
protein	O
family	O
are	O
important	O
for	O
a	O
wide	O
array	O
of	O
biological	O
processes	O
,	O
the	O
function	O
of	O
chodl	O
was	O
investigated	O
by	O
searching	O
for	O
its	O
protein	O
interaction	O
partners	O
.	O

The	O
beta	O
-	O
subunit	O
of	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
(	O
Rabggtb	B-Complex
)	O
was	O
isolated	O
8	O
times	O
after	O
a	O
complete	O
Sos	O
recruitment	O
system	O
(	O
SRS	O
)	O
screen	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
chodl	O
.	O

The	O
interaction	O
was	O
confirmed	O
with	O
in	O
vitro	O
transcription	O
/	O
translation	O
and	O
co	O
-	O
immunoprecipitation	O
(	O
co	O
-	O
IP	O
)	O
experiments	O
.	O

H2O2	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	B-Complex
determined	O
by	O
mass	O
spectrometry	O
:	O
redox	O
regulation	O
of	O
tyrosine	O
nitration	O
and	O
3	O
-	O
nitrotyrosine	O
reduction	O
by	O
antioxidants	O
.	O

Covalent	O
modifications	O
of	O
proteins	O
by	O
endogenous	O
reactive	O
nitrogen	O
oxide	O
species	O
lead	O
to	O
cytotoxic	O
effects	O
that	O
are	O
implicated	O
in	O
diseases	O
associated	O
with	O
chronic	O
infections	O
and	O
inflammation	O
.	O

Tyrosine	O
nitration	O
is	O
a	O
major	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
by	O
reactive	O
nitrogen	O
oxide	O
species	O
.	O

Recent	O
studies	O
suggest	O
that	O
nitrotyrosine	O
is	O
not	O
a	O
permanent	O
protein	O
modification	O
.	O

We	O
previously	O
demonstrated	O
that	O
lipoyl	O
dehydrogenase	O
is	O
capable	O
of	O
converting	O
3	O
-	O
nitrotyrosine	O
into	O
3	O
-	O
aminotyrosine	O
in	O
the	O
presence	O
of	O
certain	O
reducing	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
various	O
hemoproteins	O
,	O
hemin	O
,	O
and	O
the	O
cobalt	O
-	O
containing	O
cofactor	O
cyanocobalamin	O
to	O
mediate	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
dependent	O
tyrosine	O
nitration	O
and	O
found	O
that	O
these	O
hemoproteins	O
and	O
metal	O
-	O
containing	O
cofactors	O
also	O
catalyzed	O
the	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
various	O
extents	O
in	O
the	O
presence	O
of	O
thiol	O
reducing	O
agents	O
or	O
ascorbate	O
.	O

The	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	B-Complex
identified	O
by	O
nanoLC	O
/	O
nanospray	O
ionization	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
digest	O
include	O
nitration	O
of	O
tyrosine	O
and	O
tryptophan	O
,	O
as	O
well	O
as	O
oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
.	O

Nitration	O
of	O
human	O
hemoglobin	B-Complex
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
was	O
detected	O
on	O
Tyr24	O
and	O
Tyr42	O
(	O
alpha	O
-	O
chain	O
)	O
and	O
on	O
Tyr130	O
and	O
Trp15	O
(	O
beta	O
-	O
chain	O
)	O
in	O
the	O
alphabeta	B-OOS
-	O
dimer	O
.	O

Oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
hemoglobin	B-Complex
also	O
catalyzed	O
nitro	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
form	O
3	O
-	O
aminotyrosine	O
,	O
at	O
Tyr24	O
in	O
the	O
alpha	O
-	O
chain	O
peptide	O
of	O
human	O
Hb	B-Complex
in	O
the	O
presence	O
of	O
ascorbate	O
.	O

The	O
enhanced	O
peroxidase	O
activity	O
of	O
nitrated	O
hemoglobin	B-Complex
can	O
be	O
reversed	O
by	O
the	O
antioxidant	O
ascorbate	O
.	O

These	O
results	O
suggest	O
a	O
possible	O
in	O
vivo	O
pathway	O
for	O
hemoglobin	B-Complex
contributing	O
to	O
denitration	O
of	O
nitrated	O
proteins	O
through	O
redox	O
regulation	O
.	O

High	O
yield	O
production	O
of	O
recombinant	O
native	O
and	O
modified	O
peptides	O
exemplified	O
by	O
ligands	O
for	O
G	O
-	O
protein	O
coupled	O
receptors	O
.	O

G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
comprise	O
a	O
large	O
family	O
of	O
membrane	O
proteins	O
and	O
attract	O
pharmaceutical	O
interest	O
as	O
therapeutic	O
targets	O
.	O

Two	O
examples	O
of	O
class	O
B	O
GPCRs	O
that	O
are	O
involved	O
in	O
metabolic	O
diseases	O
are	O
the	O
Parathyroid	O
hormone	O
receptor	O
1	O
(	O
PTHR1	O
)	O
and	O
the	O
Glucagon	O
-	O
like	O
-	O
peptide	O
-	O
1	O
receptor	O
(	O
GLP	O
-	O
1R	O
)	O
which	O
play	O
central	O
roles	O
in	O
osteoporosis	O
and	O
diabetes	O
mellitus	O
type	O
II	O
,	O
respectively	O
.	O

Class	O
B	O
GPCRs	O
are	O
characterised	O
by	O
a	O
large	O
extracellular	O
N	O
-	O
terminal	O
domain	O
with	O
a	O
typical	O
disulfide	O
bridge	O
pattern	O
.	O

This	O
domain	O
is	O
responsible	O
for	O
the	O
binding	O
of	O
peptide	O
hormone	O
ligands	O
.	O

Here	O
we	O
report	O
the	O
recombinant	O
expression	O
of	O
these	O
ligands	O
in	O
natural	O
and	O
several	O
modified	O
forms	O
for	O
their	O
use	O
in	O
functional	O
assays	O
,	O
NMR	O
analyses	O
or	O
affinity	O
purification	O
of	O
receptor	O
/	O
ligand	O
complexes	O
for	O
crystallisation	O
.	O

Applying	O
the	O
SUMO	O
system	O
,	O
low	O
cost	O
expression	O
of	O
soluble	O
fusion	O
-	O
proteins	O
is	O
achieved	O
.	O

Moreover	O
,	O
via	O
the	O
SUMO	O
cleavage	O
site	O
,	O
the	O
authentic	O
N	O
-	O
terminal	O
sequence	O
which	O
is	O
essential	O
for	O
ligand	O
-	O
receptor	O
interactions	O
can	O
be	O
obtained	O
.	O

Purification	O
of	O
the	O
peptide	O
by	O
RP	O
-	O
HPLC	O
results	O
in	O
>	O
98	O
%	O
pure	O
preparations	O
.	O

The	O
strategy	O
can	O
also	O
be	O
adopted	O
for	O
many	O
other	O
purposes	O
,	O
especially	O
if	O
small	O
peptides	O
are	O
needed	O
at	O
either	O
large	O
amounts	O
or	O
with	O
specific	O
features	O
like	O
isotope	O
,	O
affinity	O
or	O
fluorescent	O
labels	O
.	O

Furthermore	O
,	O
for	O
the	O
growing	O
demand	O
for	O
therapeutic	O
peptides	O
,	O
this	O
method	O
could	O
represent	O
a	O
straightforward	O
production	O
process	O
.	O

Association	O
of	O
guanine	O
nucleotide	O
-	O
exchange	O
protein	O
BIG1	O
in	O
HepG2	O
cell	O
nuclei	O
with	O
nucleolin	O
,	O
U3	O
snoRNA	O
,	O
and	O
fibrillarin	O
.	O

BIG1	O
,	O
a	O
brefeldin	O
A	O
-	O
inhibited	O
guanine	O
nucleotide	O
-	O
exchange	O
protein	O
,	O
activates	O
class	O
I	O
ADP	O
-	O
ribosylation	O
factors	O
(	O
ARF1	O
-	O
3	O
)	O
by	O
catalyzing	O
the	O
replacement	O
of	O
bound	O
GDP	O
by	O
GTP	O
,	O
an	O
action	O
critical	O
for	O
the	O
regulation	O
of	O
protein	O
transport	O
in	O
eukaryotic	O
cells	O
.	O

Our	O
earlier	O
report	O
[	O
Padilla	O
PI	O
,	O
Pancheco	O
-	O
Rodriguez	O
G	O
,	O
Moss	O
J	O
,	O
Vaughan	O
M	O
(	O
2004	O
)	O
Proc	O
Natl	O
Acad	O
Sci	O
USA	O
101	O
:	O
2752	O
-	O
2757	O
]	O
that	O
BIG1	O
concentrated	O
in	O
nucleoli	O
of	O
serum	O
-	O
starved	O
HepG2	O
cells	O
prompted	O
us	O
to	O
identify	O
molecules	O
associated	O
with	O
BIG1	O
in	O
dynamic	O
nucleolar	O
structures	O
.	O

Antibodies	O
against	O
BIG1	O
or	O
nucleolin	O
coprecipitated	O
both	O
proteins	O
from	O
nuclei	O
,	O
which	O
was	O
abolished	O
by	O
the	O
incubation	O
of	O
nuclei	O
with	O
RNase	O
A	O
or	O
DNase	O
,	O
indicating	O
that	O
the	O
interaction	O
depended	O
on	O
nucleic	O
acids	O
.	O

(	O
32	O
)	O
P	O
labeling	O
of	O
RNAs	O
immunoprecipitated	O
with	O
BIG1	O
or	O
nucleolin	O
from	O
nuclei	O
revealed	O
bands	O
of	O
approximately	O
210	O
bases	O
that	O
also	O
hybridized	O
with	O
U3	O
small	O
nucleolar	O
(	O
sno	O
)	O
RNA	O
-	O
specific	O
oligonucleotides	O
.	O

Clones	O
of	O
U3	O
snoRNA	O
cDNAs	O
from	O
the	O
material	O
precipitated	O
by	O
antibodies	O
against	O
BIG1	O
or	O
nucleolin	O
yielded	O
identical	O
nucleotide	O
sequences	O
that	O
also	O
were	O
found	O
in	O
genomic	O
DNA	O
.	O

Later	O
analyses	O
revealed	O
the	O
presence	O
of	O
fibrillarin	O
,	O
nucleoporin	O
p62	O
,	O
and	O
La	O
in	O
BIG1	O
and	O
nucleolin	O
immunoprecipitates	O
.	O

Our	O
data	O
demonstrate	O
that	O
BIG1	O
,	O
nucleolin	O
,	O
U3	O
,	O
the	O
U3	O
-	O
binding	O
protein	O
fibrillarin	O
,	O
and	O
the	O
RNA	O
-	O
binding	O
protein	O
La	O
may	O
exist	O
together	O
in	O
nuclear	O
complexes	O
,	O
consistent	O
with	O
a	O
potential	O
role	O
for	O
BIG1	O
in	O
nucleolar	O
processes	O
.	O

Evidence	O
that	O
BIG1	O
and	O
nucleolin	O
,	O
but	O
not	O
fibrillarin	O
,	O
can	O
be	O
present	O
with	O
p62	O
at	O
the	O
nuclear	O
envelope	O
confirms	O
the	O
presence	O
of	O
BIG1	O
and	O
nucleolin	O
in	O
dynamic	O
molecular	O
complexes	O
that	O
change	O
in	O
composition	O
while	O
moving	O
through	O
nuclei	O
.	O

Nuclear	O
functions	O
of	O
BIG1	O
remain	O
to	O
be	O
determined	O
.	O

NEDD8	O
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	O
.	O

The	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumour	O
suppressor	O
protein	O
is	O
important	O
in	O
the	O
E3	O
ubiquitin	O
ligase	O
ECV	B-Complex
(	O
Elongin	B-Complex
B	I-Complex
/	I-Complex
C	I-Complex
-	I-Complex
CUL2	I-Complex
-	I-Complex
VHL	I-Complex
)	O
-	O
mediated	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
and	O
the	O
promotion	O
of	O
fibronectin	O
(	O
FN	O
)	O
extracellular	O
matrix	O
assembly	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanism	O
controlling	O
the	O
selectivity	O
of	O
VHL	O
function	O
remains	O
unknown	O
,	O
a	O
failure	O
in	O
either	O
process	O
is	O
associated	O
with	O
oncogenic	O
progression	O
.	O

Here	O
,	O
we	O
show	O
that	O
VHL	O
performs	O
its	O
FN	O
-	O
associated	O
function	O
independently	O
of	O
the	O
ECV	B-Complex
complex	O
,	O
highlighting	O
the	O
autonomy	O
of	O
these	O
pathways	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
NEDD8	O
,	O
a	O
ubiquitin	O
-	O
like	O
molecule	O
,	O
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
in	O
which	O
its	O
covalent	O
conjugation	O
to	O
VHL	O
prohibits	O
the	O
engagement	O
of	O
the	O
scaffold	O
component	O
CUL2	O
and	O
,	O
concomitantly	O
,	O
activates	O
the	O
association	O
with	O
FN	O
.	O

These	O
findings	O
provide	O
the	O
first	O
mechanistic	O
step	O
in	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	O
and	O
explain	O
a	O
previously	O
unrecognized	O
function	O
of	O
NEDD8	O
.	O

Redox	O
-	O
mediated	O
modification	O
of	O
PLZF	O
by	O
SUMO	O
-	O
1	O
and	O
ubiquitin	O
.	O

Earlier	O
,	O
we	O
reported	O
that	O
the	O
transcriptional	O
repressor	O
promyelocytic	O
leukemia	O
zinc	O
-	O
finger	O
protein	O
(	O
PLZF	O
)	O
is	O
sumoylated	O
at	O
position	O
K242	O
,	O
and	O
the	O
sumoylation	O
regulated	O
its	O
biological	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
sumoylation	O
site	O
can	O
be	O
modified	O
by	O
ubiquitin	O
.	O

The	O
stability	O
and	O
nuclear	O
localization	O
of	O
PLZF	O
were	O
regulated	O
by	O
the	O
antagonistic	O
relationship	O
between	O
sumoylation	O
and	O
ubiquitination	O
.	O

We	O
observed	O
the	O
antagonistic	O
effects	O
of	O
ubiquitin	O
and	O
SUMO	O
-	O
1	O
on	O
PLZF	O
under	O
oxidative	O
stress	O
induced	O
by	O
serum	O
deprivation	O
.	O

Thus	O
,	O
the	O
choice	O
between	O
modification	O
of	O
PLZF	O
by	O
SUMO	O
or	O
ubiquitin	O
was	O
determined	O
by	O
the	O
intracellular	O
level	O
of	O
ROS	O
,	O
which	O
was	O
generated	O
by	O
serum	O
deprivation	O
that	O
inactivated	O
the	O
SUMO	O
-	O
conjugating	O
enzymes	O
Uba2	O
and	O
Ubc9	O
,	O
and	O
resulted	O
in	O
decrease	O
of	O
sumoylation	O
.	O

The	O
ubiquitination	O
was	O
increased	O
under	O
these	O
conditions	O
.	O

The	O
expression	O
of	O
BID	O
,	O
a	O
known	O
transcriptional	O
target	O
protein	O
of	O
PLZF	O
,	O
was	O
decreased	O
,	O
and	O
the	O
consequent	O
apoptosis	O
was	O
induced	O
by	O
the	O
ROS	O
generated	O
during	O
serum	O
starvation	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
PLZF	O
post	O
-	O
translational	O
modification	O
is	O
controlled	O
by	O
intracellular	O
ROS	O
,	O
and	O
the	O
biological	O
function	O
of	O
PLZF	O
is	O
regulated	O
by	O
sumoylation	O
and	O
ubiquitination	O
.	O

Palmitoylation	O
and	O
ubiquitination	O
regulate	O
exit	O
of	O
the	O
Wnt	O
signaling	O
protein	O
LRP6	O
from	O
the	O
endoplasmic	O
reticulum	O
.	O

Canonical	O
Wnt	O
signaling	O
is	O
initiated	O
by	O
binding	O
of	O
Wnt	O
proteins	O
to	O
members	O
of	O
the	O
Frizzled	O
family	O
and	O
subsequent	O
complex	O
formation	O
with	O
lipoprotein	O
receptor	O
-	O
related	O
proteins	O
5	O
/	O
6	O
(	O
LRP5	O
/	O
6	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
LRP6	O
is	O
palmitoylated	O
on	O
a	O
juxtamembranous	O
cysteine	O
and	O
that	O
palmitoylation	O
is	O
required	O
for	O
exit	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

We	O
propose	O
that	O
palmitoylation	O
serves	O
to	O
tilt	O
the	O
long	O
,	O
23	O
-	O
residue	O
transmembrane	O
domain	O
of	O
LRP6	O
with	O
respect	O
to	O
the	O
plane	O
of	O
membrane	O
to	O
prevent	O
a	O
hydrophobic	O
mismatch	O
and	O
subsequent	O
recognition	O
by	O
the	O
ER	O
quality	O
control	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
a	O
palmitoylation	O
-	O
deficient	O
LRP6	O
mutant	O
could	O
be	O
rescued	O
from	O
ER	O
retention	O
by	O
deletion	O
of	O
two	O
to	O
four	O
residues	O
in	O
the	O
transmembrane	O
domain	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
palmitoylation	O
-	O
deficient	O
LRP6	O
was	O
retained	O
in	O
the	O
ER	O
by	O
a	O
completely	O
novel	O
monoubiquitination	O
-	O
dependent	O
ER	O
retention	O
mechanism	O
.	O

Mutation	O
of	O
a	O
specific	O
lysine	O
indeed	O
abolished	O
ubiquitination	O
of	O
palmitoylation	O
-	O
deficient	O
LRP6	O
and	O
led	O
to	O
a	O
rescue	O
from	O
ER	O
retention	O
.	O

Finally	O
,	O
at	O
the	O
cell	O
surface	O
,	O
we	O
found	O
that	O
interplay	O
between	O
palmitoylation	O
and	O
ubiquitination	O
was	O
necessary	O
for	O
efficient	O
Wnt	O
signaling	O
.	O

Sumoylation	O
and	O
the	O
function	O
of	O
CCAAT	O
enhancer	O
binding	O
protein	O
alpha	O
(	O
C	O
/	O
EBP	O
alpha	O
)	O
.	O

CCAAT	O
enhancer	O
binding	O
protein	O
alpha	O
(	O
C	O
/	O
EBP	O
alpha	O
)	O
is	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
transcription	O
factors	O
and	O
is	O
a	O
master	O
regulator	O
of	O
granulopoiesis	O
.	O

It	O
is	O
expressed	O
at	O
high	O
levels	O
throughout	O
myeloid	O
differentiation	O
and	O
binds	O
to	O
the	O
promoters	O
of	O
multiple	O
myeloid	O
-	O
specific	O
genes	O
at	O
different	O
stages	O
of	O
myeloid	O
maturation	O
.	O

Profound	O
hematopoietic	O
abnormalities	O
occur	O
in	O
mice	O
nullizygous	O
for	O
C	O
/	O
EBP	O
alpha	O
including	O
a	O
selective	O
early	O
block	O
in	O
the	O
differentiation	O
of	O
granulocytes	O
.	O

Mutations	O
in	O
C	O
/	O
EBP	O
alpha	O
are	O
present	O
in	O
a	O
subset	O
of	O
patients	O
with	O
AML	O
presenting	O
with	O
a	O
normal	O
karyotype	O
.	O

These	O
mutations	O
can	O
result	O
in	O
the	O
expression	O
of	O
a	O
30	O
kDa	O
dominant	O
negative	O
C	O
/	O
EBP	O
alpha	O
isoform	O
,	O
which	O
contributes	O
to	O
loss	O
of	O
C	O
/	O
EBP	O
alpha	O
function	O
.	O

The	O
molecular	O
basis	O
for	O
this	O
observation	O
remains	O
unknown	O
.	O

In	O
addition	O
to	O
phosphorylation	O
,	O
C	O
/	O
EBP	O
alpha	O
is	O
modified	O
,	O
post	O
-	O
translationally	O
by	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
at	O
a	O
lysine	O
residue	O
(	O
K159	O
)	O
,	O
which	O
lies	O
within	O
the	O
growth	O
inhibitory	O
region	O
of	O
the	O
C	O
/	O
EBP	O
alpha	O
protein	O
.	O

Sumoylation	O
at	O
K159	O
in	O
the	O
C	O
/	O
EBP	O
alpha	O
protein	O
prevents	O
association	O
of	O
the	O
SWI	B-Complex
/	I-Complex
SNF	I-Complex
chromatin	O
remodeling	O
complex	O
with	O
C	O
/	O
EBP	O
alpha	O
,	O
thereby	O
hampering	O
transactivation	O
.	O

In	O
this	O
review	O
,	O
the	O
functional	O
implications	O
of	O
post	O
-	O
translational	O
modification	O
,	O
particularly	O
sumoylation	O
,	O
of	O
C	O
/	O
EBP	O
alpha	O
in	O
normal	O
granulopoiesis	O
and	O
leukemia	O
are	O
considered	O
.	O

Survival	O
of	O
cancer	O
cells	O
is	O
maintained	O
by	O
EGFR	O
independent	O
of	O
its	O
kinase	O
activity	O
.	O

Expression	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
a	O
receptor	O
tyrosine	O
kinase	O
associated	O
with	O
cell	O
proliferation	O
and	O
survival	O
,	O
is	O
overactive	O
in	O
many	O
tumors	O
of	O
epithelial	O
origin	O
.	O

Blockade	O
of	O
the	O
kinase	O
activity	O
of	O
EGFR	O
has	O
been	O
used	O
for	O
cancer	O
therapy	O
;	O
however	O
,	O
by	O
itself	O
,	O
it	O
does	O
not	O
seem	O
to	O
reach	O
maximum	O
therapeutic	O
efficacy	O
.	O

We	O
report	O
here	O
that	O
in	O
human	O
cancer	O
cells	O
,	O
the	O
function	O
of	O
kinase	O
-	O
independent	O
EGFR	O
is	O
to	O
prevent	O
autophagic	O
cell	O
death	O
by	O
maintaining	O
intracellular	O
glucose	O
level	O
through	O
interaction	O
and	O
stabilization	O
of	O
the	O
sodium	O
/	O
glucose	O
cotransporter	O
1	O
(	O
SGLT1	O
)	O
.	O

Hhat	O
is	O
a	O
palmitoylacyltransferase	O
with	O
specificity	O
for	O
N	O
-	O
palmitoylation	O
of	O
Sonic	O
Hedgehog	O
.	O

Palmitoylation	O
of	O
Sonic	O
Hedgehog	O
(	O
Shh	O
)	O
is	O
critical	O
for	O
effective	O
long	O
-	O
and	O
short	O
-	O
range	O
signaling	O
.	O

Genetic	O
screens	O
uncovered	O
a	O
potential	O
palmitoylacyltransferase	O
(	O
PAT	O
)	O
for	O
Shh	O
,	O
Hhat	O
,	O
but	O
the	O
molecular	O
mechanism	O
of	O
Shh	O
palmitoylation	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
have	O
developed	O
and	O
exploited	O
an	O
in	O
vitro	O
Shh	O
palmitoylation	O
assay	O
to	O
purify	O
Hhat	O
to	O
homogeneity	O
.	O

We	O
provide	O
direct	O
biochemical	O
evidence	O
that	O
Hhat	O
is	O
a	O
PAT	O
with	O
specificity	O
for	O
attaching	O
palmitate	O
via	O
amide	O
linkage	O
to	O
the	O
N	O
-	O
terminal	O
cysteine	O
of	O
Shh	O
.	O

Other	O
palmitoylated	O
proteins	O
(	O
e	O
.	O
g	O
.	O
PSD95	O
and	O
Wnt	O
)	O
are	O
not	O
substrates	O
for	O
Hhat	O
,	O
and	O
Porcupine	O
,	O
a	O
putative	O
Wnt	O
PAT	O
,	O
does	O
not	O
palmitoylate	O
Shh	O
.	O

Neither	O
autocleavage	O
nor	O
cholesterol	O
modification	O
is	O
required	O
for	O
Shh	O
palmitoylation	O
.	O

Both	O
the	O
Shh	O
precursor	O
and	O
mature	O
protein	O
are	O
N	O
-	O
palmitoylated	O
by	O
Hhat	O
,	O
and	O
the	O
reaction	O
occurs	O
during	O
passage	O
through	O
the	O
secretory	O
pathway	O
.	O

This	O
study	O
establishes	O
Hhat	O
as	O
a	O
bona	O
fide	O
Shh	O
PAT	O
and	O
serves	O
as	O
a	O
model	O
for	O
understanding	O
how	O
secreted	O
morphogens	O
are	O
modified	O
by	O
distinct	O
PATs	O
.	O

Parkin	O
is	O
ubiquitinated	O
by	O
Nrdp1	O
and	O
abrogates	O
Nrdp1	O
-	O
induced	O
oxidative	O
stress	O
.	O

Parkin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

We	O
previously	O
described	O
that	O
Nrdp1	O
,	O
a	O
RING	O
-	O
finger	O
ubiquitin	O
E3	O
ligase	O
,	O
interacted	O
with	O
Parkin	O
by	O
the	O
yeast	O
two	O
-	O
hybrid	O
assay	O
and	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Here	O
we	O
further	O
demonstrated	O
that	O
overexpression	O
of	O
Nrdp1	O
significantly	O
reduced	O
the	O
endogenous	O
Parkin	O
level	O
in	O
an	O
Nrdp1	O
dosage	O
-	O
dependent	O
and	O
proteasome	B-Complex
-	O
dependent	O
manner	O
.	O

More	O
importantly	O
,	O
Nrdp1	O
ubiquitinated	O
Parkin	O
and	O
catalyzed	O
the	O
poly	O
-	O
ubiquitin	O
chains	O
on	O
Parkin	O
in	O
vitro	O
as	O
well	O
as	O
in	O
cells	O
,	O
indicating	O
Parkin	O
is	O
an	O
Nrdp1	O
substrate	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
overexpression	O
of	O
Nrdp1	O
increased	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
which	O
was	O
abrogated	O
by	O
co	O
-	O
expression	O
of	O
Parkin	O
.	O

Conversely	O
,	O
suppression	O
of	O
Nrdp1	O
by	O
shRNA	O
conferred	O
SH	O
-	O
SY5Y	O
cells	O
a	O
lower	O
ROS	O
level	O
.	O

Together	O
,	O
we	O
provided	O
evidence	O
that	O
interactions	O
between	O
Nrdp1	O
and	O
Parkin	O
negatively	O
regulated	O
Parkin	O
level	O
and	O
affected	O
ROS	O
production	O
,	O
suggesting	O
that	O
Nrdp1	O
may	O
play	O
a	O
role	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

SUMO1	O
modification	O
of	O
NF	O
-	O
kappaB2	O
/	O
p100	O
is	O
essential	O
for	O
stimuli	O
-	O
induced	O
p100	O
phosphorylation	O
and	O
processing	O
.	O

A	O
primary	O
step	O
in	O
activating	O
the	O
alternative	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappaB	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
)	O
pathway	O
requires	O
NF	O
-	O
kappaB2	O
/	O
p100	O
processing	O
to	O
generate	O
p52	O
.	O

In	O
most	O
cases	O
,	O
stimuli	O
-	O
induced	O
p100	O
processing	O
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
/	O
IkappaB	O
kinase	O
alpha	O
-	O
mediated	O
phosphorylation	O
and	O
ubiquitination	O
.	O

Here	O
,	O
we	O
report	O
that	O
post	O
-	O
translational	O
modification	O
of	O
p100	O
at	O
specific	O
sites	O
by	O
the	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
SUMO	O
)	O
is	O
another	O
determining	O
factor	O
for	O
stimuli	O
-	O
induced	O
p100	O
processing	O
.	O

The	O
results	O
show	O
that	O
basal	O
SUMO	O
modification	O
is	O
required	O
for	O
stimuli	O
-	O
induced	O
p100	O
phosphorylation	O
and	O
that	O
blocking	O
SUMOylation	O
of	O
p100	O
,	O
either	O
by	O
site	O
-	O
directed	O
mutation	O
or	O
by	O
short	O
interfering	O
RNA	O
-	O
targeted	O
diminution	O
of	O
E2	O
SUMO	O
-	O
conjugating	O
enzyme	O
Ubc9	O
,	O
inhibits	O
various	O
physiological	O
stimuli	O
-	O
induced	O
p100	O
processing	O
and	O
ultimate	O
activation	O
of	O
the	O
alternative	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
.	O

Together	O
,	O
these	O
findings	O
show	O
the	O
crucial	O
role	O
of	O
SUMO1	O
modification	O
in	O
p100	O
processing	O
and	O
provide	O
mechanistic	O
insights	O
into	O
the	O
participation	O
of	O
SUMO1	O
modification	O
in	O
the	O
regulation	O
of	O
signal	O
transduction	O
.	O

In	O
addition	O
,	O
consistent	O
with	O
the	O
fact	O
that	O
Cdc3	O
and	O
Cdc12	O
form	O
a	O
stoichiometric	O
complex	O
that	O
is	O
essential	O
for	O
hetero	O
-	O
octamer	O
formation	O
in	O
mitotic	O
cells	O
,	O
we	O
found	O
that	O
either	O
anti	O
-	O
Cdc12	O
or	O
anti	O
-	O
Cdc3	O
antibodies	O
co	O
-	O
precipitated	O
equivalent	O
amounts	O
of	O
Cdc3	O
when	O
lysates	O
were	O
prepared	O
from	O
vegetatively	O
-	O
dividing	O
diploid	O
cells	O
,	O
whereas	O
anti	O
-	O
Cdc12	O
antibodies	O
precipitated	O
only	O
~	O
25	O
%	O
of	O
the	O
amount	O
of	O
Cdc3	O
as	O
that	O
precipitated	O
with	O
the	O
anti	O
-	O
Cdc3	O
antibodies	O
when	O
lysates	O
were	O
prepared	O
from	O
a	O
sporulating	O
culture	O
of	O
diploid	O
cells	O
(	O
Fig	O
.	O
3G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
in	O
the	O
sporulating	O
cultures	O
used	O
for	O
such	O
experiments	O
,	O
25	O
-	O
30	O
%	O
of	O
cells	O
did	O
not	O
sporulate	O
,	O
based	O
on	O
the	O
fraction	O
of	O
the	O
total	O
cells	O
counted	O
(	O
n	O
=	O
200	O
per	O
experiment	O
)	O
that	O
lacked	O
evidence	O
of	O
spore	O
formation	O
visible	O
by	O
transmitted	O
light	O
microscopy	O
or	O
lacked	O
detectable	O
Spr3	O
-	O
GFP	O
fluorescence	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
level	O
of	O
sporulation	O
proficiency	O
is	O
nearly	O
identical	O
(	O
75	O
%	O
)	O
to	O
that	O
reported	O
by	O
others	O
for	O
this	O
same	O
mixed	O
strain	O
background	O
.	O

Thus	O
,	O
these	O
data	O
support	O
our	O
conclusion	O
that	O
,	O
in	O
sporulating	O
cells	O
,	O
Cdc12	O
does	O
not	O
associate	O
stably	O
with	O
Cdc3	O
,	O
and	O
exists	O
free	O
of	O
other	O
septins	O
(	O
or	O
is	O
associated	O
with	O
Shs1	O
,	O
which	O
also	O
is	O
excluded	O
from	O
spore	O
-	O
associated	O
structures	O
)	O
.	O

Sister	O
chromatid	O
cohesion	O
role	O
for	O
CDC28	O
-	O
CDK	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

High	O
-	O
fidelity	O
chromosome	O
segregation	O
requires	O
that	O
the	O
sister	O
chromatids	O
produced	O
during	O
S	O
phase	O
also	O
become	O
paired	O
during	O
S	O
phase	O
.	O

Ctf7p	O
(	O
Eco1p	O
)	O
is	O
required	O
to	O
establish	O
sister	O
chromatid	O
pairing	O
specifically	O
during	O
DNA	O
replication	O
.	O

However	O
,	O
Ctf7p	O
also	O
becomes	O
active	O
during	O
G2	O
/	O
M	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Ctf7p	O
is	O
a	O
phosphoprotein	O
and	O
an	O
in	O
vitro	O
target	O
of	O
Cdc28p	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
,	O
suggesting	O
one	O
possible	O
mechanism	O
for	O
regulating	O
the	O
essential	O
function	O
of	O
Ctf7p	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
synthetic	O
lethal	O
interaction	O
between	O
ctf7	O
and	O
cdc28	O
.	O

However	O
,	O
neither	O
elevated	O
CDC28	O
levels	O
nor	O
CDC28	O
Cak1p	O
-	O
bypass	O
alleles	O
rescue	O
ctf7	O
cell	O
phenotypes	O
.	O

Moreover	O
,	O
cells	O
expressing	O
Ctf7p	O
mutated	O
at	O
all	O
full	O
-	O
and	O
partial	O
-	O
consensus	O
CDK	O
-	O
phosphorylation	O
sites	O
exhibit	O
robust	O
cell	O
growth	O
.	O

These	O
and	O
other	O
results	O
reveal	O
that	O
Ctf7p	O
regulation	O
is	O
more	O
complicated	O
than	O
previously	O
envisioned	O
and	O
suggest	O
that	O
CDK	O
acts	O
in	O
sister	O
chromatid	O
cohesion	O
parallel	O
to	O
Ctf7p	O
reactions	O
.	O

A	O
screen	O
for	O
BCA2	O
interacting	O
proteins	O
was	O
performed	O
using	O
the	O
BacterioMatch	O
II	O
Two	O
-	O
Hybrid	O
System	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Full	O
-	O
length	O
human	O
BCA2	O
cDNA	O
was	O
cloned	O
as	O
a	O
NotI	O
-	O
SalI	O
fragment	O
from	O
FLAG	O
-	O
tagged	O
pCMV	O
-	O
BCA2	O
into	O
the	O
NotI	O
-	O
XhoI	O
digested	O
bait	O
vector	O
,	O
pBT	O
.	O

The	O
BacterioMatch	O
human	O
breast	O
and	O
fetal	O
brain	O
cDNA	O
libraries	O
constructed	O
by	O
pTRG	O
vector	O
were	O
purchased	O
from	O
Stratagene	O
.	O

Cotransformants	O
were	O
screened	O
by	O
using	O
medium	O
lacking	O
histidine	O
and	O
containing	O
5	O
mM	O
3	O
-	O
amino	O
-	O
1	O
,	O
2	O
,	O
4	O
-	O
triazole	O
,	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

The	O
plates	O
were	O
incubated	O
at	O
37degreesC	O
for	O
24hrs	O
and	O
then	O
at	O
room	O
temperature	O
for	O
24hrs	O
to	O
detect	O
weak	O
interactors	O
.	O

Positive	O
interactions	O
were	O
further	O
confirmed	O
by	O
activation	O
of	O
the	O
streptomycin	O
resistance	O
gene	O
on	O
selective	O
plates	O
.	O

For	O
negative	O
controls	O
,	O
empty	O
pBT	O
and	O
pTRG	O
plasmids	O
were	O
co	O
-	O
transformed	O
with	O
pTRG	O
library	O
and	O
pBT	O
-	O
BCA2	O
,	O
respectively	O
.	O

A	O
positive	O
control	O
included	O
the	O
co	O
-	O
transformation	O
of	O
pBT	O
-	O
LGF2	O
and	O
pTRG	O
-	O
Gal11	O
,	O
provided	O
by	O
Stratagene	O
.	O

DNA	O
sequencing	O
reactions	O
of	O
the	O
respective	O
inserts	O
in	O
pTRG	O
vector	O
were	O
performed	O
at	O
the	O
Sunnybrook	O
Research	O
Institute	O
Genomic	O
Core	O
Facility	O
.	O

A	O
BLAST	O
search	O
at	O
the	O
NCBI	O
website	O
was	O
performed	O
to	O
identify	O
proteins	O
encoded	O
by	O
the	O
respective	O
cDNAs	O
.	O

Dynamic	O
compartmentalization	O
of	O
base	O
excision	O
repair	O
proteins	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

DNAs	O
harbored	O
in	O
both	O
nuclei	O
and	O
mitochondria	O
of	O
eukaryotic	O
cells	O
are	O
subject	O
to	O
continuous	O
oxidative	O
damage	O
resulting	O
from	O
normal	O
metabolic	O
activities	O
or	O
environmental	O
insults	O
.	O

Oxidative	O
DNA	O
damage	O
is	O
primarily	O
reversed	O
by	O
the	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
pathway	O
,	O
initiated	O
by	O
N	O
-	O
glycosylase	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
lyase	O
proteins	O
.	O

To	O
execute	O
an	O
appropriate	O
repair	O
response	O
,	O
BER	O
components	O
must	O
be	O
distributed	O
to	O
accommodate	O
levels	O
of	O
genotoxic	O
stress	O
that	O
may	O
vary	O
considerably	O
between	O
nuclei	O
and	O
mitochondria	O
,	O
depending	O
on	O
the	O
growth	O
state	O
and	O
stress	O
environment	O
of	O
the	O
cell	O
.	O

Numerous	O
examples	O
exist	O
where	O
cells	O
respond	O
to	O
signals	O
,	O
resulting	O
in	O
relocalization	O
of	O
proteins	O
involved	O
in	O
key	O
biological	O
transactions	O
.	O

To	O
address	O
whether	O
such	O
dynamic	O
localization	O
contributes	O
to	O
efficient	O
organelle	O
-	O
specific	O
DNA	O
repair	O
,	O
we	O
determined	O
the	O
intracellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
N	O
-	O
glycosylase	O
/	O
AP	O
lyases	O
,	O
Ntg1	O
and	O
Ntg2	O
,	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

Fluorescence	O
microscopy	O
revealed	O
that	O
Ntg1	O
is	O
differentially	O
localized	O
to	O
nuclei	O
and	O
mitochondria	O
,	O
likely	O
in	O
response	O
to	O
the	O
oxidative	O
DNA	O
damage	O
status	O
of	O
the	O
organelle	O
.	O

Sumoylation	O
is	O
associated	O
with	O
targeting	O
of	O
Ntg1	O
to	O
nuclei	O
containing	O
oxidative	O
DNA	O
damage	O
.	O

These	O
studies	O
demonstrate	O
that	O
trafficking	O
of	O
DNA	O
repair	O
proteins	O
to	O
organelles	O
containing	O
high	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
may	O
be	O
a	O
central	O
point	O
for	O
regulating	O
BER	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O

FAM	O
/	O
USP9x	O
,	O
a	O
deubiquitinating	O
enzyme	O
essential	O
for	O
TGFbeta	O
signaling	O
,	O
controls	O
Smad4	O
monoubiquitination	O
.	O

The	O
assembly	O
of	O
the	O
Smad	O
complex	O
is	O
critical	O
for	O
TGFbeta	O
signaling	O
,	O
yet	O
the	O
mechanisms	O
that	O
inactivate	O
or	O
empower	O
nuclear	O
Smad	O
complexes	O
are	O
less	O
understood	O
.	O

By	O
means	O
of	O
siRNA	O
screen	O
we	O
identified	O
FAM	O
(	O
USP9x	O
)	O
,	O
a	O
deubiquitinase	O
acting	O
as	O
essential	O
and	O
evolutionarily	O
conserved	O
component	O
in	O
TGFbeta	O
and	O
bone	O
morphogenetic	O
protein	O
signaling	O
.	O

Smad4	O
is	O
monoubiquitinated	O
in	O
lysine	O
519	O
in	O
vivo	O
,	O
a	O
modification	O
that	O
inhibits	O
Smad4	O
by	O
impeding	O
association	O
with	O
phospho	O
-	O
Smad2	O
.	O

FAM	O
reverts	O
this	O
negative	O
modification	O
,	O
re	O
-	O
empowering	O
Smad4	O
function	O
.	O

FAM	O
opposes	O
the	O
activity	O
of	O
Ectodermin	O
/	O
Tif1gamma	O
(	O
Ecto	O
)	O
,	O
a	O
nuclear	O
factor	O
for	O
which	O
we	O
now	O
clarify	O
a	O
prominent	O
role	O
as	O
Smad4	O
monoubiquitin	O
ligase	O
.	O

Our	O
study	O
points	O
to	O
Smad4	O
monoubiquitination	O
and	O
deubiquitination	O
as	O
a	O
way	O
for	O
cells	O
to	O
set	O
their	O
TGFbeta	O
responsiveness	O
:	O
loss	O
of	O
FAM	O
disables	O
Smad4	O
-	O
dependent	O
responses	O
in	O
several	O
model	O
systems	O
,	O
with	O
Ecto	O
being	O
epistatic	O
to	O
FAM	O
.	O

This	O
defines	O
a	O
regulative	O
ubiquitination	O
step	O
controlling	O
Smads	O
that	O
is	O
parallel	O
to	O
those	O
impinging	O
on	O
R	O
-	O
Smad	O
phosphorylation	O
.	O

The	O
PhK	O
/	O
GPb	O
complex	O
was	O
formed	O
in	O
solution	O
before	O
deposition	O
on	O
the	O
electron	O
microscope	O
grid	O
.	O

Divalent	O
cations	O
Mg2	O
+	O
and	O
Ca2	O
+	O
were	O
included	O
in	O
the	O
buffer	O
,	O
because	O
these	O
enhance	O
the	O
affinity	O
of	O
PhK	O
for	O
GPb	O
by	O
about	O
8	O
-	O
fold	O
.	O

Quantitative	O
assessment	O
of	O
the	O
affinity	O
of	O
the	O
multivalent	O
proteins	O
PhK	O
tetramer	O
(	O
MW	O
1	O
.	O
3	O
x	O
106	O
)	O
and	O
GPb	O
dimer	O
(	O
MW	O
1	O
.	O
94	O
x	O
105	O
)	O
is	O
not	O
easy	O
.	O

The	O
PhK	O
/	O
GPb	O
complex	O
was	O
analyzed	O
by	O
gel	O
filtration	O
on	O
a	O
Superose	O
6	O
column	O
,	O
but	O
the	O
results	O
were	O
inconclusive	O
.	O

The	O
Km	O
for	O
the	O
PhK	O
phosphorylation	O
of	O
GPb	O
is	O
9	O
muM	O
(	O
Table	O
1	O
)	O
.	O

For	O
the	O
truncated	O
gamma	O
kinase	O
subunit	O
of	O
PhK	O
and	O
for	O
some	O
other	O
protein	O
kinases	O
,	O
the	O
kinetic	O
constant	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
.	O

Hence	O
,	O
Kd	O
for	O
PhK	O
/	O
GPb	O
could	O
be	O
~	O
9	O
muM	O
.	O

However	O
,	O
used	O
an	O
ELISA	O
assay	O
to	O
measure	O
affinities	O
and	O
found	O
an	O
apparent	O
Kd	O
~	O
40	O
nM	O
for	O
control	O
conditions	O
that	O
was	O
reduced	O
to	O
an	O
apparent	O
Kd	O
5	O
nM	O
in	O
the	O
presence	O
of	O
Mg2	O
+	O
and	O
Ca2	O
+	O
.	O

Although	O
the	O
work	O
provided	O
valuable	O
comparative	O
values	O
,	O
as	O
the	O
authors	O
comment	O
,	O
because	O
the	O
ELISA	O
assay	O
requires	O
immobilization	O
of	O
one	O
of	O
the	O
pairs	O
,	O
the	O
Kd	O
values	O
do	O
not	O
necessarily	O
reflect	O
the	O
Kd	O
for	O
binding	O
in	O
solution	O
.	O

The	O
concentrations	O
used	O
in	O
preparing	O
the	O
PhK	O
/	O
GPb	O
sample	O
(	O
PhK	O
tetramer	O
2	O
.	O
22	O
mg	O
/	O
ml	O
[	O
1	O
.	O
71	O
muM	O
]	O
and	O
GPb	O
dimer	O
1	O
.	O
08	O
mg	O
/	O
ml	O
[	O
5	O
.	O
54	O
muM	O
]	O
)	O
correspond	O
to	O
1	O
PhK	O
(	O
alphabetagammadelta	O
)	O
:	O
0	O
.	O
8	O
GPb	O
dimer	O
.	O

Depending	O
on	O
the	O
value	O
of	O
Kd	O
,	O
saturation	O
of	O
PhK	O
with	O
GPb	O
could	O
have	O
been	O
between	O
1	O
%	O
and	O
80	O
%	O
.	O

The	O
appearance	O
of	O
the	O
particles	O
on	O
the	O
grids	O
showed	O
all	O
particles	O
with	O
an	O
increase	O
in	O
size	O
,	O
indicating	O
that	O
some	O
were	O
GPb	O
bound	O
,	O
compared	O
with	O
the	O
native	O
PhK	O
particles	O
.	O

Human	O
proline	O
-	O
rich	O
nuclear	O
receptor	O
coregulatory	O
protein	O
2	O
mediates	O
an	O
interaction	O
between	O
mRNA	O
surveillance	O
machinery	O
and	O
decapping	B-Complex
complex	I-Complex
.	O

Nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
is	O
the	O
best	O
-	O
characterized	O
mRNA	O
surveillance	O
mechanism	O
by	O
which	O
aberrant	O
mRNAs	O
harboring	O
premature	O
termination	O
codons	O
are	O
degraded	O
before	O
translation	O
.	O

However	O
,	O
to	O
date	O
,	O
how	O
NMD	O
machinery	O
recruits	O
the	O
general	O
decay	O
complex	O
to	O
faulty	O
mRNAs	O
and	O
degrades	O
those	O
mRNAs	O
remains	O
unclear	O
.	O

Here	O
we	O
identify	O
human	O
proline	O
-	O
rich	O
nuclear	O
receptor	O
coregulatory	O
protein	O
2	O
(	O
PNRC2	O
)	O
as	O
a	O
Upf1	O
-	O
and	O
Dcp1a	O
-	O
interacting	O
protein	O
.	O

Downregulation	O
of	O
PNRC2	O
abrogates	O
NMD	O
,	O
and	O
artificially	O
tethering	O
PNRC2	O
downstream	O
of	O
a	O
normal	O
termination	O
codon	O
reduces	O
mRNA	O
abundance	O
.	O

Accordingly	O
,	O
PNRC2	O
preferentially	O
interacts	O
with	O
hyperphosphorylated	O
Upf1	O
compared	O
with	O
wild	O
-	O
type	O
Upf1	O
and	O
triggers	O
movement	O
of	O
hyperphosphorylated	O
Upf1	O
into	O
processing	O
bodies	O
(	O
P	O
bodies	O
)	O
.	O

Our	O
observations	O
suggest	O
that	O
PNRC2	O
plays	O
an	O
essential	O
role	O
in	O
mammalian	O
NMD	O
,	O
mediating	O
the	O
interaction	O
between	O
the	O
NMD	O
machinery	O
and	O
the	O
decapping	B-Complex
complex	I-Complex
,	O
so	O
as	O
to	O
target	O
the	O
aberrant	O
mRNA	O
-	O
containing	O
RNPs	B-OOS
into	O
P	O
bodies	O
.	O

Using	O
antibodies	O
specific	O
for	O
Ftz	O
or	O
Eve	O
,	O
we	O
performed	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
and	O
mapped	O
genome	O
-	O
wide	O
transcription	O
factor	O
binding	O
in	O
cellular	O
blastoderm	O
embryos	O
2	O
hours	O
AEL	O
on	O
custom	O
designed	O
high	O
density	O
DNA	O
microarrays	O
.	O

We	O
found	O
1286	O
Ftz	O
and	O
1499	O
Eve	O
bound	O
probes	O
(	O
intensity	O
P	O
<	O
0	O
.	O
0001	O
and	O
Z	O
score	O
>	O
1	O
.	O
96	O
,	O
see	O
supplemental	O
method	O
;	O
21	O
probes	O
on	O
both	O
lists	O
map	O
within	O
500bp	O
)	O
.	O

We	O
analyzed	O
several	O
methods	O
for	O
probe	O
to	O
target	O
gene	O
mapping	O
to	O
maximize	O
the	O
overlap	O
between	O
the	O
differentially	O
expressed	O
and	O
ChIP	O
target	O
gene	O
sets	O
(	O
see	O
supplemental	O
methods	O
;	O
fig	O
.	O
S1	O
)	O
.	O

The	O
greatest	O
such	O
enrichment	O
was	O
obtained	O
by	O
designating	O
genes	O
within	O
1kb	O
of	O
a	O
binding	O
site	O
as	O
targets	O
.	O

At	O
this	O
threshold	O
,	O
we	O
identified	O
969	O
Ftz	O
ChIP	O
-	O
chip	O
target	O
genes	O
and	O
932	O
Eve	O
ChIP	O
-	O
chip	O
target	O
genes	O
(	O
overlap	O
175	O
genes	O
;	O
table	O
S3	O
,	O
S4	O
)	O
.	O

Effect	O
of	O
trehalose	O
accumulation	O
on	O
response	O
to	O
saline	O
stress	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

To	O
examine	O
the	O
effect	O
of	O
trehalose	O
accumulation	O
on	O
response	O
to	O
saline	O
stress	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
we	O
constructed	O
deletion	O
strains	O
of	O
all	O
combinations	O
of	O
the	O
trehalase	O
genes	O
ATH1	O
,	O
NTH1	O
and	O
NTH2	O
and	O
examined	O
their	O
growth	O
behaviour	O
and	O
intracellular	O
trehalose	O
accumulation	O
under	O
non	O
-	O
stress	O
and	O
saline	O
-	O
stress	O
conditions	O
.	O

Saline	O
stress	O
was	O
induced	O
in	O
yeast	O
cells	O
by	O
NaCl	O
addition	O
at	O
the	O
exponential	O
growth	O
phase	O
.	O

All	O
deletion	O
strains	O
showed	O
similar	O
specific	O
growth	O
rates	O
and	O
trehalose	O
accumulation	O
to	O
their	O
parent	O
strain	O
under	O
non	O
-	O
stress	O
conditions	O
.	O

However	O
,	O
under	O
the	O
saline	O
stress	O
condition	O
,	O
one	O
single	O
deletion	O
strain	O
,	O
nth1Delta	O
,	O
two	O
double	O
deletion	O
strains	O
,	O
nth1Delta	O
ath1Delta	O
and	O
nth1Delta	O
nth2Delta	O
,	O
and	O
the	O
triple	O
deletion	O
strain	O
nth1Deltanth2Delta	O
ath1Delta	O
,	O
all	O
of	O
which	O
carry	O
the	O
nth1Delta	O
deletion	O
,	O
showed	O
increased	O
trehalose	O
accumulation	O
as	O
compared	O
to	O
the	O
parent	O
and	O
other	O
deletion	O
strains	O
.	O

In	O
particular	O
,	O
our	O
statistical	O
analysis	O
revealed	O
that	O
the	O
triple	O
deletion	O
strain	O
showed	O
a	O
higher	O
growth	O
rate	O
under	O
the	O
saline	O
stress	O
condition	O
than	O
the	O
parent	O
strain	O
.	O

Moreover	O
,	O
some	O
deletion	O
strains	O
showed	O
further	O
trehalose	O
accumulation	O
under	O
non	O
-	O
stress	O
conditions	O
by	O
overexpression	O
of	O
the	O
TPS1	O
or	O
TPS2	O
genes	O
encoding	O
the	O
enzymes	O
related	O
to	O
trehalose	O
biosynthesis	O
at	O
the	O
mid	O
-	O
exponential	O
phase	O
.	O

Such	O
increased	O
trehalose	O
accumulation	O
prior	O
to	O
NaCl	O
addition	O
could	O
improve	O
the	O
growth	O
of	O
these	O
strains	O
under	O
saline	O
stress	O
.	O

Our	O
results	O
indicate	O
that	O
high	O
trehalose	O
accumulation	O
prior	O
to	O
NaCl	O
addition	O
,	O
rather	O
than	O
after	O
NaCl	O
addition	O
,	O
is	O
necessary	O
to	O
achieve	O
high	O
growth	O
activity	O
under	O
stress	O
conditions	O
.	O

ING4	O
mediates	O
crosstalk	O
between	O
histone	O
H3	O
K4	O
trimethylation	O
and	O
H3	O
acetylation	O
to	O
attenuate	O
cellular	O
transformation	O
.	O

Aberrations	O
in	O
chromatin	O
dynamics	O
play	O
a	O
fundamental	O
role	O
in	O
tumorigenesis	O
,	O
yet	O
relatively	O
little	O
is	O
known	O
of	O
the	O
molecular	O
mechanisms	O
linking	O
histone	O
lysine	O
methylation	O
to	O
neoplastic	O
disease	O
.	O

ING4	O
(	O
Inhibitor	O
of	O
Growth	O
4	O
)	O
is	O
a	O
native	O
subunit	O
of	O
an	O
HBO1	B-OOS
histone	I-OOS
acetyltransferase	I-OOS
(	O
HAT	B-OOS
)	O
complex	O
and	O
a	O
tumor	O
suppressor	O
protein	O
.	O

Here	O
we	O
show	O
a	O
critical	O
role	O
for	O
specific	O
recognition	O
of	O
histone	O
H3	O
trimethylated	O
at	O
lysine	O
4	O
(	O
H3K4me3	O
)	O
by	O
the	O
ING4	O
PHD	O
finger	O
in	O
mediating	O
ING4	O
gene	O
expression	O
and	O
tumor	O
suppressor	O
functions	O
.	O

The	O
interaction	O
between	O
ING4	O
and	O
H3K4me3	O
augments	O
HBO1	B-OOS
acetylation	O
activity	O
on	O
H3	O
tails	O
and	O
drives	O
H3	O
acetylation	O
at	O
ING4	O
target	O
promoters	O
.	O

Further	O
,	O
ING4	O
facilitates	O
apoptosis	O
in	O
response	O
to	O
genotoxic	O
stress	O
and	O
inhibits	O
anchorage	O
-	O
independent	O
cell	O
growth	O
,	O
and	O
these	O
functions	O
depend	O
on	O
ING4	O
interactions	O
with	O
H3K4me3	O
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
a	O
mechanism	O
for	O
brokering	O
crosstalk	O
between	O
H3K4	O
methylation	O
and	O
H3	O
acetylation	O
and	O
reveal	O
a	O
molecular	O
link	O
between	O
chromatin	O
modulation	O
and	O
tumor	O
suppressor	O
mechanisms	O
.	O

Fission	O
yeast	O
Scm3	O
:	O
A	O
CENP	O
-	O
A	O
receptor	O
required	O
for	O
integrity	O
of	O
subkinetochore	O
chromatin	O
.	O

The	O
mechanisms	O
ensuring	O
specific	O
incorporation	O
of	O
CENP	O
-	O
A	O
at	O
centromeres	O
are	O
poorly	O
understood	O
.	O

Mis16	O
and	O
Mis18	O
are	O
required	O
for	O
CENP	O
-	O
A	O
localization	O
at	O
centromeres	O
and	O
form	O
a	O
complex	O
that	O
is	O
conserved	O
from	O
fission	O
yeast	O
to	O
human	O
.	O

Fission	O
yeast	O
sim1	O
mutants	O
that	O
alleviate	O
kinetochore	O
domain	O
silencing	O
are	O
defective	O
in	O
Scm3	O
(	O
Sp	O
)	O
,	O
the	O
ortholog	O
of	O
budding	O
yeast	O
Scm3	O
(	O
Sc	O
)	O
.	O

Scm3	O
(	O
Sp	O
)	O
depends	O
on	O
Mis16	O
/	O
18	O
for	O
its	O
centromere	O
localization	O
and	O
like	O
them	O
is	O
recruited	O
to	O
centromeres	O
in	O
late	O
anaphase	O
.	O

Importantly	O
,	O
Scm3	O
(	O
Sp	O
)	O
coaffinity	O
purifies	O
with	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
and	O
associates	O
with	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
in	O
vitro	O
,	O
yet	O
localizes	O
independently	O
of	O
intact	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
chromatin	O
and	O
is	O
differentially	O
released	O
from	O
chromatin	O
.	O

While	O
Scm3	O
(	O
Sc	O
)	O
has	O
been	O
proposed	O
to	O
form	O
a	O
unique	O
hexameric	O
nucleosome	O
with	O
CENP	O
-	O
A	O
(	O
Cse4	O
)	O
and	O
histone	O
H4	O
at	O
budding	O
yeast	O
point	O
centromeres	O
,	O
we	O
favor	O
a	O
model	O
in	O
which	O
Scm3	O
(	O
Sp	O
)	O
acts	O
as	O
a	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
receptor	O
/	O
assembly	O
factor	O
,	O
cooperating	O
with	O
Mis16	O
and	O
Mis18	O
to	O
receive	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
from	O
the	O
Sim3	O
escort	O
and	O
mediate	O
assembly	O
of	O
CENP	O
-	O
A	O
(	O
Cnp1	O
)	O
into	O
subkinetochore	O
chromatin	O
.	O

PRMT5	O
-	O
mediated	O
methylation	O
of	O
histone	O
H4R3	O
recruits	O
DNMT3A	O
,	O
coupling	O
histone	O
and	O
DNA	O
methylation	O
in	O
gene	O
silencing	O
.	O

Mammalian	O
gene	O
silencing	O
is	O
established	O
through	O
methylation	O
of	O
histones	O
and	O
DNA	O
,	O
although	O
the	O
order	O
in	O
which	O
these	O
modifications	O
occur	O
remains	O
contentious	O
.	O

Using	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
as	O
a	O
model	O
,	O
we	O
demonstrate	O
that	O
symmetric	O
methylation	O
of	O
histone	O
H4	O
arginine	O
3	O
(	O
H4R3me2s	O
)	O
by	O
the	O
protein	O
arginine	O
methyltransferase	O
PRMT5	O
is	O
required	O
for	O
subsequent	O
DNA	O
methylation	O
.	O

H4R3me2s	O
serves	O
as	O
a	O
direct	O
binding	O
target	O
for	O
the	O
DNA	O
methyltransferase	O
DNMT3A	O
,	O
which	O
interacts	O
through	O
the	O
ADD	O
domain	O
containing	O
the	O
PHD	O
motif	O
.	O

Loss	O
of	O
the	O
H4R3me2s	O
mark	O
through	O
short	O
hairpin	O
RNA	O
-	O
mediated	O
knockdown	O
of	O
PRMT5	O
leads	O
to	O
reduced	O
DNMT3A	O
binding	O
,	O
loss	O
of	O
DNA	O
methylation	O
and	O
gene	O
activation	O
.	O

In	O
primary	O
erythroid	O
progenitors	O
from	O
adult	O
bone	O
marrow	O
,	O
H4R3me2s	O
marks	O
the	O
inactive	O
methylated	O
globin	O
genes	O
coincident	O
with	O
localization	O
of	O
PRMT5	O
.	O

Our	O
findings	O
define	O
DNMT3A	O
as	O
both	O
a	O
reader	O
and	O
a	O
writer	O
of	O
repressive	O
epigenetic	O
marks	O
,	O
thereby	O
directly	O
linking	O
histone	O
and	O
DNA	O
methylation	O
in	O
gene	O
silencing	O
.	O

Membrane	O
repair	O
defects	O
in	O
muscular	O
dystrophy	O
are	O
linked	O
to	O
altered	O
interaction	O
between	O
MG53	O
,	O
caveolin	O
-	O
3	O
,	O
and	O
dysferlin	O
.	O

Defective	O
membrane	O
repair	O
can	O
contribute	O
to	O
the	O
progression	O
of	O
muscular	O
dystrophy	O
.	O

Although	O
mutations	O
in	O
caveolin	O
-	O
3	O
(	O
Cav3	O
)	O
and	O
dysferlin	O
are	O
linked	O
to	O
muscular	O
dystrophy	O
in	O
human	O
patients	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
functional	O
interplay	O
between	O
Cav3	O
and	O
dysferlin	O
in	O
membrane	O
repair	O
of	O
muscle	O
physiology	O
and	O
disease	O
has	O
not	O
been	O
fully	O
resolved	O
.	O

We	O
recently	O
discovered	O
that	O
mitsugumin	O
53	O
(	O
MG53	O
)	O
,	O
a	O
muscle	O
-	O
specific	O
TRIM	O
(	O
Tri	O
-	O
partite	O
motif	O
)	O
family	O
protein	O
(	O
TRIM72	O
)	O
,	O
contributes	O
to	O
intracellular	O
vesicle	O
trafficking	O
and	O
is	O
an	O
essential	O
component	O
of	O
the	O
membrane	O
repair	O
machinery	O
in	O
striated	O
muscle	O
.	O

Here	O
we	O
show	O
that	O
MG53	O
interacts	O
with	O
dysferlin	O
and	O
Cav3	O
to	O
regulate	O
membrane	O
repair	O
in	O
skeletal	O
muscle	O
.	O

MG53	O
mediates	O
active	O
trafficking	O
of	O
intracellular	O
vesicles	O
to	O
the	O
sarcolemma	O
and	O
is	O
required	O
for	O
movement	O
of	O
dysferlin	O
to	O
sites	O
of	O
cell	O
injury	O
during	O
repair	O
patch	O
formation	O
.	O

Mutations	O
in	O
Cav3	O
(	O
P104L	O
,	O
R26Q	O
)	O
that	O
cause	O
retention	O
of	O
Cav3	O
in	O
Golgi	O
apparatus	O
result	O
in	O
aberrant	O
localization	O
of	O
MG53	O
and	O
dysferlin	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
,	O
leading	O
to	O
defective	O
membrane	O
repair	O
.	O

Our	O
data	O
reveal	O
that	O
a	O
molecular	O
complex	O
formed	O
by	O
MG53	O
,	O
dysferlin	O
,	O
and	O
Cav3	O
is	O
essential	O
for	O
repair	O
of	O
muscle	O
membrane	O
damage	O
and	O
also	O
provide	O
a	O
therapeutic	O
target	O
for	O
treatment	O
of	O
muscular	O
and	O
cardiovascular	O
diseases	O
that	O
are	O
linked	O
to	O
compromised	O
membrane	O
repair	O
.	O

The	O
nup	O
localization	O
patterns	O
seen	O
after	O
the	O
loss	O
of	O
Nup170p	O
and	O
Nup157p	O
provide	O
important	O
insights	O
into	O
their	O
role	O
in	O
NPC	B-Complex
assembly	O
.	O

We	O
conclude	O
that	O
the	O
removal	O
of	O
Nup170p	O
and	O
Nup157p	O
does	O
not	O
inhibit	O
the	O
targeting	O
of	O
core	O
and	O
nucleoplasmic	O
nups	O
to	O
the	O
nuclear	O
periphery	O
or	O
their	O
assembly	O
into	O
structural	O
precursors	O
of	O
the	O
NPC	B-Complex
,	O
which	O
are	O
what	O
we	O
interpret	O
the	O
inner	O
nuclear	O
membrane	O
-	O
associated	O
structures	O
to	O
represent	O
.	O

In	O
contrast	O
,	O
Nup170p	O
and	O
Nup157p	O
appear	O
essential	O
for	O
the	O
incorporation	O
of	O
the	O
cytoplasmically	O
positioned	O
nups	O
into	O
NPCs	B-Complex
.	O

Although	O
displaced	O
from	O
the	O
NE	O
,	O
these	O
nups	O
appear	O
to	O
associate	O
with	O
known	O
binding	O
partners	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
interaction	O
of	O
the	O
Nup82p	O
/	O
Nup159p	O
with	O
the	O
Nup84p	O
complex	O
)	O
within	O
cytoplasmic	O
foci	O
.	O

These	O
foci	O
are	O
likely	O
composed	O
of	O
assembly	O
intermediates	O
,	O
not	O
nonspecific	O
aggregates	O
,	O
as	O
their	O
nups	O
remain	O
competent	O
to	O
target	O
to	O
the	O
NE	O
after	O
derepression	O
of	O
NUP170	O
,	O
and	O
appear	O
to	O
assemble	O
into	O
NPCs	B-Complex
(	O
Fig	O
.	O
8	O
C	O
)	O
.	O

To	O
test	O
whether	O
GOF	O
and	O
LOF	O
of	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
affected	O
the	O
levels	O
of	O
mstn	O
RNA	O
,	O
we	O
employed	O
quantitative	O
real	O
-	O
time	O
PCR	O
to	O
quantify	O
expression	O
of	O
mstn	O
mRNA	O
in	O
axin1	O
/	O
apc1	O
mutants	O
versus	O
Lef1	O
-	O
morphants	O
at	O
different	O
developmental	O
times	O
.	O

The	O
data	O
showed	O
that	O
reduced	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
in	O
Lef1	O
morphants	O
resulted	O
in	O
upregulation	O
of	O
mstn	O
mRNA	O
(	O
Fig	O
.	O
7B	O
,	O
C	O
)	O
,	O
whereas	O
hyperactivity	O
of	O
the	O
pathway	O
in	O
the	O
axin1	O
/	O
apc1	O
mutants	O
led	O
to	O
a	O
slight	O
mstn	O
downregulation	O
at	O
36	O
hpf	O
(	O
Fig	O
.	O
7B	O
)	O
,	O
and	O
a	O
more	O
significant	O
downregulation	O
at	O
54	O
hpf	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

We	O
then	O
analyzed	O
the	O
level	O
of	O
Myostatin	O
protein	O
at	O
54	O
hpf	O
.	O

Predictably	O
and	O
in	O
agreement	O
with	O
the	O
qPCR	O
data	O
,	O
the	O
level	O
of	O
processed	O
mature	O
monomeric	O
Myostatin	O
protein	O
was	O
significantly	O
induced	O
in	O
Lef1	O
-	O
morphants	O
suggesting	O
that	O
reduced	O
Wnt	O
signaling	O
through	O
Lef1	O
leads	O
to	O
de	O
-	O
repression	O
of	O
Myostatin	O
.	O

Surprisingly	O
,	O
in	O
axin1	O
/	O
apc1	O
embryos	O
,	O
the	O
level	O
of	O
Myostatin	O
protein	O
is	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
embryos	O
,	O
suggesting	O
that	O
subtle	O
increase	O
of	O
myostatin	O
mRNA	O
in	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
GOF	O
context	O
,	O
does	O
not	O
translate	O
into	O
an	O
increase	O
in	O
the	O
stable	O
protein	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

Why	O
and	O
how	O
this	O
mechanistically	O
takes	O
place	O
need	O
further	O
investigation	O
.	O

As	O
lef1	O
was	O
upregulated	O
in	O
the	O
somites	O
of	O
axin	O
/	O
apc	O
mutants	O
at	O
30	O
hpf	O
,	O
we	O
tested	O
whether	O
misexpression	O
of	O
mstn	O
would	O
alter	O
this	O
Wnt	O
/	O
beta	O
-	O
catenin	O
downstream	O
target	O
gene	O
.	O

Misexpression	O
of	O
mstn	O
downregulated	O
ectopic	O
lef1	O
in	O
the	O
mutants	O
as	O
well	O
as	O
slightly	O
downregulating	O
lef1	O
expression	O
in	O
wildtype	O
siblings	O
(	O
Fig	O
.	O
7E	O
)	O
showing	O
genetic	O
interaction	O
between	O
Mstn	O
and	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signalling	O
and	O
probably	O
underlying	O
the	O
mechanism	O
of	O
muscle	O
fiber	O
rescue	O
.	O

To	O
corroborate	O
possible	O
interaction	O
between	O
the	O
two	O
pathways	O
we	O
performed	O
in	O
silico	O
analysis	O
to	O
identify	O
putative	O
TCF	O
-	O
binding	O
elements	O
(	O
TBE	O
)	O
in	O
myostatin	O
promoter	O
,	O
as	O
have	O
been	O
identified	O
in	O
the	O
promoters	O
of	O
Wnt	O
target	O
genes	O
.	O

Indeed	O
,	O
we	O
found	O
3	O
putative	O
TBE	O
(	O
NNCAAAG	O
)	O
within	O
a	O
2	O
.	O
8	O
kb	O
sequence	O
upstream	O
of	O
the	O
myostatin	O
gene	O
at	O
positions	O
-	O
2790	O
,	O
-	O
2389	O
and	O
-	O
1578	O
(	O
data	O
not	O
shown	O
)	O
opening	O
up	O
the	O
possibility	O
of	O
a	O
direct	O
interaction	O
between	O
Wnt	O
and	O
Myostatin	O
.	O

Previously	O
,	O
we	O
constructed	O
an	O
NFAT	O
-	O
GFP	O
reporter	O
cell	O
line	O
expressing	O
ILT7	O
and	O
FcepsilonRIgamma	O
that	O
expresses	O
GFP	O
in	O
response	O
to	O
ILT7	O
surface	O
ligation	O
.	O

To	O
detect	O
the	O
presence	O
of	O
ILT7	O
ligands	O
(	O
ILT7	O
-	O
L	O
)	O
,	O
we	O
used	O
these	O
cells	O
to	O
screen	O
virus	O
-	O
infected	O
cells	O
and	O
a	O
large	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O

Co	O
-	O
culture	O
of	O
the	O
ILT7	O
reporter	O
cells	O
with	O
human	O
breast	O
carcinoma	O
MDA	O
-	O
MB	O
-	O
468	O
,	O
MCF7	O
,	O
and	O
T47D	O
cells	O
,	O
but	O
not	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
or	O
ZR	O
-	O
75	O
-	O
1	O
cells	O
,	O
induced	O
GFP	O
expression	O
by	O
the	O
reporter	O
cells	O
(	O
Fig	O
.	O
1	O
A	O
)	O
.	O

We	O
further	O
tested	O
several	O
human	O
ovarian	O
,	O
colon	O
,	O
melanoma	O
,	O
glioma	O
,	O
and	O
lung	O
cancer	O
cell	O
lines	O
and	O
found	O
that	O
two	O
melanoma	O
lines	O
,	O
WM35	O
and	O
Mel938	O
,	O
were	O
able	O
to	O
similarly	O
activate	O
the	O
ILT7	O
reporter	O
cells	O
(	O
Fig	O
.	O
1	O
B	O
)	O
.	O

Other	O
transformed	O
cell	O
lines	O
,	O
such	O
as	O
HEK293	O
,	O
Vero	O
,	O
CHO	O
,	O
Cos7	O
,	O
and	O
Jurkat	O
,	O
were	O
unable	O
to	O
stimulate	O
the	O
ILT7	O
reporter	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

Redox	O
-	O
sensitive	O
cysteines	O
bridge	O
p300	O
/	O
CBP	O
-	O
mediated	O
acetylation	O
and	O
FoxO4	O
activity	O
.	O

Cellular	O
damage	O
invoked	O
by	O
reactive	O
oxygen	O
species	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathobiology	O
of	O
cancer	O
and	O
aging	O
.	O

Forkhead	O
box	O
class	O
O	O
(	O
FoxO	O
)	O
transcription	O
factors	O
are	O
involved	O
in	O
various	O
cellular	O
processes	O
including	O
cell	O
cycle	O
regulation	O
,	O
apoptosis	O
and	O
resistance	O
to	O
reactive	O
oxygen	O
species	O
,	O
and	O
studies	O
in	O
animal	O
models	O
have	O
shown	O
that	O
these	O
transcription	O
factors	O
are	O
of	O
vital	O
importance	O
in	O
tumor	O
suppression	O
,	O
stem	O
cell	O
maintenance	O
and	O
lifespan	O
extension	O
.	O

Here	O
we	O
report	O
that	O
the	O
activity	O
of	O
FoxO	O
in	O
human	O
cells	O
is	O
directly	O
regulated	O
by	O
the	O
cellular	O
redox	O
state	O
through	O
a	O
unique	O
mechanism	O
in	O
signal	O
transduction	O
.	O

We	O
show	O
that	O
reactive	O
oxygen	O
species	O
induce	O
the	O
formation	O
of	O
cysteine	O
-	O
thiol	O
disulfide	O
-	O
dependent	O
complexes	O
of	O
FoxO	O
and	O
the	O
p300	O
/	O
CBP	O
acetyltransferase	O
,	O
and	O
that	O
modulation	O
of	O
FoxO	O
biological	O
activity	O
by	O
p300	O
/	O
CBP	O
-	O
mediated	O
acetylation	O
is	O
fully	O
dependent	O
on	O
the	O
formation	O
of	O
this	O
redox	O
-	O
dependent	O
complex	O
.	O

These	O
findings	O
directly	O
link	O
cellular	O
redox	O
status	O
to	O
the	O
activity	O
of	O
the	O
longevity	O
protein	O
FoxO	O
.	O

Endotoxin	O
tolerance	O
dysregulates	O
MyD88	O
-	O
and	O
Toll	O
/	O
IL	O
-	O
1R	O
domain	O
-	O
containing	O
adapter	O
inducing	O
IFN	O
-	O
beta	O
-	O
dependent	O
pathways	O
and	O
increases	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
signaling	O
.	O

Endotoxin	O
tolerance	O
reprograms	O
cell	O
responses	O
to	O
LPS	O
by	O
repressing	O
expression	O
of	O
proinflammatory	O
cytokines	O
,	O
while	O
not	O
inhibiting	O
production	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
antimicrobial	O
effectors	O
.	O

Molecular	O
mechanisms	O
of	O
induction	O
and	O
maintenance	O
of	O
endotoxin	O
tolerance	O
are	O
incompletely	O
understood	O
,	O
particularly	O
with	O
regard	O
to	O
the	O
impact	O
of	O
endotoxin	O
tolerization	O
on	O
signalosome	B-Complex
assembly	O
,	O
activation	O
of	O
adaptor	O
-	O
kinase	O
modules	O
,	O
and	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
signaling	O
in	O
human	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
LPS	O
-	O
mediated	O
activation	O
of	O
MyD88	O
-	O
dependent	O
and	O
Toll	O
-	O
IL	O
-	O
1R	O
-	O
containing	O
adaptor	O
inducing	O
IFN	O
-	O
beta	O
(	O
TRIF	O
)	O
-	O
dependent	O
pathways	O
emanating	O
from	O
TLR4	O
and	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
signaling	O
in	O
control	O
and	O
endotoxin	O
-	O
tolerant	O
human	O
monocytes	O
.	O

Endotoxin	O
tolerization	O
suppressed	O
LPS	O
-	O
inducible	O
TLR4	O
-	O
TRIF	O
and	O
TRIF	O
-	O
TANK	O
binding	O
kinase	O
(	O
TBK	O
)	O
1	O
associations	O
,	O
induction	O
of	O
TBK1	O
kinase	O
activity	O
,	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
-	O
3	O
,	O
and	O
expression	O
of	O
RANTES	O
and	O
IFN	O
-	O
beta	O
.	O

Tolerance	O
-	O
mediated	O
dysregulation	O
of	O
the	O
TLR4	O
-	O
TRIF	O
-	O
TBK1	O
signaling	O
module	O
was	O
accompanied	O
by	O
increased	O
levels	O
of	O
suppressor	O
of	O
IkappaB	O
kinase	O
-	O
epsilon	O
(	O
SIKE	O
)	O
and	O
sterile	O
alpha	O
and	O
Armadillo	O
motif	O
-	O
containing	O
molecule	O
(	O
SARM	O
)	O
.	O

LPS	O
-	O
tolerant	O
cells	O
showed	O
increased	O
expression	O
of	O
negative	O
regulators	O
Toll	O
-	O
interacting	O
protein	O
(	O
Tollip	O
)	O
,	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
)	O
-	O
1	O
,	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
-	O
M	O
,	O
and	O
SHIP	O
-	O
1	O
,	O
which	O
correlated	O
with	O
reduced	O
p38	O
phosphorylation	O
,	O
IkappaB	O
-	O
alpha	O
degradation	O
,	O
and	O
inhibited	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
IL	O
-	O
8	O
.	O

To	O
examine	O
functional	O
consequences	O
of	O
increased	O
expression	O
of	O
Tollip	O
in	O
LPS	O
-	O
tolerized	O
cells	O
,	O
we	O
overexpressed	O
Tollip	O
in	O
293	O
/	O
TLR4	O
/	O
MD	O
-	O
2	O
transfectants	O
and	O
observed	O
blunted	O
LPS	O
-	O
inducible	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
RANTES	O
,	O
while	O
TNF	O
-	O
alpha	O
responses	O
were	O
not	O
affected	O
.	O

These	O
data	O
demonstrate	O
dysregulation	O
of	O
TLR4	O
-	O
triggered	O
MyD88	O
-	O
and	O
TRIF	O
-	O
dependent	O
signaling	O
pathways	O
and	O
increased	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
signaling	O
in	O
endotoxin	O
-	O
tolerant	O
human	O
monocytes	O
.	O

Distinct	O
domains	O
within	O
PSD	O
-	O
95	O
mediate	O
synaptic	O
incorporation	O
,	O
stabilization	O
,	O
and	O
activity	O
-	O
dependent	O
trafficking	O
.	O

The	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
consists	O
of	O
a	O
lattice	O
-	O
like	O
array	O
of	O
interacting	O
proteins	O
that	O
organizes	O
and	O
stabilizes	O
receptors	O
,	O
ion	O
channels	O
,	O
structural	O
,	O
and	O
signaling	O
proteins	O
necessary	O
for	O
synaptic	O
function	O
.	O

To	O
study	O
the	O
stabilization	O
of	O
proteins	O
within	O
this	O
structure	O
and	O
the	O
contribution	O
of	O
these	O
proteins	O
to	O
the	O
integrity	O
of	O
the	O
PSD	O
,	O
we	O
tagged	O
synaptic	O
proteins	O
with	O
PAGFP	O
(	O
photoactivatable	O
green	O
fluorescent	O
protein	O
)	O
and	O
used	O
combined	O
two	O
-	O
photon	O
laser	O
-	O
scanning	O
microscopy	O
and	O
two	O
-	O
photon	O
laser	O
photoactivation	O
to	O
measure	O
their	O
rate	O
of	O
turnover	O
in	O
individual	O
spines	O
of	O
rat	O
CA1	O
pyramidal	O
neurons	O
.	O

We	O
find	O
that	O
PSD	O
-	O
95	O
is	O
highly	O
stable	O
within	O
the	O
spine	O
,	O
more	O
so	O
than	O
other	O
PSD	O
-	O
associated	O
proteins	O
such	O
as	O
CaMKIIalpha	O
,	O
CaMKIIbeta	O
,	O
GluR2	O
,	O
and	O
Stargazin	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
PSD	O
-	O
95	O
mutants	O
revealed	O
that	O
distinct	O
domains	O
stabilize	O
PSD	O
-	O
95	O
within	O
the	O
PSD	O
and	O
contribute	O
to	O
PSD	O
formation	O
.	O

Stabilization	O
of	O
PSD	O
-	O
95	O
within	O
the	O
PSD	O
requires	O
N	O
-	O
terminal	O
palmitoylation	O
and	O
protein	O
interactions	O
mediated	O
by	O
the	O
first	O
and	O
second	O
PDZ	O
domains	O
,	O
whereas	O
formation	O
of	O
a	O
stable	O
lattice	O
of	O
PSD	O
-	O
95	O
molecules	O
within	O
the	O
PSD	O
additionally	O
requires	O
the	O
C	O
-	O
terminal	O
SH3	O
domain	O
.	O

Furthermore	O
,	O
in	O
a	O
PDZ	O
domain	O
1	O
and	O
2	O
dependent	O
manner	O
,	O
activation	O
of	O
NMDA	O
receptors	O
with	O
a	O
chemical	O
long	O
-	O
term	O
depression	O
protocol	O
rapidly	O
destabilizes	O
PSD	O
-	O
95	O
and	O
causes	O
a	O
subset	O
of	O
the	O
PSD	O
-	O
95	O
molecules	O
previously	O
anchored	O
in	O
the	O
spine	O
to	O
be	O
released	O
.	O

Thus	O
,	O
through	O
the	O
analysis	O
of	O
rates	O
of	O
exchange	O
of	O
synaptic	O
PSD	O
-	O
95	O
,	O
we	O
determine	O
separate	O
domains	O
of	O
PSD	O
-	O
95	O
that	O
play	O
specific	O
roles	O
in	O
establishing	O
a	O
stable	O
postsynaptic	O
lattice	O
,	O
in	O
allowing	O
proteins	O
to	O
enter	O
this	O
lattice	O
,	O
and	O
in	O
reorganizing	O
this	O
structure	O
in	O
response	O
to	O
plasticity	O
-	O
inducing	O
stimuli	O
.	O

Orientation	O
of	O
palmitoylated	O
CaVbeta2a	O
relative	O
to	O
CaV2	B-OOS
.	I-OOS
2	I-OOS
is	O
critical	O
for	O
slow	O
pathway	O
modulation	O
of	O
N	B-OOS
-	I-OOS
type	I-OOS
Ca2	I-OOS
+	I-OOS
current	O
by	O
tachykinin	O
receptor	O
activation	O
.	O

The	O
G	O
(	O
q	O
)	O
-	O
coupled	O
tachykinin	O
receptor	O
(	O
neurokinin	O
-	O
1	O
receptor	O
[	O
NK	O
-	O
1R	O
]	O
)	O
modulates	O
N	B-OOS
-	I-OOS
type	I-OOS
Ca	I-OOS
(	I-OOS
2	I-OOS
+	I-OOS
)	I-OOS
channel	I-OOS
(	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
or	O
N	B-OOS
channel	I-OOS
)	O
activity	O
at	O
two	O
distinct	O
sites	O
by	O
a	O
pathway	O
involving	O
a	O
lipid	O
metabolite	O
,	O
most	O
likely	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O

In	O
another	O
study	O
published	O
in	O
this	O
issue	O
(	O
Heneghan	O
et	O
al	O
.	O
2009	O
.	O
J	O
.	O
Gen	O
Physiol	O
.	O
doi	O
:	O
10	O
.	O
1085	O
/	O
jgp	O
.	O
200910203	O
)	O
,	O
we	O
found	O
that	O
the	O
form	O
of	O
modulation	O
observed	O
depends	O
on	O
which	O
Ca	O
(	O
V	O
)	O
beta	O
is	O
coexpressed	O
with	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
.	O

When	O
palmitoylated	O
Ca	O
(	O
V	O
)	O
beta2a	O
is	O
coexpressed	O
,	O
activation	O
of	O
NK	O
-	O
1Rs	O
by	O
substance	O
P	O
(	O
SP	O
)	O
enhances	O
N	O
current	O
.	O

In	O
contrast	O
,	O
when	O
Ca	O
(	O
V	O
)	O
beta3	O
is	O
coexpressed	O
,	O
SP	O
inhibits	O
N	O
current	O
.	O

However	O
,	O
exogenously	O
applied	O
palmitic	O
acid	O
minimizes	O
this	O
inhibition	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
palmitoyl	O
groups	O
of	O
Ca	O
(	O
V	O
)	O
beta2a	O
may	O
occupy	O
an	O
inhibitory	O
site	O
on	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
or	O
prevent	O
AA	O
from	O
interacting	O
with	O
that	O
site	O
,	O
thereby	O
minimizing	O
inhibition	O
.	O

If	O
so	O
,	O
changing	O
the	O
orientation	O
of	O
Ca	O
(	O
V	O
)	O
beta2a	O
relative	O
to	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
may	O
displace	O
the	O
palmitoyl	O
groups	O
and	O
prevent	O
them	O
from	O
antagonizing	O
AA	O
'	O
s	O
actions	O
,	O
thereby	O
allowing	O
inhibition	O
even	O
in	O
the	O
presence	O
of	O
Ca	O
(	O
V	O
)	O
beta2a	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
this	O
hypothesis	O
by	O
deleting	O
one	O
(	O
Bdel1	O
)	O
or	O
two	O
(	O
Bdel2	O
)	O
amino	O
acids	O
proximal	O
to	O
the	O
alpha	O
interacting	O
domain	O
(	O
AID	O
)	O
of	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
'	O
s	O
I	O
-	O
II	O
linker	O
.	O

Ca	O
(	O
V	O
)	O
betas	O
bind	O
tightly	O
to	O
the	O
AID	O
,	O
whereas	O
the	O
rigid	O
region	O
proximal	O
to	O
the	O
AID	O
is	O
thought	O
to	O
couple	O
Ca	O
(	O
V	O
)	O
beta	O
'	O
s	O
movements	O
to	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
gating	O
.	O

Although	O
Bdel1	O
/	O
beta2a	O
currents	O
exhibited	O
more	O
variable	O
enhancement	O
by	O
SP	O
,	O
Bdel2	O
/	O
beta2a	O
current	O
enhancement	O
was	O
lost	O
at	O
all	O
voltages	O
.	O

Instead	O
,	O
inhibition	O
was	O
observed	O
that	O
matched	O
the	O
profile	O
of	O
N	O
-	O
current	O
inhibition	O
from	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
coexpressed	O
with	O
Ca	O
(	O
V	O
)	O
beta3	O
.	O

Moreover	O
,	O
adding	O
back	O
exogenous	O
palmitic	O
acid	O
minimized	O
inhibition	O
of	O
Bdel2	O
/	O
beta2a	O
currents	O
,	O
suggesting	O
that	O
when	O
palmitoylated	O
Ca	O
(	O
V	O
)	O
beta2a	O
is	O
sufficiently	O
displaced	O
,	O
endogenously	O
released	O
AA	O
can	O
bind	O
to	O
the	O
inhibitory	O
site	O
.	O

These	O
findings	O
support	O
our	O
previous	O
hypothesis	O
that	O
Ca	O
(	O
V	O
)	O
beta2a	O
'	O
s	O
palmitoyl	O
groups	O
directly	O
interact	O
with	O
an	O
inhibitory	O
site	O
on	O
Ca	B-OOS
(	I-OOS
V	I-OOS
)	I-OOS
2	I-OOS
.	I-OOS
2	I-OOS
to	O
block	O
N	O
-	O
current	O
inhibition	O
by	O
SP	O
.	O

Nuclear	B-Complex
factor	I-Complex
kappa	I-Complex
B	I-Complex
activates	O
proenkephalin	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	B-Complex
B	I-Complex
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	O
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	O
plus	O
two	O
p50s	O
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
is	O
mediated	O
by	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

However	O
,	O
as	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
should	O
be	O
considered	O
.	O

Direct	O
inhibition	O
of	O
the	O
NOTCH	O
transcription	O
factor	O
complex	O
.	O

Direct	O
inhibition	O
of	O
transcription	O
factor	O
complexes	O
remains	O
a	O
central	O
challenge	O
in	O
the	O
discipline	O
of	O
ligand	O
discovery	O
.	O

In	O
general	O
,	O
these	O
proteins	O
lack	O
surface	O
involutions	O
suitable	O
for	O
high	O
-	O
affinity	O
binding	O
by	O
small	O
molecules	O
.	O

Here	O
we	O
report	O
the	O
design	O
of	O
synthetic	O
,	O
cell	O
-	O
permeable	O
,	O
stabilized	O
alpha	O
-	O
helical	O
peptides	O
that	O
target	O
a	O
critical	O
protein	O
-	O
protein	O
interface	O
in	O
the	O
NOTCH	O
transactivation	O
complex	O
.	O

We	O
demonstrate	O
that	O
direct	O
,	O
high	O
-	O
affinity	O
binding	O
of	O
the	O
hydrocarbon	O
-	O
stapled	O
peptide	O
SAHM1	O
prevents	O
assembly	O
of	O
the	O
active	O
transcriptional	O
complex	O
.	O

Inappropriate	O
NOTCH	O
activation	O
is	O
directly	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
disease	O
states	O
,	O
including	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

The	O
treatment	O
of	O
leukaemic	O
cells	O
with	O
SAHM1	O
results	O
in	O
genome	O
-	O
wide	O
suppression	O
of	O
NOTCH	O
-	O
activated	O
genes	O
.	O

Direct	O
antagonism	O
of	O
the	O
NOTCH	O
transcriptional	O
program	O
causes	O
potent	O
,	O
NOTCH	O
-	O
specific	O
anti	O
-	O
proliferative	O
effects	O
in	O
cultured	O
cells	O
and	O
in	O
a	O
mouse	O
model	O
of	O
NOTCH1	O
-	O
driven	O
T	O
-	O
ALL	O
.	O

In	O
conclusion	O
,	O
as	O
proof	O
-	O
of	O
-	O
concept	O
,	O
we	O
show	O
that	O
an	O
SDL	O
screen	O
offers	O
an	O
effective	O
,	O
complementary	O
method	O
to	O
elucidating	O
biological	O
functions	O
of	O
proteolytic	O
pathways	O
.	O

Dsk2	O
was	O
first	O
identified	O
11	O
years	O
ago	O
in	O
a	O
genetic	O
screen	O
for	O
genes	O
involved	O
in	O
SPB	O
duplication	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
Spc98	O
-	O
induced	O
toxicity	O
in	O
rad23	O
dsk2	O
mutant	O
cells	O
is	O
the	O
second	O
piece	O
of	O
evidence	O
linking	O
Dsk2	O
and	O
Rad23	O
to	O
SPB	O
duplication	O
,	O
which	O
will	O
help	O
us	O
to	O
unravel	O
the	O
specific	O
role	O
of	O
Rad23	O
and	O
Dsk2	O
in	O
this	O
process	O
.	O

It	O
is	O
also	O
conceivable	O
that	O
the	O
SDL	O
screen	O
can	O
be	O
adapted	O
to	O
identify	O
relevant	O
ubiquitylation	O
enzymes	O
involved	O
in	O
substrate	O
turnover	O
.	O

The	O
creation	O
of	O
RNAi	O
knock	O
-	O
down	O
libraries	O
and	O
ORF	O
overexpression	O
collections	O
would	O
extend	O
the	O
use	O
of	O
SDL	O
screens	O
in	O
the	O
Ub	O
/	O
proteasome	B-Complex
system	O
to	O
higher	O
eukaryotes	O
.	O

A	O
novel	O
class	O
of	O
small	O
RNAs	O
:	O
tRNA	O
-	O
derived	O
RNA	O
fragments	O
(	O
tRFs	O
)	O
.	O

New	O
types	O
of	O
small	O
RNAs	O
distinct	O
from	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
progressively	O
being	O
discovered	O
in	O
various	O
organisms	O
.	O

In	O
order	O
to	O
discover	O
such	O
novel	O
small	O
RNAs	O
,	O
a	O
library	O
of	O
17	O
-	O
to	O
26	O
-	O
base	O
-	O
long	O
RNAs	O
was	O
created	O
from	O
prostate	O
cancer	O
cell	O
lines	O
and	O
sequenced	O
by	O
ultra	O
-	O
high	O
-	O
throughput	O
sequencing	O
.	O

A	O
significant	O
number	O
of	O
the	O
sequences	O
are	O
derived	O
from	O
precise	O
processing	O
at	O
the	O
5	O
'	O
or	O
3	O
'	O
end	O
of	O
mature	O
or	O
precursor	O
tRNAs	O
to	O
form	O
three	O
series	O
of	O
tRFs	O
(	O
tRNA	O
-	O
derived	O
RNA	O
fragments	O
)	O
:	O
the	O
tRF	O
-	O
5	O
,	O
tRF	O
-	O
3	O
,	O
and	O
tRF	O
-	O
1	O
series	O
.	O

These	O
sequences	O
constitute	O
a	O
class	O
of	O
short	O
RNAs	O
that	O
are	O
second	O
most	O
abundant	O
to	O
miRNAs	O
.	O

Northern	O
hybridization	O
,	O
quantitative	O
RT	O
-	O
PCR	O
,	O
and	O
splinted	O
ligation	O
assays	O
independently	O
measured	O
the	O
levels	O
of	O
at	O
least	O
17	O
tRFs	O
.	O

To	O
demonstrate	O
the	O
biological	O
importance	O
of	O
tRFs	O
,	O
we	O
further	O
investigated	O
tRF	O
-	O
1001	O
,	O
derived	O
from	O
the	O
3	O
'	O
end	O
of	O
a	O
Ser	O
-	O
TGA	O
tRNA	O
precursor	O
transcript	O
that	O
is	O
not	O
retained	O
in	O
the	O
mature	O
tRNA	O
.	O

tRF	O
-	O
1001	O
is	O
expressed	O
highly	O
in	O
a	O
wide	O
range	O
of	O
cancer	O
cell	O
lines	O
but	O
much	O
less	O
in	O
tissues	O
,	O
and	O
its	O
expression	O
in	O
cell	O
lines	O
was	O
tightly	O
correlated	O
with	O
cell	O
proliferation	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
tRF	O
-	O
1001	O
impaired	O
cell	O
proliferation	O
with	O
the	O
specific	O
accumulation	O
of	O
cells	O
in	O
G2	O
,	O
phenotypes	O
that	O
were	O
reversed	O
specifically	O
by	O
cointroducing	O
a	O
synthetic	O
2	O
'	O
-	O
O	O
-	O
methyl	O
tRF	O
-	O
1001	O
oligoribonucleotide	O
resistant	O
to	O
the	O
siRNA	O
.	O

tRF	O
-	O
1001	O
is	O
generated	O
in	O
the	O
cytoplasm	O
by	O
tRNA	O
3	O
'	O
-	O
endonuclease	O
ELAC2	O
,	O
a	O
prostate	O
cancer	O
susceptibility	O
gene	O
.	O

Our	O
data	O
suggest	O
that	O
tRFs	O
are	O
not	O
random	O
by	O
-	O
products	O
of	O
tRNA	O
degradation	O
or	O
biogenesis	O
,	O
but	O
an	O
abundant	O
and	O
novel	O
class	O
of	O
short	O
RNAs	O
with	O
precise	O
sequence	O
structure	O
that	O
have	O
specific	O
expression	O
patterns	O
and	O
specific	O
biological	O
roles	O
.	O

Detection	O
of	O
sequential	O
polyubiquitylation	O
on	O
a	O
millisecond	O
timescale	O
.	O

The	O
pathway	O
by	O
which	O
ubiquitin	O
chains	O
are	O
generated	O
on	O
substrate	O
through	O
a	O
cascade	O
of	O
enzymes	O
consisting	O
of	O
an	O
E1	O
,	O
E2	O
and	O
E3	O
remains	O
unclear	O
.	O

Multiple	O
distinct	O
models	O
involving	O
chain	O
assembly	O
on	O
E2	O
or	O
substrate	O
have	O
been	O
proposed	O
.	O

However	O
,	O
the	O
speed	O
and	O
complexity	O
of	O
the	O
reaction	O
have	O
precluded	O
direct	O
experimental	O
tests	O
to	O
distinguish	O
between	O
potential	O
pathways	O
.	O

Here	O
we	O
introduce	O
new	O
theoretical	O
and	O
experimental	O
methodologies	O
to	O
address	O
both	O
limitations	O
.	O

A	O
quantitative	O
framework	O
based	O
on	O
product	O
distribution	O
predicts	O
that	O
the	O
really	O
interesting	O
new	O
gene	O
(	O
RING	O
)	O
E3	O
enzymes	O
SCF	B-Complex
(	I-Complex
Cdc4	I-Complex
)	I-Complex
and	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
-	I-Complex
TrCP	I-Complex
)	I-Complex
work	O
with	O
the	O
E2	O
Cdc34	O
to	O
build	O
polyubiquitin	O
chains	O
on	O
substrates	O
by	O
sequential	O
transfers	O
of	O
single	O
ubiquitins	O
.	O

Measurements	O
with	O
millisecond	O
time	O
resolution	O
directly	O
demonstrate	O
that	O
substrate	O
polyubiquitylation	O
proceeds	O
sequentially	O
.	O

Our	O
results	O
present	O
an	O
unprecedented	O
glimpse	O
into	O
the	O
mechanism	O
of	O
RING	O
ubiquitin	O
ligases	O
and	O
illuminate	O
the	O
quantitative	O
parameters	O
that	O
underlie	O
the	O
rate	O
and	O
pattern	O
of	O
ubiquitin	O
chain	O
assembly	O
.	O

Palmitoylation	O
regulates	O
epidermal	O
homeostasis	O
and	O
hair	O
follicle	O
differentiation	O
.	O

Palmitoylation	O
is	O
a	O
key	O
post	O
-	O
translational	O
modification	O
mediated	O
by	O
a	O
family	O
of	O
DHHC	O
-	O
containing	O
palmitoyl	O
acyl	O
-	O
transferases	O
(	O
PATs	O
)	O
.	O

Unlike	O
other	O
lipid	O
modifications	O
,	O
palmitoylation	O
is	O
reversible	O
and	O
thus	O
often	O
regulates	O
dynamic	O
protein	O
interactions	O
.	O

We	O
find	O
that	O
the	O
mouse	O
hair	O
loss	O
mutant	O
,	O
depilated	O
,	O
(	O
dep	O
)	O
is	O
due	O
to	O
a	O
single	O
amino	O
acid	O
deletion	O
in	O
the	O
PAT	O
,	O
Zdhhc21	O
,	O
resulting	O
in	O
protein	O
mislocalization	O
and	O
loss	O
of	O
palmitoylation	O
activity	O
.	O

We	O
examined	O
expression	O
of	O
Zdhhc21	O
protein	O
in	O
skin	O
and	O
find	O
it	O
restricted	O
to	O
specific	O
hair	O
lineages	O
.	O

Loss	O
of	O
Zdhhc21	O
function	O
results	O
in	O
delayed	O
hair	O
shaft	O
differentiation	O
,	O
at	O
the	O
site	O
of	O
expression	O
of	O
the	O
gene	O
,	O
but	O
also	O
leads	O
to	O
hyperplasia	O
of	O
the	O
interfollicular	O
epidermis	O
(	O
IFE	O
)	O
and	O
sebaceous	O
glands	O
,	O
distant	O
from	O
the	O
expression	O
site	O
.	O

The	O
specific	O
delay	O
in	O
follicle	O
differentiation	O
is	O
associated	O
with	O
attenuated	O
anagen	O
propagation	O
and	O
is	O
reflected	O
by	O
decreased	O
levels	O
of	O
Lef1	O
,	O
nuclear	O
beta	O
-	O
catenin	O
,	O
and	O
Foxn1	O
in	O
hair	O
shaft	O
progenitors	O
.	O

In	O
the	O
thickened	O
basal	O
compartment	O
of	O
mutant	O
IFE	O
,	O
phospho	O
-	O
ERK	O
and	O
cell	O
proliferation	O
are	O
increased	O
,	O
suggesting	O
increased	O
signaling	O
through	O
EGFR	O
or	O
integrin	O
-	O
related	O
receptors	O
,	O
with	O
a	O
parallel	O
reduction	O
in	O
expression	O
of	O
the	O
key	O
differentiation	O
factor	O
Gata3	O
.	O

We	O
show	O
that	O
the	O
Src	O
-	O
family	O
kinase	O
,	O
Fyn	O
,	O
involved	O
in	O
keratinocyte	O
differentiation	O
,	O
is	O
a	O
direct	O
palmitoylation	O
target	O
of	O
Zdhhc21	O
and	O
is	O
mislocalized	O
in	O
mutant	O
follicles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
a	O
key	O
role	O
for	O
palmitoylation	O
in	O
regulating	O
developmental	O
signals	O
in	O
mammalian	O
tissue	O
homeostasis	O
.	O

Rapid	O
and	O
selective	O
detection	O
of	O
fatty	O
acylated	O
proteins	O
using	O
omega	O
-	O
alkynyl	O
-	O
fatty	O
acids	O
and	O
click	O
chemistry	O
.	O

Progress	O
in	O
understanding	O
the	O
biology	O
of	O
protein	O
fatty	O
acylation	O
has	O
been	O
impeded	O
by	O
the	O
lack	O
of	O
rapid	O
direct	O
detection	O
and	O
identification	O
methods	O
.	O

We	O
first	O
report	O
that	O
a	O
synthetic	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
analog	O
can	O
be	O
readily	O
and	O
specifically	O
incorporated	O
into	O
GAPDH	O
or	O
mitochondrial	O
3	O
-	O
hydroxyl	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
synthase	O
in	O
vitro	O
and	O
reacted	O
with	O
an	O
azido	O
-	O
biotin	O
probe	O
or	O
the	O
fluorogenic	O
probe	O
3	O
-	O
azido	O
-	O
7	O
-	O
hydroxycoumarin	O
using	O
click	O
chemistry	O
for	O
rapid	O
detection	O
by	O
Western	O
blotting	O
or	O
flat	O
bed	O
fluorescence	O
scanning	O
.	O

The	O
acylated	O
cysteine	O
residues	O
were	O
confirmed	O
by	O
MS	O
.	O

Second	O
,	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
is	O
preferentially	O
incorporated	O
into	O
transiently	O
expressed	O
H	O
-	O
or	O
N	O
-	O
Ras	O
proteins	O
(	O
but	O
not	O
nonpalmitoylated	O
K	O
-	O
Ras	O
)	O
,	O
compared	O
with	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
or	O
omega	O
-	O
alkynyl	O
-	O
stearate	O
,	O
via	O
an	O
alkali	O
sensitive	O
thioester	O
bond	O
.	O

Third	O
,	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
is	O
specifically	O
incorporated	O
into	O
endogenous	O
co	O
-	O
and	O
posttranslationally	O
myristoylated	O
proteins	O
.	O

The	O
competitive	O
inhibitors	O
2	O
-	O
bromopalmitate	O
and	O
2	O
-	O
hydroxymyristate	O
prevented	O
incorporation	O
of	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
and	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
into	O
palmitoylated	O
and	O
myristoylated	O
proteins	O
,	O
respectively	O
.	O

Labeling	O
cells	O
with	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
does	O
not	O
affect	O
membrane	O
association	O
of	O
N	O
-	O
Ras	O
.	O

Furthermore	O
,	O
the	O
palmitoylation	O
of	O
endogenous	O
proteins	O
including	O
H	O
-	O
and	O
N	O
-	O
Ras	O
could	O
be	O
easily	O
detected	O
using	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
as	O
label	O
in	O
cultured	O
HeLa	O
,	O
Jurkat	O
,	O
and	O
COS	O
-	O
7	O
cells	O
,	O
and	O
,	O
promisingly	O
,	O
in	O
mice	O
.	O

The	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
and	O
-	O
palmitate	O
analogs	O
used	O
with	O
click	O
chemistry	O
and	O
azido	O
-	O
probes	O
will	O
be	O
invaluable	O
to	O
study	O
protein	O
acylation	O
in	O
vitro	O
,	O
in	O
cells	O
,	O
and	O
in	O
vivo	O
.	O

The	O
enhancement	O
of	O
antiproliferative	O
and	O
proapoptotic	O
activity	O
of	O
HDAC	O
inhibitors	O
by	O
curcumin	O
is	O
mediated	O
by	O
Hsp90	O
inhibition	O
.	O

Curcumin	O
,	O
a	O
natural	O
polyphenol	O
,	O
has	O
been	O
described	O
to	O
exhibit	O
effects	O
on	O
signaling	O
pathways	O
,	O
leading	O
to	O
induction	O
of	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
inhibited	O
Hsp90	O
activity	O
causing	O
depletion	O
of	O
client	O
proteins	O
implicated	O
in	O
survival	O
pathways	O
.	O

Based	O
on	O
this	O
observation	O
,	O
this	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cellular	O
effects	O
of	O
curcumin	O
combination	O
with	O
the	O
pan	O
-	O
HDAC	O
inhibitors	O
,	O
vorinostat	O
and	O
panobinostat	O
,	O
which	O
induce	O
hyperacetylation	O
of	O
Hsp90	O
,	O
resulting	O
in	O
inhibition	O
of	O
its	O
chaperone	O
function	O
.	O

The	O
results	O
showed	O
that	O
,	O
at	O
subtoxic	O
concentrations	O
,	O
curcumin	O
markedly	O
sensitized	O
tumor	O
cells	O
to	O
vorinostat	O
-	O
and	O
panobinostat	O
-	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
.	O

The	O
sensitization	O
was	O
associated	O
with	O
persistent	O
depletion	O
of	O
Hsp90	O
client	O
proteins	O
(	O
EGFR	O
,	O
Raf	O
-	O
1	O
,	O
Akt	O
,	O
and	O
survivin	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
document	O
a	O
novel	O
mechanism	O
of	O
action	O
of	O
curcumin	O
and	O
support	O
the	O
therapeutic	O
potential	O
of	O
curcumin	O
/	O
HDAC	O
inhibitors	O
combination	O
,	O
because	O
the	O
synergistic	O
interaction	O
was	O
observed	O
at	O
pharmacologically	O
achievable	O
concentrations	O
,	O
which	O
were	O
ineffective	O
when	O
each	O
drug	O
was	O
used	O
alone	O
.	O

TRAP150	O
activates	O
pre	O
-	O
mRNA	O
splicing	O
.	O

(	O
A	O
)	O
The	O
splicing	O
report	O
pSV40	O
-	O
CAT	O
(	O
In1	O
)	O
encodes	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
,	O
in	O
which	O
human	O
beta	O
-	O
globin	O
intron	O
1	O
was	O
inserted	O
.	O

The	O
pSV40	O
-	O
CAT	O
(	O
In1	O
)	O
reporter	O
was	O
co	O
-	O
transfected	O
with	O
indicated	O
siRNA	O
into	O
HeLa	O
cells	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
primers	O
specific	O
for	O
the	O
reporter	O
exons	O
;	O
the	O
PCR	O
products	O
were	O
analyzed	O
by	O
Southern	O
blotting	O
using	O
primers	O
specific	O
for	O
the	O
exons	O
(	O
left	O
)	O
.	O

Splicing	O
efficiency	O
in	O
individual	O
transfectants	O
was	O
calculated	O
as	O
the	O
intensity	O
of	O
the	O
spliced	O
RNA	O
over	O
the	O
sum	O
of	O
the	O
spliced	O
RNA	O
and	O
the	O
precursor	O
.	O

Splicing	O
activation	O
fold	O
was	O
obtained	O
from	O
three	O
independent	O
experiments	O
.	O

Immunoblotting	O
using	O
antibodies	O
specific	O
to	O
indicated	O
protein	O
was	O
performed	O
to	O
reveal	O
knockdown	O
efficiency	O
(	O
right	O
)	O
.	O

(	O
B	O
)	O
HeLa	O
cells	O
were	O
mock	O
-	O
transfected	O
or	O
transfected	O
with	O
si	O
-	O
TRAP150	O
(	O
J5	O
)	O
.	O

The	O
nuclear	O
extract	O
was	O
prepared	O
from	O
transfected	O
cells	O
and	O
analyzed	O
by	O
immunoblotting	O
(	O
upper	O
)	O
.	O

Lower	O
panel	O
shows	O
that	O
in	O
vitro	O
splicing	O
using	O
32P	O
-	O
labeled	O
PIP85a	O
pre	O
-	O
mRNA	O
in	O
the	O
mock	O
-	O
or	O
TRAP150	O
-	O
depleted	O
nuclear	O
extract	O
.	O

(	O
C	O
)	O
Schematic	O
representation	O
of	O
full	O
-	O
length	O
and	O
truncated	O
TRAP150	O
proteins	O
.	O

Domains	O
are	O
depicted	O
as	O
in	O
Figure	O
1	O
.	O

The	O
pSV40	O
-	O
CAT	O
(	O
In1	O
)	O
vector	O
was	O
co	O
-	O
transfected	O
with	O
an	O
expression	O
vector	O
encoding	O
the	O
indicated	O
effector	O
into	O
HeLa	O
cells	O
.	O

PCR	O
was	O
performed	O
as	O
in	O
(	O
A	O
)	O
;	O
asterisk	O
denotes	O
the	O
precursor	O
/	O
spliced	O
RNA	O
hybrid	O
.	O

Splicing	O
efficiency	O
was	O
also	O
calculated	O
as	O
in	O
(	O
A	O
)	O
and	O
the	O
splicing	O
activation	O
fold	O
relative	O
to	O
the	O
reporter	O
only	O
was	O
indicated	O
below	O
the	O
gel	O
.	O

Immunoblotting	O
using	O
anti	O
-	O
HA	O
shows	O
the	O
expression	O
level	O
of	O
the	O
effectors	O
;	O
actin	O
was	O
used	O
as	O
the	O
loading	O
control	O
.	O

As	O
the	O
first	O
step	O
in	O
exploring	O
the	O
mechanism	O
of	O
Ams2	O
proteolysis	O
,	O
we	O
examined	O
the	O
role	O
of	O
the	O
proteasome	B-Complex
pathway	O
in	O
this	O
process	O
.	O

In	O
fission	O
yeast	O
,	O
the	O
mts2	O
+	O
and	O
mts3	O
+	O
gene	O
products	O
have	O
been	O
identified	O
as	O
subunits	O
of	O
the	O
26S	B-Complex
proteasome	I-Complex
.	O

We	O
used	O
temperature	O
-	O
sensitive	O
mutations	O
mts2	O
-	O
1	O
and	O
mts3	O
-	O
1	O
to	O
inactivate	O
proteasome	B-Complex
function	O
.	O

Mutant	O
cells	O
carrying	O
pREP41	O
-	O
Ams2	O
were	O
cultured	O
at	O
the	O
restrictive	O
temperature	O
(	O
36degreesC	O
)	O
for	O
3	O
hr	O
and	O
Ams2	O
synthesis	O
was	O
repressed	O
by	O
addition	O
of	O
thiamine	O
and	O
CHX	O
as	O
described	O
above	O
(	O
Figure	O
2A	O
)	O
.	O

Whereas	O
Ams2	O
underwent	O
rapid	O
proteolysis	O
in	O
wild	O
-	O
type	O
cells	O
(	O
Figures	O
2A	O
and	O
2B	O
,	O
open	O
circles	O
)	O
,	O
degradation	O
of	O
Ams2	O
was	O
markedly	O
decreased	O
in	O
arrested	O
mts2	O
-	O
1	O
(	O
filled	O
circles	O
)	O
and	O
mts3	O
-	O
1	O
(	O
data	O
not	O
shown	O
)	O
cells	O
.	O

These	O
observations	O
indicated	O
that	O
Ams2	O
proteolysis	O
requires	O
the	O
proteasome	B-Complex
-	O
dependent	O
pathway	O
.	O

Regulation	O
of	O
proapoptotic	O
mammalian	O
ste20	O
-	O
like	O
kinase	O
MST2	O
by	O
the	O
IGF1	O
-	O
Akt	O
pathway	O
.	O

BACKGROUND	O
:	O
Hippo	O
,	O
a	O
Drosophila	O
serine	O
/	O
threonine	O
kinase	O
,	O
promotes	O
apoptosis	O
and	O
restricts	O
cell	O
growth	O
and	O
proliferation	O
.	O

Its	O
mammalian	O
homolog	O
MST2	O
has	O
been	O
shown	O
to	O
play	O
similar	O
role	O
and	O
be	O
regulated	O
by	O
Raf	O
-	O
1	O
via	O
a	O
kinase	O
-	O
independent	O
mechanism	O
and	O
by	O
RASSF	O
family	O
proteins	O
through	O
forming	O
complex	O
with	O
MST2	O
.	O

However	O
,	O
regulation	O
of	O
MST2	O
by	O
cell	O
survival	O
signal	O
remains	O
largely	O
unknown	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Using	O
immunoblotting	O
,	O
in	O
vitro	O
kinase	O
and	O
in	O
vivo	O
labeling	O
assays	O
,	O
we	O
show	O
that	O
IGF1	O
inhibits	O
MST2	O
cleavage	O
and	O
activation	O
induced	O
by	O
DNA	O
damage	O
through	O
the	O
phosphatidylinosotol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
pathway	O
.	O

Akt	O
phosphorylates	O
a	O
highly	O
conserved	O
threonine	O
-	O
117	O
residue	O
of	O
MST2	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
leads	O
to	O
inhibition	O
of	O
MST2	O
cleavage	O
,	O
nuclear	O
translocation	O
,	O
autophosphorylation	O
-	O
Thr180	O
and	O
kinase	O
activity	O
.	O

As	O
a	O
result	O
,	O
MST2	O
proapoptotic	O
and	O
growth	O
arrest	O
function	O
was	O
significantly	O
reduced	O
.	O

Further	O
,	O
inverse	O
correlation	O
between	O
pMST2	O
-	O
T117	O
/	O
pAkt	O
and	O
pMST2	O
-	O
T180	O
was	O
observed	O
in	O
human	O
breast	O
tumors	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
extracellular	O
cell	O
survival	O
signal	O
IGF1	O
regulates	O
MST2	O
and	O
that	O
Akt	O
is	O
a	O
key	O
upstream	O
regulator	O
of	O
MST2	O
.	O

(	O
D	O
-	O
I	O
)	O
Localization	O
of	O
YcgR	O
-	O
GFP	O
in	O
various	O
Salmonella	O
strains	O
.	O

Strains	O
expressing	O
either	O
GFP	O
or	O
YcgR	O
-	O
GFP	O
were	O
grown	O
in	O
the	O
presence	O
of	O
arabinose	O
and	O
analyzed	O
by	O
fluorescence	O
microscopy	O
as	O
described	O
in	O
the	O
Experimental	O
Procedures	O
.	O

(	O
D	O
)	O
Wild	O
-	O
type	O
(	O
pgfpOE	O
)	O
.	O

(	O
E	O
)	O
Wild	O
-	O
type	O
(	O
pycgROE	O
)	O
.	O

(	O
F	O
)	O
DeltayhjH	O
(	O
pycgROE	O
)	O
.	O

(	O
G	O
)	O
DeltayhjH	O
DeltafliM	O
(	O
pycgROE	O
)	O
.	O

(	O
H	O
)	O
DeltayhjH	O
DeltafliG	O
(	O
pycgROE	O
)	O
.	O

(	O
I	O
)	O
DeltayhjH	O
DeltamotA	O
(	O
pycgROE	O
)	O
.	O

Characterization	O
of	O
the	O
self	O
-	O
palmitoylation	O
activity	O
of	O
the	O
transport	O
protein	O
particle	O
component	O
Bet3	O
.	O

Bet3	O
,	O
a	O
transport	O
protein	O
particle	O
component	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
contains	O
a	O
hydrophobic	O
tunnel	O
occupied	O
by	O
a	O
fatty	O
acid	O
linked	O
to	O
cysteine	O
68	O
.	O

We	O
reported	O
that	O
Bet3	O
has	O
a	O
unique	O
self	O
-	O
palmitoylating	O
activity	O
.	O

Here	O
we	O
show	O
that	O
mutation	O
of	O
arginine	O
67	O
reduced	O
self	O
-	O
palmitoylation	O
of	O
Bet3	O
,	O
but	O
the	O
effect	O
was	O
compensated	O
by	O
increasing	O
the	O
pH	O
.	O

Thus	O
,	O
arginine	O
helps	O
to	O
deprotonate	O
cysteine	O
such	O
that	O
it	O
could	O
function	O
as	O
a	O
nucleophile	O
in	O
the	O
acylation	O
reaction	O
which	O
is	O
supported	O
by	O
the	O
structural	O
analysis	O
of	O
non	O
-	O
acylated	O
Bet3	O
.	O

Using	O
fluorescence	O
spectroscopy	O
we	O
show	O
that	O
long	O
-	O
chain	O
acyl	O
-	O
CoAs	O
bind	O
with	O
micromolar	O
affinity	O
to	O
Bet3	O
,	O
whereas	O
shorter	O
-	O
chain	O
acyl	O
-	O
CoAs	O
do	O
not	O
interact	O
.	O

Mutants	O
with	O
a	O
deleted	O
acylation	O
site	O
or	O
a	O
blocked	O
tunnel	O
bind	O
to	O
Pal	O
-	O
CoA	O
,	O
only	O
the	O
latter	O
with	O
slightly	O
reduced	O
affinity	O
.	O

Bet3	O
contains	O
three	O
binding	O
sites	O
for	O
Pal	O
-	O
CoA	O
,	O
but	O
their	O
number	O
was	O
reduced	O
to	O
two	O
in	O
the	O
mutant	O
with	O
an	O
obstructed	O
tunnel	O
,	O
indicating	O
that	O
Bet3	O
contains	O
binding	O
sites	O
on	O
its	O
surface	O
.	O

Small	O
-	O
molecule	O
inhibition	O
of	O
APT1	O
affects	O
Ras	O
localization	O
and	O
signaling	O
.	O

Cycles	O
of	O
depalmitoylation	O
and	O
repalmitoylation	O
critically	O
control	O
the	O
steady	O
-	O
state	O
localization	O
and	O
function	O
of	O
various	O
peripheral	O
membrane	O
proteins	O
,	O
such	O
as	O
Ras	O
proto	O
-	O
oncogene	O
products	O
.	O

Interference	O
with	O
acylation	O
using	O
small	O
molecules	O
is	O
a	O
strategy	O
to	O
modulate	O
cellular	O
localization	O
-	O
-	O
and	O
thereby	O
unregulated	O
signaling	O
-	O
-	O
caused	O
by	O
palmitoylated	O
Ras	O
proteins	O
.	O

We	O
present	O
the	O
knowledge	O
-	O
based	O
development	O
and	O
characterization	O
of	O
a	O
potent	O
inhibitor	O
of	O
acyl	O
protein	O
thioesterase	O
1	O
(	O
APT1	O
)	O
,	O
a	O
bona	O
fide	O
depalmitoylating	O
enzyme	O
that	O
is	O
,	O
so	O
far	O
,	O
poorly	O
characterized	O
in	O
cells	O
.	O

The	O
inhibitor	O
,	O
palmostatin	O
B	O
,	O
perturbs	O
the	O
cellular	O
acylation	O
cycle	O
at	O
the	O
level	O
of	O
depalmitoylation	O
and	O
thereby	O
causes	O
a	O
loss	O
of	O
the	O
precise	O
steady	O
-	O
state	O
localization	O
of	O
palmitoylated	O
Ras	O
.	O

As	O
a	O
consequence	O
,	O
palmostatin	O
B	O
induces	O
partial	O
phenotypic	O
reversion	O
in	O
oncogenic	O
HRasG12V	O
-	O
transformed	O
fibroblasts	O
.	O

We	O
identify	O
APT1	O
as	O
one	O
of	O
the	O
thioesterases	O
in	O
the	O
acylation	O
cycle	O
and	O
show	O
that	O
this	O
protein	O
is	O
a	O
cellular	O
target	O
of	O
the	O
inhibitor	O
.	O

Low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
(	O
LRP1	O
)	O
regulates	O
thrombospondin	O
-	O
2	O
(	O
TSP2	O
)	O
enhancement	O
of	O
Notch3	O
signaling	O
.	O

Intracellular	O
trafficking	O
of	O
Notch	O
and	O
Notch	O
ligands	O
modulates	O
signaling	O
,	O
suggesting	O
that	O
choreography	O
of	O
ligand	O
and	O
receptor	O
translocation	O
is	O
essential	O
for	O
optimal	O
Notch	O
activity	O
.	O

Indeed	O
,	O
a	O
major	O
model	O
for	O
Notch	O
signaling	O
posits	O
that	O
Notch	O
trans	O
-	O
endocytosis	O
into	O
the	O
ligand	O
-	O
expressing	O
(	O
signal	O
sending	O
)	O
cell	O
is	O
a	O
key	O
driving	O
force	O
for	O
Notch	O
signal	O
transduction	O
.	O

The	O
extracellular	O
protein	O
thrombospondin	O
-	O
2	O
(	O
TSP2	O
)	O
enhances	O
Notch	O
signaling	O
and	O
binds	O
to	O
both	O
Jagged1	O
and	O
Notch3	O
ectodomains	O
,	O
potentially	O
bridging	O
two	O
essential	O
extracellular	O
components	O
of	O
Notch	O
signaling	O
.	O

We	O
investigated	O
the	O
role	O
of	O
low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
(	O
LRP1	O
)	O
,	O
a	O
TSP2	O
receptor	O
,	O
in	O
the	O
regulation	O
of	O
Notch3	O
signaling	O
.	O

TSP2	O
potentiation	O
of	O
Notch	O
is	O
blocked	O
by	O
the	O
receptor	O
-	O
associated	O
protein	O
(	O
an	O
inhibitor	O
of	O
low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
function	O
)	O
and	O
requires	O
LRP1	O
expression	O
in	O
the	O
signal	O
-	O
sending	O
cell	O
.	O

TSP2	O
stimulates	O
Notch3	O
endocytosis	O
into	O
wild	O
type	O
fibroblasts	O
but	O
not	O
LRP1	O
-	O
deficient	O
fibroblasts	O
.	O

Finally	O
,	O
recombinant	O
Notch3	O
and	O
Jagged1	O
interact	O
with	O
the	O
LRP1	O
85	O
-	O
kDa	O
B	O
-	O
chain	O
,	O
a	O
subunit	O
that	O
lacks	O
known	O
ligand	O
binding	O
function	O
.	O

Our	O
data	O
suggest	O
that	O
LRP1	O
and	O
TSP2	O
stimulate	O
Notch	O
activity	O
by	O
driving	O
trans	O
-	O
endocytosis	O
of	O
the	O
Notch	O
ectodomain	O
into	O
the	O
signal	O
-	O
sending	O
cell	O
and	O
demonstrate	O
a	O
novel	O
,	O
non	O
-	O
cell	O
autonomous	O
function	O
of	O
LRP1	O
in	O
cell	O
-	O
cell	O
signaling	O
.	O

The	O
MLL1	O
gene	O
is	O
a	O
frequent	O
target	O
for	O
recurrent	O
chromosomal	O
translocations	O
,	O
resulting	O
in	O
transformation	O
of	O
hematopoietic	O
precursors	O
into	O
leukemia	O
stem	O
cells	O
.	O

Here	O
,	O
we	O
report	O
on	O
structure	O
-	O
function	O
studies	O
that	O
elucidate	O
molecular	O
events	O
in	O
MLL1	O
binding	O
of	O
histone	O
H3K4me3	O
/	O
2	O
marks	O
and	O
recruitment	O
of	O
the	O
cyclophilin	O
CyP33	O
.	O

CyP33	O
contains	O
a	O
PPIase	O
and	O
a	O
RRM	O
domain	O
and	O
regulates	O
MLL1	O
function	O
through	O
HDAC	O
recruitment	O
.	O

We	O
find	O
that	O
the	O
PPIase	O
domain	O
of	O
CyP33	O
regulates	O
the	O
conformation	O
of	O
MLL1	O
through	O
proline	O
isomerization	O
within	O
the	O
PHD3	O
-	O
Bromo	O
linker	O
,	O
thereby	O
disrupting	O
the	O
PHD3	O
-	O
Bromo	O
interface	O
and	O
facilitating	O
binding	O
of	O
the	O
MLL1	O
-	O
PHD3	O
domain	O
to	O
the	O
CyP33	O
-	O
RRM	O
domain	O
.	O

H3K4me3	O
/	O
2	O
and	O
CyP33	O
-	O
RRM	O
target	O
different	O
surfaces	O
of	O
MLL1	O
-	O
PHD3	O
and	O
can	O
bind	O
simultaneously	O
to	O
form	O
a	O
ternary	O
complex	O
.	O

Furthermore	O
,	O
the	O
MLL1	O
-	O
CyP33	O
interaction	O
is	O
required	O
for	O
repression	O
of	O
HOXA9	O
and	O
HOXC8	O
genes	O
in	O
vivo	O
.	O

Our	O
results	O
highlight	O
the	O
role	O
of	O
PHD3	O
-	O
Bromo	O
cassette	O
as	O
a	O
regulatory	O
platform	O
,	O
orchestrating	O
MLL1	O
binding	O
of	O
H3K4me3	O
/	O
2	O
marks	O
and	O
cyclophilin	O
-	O
mediated	O
repression	O
through	O
HDAC	O
recruitment	O
.	O

Uga3	O
and	O
Uga35	O
/	O
Dal81	O
transcription	O
factors	O
regulate	O
UGA4	O
transcription	O
in	O
response	O
to	O
gamma	O
-	O
aminobutyric	O
acid	O
and	O
leucine	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
UGA4	O
gene	O
encodes	O
a	O
permease	O
capable	O
of	O
importing	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
and	O
delta	O
-	O
aminolevulinic	O
acid	O
(	O
ALA	O
)	O
into	O
the	O
cell	O
.	O

GABA	O
-	O
dependent	O
induction	O
of	O
this	O
permease	O
requires	O
at	O
least	O
two	O
positive	O
-	O
acting	O
proteins	O
,	O
the	O
specific	O
factor	O
Uga3	O
and	O
the	O
pleiotropic	O
factor	O
Uga35	O
/	O
Dal81	O
.	O

UGA4	O
is	O
subjected	O
to	O
a	O
very	O
complex	O
regulation	O
,	O
and	O
its	O
induction	O
is	O
affected	O
by	O
the	O
presence	O
of	O
extracellular	O
amino	O
acids	O
;	O
this	O
effect	O
is	O
mediated	O
by	O
the	O
plasma	O
membrane	O
amino	O
acid	O
sensor	O
SPS	O
.	O

Our	O
results	O
show	O
that	O
leucine	O
affects	O
UGA4	O
induction	O
and	O
that	O
the	O
SPS	O
sensor	O
and	O
the	O
downstream	O
effectors	O
Stp1	O
and	O
Stp2	O
participate	O
in	O
this	O
regulation	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
Uga3	O
and	O
Uga35	O
/	O
Dal81	O
transcription	O
factors	O
bind	O
to	O
the	O
UGA4	O
promoter	O
in	O
a	O
GABA	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
binding	O
is	O
impaired	O
by	O
the	O
presence	O
of	O
leucine	O
.	O

We	O
also	O
found	O
that	O
the	O
Leu3	O
transcription	O
factor	O
negatively	O
regulates	O
UGA4	O
transcription	O
,	O
although	O
this	O
seems	O
to	O
be	O
through	O
an	O
indirect	O
mechanism	O
.	O

Identification	O
of	O
KIAA1018	O
/	O
FAN1	O
,	O
a	O
DNA	O
repair	O
nuclease	O
recruited	O
to	O
DNA	O
damage	O
by	O
monoubiquitinated	O
FANCD2	O
.	O

DNA	O
interstrand	O
crosslinks	O
(	O
ICLs	O
)	O
are	O
highly	O
toxic	O
because	O
they	O
block	O
the	O
progression	O
of	O
replisomes	O
.	O

The	O
Fanconi	B-OOS
Anemia	I-OOS
(	O
FA	B-OOS
)	O
proteins	O
,	O
encoded	O
by	O
genes	O
that	O
are	O
mutated	O
in	O
FA	O
,	O
are	O
important	O
for	O
repair	O
of	O
ICLs	O
.	O

The	O
FA	B-Complex
core	I-Complex
complex	O
catalyzes	O
the	O
monoubiquitination	O
of	O
FANCD2	O
,	O
and	O
this	O
event	O
is	O
essential	O
for	O
several	O
steps	O
of	O
ICL	O
repair	O
.	O

However	O
,	O
how	O
monoubiquitination	O
of	O
FANCD2	O
promotes	O
ICL	O
repair	O
at	O
the	O
molecular	O
level	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
a	O
highly	O
conserved	O
protein	O
,	O
KIAA1018	O
/	O
MTMR15	O
/	O
FAN1	O
,	O
that	O
interacts	O
with	O
,	O
and	O
is	O
recruited	O
to	O
sites	O
of	O
DNA	O
damage	O
by	O
,	O
the	O
monoubiquitinated	O
form	O
of	O
FANCD2	O
.	O

FAN1	O
exhibits	O
endonuclease	O
activity	O
toward	O
5	O
'	O
flaps	O
and	O
has	O
5	O
'	O
exonuclease	O
activity	O
,	O
and	O
these	O
activities	O
are	O
mediated	O
by	O
an	O
ancient	O
VRR	O
_	O
nuc	O
domain	O
.	O

Depletion	O
of	O
FAN1	O
from	O
human	O
cells	O
causes	O
hypersensitivity	O
to	O
ICLs	O
,	O
defects	O
in	O
ICL	O
repair	O
,	O
and	O
genome	O
instability	O
.	O

These	O
data	O
at	O
least	O
partly	O
explain	O
how	O
ubiquitination	O
of	O
FANCD2	O
promotes	O
DNA	O
repair	O
.	O

GlcNAcylation	O
plays	O
an	O
essential	O
role	O
in	O
breast	O
cancer	O
metastasis	O
.	O

GlcNAcylation	O
,	O
a	O
dynamic	O
posttranslational	O
modification	O
,	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
and	O
some	O
human	O
diseases	O
.	O

Although	O
there	O
is	O
emerging	O
evidence	O
that	O
some	O
tumor	O
-	O
associated	O
proteins	O
are	O
modified	O
by	O
GlcNAcylation	O
,	O
the	O
role	O
of	O
GlcNAcylation	O
in	O
tumor	O
progression	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
GlcNAcylation	O
enhances	O
the	O
migration	O
/	O
invasion	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
lung	O
metastasis	O
in	O
vivo	O
.	O

The	O
decrease	O
of	O
cell	O
surface	O
E	O
-	O
cadherin	O
is	O
the	O
molecular	O
mechanism	O
underlying	O
GlcNAcylation	O
-	O
induced	O
breast	O
cancer	O
metastasis	O
.	O

p120	O
and	O
beta	O
-	O
catenin	O
,	O
but	O
not	O
E	O
-	O
cadherin	O
,	O
are	O
GlcNAcylated	O
;	O
the	O
GlcNAcylation	O
of	O
p120	O
and	O
beta	O
-	O
catenin	O
might	O
play	O
roles	O
in	O
the	O
decrease	O
of	O
cell	O
surface	O
E	O
-	O
cadherin	O
.	O

Moreover	O
,	O
immunohistochemistry	O
analysis	O
indicated	O
that	O
the	O
global	O
GlcNAcylation	O
level	O
in	O
breast	O
tumor	O
tissues	O
is	O
elevated	O
significantly	O
as	O
compared	O
with	O
that	O
in	O
the	O
corresponding	O
adjacent	O
tissues	O
;	O
further	O
,	O
GlcNAcylation	O
was	O
significantly	O
enhanced	O
in	O
metastatic	O
lymph	O
nodes	O
compared	O
with	O
their	O
corresponding	O
primary	O
tumor	O
tissues	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
clearly	O
elucidate	O
the	O
roles	O
and	O
mechanisms	O
whereby	O
GlcNAcylation	O
influences	O
the	O
malignant	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O

These	O
results	O
also	O
suggest	O
that	O
GlcNAcylation	O
might	O
be	O
a	O
potential	O
target	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
breast	O
cancer	O
.	O

Increased	O
apoptosis	O
of	O
myoblasts	O
in	O
Drosophila	O
model	O
for	O
the	O
Walker	O
-	O
Warburg	O
syndrome	O
.	O

Walker	O
-	O
Warburg	O
syndrome	O
,	O
a	O
progressive	O
muscular	O
dystrophy	O
,	O
is	O
a	O
severe	O
disease	O
with	O
various	O
kinds	O
of	O
symptoms	O
such	O
as	O
muscle	O
weakness	O
and	O
occasional	O
seizures	O
.	O

The	O
genes	O
of	O
protein	O
O	O
-	O
mannosyltransferases	O
1	O
and	O
2	O
(	O
POMT1	O
and	O
POMT2	O
)	O
,	O
fukutin	O
,	O
and	O
fukutin	O
-	O
related	O
protein	O
are	O
responsible	O
for	O
this	O
syndrome	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
cloned	O
Drosophila	O
orthologs	O
of	O
human	O
POMT1	O
and	O
POMT2	O
and	O
identified	O
their	O
activity	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
onset	O
of	O
this	O
syndrome	O
is	O
not	O
well	O
understood	O
.	O

Furthermore	O
,	O
little	O
is	O
known	O
about	O
the	O
behavioral	O
properties	O
of	O
the	O
Drosophila	O
POMT1	O
and	O
POMT2	O
mutants	O
,	O
which	O
are	O
called	O
rotated	O
abdomen	O
(	O
rt	O
)	O
and	O
twisted	O
(	O
tw	O
)	O
,	O
respectively	O
.	O

First	O
,	O
we	O
performed	O
various	O
kinds	O
of	O
behavioral	O
tests	O
and	O
described	O
in	O
detail	O
the	O
muscle	O
structures	O
by	O
using	O
these	O
mutants	O
.	O

The	O
mutant	O
flies	O
exhibited	O
abnormalities	O
in	O
heavy	O
exercises	O
such	O
as	O
climbing	O
or	O
flight	O
but	O
not	O
in	O
light	O
movements	O
such	O
as	O
locomotion	O
.	O

Defective	O
motor	O
function	O
in	O
mutants	O
appeared	O
immediately	O
after	O
eclosion	O
and	O
was	O
exaggerated	O
with	O
aging	O
.	O

Along	O
with	O
motor	O
function	O
,	O
muscle	O
ultrastructure	O
in	O
the	O
tw	O
mutant	O
was	O
altered	O
,	O
as	O
seen	O
in	O
human	O
patients	O
.	O

We	O
demonstrated	O
that	O
expression	O
of	O
RNA	O
interference	O
(	O
RNAi	O
)	O
for	O
the	O
rt	O
gene	O
and	O
the	O
tw	O
mutant	O
was	O
almost	O
completely	O
lethal	O
and	O
semi	O
-	O
lethal	O
,	O
respectively	O
.	O

Flies	O
expressing	O
RNAi	O
had	O
reduced	O
lifespans	O
.	O

These	O
findings	O
clearly	O
demonstrate	O
that	O
Drosophila	O
POMT	O
mutants	O
are	O
models	O
for	O
human	O
muscular	O
dystrophy	O
.	O

We	O
then	O
observed	O
a	O
high	O
density	O
of	O
myoblasts	O
with	O
an	O
enhanced	O
degree	O
of	O
apoptosis	O
in	O
the	O
tw	O
mutant	O
,	O
which	O
completely	O
lost	O
enzymatic	O
activity	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
a	O
novel	O
mechanism	O
for	O
the	O
development	O
of	O
muscular	O
dystrophy	O
:	O
POMT	O
mutation	O
causes	O
high	O
myoblast	O
density	O
and	O
position	O
derangement	O
,	O
which	O
result	O
in	O
apoptosis	O
,	O
muscle	O
disorganization	O
,	O
and	O
muscle	O
cell	O
defects	O
.	O

Characterization	O
of	O
an	O
acyltransferase	O
acting	O
on	O
p21N	O
-	O
ras	O
protein	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

We	O
have	O
identified	O
a	O
protein	O
-	O
acyltransferase	O
activity	O
in	O
membranes	O
from	O
mouse	O
fibroblasts	O
which	O
transfers	O
palmitate	O
from	O
palmitoyl	O
-	O
CoA	O
to	O
p21N	O
-	O
ras	O
.	O

Specificity	O
of	O
acylation	O
has	O
been	O
confirmed	O
by	O
linkage	O
analysis	O
using	O
hydroxylamine	O
and	O
by	O
peptide	O
mapping	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
acylated	O
p21N	O
-	O
ras	O
.	O

The	O
acylation	O
was	O
temperature	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
prevented	O
by	O
prior	O
boiling	O
of	O
membranes	O
,	O
consistent	O
with	O
an	O
enzymatic	O
process	O
.	O

The	O
activity	O
was	O
detected	O
in	O
membranes	O
,	O
but	O
not	O
cytosol	O
,	O
and	O
co	O
-	O
fractionated	O
on	O
Percoll	O
gradients	O
with	O
Golgi	O
markers	O
.	O

Cytosolic	O
p21N	O
-	O
ras	O
from	O
mouse	O
fibroblasts	O
,	O
which	O
is	O
C	O
-	O
terminally	O
modified	O
at	O
its	O
CAAX	O
sequence	O
,	O
was	O
a	O
better	O
substrate	O
for	O
the	O
enzyme	O
that	O
recombinant	O
bacterially	O
expressed	O
,	O
unmodified	O
p21N	O
-	O
ras	O
.	O

The	O
activity	O
could	O
be	O
solubilised	O
in	O
non	O
-	O
ionic	O
detergents	O
,	O
making	O
it	O
amenable	O
to	O
purification	O
.	O

Coupling	O
of	O
tandem	O
Smad	O
ubiquitination	O
regulatory	O
factor	O
(	O
Smurf	O
)	O
WW	O
domains	O
modulates	O
target	O
specificity	O
.	O

Smad	O
ubiquitination	O
regulatory	O
factor	O
2	O
(	O
Smurf2	O
)	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
participates	O
in	O
degradation	O
of	O
TGF	O
-	O
beta	O
receptors	O
and	O
other	O
targets	O
.	O

Smurf2	O
WW	O
domains	O
recognize	O
PPXY	O
(	O
PY	O
)	O
motifs	O
on	O
ubiquitin	O
ligase	O
target	O
proteins	O
or	O
on	O
adapters	O
,	O
such	O
as	O
Smad7	O
,	O
that	O
bind	O
to	O
E3	O
target	O
proteins	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
isolated	O
WW3	O
domain	O
of	O
Smurf2	O
,	O
but	O
not	O
the	O
WW2	O
domain	O
,	O
can	O
directly	O
bind	O
to	O
a	O
Smad7	O
PY	O
motif	O
.	O

We	O
show	O
here	O
that	O
the	O
WW2	O
augments	O
this	O
interaction	O
by	O
binding	O
to	O
the	O
WW3	O
and	O
making	O
auxiliary	O
contacts	O
with	O
the	O
PY	O
motif	O
and	O
a	O
novel	O
E	O
/	O
D	O
-	O
S	O
/	O
T	O
-	O
P	O
motif	O
,	O
which	O
is	O
N	O
-	O
terminal	O
to	O
all	O
Smad	O
PY	O
motifs	O
.	O

The	O
WW2	O
likely	O
enhances	O
the	O
selectivity	O
of	O
Smurf2	O
for	O
the	O
Smad	O
proteins	O
.	O

NMR	O
titrations	O
confirm	O
that	O
Smad1	O
and	O
Smad2	O
are	O
bound	O
by	O
Smurf2	O
with	O
the	O
same	O
coupled	O
WW	O
domain	O
arrangement	O
used	O
to	O
bind	O
Smad7	O
.	O

The	O
analogous	O
WW	O
domains	O
in	O
the	O
short	O
isoform	O
of	O
Smurf1	O
recognize	O
the	O
Smad7	O
PY	O
peptide	O
using	O
the	O
same	O
coupled	O
mechanism	O
.	O

However	O
,	O
a	O
longer	O
Smurf1	O
isoform	O
,	O
which	O
has	O
an	O
additional	O
26	O
residues	O
in	O
the	O
inter	O
-	O
WW	O
domain	O
linker	O
,	O
is	O
only	O
partially	O
able	O
to	O
use	O
the	O
coupled	O
WW	O
domain	O
binding	O
mechanism	O
.	O

The	O
longer	O
linker	O
results	O
in	O
a	O
decrease	O
in	O
affinity	O
for	O
the	O
Smad7	O
peptide	O
.	O

Interdomain	O
coupling	O
of	O
WW	O
domains	O
enhances	O
selectivity	O
and	O
enables	O
the	O
tuning	O
of	O
interactions	O
by	O
isoform	O
switching	O
.	O

CtBPs	O
promote	O
mitotic	O
fidelity	O
through	O
their	O
activities	O
in	O
the	O
cell	O
nucleus	O
.	O

CtBPs	O
form	O
NADH	O
-	O
sensitive	O
chromatin	O
-	O
modifying	O
complexes	O
,	O
which	O
link	O
cellular	O
metabolism	O
to	O
gene	O
transcription	O
.	O

They	O
also	O
function	O
in	O
the	O
cytoplasm	O
to	O
regulate	O
Golgi	O
fissioning	O
;	O
their	O
inhibition	O
can	O
consequently	O
cause	O
a	O
Golgi	O
-	O
dependent	O
checkpoint	O
in	O
G	O
(	O
2	O
)	O
.	O

We	O
have	O
recently	O
identified	O
a	O
novel	O
role	O
of	O
CtBPs	O
in	O
the	O
maintenance	O
of	O
mitotic	O
fidelity	O
;	O
inhibition	O
of	O
CtBP	O
synthesis	O
resulting	O
in	O
reduced	O
association	O
of	O
aurora	O
B	O
with	O
mitotic	O
chromatin	O
and	O
aberrant	O
segregation	O
of	O
chromosomes	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
it	O
is	O
the	O
interaction	O
of	O
CtBPs	O
with	O
transcriptional	O
regulators	O
and	O
/	O
or	O
chromatin	O
-	O
modifying	O
enzymes	O
in	O
the	O
cell	O
nucleus	O
,	O
rather	O
than	O
their	O
role	O
in	O
Golgi	O
fission	O
,	O
which	O
is	O
critical	O
for	O
the	O
maintenance	O
of	O
mitotic	O
fidelity	O
.	O

Structural	O
basis	O
of	O
oligomerization	O
in	O
septin	O
-	O
like	O
GTPase	O
of	O
immunity	O
-	O
associated	O
protein	O
2	O
(	O
GIMAP2	O
)	O
.	O

GTPases	O
of	O
immunity	O
-	O
associated	O
proteins	O
(	O
GIMAPs	O
)	O
are	O
a	O
distinctive	O
family	O
of	O
GTPases	O
,	O
which	O
control	O
apoptosis	O
in	O
lymphocytes	O
and	O
play	O
a	O
central	O
role	O
in	O
lymphocyte	O
maturation	O
and	O
lymphocyte	O
-	O
associated	O
diseases	O
.	O

To	O
explore	O
their	O
function	O
and	O
mechanism	O
,	O
we	O
determined	O
crystal	O
structures	O
of	O
a	O
representative	O
member	O
,	O
GIMAP2	O
,	O
in	O
different	O
nucleotide	O
-	O
loading	O
and	O
oligomerization	O
states	O
.	O

Nucleotide	O
-	O
free	O
and	O
GDP	O
-	O
bound	O
GIMAP2	O
were	O
monomeric	O
and	O
revealed	O
a	O
guanine	O
nucleotide	O
-	O
binding	O
domain	O
of	O
the	O
TRAFAC	O
(	O
translation	O
factor	O
associated	O
)	O
class	O
with	O
a	O
unique	O
amphipathic	O
helix	O
alpha7	O
packing	O
against	O
switch	O
II	O
.	O

In	O
the	O
absence	O
of	O
alpha7	O
and	O
the	O
presence	O
of	O
GTP	O
,	O
GIMAP2	O
oligomerized	O
via	O
two	O
distinct	O
interfaces	O
in	O
the	O
crystal	O
.	O

GTP	O
-	O
induced	O
stabilization	O
of	O
switch	O
I	O
mediates	O
dimerization	O
across	O
the	O
nucleotide	O
-	O
binding	O
site	O
,	O
which	O
also	O
involves	O
the	O
GIMAP	O
specificity	O
motif	O
and	O
the	O
nucleotide	O
base	O
.	O

Structural	O
rearrangements	O
in	O
switch	O
II	O
appear	O
to	O
induce	O
the	O
release	O
of	O
alpha7	O
allowing	O
oligomerization	O
to	O
proceed	O
via	O
a	O
second	O
interface	O
.	O

The	O
unique	O
architecture	O
of	O
the	O
linear	O
oligomer	O
was	O
confirmed	O
by	O
mutagenesis	O
.	O

Furthermore	O
,	O
we	O
showed	O
a	O
function	O
for	O
the	O
GIMAP2	O
oligomer	O
at	O
the	O
surface	O
of	O
lipid	O
droplets	O
.	O

Although	O
earlier	O
studies	O
indicated	O
that	O
GIMAPs	O
are	O
related	O
to	O
the	O
septins	O
,	O
the	O
current	O
structure	O
also	O
revealed	O
a	O
strikingly	O
similar	O
nucleotide	O
coordination	O
and	O
dimerization	O
mode	O
as	O
in	O
the	O
dynamin	O
GTPase	O
.	O

Based	O
on	O
this	O
,	O
we	O
reexamined	O
the	O
relationships	O
of	O
the	O
septin	O
-	O
and	O
dynamin	O
-	O
like	O
GTPases	O
and	O
demonstrate	O
that	O
these	O
are	O
likely	O
to	O
have	O
emerged	O
from	O
a	O
common	O
membrane	O
-	O
associated	O
dimerizing	O
ancestor	O
.	O

This	O
ancestral	O
property	O
appears	O
to	O
be	O
critical	O
for	O
the	O
role	O
of	O
GIMAPs	O
as	O
nucleotide	O
-	O
regulated	O
scaffolds	O
on	O
intracellular	O
membranes	O
.	O

miRNA	O
-	O
mediated	O
gene	O
silencing	O
requires	O
the	O
GW182	O
proteins	O
,	O
which	O
are	O
characterized	O
by	O
an	O
N	O
-	O
terminal	O
domain	O
that	O
interacts	O
with	O
Argonaute	O
proteins	O
(	O
AGOs	O
)	O
,	O
and	O
a	O
C	O
-	O
terminal	O
silencing	O
domain	O
(	O
SD	O
)	O
.	O

In	O
Drosophila	O
melanogaster	O
(	O
Dm	O
)	O
GW182	O
and	O
a	O
human	O
(	O
Hs	O
)	O
orthologue	O
,	O
TNRC6C	O
,	O
the	O
SD	O
was	O
previously	O
shown	O
to	O
interact	O
with	O
the	O
cytoplasmic	O
poly	O
(	O
A	O
)	O
-	O
binding	O
protein	O
(	O
PABPC1	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
two	O
regions	O
of	O
GW182	O
proteins	O
interact	O
with	O
PABPC1	O
:	O
the	O
first	O
contains	O
a	O
PABP	O
-	O
interacting	O
motif	O
2	O
(	O
PAM2	O
;	O
as	O
shown	O
before	O
for	O
TNRC6C	O
)	O
and	O
the	O
second	O
contains	O
the	O
M2	O
and	O
C	O
-	O
terminal	O
sequences	O
in	O
the	O
SD	O
.	O

The	O
latter	O
mediates	O
indirect	O
binding	O
to	O
the	O
PABPC1	O
N	O
-	O
terminal	O
domain	O
.	O

In	O
D	O
.	O
melanogaster	O
cells	O
,	O
the	O
second	O
binding	O
site	O
dominates	O
;	O
however	O
,	O
in	O
HsTNRC6A	O
-	O
C	O
the	O
PAM2	O
motif	O
is	O
essential	O
for	O
binding	O
to	O
both	O
Hs	O
and	O
DmPABPC1	O
.	O

Accordingly	O
,	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
TNRC6A	O
-	O
C	O
PAM2	O
motif	O
abolishes	O
the	O
interaction	O
with	O
PABPC1	O
.	O

This	O
mutation	O
also	O
impairs	O
TNRC6s	O
silencing	O
activity	O
.	O

Our	O
findings	O
reveal	O
that	O
despite	O
species	O
-	O
specific	O
differences	O
in	O
the	O
relative	O
strength	O
of	O
the	O
PABPC1	O
-	O
binding	O
sites	O
,	O
the	O
interaction	O
between	O
GW182	O
proteins	O
and	O
PABPC1	O
is	O
critical	O
for	O
miRNA	O
-	O
mediated	O
silencing	O
in	O
animal	O
cells	O
.	O

Homologous	O
activators	O
of	O
ras	O
in	O
fission	O
and	O
budding	O
yeast	O
.	O

The	O
ras	O
proto	O
-	O
oncogene	O
products	O
are	O
plasma	O
membrane	O
-	O
bound	O
,	O
guanine	O
nucleotide	O
-	O
binding	O
proteins	O
implicated	O
in	O
signal	O
transduction	O
across	O
the	O
plasma	O
membrane	O
.	O

But	O
the	O
signal	O
(	O
s	O
)	O
that	O
activates	O
the	O
ras	O
pathway	O
(	O
s	O
)	O
is	O
not	O
known	O
.	O

In	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
CDC25	O
gene	O
product	O
acts	O
upstream	O
of	O
Ras	O
proteins	O
,	O
but	O
it	O
has	O
not	O
been	O
clear	O
whether	O
CDC25	O
function	O
is	O
unique	O
to	O
the	O
S	O
.	O
cerevisiae	O
ras	O
pathway	O
.	O

Here	O
we	O
report	O
that	O
the	O
ste6	O
gene	O
of	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
is	O
a	O
homologue	O
of	O
CDC25	O
:	O
the	O
ste6	O
gene	O
product	O
and	O
the	O
CDC25	O
gene	O
product	O
have	O
significant	O
amino	O
-	O
acid	O
similarity	O
in	O
their	O
C	O
-	O
terminal	O
regions	O
.	O

Like	O
the	O
S	O
.	O
pombe	O
ras1	O
gene	O
,	O
ste6	O
is	O
essential	O
for	O
mating	O
.	O

Epistatic	O
interactions	O
indicate	O
that	O
the	O
ste6	O
gene	O
functions	O
upstream	O
of	O
ras1	O
.	O

We	O
propose	O
that	O
ste6	O
and	O
CDC25	O
activate	O
Ras	O
protein	O
through	O
a	O
common	O
mechanism	O
,	O
perhaps	O
by	O
promoting	O
GDP	O
-	O
GTP	O
exchange	O
,	O
even	O
though	O
it	O
seems	O
that	O
the	O
function	O
of	O
Ras	O
protein	O
in	O
budding	O
yeast	O
differs	O
from	O
that	O
in	O
fission	O
yeast	O
.	O

Homologues	O
of	O
ste6	O
and	O
CDC25	O
could	O
regulate	O
ras	O
activity	O
in	O
other	O
eukaryotic	O
cells	O
.	O

CSN	B-Complex
complex	O
controls	O
the	O
stability	O
of	O
selected	O
synaptic	O
proteins	O
via	O
a	O
torsinA	O
-	O
dependent	O
process	O
.	O

DYT1	O
dystonia	O
is	O
caused	O
by	O
an	O
autosomal	O
dominant	O
mutation	O
that	O
leads	O
to	O
a	O
glutamic	O
acid	O
deletion	O
in	O
torsinA	O
(	O
TA	O
)	O
,	O
a	O
member	O
of	O
the	O
AAA	O
+	O
ATPase	O
superfamily	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
-	O
binding	O
partner	O
of	O
TA	O
,	O
the	O
subunit	O
4	O
(	O
CSN4	O
)	O
of	O
CSN	B-Complex
signalosome	I-Complex
.	O

TA	O
binds	O
CSN4	O
and	O
the	O
synaptic	O
regulator	O
snapin	O
in	O
neuroblastoma	O
cells	O
and	O
in	O
brain	O
synaptosomes	O
.	O

CSN4	O
and	O
TA	O
are	O
required	O
for	O
the	O
stability	O
of	O
both	O
snapin	O
and	O
the	O
synaptotagmin	O
-	O
specific	O
endocytic	O
adaptor	O
stonin	O
2	O
,	O
as	O
downregulation	O
of	O
CSN4	O
or	O
TA	O
reduces	O
the	O
levels	O
of	O
both	O
proteins	O
.	O

Snapin	O
is	O
phosphorylated	O
by	O
the	O
CSN	B-Complex
-	O
associated	O
kinase	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
and	O
its	O
expression	O
is	O
decreased	O
upon	O
PKD	O
inhibition	O
.	O

In	O
contrast	O
,	O
the	O
stability	O
of	O
stonin	O
2	O
is	O
regulated	O
by	O
neddylation	O
,	O
another	O
CSN	B-Complex
-	O
associated	O
activity	O
.	O

Overexpression	O
of	O
the	O
pathological	O
TA	O
mutant	O
(	O
DeltaE	O
-	O
TA	O
)	O
reduces	O
stonin	O
2	O
expression	O
,	O
causing	O
the	O
accumulation	O
of	O
the	O
calcium	O
sensor	O
synaptotagmin	O
1	O
on	O
the	O
cell	O
surface	O
.	O

Retrieval	O
of	O
surface	O
-	O
stranded	O
synaptotagmin	O
1	O
is	O
restored	O
by	O
overexpression	O
of	O
stonin	O
2	O
in	O
DeltaE	O
-	O
TA	O
-	O
expressing	O
cells	O
,	O
suggesting	O
that	O
the	O
DYT1	O
mutation	O
compromises	O
the	O
role	O
of	O
TA	O
in	O
protein	O
stabilisation	O
and	O
synaptic	O
vesicle	O
recycling	O
.	O

Osh	O
proteins	O
regulate	O
phosphoinositide	O
metabolism	O
at	O
ER	O
-	O
plasma	O
membrane	O
contact	O
sites	O
.	O

Sac1	O
phosphoinositide	O
(	O
PI	O
)	O
phosphatases	O
are	O
essential	O
regulators	O
of	O
PI	O
-	O
signaling	O
networks	O
.	O

Yeast	O
Sac1	O
,	O
an	O
integral	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membrane	O
protein	O
,	O
controls	O
PI4P	O
levels	O
at	O
the	O
ER	O
,	O
Golgi	O
,	O
and	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O

Whether	O
Sac1	O
can	O
act	O
in	O
trans	O
and	O
turn	O
over	O
PI4P	O
at	O
the	O
Golgi	O
and	O
PM	O
from	O
the	O
ER	O
remains	O
a	O
paradox	O
.	O

We	O
find	O
that	O
Sac1	O
-	O
mediated	O
PI4P	O
metabolism	O
requires	O
the	O
oxysterol	O
-	O
binding	O
homology	O
(	O
Osh	O
)	O
proteins	O
.	O

The	O
PH	O
domain	O
-	O
containing	O
family	O
member	O
,	O
Osh3	O
,	O
localizes	O
to	O
PM	O
/	O
ER	O
membrane	O
contact	O
sites	O
dependent	O
upon	O
PM	O
PI4P	O
levels	O
.	O

We	O
reconstitute	O
Osh	O
protein	O
-	O
stimulated	O
Sac1	O
PI	O
phosphatase	O
activity	O
in	O
vitro	O
.	O

We	O
also	O
show	O
that	O
the	O
ER	O
membrane	O
VAP	O
proteins	O
,	O
Scs2	O
/	O
Scs22	O
,	O
control	O
PM	O
PI4P	O
levels	O
and	O
Sac1	O
activity	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
Osh3	O
functions	O
at	O
ER	O
/	O
PM	O
contact	O
sites	O
as	O
both	O
a	O
sensor	O
of	O
PM	O
PI4P	O
and	O
an	O
activator	O
of	O
the	O
ER	O
Sac1	O
phosphatase	O
.	O

Our	O
findings	O
further	O
suggest	O
that	O
the	O
conserved	O
Osh	O
proteins	O
control	O
PI	O
metabolism	O
at	O
additional	O
membrane	O
contact	O
sites	O
.	O

Residues	O
that	O
distinguish	O
the	O
two	O
distinct	O
beta	O
-	O
sheet	O
conformations	O
are	O
among	O
the	O
most	O
conserved	O
in	O
the	O
beta	O
-	O
sheet	O
region	O
of	O
Boca	O
/	O
Mesd	O
proteins	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
a	O
few	O
of	O
these	O
residues	O
,	O
those	O
from	O
the	O
C	O
-	O
terminus	O
of	O
beta4	O
and	O
the	O
turn	O
into	O
beta5	O
,	O
participate	O
in	O
the	O
dimer	O
interface	O
.	O

These	O
observations	O
suggest	O
the	O
possibility	O
of	O
a	O
separate	O
function	O
that	O
provides	O
evolutionary	O
pressure	O
for	O
this	O
region	O
.	O

An	O
almost	O
invariant	O
valine	O
-	O
threonine	O
residue	O
pair	O
(	O
mmMesd	O
Val174	O
-	O
Thr175	O
,	O
dmBoca	O
Val163	O
-	O
Thr164	O
,	O
ceBMY	O
-	O
1	O
Val165	O
-	O
Thr166	O
)	O
anchors	O
the	O
beta4	O
strand	O
to	O
the	O
adjacent	O
beta1	O
strand	O
and	O
hydrophobic	O
core	O
.	O

The	O
four	O
residues	O
following	O
the	O
threonine	O
are	O
also	O
highly	O
conserved	O
,	O
potentially	O
because	O
they	O
must	O
retain	O
flexibility	O
to	O
form	O
the	O
discrete	O
secondary	O
structural	O
states	O
seen	O
in	O
the	O
two	O
conformations	O
.	O

The	O
two	O
central	O
residues	O
of	O
type	O
I	O
'	O
beta	O
-	O
turns	O
,	O
named	O
i	O
+	O
1	O
and	O
i	O
+	O
2	O
,	O
are	O
located	O
in	O
the	O
alphaL	O
energy	O
minima	O
of	O
the	O
Ramachandran	O
plot	O
whereby	O
type	O
I	O
'	O
beta	O
-	O
turns	O
are	O
intrinsically	O
less	O
stable	O
.	O

Only	O
the	O
i	O
+	O
1	O
and	O
i	O
+	O
2	O
residues	O
undergo	O
a	O
drastic	O
phi	O
and	O
phi	O
change	O
between	O
the	O
two	O
secondary	O
structure	O
states	O
seen	O
in	O
the	O
crystals	O
.	O

The	O
phi	O
and	O
phi	O
angles	O
of	O
the	O
i	O
and	O
i	O
+	O
3	O
beta	O
-	O
turn	O
residues	O
remain	O
the	O
same	O
between	O
the	O
two	O
conformational	O
states	O
,	O
allowing	O
similar	O
backbone	O
hydrogen	O
bonds	O
to	O
form	O
even	O
though	O
the	O
i	O
+	O
3	O
residues	O
moves	O
~	O
13Aa	O
.	O

Both	O
these	O
factors	O
may	O
reduce	O
the	O
energy	O
required	O
to	O
undergo	O
the	O
transition	O
between	O
the	O
beta	O
-	O
turn	O
and	O
beta	O
-	O
sheet	O
conformations	O
.	O

The	O
threonine	O
residue	O
preceding	O
the	O
beta	O
-	O
turn	O
may	O
act	O
as	O
a	O
conformational	O
switch	O
in	O
this	O
region	O
,	O
because	O
the	O
p	O
and	O
m	O
side	O
chain	O
conformations	O
correlate	O
to	O
the	O
4	O
-	O
strand	O
and	O
5	O
-	O
strand	O
beta	O
-	O
sheet	O
conformations	O
.	O

A	O
conserved	O
mechanism	O
of	O
DEAD	O
-	O
box	O
ATPase	O
activation	O
by	O
nucleoporins	O
and	O
InsP6	O
in	O
mRNA	O
export	O
.	O

Superfamily	O
1	O
and	O
superfamily	O
2	O
RNA	O
helicases	O
are	O
ubiquitous	O
messenger	O
-	O
RNA	O
-	O
protein	O
complex	O
(	O
mRNP	O
)	O
remodelling	O
enzymes	O
that	O
have	O
critical	O
roles	O
in	O
all	O
aspects	O
of	O
RNA	O
metabolism	O
.	O

The	O
superfamily	O
2	O
DEAD	O
-	O
box	O
ATPase	O
Dbp5	O
(	O
human	O
DDX19	O
)	O
functions	O
in	O
mRNA	O
export	O
and	O
is	O
thought	O
to	O
remodel	O
mRNPs	O
at	O
the	O
nuclear	B-Complex
pore	I-Complex
complex	I-Complex
(	O
NPC	B-Complex
)	O
.	O

Dbp5	O
is	O
localized	O
to	O
the	O
NPC	B-Complex
via	O
an	O
interaction	O
with	O
Nup159	O
(	O
NUP214	O
in	O
vertebrates	O
)	O
and	O
is	O
locally	O
activated	O
there	O
by	O
Gle1	O
together	O
with	O
the	O
small	O
-	O
molecule	O
inositol	O
hexakisphosphate	O
(	O
InsP	O
(	O
6	O
)	O
)	O
.	O

Local	O
activation	O
of	O
Dbp5	O
at	O
the	O
NPC	B-Complex
by	O
Gle1	O
is	O
essential	O
for	O
mRNA	O
export	O
in	O
vivo	O
;	O
however	O
,	O
the	O
mechanistic	O
role	O
of	O
Dbp5	O
in	O
mRNP	O
export	O
is	O
poorly	O
understood	O
and	O
it	O
is	O
not	O
known	O
how	O
Gle1	O
(	O
InsP6	O
)	O
and	O
Nup159	O
regulate	O
the	O
activity	O
of	O
Dbp5	O
.	O

Here	O
we	O
report	O
,	O
from	O
yeast	O
,	O
structures	O
of	O
Dbp5	O
in	O
complex	O
with	O
Gle1	O
(	O
InsP6	O
)	O
,	O
Nup159	O
/	O
Gle1	O
(	O
InsP6	O
)	O
and	O
RNA	O
.	O

These	O
structures	O
reveal	O
that	O
InsP	O
(	O
6	O
)	O
functions	O
as	O
a	O
small	O
-	O
molecule	O
tether	O
for	O
the	O
Gle1	O
-	O
Dbp5	O
interaction	O
.	O

Surprisingly	O
,	O
the	O
Gle1	O
(	O
InsP6	O
)	O
-	O
Dbp5	O
complex	O
is	O
structurally	O
similar	O
to	O
another	O
DEAD	O
-	O
box	O
ATPase	O
complex	O
essential	O
for	O
translation	O
initiation	O
,	O
eIF4G	O
-	O
eIF4A	O
,	O
and	O
we	O
demonstrate	O
that	O
Gle1	O
(	O
InsP6	O
)	O
and	O
eIF4G	O
both	O
activate	O
their	O
DEAD	O
-	O
box	O
partner	O
by	O
stimulating	O
RNA	O
release	O
.	O

Furthermore	O
,	O
Gle1	O
(	O
InsP6	O
)	O
relieves	O
Dbp5	O
autoregulation	O
and	O
cooperates	O
with	O
Nup159	O
in	O
stabilizing	O
an	O
open	O
Dbp5	O
intermediate	O
that	O
precludes	O
RNA	O
binding	O
.	O

These	O
findings	O
explain	O
how	O
Gle1	O
(	O
InsP6	O
)	O
,	O
Nup159	O
and	O
Dbp5	O
collaborate	O
in	O
mRNA	O
export	O
and	O
provide	O
a	O
general	O
mechanism	O
for	O
DEAD	O
-	O
box	O
ATPase	O
regulation	O
by	O
Gle1	O
/	O
eIF4G	O
-	O
like	O
activators	O
.	O

To	O
avoid	O
the	O
lethality	O
of	O
Thorase	O
KO	O
mice	O
,	O
Thorase	O
flox	O
/	O
+	O
mice	O
were	O
crossed	O
with	O
CaMKIIa	O
-	O
iCre	O
transgenic	O
mice	O
to	O
restrict	O
the	O
temporal	O
and	O
spatial	O
deletion	O
of	O
Thorase	O
to	O
the	O
adult	O
forebrain	O
.	O

Immunoblot	O
analysis	O
and	O
immunohistochemistry	O
verifies	O
that	O
Thorase	O
is	O
largely	O
eliminated	O
from	O
forebrain	O
structures	O
including	O
the	O
hippocampus	O
and	O
cortex	O
but	O
not	O
in	O
other	O
regions	O
such	O
as	O
the	O
cerebellum	O
(	O
Figure	O
S5	O
)	O
.	O

There	O
are	O
no	O
gross	O
anatomical	O
changes	O
in	O
the	O
hippocampus	O
or	O
other	O
forebrain	O
structures	O
in	O
the	O
conditional	O
Thorase	O
KO	O
(	O
cKO	O
)	O
mice	O
compared	O
to	O
WT	O
control	O
(	O
Figure	O
S5	O
)	O
.	O

The	O
atomic	O
models	O
of	O
the	O
RGS	O
-	O
domains	O
-	O
Galpha	O
complexes	O
used	O
in	O
the	O
calculations	O
were	O
taken	O
from	O
the	O
following	O
PDB	O
entries	O
:	O
1AGR	B-OOS
(	O
Galphai1	O
-	O
RGS4	O
)	O
;	O
2IK8	B-OOS
(	O
Galphai1	O
-	O
RGS16	O
)	O
;	O
3C7K	B-OOS
(	O
Galphao	O
-	O
RGS16	O
)	O
;	O
2IHB	B-OOS
(	O
Galphai3	O
-	O
RGS10	O
)	O
;	O
2GTP	B-OOS
(	O
Galphai1	O
-	O
RGS1	O
)	O
;	O
2ODE	B-OOS
(	O
Galphai3	O
-	O
RGS8	O
)	O
;	O
1FQJ	B-OOS
(	O
Galphai1	O
/	O
t	O
-	O
RGS9	O
)	O
;	O
2V4Z	B-OOS
(	O
Galphai3	O
-	O
RGS2	O
-	O
C106S	O
/	O
N184D	O
/	O
E191K	O
triple	O
mutant	O
)	O
.	O

Colicin	O
-	O
immunity	O
-	O
protein	O
atomic	O
models	O
were	O
taken	O
from	O
the	O
following	O
PDB	O
entries	O
:	O
7CEI	B-OOS
,	O
2JAZ	B-OOS
,	O
2JB0	B-OOS
,	O
2JBG	B-OOS
,	O
1ZNV	B-OOS
(	O
wild	O
-	O
type	O
E7	O
-	O
Im7	O
)	O
.	O

Although	O
some	O
of	O
these	O
E7	O
proteins	O
contain	O
point	O
mutations	O
,	O
these	O
mutations	O
are	O
far	O
from	O
the	O
Im7	O
binding	O
site	O
and	O
therefore	O
these	O
chains	O
were	O
considered	O
wild	O
type	O
)	O
;	O
1UJZ	B-OOS
,	O
2ERH	B-OOS
(	O
Computationally	O
-	O
redesigned	O
E7	O
-	O
Im7	O
)	O
;	O
3GJN	B-OOS
,	O
3GKL	B-OOS
(	O
E7	O
bound	O
to	O
in	O
vitro	O
evolved	O
Im9	O
)	O
.	O

Missing	O
short	O
segments	O
in	O
2IK8	B-OOS
(	O
Galphai1	O
residues	O
112	O
-	O
118	O
)	O
,	O
2IHB	B-OOS
(	O
RGS10	O
residues	O
103	O
-	O
113	O
)	O
,	O
and	O
2GTP	B-OOS
(	O
Galphai1	O
residues	O
112	O
-	O
118	O
)	O
were	O
modeled	O
based	O
on	O
the	O
structure	O
of	O
Galphai1	O
-	O
RGS4	O
(	O
PDB	O
id	O
1AGR	B-OOS
)	O
using	O
the	O
program	O
Nest	O
and	O
partial	O
or	O
missing	O
side	O
chains	O
were	O
modeled	O
using	O
Scap	O
.	O

Similarly	O
,	O
a	O
short	O
missing	O
E7	O
segment	O
in	O
the	O
following	O
structures	O
was	O
modeled	O
based	O
on	O
PDB	O
id	O
7CEI	B-OOS
:	O
2JBG	B-OOS
(	O
residues	O
547	O
-	O
554	O
)	O
,	O
2JAZ	B-OOS
(	O
residues	O
548	O
-	O
554	O
)	O
,	O
2JB0	B-OOS
(	O
residues	O
551	O
-	O
552	O
)	O
,	O
1ZNV	B-OOS
(	O
residues	O
547	O
-	O
554	O
)	O
,	O
3GJN	B-OOS
(	O
residues	O
549	O
-	O
554	O
)	O
,	O
3GKL	B-OOS
(	O
residues	O
548	O
-	O
554	O
)	O
.	O

Hydrogen	O
atoms	O
were	O
added	O
using	O
CHARMM	O
,	O
and	O
the	O
structures	O
were	O
subjected	O
to	O
conjugate	O
gradient	O
minimization	O
with	O
a	O
harmonic	O
restraint	O
force	O
of	O
50	O
kcal	O
mol	O
-	O
1	O
Aa	O
-	O
2	O
applied	O
to	O
the	O
heavy	O
atoms	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
SHP2	O
,	O
we	O
set	O
out	O
to	O
investigate	O
SHP2	O
substrates	O
by	O
combining	O
a	O
substrate	O
-	O
trapping	O
technique	O
and	O
mass	O
spectrometry	O
.	O

This	O
was	O
enabled	O
,	O
in	O
part	O
,	O
by	O
our	O
recent	O
isolation	O
of	O
a	O
T507K	O
mutant	O
of	O
SHP2	O
(	O
SHP2	O
-	O
T507K	O
)	O
from	O
a	O
hepatocellular	O
carcinoma	O
.	O

This	O
mutation	O
affects	O
the	O
phosphatase	O
domain	O
,	O
but	O
results	O
in	O
only	O
a	O
slightly	O
elevated	O
basal	O
phosphatase	O
activity	O
,	O
as	O
assayed	O
by	O
its	O
effects	O
on	O
the	O
p	O
-	O
nitrophenylphosphate	O
(	O
pNPP	O
)	O
substrate	O
.	O

However	O
,	O
in	O
sharp	O
contrast	O
with	O
the	O
SHP2	O
mutants	O
associated	O
with	O
Noonan	O
syndrome	O
and	O
JMML	O
,	O
the	O
SHP2	O
-	O
T507K	O
point	O
mutant	O
confers	O
anchorage	O
-	O
independent	O
growth	O
and	O
in	O
vivo	O
tumorigenesis	O
when	O
the	O
mutant	O
allele	O
is	O
introduced	O
into	O
NIH3T3	O
mouse	O
fibroblast	O
cells	O
.	O

These	O
findings	O
raised	O
the	O
possibility	O
either	O
that	O
the	O
SHP2	O
-	O
T507K	O
mutant	O
protein	O
had	O
an	O
enhanced	O
activity	O
toward	O
a	O
selected	O
subset	O
of	O
SHP2	O
substrates	O
or	O
that	O
the	O
mutant	O
enzyme	O
acquired	O
a	O
new	O
substrate	O
specificity	O
that	O
potentiated	O
its	O
oncogenic	O
activity	O
.	O

HCF243	O
encodes	O
a	O
chloroplast	O
-	O
localized	O
protein	O
involved	O
in	O
the	O
D1	O
protein	O
stability	O
of	O
the	O
arabidopsis	O
photosystem	B-Complex
II	I-Complex
complex	O
.	O

Numerous	O
auxiliary	O
nuclear	O
factors	O
have	O
been	O
identified	O
to	O
be	O
involved	O
in	O
the	O
dynamics	O
of	O
the	O
photosystem	B-Complex
II	I-Complex
(	O
PSII	B-Complex
)	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
high	O
chlorophyll	O
fluorescence243	O
(	O
hcf243	O
)	O
mutant	O
of	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
,	O
which	O
shows	O
higher	O
chlorophyll	O
fluorescence	O
and	O
is	O
severely	O
deficient	O
in	O
the	O
accumulation	O
of	O
PSII	B-Complex
supercomplexes	O
compared	O
with	O
the	O
wild	O
type	O
.	O

The	O
amount	O
of	O
core	O
subunits	O
was	O
greatly	O
decreased	O
,	O
while	O
the	O
outer	O
antenna	O
subunits	O
and	O
other	O
subunits	O
were	O
hardly	O
affected	O
in	O
hcf243	O
.	O

In	O
vivo	O
protein	O
-	O
labeling	O
experiments	O
indicated	O
that	O
the	O
synthesis	O
rate	O
of	O
both	O
D1	O
and	O
D2	O
proteins	O
decreased	O
severely	O
in	O
hcf243	O
,	O
whereas	O
no	O
change	O
was	O
found	O
in	O
the	O
rate	O
of	O
other	O
plastid	O
-	O
encoded	O
proteins	O
.	O

Furthermore	O
,	O
the	O
degradation	O
rate	O
of	O
the	O
PSII	B-Complex
core	O
subunit	O
D1	O
protein	O
is	O
higher	O
in	O
hcf243	O
than	O
in	O
the	O
wild	O
type	O
,	O
and	O
the	O
assembly	O
of	O
PSII	B-Complex
is	O
retarded	O
significantly	O
in	O
the	O
hcf243	O
mutant	O
.	O

HCF243	O
,	O
a	O
nuclear	O
gene	O
,	O
encodes	O
a	O
chloroplast	O
protein	O
that	O
interacts	O
with	O
the	O
D1	O
protein	O
.	O

HCF243	O
homologs	O
were	O
identified	O
in	O
angiosperms	O
with	O
one	O
or	O
two	O
copies	O
but	O
were	O
not	O
found	O
in	O
lower	O
plants	O
and	O
prokaryotes	O
.	O

These	O
results	O
suggest	O
that	O
HCF243	O
,	O
which	O
arose	O
after	O
the	O
origin	O
of	O
the	O
higher	O
plants	O
,	O
may	O
act	O
as	O
a	O
cofactor	O
to	O
maintain	O
the	O
stability	O
of	O
D1	O
protein	O
and	O
to	O
promote	O
the	O
subsequent	O
assembly	O
of	O
the	O
PSII	B-Complex
complex	O
.	O

Shiga	O
toxin	O
1	O
is	O
more	O
dependent	O
on	O
the	O
P	O
proteins	O
of	O
the	O
ribosomal	O
stalk	O
for	O
depurination	O
activity	O
than	O
Shiga	O
toxin	O
2	O
.	O

Shiga	O
toxins	O
produced	O
by	O
Escherichia	O
coli	O
O157	O
:	O
H7	O
are	O
responsible	O
for	O
food	O
poisoning	O
and	O
hemolytic	O
uremic	O
syndrome	O
(	O
HUS	O
)	O
.	O

The	O
A	O
subunits	O
of	O
Shiga	O
toxins	O
(	O
Stx1A	O
and	O
Stx2A	O
)	O
inhibit	O
translation	O
by	O
depurinating	O
a	O
specific	O
adenine	O
in	O
the	O
large	O
rRNA	O
.	O

To	O
determine	O
if	O
Stx1A	O
and	O
Stx2A	O
require	O
the	O
ribosomal	O
stalk	O
for	O
depurination	O
,	O
their	O
activity	O
and	O
cytotoxicity	O
were	O
examined	O
in	O
the	O
yeast	O
P	O
protein	O
deletion	O
mutants	O
.	O

Stx1A	O
and	O
Stx2A	O
were	O
less	O
toxic	O
and	O
depurinated	O
ribosomes	B-OOS
less	O
in	O
a	O
strain	O
lacking	O
P1	O
/	O
P2	O
on	O
the	O
ribosome	B-OOS
and	O
in	O
the	O
cytosol	O
(	O
DeltaP2	O
)	O
than	O
in	O
a	O
strain	O
lacking	O
P1	O
/	O
P2	O
on	O
the	O
ribosome	B-OOS
,	O
but	O
containing	O
free	O
P2	O
in	O
the	O
cytosol	O
(	O
DeltaP1	O
)	O
.	O

To	O
determine	O
if	O
cytoplasmic	O
P	O
proteins	O
facilitated	O
depurination	O
,	O
Stx1A	O
and	O
Stx2A	O
were	O
expressed	O
in	O
the	O
P0DeltaAB	O
mutant	O
,	O
in	O
which	O
the	O
binding	O
sites	O
for	O
P1	O
/	O
P2	O
were	O
deleted	O
on	O
the	O
ribosome	B-OOS
,	O
and	O
P1	O
/	O
P2	O
accumulated	O
in	O
the	O
cytosol	O
.	O

Stx1A	O
was	O
less	O
toxic	O
and	O
depurinated	O
ribosomes	B-OOS
less	O
in	O
P0DeltaAB	O
,	O
suggesting	O
that	O
intact	O
binding	O
sites	O
for	O
P1	O
/	O
P2	O
were	O
critical	O
.	O

In	O
contrast	O
,	O
Stx2A	O
was	O
toxic	O
and	O
depurinated	O
ribosomes	B-OOS
in	O
P0DeltaAB	O
as	O
in	O
wild	O
type	O
,	O
suggesting	O
that	O
it	O
did	O
not	O
require	O
the	O
P1	O
/	O
P2	O
binding	O
sites	O
.	O

Depurination	O
of	O
DeltaP1	O
,	O
but	O
not	O
P0DeltaAB	O
ribosomes	B-OOS
increased	O
upon	O
addition	O
of	O
purified	O
P1alpha	O
/	O
P2betain	O
vitro	O
,	O
and	O
the	O
increase	O
was	O
greater	O
for	O
Stx1	O
than	O
for	O
Stx2	O
.	O

We	O
conclude	O
that	O
cytoplasmic	O
P	O
proteins	O
stimulate	O
depurination	O
by	O
Stx1	O
by	O
facilitating	O
the	O
access	O
of	O
the	O
toxin	O
to	O
the	O
ribosome	B-OOS
.	O

Although	O
ribosomal	O
stalk	O
is	O
important	O
for	O
Stx1	O
and	O
Stx2	O
to	O
depurinate	O
the	O
ribosome	B-OOS
,	O
Stx2	O
is	O
less	O
dependent	O
on	O
the	O
stalk	O
proteins	O
for	O
activity	O
than	O
Stx1	O
and	O
can	O
depurinate	O
ribosomes	B-OOS
with	O
an	O
incomplete	O
stalk	O
better	O
than	O
Stx1	O
.	O

Vacuolar	O
protein	O
sorting	O
genes	O
regulate	O
mat	O
formation	O
in	O
Saccharomyces	O
cerevisiae	O
by	O
Flo11p	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Saccharomyces	O
cerevisiae	O
generates	O
complex	O
biofilms	O
called	O
mats	O
on	O
low	O
-	O
density	O
(	O
0	O
.	O
3	O
%	O
)	O
agar	O
plates	O
.	O

The	O
mats	O
can	O
be	O
morphologically	O
divided	O
into	O
two	O
regions	O
:	O
(	O
i	O
)	O
hub	O
,	O
the	O
interior	O
region	O
characterized	O
by	O
the	O
presence	O
of	O
wrinkles	O
and	O
channels	O
,	O
and	O
(	O
ii	O
)	O
rim	O
,	O
the	O
smooth	O
periphery	O
.	O

Formation	O
of	O
mats	O
depends	O
on	O
the	O
adhesin	O
Flo11p	O
,	O
which	O
is	O
also	O
required	O
for	O
invasive	O
growth	O
,	O
a	O
phenotype	O
in	O
which	O
the	O
S	O
.	O
cerevisiae	O
yeasts	O
grow	O
as	O
chains	O
of	O
cells	O
that	O
dig	O
into	O
standard	O
-	O
density	O
(	O
2	O
%	O
)	O
agar	O
plates	O
.	O

Although	O
both	O
invasive	O
growth	O
and	O
mat	O
formation	O
depend	O
on	O
Flo11p	O
,	O
mutations	O
that	O
perturb	O
the	O
multivesicular	O
body	O
(	O
MVB	O
)	O
protein	O
sorting	O
pathway	O
inhibit	O
mat	O
formation	O
in	O
a	O
FLO11	O
-	O
independent	O
manner	O
.	O

These	O
mutants	O
,	O
represented	O
by	O
vps27Delta	O
,	O
disrupt	O
mat	O
formation	O
but	O
do	O
not	O
affect	O
invasive	O
growth	O
,	O
FLO11	O
gene	O
or	O
protein	O
expression	O
,	O
or	O
Flo11p	O
localization	O
.	O

In	O
contrast	O
,	O
an	O
overlapping	O
subset	O
of	O
MVB	O
mutants	O
(	O
represented	O
by	O
ESCRT	B-Complex
[	O
endosomal	B-Complex
sorting	I-Complex
complex	I-Complex
required	I-Complex
for	I-Complex
transport	I-Complex
]	O
complex	O
genes	O
such	O
as	O
VPS25	O
)	O
interrupt	O
the	O
Rim101p	O
signal	O
transduction	O
cascade	O
,	O
which	O
is	O
required	O
for	O
FLO11	O
expression	O
,	O
and	O
thus	O
block	O
both	O
invasive	O
growth	O
and	O
mat	O
formation	O
.	O

In	O
addition	O
,	O
this	O
report	O
shows	O
that	O
mature	O
Flo11p	O
is	O
covalently	O
associated	O
with	O
the	O
cell	O
wall	O
and	O
shed	O
into	O
the	O
extracellular	O
matrix	O
of	O
the	O
growing	O
mat	O
.	O

Identification	O
of	O
the	O
endogenous	O
cysteine	O
-	O
rich	O
peptide	O
trissin	O
,	O
a	O
ligand	O
for	O
an	O
orphan	O
G	O
protein	O
-	O
coupled	O
receptor	O
in	O
Drosophila	O
.	O

There	O
are	O
many	O
orphan	O
G	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
,	O
for	O
which	O
ligands	O
have	O
not	O
yet	O
been	O
identified	O
,	O
in	O
both	O
vertebrates	O
and	O
invertebrates	O
,	O
such	O
as	O
Drosophila	O
melanogaster	O
.	O

Identification	O
of	O
their	O
cognate	O
ligands	O
is	O
critical	O
for	O
understanding	O
the	O
function	O
and	O
regulation	O
of	O
such	O
GPCRs	O
.	O

Indeed	O
,	O
the	O
discovery	O
of	O
bioactive	O
peptides	O
that	O
bind	O
GPCRs	O
has	O
enhanced	O
our	O
understanding	O
of	O
mechanisms	O
underlying	O
many	O
physiological	O
processes	O
.	O

Here	O
,	O
we	O
identified	O
an	O
endogenous	O
ligand	O
of	O
the	O
Drosophila	O
orphan	O
GPCR	O
,	O
CG34381	O
.	O

The	O
purified	O
ligand	O
is	O
a	O
peptide	O
comprised	O
of	O
28	O
amino	O
acids	O
with	O
three	O
intrachain	O
disulfide	O
bonds	O
.	O

The	O
preprotein	O
is	O
coded	O
for	O
by	O
gene	O
CG14871	O
.	O

We	O
designated	O
the	O
cysteine	O
-	O
rich	O
peptide	O
"	O
trissin	O
"	O
(	O
it	O
means	O
for	O
triple	O
S	O
-	O
S	O
bonds	O
)	O
and	O
characterized	O
the	O
structure	O
of	O
intrachain	O
disulfide	O
bonds	O
formation	O
in	O
a	O
synthetic	O
trissin	O
peptide	O
.	O

Because	O
the	O
expression	O
of	O
trissin	O
and	O
its	O
receptor	O
is	O
reported	O
to	O
predominantly	O
localize	O
to	O
the	O
brain	O
and	O
thoracicoabdominal	O
ganglion	O
,	O
trissin	O
is	O
expected	O
to	O
behave	O
as	O
a	O
neuropeptide	O
.	O

The	O
discovery	O
of	O
trissin	O
provides	O
an	O
important	O
lead	O
to	O
aid	O
our	O
understanding	O
of	O
cysteine	O
-	O
rich	O
peptides	O
and	O
their	O
functional	O
interaction	O
with	O
GPCRs	O
.	O

Here	O
,	O
we	O
report	O
the	O
results	O
of	O
our	O
investigation	O
of	O
the	O
mechanisms	O
by	O
which	O
Catsup	O
mutations	O
can	O
enhance	O
BH4	O
and	O
DA	O
synthesis	O
and	O
yet	O
simultaneously	O
confer	O
neuroprotection	O
against	O
PQ	O
-	O
induced	O
oxidative	O
insult	O
.	O

We	O
find	O
that	O
Catsup	O
acts	O
to	O
negatively	O
regulate	O
BH4	O
and	O
DA	O
synthesis	O
pathways	O
through	O
physical	O
interactions	O
with	O
the	O
rate	O
-	O
limiting	O
enzymes	O
of	O
both	O
pathways	O
,	O
GTP	O
cyclohydrolase	O
I	O
(	O
GTPCH	O
;	O
EC3	O
.	O
5	O
.	O
4	O
.	O
16	O
)	O
and	O
TH	O
,	O
respectively	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
Catsup	O
is	O
localized	O
to	O
synaptic	O
termini	O
and	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
vesicular	O
monoamine	O
transporter	O
(	O
VMAT	O
)	O
,	O
which	O
is	O
responsible	O
for	O
synaptic	O
vesicle	O
uptake	O
of	O
DA	O
.	O

We	O
conclude	O
that	O
Catsup	O
has	O
the	O
ability	O
to	O
regulate	O
DA	O
homeostasis	O
by	O
effectively	O
integrating	O
the	O
synthesis	O
of	O
both	O
the	O
BH4	O
and	O
DA	O
pathways	O
through	O
their	O
respective	O
rate	O
-	O
limiting	O
enzymes	O
,	O
with	O
the	O
transport	O
and	O
synaptic	O
release	O
of	O
DA	O
.	O

HECT	O
-	O
type	O
ubiquitin	O
ligase	O
ITCH	O
targets	O
lysosomal	O
-	O
associated	O
protein	O
multispanning	O
transmembrane	O
5	O
(	O
LAPTM5	O
)	O
and	O
prevents	O
LAPTM5	O
-	O
mediated	O
cell	O
death	O
.	O

LAPTM5	O
(	O
lysosomal	O
-	O
associated	O
protein	O
multispanning	O
transmembrane	O
5	O
)	O
is	O
a	O
membrane	O
protein	O
on	O
the	O
intracellular	O
vesicles	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
the	O
accumulation	O
of	O
LAPTM5	O
-	O
positive	O
vesicles	O
was	O
closely	O
associated	O
with	O
the	O
programmed	O
cell	O
death	O
occurring	O
during	O
the	O
spontaneous	O
regression	O
of	O
neuroblastomas	O
.	O

Although	O
the	O
accumulation	O
of	O
LAPTM5	O
protein	O
might	O
occur	O
at	O
the	O
post	O
-	O
translational	O
level	O
,	O
the	O
molecular	O
mechanism	O
has	O
been	O
unclear	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
level	O
of	O
LAPTM5	O
protein	O
is	O
regulated	O
negatively	O
by	O
the	O
degradation	O
through	O
ubiquitination	O
by	O
ITCH	O
,	O
an	O
E3	O
ubiquitin	O
ligase	O
.	O

ITCH	O
directly	O
binds	O
to	O
the	O
PPxY	O
motif	O
of	O
LAPTM5	O
via	O
its	O
WW	O
domains	O
and	O
promotes	O
ubiquitination	O
through	O
a	O
HECT	O
-	O
type	O
ligase	O
domain	O
.	O

Overexpression	O
of	O
ITCH	O
led	O
to	O
the	O
degradation	O
of	O
LAPTM5	O
protein	O
,	O
and	O
conversely	O
,	O
knockdown	O
of	O
ITCH	O
by	O
siRNA	O
resulted	O
in	O
the	O
stabilization	O
of	O
LAPTM5	O
protein	O
.	O

In	O
addition	O
,	O
the	O
inhibition	O
of	O
ITCH	O
enhanced	O
the	O
cell	O
death	O
occurred	O
by	O
accumulation	O
of	O
LAPTM5	O
in	O
neuroblastoma	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
LAPTM5	O
is	O
a	O
novel	O
substrate	O
in	O
terms	O
of	O
degradation	O
by	O
the	O
ubiquitin	O
ligase	O
ITCH	O
,	O
and	O
this	O
system	O
might	O
act	O
as	O
a	O
negative	O
regulator	O
in	O
the	O
spontaneous	O
regression	O
of	O
neuroblastomas	O
by	O
preventing	O
LAPTM5	O
-	O
mediated	O
cell	O
death	O
.	O

HIV	O
-	O
1	O
restriction	O
factor	O
SAMHD1	O
is	O
a	O
deoxynucleoside	O
triphosphate	O
triphosphohydrolase	O
.	O

SAMHD1	O
,	O
an	O
analogue	O
of	O
the	O
murine	O
interferon	O
(	O
IFN	O
)	O
-	O
gamma	O
-	O
induced	O
gene	O
Mg11	O
(	O
ref	O
.	O
1	O
)	O
,	O
has	O
recently	O
been	O
identified	O
as	O
a	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
restriction	O
factor	O
that	O
blocks	O
early	O
-	O
stage	O
virus	O
replication	O
in	O
dendritic	O
and	O
other	O
myeloid	O
cells	O
and	O
is	O
the	O
target	O
of	O
the	O
lentiviral	O
protein	O
Vpx	O
,	O
which	O
can	O
relieve	O
HIV	O
-	O
1	O
restriction	O
.	O

SAMHD1	O
is	O
also	O
associated	O
with	O
Aicardi	O
-	O
Goutieres	O
syndrome	O
(	O
AGS	O
)	O
,	O
an	O
inflammatory	O
encephalopathy	O
characterized	O
by	O
chronic	O
cerebrospinal	O
fluid	O
lymphocytosis	O
and	O
elevated	O
levels	O
of	O
the	O
antiviral	O
cytokine	O
IFN	O
-	O
alpha	O
.	O

The	O
pathology	O
associated	O
with	O
AGS	O
resembles	O
congenital	O
viral	O
infection	O
,	O
such	O
as	O
transplacentally	O
acquired	O
HIV	O
.	O

Here	O
we	O
show	O
that	O
human	O
SAMHD1	O
is	O
a	O
potent	O
dGTP	O
-	O
stimulated	O
triphosphohydrolase	O
that	O
converts	O
deoxynucleoside	O
triphosphates	O
to	O
the	O
constituent	O
deoxynucleoside	O
and	O
inorganic	O
triphosphate	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
catalytic	O
core	O
of	O
SAMHD1	O
reveals	O
that	O
the	O
protein	O
is	O
dimeric	O
and	O
indicates	O
a	O
molecular	O
basis	O
for	O
dGTP	O
stimulation	O
of	O
catalytic	O
activity	O
against	O
dNTPs	O
.	O

We	O
propose	O
that	O
SAMHD1	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
dendritic	O
cells	O
,	O
restricts	O
HIV	O
-	O
1	O
replication	O
by	O
hydrolysing	O
the	O
majority	O
of	O
cellular	O
dNTPs	O
,	O
thus	O
inhibiting	O
reverse	O
transcription	O
and	O
viral	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
synthesis	O
.	O

alpha	O
-	O
Synuclein	O
fate	O
is	O
determined	O
by	O
USP9X	O
-	O
regulated	O
monoubiquitination	O
.	O

alpha	O
-	O
Synuclein	O
is	O
central	O
to	O
the	O
pathogenesis	O
of	O
Parkinson	O
disease	O
(	O
PD	O
)	O
.	O

Mutations	O
as	O
well	O
as	O
accumulation	O
of	O
alpha	O
-	O
synuclein	O
promote	O
the	O
death	O
of	O
dopaminergic	O
neurons	O
and	O
the	O
formation	O
of	O
Lewy	O
bodies	O
.	O

alpha	O
-	O
Synuclein	O
is	O
monoubiquitinated	O
by	O
SIAH	O
,	O
but	O
the	O
regulation	O
and	O
roles	O
of	O
monoubiquitination	O
in	O
alpha	O
-	O
synuclein	O
biology	O
are	O
poorly	O
understood	O
.	O

We	O
now	O
report	O
that	O
the	O
deubiquitinase	O
USP9X	O
interacts	O
in	O
vivo	O
with	O
and	O
deubiquitinates	O
alpha	O
-	O
synuclein	O
.	O

USP9X	O
levels	O
are	O
significantly	O
lower	O
in	O
cytosolic	O
fractions	O
of	O
PD	O
substantia	O
nigra	O
and	O
Diffuse	O
Lewy	O
Body	O
disease	O
(	O
DLBD	O
)	O
cortices	O
compared	O
to	O
controls	O
.	O

This	O
was	O
associated	O
to	O
lower	O
deubiquitinase	O
activity	O
toward	O
monoubiquitinated	O
alpha	O
-	O
synuclein	O
in	O
DLBD	O
cortical	O
extracts	O
.	O

A	O
fraction	O
of	O
USP9X	O
seems	O
to	O
be	O
aggregated	O
in	O
PD	O
and	O
DLBD	O
,	O
as	O
USP9X	O
immunoreactivity	O
is	O
detected	O
in	O
Lewy	O
bodies	O
.	O

Knockdown	O
of	O
USP9X	O
expression	O
promotes	O
accumulation	O
of	O
monoubiquitinated	O
alpha	O
-	O
synuclein	O
species	O
and	O
enhances	O
the	O
formation	O
of	O
toxic	O
alpha	O
-	O
synuclein	O
inclusions	O
upon	O
proteolytic	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
by	O
manipulating	O
USP9X	O
expression	O
levels	O
in	O
the	O
absence	O
of	O
proteolytic	O
impairment	O
,	O
we	O
demonstrate	O
that	O
monoubiquitination	O
controls	O
the	O
partition	O
of	O
alpha	O
-	O
synuclein	O
between	O
different	O
protein	O
degradation	O
systems	O
.	O

Deubiquitinated	O
alpha	O
-	O
synuclein	O
is	O
mostly	O
degraded	O
by	O
autophagy	O
,	O
while	O
monoubiquitinated	O
alpha	O
-	O
synuclein	O
is	O
preferentially	O
degraded	O
by	O
the	O
proteasome	B-Complex
.	O

Moreover	O
,	O
monoubiquitination	O
promotes	O
the	O
degradation	O
of	O
alpha	O
-	O
synuclein	O
,	O
whereas	O
deubiquitination	O
leads	O
to	O
its	O
accumulation	O
,	O
suggesting	O
that	O
the	O
degradation	O
of	O
deubiquitinated	O
alpha	O
-	O
synuclein	O
by	O
the	O
autophagy	O
pathway	O
is	O
less	O
efficient	O
than	O
the	O
proteasomal	O
one	O
.	O

Lower	O
levels	O
of	O
cytosolic	O
USP9X	O
and	O
deubiquitinase	O
activity	O
in	O
alpha	O
-	O
synucleinopathies	O
may	O
contribute	O
to	O
the	O
accumulation	O
and	O
aggregation	O
of	O
monoubiquitinated	O
alpha	O
-	O
synuclein	O
in	O
Lewy	O
bodies	O
.	O

Our	O
data	O
indicate	O
that	O
monoubiquitination	O
is	O
a	O
key	O
determinant	O
of	O
alpha	O
-	O
synuclein	O
fate	O
.	O

cDNA	O
sequence	O
,	O
in	O
vitro	O
synthesis	O
,	O
and	O
intramitochondrial	O
lipoylation	O
of	O
H	O
-	O
protein	O
of	O
the	O
glycine	O
cleavage	O
system	O
.	O

H	O
-	O
protein	O
is	O
a	O
component	O
of	O
the	O
glycine	O
cleavage	O
system	O
loosely	O
associated	O
with	O
the	O
mitochondrial	O
inner	O
membrane	O
and	O
has	O
lipoic	O
acid	O
as	O
a	O
prosthetic	O
group	O
.	O

cDNA	O
clones	O
encoding	O
H	O
-	O
protein	O
were	O
isolated	O
from	O
a	O
bovine	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
from	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
NH2	O
-	O
terminal	O
region	O
.	O

DNA	O
sequence	O
analysis	O
and	O
deduced	O
amino	O
acid	O
sequence	O
showed	O
that	O
the	O
cDNAs	O
encoded	O
an	O
H	O
-	O
protein	O
precursor	O
of	O
173	O
amino	O
acids	O
including	O
a	O
48	O
-	O
amino	O
acid	O
presequence	O
.	O

Calculated	O
molecular	O
mass	O
of	O
the	O
precursor	O
and	O
mature	O
protein	O
without	O
lipoic	O
acid	O
were	O
18	O
,	O
790	O
and	O
13	O
,	O
846	O
,	O
respectively	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
a	O
major	O
mRNA	O
component	O
of	O
1	O
.	O
1	O
kilobases	O
and	O
a	O
minor	O
component	O
of	O
0	O
.	O
6	O
kilobase	O
.	O

The	O
result	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
two	O
adenylation	O
signals	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
cDNA	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
H	O
-	O
protein	O
cDNA	O
produced	O
a	O
19	O
-	O
kDa	O
protein	O
recognized	O
by	O
antibody	O
raised	O
to	O
chicken	O
H	O
-	O
protein	O
.	O

Bovine	O
liver	O
H	O
-	O
protein	O
precursor	O
has	O
no	O
lipoic	O
acid	O
prosthetic	O
group	O
.	O

When	O
incubated	O
with	O
isolated	O
bovine	O
liver	O
mitochondria	O
,	O
the	O
precursor	O
was	O
imported	O
into	O
mitochondria	O
,	O
processed	O
to	O
its	O
mature	O
form	O
with	O
a	O
molecular	O
mass	O
of	O
14	O
kDa	O
,	O
and	O
lipoylated	O
at	O
lysine	O
59	O
.	O

These	O
results	O
indicate	O
that	O
lipoylation	O
is	O
not	O
required	O
for	O
the	O
import	O
of	O
H	O
-	O
protein	O
precursor	O
into	O
mitochondria	O
and	O
H	O
-	O
protein	O
is	O
lipoylated	O
in	O
mitochondria	O
which	O
probably	O
contain	O
the	O
physiologically	O
active	O
form	O
of	O
lipoic	O
acid	O
as	O
well	O
as	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
the	O
attachment	O
.	O

Histone	O
deacetylase	O
inhibitors	O
prevent	O
the	O
degradation	O
and	O
restore	O
the	O
activity	O
of	O
glucocerebrosidase	O
in	O
Gaucher	O
disease	O
.	O

Gaucher	O
disease	O
(	O
GD	O
)	O
is	O
caused	O
by	O
a	O
spectrum	O
of	O
genetic	O
mutations	O
within	O
the	O
gene	O
encoding	O
the	O
lysosomal	O
enzyme	O
glucocerebrosidase	O
(	O
GCase	O
)	O
.	O

These	O
mutations	O
often	O
lead	O
to	O
misfolded	O
proteins	O
that	O
are	O
recognized	O
by	O
the	O
unfolded	O
protein	O
response	O
system	O
and	O
are	O
degraded	O
through	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
.	O

Modulating	O
this	O
pathway	O
with	O
histone	O
deacetylase	O
inhibitors	O
(	O
HDACis	O
)	O
has	O
been	O
shown	O
to	O
improve	O
protein	O
stability	O
in	O
other	O
disease	O
settings	O
.	O

To	O
identify	O
the	O
mechanisms	O
involved	O
in	O
the	O
regulation	O
of	O
GCase	O
and	O
determine	O
the	O
effects	O
of	O
HDACis	O
on	O
protein	O
stability	O
,	O
we	O
investigated	O
the	O
most	O
prevalent	O
mutations	O
for	O
nonneuronopathic	O
(	O
N370S	O
)	O
and	O
neuronopathic	O
(	O
L444P	O
)	O
GD	O
in	O
cultured	O
fibroblasts	O
derived	O
from	O
GD	O
patients	O
and	O
HeLa	O
cells	O
transfected	O
with	O
these	O
mutations	O
.	O

The	O
half	O
-	O
lives	O
of	O
mutant	O
GCase	O
proteins	O
correspond	O
to	O
decreases	O
in	O
protein	O
levels	O
and	O
enzymatic	O
activity	O
.	O

GCase	O
was	O
found	O
to	O
bind	O
to	O
Hsp70	O
,	O
which	O
directed	O
the	O
protein	O
to	O
TCP1	O
for	O
proper	O
folding	O
,	O
and	O
to	O
Hsp90	O
,	O
which	O
directed	O
the	O
protein	O
to	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
.	O

Using	O
a	O
known	O
HDACi	O
(	O
SAHA	O
)	O
and	O
a	O
unique	O
small	O
-	O
molecule	O
HDACi	O
(	O
LB	O
-	O
205	O
)	O
,	O
GCase	O
levels	O
increased	O
rescuing	O
enzymatic	O
activity	O
in	O
mutant	O
cells	O
.	O

The	O
increase	O
in	O
the	O
quantity	O
of	O
protein	O
can	O
be	O
attributed	O
to	O
increases	O
in	O
protein	O
half	O
-	O
life	O
that	O
correspond	O
primarily	O
with	O
a	O
decrease	O
in	O
degradation	O
rather	O
than	O
an	O
increase	O
in	O
chaperoned	O
folding	O
.	O

HDACis	O
reduce	O
binding	O
to	O
Hsp90	O
and	O
prevent	O
subsequent	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
without	O
affecting	O
binding	O
to	O
Hsp70	O
or	O
TCP1	O
.	O

These	O
findings	O
provide	O
insight	O
into	O
the	O
pathogenesis	O
of	O
GD	O
and	O
indicate	O
a	O
potent	O
therapeutic	O
potential	O
of	O
HDAC	O
inhibitors	O
for	O
the	O
treatment	O
of	O
GD	O
and	O
other	O
human	O
protein	O
misfolding	O
disorders	O
.	O

Next	O
,	O
we	O
examined	O
expression	O
of	O
Nkx2	O
.	O
5	O
and	O
Tbx5	O
in	O
E9	O
UTX	O
-	O
null	O
and	O
control	O
littermate	O
embryos	O
using	O
whole	O
mount	O
in	O
situ	O
hybridization	O
analyses	O
.	O

Nkx2	O
.	O
5	O
and	O
Tbx5	O
were	O
highly	O
expressed	O
in	O
the	O
sinoatrial	O
structures	O
and	O
heart	O
tube	O
of	O
UTXDelta	O
/	O
Delta	O
embryos	O
,	O
but	O
the	O
overall	O
levels	O
were	O
reduced	O
compared	O
to	O
those	O
in	O
UTXDelta	O
/	O
+	O
littermates	O
(	O
Fig	O
.	O
3I	O
-	O
P	O
)	O
,	O
suggesting	O
that	O
UTX	O
plays	O
a	O
role	O
in	O
maintaining	O
high	O
levels	O
of	O
Nkx2	O
.	O
5	O
and	O
Tbx5	O
in	O
the	O
developing	O
heart	O
.	O

To	O
monitor	O
the	O
expression	O
of	O
heart	O
-	O
specific	O
genes	O
that	O
are	O
regulated	O
by	O
the	O
core	O
cardiac	O
transcription	O
factors	O
,	O
we	O
performed	O
whole	O
mount	O
in	O
situ	O
hybridization	O
analyses	O
in	O
littermate	O
embryos	O
.	O

ANF	O
,	O
an	O
atrial	O
natriuretic	O
peptide	O
,	O
is	O
a	O
marker	O
of	O
the	O
differentiating	O
chamber	O
myocardium	O
.	O

SRF	O
,	O
Tbx5	O
,	O
Nkx2	O
.	O
5	O
and	O
GATA4	O
,	O
alone	O
or	O
in	O
combination	O
,	O
bind	O
to	O
their	O
cognate	O
sites	O
in	O
the	O
ANF	O
enhancer	O
and	O
activate	O
its	O
transcription	O
.	O

In	O
addition	O
,	O
Nkx2	O
.	O
5	O
and	O
Tbx5	O
also	O
activate	O
expression	O
of	O
the	O
ventricle	O
-	O
specific	O
contractile	O
protein	O
MLC2v	O
.	O

Whole	O
mount	O
in	O
situ	O
hybridization	O
revealed	O
that	O
ANF	O
expression	O
was	O
greatly	O
reduced	O
in	O
UTXDelta	O
/	O
Delta	O
embryonic	O
heart	O
(	O
Fig	O
.	O
3Q	O
-	O
T	O
)	O
.	O

In	O
addition	O
,	O
MLC2v	O
was	O
also	O
substantially	O
decreased	O
and	O
the	O
expression	O
pattern	O
of	O
MLC2v	O
was	O
severely	O
altered	O
in	O
UTXDelta	O
/	O
Delta	O
embryos	O
(	O
Fig	O
.	O
3U	O
-	O
Z	O
)	O
.	O

Together	O
,	O
our	O
data	O
establish	O
that	O
UTX	O
plays	O
a	O
crucial	O
role	O
in	O
maintaining	O
high	O
levels	O
of	O
Nxk2	O
.	O
5	O
and	O
Tbx5	O
expression	O
and	O
marked	O
upregulation	O
of	O
heart	O
-	O
specific	O
genes	O
during	O
embryonic	O
development	O
.	O

Interaction	O
of	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
2	O
(	O
PIAS2	O
)	O
with	O
receptor	O
of	O
activated	O
C	O
kinase	O
1	O
,	O
RACK1	O
.	O

In	O
this	O
study	O
,	O
the	O
evolutionarily	O
conserved	O
intracellular	O
adaptor	O
protein	O
,	O
receptor	O
of	O
activated	O
C	O
kinase	O
1	O
(	O
RACK1	O
)	O
was	O
identified	O
as	O
a	O
novel	O
interaction	O
partner	O
of	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
2	O
(	O
PIAS2	O
)	O
using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screening	O
system	O
.	O

The	O
direct	O
interaction	O
and	O
co	O
-	O
localization	O
of	O
RACK1	O
with	O
PIAS2	O
was	O
confirmed	O
by	O
immunoprecipitation	O
and	O
immunofluorescence	O
staining	O
analysis	O
,	O
respectively	O
.	O

The	O
5th	O
to	O
7th	O
Trp	O
-	O
Asp	O
40	O
(	O
5	O
-	O
7	O
WD40	O
)	O
repeats	O
of	O
RACK1	O
were	O
identified	O
as	O
the	O
minimal	O
domain	O
required	O
for	O
interaction	O
with	O
PIAS2	O
by	O
deletion	O
analysis	O
.	O

Furthermore	O
,	O
multiple	O
PIAS2	O
-	O
domains	O
,	O
particularly	O
the	O
'	O
PINIT	O
'	O
and	O
RLD	O
domains	O
,	O
bind	O
the	O
RACK1	O
5	O
-	O
7	O
WD40	O
domain	O
.	O

Based	O
on	O
our	O
results	O
,	O
it	O
was	O
speculated	O
that	O
TTP	O
induces	O
let	O
-	O
7b	O
level	O
through	O
down	O
-	O
regulation	O
of	O
Lin28a	O
.	O

To	O
confirm	O
this	O
hypothesis	O
,	O
we	O
first	O
determined	O
whether	O
knockdown	O
of	O
Lin28a	O
by	O
siRNA	O
enhanced	O
let	O
-	O
7b	O
expression	O
in	O
PA1	O
cells	O
.	O

Western	O
blot	O
analysis	O
confirmed	O
the	O
inhibition	O
of	O
Lin28a	O
expression	O
in	O
PA1	O
cells	O
(	O
PA1	O
/	O
Lin28a	O
-	O
siRNA	O
)	O
by	O
siRNA	O
treatment	O
(	O
Figure	O
6A	O
)	O
.	O

As	O
expected	O
,	O
let	O
-	O
7b	O
expression	O
level	O
in	O
PA1	O
/	O
Lin28a	O
-	O
siRNA	O
was	O
increased	O
compared	O
to	O
PA1	O
cells	O
treated	O
with	O
control	O
siRNA	O
(	O
PA1	O
/	O
scRNA	O
)	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
Lin28a	O
decreased	O
the	O
level	O
of	O
CDC34	O
(	O
Figure	O
6C	O
)	O
.	O

To	O
confirm	O
the	O
involvement	O
of	O
Lin28a	O
for	O
the	O
TTP	O
-	O
induced	O
increase	O
of	O
let	O
-	O
7b	O
level	O
,	O
we	O
co	O
-	O
transfected	O
PA1	O
cells	O
with	O
pcDNA6	O
/	O
V5	O
-	O
TTP	O
and	O
pcDNA3	O
/	O
Flag	O
-	O
Lin28a	O
,	O
which	O
does	O
not	O
contain	O
the	O
Lin28a	O
3	O
'	O
-	O
UTR	O
.	O

At	O
24	O
-	O
h	O
post	O
-	O
transfection	O
,	O
cells	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
let	O
-	O
7b	O
,	O
CDC34	O
and	O
proliferation	O
.	O

Overexpression	O
of	O
Lin28a	O
(	O
Figure	O
6D	O
)	O
abrogated	O
the	O
effect	O
of	O
TTP	O
on	O
the	O
expression	O
of	O
let	O
-	O
7b	O
and	O
CDC34	O
(	O
Figure	O
6E	O
)	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
Lin28a	O
restored	O
the	O
growth	O
of	O
PA1	O
/	O
TTP	O
to	O
87	O
%	O
of	O
PA1	O
/	O
pcDNA	O
(	O
Figure	O
6F	O
)	O
.	O

These	O
results	O
indicate	O
that	O
TTP	O
affects	O
the	O
expression	O
level	O
of	O
let	O
-	O
7b	O
and	O
CDC34	O
and	O
the	O
cell	O
growth	O
through	O
down	O
-	O
regulation	O
of	O
Lin28a	O
in	O
PA1	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
OS9	O
interacts	O
with	O
both	O
BRI1	O
-	O
5	O
and	O
BRI1	O
-	O
9	O
,	O
but	O
kifunensine	O
treatment	O
disturbed	O
the	O
association	O
with	O
BRI1	O
-	O
5	O
much	O
more	O
than	O
with	O
BRI1	O
-	O
9	O
.	O

The	O
two	O
distinct	O
mutations	O
affect	O
very	O
different	O
regions	O
of	O
BRI1	O
(	O
Hothorn	O
et	O
al	O
.	O
;	O
She	O
et	O
al	O
.	O
)	O
and	O
genetic	O
as	O
well	O
as	O
biochemical	O
studies	O
have	O
shown	O
that	O
the	O
two	O
mutated	O
BRI1	O
forms	O
have	O
different	O
requirements	O
for	O
ER	O
quality	O
control	O
(	O
Jin	O
et	O
al	O
.	O
;	O
Hong	O
et	O
al	O
.	O
)	O
.	O

Consequently	O
our	O
data	O
argue	O
that	O
BRI1	O
-	O
5	O
and	O
BRI1	O
-	O
9	O
represent	O
different	O
classes	O
of	O
ERAD	O
substrates	O
that	O
require	O
distinct	O
components	O
for	O
degradation	O
like	O
it	O
has	O
also	O
been	O
proposed	O
for	O
mammalian	O
ERAD	O
substrates	O
(	O
Bernasconi	O
et	O
al	O
.	O
)	O
.	O

The	O
interaction	O
of	O
BRI1	O
-	O
9	O
with	O
OS9	O
might	O
be	O
more	O
dependent	O
on	O
interaction	O
with	O
exposed	O
protein	O
segments	O
and	O
OS9	O
may	O
-	O
-	O
like	O
YOS9	O
-	O
-	O
also	O
bind	O
and	O
assist	O
in	O
degradation	O
of	O
certain	O
non	O
-	O
glycosylated	O
substrates	O
(	O
Bhamidipati	O
et	O
al	O
.	O
;	O
Jaenicke	O
et	O
al	O
.	O
)	O
.	O

Histone	O
deacetylase	O
6	O
(	O
HDAC6	O
)	O
deacetylates	O
survivin	O
for	O
its	O
nuclear	O
export	O
in	O
breast	O
cancer	O
.	O

Survivin	O
is	O
an	O
oncogenic	O
protein	O
that	O
is	O
highly	O
expressed	O
in	O
breast	O
cancer	O
and	O
has	O
a	O
dual	O
function	O
that	O
is	O
dependent	O
on	O
its	O
subcellular	O
localization	O
.	O

In	O
the	O
cytosol	O
,	O
survivin	O
blocks	O
programmed	O
cell	O
death	O
by	O
inactivating	O
caspase	O
proteins	O
;	O
however	O
,	O
in	O
the	O
nucleus	O
it	O
facilitates	O
cell	O
division	O
by	O
regulating	O
chromosomal	O
movement	O
and	O
cytokinesis	O
.	O

In	O
prior	O
work	O
,	O
we	O
showed	O
that	O
survivin	O
is	O
acetylated	O
by	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
,	O
which	O
restricts	O
its	O
localization	O
to	O
the	O
nuclear	O
compartment	O
and	O
thereby	O
inhibits	O
its	O
anti	O
-	O
apoptotic	O
function	O
.	O

Here	O
,	O
we	O
identify	O
histone	O
deacetylase	O
6	O
(	O
HDAC6	O
)	O
as	O
responsible	O
for	O
abrogating	O
CBP	O
-	O
mediated	O
survivin	O
acetylation	O
in	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-	O
positive	O
breast	O
cancer	O
cell	O
line	O
,	O
MCF	O
-	O
7	O
.	O

HDAC6	O
directly	O
binds	O
survivin	O
,	O
an	O
interaction	O
that	O
is	O
enhanced	O
by	O
CBP	O
.	O

In	O
quiescent	O
breast	O
cancer	O
cells	O
in	O
culture	O
and	O
in	O
malignant	O
tissue	O
sections	O
from	O
ER	O
+	O
breast	O
tumors	O
,	O
HDAC6	O
localizes	O
to	O
a	O
perinuclear	O
region	O
of	O
the	O
cell	O
,	O
undergoing	O
transport	O
to	O
the	O
nucleus	O
following	O
CBP	O
activation	O
where	O
it	O
then	O
deacetylates	O
survivin	O
.	O

Genetically	O
modified	O
mouse	O
embryonic	O
fibroblasts	O
that	O
lack	O
mhdac6	O
localize	O
survivin	O
predominantly	O
to	O
the	O
nuclear	O
compartment	O
,	O
whereas	O
wild	O
-	O
type	O
mouse	O
embryonic	O
fibroblasts	O
localize	O
survivin	O
to	O
distinct	O
cytoplasmic	O
structures	O
.	O

Together	O
,	O
these	O
data	O
imply	O
that	O
HDAC6	O
deacetylates	O
survivin	O
to	O
regulate	O
its	O
nuclear	O
export	O
,	O
a	O
feature	O
that	O
may	O
provide	O
a	O
novel	O
target	O
for	O
patients	O
with	O
ER	O
+	O
breast	O
cancer	O
.	O

Identification	O
of	O
ubiquitin	O
-	O
specific	O
protease	O
9X	O
(	O
USP9X	O
)	O
as	O
a	O
deubiquitinase	O
acting	O
on	O
ubiquitin	O
-	O
peroxin	O
5	O
(	O
PEX5	O
)	O
thioester	O
conjugate	O
.	O

Peroxin	O
5	O
(	O
PEX5	O
)	O
,	O
the	O
peroxisomal	O
protein	O
shuttling	O
receptor	O
,	O
binds	O
newly	O
synthesized	O
peroxisomal	O
matrix	O
proteins	O
in	O
the	O
cytosol	O
and	O
promotes	O
their	O
translocation	O
across	O
the	O
organelle	O
membrane	O
.	O

During	O
the	O
translocation	O
step	O
,	O
PEX5	O
itself	O
becomes	O
inserted	O
into	O
the	O
peroxisomal	O
docking	O
/	O
translocation	O
machinery	O
.	O

PEX5	O
is	O
then	O
monoubiquitinated	O
at	O
a	O
conserved	O
cysteine	O
residue	O
and	O
extracted	O
back	O
into	O
the	O
cytosol	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
ubiquitin	O
-	O
PEX5	O
thioester	O
conjugate	O
(	O
Ub	O
-	O
PEX5	O
)	O
released	O
into	O
the	O
cytosol	O
can	O
be	O
efficiently	O
disrupted	O
by	O
physiological	O
concentrations	O
of	O
glutathione	O
,	O
raising	O
the	O
possibility	O
that	O
a	O
fraction	O
of	O
Ub	O
-	O
PEX5	O
is	O
nonenzymatically	O
deubiquitinated	O
in	O
vivo	O
.	O

However	O
,	O
data	O
suggesting	O
that	O
Ub	O
-	O
PEX5	O
is	O
also	O
a	O
target	O
of	O
a	O
deubiquitinase	O
were	O
also	O
obtained	O
in	O
that	O
work	O
.	O

Here	O
,	O
we	O
used	O
an	O
unbiased	O
biochemical	O
approach	O
to	O
identify	O
this	O
enzyme	O
.	O

Our	O
results	O
suggest	O
that	O
ubiquitin	O
-	O
specific	O
protease	O
9X	O
(	O
USP9X	O
)	O
is	O
by	O
far	O
the	O
most	O
active	O
deubiquitinase	O
acting	O
on	O
Ub	O
-	O
PEX5	O
,	O
both	O
in	O
female	O
rat	O
liver	O
and	O
HeLa	O
cells	O
.	O

We	O
also	O
show	O
that	O
USP9X	O
is	O
an	O
elongated	O
monomeric	O
protein	O
with	O
the	O
capacity	O
to	O
hydrolyze	O
thioester	O
,	O
isopeptide	O
,	O
and	O
peptide	O
bonds	O
.	O

The	O
strategy	O
described	O
here	O
will	O
be	O
useful	O
in	O
identifying	O
deubiquitinases	O
acting	O
on	O
other	O
ubiquitin	O
conjugates	O
.	O

The	O
role	O
of	O
the	O
Snf1	O
kinase	O
in	O
the	O
adaptive	O
response	O
of	O
Saccharomyces	O
cerevisiae	O
to	O
alkaline	O
pH	O
stress	O
.	O

Alkaline	O
pH	O
stress	O
invokes	O
a	O
potent	O
and	O
fast	O
transcriptional	O
response	O
in	O
Saccharomyces	O
cerevisiae	O
that	O
includes	O
many	O
genes	O
repressed	O
by	O
glucose	O
.	O

Certain	O
mutants	O
in	O
the	O
glucose	O
-	O
sensing	O
and	O
-	O
response	O
pathways	O
,	O
such	O
as	O
those	O
lacking	O
the	O
Snf1	O
kinase	O
,	O
are	O
sensitive	O
to	O
alkalinization	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
addition	O
of	O
glucose	O
to	O
the	O
medium	O
improves	O
the	O
growth	O
of	O
wild	O
-	O
type	O
cells	O
at	O
high	O
pH	O
,	O
fully	O
abolishes	O
the	O
snf1	O
alkali	O
-	O
sensitive	O
phenotype	O
and	O
attenuates	O
high	O
pH	O
-	O
induced	O
Snf1	O
phosphorylation	O
at	O
Thr	O
(	O
210	O
)	O
.	O

Lack	O
of	O
Elm1	O
,	O
one	O
of	O
the	O
three	O
upstream	O
Snf1	O
kinases	O
(	O
Tos3	O
,	O
Elm1	O
and	O
Sak1	O
)	O
,	O
markedly	O
increases	O
alkali	O
sensitivity	O
,	O
whereas	O
the	O
phenotype	O
of	O
the	O
triple	O
mutant	O
tos3	O
elm1	O
sak1	O
is	O
even	O
more	O
pronounced	O
than	O
that	O
of	O
snf1	O
cells	O
and	O
is	O
poorly	O
rescued	O
by	O
glucose	O
supplementation	O
.	O

DNA	O
microarray	O
analysis	O
reveals	O
that	O
about	O
75	O
%	O
of	O
the	O
genes	O
induced	O
in	O
the	O
short	O
term	O
by	O
high	O
pH	O
are	O
also	O
induced	O
by	O
glucose	O
scarcity	O
.	O

Snf1	O
mediates	O
,	O
in	O
full	O
or	O
in	O
part	O
,	O
the	O
activation	O
of	O
a	O
significant	O
subset	O
(	O
38	O
%	O
)	O
of	O
short	O
-	O
term	O
alkali	O
-	O
induced	O
genes	O
,	O
including	O
those	O
encoding	O
high	O
-	O
affinity	O
hexose	O
transporters	O
and	O
phosphorylating	O
enzymes	O
.	O

The	O
induction	O
of	O
genes	O
encoding	O
enzymes	O
involved	O
in	O
glycogen	O
,	O
but	O
not	O
trehalose	O
,	O
metabolism	O
is	O
largely	O
dependent	O
of	O
the	O
presence	O
of	O
Snf1	O
.	O

Therefore	O
the	O
function	O
of	O
Snf1	O
in	O
adaptation	O
to	O
glucose	O
scarcity	O
appears	O
crucial	O
for	O
alkaline	O
pH	O
tolerance	O
.	O

Incorporation	O
of	O
micromolar	O
amounts	O
of	O
iron	O
and	O
copper	O
to	O
a	O
glucose	O
-	O
supplemented	O
medium	O
resulted	O
in	O
an	O
additive	O
effect	O
and	O
allows	O
near	O
-	O
normal	O
growth	O
at	O
high	O
pH	O
,	O
thus	O
indicating	O
that	O
these	O
three	O
nutrients	O
are	O
key	O
limiting	O
factors	O
for	O
growth	O
in	O
an	O
alkaline	O
environment	O
.	O

Evidence	O
for	O
a	O
non	O
-	O
myristoylated	O
pool	O
of	O
the	O
80	O
kDa	O
protein	O
kinase	O
C	O
substrate	O
of	O
rat	O
brain	O
.	O

A	O
protein	O
of	O
80	O
kDa	O
apparent	O
molecular	O
mass	O
was	O
found	O
to	O
be	O
specifically	O
myristolylated	O
in	O
rat	O
brain	O
cytosols	O
derived	O
from	O
either	O
whole	O
brain	O
or	O
synaptosomes	O
.	O

The	O
attachment	O
of	O
the	O
fatty	O
acid	O
took	O
place	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
,	O
since	O
the	O
cytosols	O
did	O
not	O
incorporate	O
[	O
14C	O
]	O
lysine	O
into	O
protein	O
,	O
nor	O
did	O
cycloheximide	O
affect	O
the	O
incorporation	O
of	O
the	O
myristic	O
acid	O
into	O
the	O
protein	O
.	O

The	O
fatty	O
acid	O
was	O
incorporated	O
into	O
the	O
protein	O
via	O
an	O
acid	O
-	O
labile	O
/	O
alkali	O
-	O
resistant	O
band	O
,	O
and	O
Pronase	O
digestion	O
of	O
the	O
labelled	O
protein	O
showed	O
that	O
the	O
lipid	O
was	O
covalently	O
linked	O
to	O
a	O
glycine	O
residue	O
.	O

Together	O
,	O
these	O
data	O
suggested	O
that	O
the	O
myristic	O
acid	O
was	O
amide	O
-	O
linked	O
to	O
the	O
N	O
-	O
terminal	O
residue	O
of	O
the	O
protein	O
.	O

The	O
protein	O
was	O
identified	O
as	O
one	O
of	O
the	O
major	O
protein	O
kinase	O
C	O
substrates	O
,	O
the	O
MARCKS	O
(	O
myristoylated	O
alanine	O
-	O
rich	O
C	O
kinase	O
substrate	O
)	O
protein	O
,	O
by	O
showing	O
that	O
Ca2	O
+	O
stimulated	O
its	O
phosphorylation	O
,	O
by	O
its	O
heat	O
stability	O
and	O
by	O
immune	O
precipitation	O
(	O
using	O
an	O
antiserum	O
to	O
the	O
MARCKS	O
protein	O
)	O
.	O

Incorporation	O
of	O
myristic	O
acid	O
into	O
intact	O
protein	O
continued	O
for	O
up	O
to	O
12	O
h	O
,	O
despite	O
the	O
fact	O
that	O
over	O
this	O
period	O
some	O
degradation	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
.	O

In	O
pulse	O
-	O
chase	O
experiments	O
,	O
the	O
pattern	O
of	O
loss	O
of	O
the	O
incorporated	O
fatty	O
acid	O
was	O
similar	O
to	O
that	O
of	O
the	O
protein	O
itself	O
,	O
and	O
therefore	O
the	O
loss	O
of	O
radioactivity	O
probably	O
reflects	O
protein	O
degradation	O
rather	O
than	O
specific	O
de	O
-	O
acylation	O
of	O
the	O
protein	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
a	O
pool	O
of	O
unacylated	O
MARCKS	O
protein	O
in	O
the	O
rat	O
brain	O
.	O

Lipid	O
transport	O
in	O
blood	O
is	O
accomplished	O
by	O
lipoproteins	O
,	O
nanometer	O
-	O
scale	O
emulsions	O
of	O
lipid	O
and	O
protein	O
that	O
solve	O
the	O
fundamental	O
oil	O
-	O
in	O
-	O
water	O
solubility	O
problem	O
.	O

One	O
lipoprotein	O
class	O
,	O
high	B-Complex
-	I-Complex
density	I-Complex
lipoproteins	I-Complex
(	O
HDL	B-Complex
)	O
,	O
has	O
been	O
intensively	O
studied	O
due	O
to	O
its	O
association	O
with	O
various	O
cardioprotective	O
functions	O
(	O
recently	O
reviewed	O
in	O
)	O
.	O

HDL	B-Complex
proteins	O
,	O
called	O
apolipoproteins	O
,	O
include	O
(	O
apo	O
)	O
A	O
-	O
I	O
,	O
apoA	O
-	O
II	O
,	O
apoA	O
-	O
IV	O
,	O
and	O
many	O
less	O
abundant	O
species	O
(	O
;	O
;	O
)	O
.	O

Many	O
of	O
these	O
can	O
interconvert	O
between	O
a	O
soluble	O
lipid	O
-	O
free	O
state	O
and	O
the	O
lipid	O
-	O
bound	O
form	O
,	O
with	O
the	O
lipid	O
-	O
free	O
form	O
able	O
to	O
interact	O
with	O
the	O
cell	O
surface	O
ATP	O
binding	O
cassette	O
transporter	O
(	O
ABCA1	O
)	O
to	O
produce	O
HDL	B-Complex
particles	O
.	O

Unfortunately	O
,	O
the	O
details	O
of	O
this	O
process	O
are	O
poorly	O
understood	O
,	O
largely	O
because	O
the	O
basic	O
structures	O
of	O
both	O
the	O
lipid	O
-	O
free	O
and	O
-	O
bound	O
forms	O
of	O
most	O
HDL	B-Complex
apolipoproteins	O
have	O
not	O
been	O
clearly	O
determined	O
.	O

The	O
transparency	O
of	O
the	O
eye	O
lens	O
depends	O
upon	O
maintenance	O
of	O
the	O
native	O
state	O
of	O
the	O
Gamma	O
-	O
and	O
Beta	O
-	O
crystallins	O
,	O
which	O
is	O
aided	O
by	O
the	O
abundant	O
chaperones	O
AlfaA	O
-	O
and	O
AlfaB	O
-	O
crystallin	O
.	O

Mature	O
onset	O
cataract	O
,	O
the	O
leading	O
cause	O
of	O
blindness	O
worldwide	O
,	O
involves	O
the	O
polymerization	O
of	O
covalently	O
damaged	O
or	O
partially	O
unfolded	O
crystallins	O
into	O
light	O
-	O
scattering	O
aggregates	O
.	O

A	O
number	O
of	O
single	O
amino	O
acid	O
substitutions	O
and	O
truncations	O
of	O
Gamma	O
-	O
crystallins	O
result	O
in	O
congenital	O
cataract	O
in	O
both	O
humans	O
and	O
mice	O
,	O
though	O
in	O
many	O
cases	O
the	O
coupling	O
between	O
the	O
protein	O
alterations	O
and	O
the	O
accumulation	O
of	O
aggregates	O
is	O
poorly	O
defined	O
.	O

We	O
have	O
studied	O
the	O
aggregation	O
properties	O
and	O
chaperone	O
interactions	O
of	O
human	O
GammaD	O
-	O
crystallin	O
carrying	O
substitutions	O
of	O
two	O
buried	O
core	O
mutants	O
,	O
I90F	O
and	O
V75D	O
,	O
which	O
cause	O
congenital	O
cataract	O
in	O
mice	O
.	O

The	O
in	O
vitro	O
aggregation	O
pathway	O
competing	O
with	O
productive	O
refolding	O
was	O
not	O
altered	O
by	O
either	O
substitution	O
.	O

Furthermore	O
,	O
this	O
aggregation	O
pathway	O
for	O
both	O
mutant	O
proteins	O
-	O
-	O
originating	O
from	O
a	O
partially	O
folded	O
intermediate	O
-	O
-	O
was	O
efficiently	O
suppressed	O
by	O
AlfaB	O
-	O
crystallin	O
.	O

Thus	O
the	O
cataract	O
pathology	O
was	O
unlikely	O
to	O
be	O
associated	O
with	O
a	O
direct	O
folding	O
defect	O
.	O

The	O
native	O
state	O
of	O
wild	O
-	O
type	O
human	O
GammaD	O
-	O
crystallin	O
exhibited	O
no	O
tendency	O
to	O
aggregate	O
under	O
physiological	O
conditions	O
.	O

However	O
both	O
I90F	O
and	O
V75D	O
native	O
-	O
like	O
proteins	O
exhibited	O
slow	O
(	O
days	O
)	O
aggregation	O
to	O
high	O
molecular	O
weight	O
aggregates	O
under	O
physiological	O
conditions	O
.	O

The	O
perturbed	O
conformation	O
of	O
I90F	O
was	O
recognized	O
and	O
bound	O
by	O
both	O
AlfaA	O
and	O
AlfaB	O
chaperones	O
.	O

In	O
contrast	O
,	O
the	O
aggregation	O
derived	O
from	O
the	O
perturbed	O
state	O
of	O
V75D	O
was	O
not	O
suppressed	O
by	O
either	O
chaperone	O
,	O
and	O
the	O
aggregating	O
species	O
were	O
not	O
bound	O
by	O
the	O
chaperone	O
.	O

The	O
cataract	O
phenotype	O
of	O
I90F	O
in	O
mice	O
may	O
be	O
due	O
to	O
premature	O
saturation	O
of	O
the	O
finite	O
Alfa	O
-	O
crystallin	O
pool	O
.	O

The	O
V75D	O
aggregation	O
pathway	O
and	O
its	O
escape	O
from	O
chaperone	O
surveillance	O
and	O
aggregation	O
suppression	O
can	O
account	O
for	O
the	O
congenital	O
cataract	O
pathology	O
of	O
this	O
mutant	O
.	O

Failure	O
of	O
chaperone	O
recognition	O
may	O
be	O
an	O
important	O
source	O
of	O
pathology	O
for	O
many	O
other	O
protein	O
folding	O
defects	O
.	O

Confocal	O
images	O
of	O
S2R	O
+	O
cells	O
expressing	O
DmRad9A	O
mutated	O
in	O
suspected	O
NLS	O
sequences	O
.	O

(	O
A	O
)	O
DmRad9A	O
mutated	O
at	O
position	O
287	O
-	O
289	O
(	O
NLS1	O
)	O
.	O

(	O
D	O
)	O
DmRad9A	O
mutated	O
Position	O
300	O
-	O
302	O
(	O
NLS2	O
)	O
.	O

(	O
G	O
)	O
DmRad9A	O
mutated	O
Position	O
314	O
-	O
316	O
(	O
NLS3	O
)	O
.	O

(	O
B	O
,	O
E	O
and	O
H	O
)	O
stained	O
with	O
anti	O
-	O
lamin	O
antibodies	O
,	O
which	O
mark	O
the	O
nuclear	O
membrane	O
,	O
in	O
red	O
.	O

(	O
C	O
)	O
Merged	O
image	O
of	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
.	O

(	O
F	O
)	O
Merged	O
image	O
of	O
(	O
D	O
)	O
and	O
(	O
E	O
)	O
.	O

(	O
I	O
)	O
Merged	O
image	O
of	O
(	O
G	O
)	O
and	O
(	O
H	O
)	O
.	O

In	O
Western	O
blot	O
analysis	O
we	O
showed	O
that	O
14	O
.	O
7K	O
,	O
TNFR1	O
and	O
RIP1	O
coimmunoprecipitated	O
with	O
HA	O
-	O
tagged	O
optineurin	O
,	O
indicating	O
formation	O
of	O
a	O
protein	O
complex	O
(	O
Figure	O
1A	O
)	O
.	O

This	O
result	O
was	O
in	O
good	O
accordance	O
with	O
previous	O
studies	O
,	O
describing	O
optineurin	O
as	O
a	O
14	O
.	O
7K	O
and	O
RIP1	O
interacting	O
protein	O
.	O

Of	O
note	O
,	O
formation	O
of	O
the	O
14	O
.	O
7K	O
-	O
optineurin	O
complex	O
was	O
also	O
detectable	O
without	O
stimulation	O
while	O
recruitment	O
to	O
the	O
TNFR1	O
complex	O
and	O
ubiquitination	O
of	O
TNFR1	O
-	O
associated	O
RIP1	O
were	O
dependent	O
on	O
TNF	O
treatment	O
.	O

Interestingly	O
,	O
even	O
though	O
the	O
predicted	O
binding	O
sites	O
of	O
14	O
.	O
7K	O
and	O
RIP1	O
were	O
both	O
located	O
in	O
the	O
C	O
-	O
terminus	O
of	O
optineurin	O
,	O
14	O
.	O
7K	O
obviously	O
did	O
not	O
disturb	O
interaction	O
of	O
optineurin	O
and	O
RIP1	O
.	O

L1CAM	O
binds	O
ErbB	O
receptors	O
through	O
Ig	O
-	O
like	O
domains	O
coupling	O
cell	O
adhesion	O
and	O
neuregulin	O
signalling	O
.	O

During	O
nervous	O
system	O
development	O
different	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
mechanisms	O
operate	O
in	O
parallel	O
guiding	O
migrating	O
neurons	O
and	O
growing	O
axons	O
to	O
generate	O
complex	O
arrays	O
of	O
neural	O
circuits	O
.	O

How	O
such	O
a	O
system	O
works	O
in	O
coordination	O
is	O
not	O
well	O
understood	O
.	O

Cross	O
-	O
regulatory	O
interactions	O
between	O
different	O
signalling	O
pathways	O
and	O
redundancy	O
between	O
them	O
can	O
increase	O
precision	O
and	O
fidelity	O
of	O
guidance	O
systems	O
.	O

Immunoglobulin	O
superfamily	O
proteins	O
of	O
the	O
NCAM	O
and	O
L1	O
families	O
couple	O
specific	O
substrate	O
recognition	O
and	O
cell	O
adhesion	O
with	O
the	O
activation	O
of	O
receptor	O
tyrosine	O
kinases	O
.	O

Thus	O
it	O
has	O
been	O
shown	O
that	O
L1CAM	O
-	O
mediated	O
cell	O
adhesion	O
promotes	O
the	O
activation	O
of	O
the	O
EGFR	O
(	O
erbB1	O
)	O
from	O
Drosophila	O
to	O
humans	O
.	O

Here	O
we	O
explore	O
the	O
specificity	O
of	O
the	O
molecular	O
interaction	O
between	O
L1CAM	O
and	O
the	O
erbB	O
receptor	O
family	O
.	O

We	O
show	O
that	O
L1CAM	O
binds	O
physically	O
erbB	O
receptors	O
in	O
both	O
heterologous	O
systems	O
and	O
the	O
mammalian	O
developing	O
brain	O
.	O

Different	O
Ig	O
-	O
like	O
domains	O
located	O
in	O
the	O
extracellular	O
part	O
of	O
L1CAM	O
can	O
support	O
this	O
interaction	O
.	O

Interestingly	O
,	O
binding	O
of	O
L1CAM	O
to	O
erbB	O
enhances	O
its	O
response	O
to	O
neuregulins	O
.	O

During	O
development	O
this	O
may	O
synergize	O
with	O
the	O
activation	O
of	O
erbB	O
receptors	O
through	O
L1CAM	O
homophilic	O
interactions	O
,	O
conferring	O
diffusible	O
neuregulins	O
specificity	O
for	O
cells	O
or	O
axons	O
that	O
interact	O
with	O
the	O
substrate	O
through	O
L1CAM	O
.	O

We	O
examined	O
whether	O
BR	O
response	O
requires	O
PIFs	O
.	O

Members	O
of	O
the	O
PIF	O
family	O
play	O
overlapping	O
roles	O
in	O
promoting	O
skotomorphogenesis	O
and	O
cell	O
elongation	O
.	O

The	O
quadruple	O
mutant	O
(	O
pifq	O
)	O
lacking	O
four	O
PIFs	O
(	O
PIF1	O
/	O
PIL5	O
,	O
PIF3	O
,	O
PIF4	O
and	O
PIF5	O
/	O
PIL6	O
)	O
exhibits	O
a	O
constitutive	O
de	O
-	O
etiolation	O
phenotype	O
in	O
the	O
dark	O
,	O
characterized	O
by	O
short	O
hypocotyl	O
and	O
open	O
cotyledons	O
,	O
similar	O
to	O
the	O
BR	O
-	O
deficient	O
or	O
insensitive	O
mutants	O
.	O

The	O
pifq	O
mutant	O
was	O
less	O
sensitive	O
to	O
exogenous	O
brassinolide	O
(	O
BL	O
,	O
the	O
most	O
active	O
form	O
of	O
BR	O
)	O
and	O
more	O
sensitive	O
to	O
BR	O
biosynthesis	O
inhibitor	O
,	O
brassinazole	O
(	O
BRZ	O
)	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
,	O
suggesting	O
that	O
the	O
loss	O
of	O
PIFs	O
compromises	O
BR	O
response	O
.	O

However	O
,	O
pif4	O
single	O
mutant	O
responded	O
to	O
BRZ	O
similar	O
to	O
wild	O
type	O
(	O
Fig	O
.	O
2b	O
)	O
,	O
indicating	O
redundant	O
functions	O
of	O
PIFs	O
with	O
regard	O
to	O
BR	O
response	O
.	O

The	O
bzr1	O
-	O
1D	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
causes	O
constitutive	O
dephosphorylation	O
of	O
BZR1	O
by	O
PP2A	B-Complex
(	O
Ref	O
.	O
)	O
and	O
a	O
BRZ	O
-	O
resistant	O
phenotype	O
.	O

However	O
,	O
the	O
pifq	O
;	O
bzr1	O
-	O
1D	O
quintuple	O
mutant	O
had	O
similar	O
short	O
hypocotyl	O
as	O
pifq	O
grown	O
on	O
the	O
medium	O
with	O
or	O
without	O
BRZ	O
(	O
Fig	O
.	O
2c	O
,	O
d	O
)	O
,	O
suggesting	O
that	O
PIFs	O
are	O
required	O
for	O
the	O
BZR1	O
promotion	O
of	O
hypocotyl	O
elongation	O
in	O
the	O
dark	O
.	O

Rrp44	O
contains	O
a	O
conserved	O
CCCH	O
motif	O
.	O

(	O
A	O
)	O
Top	O
:	O
Diagram	O
depicting	O
the	O
five	O
recognized	O
domains	O
in	O
Rrp44	O
and	O
the	O
CR3	O
motif	O
.	O

PIN	O
denotes	O
the	O
endonuclease	O
domain	O
,	O
CSD1	O
and	O
CSD2	O
denote	O
RNA	O
-	O
binding	O
cold	O
shock	O
domains	O
,	O
RNB	O
denotes	O
the	O
exonuclease	O
domain	O
and	O
S1	O
denotes	O
an	O
RNA	O
-	O
binding	O
S1	O
domain	O
.	O

Collectively	O
the	O
CSD1	O
,	O
CSD2	O
,	O
RNB	O
and	O
S1	O
domains	O
are	O
responsible	O
for	O
exonuclease	O
activity	O
.	O

Bottom	O
:	O
the	O
N	O
-	O
terminus	O
of	O
Rrp44p	O
contains	O
a	O
conserved	O
CCCH	O
motif	O
(	O
black	O
letters	O
)	O
in	O
addition	O
to	O
the	O
catalytic	O
residues	O
of	O
the	O
PIN	O
domain	O
(	O
white	O
letters	O
)	O
.	O

(	O
B	O
)	O
Overview	O
of	O
the	O
Rrp44	O
structure	O
(	O
colored	O
as	O
in	O
panel	O
A	O
)	O
bound	O
to	O
exosome	B-Complex
subunits	O
Rrp41	O
and	O
Rrp45	O
(	O
PDB	O
ID	O
2WP8	B-OOS
;	O
13	O
)	O
.	O

(	O
C	O
)	O
The	O
three	O
conserved	O
Cys	O
residues	O
and	O
the	O
conserved	O
His	O
residue	O
form	O
a	O
tetrahedral	O
cluster	O
in	O
the	O
crystal	O
structure	O
.	O

Note	O
that	O
the	O
sulfur	O
atom	O
of	O
Cys47	O
was	O
not	O
modeled	O
.	O

(	O
D	O
)	O
The	O
CR3	O
motif	O
is	O
physically	O
connected	O
to	O
the	O
exosome	O
-	O
binding	O
site	O
(	O
Y40	O
,	O
R42	O
and	O
D44	O
)	O
and	O
the	O
endonuclease	O
active	O
site	O
of	O
the	O
PIN	O
domain	O
(	O
D91	O
,	O
D171	O
and	O
D198	O
)	O
.	O

Note	O
that	O
the	O
D198	O
side	O
chain	O
was	O
not	O
modeled	O
.	O

Structures	O
were	O
rendered	O
using	O
PyMOL	O
(	O
The	O
PyMOL	O
Molecular	O
Graphics	O
System	O
,	O
Version	O
1	O
.	O
5	O
.	O
0	O
.	O
1	O
Schroedinger	O
,	O
LLC	O
.	O
)	O
.	O

Mili	O
and	O
Miwi	O
target	O
RNA	O
repertoire	O
reveals	O
piRNA	O
biogenesis	O
and	O
function	O
of	O
Miwi	O
in	O
spermiogenesis	O
.	O

Germ	O
cells	O
implement	O
elaborate	O
mechanisms	O
to	O
protect	O
their	O
genetic	O
material	O
and	O
to	O
regulate	O
gene	O
expression	O
during	O
differentiation	O
.	O

Piwi	O
proteins	O
bind	O
Piwi	O
-	O
interacting	O
RNAs	O
(	O
piRNAs	O
)	O
,	O
small	O
germline	O
RNAs	O
whose	O
biogenesis	O
and	O
functions	O
are	O
still	O
largely	O
elusive	O
.	O

We	O
used	O
high	O
-	O
throughput	O
sequencing	O
after	O
cross	O
-	O
linking	O
and	O
immunoprecipitation	O
(	O
HITS	O
-	O
CLIP	O
)	O
coupled	O
with	O
RNA	O
-	O
sequencing	O
(	O
RNA	O
-	O
seq	O
)	O
to	O
characterize	O
the	O
genome	O
-	O
wide	O
target	O
RNA	O
repertoire	O
of	O
Mili	O
(	O
Piwil2	O
)	O
and	O
Miwi	O
(	O
Piwil1	O
)	O
,	O
two	O
Piwi	O
proteins	O
expressed	O
in	O
mouse	O
postnatal	O
testis	O
.	O

We	O
report	O
the	O
in	O
vivo	O
pathway	O
of	O
primary	O
piRNA	O
biogenesis	O
and	O
implicate	O
distinct	O
nucleolytic	O
activities	O
that	O
process	O
Piwi	O
-	O
bound	O
precursor	O
transcripts	O
.	O

Our	O
studies	O
indicate	O
that	O
pachytene	O
piRNAs	O
are	O
the	O
end	O
products	O
of	O
RNA	O
processing	O
.	O

HITS	O
-	O
CLIP	O
demonstrated	O
that	O
Miwi	O
binds	O
spermiogenic	O
mRNAs	O
directly	O
,	O
without	O
using	O
piRNAs	O
as	O
guides	O
,	O
and	O
independent	O
biochemical	O
analyses	O
of	O
testis	O
mRNA	O
ribonucleoproteins	O
(	O
mRNPs	O
)	O
established	O
that	O
Miwi	O
functions	O
in	O
the	O
formation	O
of	O
mRNP	O
complexes	O
that	O
stabilize	O
mRNAs	O
essential	O
for	O
spermiogenesis	O
.	O

Functional	O
dissection	O
of	O
HOXD	O
cluster	O
genes	O
in	O
regulation	O
of	O
neuroblastoma	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
can	O
induce	O
growth	O
arrest	O
and	O
neuronal	O
differentiation	O
of	O
neuroblastoma	O
cells	O
and	O
has	O
been	O
used	O
in	O
clinic	O
for	O
treatment	O
of	O
neuroblastoma	O
.	O

It	O
has	O
been	O
reported	O
that	O
RA	O
induces	O
the	O
expression	O
of	O
several	O
HOXD	O
genes	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
,	O
but	O
their	O
roles	O
in	O
RA	O
action	O
are	O
largely	O
unknown	O
.	O

The	O
HOXD	O
cluster	O
contains	O
nine	O
genes	O
(	O
HOXD1	O
,	O
HOXD3	O
,	O
HOXD4	O
,	O
and	O
HOXD8	O
-	O
13	O
)	O
that	O
are	O
positioned	O
sequentially	O
from	O
3	O
'	O
to	O
5	O
'	O
,	O
with	O
HOXD1	O
at	O
the	O
3	O
'	O
end	O
and	O
HOXD13	O
the	O
5	O
'	O
end	O
.	O

Here	O
we	O
show	O
that	O
all	O
HOXD	O
genes	O
are	O
induced	O
by	O
RA	O
in	O
the	O
human	O
neuroblastoma	O
BE	O
(	O
2	O
)	O
-	O
C	O
cells	O
,	O
with	O
the	O
genes	O
located	O
at	O
the	O
3	O
'	O
end	O
being	O
activated	O
generally	O
earlier	O
than	O
those	O
positioned	O
more	O
5	O
'	O
within	O
the	O
cluster	O
.	O

Individual	O
induction	O
of	O
HOXD8	O
,	O
HOXD9	O
,	O
HOXD10	O
or	O
HOXD12	O
is	O
sufficient	O
to	O
induce	O
both	O
growth	O
arrest	O
and	O
neuronal	O
differentiation	O
,	O
which	O
is	O
associated	O
with	O
downregulation	O
of	O
cell	O
cycle	O
-	O
promoting	O
genes	O
and	O
upregulation	O
of	O
neuronal	O
differentiation	O
genes	O
.	O

However	O
,	O
induction	O
of	O
other	O
HOXD	O
genes	O
either	O
has	O
no	O
effect	O
(	O
HOXD1	O
)	O
or	O
has	O
partial	O
effects	O
(	O
HOXD3	O
,	O
HOXD4	O
,	O
HOXD11	O
and	O
HOXD13	O
)	O
on	O
BE	O
(	O
2	O
)	O
-	O
C	O
cell	O
proliferation	O
or	O
differentiation	O
.	O

We	O
further	O
show	O
that	O
knockdown	O
of	O
HOXD8	O
expression	O
,	O
but	O
not	O
that	O
of	O
HOXD9	O
expression	O
,	O
significantly	O
inhibits	O
the	O
differentiation	O
-	O
inducing	O
activity	O
of	O
RA	O
.	O

HOXD8	O
directly	O
activates	O
the	O
transcription	O
of	O
HOXC9	O
,	O
a	O
key	O
effector	O
of	O
RA	O
action	O
in	O
neuroblastoma	O
cells	O
.	O

These	O
findings	O
highlight	O
the	O
distinct	O
functions	O
of	O
HOXD	O
genes	O
in	O
RA	O
induction	O
of	O
neuroblastoma	O
cell	O
differentiation	O
.	O

The	O
filamentous	O
growth	O
MAPK	O
Pathway	O
Responds	O
to	O
Glucose	O
Starvation	O
Through	O
the	O
Mig1	O
/	O
2	O
transcriptional	O
repressors	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
the	O
budding	O
yeast	O
S	O
.	O
cerevisiae	O
,	O
nutrient	O
limitation	O
induces	O
a	O
MAPK	O
pathway	O
that	O
regulates	O
filamentous	O
growth	O
and	O
biofilm	O
/	O
mat	O
formation	O
.	O

How	O
nutrient	O
levels	O
feed	O
into	O
the	O
regulation	O
of	O
the	O
filamentous	O
growth	O
pathway	O
is	O
not	O
entirely	O
clear	O
.	O

We	O
characterized	O
a	O
newly	O
identified	O
MAPK	O
regulatory	O
protein	O
of	O
the	O
filamentous	O
growth	O
pathway	O
,	O
Opy2	O
.	O

A	O
two	O
-	O
hybrid	O
screen	O
with	O
the	O
cytosolic	O
domain	O
of	O
Opy2	O
uncovered	O
new	O
interacting	O
partners	O
including	O
a	O
transcriptional	O
repressor	O
that	O
functions	O
in	O
the	O
AMPK	B-Complex
pathway	O
,	O
Mig1	O
,	O
and	O
its	O
close	O
functional	O
homolog	O
,	O
Mig2	O
.	O

Mig1	O
and	O
Mig2	O
coregulated	O
the	O
filamentous	O
growth	O
pathway	O
in	O
response	O
to	O
glucose	O
limitation	O
,	O
as	O
did	O
the	O
AMP	B-Complex
kinase	I-Complex
Snf1	O
.	O

In	O
addition	O
to	O
associating	O
with	O
Opy2	O
,	O
Mig1	O
and	O
Mig2	O
interacted	O
with	O
other	O
regulators	O
of	O
the	O
filamentous	O
growth	O
pathway	O
including	O
the	O
cytosolic	O
domain	O
of	O
the	O
signaling	O
mucin	O
Msb2	O
,	O
the	O
MAP	O
kinase	O
kinase	O
Ste7	O
,	O
and	O
the	O
MAP	O
kinase	O
Kss1	O
.	O

As	O
for	O
Opy2	O
,	O
Mig1	O
overproduction	O
dampened	O
the	O
pheromone	O
response	O
pathway	O
,	O
which	O
implicates	O
Mig1	O
and	O
Opy2	O
as	O
potential	O
regulators	O
of	O
pathway	O
specificity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
provide	O
the	O
first	O
regulatory	O
link	O
in	O
yeast	O
between	O
components	O
of	O
the	O
AMPK	B-Complex
pathway	O
and	O
a	O
MAPK	O
pathway	O
that	O
controls	O
cellular	O
differentiation	O
.	O

The	O
C	O
-	O
terminal	O
TGS	O
domain	O
(	O
294	O
-	O
369	O
)	O
has	O
predominantly	O
beta	O
sheet	O
structure	O
with	O
five	O
beta	O
strands	O
(	O
beta12	O
-	O
beta16	O
)	O
and	O
two	O
helices	O
,	O
alpha10	O
and	O
alpha11	O
(	O
Figure	O
1	O
)	O
.	O

Superimposition	O
of	O
the	O
Rbg1	O
TGS	O
domain	O
with	O
the	O
previously	O
reported	O
NMR	O
solution	O
structure	O
of	O
human	O
Drg1	O
TGS	O
domain	O
(	O
PDB	O
ID	O
2EKI	O
)	O
gave	O
an	O
RMSD	O
of	O
1	O
.	O
31	O
Aa	O
over	O
76	O
Calpha	O
atoms	O
.	O

The	O
TGS	O
domain	O
was	O
found	O
to	O
be	O
structurally	O
very	O
similar	O
to	O
threonyl	O
tRNA	O
synthetase	O
,	O
YchF	O
and	O
hOLA1	O
TGS	O
domains	O
and	O
ubiquitin	O
.	O

The	O
p23	O
molecular	O
chaperone	O
and	O
GCN5	O
acetylase	O
jointly	O
modulate	O
protein	O
-	O
DNA	O
dynamics	O
and	O
open	O
chromatin	O
status	O
.	O

Cellular	O
processes	O
function	O
through	O
multistep	O
pathways	O
that	O
are	O
reliant	O
on	O
the	O
controlled	O
association	O
and	O
disassociation	O
of	O
sequential	O
protein	O
complexes	O
.	O

While	O
dynamic	O
action	O
is	O
critical	O
to	O
propagate	O
and	O
terminate	O
work	O
,	O
the	O
mechanisms	O
used	O
to	O
disassemble	O
biological	O
structures	O
are	O
not	O
fully	O
understood	O
.	O

Here	O
we	O
show	O
that	O
the	O
p23	O
molecular	O
chaperone	O
initiates	O
disassembly	O
of	O
protein	O
-	O
DNA	O
complexes	O
and	O
that	O
the	O
GCN5	O
acetyltransferase	O
prolongs	O
the	O
dissociated	O
state	O
through	O
lysine	O
acetylation	O
.	O

By	O
modulating	O
the	O
DNA	O
-	O
bound	O
state	O
,	O
we	O
found	O
that	O
the	O
conserved	O
and	O
essential	O
joint	O
activities	O
of	O
p23	O
and	O
GCN5	O
impacted	O
transcription	O
factor	O
activation	O
potential	O
and	O
response	O
time	O
to	O
an	O
environmental	O
cue	O
.	O

Notably	O
,	O
p23	O
and	O
GCN5	O
were	O
required	O
to	O
maintain	O
open	O
chromatin	O
regions	O
along	O
the	O
genome	O
,	O
indicating	O
that	O
dynamic	O
protein	O
behavior	O
is	O
a	O
critical	O
feature	O
of	O
various	O
DNA	O
-	O
associated	O
events	O
.	O

Our	O
data	O
support	O
a	O
model	O
in	O
which	O
p23	O
and	O
GCN5	O
regulate	O
diverse	O
multistep	O
pathways	O
by	O
controlling	O
the	O
longevity	O
of	O
protein	O
-	O
DNA	O
complexes	O
.	O

An	O
interaction	O
between	O
BZR1	O
and	O
DELLAs	O
mediates	O
direct	O
signaling	O
crosstalk	O
between	O
brassinosteroids	O
and	O
gibberellins	O
in	O
Arabidopsis	O
.	O

Plant	O
growth	O
and	O
development	O
are	O
coordinated	O
by	O
several	O
groups	O
of	O
small	O
-	O
molecule	O
hormones	O
,	O
including	O
brassinosteroids	O
(	O
BRs	O
)	O
and	O
gibberellins	O
(	O
GAs	O
)	O
.	O

Physiological	O
and	O
molecular	O
studies	O
have	O
suggested	O
the	O
existence	O
of	O
crosstalk	O
between	O
BR	O
and	O
GA	O
signaling	O
.	O

We	O
report	O
that	O
BZR1	O
,	O
a	O
key	O
transcription	O
factor	O
activated	O
by	O
BR	O
signaling	O
,	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
REPRESSOR	O
OF	O
ga1	O
-	O
3	O
(	O
RGA	O
)	O
,	O
a	O
member	O
of	O
the	O
DELLA	O
family	O
of	O
transcriptional	O
regulators	O
that	O
inhibits	O
the	O
GA	O
signaling	O
pathway	O
in	O
Arabidopsis	O
thaliana	O
.	O

Genetic	O
analyses	O
of	O
plants	O
with	O
mutations	O
in	O
the	O
genes	O
encoding	O
RGA	O
and	O
BZR1	O
revealed	O
that	O
RGA	O
suppressed	O
root	O
and	O
hypocotyl	O
elongation	O
of	O
the	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
bzr1	O
-	O
1D	O
.	O

Ectopic	O
expression	O
of	O
proteins	O
of	O
the	O
DELLA	O
family	O
reduced	O
the	O
abundance	O
and	O
transcriptional	O
activity	O
of	O
BZR1	O
.	O

Reporter	O
gene	O
analyses	O
further	O
indicated	O
that	O
BZR1	O
and	O
RGA	O
antagonize	O
each	O
other	O
'	O
s	O
transcriptional	O
activity	O
.	O

Our	O
data	O
indicated	O
that	O
BZR1	O
and	O
RGA	O
served	O
as	O
positive	O
and	O
negative	O
regulators	O
,	O
respectively	O
,	O
of	O
both	O
the	O
BR	O
and	O
the	O
GA	O
signaling	O
pathways	O
and	O
establish	O
DELLAs	O
as	O
mediators	O
of	O
signaling	O
crosstalk	O
between	O
BRs	O
and	O
GAs	O
in	O
controlling	O
cell	O
elongation	O
and	O
regulation	O
of	O
plant	O
growth	O
.	O

To	O
analyze	O
the	O
generated	O
GFP	O
-	O
WIPI	O
-	O
1	O
mutants	O
in	O
their	O
ability	O
to	O
bind	O
PtdIns	O
(	O
3	O
)	O
P	O
and	O
PtdIns	O
(	O
3	O
,	O
5	O
)	O
P2	O
,	O
we	O
first	O
confirmed	O
that	O
over	O
-	O
expressed	O
wild	O
-	O
type	O
GFP	O
-	O
WIPI	O
-	O
1	O
in	O
different	O
cell	O
lines	O
that	O
either	O
express	O
detectable	O
(	O
G361	O
)	O
or	O
undetectable	O
(	O
HeLa	O
,	O
U2OS	O
)	O
levels	O
of	O
endogenous	O
WIPI	O
-	O
1	O
protein	O
(	O
Figure	O
6A	O
)	O
,	O
predominantly	O
binds	O
PtdIns	O
(	O
3	O
)	O
P	O
and	O
to	O
a	O
minor	O
extend	O
PtdIns	O
(	O
3	O
,	O
5	O
)	O
P2	O
(	O
Figure	O
6B	O
and	O
6C	O
upper	O
panel	O
)	O
.	O

As	O
expected	O
,	O
the	O
RR	O
mutant	O
(	O
R226A	O
/	O
R227A	O
)	O
did	O
not	O
bind	O
to	O
either	O
of	O
the	O
phospholipids	O
(	O
Figure	O
6C	O
lower	O
panel	O
)	O
.	O

Aspergillus	O
fumigatus	O
strain	O
CBS	O
144	O
.	O
89	O
(	O
Centraalbureau	O
voor	O
Schimmelcultures	O
,	O
Utrecht	O
,	O
the	O
Netherlands	O
)	O
was	O
the	O
parental	O
strain	O
in	O
all	O
experiments	O
.	O

For	O
gene	O
deletions	O
a	O
derivative	O
with	O
deleted	O
akuB	O
gene	O
was	O
used	O
that	O
shows	O
increased	O
frequency	O
of	O
homologous	O
recombination	O
(	O
da	O
Silva	O
Ferreira	O
et	O
al	O
.	O
,	O
)	O
.	O

A	O
.	O
fumigatus	O
was	O
cultivated	O
at	O
37degreesC	O
and	O
liquid	O
cultures	O
were	O
shaken	O
at	O
200	O
r	O
.	O
p	O
.	O
m	O
.	O

Growth	O
media	O
were	O
based	O
on	O
the	O
Aspergillus	O
minimal	O
medium	O
(	O
AMM	O
)	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
fgsc	O
.	O
net	O
/	O
methods	O
/	O
anidmed	O
.	O
html	O
)	O
with	O
addition	O
of	O
50	O
mM	O
glucose	O
or	O
100	O
mM	O
ethanol	O
.	O

When	O
required	O
,	O
5	O
mM	O
lysine	O
was	O
added	O
to	O
growth	O
media	O
.	O

Media	O
were	O
inoculated	O
with	O
conidia	O
suspensions	O
.	O

These	O
suspensions	O
derived	O
from	O
cultures	O
grown	O
for	O
at	O
least	O
48	O
h	O
at	O
37degreesC	O
on	O
AMM	O
glucose	O
agar	O
plates	O
.	O

Conidia	O
were	O
harvested	O
in	O
sterile	O
water	O
and	O
hyphal	O
elements	O
and	O
clumps	O
were	O
removed	O
by	O
filtration	O
over	O
a	O
40	O
mum	O
cell	O
strainer	O
(	O
BD	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

A	O
.	O
nidulans	O
strain	O
FGSCA4	O
(	O
Fungal	O
genetic	O
stock	O
centre	O
,	O
Kansas	O
,	O
USA	O
)	O
served	O
for	O
isolation	O
of	O
genomic	O
DNA	O
and	O
RNA	O
and	O
was	O
cultivated	O
identical	O
to	O
A	O
.	O
fumigatus	O
in	O
AMM	O
with	O
glucose	O
.	O

The	O
A	O
.	O
fumigatus	O
transformant	O
expressing	O
the	O
aconitase	O
acoA	O
under	O
control	O
of	O
the	O
xylP	O
promoter	O
from	O
P	O
.	O
chrysogenum	O
was	O
maintained	O
on	O
50	O
mM	O
xylose	O
containing	O
minimal	O
medium	O
.	O

Carbon	O
shift	O
experiments	O
were	O
performed	O
by	O
incubating	O
A	O
.	O
fumigatus	O
strains	O
for	O
24	O
h	O
at	O
37degreesC	O
and	O
200	O
r	O
.	O
p	O
.	O
m	O
.	O
shaking	O
on	O
50	O
mM	O
xylose	O
liquid	O
medium	O
.	O

Subsequently	O
,	O
mycelium	O
was	O
harvested	O
over	O
sterile	O
miracloth	O
(	O
Merck	O
/	O
Calbiochem	O
,	O
Schwalbach	O
/	O
Ts	O
.	O
Germany	O
)	O
extensively	O
washed	O
with	O
phosphate	O
-	O
buffered	O
saline	O
and	O
transferred	O
to	O
fresh	O
glucose	O
or	O
xylose	O
-	O
containing	O
media	O
.	O

L1CAM	O
stimulates	O
glioma	O
cell	O
motility	O
and	O
proliferation	O
through	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
.	O

The	O
L1CAM	O
cell	O
adhesion	O
/	O
recognition	O
molecule	O
(	O
L1	O
,	O
CD171	O
)	O
and	O
fibroblast	O
growth	O
factor	O
receptor	O
(	O
FGFR	O
)	O
both	O
are	O
expressed	O
by	O
human	O
high	O
-	O
grade	O
glioma	O
cells	O
,	O
but	O
their	O
potential	O
actions	O
in	O
controlling	O
cell	O
behavior	O
have	O
not	O
been	O
linked	O
.	O

L1	O
actions	O
in	O
cancer	O
cells	O
have	O
been	O
attributed	O
mainly	O
to	O
integrin	O
receptors	O
,	O
and	O
we	O
demonstrated	O
previously	O
that	O
L1	O
-	O
stimulated	O
glioma	O
cell	O
migration	O
correlates	O
with	O
integrin	O
expression	O
,	O
increased	O
focal	O
adhesion	O
kinase	O
activation	O
and	O
focal	O
complex	O
turnover	O
.	O

Our	O
analyses	O
of	O
datasets	O
revealed	O
FGFR	O
is	O
overexpressed	O
in	O
glioma	O
regardless	O
of	O
grade	O
,	O
while	O
ADAM10	O
metalloprotease	O
expression	O
increases	O
with	O
glioma	O
grade	O
.	O

Here	O
,	O
we	O
used	O
dominant	O
-	O
negative	O
and	O
short	O
hairpin	O
RNA	O
approaches	O
to	O
inhibit	O
the	O
activation	O
of	O
FGFR1	O
and	O
expression	O
of	O
L1	O
,	O
respectively	O
.	O

An	O
L1	O
peptide	O
that	O
inhibits	O
L1	O
-	O
FGFR	O
interaction	O
and	O
PD173074	O
,	O
a	O
chemical	O
inhibitor	O
of	O
FGFR1	O
activity	O
,	O
also	O
were	O
used	O
to	O
elucidate	O
the	O
involvement	O
of	O
L1	O
-	O
FGFR	O
interactions	O
on	O
glioma	O
cell	O
behavior	O
.	O

Time	O
-	O
lapse	O
cell	O
motility	O
studies	O
and	O
flow	O
cytometry	O
cell	O
cycle	O
analyses	O
showed	O
that	O
L1	O
operates	O
to	O
increase	O
glioma	O
cell	O
motility	O
and	O
proliferation	O
through	O
FGFR	O
activation	O
.	O

Shutdown	O
of	O
both	O
L1	O
expression	O
and	O
FGFR	O
activity	O
in	O
glioma	O
cells	O
resulted	O
in	O
a	O
complete	O
termination	O
of	O
cell	O
migration	O
in	O
vitro	O
.	O

These	O
studies	O
show	O
for	O
the	O
first	O
time	O
that	O
soluble	O
L1	O
ectodomain	O
(	O
L1LE	O
)	O
acts	O
on	O
glioma	O
cells	O
through	O
FGFRs	O
,	O
and	O
that	O
FGFRs	O
are	O
used	O
by	O
glioma	O
cells	O
for	O
increasing	O
motility	O
as	O
well	O
as	O
proliferation	O
in	O
response	O
to	O
activation	O
by	O
L1LE	O
ligand	O
.	O

Thus	O
,	O
effective	O
treatment	O
of	O
high	O
-	O
grade	O
glioma	O
may	O
require	O
simultaneous	O
targeting	O
of	O
L1	O
,	O
FGFRs	O
,	O
and	O
integrin	O
receptors	O
,	O
which	O
would	O
reduce	O
glioma	O
cell	O
motility	O
as	O
well	O
as	O
proliferation	O
.	O

FBH1	O
promotes	O
DNA	O
double	O
-	O
strand	O
breakage	O
and	O
apoptosis	O
in	O
response	O
to	O
DNA	O
replication	O
stress	O
.	O

Proper	O
resolution	O
of	O
stalled	O
replication	O
forks	O
is	O
essential	O
for	O
genome	O
stability	O
.	O

Purification	O
of	O
FBH1	O
,	O
a	O
UvrD	O
DNA	O
helicase	O
,	O
identified	O
a	O
physical	O
interaction	O
with	O
replication	O
protein	O
A	O
(	O
RPA	O
)	O
,	O
the	O
major	O
cellular	O
single	O
-	O
stranded	O
DNA	O
(	O
ssDNA	O
)	O
-	O
binding	O
protein	O
complex	O
.	O

Compared	O
with	O
control	O
cells	O
,	O
FBH1	O
-	O
depleted	O
cells	O
responded	O
to	O
replication	O
stress	O
with	O
considerably	O
fewer	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
,	O
a	O
dramatic	O
reduction	O
in	O
the	O
activation	O
of	O
ATM	O
and	O
DNA	B-OOS
-	I-OOS
PK	I-OOS
and	O
phosphorylation	O
of	O
RPA2	O
and	O
p53	O
,	O
and	O
a	O
significantly	O
increased	O
rate	O
of	O
survival	O
.	O

A	O
minor	O
decrease	O
in	O
ssDNA	O
levels	O
was	O
also	O
observed	O
.	O

All	O
these	O
phenotypes	O
were	O
rescued	O
by	O
wild	O
-	O
type	O
FBH1	O
,	O
but	O
not	O
a	O
FBH1	O
mutant	O
lacking	O
helicase	O
activity	O
.	O

FBH1	O
depletion	O
had	O
no	O
effect	O
on	O
other	O
forms	O
of	O
genotoxic	O
stress	O
in	O
which	O
DSBs	O
form	O
by	O
means	O
that	O
do	O
not	O
require	O
ssDNA	O
intermediates	O
.	O

In	O
response	O
to	O
catastrophic	O
genotoxic	O
stress	O
,	O
apoptosis	O
prevents	O
the	O
persistence	O
and	O
propagation	O
of	O
DNA	O
lesions	O
.	O

Our	O
findings	O
show	O
that	O
FBH1	O
helicase	O
activity	O
is	O
required	O
for	O
the	O
efficient	O
induction	O
of	O
DSBs	O
and	O
apoptosis	O
specifically	O
in	O
response	O
to	O
DNA	O
replication	O
stress	O
.	O

The	O
tumor	O
suppressor	O
kinase	O
LKB1	O
activates	O
the	O
downstream	O
kinases	O
SIK2	O
and	O
SIK3	O
to	O
stimulate	O
nuclear	O
export	O
of	O
class	O
IIa	O
histone	O
deacetylases	O
.	O

Histone	O
deacetylases	O
4	O
(	O
HDAC4	O
)	O
,	O
-	O
5	O
,	O
-	O
7	O
,	O
and	O
-	O
9	O
form	O
class	O
IIa	O
within	O
the	O
HDAC	O
superfamily	O
and	O
regulate	O
diverse	O
physiological	O
and	O
pathological	O
cellular	O
programs	O
.	O

With	O
conserved	O
motifs	O
for	O
phosphorylation	O
-	O
dependent	O
14	O
-	O
3	O
-	O
3	O
binding	O
,	O
these	O
deacetylases	O
serve	O
as	O
novel	O
signal	O
transducers	O
that	O
are	O
able	O
to	O
modulate	O
histone	O
acetylation	O
and	O
gene	O
expression	O
in	O
response	O
to	O
extracellular	O
cues	O
.	O

Here	O
,	O
we	O
report	O
that	O
in	O
a	O
PKA	O
-	O
sensitive	O
manner	O
the	O
tumor	O
suppressor	O
kinase	O
LKB1	O
acts	O
through	O
salt	O
-	O
inducible	O
kinase	O
2	O
(	O
SIK2	O
)	O
and	O
SIK3	O
to	O
promote	O
nucleocytoplasmic	O
trafficking	O
of	O
class	O
IIa	O
HDACs	O
.	O

Both	O
SIK2	O
and	O
SIK3	O
phosphorylate	O
the	O
deacetylases	O
at	O
the	O
conserved	O
motifs	O
and	O
stimulate	O
14	O
-	O
3	O
-	O
3	O
binding	O
.	O

SIK2	O
activates	O
MEF2	O
-	O
dependent	O
transcription	O
and	O
relieves	O
repression	O
of	O
myogenesis	O
by	O
the	O
deacetylases	O
.	O

Distinct	O
from	O
SIK2	O
,	O
SIK3	O
induces	O
nuclear	O
export	O
of	O
the	O
deacetylases	O
independent	O
of	O
kinase	O
activity	O
and	O
14	O
-	O
3	O
-	O
3	O
binding	O
.	O

These	O
findings	O
highlight	O
the	O
difference	O
among	O
members	O
of	O
the	O
SIK	O
family	O
and	O
indicate	O
that	O
LKB1	O
-	O
dependent	O
SIK	O
activation	O
constitutes	O
an	O
important	O
signaling	O
module	O
upstream	O
from	O
class	O
IIa	O
deacetylases	O
for	O
regulating	O
cellular	O
programs	O
controlled	O
by	O
MEF2	O
and	O
other	O
transcription	O
factors	O
.	O

Pathogenic	O
NPHP5	O
mutations	O
impair	O
protein	O
interaction	O
with	O
Cep290	O
,	O
a	O
prerequisite	O
for	O
ciliogenesis	O
.	O

Mutations	O
in	O
the	O
human	O
NPHP5	O
gene	O
cause	O
retinal	O
and	O
renal	O
disease	O
,	O
but	O
the	O
precise	O
mechanism	O
by	O
which	O
NPHP5	O
functions	O
is	O
not	O
understood	O
.	O

We	O
report	O
that	O
NPHP5	O
is	O
a	O
centriolar	O
protein	O
whose	O
depletion	O
inhibits	O
an	O
early	O
step	O
of	O
ciliogenesis	O
,	O
a	O
phenotype	O
reminiscent	O
of	O
Cep290	O
loss	O
and	O
contrary	O
to	O
IFT88	O
loss	O
.	O

Functional	O
dissection	O
of	O
NPHP5	O
interactions	O
with	O
Cep290	O
and	O
CaM	O
reveals	O
a	O
requirement	O
of	O
the	O
former	O
for	O
ciliogenesis	O
,	O
while	O
the	O
latter	O
prevents	O
NPHP5	O
self	O
-	O
aggregation	O
.	O

Disease	O
-	O
causing	O
mutations	O
lead	O
to	O
truncated	O
products	O
unable	O
to	O
bind	O
Cep290	O
and	O
localize	O
to	O
centrosomes	O
,	O
thereby	O
compromising	O
cilia	O
formation	O
.	O

In	O
contrast	O
,	O
a	O
modifier	O
mutation	O
cripples	O
CaM	O
binding	O
but	O
has	O
no	O
overt	O
effect	O
on	O
ciliogenesis	O
.	O

Drugs	O
that	O
antagonize	O
negative	O
regulators	O
of	O
the	O
ciliogenic	O
pathway	O
can	O
rescue	O
ciliogenesis	O
in	O
cells	O
depleted	O
of	O
NPHP5	O
,	O
with	O
response	O
profiles	O
similar	O
to	O
those	O
of	O
Cep290	O
-	O
but	O
not	O
IFT88	O
-	O
depleted	O
cells	O
.	O

Our	O
results	O
uncover	O
the	O
underlying	O
molecular	O
basis	O
of	O
disease	O
and	O
provide	O
novel	O
insights	O
into	O
mitigating	O
NPHP5	O
deficiency	O
.	O

VCP	O
is	O
essential	O
for	O
mitochondrial	O
quality	O
control	O
by	O
PINK1	O
/	O
Parkin	O
and	O
this	O
function	O
is	O
impaired	O
by	O
VCP	O
mutations	O
.	O

Mutations	O
in	O
VCP	O
cause	O
multisystem	O
degeneration	O
impacting	O
the	O
nervous	O
system	O
,	O
muscle	O
,	O
and	O
/	O
or	O
bone	O
.	O

Patients	O
may	O
present	O
with	O
ALS	O
,	O
Parkinsonism	O
,	O
frontotemporal	O
dementia	O
,	O
myopathy	O
,	O
Paget	O
'	O
s	O
disease	O
,	O
or	O
a	O
combination	O
of	O
these	O
.	O

The	O
disease	O
mechanism	O
is	O
unknown	O
.	O

We	O
developed	O
a	O
Drosophila	O
model	O
of	O
VCP	O
mutation	O
-	O
dependent	O
degeneration	O
.	O

The	O
phenotype	O
is	O
reminiscent	O
of	O
PINK1	O
and	O
parkin	O
mutants	O
,	O
including	O
a	O
pronounced	O
mitochondrial	O
defect	O
.	O

Indeed	O
,	O
VCP	O
interacts	O
genetically	O
with	O
the	O
PINK1	O
/	O
parkin	O
pathway	O
in	O
vivo	O
.	O

Paradoxically	O
,	O
VCP	O
complements	O
PINK1	O
deficiency	O
but	O
not	O
parkin	O
deficiency	O
.	O

The	O
basis	O
of	O
this	O
paradox	O
is	O
resolved	O
by	O
mechanistic	O
studies	O
in	O
vitro	O
showing	O
that	O
VCP	O
recruitment	O
to	O
damaged	O
mitochondria	O
requires	O
Parkin	O
-	O
mediated	O
ubiquitination	O
of	O
mitochondrial	O
targets	O
.	O

VCP	O
recruitment	O
coincides	O
temporally	O
with	O
mitochondrial	O
fission	O
,	O
and	O
VCP	O
is	O
required	O
for	O
proteasome	B-Complex
-	O
dependent	O
degradation	O
of	O
Mitofusins	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Further	O
,	O
VCP	O
and	O
its	O
adaptor	O
Npl4	O
/	O
Ufd1	O
are	O
required	O
for	O
clearance	O
of	O
damaged	O
mitochondria	O
via	O
the	O
PINK1	O
/	O
Parkin	O
pathway	O
,	O
and	O
this	O
is	O
impaired	O
by	O
pathogenic	O
mutations	O
in	O
VCP	O
.	O

To	O
understand	O
the	O
physiological	O
role	O
of	O
RASSF5	O
downregulation	O
by	O
Itch	O
during	O
cell	O
cycle	O
progression	O
,	O
RASSF5A	O
was	O
coexpressed	O
with	O
either	O
Itchwt	O
or	O
ItchC830A	O
in	O
HEK293T	O
cells	O
.	O

As	O
shown	O
in	O
Figure	O
6A	O
,	O
transient	O
overexpression	O
of	O
Itchwt	O
but	O
not	O
ItchC830A	O
significantly	O
suppresses	O
RASSF5A	O
-	O
mediated	O
G1	O
arrest	O
.	O

However	O
,	O
the	O
profile	O
of	O
S	O
and	O
G2	O
/	O
M	O
phases	O
of	O
the	O
cell	O
cycle	O
was	O
not	O
significantly	O
altered	O
when	O
RASSF5A	O
coexpressed	O
with	O
Itch	O
(	O
Supplementary	O
Figures	O
S8A	O
,	O
B	O
and	O
C	O
)	O
.	O

Furthermore	O
,	O
C646	O
-	O
promoted	O
G1	O
arrest	O
was	O
downregulated	O
by	O
Itch	O
overexpression	O
(	O
Supplementary	O
Figures	O
S9A	O
and	O
B	O
)	O
.	O

The	O
patterns	O
of	O
G1	O
arrest	O
inversely	O
correlated	O
with	O
the	O
acetylation	O
status	O
of	O
RASSF5	O
(	O
Figure	O
5a	O
)	O
,	O
suggesting	O
that	O
acetylation	O
modulates	O
RASSF5	O
function	O
during	O
cell	O
cycle	O
.	O

Interestingly	O
,	O
RASSF5	O
-	O
mediated	O
apoptosis	O
was	O
impaired	O
by	O
Itchwt	O
but	O
not	O
ItchC830A	O
(	O
Figure	O
6b	O
)	O
.	O

The	O
specificity	O
of	O
regulation	O
was	O
further	O
confirmed	O
by	O
the	O
fact	O
that	O
Itch	O
failed	O
to	O
alter	O
the	O
G1	O
cell	O
cycle	O
pattern	O
as	O
well	O
as	O
apoptosis	O
when	O
it	O
is	O
overexpressed	O
with	O
RASSF5AY24A	O
(	O
defective	O
for	O
Itch	O
interaction	O
)	O
(	O
Figures	O
6a	O
and	O
b	O
)	O
.	O

These	O
data	O
indicate	O
that	O
the	O
association	O
of	O
RASSF5	O
with	O
Itch	O
,	O
or	O
additional	O
PPxY	O
-	O
dependent	O
protein	O
interaction	O
,	O
may	O
be	O
required	O
to	O
elicit	O
apoptosis	O
(	O
Figure	O
6b	O
)	O
.	O

This	O
later	O
fact	O
is	O
a	O
likely	O
reason	O
behind	O
the	O
inconsistency	O
between	O
RASSF5A	O
expression	O
in	O
tumor	O
cells	O
and	O
its	O
role	O
as	O
a	O
tumor	O
suppressor	O
,	O
as	O
high	O
levels	O
may	O
indicate	O
enhance	O
protein	O
acetylation	O
and	O
inactivation	O
of	O
the	O
ability	O
to	O
promote	O
apoptosis	O
of	O
tumor	O
cells	O
.	O

Rap1	O
leads	O
to	O
cellular	O
lethality	O
,	O
we	O
utilized	O
the	O
rap1	O
-	O
17	O
allele	O
that	O
encodes	O
a	O
Rap1	O
protein	O
with	O
C	O
-	O
terminal	O
truncation	O
(	O
missing	O
amino	O
acids	O
663	O
-	O
827	O
)	O
.	O

The	O
rap1	O
-	O
17	O
mutant	O
is	O
incapable	O
of	O
interacting	O
Rif1	O
and	O
Rif2	O
,	O
but	O
efficiently	O
binds	O
to	O
telomere	O
DNA	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

4C	O
,	O
the	O
tsa1	O
rap1	O
-	O
17	O
double	O
mutant	O
had	O
a	O
similar	O
telomere	O
length	O
as	O
the	O
rap1	O
-	O
17	O
single	O
mutant	O
,	O
supporting	O
that	O
Rap1	O
is	O
required	O
for	O
telomere	O
lengthening	O
in	O
the	O
tsa1	O
mutant	O
.	O

Similarly	O
,	O
the	O
tsa1	O
rif2	O
double	O
mutant	O
displayed	O
a	O
similar	O
telomere	O
length	O
as	O
the	O
rif2	O
single	O
mutant	O
(	O
Fig	O
.	O
4D	O
)	O
,	O
implying	O
the	O
importance	O
of	O
Rif2	O
in	O
telomere	O
lengthening	O
in	O
the	O
tsa1	O
mutant	O
.	O

Interestingly	O
,	O
telomere	O
length	O
of	O
the	O
tsa1	O
rif1	O
double	O
mutant	O
is	O
significantly	O
longer	O
than	O
that	O
of	O
the	O
rif1	O
single	O
mutant	O
,	O
suggesting	O
that	O
tsa1	O
and	O
rif1	O
mutations	O
causes	O
telomere	O
lengthening	O
via	O
distinct	O
pathways	O
.	O

Identification	O
of	O
amino	O
acids	O
in	O
the	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
prothrombin	O
.	O

A	O
gamma	O
-	O
carboxylation	O
recognition	O
site	O
on	O
the	O
propeptide	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
blood	O
coagulation	O
proteins	O
directs	O
the	O
carboxylation	O
of	O
glutamic	O
acid	O
residues	O
by	O
binding	O
to	O
the	O
vitamin	O
K	O
-	O
dependent	O
carboxylase	O
.	O

To	O
determine	O
residues	O
that	O
define	O
this	O
site	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
mutation	O
of	O
certain	O
residues	O
in	O
the	O
prothrombin	O
propeptide	O
on	O
the	O
extent	O
of	O
carboxylation	O
.	O

The	O
prothrombin	O
cDNA	O
modified	O
by	O
site	O
-	O
specific	O
mutagenesis	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
using	O
a	O
system	O
that	O
yields	O
functional	O
fully	O
carboxylated	O
prothrombin	O
.	O

The	O
cell	O
supernatants	O
containing	O
recombinant	O
prothrombin	O
were	O
evaluated	O
for	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
by	O
immunoassay	O
.	O

Conformation	O
-	O
specific	O
anti	O
-	O
prothrombin	O
:	O
Ca	O
(	O
II	O
)	O
-	O
specific	O
antibodies	O
measure	O
native	O
completely	O
carboxylated	O
prothrombin	O
;	O
anti	O
-	O
prothrombin	O
:	O
total	O
antibodies	O
measure	O
all	O
forms	O
of	O
prothrombin	O
,	O
regardless	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
content	O
.	O

Mutation	O
of	O
His	O
-	O
18	O
to	O
Gly	O
,	O
Val	O
-	O
17	O
to	O
Ser	O
,	O
Leu	O
-	O
15	O
to	O
Gly	O
or	O
Asp	O
,	O
or	O
Ala	O
-	O
10	O
to	O
Asp	O
was	O
associated	O
with	O
a	O
partial	O
(	O
30	O
-	O
65	O
%	O
)	O
inhibition	O
of	O
gamma	O
-	O
carboxylation	O
.	O

Mutation	O
of	O
Ala	O
-	O
14	O
to	O
Ser	O
or	O
Ser	O
-	O
8	O
to	O
Val	O
did	O
not	O
inhibit	O
gamma	O
-	O
carboxylation	O
.	O

From	O
this	O
and	O
earlier	O
work	O
,	O
residues	O
whose	O
mutation	O
leads	O
to	O
a	O
significant	O
impairment	O
of	O
carboxylation	O
include	O
His	O
-	O
18	O
,	O
Val	O
-	O
17	O
,	O
Phe	O
-	O
16	O
,	O
Leu	O
-	O
15	O
,	O
and	O
Ala	O
-	O
10	O
.	O

Residues	O
whose	O
mutation	O
does	O
not	O
alter	O
the	O
carboxylation	O
recognition	O
site	O
include	O
Ala	O
-	O
14	O
,	O
Ser	O
-	O
8	O
,	O
Arg	O
-	O
4	O
,	O
and	O
Arg	O
-	O
1	O
.	O

To	O
determine	O
the	O
size	O
of	O
the	O
recognition	O
site	O
,	O
the	O
in	O
vitro	O
carboxylation	O
of	O
propeptide	O
-	O
containing	O
synthetic	O
peptides	O
was	O
compared	O
.	O

A	O
28	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
prothrombin	O
,	O
and	O
a	O
54	O
-	O
residue	O
peptide	O
,	O
based	O
upon	O
residues	O
-	O
18	O
to	O
+	O
36	O
of	O
prothrombin	O
,	O
were	O
carboxylated	O
by	O
partially	O
purified	O
bovine	O
carboxylase	O
with	O
similar	O
Km	O
values	O
of	O
2	O
-	O
5	O
microM	O
.	O

These	O
results	O
indicate	O
that	O
the	O
gamma	O
-	O
carboxyglutamic	O
acid	O
-	O
rich	O
region	O
of	O
prothrombin	O
makes	O
a	O
minimal	O
contribution	O
to	O
carboxylase	O
binding	O
.	O

A	O
molecular	O
surface	O
of	O
about	O
five	O
amino	O
acids	O
located	O
within	O
the	O
propeptide	O
appears	O
to	O
define	O
the	O
carboxylation	O
recognition	O
site	O
on	O
the	O
precursor	O
forms	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O

The	O
activity	O
of	O
potassium	O
(	O
K	O
(	O
+	O
)	O
)	O
channels	O
critically	O
depends	O
on	O
their	O
density	O
on	O
the	O
cell	O
surface	O
membrane	O
,	O
which	O
is	O
regulated	O
by	O
dynamic	O
protein	O
-	O
protein	O
interactions	O
that	O
often	O
involve	O
distinct	O
trafficking	O
signals	O
on	O
the	O
cargo	O
proteins	O
.	O

In	O
this	O
paper	O
we	O
explored	O
the	O
possibility	O
of	O
utilizing	O
the	O
Saccharomyces	O
cerevisiae	O
strain	O
B31	O
for	O
identification	O
of	O
the	O
signal	O
motifs	O
that	O
regulate	O
surface	O
expression	O
of	O
membrane	O
proteins	O
and	O
for	O
studying	O
structure	O
-	O
function	O
relationships	O
of	O
K	O
(	O
+	O
)	O
channels	O
.	O

B31	O
cells	O
lack	O
the	O
K	O
(	O
+	O
)	O
efflux	O
system	O
and	O
were	O
reported	O
to	O
show	O
overloaded	O
K	O
(	O
+	O
)	O
-	O
mediated	O
growth	O
inhibition	O
in	O
high	O
K	O
(	O
+	O
)	O
media	O
upon	O
heterologous	O
expression	O
of	O
a	O
mammalian	O
inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
channel	O
(	O
Kir2	O
.	O
1	O
)	O
.	O

We	O
show	O
that	O
while	O
the	O
expression	O
of	O
wild	O
-	O
type	O
Kir2	O
.	O
1	O
channel	O
inhibits	O
the	O
growth	O
of	O
B31	O
cells	O
in	O
high	O
K	O
(	O
+	O
)	O
media	O
,	O
the	O
human	O
disease	O
-	O
causing	O
mutations	O
of	O
Kir2	O
.	O
1	O
that	O
abolish	O
K	O
(	O
+	O
)	O
conduction	O
(	O
V302M	O
)	O
or	O
surface	O
trafficking	O
(	O
Delta314	O
/	O
315	O
)	O
fully	O
restores	O
the	O
growth	O
.	O

The	O
expression	O
of	O
two	O
-	O
pore	O
-	O
domain	O
K	O
(	O
+	O
)	O
channel	O
KCNK3	O
or	O
KCNK9	O
also	O
inhibited	O
the	O
growth	O
of	O
B31	O
in	O
high	O
K	O
(	O
+	O
)	O
media	O
while	O
C	O
-	O
terminal	O
mutations	O
that	O
reduce	O
their	O
14	O
-	O
3	O
-	O
3	O
protein	O
-	O
dependent	O
cell	O
surface	O
trafficking	O
restored	O
the	O
growth	O
of	O
B31	O
.	O

Finally	O
,	O
the	O
expression	O
of	O
Kir2	O
.	O
1	O
channels	O
that	O
were	O
C	O
-	O
terminally	O
fused	O
with	O
known	O
sequence	O
motifs	O
including	O
ER	O
retention	O
/	O
retrieval	O
signals	O
and	O
an	O
endocytosis	O
signal	O
allowed	O
the	O
growth	O
of	O
B31	O
in	O
high	O
K	O
(	O
+	O
)	O
media	O
.	O

These	O
results	O
demonstrate	O
the	O
potential	O
of	O
B31	O
yeast	O
strain	O
as	O
a	O
unique	O
biological	O
tool	O
to	O
screen	O
the	O
random	O
peptide	O
libraries	O
for	O
novel	O
sequence	O
signals	O
that	O
down	O
-	O
regulate	O
surface	O
expression	O
of	O
membrane	O
proteins	O
,	O
as	O
well	O
as	O
to	O
systematically	O
identify	O
the	O
structural	O
determinants	O
for	O
cell	O
surface	O
trafficking	O
and	O
/	O
or	O
ion	O
conductance	O
of	O
K	O
(	O
+	O
)	O
channels	O
.	O

Glutathione	O
S	O
-	O
transferase	O
omega	O
suppresses	O
the	O
defective	O
phenotypes	O
caused	O
by	O
PINK1	O
loss	O
-	O
of	O
-	O
function	O
in	O
Drosophila	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
PTEN	O
-	O
induced	O
kinase	O
1	O
(	O
PINK1	O
)	O
gene	O
is	O
a	O
common	O
cause	O
of	O
early	O
-	O
onset	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Glutathione	O
S	O
-	O
transferase	O
omega	O
(	O
GSTO	O
)	O
is	O
a	O
phase	O
II	O
detoxification	O
enzyme	O
that	O
conjugates	O
targets	O
to	O
glutathione	O
,	O
and	O
has	O
recently	O
been	O
implicated	O
in	O
parkin	O
-	O
associated	O
PD	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
Drosophila	O
GstO2	O
to	O
be	O
a	O
novel	O
genetic	O
suppressor	O
of	O
the	O
PINK1	O
loss	O
-	O
of	O
-	O
function	O
mutant	O
.	O

We	O
show	O
that	O
GstO2A	O
expression	O
is	O
reduced	O
in	O
PINK1	O
mutants	O
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
GstO2A	O
restores	O
muscle	O
degeneration	O
and	O
dopaminergic	O
neuron	O
loss	O
in	O
PINK1	O
mutants	O
.	O

Given	O
the	O
previous	O
data	O
of	O
a	O
reduced	O
expression	O
of	O
GstO2A	O
and	O
decreased	O
glutathionylation	O
of	O
ATP	O
synthase	O
beta	O
subunit	O
in	O
parkin	O
or	O
PINK1	O
mutants	O
,	O
these	O
results	O
suggest	O
that	O
the	O
function	O
of	O
GstO2	O
is	O
regulated	O
by	O
the	O
PINK1	O
/	O
parkin	O
pathway	O
and	O
that	O
GstO2	O
also	O
has	O
a	O
protective	O
role	O
in	O
PINK1	O
-	O
associated	O
PD	O
.	O

The	O
effect	O
of	O
those	O
alterations	O
in	O
the	O
endocytic	O
machinery	O
on	O
bulk	O
lipid	O
endocytosis	O
was	O
assessed	O
by	O
observing	O
FM4	O
-	O
64	O
uptake	O
in	O
mixed	O
cultures	O
from	O
a	O
control	O
strain	O
bearing	O
the	O
spindle	O
pole	O
body	O
protein	O
Sad1	O
-	O
GFP	O
and	O
the	O
41XHAclc1	O
strain	O
.	O

The	O
cultures	O
were	O
incubated	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
thiamine	O
;	O
photographs	O
were	O
taken	O
0	O
,	O
2	O
,	O
and	O
30	O
minutes	O
after	O
the	O
addition	O
of	O
the	O
dye	O
(	O
figure	O
7	O
D	O
.	O
The	O
experiment	O
was	O
performed	O
three	O
times	O
with	O
similar	O
results	O
)	O
.	O

In	O
the	O
absence	O
of	O
thiamine	O
,	O
FM4	O
-	O
64	O
was	O
observed	O
at	O
the	O
cell	O
surface	O
at	O
the	O
0	O
-	O
minute	O
time	O
-	O
point	O
,	O
in	O
internal	O
endosomes	O
after	O
2	O
minutes	O
,	O
and	O
in	O
the	O
vacuoles	O
after	O
30	O
minutes	O
in	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
strains	O
(	O
cells	O
bearing	O
and	O
lacking	O
the	O
green	O
Sad1	O
-	O
GFP	O
dots	O
,	O
respectively	O
)	O
.	O

When	O
cells	O
were	O
incubated	O
for	O
6	O
hours	O
in	O
the	O
presence	O
of	O
thiamine	O
,	O
FM4	O
-	O
64	O
stained	O
the	O
cell	O
surface	O
of	O
both	O
strains	O
at	O
the	O
beginning	O
of	O
the	O
experiment	O
(	O
0	O
'	O
)	O
;	O
after	O
2	O
minutes	O
,	O
the	O
dye	O
was	O
observed	O
inside	O
the	O
wild	O
-	O
type	O
cells	O
(	O
marked	O
by	O
the	O
green	O
Sad1	O
-	O
GFP	O
dots	O
)	O
but	O
not	O
inside	O
the	O
mutant	O
cells	O
(	O
those	O
lacking	O
the	O
GFP	O
dot	O
)	O
;	O
after	O
30	O
minutes	O
of	O
incubation	O
,	O
FM4	O
-	O
64	O
was	O
observed	O
in	O
the	O
vacuoles	O
of	O
the	O
control	O
strain	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
dye	O
was	O
still	O
detected	O
at	O
the	O
cell	O
surface	O
in	O
the	O
mutant	O
cells	O
;	O
only	O
a	O
weak	O
staining	O
was	O
observed	O
inside	O
some	O
cells	O
(	O
arrows	O
in	O
the	O
corresponding	O
panel	O
of	O
figure	O
7	O
D	O
)	O
.	O

Thus	O
,	O
a	O
40	O
%	O
reduction	O
in	O
the	O
amount	O
of	O
Clc1p	O
did	O
not	O
affect	O
FM4	O
-	O
64	O
uptake	O
,	O
and	O
a	O
90	O
%	O
reduction	O
in	O
this	O
protein	O
delayed	O
this	O
process	O
,	O
but	O
did	O
not	O
abrogate	O
it	O
.	O

Deubiquitinating	O
enzyme	O
Usp12	O
is	O
a	O
novel	O
co	O
-	O
activator	O
of	O
the	O
androgen	O
receptor	O
.	O

The	O
androgen	O
receptor	O
(	O
AR	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
family	O
,	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
prostate	O
cell	O
growth	O
,	O
homeostasis	O
,	O
and	O
transformation	O
.	O

AR	O
is	O
a	O
key	O
protein	O
in	O
growth	O
and	O
development	O
of	O
both	O
normal	O
and	O
malignant	O
prostate	O
,	O
making	O
it	O
a	O
common	O
therapeutic	O
target	O
in	O
prostate	O
cancer	O
.	O

AR	O
is	O
regulated	O
by	O
an	O
interplay	O
of	O
multiple	O
post	O
-	O
translational	O
modifications	O
including	O
ubiquitination	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
the	O
AR	O
is	O
ubiquitinated	O
by	O
a	O
number	O
of	O
E3	O
ubiquitin	O
ligases	O
,	O
including	O
MDM2	O
,	O
CHIP	O
,	O
and	O
NEDD4	O
,	O
which	O
can	O
result	O
in	O
its	O
proteosomal	O
degradation	O
or	O
enhanced	O
transcriptional	O
activity	O
.	O

As	O
ubiquitination	O
of	O
AR	O
causes	O
a	O
change	O
in	O
AR	O
activity	O
or	O
stability	O
and	O
impacts	O
both	O
survival	O
and	O
growth	O
of	O
prostate	O
cancer	O
cells	O
,	O
deubiquitination	O
of	O
these	O
sites	O
has	O
an	O
equally	O
important	O
role	O
.	O

Hence	O
,	O
deubiquitinating	O
enzymes	O
could	O
offer	O
novel	O
therapeutic	O
targets	O
.	O

We	O
performed	O
an	O
siRNA	O
screen	O
to	O
identify	O
deubiquitinating	O
enzymes	O
that	O
regulate	O
AR	O
;	O
in	O
that	O
screen	O
ubiquitin	O
-	O
specific	O
protease	O
12	O
(	O
Usp12	O
)	O
was	O
identified	O
as	O
a	O
novel	O
positive	O
regulator	O
of	O
AR	O
.	O

Usp12	O
is	O
a	O
poorly	O
characterized	O
protein	O
with	O
few	O
known	O
functions	O
and	O
requires	O
the	O
interaction	O
with	O
two	O
cofactors	O
,	O
Uaf	O
-	O
1	O
and	O
WDR20	O
,	O
for	O
its	O
enzymatic	O
activity	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
Usp12	O
,	O
in	O
complex	O
with	O
Uaf	O
-	O
1	O
and	O
WDR20	O
,	O
deubiquitinates	O
the	O
AR	O
to	O
enhance	O
receptor	O
stability	O
and	O
transcriptional	O
activity	O
.	O

Our	O
data	O
show	O
that	O
Usp12	O
acts	O
in	O
a	O
pro	O
-	O
proliferative	O
manner	O
by	O
stabilizing	O
AR	O
and	O
enhancing	O
its	O
cellular	O
function	O
.	O

14	O
-	O
3	O
-	O
3theta	O
facilitates	O
plasma	O
membrane	O
delivery	O
and	O
function	O
of	O
mechanosensitive	O
connexin	O
43	O
hemichannels	O
.	O

Intracellular	O
signaling	O
in	O
osteocytes	O
activated	O
by	O
mechanical	O
loading	O
is	O
important	O
for	O
bone	O
formation	O
and	O
remodeling	O
.	O

These	O
signaling	O
events	O
are	O
mediated	O
by	O
small	O
modulators	O
released	O
from	O
Cx43	O
hemichannels	O
(	O
HC	O
)	O
.	O

We	O
have	O
recently	O
shown	O
that	O
integrin	O
alpha5	O
senses	O
the	O
mechanical	O
stimulation	O
and	O
induces	O
the	O
opening	O
of	O
Cx43	O
HC	O
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
both	O
Cx43	O
and	O
integrin	O
alpha5	O
interact	O
with	O
14	O
-	O
3	O
-	O
3theta	O
,	O
and	O
this	O
interaction	O
is	O
required	O
for	O
the	O
opening	O
of	O
Cx43	O
HC	O
upon	O
mechanical	O
stress	O
.	O

The	O
absence	O
of	O
14	O
-	O
3	O
-	O
3theta	O
prevented	O
the	O
interaction	O
between	O
Cx43	O
and	O
integrin	O
alpha5	O
,	O
and	O
blocked	O
HC	O
opening	O
.	O

Furthermore	O
,	O
it	O
decreased	O
the	O
transport	O
of	O
Cx43	O
and	O
integrin	O
alpha5	O
from	O
the	O
Golgi	O
apparatus	O
to	O
the	O
plasma	O
membrane	O
.	O

Mechanical	O
loading	O
promoted	O
the	O
movement	O
of	O
Cx43	O
to	O
the	O
surface	O
which	O
was	O
associated	O
not	O
only	O
with	O
an	O
increase	O
in	O
14	O
-	O
3	O
-	O
3theta	O
levels	O
but	O
also	O
its	O
interaction	O
with	O
Cx43	O
and	O
integrin	O
alpha5	O
.	O

This	O
stimulatory	O
effect	O
on	O
forward	O
transport	O
by	O
mechanical	O
loading	O
was	O
attenuated	O
in	O
the	O
absence	O
of	O
14	O
-	O
3	O
-	O
3theta	O
and	O
the	O
majority	O
of	O
the	O
Cx43	O
accumulated	O
in	O
the	O
Golgi	O
.	O

Disruption	O
of	O
the	O
Golgi	O
by	O
brefeldin	O
A	O
reduced	O
the	O
association	O
of	O
Cx43	O
and	O
integrin	O
alpha5	O
with	O
14	O
-	O
3	O
-	O
3theta	O
,	O
further	O
suggesting	O
that	O
the	O
interaction	O
is	O
likely	O
to	O
occur	O
in	O
the	O
Golgi	O
.	O

Together	O
,	O
these	O
results	O
define	O
a	O
previously	O
unidentified	O
,	O
scaffolding	O
role	O
of	O
14	O
-	O
3	O
-	O
3theta	O
in	O
assisting	O
the	O
delivery	O
of	O
Cx43	O
and	O
integrin	O
alpha5	O
to	O
the	O
plasma	O
membrane	O
for	O
the	O
formation	O
of	O
mechanosensitive	O
HC	O
in	O
osteocytes	O
.	O

Abutting	O
the	O
F	O
pocket	O
-	O
divider	O
in	O
fly	O
Pygo	O
is	O
a	O
striking	O
groove	O
,	O
walled	O
by	O
F773	O
and	O
E767	O
,	O
and	O
floored	O
by	O
the	O
aromatic	O
ring	O
of	O
F765	O
(	O
Figures	O
1C	O
and	O
2A	O
)	O
.	O

This	O
groove	O
is	O
not	O
seen	O
in	O
human	O
Pygo	O
in	O
which	O
a	O
conserved	O
L	O
(	O
L345	O
)	O
fills	O
out	O
the	O
equivalent	O
space	O
,	O
substituting	O
for	O
F765	O
(	O
Figures	O
1D	O
,	O
2B	O
,	O
and	O
2C	O
)	O
,	O
as	O
already	O
mentioned	O
.	O

In	O
classical	O
PHD	O
fingers	O
(	O
e	O
.	O
g	O
.	O
,	O
from	O
ING2	O
)	O
,	O
a	O
deep	O
cavity	O
is	O
found	O
in	O
this	O
position	O
which	O
buries	O
R2	O
(	O
Figures	O
1E	O
and	O
2D	O
)	O
.	O

Therefore	O
,	O
Drosophila	O
Pygo	O
PHD	O
evolved	O
a	O
distinct	O
feature	O
-	O
-	O
the	O
R2	O
groove	O
.	O

Autoacylation	O
of	O
myelin	O
proteolipid	O
protein	O
with	O
acyl	O
coenzyme	O
A	O
.	O

Rat	O
brain	O
myelin	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
is	O
known	O
to	O
contain	O
long	O
chain	O
,	O
covalently	O
bound	O
fatty	O
acids	O
.	O

In	O
the	O
course	O
of	O
characterizing	O
the	O
mechanism	O
of	O
acylation	O
,	O
we	O
found	O
that	O
the	O
isolated	O
PLP	O
,	O
in	O
the	O
absence	O
of	O
any	O
membrane	O
fraction	O
,	O
was	O
esterified	O
after	O
incubation	O
with	O
[	O
3H	O
]	O
palmitoyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
.	O

This	O
observation	O
demonstrated	O
that	O
the	O
protein	O
acts	O
as	O
both	O
an	O
acylating	O
enzyme	O
and	O
an	O
acceptor	O
.	O

Thus	O
,	O
acylation	O
occurs	O
by	O
an	O
autocatalytic	O
process	O
.	O

The	O
possibility	O
of	O
a	O
separate	O
acyltransferase	O
that	O
copurifies	O
with	O
PLP	O
was	O
essentially	O
excluded	O
by	O
adding	O
brain	O
subcellular	O
fractions	O
to	O
the	O
reaction	O
mixtures	O
and	O
by	O
changing	O
the	O
isolation	O
procedure	O
.	O

After	O
deacylation	O
,	O
the	O
protein	O
was	O
acylated	O
at	O
a	O
4	O
-	O
fold	O
greater	O
rate	O
,	O
suggesting	O
that	O
the	O
original	O
sites	O
were	O
reacylated	O
.	O

The	O
palmitoyl	O
-	O
CoA	O
concentration	O
followed	O
Michaelis	O
kinetics	O
,	O
confirming	O
that	O
spontaneous	O
acylation	O
was	O
not	O
occurring	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
the	O
reaction	O
entails	O
net	O
addition	O
of	O
acyl	O
groups	O
.	O

Although	O
fatty	O
acids	O
are	O
bound	O
via	O
an	O
O	O
-	O
ester	O
linkage	O
,	O
free	O
SH	O
groups	O
are	O
required	O
in	O
the	O
reaction	O
.	O

Denaturation	O
of	O
the	O
protein	O
by	O
sodium	O
dodecyl	O
sulfate	O
or	O
heat	O
inhibits	O
the	O
reaction	O
,	O
whereas	O
cerulenin	O
has	O
little	O
or	O
no	O
effect	O
.	O

PO	O
,	O
the	O
major	O
protein	O
in	O
peripheral	O
nerve	O
myelin	O
,	O
is	O
also	O
an	O
acylated	O
protein	O
,	O
but	O
it	O
was	O
not	O
labeled	O
upon	O
incubation	O
of	O
either	O
peripheral	O
myelin	O
or	O
the	O
isolated	O
protein	O
with	O
[	O
3H	O
]	O
palmitoyl	O
-	O
CoA	O
,	O
demonstrating	O
that	O
it	O
is	O
acylated	O
by	O
a	O
different	O
route	O
.	O

Several	O
synthetic	O
peptides	O
derived	O
from	O
PLP	O
sequences	O
with	O
sites	O
known	O
to	O
be	O
acylated	O
in	O
vivo	O
as	O
well	O
as	O
a	O
series	O
of	O
deacylated	O
PLP	O
tryptic	O
peptides	O
were	O
not	O
labeled	O
,	O
indicating	O
that	O
integrity	O
of	O
the	O
protein	O
is	O
required	O
for	O
acylation	O
.	O

Limited	O
proteolysis	O
and	O
peptide	O
mapping	O
showed	O
that	O
the	O
same	O
sites	O
are	O
acylated	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
autocatalytic	O
acylation	O
reaction	O
is	O
physiological	O
.	O

We	O
have	O
also	O
reported	O
that	O
polyubiquitinated	O
proteins	O
accumulate	O
in	O
not4Delta	O
cell	O
extracts	O
.	O

So	O
we	O
compared	O
the	O
level	O
of	O
polyubiquitinated	O
proteins	O
in	O
total	O
extracts	O
and	O
in	O
protein	O
aggregates	O
from	O
wild	O
-	O
type	O
and	O
mutant	O
cells	O
lacking	O
the	O
enzymatic	O
modules	O
of	O
the	O
Ccr4	O
-	O
Not	O
complex	O
(	O
Fig	O
.	O
2A	O
,	O
middle	O
panel	O
)	O
.	O

No	O
increased	O
level	O
of	O
polyubiquitinated	O
proteins	O
was	O
detected	O
in	O
total	O
extracts	O
from	O
caf1Delta	O
or	O
ccr4Delta	O
cells	O
compared	O
to	O
wild	O
type	O
.	O

In	O
contrast	O
,	O
in	O
not4Delta	O
cells	O
polyubiquitinated	O
proteins	O
were	O
observed	O
in	O
total	O
extracts	O
.	O

A	O
slight	O
increase	O
of	O
polyubiquitinated	O
proteins	O
was	O
observed	O
in	O
the	O
aggregates	O
from	O
caf1Delta	O
and	O
ccr4Delta	O
mutants	O
,	O
whereas	O
very	O
high	O
levels	O
of	O
polyubiquitinated	O
proteins	O
were	O
found	O
in	O
the	O
aggregates	O
from	O
not4Delta	O
cells	O
.	O

These	O
aggregates	O
in	O
not4Delta	O
contained	O
the	O
Hsp70	O
cytoplasmic	O
chaperone	O
,	O
Ssa1	O
;	O
the	O
ribosome	B-OOS
associated	O
chaperones	O
Ssb1	O
and	O
Egd2	O
;	O
the	O
proteasomal	O
protein	O
,	O
Rpn8	O
;	O
and	O
the	O
ribosomal	O
protein	O
,	O
Rpl35	O
(	O
Fig	O
.	O
2A	O
,	O
lower	O
panel	O
)	O
.	O

Phosphatase	O
complex	O
Pph3	O
/	O
Psy2	O
is	O
involved	O
in	O
regulation	O
of	O
efficient	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
pathway	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

One	O
of	O
the	O
main	O
mechanisms	O
for	O
double	O
stranded	O
DNA	O
break	O
(	O
DSB	O
)	O
repair	O
is	O
through	O
the	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
(	O
NHEJ	O
)	O
pathway	O
.	O

Using	O
plasmid	O
and	O
chromosomal	O
repair	O
assays	O
,	O
we	O
showed	O
that	O
deletion	O
mutant	O
strains	O
for	O
interacting	O
proteins	O
Pph3p	O
and	O
Psy2p	O
had	O
reduced	O
efficiencies	O
in	O
NHEJ	O
.	O

We	O
further	O
observed	O
that	O
this	O
activity	O
of	O
Pph3p	O
and	O
Psy2p	O
appeared	O
linked	O
to	O
cell	O
cycle	O
Rad53p	O
and	O
Chk1p	O
checkpoint	O
proteins	O
.	O

Pph3	O
/	O
Psy2	O
is	O
a	O
phosphatase	O
complex	O
,	O
which	O
regulates	O
recovery	O
from	O
the	O
Rad53p	O
DNA	O
damage	O
checkpoint	O
.	O

Overexpression	O
of	O
Chk1p	O
checkpoint	O
protein	O
in	O
a	O
parallel	O
pathway	O
to	O
Rad53p	O
compensated	O
for	O
the	O
deletion	O
of	O
PPH3	O
or	O
PSY2	O
in	O
a	O
chromosomal	O
repair	O
assay	O
.	O

Double	O
mutant	O
strains	O
Deltapph3	O
/	O
Deltachk1	O
and	O
Deltapsy2	O
/	O
Deltachk1	O
showed	O
additional	O
reductions	O
in	O
the	O
efficiency	O
of	O
plasmid	O
repair	O
,	O
compared	O
to	O
both	O
single	O
deletions	O
which	O
is	O
in	O
agreement	O
with	O
the	O
activity	O
of	O
Pph3p	O
and	O
Psy2p	O
in	O
a	O
parallel	O
pathway	O
to	O
Chk1p	O
.	O

Genetic	O
interaction	O
analyses	O
also	O
supported	O
a	O
role	O
for	O
Pph3p	O
and	O
Psy2p	O
in	O
DNA	O
damage	O
repair	O
,	O
the	O
NHEJ	O
pathway	O
,	O
as	O
well	O
as	O
cell	O
cycle	O
progression	O
.	O

Collectively	O
,	O
we	O
report	O
that	O
the	O
activity	O
of	O
Pph3p	O
and	O
Psy2p	O
further	O
connects	O
NHEJ	O
repair	O
to	O
cell	O
cycle	O
progression	O
.	O

We	O
identified	O
16	O
in	O
vivo	O
phosphorylation	O
sites	O
on	O
Cdr2	O
as	O
part	O
of	O
a	O
large	O
-	O
scale	O
SILAC	O
-	O
based	O
phosphoproteomic	O
screen	O
for	O
substrates	O
of	O
Pom1	O
(	O
Figures	O
1A	O
and	O
Table	O
S1	O
)	O
.	O

Briefly	O
,	O
Pom1	O
kinase	O
activity	O
was	O
inhibited	O
for	O
15	O
minutes	O
using	O
an	O
analog	O
-	O
sensitive	O
pom1	O
-	O
as	O
strain	O
.	O

Changes	O
in	O
the	O
phosphoproteome	O
were	O
quantified	O
using	O
phosphopeptide	O
enrichment	O
followed	O
by	O
nanoscale	O
microcapillary	O
LC	O
-	O
MS	O
/	O
MS	O
as	O
previously	O
described	O
(	O
see	O
Experimental	O
Procedures	O
,	O
the	O
full	O
results	O
of	O
this	O
screen	O
will	O
be	O
published	O
as	O
a	O
separate	O
study	O
)	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
domain	O
(	O
CTD	O
)	O
of	O
Cdr2	O
was	O
phosphorylated	O
in	O
a	O
manner	O
that	O
heavily	O
depended	O
on	O
Pom1	O
,	O
suggesting	O
that	O
this	O
cluster	O
of	O
serine	O
residues	O
is	O
the	O
primary	O
site	O
of	O
Pom1	O
-	O
dependent	O
regulation	O
in	O
cells	O
.	O

Consistent	O
with	O
this	O
possibility	O
,	O
purified	O
Pom1	O
phosphorylated	O
the	O
Cdr2	O
-	O
CTD	O
directly	O
in	O
vitro	O
(	O
Figure	O
S1A	O
)	O
.	O

In	O
contrast	O
,	O
we	O
found	O
a	O
single	O
residue	O
(	O
Thr166	O
)	O
in	O
the	O
Cdr2	O
kinase	O
domain	O
that	O
was	O
more	O
heavily	O
phosphorylated	O
upon	O
inhibition	O
of	O
Pom1	O
(	O
Table	O
S1	O
)	O
.	O

This	O
suggests	O
that	O
Thr166	O
is	O
modified	O
by	O
a	O
different	O
kinase	O
,	O
and	O
may	O
be	O
antagonized	O
by	O
Pom1	O
.	O

Thr166	O
was	O
the	O
only	O
phosphorylation	O
site	O
that	O
we	O
found	O
in	O
the	O
Cdr2	O
kinase	O
domain	O
,	O
and	O
represents	O
a	O
well	O
-	O
conserved	O
feature	O
of	O
the	O
activation	O
loop	O
(	O
T	O
-	O
loop	O
)	O
among	O
AMPK	O
/	O
SNF1	O
-	O
related	O
kinases	O
from	O
yeast	O
through	O
humans	O
(	O
Figure	O
1B	O
)	O
.	O

This	O
T	O
-	O
loop	O
Thr	O
is	O
present	O
in	O
three	O
additional	O
fission	O
yeast	O
members	O
of	O
the	O
AMPK	O
/	O
SNF1	O
protein	O
kinase	O
family	O
,	O
but	O
not	O
in	O
the	O
Cdr2	O
-	O
related	O
protein	O
kinase	O
Cdr1	O
.	O

T	O
-	O
loop	O
phosphorylation	O
by	O
upstream	O
kinases	O
is	O
required	O
for	O
the	O
catalytic	O
activity	O
of	O
members	O
of	O
this	O
protein	O
kinase	O
family	O
.	O

Therefore	O
,	O
we	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
Cdr2	O
-	O
T166	O
phosphorylation	O
in	O
cells	O
.	O

Yeti	O
,	O
an	O
essential	O
Drosophila	O
melanogaster	O
gene	O
,	O
encodes	O
a	O
protein	O
required	O
for	O
chromatin	O
organization	O
.	O

The	O
evolutionarily	O
conserved	O
family	O
of	O
Bucentaur	O
(	O
BCNT	O
)	O
proteins	O
exhibits	O
a	O
widespread	O
distribution	O
in	O
animal	O
and	O
plants	O
,	O
yet	O
its	O
biological	O
role	O
remains	O
largely	O
unknown	O
.	O

Using	O
Drosophila	O
melanogaster	O
as	O
a	O
model	O
organism	O
,	O
we	O
investigated	O
the	O
in	O
vivo	O
role	O
of	O
the	O
Drosophila	O
BCNT	O
member	O
called	O
YETI	O
.	O

We	O
report	O
that	O
loss	O
of	O
YETI	O
causes	O
lethality	O
before	O
pupation	O
and	O
defects	O
in	O
higher	O
-	O
order	O
chromatin	O
organization	O
,	O
as	O
evidenced	O
by	O
severe	O
impairment	O
in	O
the	O
association	O
of	O
histone	O
H2A	O
.	O
V	O
,	O
nucleosomal	O
histones	O
and	O
epigenetic	O
marks	O
with	O
polytene	O
chromosomes	O
.	O

We	O
also	O
find	O
that	O
YETI	O
binds	O
to	O
polytene	O
chromosomes	O
through	O
its	O
conserved	O
BCNT	O
domain	O
and	O
interacts	O
with	O
the	O
histone	O
variant	O
H2A	O
.	O
V	O
,	O
HP1a	O
and	O
Domino	O
-	O
A	O
(	O
DOM	O
-	O
A	O
)	O
,	O
the	O
ATPase	O
subunit	O
of	O
the	O
DOM	O
/	O
Tip60	O
chromatin	O
remodeling	O
complex	O
.	O

Furthermore	O
,	O
we	O
identify	O
YETI	O
as	O
a	O
downstream	O
target	O
of	O
the	O
Drosophila	O
DOM	O
-	O
A	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
YETI	O
interacts	O
with	O
H2A	O
.	O
V	O
-	O
exchanging	O
machinery	O
,	O
as	O
a	O
chaperone	O
or	O
as	O
a	O
new	O
subunit	O
of	O
the	O
DOM	O
/	O
Tip60	O
remodeling	O
complex	O
,	O
and	O
acts	O
to	O
regulate	O
the	O
accumulation	O
of	O
H2A	O
.	O
V	O
at	O
chromatin	O
sites	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
an	O
unanticipated	O
role	O
of	O
YETI	O
protein	O
in	O
chromatin	O
organization	O
and	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
mechanistic	O
clues	O
on	O
how	O
BCNT	O
proteins	O
control	O
development	O
in	O
multicellular	O
organisms	O
.	O

PINK1	O
phosphorylates	O
ubiquitin	O
to	O
activate	O
Parkin	O
E3	O
ubiquitin	O
ligase	O
activity	O
.	O

PINK1	O
kinase	O
activates	O
the	O
E3	O
ubiquitin	O
ligase	O
Parkin	O
to	O
induce	O
selective	O
autophagy	O
of	O
damaged	O
mitochondria	O
.	O

However	O
,	O
it	O
has	O
been	O
unclear	O
how	O
PINK1	O
activates	O
and	O
recruits	O
Parkin	O
to	O
mitochondria	O
.	O

Although	O
PINK1	O
phosphorylates	O
Parkin	O
,	O
other	O
PINK1	O
substrates	O
appear	O
to	O
activate	O
Parkin	O
,	O
as	O
the	O
mutation	O
of	O
all	O
serine	O
and	O
threonine	O
residues	O
conserved	O
between	O
Drosophila	O
and	O
human	O
,	O
including	O
Parkin	O
S65	O
,	O
did	O
not	O
wholly	O
impair	O
Parkin	O
translocation	O
to	O
mitochondria	O
.	O

Using	O
mass	O
spectrometry	O
,	O
we	O
discovered	O
that	O
endogenous	O
PINK1	O
phosphorylated	O
ubiquitin	O
at	O
serine	O
65	O
,	O
homologous	O
to	O
the	O
site	O
phosphorylated	O
by	O
PINK1	O
in	O
Parkin	O
'	O
s	O
ubiquitin	O
-	O
like	O
domain	O
.	O

Recombinant	O
TcPINK1	O
directly	O
phosphorylated	O
ubiquitin	O
and	O
phospho	O
-	O
ubiquitin	O
activated	O
Parkin	O
E3	O
ubiquitin	O
ligase	O
activity	O
in	O
cell	O
-	O
free	O
assays	O
.	O

In	O
cells	O
,	O
the	O
phosphomimetic	O
ubiquitin	O
mutant	O
S65D	O
bound	O
and	O
activated	O
Parkin	O
.	O

Furthermore	O
,	O
expression	O
of	O
ubiquitin	O
S65A	O
,	O
a	O
mutant	O
that	O
cannot	O
be	O
phosphorylated	O
by	O
PINK1	O
,	O
inhibited	O
Parkin	O
translocation	O
to	O
damaged	O
mitochondria	O
.	O

These	O
results	O
explain	O
a	O
feed	O
-	O
forward	O
mechanism	O
of	O
PINK1	O
-	O
mediated	O
initiation	O
of	O
Parkin	O
E3	O
ligase	O
activity	O
.	O

We	O
tested	O
the	O
interaction	O
of	O
unmodified	O
and	O
sumoylated	O
Rad1	O
-	O
Rad10	O
with	O
both	O
Y	O
-	O
form	O
DNA	O
and	O
dsDNA	O
,	O
which	O
mimic	O
the	O
substrate	O
and	O
product	O
of	O
the	O
nucleolysis	O
reaction	O
,	O
respectively	O
.	O

We	O
found	O
that	O
unmodified	O
Rad1	O
-	O
Rad10	O
binds	O
to	O
both	O
dsDNA	O
and	O
Y	O
-	O
forms	O
(	O
Figure	O
5C	O
and	O
D	O
.	O

Although	O
Rad1	O
-	O
Rad10	O
is	O
thought	O
to	O
be	O
released	O
from	O
DNA	O
after	O
cleavage	O
simply	O
by	O
intrinsic	O
differences	O
in	O
the	O
enzyme	O
'	O
s	O
affinity	O
for	O
different	O
forms	O
of	O
DNA	O
,	O
we	O
found	O
that	O
Rad1	O
-	O
Rad10	O
interaction	O
with	O
dsDNA	O
is	O
only	O
slightly	O
weaker	O
than	O
that	O
with	O
Y	O
-	O
forms	O
.	O

This	O
result	O
suggests	O
that	O
additional	O
regulation	O
exists	O
to	O
enable	O
efficient	O
dissociation	O
of	O
Rad1	O
-	O
Rad10	O
from	O
dsDNA	O
.	O

Consistent	O
with	O
this	O
,	O
the	O
excised	O
oligomer	O
in	O
NER	O
is	O
released	O
at	O
a	O
faster	O
rate	O
in	O
vivo	O
than	O
in	O
vitro	O
,	O
implying	O
the	O
existence	O
of	O
regulatory	O
mechanisms	O
specifically	O
for	O
achieving	O
shorter	O
turnaround	O
times	O
in	O
NER	O
in	O
vivo	O
.	O

Sara	O
endosomes	O
and	O
the	O
asymmetric	O
division	O
of	O
intestinal	O
stem	O
cells	O
.	O

Tissue	O
homeostasis	O
is	O
maintained	O
by	O
adult	O
stem	O
cells	O
,	O
which	O
self	O
-	O
renew	O
and	O
give	O
rise	O
to	O
differentiating	O
cells	O
.	O

The	O
generation	O
of	O
daughter	O
cells	O
with	O
different	O
fates	O
is	O
mediated	O
by	O
signalling	O
molecules	O
coming	O
from	O
an	O
external	O
niche	O
or	O
being	O
asymmetrically	O
dispatched	O
between	O
the	O
two	O
daughters	O
upon	O
stem	O
cell	O
mitosis	O
.	O

In	O
the	O
adult	O
Drosophila	O
midgut	O
,	O
the	O
intestinal	O
stem	O
cell	O
(	O
ISC	O
)	O
divides	O
to	O
generate	O
a	O
new	O
ISC	O
and	O
an	O
enteroblast	O
(	O
EB	O
)	O
differentiating	O
daughter	O
.	O

Notch	O
signalling	O
activity	O
restricted	O
to	O
the	O
EB	O
regulates	O
intestinal	O
cell	O
fate	O
decision	O
.	O

Here	O
,	O
we	O
show	O
that	O
ISCs	O
divide	O
asymmetrically	O
,	O
and	O
Sara	O
endosomes	O
in	O
ISCs	O
are	O
specifically	O
dispatched	O
to	O
the	O
presumptive	O
EB	O
.	O

During	O
ISC	O
mitosis	O
,	O
Notch	O
and	O
Delta	O
traffic	O
through	O
Sara	O
endosomes	O
,	O
thereby	O
contributing	O
to	O
Notch	O
signalling	O
bias	O
,	O
as	O
revealed	O
in	O
Sara	O
mutants	O
:	O
Sara	O
itself	O
contributes	O
to	O
the	O
control	O
of	O
the	O
ISC	O
asymmetric	O
division	O
.	O

Our	O
data	O
uncover	O
an	O
intrinsic	O
endosomal	O
mechanism	O
during	O
ISC	O
mitosis	O
,	O
which	O
participates	O
in	O
the	O
maintenance	O
of	O
the	O
adult	O
intestinal	O
lineage	O
.	O

Activation	O
of	O
the	O
pleiotropic	O
drug	O
resistance	O
pathway	O
can	O
promote	O
mitochondrial	O
DNA	O
retention	O
by	O
fusion	O
-	O
defective	O
mitochondria	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Genetic	O
and	O
microscopic	O
approaches	O
using	O
Saccharomyces	O
cerevisiae	O
have	O
identified	O
many	O
proteins	O
that	O
play	O
a	O
role	O
in	O
mitochondrial	O
dynamics	O
,	O
but	O
it	O
is	O
possible	O
that	O
other	O
proteins	O
and	O
pathways	O
that	O
play	O
a	O
role	O
in	O
mitochondrial	O
division	O
and	O
fusion	O
remain	O
to	O
be	O
discovered	O
.	O

Mutants	O
lacking	O
mitochondrial	O
fusion	O
are	O
characterized	O
by	O
rapid	O
loss	O
of	O
mitochondrial	O
DNA	O
.	O

We	O
took	O
advantage	O
of	O
a	O
petite	O
-	O
negative	O
mutant	O
that	O
is	O
unable	O
to	O
survive	O
mitochondrial	O
DNA	O
loss	O
to	O
select	O
for	O
mutations	O
that	O
allow	O
cells	O
with	O
fusion	O
-	O
deficient	O
mitochondria	O
to	O
maintain	O
the	O
mitochondrial	O
genome	O
on	O
fermentable	O
medium	O
.	O

Next	O
-	O
generation	O
sequencing	O
revealed	O
that	O
all	O
identified	O
suppressor	O
mutations	O
not	O
associated	O
with	O
known	O
mitochondrial	O
division	O
components	O
were	O
localized	O
to	O
PDR1	O
or	O
PDR3	O
,	O
which	O
encode	O
transcription	O
factors	O
promoting	O
drug	O
resistance	O
.	O

Further	O
studies	O
revealed	O
that	O
at	O
least	O
one	O
,	O
if	O
not	O
all	O
,	O
of	O
these	O
suppressor	O
mutations	O
dominantly	O
increases	O
resistance	O
to	O
known	O
substrates	O
of	O
the	O
pleiotropic	O
drug	O
resistance	O
pathway	O
.	O

Interestingly	O
,	O
hyperactivation	O
of	O
this	O
pathway	O
did	O
not	O
significantly	O
affect	O
mitochondrial	O
shape	O
,	O
suggesting	O
that	O
mitochondrial	O
division	O
was	O
not	O
greatly	O
affected	O
.	O

Our	O
results	O
reveal	O
an	O
intriguing	O
genetic	O
connection	O
between	O
pleiotropic	O
drug	O
resistance	O
and	O
mitochondrial	O
dynamics	O
.	O

These	O
results	O
inspired	O
us	O
to	O
test	O
whether	O
one	O
specific	O
heme	O
is	O
incorporated	O
first	O
and	O
hence	O
present	O
in	O
intermediate	B-Complex
I	I-Complex
.	O

To	O
accomplish	O
this	O
,	O
we	O
created	O
two	O
mitochondrial	O
genomes	O
expressing	O
two	O
different	O
cytochrome	O
b	O
variants	O
.	O

In	O
these	O
mutants	O
,	O
one	O
of	O
the	O
coordinating	O
histidine	O
residues	O
of	O
either	O
the	O
bL	O
(	O
Cytb	O
-	O
H183T	O
)	O
or	O
bH	O
(	O
Cytb	O
-	O
H197F	O
)	O
site	O
was	O
altered	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
the	O
respective	O
heme	O
coordination	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

Because	O
both	O
heme	O
cofactors	O
are	O
essential	O
for	O
the	O
electron	O
transport	O
processes	O
of	O
the	O
bc1	B-Complex
complex	O
,	O
the	O
individual	O
mutations	O
caused	O
a	O
respiratory	O
-	O
deficient	O
phenotype	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

Consistently	O
,	O
cells	O
expressing	O
these	O
mutated	O
cytochrome	O
b	O
variants	O
failed	O
to	O
accumulate	O
normal	O
amounts	O
of	O
the	O
bc1	B-Complex
complex	O
,	O
whereas	O
levels	O
of	O
the	O
COX	B-Complex
complex	O
were	O
essentially	O
unchanged	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

We	O
then	O
constructed	O
yeast	O
strains	O
expressing	O
these	O
cytochrome	O
b	O
variants	O
and	O
a	O
His7	O
-	O
tagged	O
Cbp3	O
,	O
prepared	O
mitochondria	O
from	O
these	O
cells	O
,	O
and	O
lysed	O
them	O
in	O
digitonin	O
and	O
purified	O
intermediate	B-Complex
I	I-Complex
using	O
the	O
His7	O
-	O
tag	O
(	O
Fig	O
.	O
3	O
,	O
D	O
and	O
E	O
)	O
.	O

Next	O
,	O
we	O
determined	O
the	O
heme	O
contents	O
of	O
these	O
complexes	O
via	O
HPLC	O
(	O
Fig	O
.	O
3	O
F	O
)	O
.	O

Strikingly	O
,	O
the	O
bH	O
mutant	O
exhibited	O
identical	O
amounts	O
of	O
heme	O
bs	O
/	O
cytochrome	O
b	O
protein	O
as	O
intermediate	B-Complex
I	I-Complex
from	O
mitochondria	O
containing	O
wild	O
-	O
type	O
cytochrome	O
b	O
(	O
Fig	O
.	O
3	O
,	O
F	O
and	O
G	O
)	O
.	O

In	O
contrast	O
,	O
intermediate	B-Complex
I	I-Complex
from	O
the	O
bL	O
mutant	O
almost	O
completely	O
lacked	O
heme	O
b	O
signals	O
(	O
Fig	O
.	O
3	O
,	O
F	O
and	O
G	O
)	O
.	O

These	O
data	O
therefore	O
confirm	O
that	O
cytochrome	O
b	O
in	O
intermediate	B-Complex
I	I-Complex
contains	O
only	O
one	O
heme	O
b	O
and	O
reveal	O
that	O
this	O
heme	O
is	O
bound	O
to	O
the	O
intact	O
bL	O
site	O
(	O
Fig	O
.	O
3	O
H	O
)	O
.	O

Because	O
the	O
bL	O
mutant	O
contained	O
only	O
very	O
little	O
heme	O
b	O
,	O
these	O
results	O
suggest	O
a	O
strict	O
order	O
in	O
hemylation	O
,	O
namely	O
that	O
the	O
bL	O
site	O
must	O
be	O
hemylated	O
before	O
the	O
bH	O
site	O
.	O

Plastid	O
encoded	O
RNA	B-OOS
polymerase	I-OOS
activity	O
and	O
expression	O
of	O
photosynthesis	O
genes	O
required	O
for	O
embryo	O
and	O
seed	O
development	O
in	O
Arabidopsis	O
.	O

Chloroplast	O
biogenesis	O
and	O
function	O
is	O
essential	O
for	O
proper	O
plant	O
embryo	O
and	O
seed	O
development	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
role	O
of	O
plastids	O
during	O
embryogenesis	O
are	O
poorly	O
understood	O
.	O

Expression	O
of	O
plastid	O
encoded	O
genes	O
is	O
dependent	O
on	O
two	O
different	O
transcription	O
machineries	O
;	O
a	O
plastid	O
-	O
encoded	O
bacterial	O
-	O
type	O
RNA	O
polymerase	O
(	O
PEP	O
)	O
and	O
a	O
nuclear	O
-	O
encoded	O
phage	O
-	O
type	O
RNA	O
polymerase	O
(	O
NEP	O
)	O
,	O
which	O
recognize	O
distinct	O
types	O
of	O
promoters	O
.	O

However	O
,	O
the	O
division	O
of	O
labor	O
between	O
PEP	O
and	O
NEP	O
during	O
plastid	O
development	O
and	O
in	O
mature	O
chloroplasts	O
is	O
unclear	O
.	O

We	O
show	O
here	O
that	O
PLASTID	O
REDOX	O
INSENSITIVE	O
2	O
(	O
PRIN2	O
)	O
and	O
CHLOROPLAST	O
STEM	O
-	O
LOOP	O
BINDING	O
PROTEIN	O
41	O
kDa	O
(	O
CSP41b	O
)	O
,	O
two	O
proteins	O
identified	O
in	O
plastid	O
nucleoid	O
preparations	O
,	O
are	O
essential	O
for	O
proper	O
plant	O
embryo	O
development	O
.	O

Using	O
Co	O
-	O
IP	O
assays	O
and	O
native	O
PAGE	O
we	O
have	O
shown	O
a	O
direct	O
physical	O
interaction	O
between	O
PRIN2	O
and	O
CSP41b	O
.	O

Moreover	O
,	O
PRIN2	O
and	O
CSP41b	O
form	O
a	O
distinct	O
protein	O
complex	O
in	O
vitro	O
that	O
binds	O
DNA	O
.	O

The	O
prin2	O
.	O
2	O
and	O
csp41b	O
-	O
2	O
single	O
mutants	O
displayed	O
pale	O
phenotypes	O
,	O
abnormal	O
chloroplasts	O
with	O
reduced	O
transcript	O
levels	O
of	O
photosynthesis	O
genes	O
and	O
defects	O
in	O
embryo	O
development	O
.	O

The	O
respective	O
csp41b	O
-	O
2prin2	O
.	O
2	O
homo	O
/	O
heterozygote	O
double	O
mutants	O
produced	O
abnormal	O
white	O
colored	O
ovules	O
and	O
shrunken	O
seeds	O
.	O

Thus	O
,	O
the	O
csp41b	O
-	O
2prin2	O
.	O
2	O
double	O
mutant	O
is	O
embryo	O
lethal	O
.	O

In	O
silico	O
analysis	O
of	O
available	O
array	O
data	O
showed	O
that	O
a	O
large	O
number	O
of	O
genes	O
traditionally	O
classified	O
as	O
PEP	O
dependent	O
genes	O
are	O
transcribed	O
during	O
early	O
embryo	O
development	O
from	O
the	O
pre	O
-	O
globular	O
stage	O
to	O
the	O
mature	O
-	O
green	O
-	O
stage	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
PEP	O
activity	O
and	O
consequently	O
the	O
switch	O
from	O
NEP	O
to	O
PEP	O
activity	O
,	O
is	O
essential	O
during	O
embryo	O
development	O
and	O
that	O
the	O
PRIN2	O
-	O
CSP41b	O
DNA	O
binding	O
protein	O
complex	O
possibly	O
is	O
important	O
for	O
full	O
PEP	O
activity	O
during	O
this	O
process	O
.	O

Hrr25	O
phosphorylates	O
the	O
autophagic	O
receptor	O
Atg34	O
to	O
promote	O
vacuolar	O
transport	O
of	O
alpha	O
-	O
mannosidase	O
under	O
nitrogen	O
starvation	O
conditions	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
under	O
nitrogen	O
-	O
starvation	O
conditions	O
,	O
the	O
alpha	O
-	O
mannosidase	O
Ams1	O
is	O
recognized	O
by	O
the	O
autophagic	O
receptor	O
Atg34	O
and	O
transported	O
into	O
the	O
vacuole	O
,	O
where	O
it	O
functions	O
as	O
an	O
active	O
enzyme	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
Hrr25	O
as	O
the	O
kinase	O
that	O
phosphorylates	O
Atg34	O
under	O
these	O
conditions	O
.	O

Hrr25	O
-	O
mediated	O
phosphorylation	O
does	O
not	O
affect	O
the	O
interaction	O
of	O
Atg34	O
with	O
Ams1	O
,	O
but	O
instead	O
promotes	O
Atg34	O
binding	O
to	O
the	O
adaptor	O
protein	O
Atg11	O
,	O
which	O
recruits	O
the	O
autophagy	O
machinery	O
to	O
the	O
Ams1	O
-	O
Atg34	O
complex	O
,	O
resulting	O
in	O
activation	O
of	O
the	O
vacuolar	O
transport	O
of	O
Ams1	O
.	O

Our	O
findings	O
reveal	O
the	O
regulatory	O
mechanism	O
of	O
a	O
biosynthetic	O
pathway	O
mediated	O
by	O
the	O
autophagy	O
machinery	O
.	O

Complex	O
relationship	O
between	O
ligand	O
binding	O
and	O
dimerization	O
in	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
plays	O
pivotal	O
roles	O
in	O
development	O
and	O
is	O
mutated	O
or	O
overexpressed	O
in	O
several	O
cancers	O
.	O

Despite	O
recent	O
advances	O
,	O
the	O
complex	O
allosteric	O
regulation	O
of	O
EGFR	O
remains	O
incompletely	O
understood	O
.	O

Through	O
efforts	O
to	O
understand	O
why	O
the	O
negative	O
cooperativity	O
observed	O
for	O
intact	O
EGFR	O
is	O
lost	O
in	O
studies	O
of	O
its	O
isolated	O
extracellular	O
region	O
(	O
ECR	O
)	O
,	O
we	O
uncovered	O
unexpected	O
relationships	O
between	O
ligand	O
binding	O
and	O
receptor	O
dimerization	O
.	O

The	O
two	O
processes	O
appear	O
to	O
compete	O
.	O

Surprisingly	O
,	O
dimerization	O
does	O
not	O
enhance	O
ligand	O
binding	O
(	O
although	O
ligand	O
binding	O
promotes	O
dimerization	O
)	O
.	O

We	O
further	O
show	O
that	O
simply	O
forcing	O
EGFR	O
ECRs	O
into	O
preformed	O
dimers	O
without	O
ligand	O
yields	O
ill	O
-	O
defined	O
,	O
heterogeneous	O
structures	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
extracellular	O
EGFR	O
-	O
activating	O
mutations	O
in	O
glioblastoma	O
enhance	O
ligand	O
-	O
binding	O
affinity	O
without	O
directly	O
promoting	O
EGFR	O
dimerization	O
,	O
suggesting	O
that	O
these	O
oncogenic	O
mutations	O
alter	O
the	O
allosteric	O
linkage	O
between	O
dimerization	O
and	O
ligand	O
binding	O
.	O

Our	O
findings	O
have	O
important	O
implications	O
for	O
understanding	O
how	O
EGFR	O
and	O
its	O
relatives	O
are	O
activated	O
by	O
specific	O
ligands	O
and	O
pathological	O
mutations	O
.	O

Similar	O
to	O
DeltaPP1dis2	O
,	O
disruption	O
of	O
the	O
PP1	B-Complex
-	O
binding	O
sites	O
within	O
Klp5	O
or	O
Klp6	O
also	O
alleviated	O
ndc80	O
-	O
NH12	O
growth	O
defects	O
,	O
although	O
Klp6	O
(	O
PP1mut	O
)	O
suppressed	O
the	O
defects	O
better	O
than	O
Klp5	O
(	O
PP1mut	O
)	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

It	O
is	O
of	O
note	O
that	O
Klp5	O
contains	O
two	O
PP1	B-Complex
-	O
binding	O
consensus	O
sequences	O
,	O
whereas	O
Klp6	O
contains	O
only	O
one	O
,	O
suggesting	O
that	O
the	O
binding	O
affinity	O
of	O
Klp5	O
and	O
Klp6	O
to	O
PP1	B-Complex
might	O
not	O
be	O
the	O
same	O
.	O

We	O
envision	O
that	O
this	O
altered	O
property	O
leads	O
to	O
the	O
different	O
efficacy	O
of	O
suppression	O
towards	O
ndc80	O
-	O
NH12	O
.	O

It	O
is	O
worth	O
pointing	O
out	O
that	O
the	O
temperature	O
sensitivity	O
of	O
ndc80	O
-	O
NH12	O
is	O
not	O
ameliorated	O
by	O
the	O
full	O
deletion	O
of	O
Klp5	O
(	O
or	O
Klp6	O
)	O
,	O
nor	O
the	O
truncation	O
of	O
the	O
Klp5	O
-	O
Klp6	O
motor	O
domains	O
(	O
supplementary	O
material	O
Fig	O
.	O
S2B	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
Klp5	O
-	O
Klp6	O
motors	O
play	O
crucial	O
roles	O
in	O
regulating	O
spindle	O
length	O
and	O
microtubule	O
dynamics	O
in	O
addition	O
to	O
PP1	B-Complex
recruitment	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
Klp5	O
-	O
Klp6	O
delivers	O
PP1	B-Complex
to	O
the	O
attached	O
kinetochores	O
,	O
thereby	O
promoting	O
SAC	O
silencing	O
.	O

Coordinated	O
regulation	O
by	O
two	O
VPS9	O
domain	O
-	O
containing	O
guanine	O
nucleotide	O
exchange	O
factors	O
in	O
small	O
GTPase	O
Rab5	O
signaling	O
pathways	O
in	O
fission	O
yeast	O
.	O

The	O
small	O
GTPase	O
Rab5	O
is	O
reported	O
to	O
regulate	O
various	O
cellular	O
functions	O
,	O
such	O
as	O
vesicular	O
transport	O
and	O
endocytosis	O
.	O

VPS9	O
domain	O
-	O
containing	O
proteins	O
are	O
thought	O
to	O
activate	O
Rab5	O
(	O
s	O
)	O
by	O
their	O
guanine	O
-	O
nucleotide	O
exchange	O
activities	O
.	O

Numerous	O
VPS9	O
proteins	O
have	O
been	O
identified	O
and	O
are	O
structurally	O
conserved	O
from	O
yeast	O
to	O
mammalian	O
cells	O
.	O

However	O
,	O
the	O
functional	O
relationships	O
among	O
VPS9	O
proteins	O
in	O
cells	O
remain	O
unclear	O
.	O

Only	O
one	O
Rab5	O
and	O
two	O
VPS9	O
proteins	O
were	O
identified	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
genome	O
.	O

Here	O
,	O
we	O
examined	O
the	O
cellular	O
function	O
of	O
two	O
VPS9	O
proteins	O
and	O
the	O
relationship	O
between	O
these	O
proteins	O
in	O
cellular	O
functions	O
.	O

Vps901	O
-	O
GFP	O
and	O
Vps902	O
-	O
GFP	O
exhibited	O
dotted	O
signals	O
in	O
vegetative	O
and	O
differentiated	O
cells	O
.	O

vps901	O
deletion	O
mutant	O
(	O
Deltavps901	O
)	O
cells	O
exhibited	O
a	O
phenotype	O
deficient	O
in	O
the	O
mating	O
process	O
and	O
responses	O
to	O
high	O
concentrations	O
of	O
ions	O
,	O
such	O
as	O
calcium	O
and	O
metals	O
,	O
and	O
Deltavps901Deltavps902	O
double	O
mutant	O
cells	O
exhibited	O
round	O
cell	O
shapes	O
similar	O
to	O
ypt5	O
-	O
909	O
(	O
Rab5	O
mutant	O
allele	O
)	O
cells	O
.	O

Deletion	O
of	O
both	O
vps901	O
and	O
vps902	O
genes	O
completely	O
abolished	O
the	O
mating	O
process	O
and	O
responses	O
to	O
various	O
stresses	O
.	O

A	O
lack	O
of	O
vacuole	O
formation	O
and	O
aberrant	O
inner	O
cell	O
membrane	O
structures	O
were	O
also	O
observed	O
in	O
Deltavps901Deltavps902	O
cells	O
by	O
electron	O
microscopy	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
Vps901	O
and	O
Vps902	O
are	O
cooperatively	O
involved	O
in	O
the	O
regulation	O
of	O
cellular	O
functions	O
,	O
such	O
as	O
cell	O
morphology	O
,	O
sexual	O
development	O
,	O
response	O
to	O
ion	O
stresses	O
,	O
and	O
vacuole	O
formation	O
,	O
via	O
Rab5	O
signaling	O
pathways	O
in	O
fission	O
yeast	O
cells	O
.	O

In	O
mammals	O
,	O
SCML2	O
is	O
an	O
MBT	O
domain	O
-	O
containing	O
protein	O
that	O
is	O
essential	O
in	O
the	O
male	O
germline	O
.	O

Our	O
results	O
suggest	O
that	O
germline	O
-	O
specific	O
expression	O
of	O
SCML2	O
is	O
related	O
to	O
its	O
function	O
in	O
establishing	O
germline	O
-	O
specific	O
features	O
.	O

Although	O
a	O
previous	O
study	O
suggested	O
that	O
mammalian	O
Scm	O
homologs	O
have	O
redundant	O
functions	O
and	O
compensate	O
for	O
the	O
loss	O
of	O
Scmh1	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
the	O
phenotype	O
of	O
the	O
Scml2	O
-	O
KO	O
is	O
distinct	O
from	O
that	O
of	O
the	O
Scmh1	O
-	O
KO	O
and	O
that	O
the	O
function	O
of	O
SCML2	O
is	O
not	O
redundant	O
with	O
that	O
of	O
SCMH1	O
.	O

Thus	O
,	O
SCML2	O
has	O
a	O
unique	O
function	O
in	O
the	O
germline	O
that	O
cannot	O
be	O
compensated	O
by	O
other	O
MBT	O
domain	O
-	O
containing	O
proteins	O
.	O

A	O
recent	O
study	O
suggested	O
that	O
human	O
SCML2	O
is	O
expressed	O
ubiquitously	O
in	O
somatic	O
tissues	O
,	O
so	O
it	O
would	O
be	O
intriguing	O
to	O
examine	O
the	O
difference	O
between	O
human	O
SCML2	O
and	O
mouse	O
SCML2	O
.	O

Cardiac	O
glycosides	O
induced	O
toxicity	O
in	O
human	O
cells	O
expressing	O
alpha1	O
-	O
,	O
alpha2	O
-	O
,	O
or	O
alpha3	O
-	O
isoforms	O
of	O
Na	O
-	O
K	O
-	O
ATPase	O
.	O

The	O
Na	O
+	O
-	O
K	O
+	O
-	O
ATPase	O
is	O
specifically	O
inhibited	O
by	O
cardiac	O
glycosides	O
,	O
some	O
of	O
which	O
may	O
also	O
function	O
as	O
endogenous	O
mammalian	O
hormones	O
.	O

Previous	O
studies	O
using	O
Xenopus	O
oocytes	O
,	O
yeast	O
cells	O
,	O
or	O
purified	O
isoforms	O
demonstrated	O
that	O
affinities	O
of	O
various	O
cardiac	O
glycosides	O
for	O
three	O
isoforms	O
of	O
the	O
Na	O
+	O
-	O
K	O
+	O
-	O
ATPase	O
(	O
alpha1	O
-	O
alpha3beta1	O
)	O
may	O
differ	O
,	O
a	O
finding	O
with	O
potential	O
clinical	O
implication	O
.	O

The	O
present	O
study	O
investigates	O
isoform	O
selectivity	O
and	O
effects	O
of	O
cardiac	O
glycosides	O
on	O
cultured	O
mammalian	O
cells	O
under	O
more	O
physiological	O
conditions	O
.	O

H1299	O
cells	O
(	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
)	O
were	O
engineered	O
to	O
express	O
only	O
one	O
alpha	O
-	O
isoform	O
(	O
alpha1	O
,	O
alpha2	O
,	O
or	O
alpha3	O
)	O
by	O
combining	O
stable	O
transfection	O
of	O
isoforms	O
and	O
silencing	O
endogenous	O
alpha1	O
.	O

Cardiac	O
glycoside	O
binding	O
was	O
measured	O
by	O
displacement	O
of	O
bound	O
3H	O
-	O
ouabain	O
.	O

The	O
experiments	O
confirm	O
moderate	O
alpha1	O
/	O
alpha3	O
:	O
alpha2	O
selectivity	O
of	O
ouabain	O
,	O
moderate	O
alpha2	O
:	O
alpha1	O
selectivity	O
of	O
digoxin	O
,	O
and	O
enhanced	O
alpha2	O
:	O
alpha1	O
selectivity	O
of	O
synthetic	O
derivatives	O
(	O
Katz	O
A	O
,	O
Tal	O
DM	O
,	O
Heller	O
D	O
,	O
Haviv	O
H	O
,	O
Rabah	O
B	O
,	O
Barkana	O
Y	O
,	O
Marcovich	O
AL	O
,	O
Karlish	O
SJD	O
.	O
J	O
Biol	O
Chem	O
289	O
:	O
21153	O
-	O
21162	O
,	O
2014	O
)	O
.	O

Relative	O
alpha2	O
:	O
alpha1	O
selectivity	O
of	O
digoxin	O
vs	O
.	O
ouabain	O
was	O
also	O
manifested	O
by	O
enhanced	O
internalization	O
of	O
alpha2	O
in	O
response	O
to	O
digoxin	O
.	O

Cellular	O
proliferation	O
assays	O
of	O
H1299	O
cells	O
confirmed	O
the	O
patterns	O
of	O
alpha2	O
:	O
alpha1	O
selectivity	O
for	O
ouabain	O
,	O
digoxin	O
,	O
and	O
a	O
synthetic	O
derivative	O
and	O
reveal	O
a	O
crucial	O
role	O
of	O
surface	O
pump	O
density	O
on	O
sensitivity	O
to	O
cardiac	O
glycosides	O
.	O

Because	O
cardiac	O
glycosides	O
are	O
being	O
considered	O
as	O
drugs	O
for	O
treatment	O
of	O
cancer	O
,	O
effects	O
of	O
ouabain	O
on	O
proliferation	O
of	O
12	O
cancer	O
and	O
noncancer	O
cell	O
lines	O
,	O
with	O
variable	O
plasma	O
membrane	O
expression	O
of	O
alpha1	O
,	O
have	O
been	O
tested	O
.	O

These	O
demonstrated	O
that	O
sensitivity	O
to	O
ouabain	O
indeed	O
depends	O
linearly	O
on	O
the	O
plasma	O
membrane	O
surface	O
density	O
of	O
Na	O
+	O
-	O
K	O
+	O
-	O
ATPase	O
irrespective	O
of	O
status	O
,	O
malignant	O
or	O
nonmalignant	O
.	O

LSD1	O
and	O
HY5	O
antagonistically	O
regulate	O
red	O
light	O
induced	O
-	O
programmed	O
cell	O
death	O
in	O
Arabidopsis	O
.	O

Programmed	O
cell	O
death	O
(	O
PCD	O
)	O
in	O
plant	O
is	O
triggered	O
by	O
abiotic	O
and	O
biotic	O
stress	O
.	O

Light	O
-	O
dependent	O
PCD	O
is	O
unique	O
to	O
plants	O
.	O

Light	O
-	O
induced	O
PCD	O
also	O
requires	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
salicylic	O
acid	O
(	O
SA	O
)	O
.	O

In	O
this	O
study	O
,	O
lesion	O
simulating	O
disease1	O
(	O
LSD1	O
)	O
and	O
elongated	O
hypocotyl	O
5	O
(	O
HY5	O
)	O
perform	O
opposite	O
roles	O
to	O
regulate	O
excess	O
red	O
light	O
(	O
RL	O
)	O
-	O
triggered	O
PCD	O
associated	O
with	O
ROS	O
and	O
SA	O
production	O
.	O

Under	O
RL	O
,	O
the	O
lsd1	O
mutant	O
released	O
more	O
ROS	O
and	O
SA	O
and	O
displayed	O
a	O
stronger	O
cell	O
death	O
rate	O
than	O
the	O
hy5	O
mutant	O
.	O

It	O
was	O
shown	O
that	O
active	O
LSD1	O
converted	O
into	O
inactive	O
form	O
by	O
changing	O
the	O
redox	O
status	O
of	O
the	O
plastoquinone	O
pool	O
,	O
and	O
HY5	O
interacted	O
with	O
phytochrome	O
B	O
(	O
phyB	O
)	O
to	O
promote	O
PCD	O
in	O
response	O
to	O
RL	O
.	O

LSD1	O
inhibited	O
the	O
enhanced	O
disease	O
susceptibility	O
1	O
(	O
EDS1	O
)	O
expression	O
by	O
upregulating	O
SR1	O
,	O
whereas	O
HY5	O
enhanced	O
the	O
enhanced	O
EDS1	O
expression	O
by	O
binding	O
to	O
the	O
G	O
-	O
box	O
of	O
the	O
EDS1	O
promoter	O
.	O

This	O
study	O
suggested	O
that	O
LSD1	O
and	O
HY5	O
antagonistically	O
modulated	O
EDS1	O
-	O
dependent	O
ROS	O
and	O
SA	O
signaling	O
;	O
thus	O
,	O
PCD	O
was	O
mediated	O
in	O
response	O
to	O
RL	O
.	O

Protein	O
Arginine	O
Methyltransferase	O
1	O
Methylates	O
Smurf2	O
.	O

Smurf2	O
,	O
a	O
member	O
of	O
the	O
HECT	O
domain	O
E3	O
ligase	O
family	O
,	O
is	O
well	O
known	O
for	O
its	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
targeting	O
Smads	O
and	O
TGF	O
-	O
beta	O
receptor	O
.	O

However	O
,	O
the	O
regulatory	O
mechanism	O
of	O
Smurf2	O
has	O
not	O
been	O
elucidated	O
.	O

Arginine	O
methylation	O
is	O
a	O
type	O
of	O
post	O
-	O
translational	O
modification	O
that	O
produces	O
monomethylated	O
or	O
dimethylated	O
arginine	O
residues	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrated	O
methylation	O
of	O
Smurf2	O
by	O
PRMT1	O
.	O

In	O
vitro	O
methylation	O
assay	O
showed	O
that	O
Smurf2	O
,	O
not	O
Smurf1	O
,	O
was	O
methylated	O
by	O
PRMT1	O
.	O

Among	O
the	O
type	O
I	O
PRMT	O
family	O
,	O
only	O
PRMT1	O
showed	O
activity	O
for	O
Smurf2	O
.	O

Transiently	O
expressed	O
Smurf2	O
was	O
methylated	O
by	O
PRMT1	O
,	O
indicating	O
Smurf2	O
is	O
a	O
novel	O
substrate	O
of	O
PRMT1	O
.	O

Using	O
deletion	O
constructs	O
,	O
methylation	O
sites	O
were	O
shown	O
to	O
be	O
located	O
within	O
amino	O
acid	O
region	O
224	O
-	O
298	O
of	O
Smurf2	O
.	O

In	O
vitro	O
methylation	O
assay	O
following	O
point	O
mutation	O
of	O
putative	O
methylation	O
sites	O
confirmed	O
the	O
presence	O
of	O
Arg232	O
,	O
Arg234	O
,	O
Arg237	O
,	O
and	O
Arg239	O
.	O

Knockdown	O
of	O
PRMT1	O
resulted	O
in	O
increased	O
Smurf2	O
expression	O
as	O
well	O
as	O
inhibition	O
of	O
TGF	O
-	O
beta	O
-	O
mediated	O
reporter	O
activity	O
.	O

Although	O
it	O
is	O
unclear	O
whether	O
or	O
not	O
increased	O
Smurf2	O
expression	O
can	O
be	O
directly	O
attributed	O
to	O
lack	O
of	O
methylation	O
of	O
arginine	O
residues	O
,	O
our	O
results	O
suggest	O
that	O
methylation	O
by	O
PRMT1	O
may	O
regulate	O
Smurf2	O
stability	O
and	O
control	O
TGF	O
-	O
beta	O
signaling	O
.	O

UBQLNs	O
were	O
previously	O
reported	O
to	O
localize	O
to	O
protein	O
aggregates	O
in	O
SCA3	O
human	O
tissue	O
.	O

Using	O
a	O
UBQLN2	O
selective	O
antibody	O
(	O
Fig	O
.	O
S1	O
)	O
,	O
however	O
,	O
we	O
did	O
not	O
detect	O
UBQLN2	O
immunoreactivity	O
in	O
ATXN3	O
inclusions	O
in	O
mouse	O
models	O
of	O
SCA3	O
or	O
in	O
human	O
disease	O
tissue	O
.	O

Mori	O
et	O
al	O
used	O
an	O
anti	O
-	O
UBQLN	O
antibody	O
that	O
non	O
-	O
selectively	O
recognizes	O
both	O
UBQLN1	O
and	O
UBQLN2	O
(	O
Fig	O
.	O
S1	O
)	O
and	O
thus	O
prior	O
results	O
may	O
not	O
reflect	O
actual	O
colocalization	O
of	O
UBQLN2	O
to	O
ATXN3	O
inclusions	O
.	O

In	O
addition	O
,	O
UBQLN1	O
and	O
UBQLN2	O
both	O
can	O
form	O
cytoplasmic	O
puncta	O
when	O
overexpressed	O
in	O
cells	O
,	O
even	O
as	O
wild	O
type	O
protein	O
.	O

In	O
the	O
absence	O
of	O
co	O
-	O
immunostaining	O
with	O
ATXN3	O
,	O
it	O
is	O
difficult	O
to	O
know	O
whether	O
UBQLN2	O
-	O
positive	O
inclusions	O
detected	O
by	O
immunohistochemistry	O
in	O
cell	O
systems	O
or	O
human	O
tissue	O
reflect	O
ATXN3	O
aggregates	O
.	O

Consistent	O
with	O
the	O
results	O
from	O
SCA3	O
human	O
disease	O
tissue	O
and	O
mouse	O
models	O
,	O
co	O
-	O
precipitation	O
studies	O
in	O
cultured	O
cells	O
demonstrated	O
that	O
UBQLN2	O
fails	O
to	O
interact	O
with	O
normal	O
ATXN3	O
or	O
expanded	O
ATXN3	O
protein	O
.	O

These	O
findings	O
suggest	O
that	O
ATXN3	O
may	O
not	O
be	O
a	O
substrate	O
for	O
UBQLN2	O
-	O
mediated	O
clearance	O
.	O

Clinical	O
,	O
biochemical	O
and	O
metabolic	O
characterisation	O
of	O
a	O
mild	O
form	O
of	O
human	O
short	O
-	O
chain	O
enoyl	O
-	O
CoA	O
hydratase	O
deficiency	O
:	O
significance	O
of	O
increased	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
(	O
2	O
-	O
carboxypropyl	O
)	O
cysteine	O
excretion	O
.	O

BACKGROUND	O
:	O
Short	O
-	O
chain	O
enoyl	O
-	O
CoA	O
hydratase	O
-	O
ECHS1	O
-	O
catalyses	O
many	O
metabolic	O
pathways	O
,	O
including	O
mitochondrial	O
short	O
-	O
chain	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
and	O
branched	O
-	O
chain	O
amino	O
acid	O
catabolic	O
pathways	O
;	O
however	O
,	O
the	O
metabolic	O
products	O
essential	O
for	O
the	O
diagnosis	O
of	O
ECHS1	O
deficiency	O
have	O
not	O
yet	O
been	O
determined	O
.	O

The	O
objective	O
of	O
this	O
report	O
is	O
to	O
characterise	O
ECHS1	O
and	O
a	O
mild	O
form	O
of	O
its	O
deficiency	O
biochemically	O
,	O
and	O
to	O
determine	O
the	O
candidate	O
metabolic	O
product	O
that	O
can	O
be	O
efficiently	O
used	O
for	O
neonatal	O
diagnosis	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
detailed	O
clinical	O
,	O
molecular	O
genetics	O
,	O
biochemical	O
and	O
metabolic	O
analysis	O
of	O
sibling	O
patients	O
with	O
ECHS1	O
deficiency	O
.	O

Moreover	O
,	O
we	O
purified	O
human	O
ECHS1	O
,	O
and	O
determined	O
the	O
substrate	O
specificity	O
of	O
ECHS1	O
for	O
five	O
substrates	O
via	O
different	O
metabolic	O
pathways	O
.	O

RESULTS	O
:	O
Human	O
ECHS1	O
catalyses	O
the	O
hydration	O
of	O
five	O
substrates	O
via	O
different	O
metabolic	O
pathways	O
,	O
with	O
the	O
highest	O
specificity	O
for	O
crotonyl	O
-	O
CoA	O
and	O
the	O
lowest	O
specificity	O
for	O
tiglyl	O
-	O
CoA	O
.	O

The	O
patients	O
had	O
relatively	O
high	O
(	O
~	O
7	O
%	O
)	O
residual	O
ECHS1	O
enzyme	O
activity	O
for	O
crotonyl	O
-	O
CoA	O
and	O
methacrylyl	O
-	O
CoA	O
caused	O
by	O
the	O
compound	O
heterozygous	O
mutations	O
(	O
c	O
.	O
176A	O
>	O
G	O
,	O
(	O
p	O
.	O
N59S	O
)	O
and	O
c	O
.	O
413C	O
>	O
T	O
,	O
(	O
p	O
.	O
A138V	O
)	O
)	O
with	O
normal	O
mitochondrial	B-Complex
complex	I-Complex
I	I-Complex
-	I-Complex
IV	I-Complex
activities	O
.	O

Affected	O
patients	O
excrete	O
large	O
amounts	O
of	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
(	O
2	O
-	O
carboxypropyl	O
)	O
cysteine	O
,	O
a	O
metabolite	O
of	O
methacrylyl	O
-	O
CoA	O
.	O

CONCLUSIONS	O
:	O
Laboratory	O
data	O
and	O
clinical	O
features	O
demonstrated	O
that	O
the	O
patients	O
have	O
a	O
mild	O
form	O
of	O
ECHS1	O
deficiency	O
harbouring	O
defective	O
valine	O
catabolic	O
and	O
beta	O
-	O
oxidation	O
pathways	O
.	O

N	O
-	O
Acetyl	O
-	O
S	O
-	O
(	O
2	O
-	O
carboxypropyl	O
)	O
cysteine	O
level	O
was	O
markedly	O
high	O
in	O
the	O
urine	O
of	O
the	O
patients	O
,	O
and	O
therefore	O
,	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
(	O
2	O
-	O
carboxypropyl	O
)	O
cysteine	O
was	O
regarded	O
as	O
a	O
candidate	O
metabolite	O
for	O
the	O
diagnosis	O
of	O
ECHS1	O
deficiency	O
.	O

This	O
metabolite	O
is	O
not	O
part	O
of	O
current	O
routine	O
metabolic	O
screening	O
protocols	O
,	O
and	O
its	O
inclusion	O
,	O
therefore	O
,	O
holds	O
immense	O
potential	O
in	O
accurate	O
diagnosis	O
.	O

AAMP	O
Regulates	O
Endothelial	O
Cell	O
Migration	O
and	O
Angiogenesis	O
Through	O
RhoA	O
/	O
Rho	O
Kinase	O
Signaling	O
.	O

Angiogenesis	O
is	O
a	O
complicated	O
process	O
including	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
and	O
tube	O
formation	O
.	O

AAMP	O
plays	O
a	O
role	O
in	O
regulating	O
cell	O
migration	O
of	O
multiple	O
cell	O
types	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
AAMP	O
regulates	O
angiogenesis	O
,	O
and	O
to	O
clarify	O
the	O
role	O
of	O
AAMP	O
in	O
the	O
VEGF	O
-	O
induced	O
angiogenesis	O
.	O

We	O
found	O
that	O
AAMP	O
expressed	O
in	O
multiple	O
cell	O
types	O
and	O
mainly	O
localized	O
in	O
cytoplasm	O
and	O
membrane	O
in	O
vascular	O
endothelial	O
cells	O
.	O

Using	O
tube	O
formation	O
assay	O
in	O
vitro	O
and	O
aortic	O
ring	O
assay	O
,	O
siRNA	O
-	O
mediated	O
knockdown	O
and	O
antibody	O
blockade	O
of	O
AAMP	O
impaired	O
VEGF	O
-	O
induced	O
endothelial	O
cell	O
tube	O
formation	O
and	O
aortic	O
ring	O
angiogenic	O
sprouting	O
.	O

Mechanistic	O
studies	O
showed	O
that	O
AAMP	O
expression	O
was	O
significantly	O
upregulated	O
by	O
VEGF	O
in	O
a	O
concentration	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
VEGF	O
recruited	O
AAMP	O
to	O
the	O
cell	O
membrane	O
protrusions	O
.	O

AAMP	O
regulates	O
angiogenesis	O
by	O
mediating	O
the	O
spreading	O
and	O
migration	O
of	O
vascular	O
endothelial	O
cells	O
.	O

AAMP	O
knock	O
-	O
down	O
reduced	O
VEGF	O
-	O
induced	O
actin	O
stress	O
fibers	O
and	O
collagen	B-Complex
gel	O
contraction	O
.	O

Furthermore	O
,	O
we	O
identified	O
RhoA	O
/	O
Rho	O
kinase	O
signaling	O
as	O
an	O
important	O
factor	O
that	O
contributes	O
to	O
the	O
action	O
of	O
AAMP	O
in	O
regulating	O
endothelial	O
cell	O
migration	O
and	O
angiogenesis	O
.	O

Altogether	O
,	O
these	O
data	O
demonstrated	O
the	O
critical	O
role	O
of	O
AAMP	O
in	O
angiogenesis	O
and	O
suggested	O
blocking	O
AAMP	O
could	O
serve	O
as	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
angiogenesis	O
-	O
related	O
diseases	O
.	O

RanGTP	O
is	O
known	O
to	O
regulate	O
the	O
spindle	O
assembly	O
checkpoint	O
(	O
SAC	O
)	O
,	O
but	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
unclear	O
.	O

BuGZ	O
stabilizes	O
SAC	O
protein	O
Bub3	O
through	O
direct	O
interaction	O
and	O
facilitates	O
its	O
mitotic	O
function	O
.	O

Here	O
we	O
show	O
that	O
RanGTP	O
promotes	O
the	O
turnover	O
of	O
BuGZ	O
and	O
Bub3	O
in	O
metaphase	O
,	O
which	O
in	O
turn	O
facilitates	O
metaphase	O
-	O
to	O
-	O
anaphase	O
transition	O
.	O

BuGZ	O
and	O
Bub3	O
interact	O
with	O
either	O
importin	O
-	O
Beta	O
or	O
an	O
E3	O
ubiquitin	O
ligase	O
,	O
Ubr5	O
.	O

RanGTP	O
promotes	O
the	O
dissociation	O
of	O
importin	O
-	O
Beta	O
from	O
BuGZ	O
and	O
Bub3	O
in	O
metaphase	O
.	O

This	O
results	O
in	O
increased	O
binding	O
of	O
BuGZ	O
and	O
Bub3	O
to	O
Ubr5	O
,	O
leading	O
to	O
ubiquitination	O
and	O
subsequent	O
turnover	O
of	O
both	O
proteins	O
.	O

We	O
propose	O
that	O
elevated	O
metaphase	O
RanGTP	O
levels	O
use	O
Ubr5	O
to	O
couple	O
overall	O
chromosome	O
congression	O
to	O
SAC	O
silencing	O
.	O

Further	O
to	O
an	O
interactomic	O
screen	O
carried	O
out	O
by	O
Bergiers	O
et	O
al	O
.	O
to	O
identify	O
Hoxa2	O
partner	O
proteins	O
,	O
the	O
Hoxa2	O
protein	O
from	O
the	O
mouse	O
was	O
shown	O
to	O
interact	O
with	O
the	O
human	O
RCHY1	O
and	O
to	O
induce	O
its	O
destabilization	O
.	O

To	O
confirm	O
these	O
data	O
obtained	O
with	O
proteins	O
of	O
heterologous	O
origin	O
,	O
we	O
addressed	O
whether	O
this	O
destabilization	O
process	O
was	O
conserved	O
for	O
the	O
human	O
proteins	O
.	O

To	O
this	O
end	O
,	O
we	O
transiently	O
transfected	O
HEK293T	O
cells	O
to	O
express	O
human	O
FLAG	O
-	O
RCHY1	O
and	O
GST	O
or	O
human	O
GST	O
-	O
HOXA2	O
fusion	O
proteins	O
.	O

As	O
shown	O
in	O
Fig	O
1A	O
,	O
the	O
level	O
of	O
RCHY1	O
was	O
considerably	O
decreased	O
in	O
the	O
presence	O
of	O
HOXA2	O
supporting	O
that	O
,	O
like	O
for	O
the	O
murine	O
Hoxa2	O
,	O
expression	O
of	O
the	O
human	O
HOXA2	O
had	O
a	O
negative	O
effect	O
on	O
RCHY1	O
protein	O
accumulation	O
.	O

Identification	O
and	O
characterization	O
of	O
Csh3	O
as	O
an	O
SH3	O
protein	O
that	O
interacts	O
with	O
fission	O
yeast	O
Cap1	O
.	O

Schizosaccharomyces	O
pombe	O
Cap1	O
has	O
been	O
identified	O
as	O
the	O
(	O
adenylyl	O
)	O
cyclase	O
-	O
associated	O
protein	O
.	O

Cap1	O
was	O
able	O
to	O
bind	O
Cap1	O
itself	O
and	O
actin	O
.	O

Cap1	O
localized	O
at	O
the	O
growing	O
tip	O
,	O
and	O
this	O
localization	O
was	O
dependent	O
on	O
the	O
Cap1	O
P2	O
region	O
.	O

In	O
a	O
two	O
-	O
hybrid	O
screening	O
using	O
cap1	O
as	O
bait	O
,	O
we	O
isolated	O
csh3	O
,	O
which	O
encodes	O
a	O
protein	O
of	O
296	O
amino	O
acids	O
with	O
an	O
SH3	O
domain	O
and	O
a	O
proline	O
/	O
glutamine	O
-	O
rich	O
region	O
.	O

The	O
binding	O
of	O
Csh3	O
and	O
Cap1	O
was	O
confirmed	O
by	O
in	O
vivo	O
pull	O
down	O
assays	O
.	O

Cooperative	O
functions	O
of	O
Csh3	O
and	O
Cap1	O
were	O
observed	O
.	O

Deletion	O
of	O
both	O
csh3	O
and	O
cap1	O
resulted	O
in	O
heightened	O
sensitivity	O
to	O
CaCl2	O
,	O
while	O
disruption	O
of	O
either	O
gene	O
alone	O
did	O
not	O
have	O
any	O
effect	O
in	O
this	O
regard	O
.	O

In	O
addition	O
,	O
over	O
-	O
expression	O
of	O
csh3	O
or	O
cap1	O
alone	O
did	O
not	O
affect	O
cell	O
growth	O
,	O
while	O
over	O
-	O
expression	O
of	O
both	O
genes	O
resulted	O
in	O
growth	O
retardation	O
.	O

Finally	O
,	O
while	O
Csh3	O
-	O
GFP	O
localized	O
to	O
the	O
cytoplasm	O
in	O
wild	O
-	O
type	O
cells	O
,	O
its	O
localization	O
was	O
altered	O
in	O
cap1Delta	O
cells	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
Csh3	O
and	O
Cap1	O
controls	O
the	O
cellular	O
localization	O
of	O
Csh3	O
.	O

These	O
results	O
demonstrate	O
that	O
Cap1	O
in	O
Schizo	O
.	O
pombe	O
is	O
a	O
multifunctional	O
protein	O
that	O
functions	O
through	O
interaction	O
with	O
Cap1	O
itself	O
and	O
other	O
proteins	O
including	O
adenylyl	O
cyclase	O
,	O
actin	O
and	O
Csh3	O
.	O

Evolutionary	O
Loss	O
of	O
Activity	O
in	O
De	O
-	O
Ubiquitylating	O
Enzymes	O
of	O
the	O
OTU	O
Family	O
.	O

Understanding	O
function	O
and	O
specificity	O
of	O
de	O
-	O
ubiquitylating	O
enzymes	O
(	O
DUBs	O
)	O
is	O
a	O
major	O
goal	O
of	O
current	O
research	O
,	O
since	O
DUBs	O
are	O
key	O
regulators	O
of	O
ubiquitylation	O
events	O
and	O
have	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
human	O
diseases	O
.	O

Most	O
DUBs	O
are	O
cysteine	O
proteases	O
,	O
relying	O
on	O
a	O
catalytic	O
triad	O
of	O
cysteine	O
,	O
histidine	O
and	O
aspartate	O
to	O
cleave	O
the	O
isopeptide	O
bond	O
between	O
two	O
ubiquitin	O
units	O
in	O
a	O
poly	O
-	O
ubiquitin	O
chain	O
.	O

We	O
have	O
discovered	O
that	O
the	O
two	O
Drosophila	O
melanogaster	O
homologues	O
of	O
human	O
OTUD4	O
,	O
CG3251	O
and	O
Otu	O
,	O
contain	O
a	O
serine	O
instead	O
of	O
a	O
cysteine	O
in	O
the	O
catalytic	O
OTU	O
(	O
ovarian	O
tumor	O
)	O
domain	O
.	O

DUBs	O
that	O
are	O
serine	O
proteases	O
instead	O
of	O
cysteine	O
-	O
or	O
metallo	O
-	O
proteases	O
have	O
not	O
been	O
described	O
.	O

In	O
line	O
with	O
this	O
,	O
neither	O
CG3251	O
nor	O
Otu	O
protein	O
were	O
active	O
to	O
cleave	O
ubiquitin	O
chains	O
.	O

Re	O
-	O
introduction	O
of	O
a	O
cysteine	O
in	O
the	O
catalytic	O
center	O
did	O
not	O
render	O
the	O
enzymes	O
active	O
,	O
indicating	O
that	O
further	O
critical	O
features	O
for	O
ubiquitin	O
binding	O
or	O
cleavage	O
have	O
been	O
lost	O
in	O
these	O
proteins	O
.	O

Sequence	O
analysis	O
of	O
OTUD4	O
homologues	O
from	O
various	O
other	O
species	O
showed	O
that	O
within	O
this	O
OTU	O
subfamily	O
,	O
loss	O
of	O
the	O
catalytic	O
cysteine	O
has	O
occurred	O
frequently	O
in	O
presumably	O
independent	O
events	O
,	O
as	O
well	O
as	O
gene	O
duplications	O
or	O
triplications	O
,	O
suggesting	O
DUB	O
-	O
independent	O
functions	O
of	O
OTUD4	O
proteins	O
.	O

Using	O
an	O
in	O
vivo	O
RNAi	O
approach	O
,	O
we	O
show	O
that	O
CG3251	O
might	O
function	O
in	O
the	O
regulation	O
of	O
Inhibitor	O
of	O
Apoptosis	O
(	O
IAP	O
)	O
-	O
antagonist	O
-	O
induced	O
apoptosis	O
,	O
presumably	O
in	O
a	O
DUB	O
-	O
independent	O
manner	O
.	O

The	O
LINC	B-Complex
complex	O
component	O
Sun4	O
plays	O
a	O
crucial	O
role	O
in	O
sperm	O
head	O
formation	O
and	O
fertility	O
.	O

LINC	B-Complex
complexes	O
are	O
evolutionarily	O
conserved	O
nuclear	O
envelope	O
bridges	O
,	O
physically	O
connecting	O
the	O
nucleus	O
to	O
the	O
peripheral	O
cytoskeleton	O
.	O

They	O
are	O
pivotal	O
for	O
dynamic	O
cellular	O
and	O
developmental	O
processes	O
,	O
like	O
nuclear	O
migration	O
,	O
anchoring	O
and	O
positioning	O
,	O
meiotic	O
chromosome	O
movements	O
and	O
maintenance	O
of	O
cell	O
polarity	O
and	O
nuclear	O
shape	O
.	O

Active	O
nuclear	O
reshaping	O
is	O
a	O
hallmark	O
of	O
mammalian	O
sperm	O
development	O
and	O
,	O
by	O
transducing	O
cytoskeletal	O
forces	O
to	O
the	O
nuclear	O
envelope	O
,	O
LINC	B-Complex
complexes	O
could	O
be	O
vital	O
for	O
sperm	O
head	O
formation	O
as	O
well	O
.	O

We	O
here	O
analyzed	O
in	O
detail	O
the	O
behavior	O
and	O
function	O
of	O
Sun4	O
,	O
a	O
bona	O
fide	O
testis	O
-	O
specific	O
LINC	B-Complex
component	O
.	O

We	O
demonstrate	O
that	O
Sun4	O
is	O
solely	O
expressed	O
in	O
spermatids	O
and	O
there	O
localizes	O
to	O
the	O
posterior	O
nuclear	O
envelope	O
,	O
likely	O
interacting	O
with	O
Sun3	O
/	O
Nesprin1	O
LINC	B-Complex
components	O
.	O

Our	O
study	O
revealed	O
that	O
Sun4	O
deficiency	O
severely	O
impacts	O
the	O
nucleocytoplasmic	O
junction	O
,	O
leads	O
to	O
mislocalization	O
of	O
other	O
LINC	B-Complex
components	O
and	O
interferes	O
with	O
the	O
formation	O
of	O
the	O
microtubule	O
manchette	O
,	O
which	O
finally	O
culminates	O
in	O
a	O
globozoospermia	O
-	O
like	O
phenotype	O
.	O

Together	O
,	O
our	O
study	O
provides	O
direct	O
evidence	O
for	O
a	O
critical	O
role	O
of	O
LINC	B-Complex
complexes	O
in	O
mammalian	O
sperm	O
head	O
formation	O
and	O
male	O
fertility	O
.	O

Identification	O
of	O
RNF168	O
as	O
a	O
PML	B-OOS
nuclear	I-OOS
body	I-OOS
regulator	O
.	O

Promyelocytic	O
leukemia	O
(	O
PML	O
)	O
protein	O
forms	O
the	O
basis	O
of	O
PML	B-OOS
nuclear	I-OOS
bodies	I-OOS
(	O
PML	B-OOS
NBs	I-OOS
)	O
,	O
which	O
control	O
many	O
important	O
processes	O
.	O

We	O
have	O
screened	O
an	O
shRNA	O
library	O
targeting	O
ubiquitin	O
pathway	O
proteins	O
for	O
effects	O
on	O
PML	B-OOS
NBs	I-OOS
,	O
and	O
identified	O
RNF8	O
and	O
RNF168	O
DNA	O
-	O
damage	O
response	O
proteins	O
as	O
negative	O
regulators	O
of	O
PML	B-OOS
NBs	I-OOS
.	O

Additional	O
studies	O
confirmed	O
that	O
depletion	O
of	O
either	O
RNF8	O
or	O
RNF168	O
increased	O
the	O
levels	O
of	O
PML	B-OOS
NBs	I-OOS
and	O
proteins	O
,	O
whereas	O
overexpression	O
induced	O
loss	O
of	O
PML	B-OOS
NBs	I-OOS
.	O

RNF168	O
partially	O
localized	O
to	O
PML	B-OOS
NBs	I-OOS
through	O
its	O
UMI	O
/	O
MIU1	O
ubiquitin	O
-	O
interacting	O
region	O
and	O
associated	O
with	O
NBs	B-OOS
formed	O
by	O
any	O
PML	O
isoform	O
.	O

The	O
association	O
of	O
RNF168	O
with	O
PML	B-OOS
NBs	I-OOS
resulted	O
in	O
increased	O
ubiquitylation	O
and	O
SUMO2	O
modification	O
of	O
PML	O
.	O

In	O
addition	O
,	O
RNF168	O
was	O
found	O
to	O
associate	O
with	O
proteins	O
modified	O
by	O
SUMO2	O
and	O
/	O
or	O
SUMO3	O
in	O
a	O
manner	O
dependent	O
on	O
its	O
ubiquitin	O
-	O
binding	O
sequences	O
,	O
suggesting	O
that	O
hybrid	O
SUMO	O
-	O
ubiquitin	O
chains	O
can	O
be	O
bound	O
.	O

In	O
vitro	O
assays	O
confirmed	O
that	O
RNF168	O
,	O
preferentially	O
,	O
binds	O
hybrid	O
SUMO2	O
-	O
K63	O
ubiquitin	O
chains	O
compared	O
with	O
K63	O
-	O
ubiquitin	O
chains	O
or	O
individual	O
SUMO2	O
.	O

Our	O
study	O
identified	O
previously	O
unrecognized	O
roles	O
for	O
RNF8	O
and	O
RNF168	O
in	O
the	O
regulation	O
of	O
PML	O
,	O
and	O
a	O
so	O
far	O
unknown	O
preference	O
of	O
RNF168	O
for	O
hybrid	O
SUMO	O
-	O
ubiquitin	O
chains	O
.	O

Sedimentation	O
equilibrium	O
experiments	O
were	O
performed	O
in	O
a	O
ProteomeLab	O
XL	O
-	O
I	O
(	O
Beckman	O
Coulter	O
)	O
analytical	O
ultracentrifuge	O
.	O

HOIP	O
-	O
RBR	O
/	O
UbcH5B	O
~	O
ubiquitin	O
as	O
used	O
for	O
crystallization	O
was	O
loaded	O
into	O
a	O
6	O
-	O
channel	O
equilibrium	O
cell	O
at	O
5	O
.	O
0	O
,	O
2	O
.	O
5	O
and	O
1	O
.	O
25	O
muM	O
concentration	O
and	O
centrifuged	O
at	O
10	O
,	O
000	O
rpm	O
,	O
20degreesC	O
in	O
an	O
An	O
-	O
50	O
Ti	O
8	O
-	O
place	O
rotor	O
until	O
equilibrium	O
was	O
achieved	O
.	O

Data	O
were	O
analysed	O
using	O
HeteroAnalysis	O
software	O
(	O
J	O
.	O
L	O
.	O
Cole	O
and	O
J	O
.	O
W	O
.	O
Lary	O
,	O
University	O
of	O
Connecticut	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
biotech	O
.	O
uconn	O
.	O
edu	O
/	O
auf	O
/	O
)	O
.	O

FADD	O
regulates	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
and	O
promotes	O
ubiquitination	O
of	O
cFLIPL	O
to	O
induce	O
apoptosis	O
.	O

Tumor	O
Necrosis	O
Factor	O
-	O
alpha	O
canonically	O
induces	O
the	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
associated	O
gene	O
product	O
cellular	O
FLICE	O
-	O
like	O
inhibitory	O
protein	O
(	O
cFLIPL	O
)	O
to	O
promote	O
cell	O
survival	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
Fas	O
associated	O
death	O
domain	O
(	O
FADD	O
)	O
diminishes	O
the	O
expression	O
of	O
cFLIPL	O
and	O
transduces	O
caspases	O
-	O
8	O
mediated	O
apoptosis	O
,	O
independent	O
of	O
FasL	O
stimulation	O
in	O
HEK	O
293T	O
cells	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
of	O
FADD	O
mediated	O
ablation	O
of	O
cFLIP	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
to	O
determining	O
the	O
fate	O
of	O
cell	O
death	O
or	O
survival	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
explored	O
a	O
novel	O
molecular	O
mechanism	O
of	O
FADD	O
mediated	O
apoptotic	O
cell	O
death	O
that	O
was	O
directed	O
by	O
ubiquitination	O
of	O
cFLIPL	O
and	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
independent	O
of	O
TNF	O
-	O
alpha	O
stimulation	O
.	O

We	O
found	O
that	O
induced	O
expression	O
of	O
FADD	O
firmly	O
interacts	O
with	O
procaspase	O
-	O
8	O
and	O
precludes	O
cFLIPL	O
to	O
from	O
the	O
death	B-Complex
inducing	I-Complex
signaling	I-Complex
complex	I-Complex
(	O
DISC	B-Complex
)	O
.	O

In	O
addition	O
,	O
FADD	O
negatively	O
regulates	O
cellular	O
inhibitor	O
of	O
apoptosis	O
protein	O
2	O
(	O
cIAP2	O
)	O
and	O
Bcl	O
-	O
2	O
.	O

Furthermore	O
,	O
FADD	O
restrains	O
cIAP2	O
expression	O
and	O
interacts	O
with	O
RIP1	O
and	O
procaspase	O
-	O
8	O
to	O
accomplish	O
apoptotic	O
cell	O
death	O
signaling	O
.	O

Interestingly	O
,	O
FADD	O
was	O
also	O
found	O
to	O
promote	O
JNK1	O
mediated	O
activation	O
of	O
E3	O
ubiquitin	O
ligase	O
ITCH	O
to	O
degrade	O
cFLIPL	O
that	O
may	O
lead	O
to	O
commencement	O
of	O
apoptosis	O
.	O

Thus	O
,	O
FADD	O
is	O
an	O
important	O
regulator	O
for	O
determining	O
the	O
fate	O
of	O
cell	O
death	O
or	O
survival	O
.	O

Ubiquitin	O
-	O
like	O
modifier	O
FAT10	O
attenuates	O
RIG	O
-	O
I	O
mediated	O
antiviral	O
signaling	O
by	O
segregating	O
activated	O
RIG	O
-	O
I	O
from	O
its	O
signaling	O
platform	O
.	O

RIG	O
-	O
I	O
is	O
a	O
key	O
cytosolic	O
RNA	O
sensor	O
that	O
mediates	O
innate	O
immune	O
defense	O
against	O
RNA	O
virus	O
.	O

Aberrant	O
RIG	O
-	O
I	O
activity	O
leads	O
to	O
severe	O
pathological	O
states	O
such	O
as	O
autosomal	O
dominant	O
multi	O
-	O
system	O
disorder	O
,	O
inflammatory	O
myophathies	O
and	O
dermatomyositis	O
.	O

Therefore	O
,	O
identification	O
of	O
regulators	O
that	O
ensure	O
efficient	O
defense	O
without	O
harmful	O
immune	O
-	O
pathology	O
is	O
particularly	O
critical	O
to	O
deal	O
with	O
RIG	O
-	O
I	O
-	O
associated	O
diseases	O
.	O

Here	O
,	O
we	O
presented	O
the	O
inflammatory	O
inducible	O
FAT10	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
RIG	O
-	O
I	O
-	O
mediated	O
inflammatory	O
response	O
.	O

In	O
various	O
cell	O
lines	O
,	O
FAT10	O
protein	O
is	O
undetectable	O
unless	O
it	O
is	O
induced	O
by	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

FAT10	O
non	O
-	O
covalently	O
associated	O
with	O
the	O
2CARD	O
domain	O
of	O
RIG	O
-	O
I	O
,	O
and	O
inhibited	O
viral	O
RNA	O
-	O
induced	O
IRF3	O
and	O
NF	B-Complex
-	I-Complex
kB	I-Complex
activation	O
through	O
modulating	O
the	O
RIG	O
-	O
I	O
protein	O
solubility	O
.	O

We	O
further	O
demonstrated	O
that	O
FAT10	O
was	O
recruited	O
to	O
RIG	O
-	O
I	O
-	O
TRIM25	O
to	O
form	O
an	O
inhibitory	O
complex	O
where	O
FAT10	O
was	O
stabilized	O
by	O
E3	O
ligase	O
TRIM25	O
.	O

As	O
the	O
result	O
,	O
FAT10	O
inhibited	O
the	O
antiviral	O
stress	O
granules	O
formation	O
contains	O
RIG	O
-	O
I	O
and	O
sequestered	O
the	O
active	O
RIG	O
-	O
I	O
away	O
from	O
the	O
mitochondria	O
.	O

Our	O
study	O
presented	O
a	O
novel	O
mechanism	O
to	O
dampen	O
RIG	O
-	O
I	O
activity	O
.	O

Highly	O
accumulated	O
FAT10	O
is	O
observed	O
in	O
various	O
cancers	O
with	O
pro	O
-	O
inflammatory	O
environment	O
,	O
therefore	O
,	O
our	O
finding	O
which	O
uncovered	O
the	O
suppressive	O
effect	O
of	O
the	O
accumulated	O
FAT10	O
during	O
virus	O
-	O
mediated	O
inflammatory	O
response	O
may	O
also	O
provide	O
molecular	O
clue	O
to	O
understand	O
the	O
carcinogenesis	O
related	O
with	O
infection	O
and	O
inflammation	O
.	O

Phosphorylation	O
of	O
Yeast	O
Pah1	O
Phosphatidate	O
Phosphatase	O
by	O
Casein	O
Kinase	O
II	O
Regulates	O
Its	O
Function	O
in	O
Lipid	O
Metabolism	O
.	O

Pah1	O
phosphatidate	O
phosphatase	O
in	O
Saccharomyces	O
cerevisiae	O
catalyzes	O
the	O
penultimate	O
step	O
in	O
the	O
synthesis	O
of	O
triacylglycerol	O
(	O
i	O
.	O
e	O
.	O
the	O
production	O
of	O
diacylglycerol	O
by	O
dephosphorylation	O
of	O
phosphatidate	O
)	O
.	O

The	O
enzyme	O
playing	O
a	O
major	O
role	O
in	O
lipid	O
metabolism	O
is	O
subject	O
to	O
phosphorylation	O
(	O
e	O
.	O
g	O
.	O
by	O
Pho85	O
-	O
Pho80	O
,	O
Cdc28	O
-	O
cyclin	O
B	O
,	O
and	O
protein	O
kinases	O
A	O
and	O
C	O
)	O
and	O
dephosphorylation	O
(	O
e	O
.	O
g	O
.	O
by	O
Nem1	O
-	O
Spo7	O
)	O
that	O
regulate	O
its	O
cellular	O
location	O
,	O
catalytic	O
activity	O
,	O
and	O
stability	O
/	O
degradation	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
Pah1	O
is	O
a	O
substrate	O
for	O
casein	O
kinase	O
II	O
(	O
CKII	O
)	O
;	O
its	O
phosphorylation	O
was	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
and	O
was	O
dependent	O
on	O
the	O
concentrations	O
of	O
Pah1	O
(	O
Km	O
=	O
0	O
.	O
23	O
mum	O
)	O
and	O
ATP	O
(	O
Km	O
=	O
5	O
.	O
5	O
mum	O
)	O
.	O

By	O
mass	O
spectrometry	O
,	O
truncation	O
analysis	O
,	O
site	O
-	O
directed	O
mutagenesis	O
,	O
phosphopeptide	O
mapping	O
,	O
and	O
phosphoamino	O
acid	O
analysis	O
,	O
we	O
identified	O
that	O
>	O
90	O
%	O
of	O
its	O
phosphorylation	O
occurs	O
on	O
Thr	O
-	O
170	O
,	O
Ser	O
-	O
250	O
,	O
Ser	O
-	O
313	O
,	O
Ser	O
-	O
705	O
,	O
Ser	O
-	O
814	O
,	O
and	O
Ser	O
-	O
818	O
.	O

The	O
CKII	O
-	O
phosphorylated	O
Pah1	O
was	O
a	O
substrate	O
for	O
the	O
Nem1	O
-	O
Spo7	O
protein	O
phosphatase	O
and	O
was	O
degraded	O
by	O
the	O
20S	B-Complex
proteasome	I-Complex
.	O

The	O
prephosphorylation	O
of	O
Pah1	O
by	O
protein	O
kinase	O
A	O
or	O
protein	O
kinase	O
C	O
reduced	O
its	O
subsequent	O
phosphorylation	O
by	O
CKII	O
.	O

The	O
prephosphorylation	O
of	O
Pah1	O
by	O
CKII	O
reduced	O
its	O
subsequent	O
phosphorylation	O
by	O
protein	O
kinase	O
A	O
but	O
not	O
by	O
protein	O
kinase	O
C	O
.	O

The	O
expression	O
of	O
Pah1	O
with	O
combined	O
mutations	O
of	O
S705D	O
and	O
7A	O
,	O
which	O
mimic	O
its	O
phosphorylation	O
by	O
CKII	O
and	O
lack	O
of	O
phosphorylation	O
by	O
Pho85	O
-	O
Pho80	O
,	O
caused	O
an	O
increase	O
in	O
triacylglycerol	O
content	O
and	O
lipid	O
droplet	O
number	O
in	O
cells	O
expressing	O
the	O
Nem1	O
-	O
Spo7	O
phosphatase	O
complex	O
.	O

To	O
further	O
characterize	O
all	O
the	O
mutants	O
retaining	O
mtDNA	O
at	O
the	O
molecular	O
level	O
,	O
we	O
blocked	O
cytoplasmic	O
translation	O
with	O
cycloheximide	O
,	O
used	O
a	O
short	O
incubation	O
in	O
the	O
presence	O
of	O
35S	O
amino	O
acids	O
to	O
label	O
mitochondrial	O
translation	O
products	O
and	O
equal	O
amounts	O
of	O
total	O
proteins	O
were	O
subjected	O
to	O
SDS	O
PAGE	O
(	O
Figure	O
2A	O
)	O
.	O

As	O
expected	O
,	O
the	O
three	O
point	O
mutants	O
that	O
had	O
a	O
compromised	O
respiratory	O
growth	O
showed	O
a	O
lower	O
level	O
of	O
labeling	O
than	O
the	O
wild	O
type	O
.	O

However	O
,	O
for	O
the	O
three	O
deletion	O
mutants	O
,	O
all	O
mitochondrial	O
translation	O
products	O
were	O
detected	O
and	O
the	O
Deltamif3	O
and	O
Deltarrf1	O
strains	O
displayed	O
stronger	O
labeling	O
of	O
Cox1	O
,	O
Cytb	O
and	O
Atp9	O
when	O
compared	O
to	O
the	O
wild	O
type	O
(	O
Figure	O
2B	O
)	O
.	O

In	O
the	O
Deltaifm1	O
strain	O
,	O
Cytb	O
and	O
Atp9	O
levels	O
were	O
similar	O
to	O
the	O
wild	O
type	O
while	O
labeling	O
of	O
the	O
other	O
mitochondrial	O
proteins	O
was	O
decreased	O
.	O

Thus	O
,	O
in	O
all	O
three	O
deletion	O
mutants	O
,	O
we	O
observed	O
a	O
differential	O
effect	O
on	O
the	O
labeling	O
of	O
specific	O
mitochondrial	O
proteins	O
.	O

Oncogenic	O
Sox2	O
regulates	O
and	O
cooperates	O
with	O
VRK1	O
in	O
cell	O
cycle	O
progression	O
and	O
differentiation	O
.	O

Sox2	O
is	O
a	O
pluripotency	O
transcription	O
factor	O
that	O
as	O
an	O
oncogene	O
can	O
also	O
regulate	O
cell	O
proliferation	O
.	O

Therefore	O
,	O
genes	O
implicated	O
in	O
several	O
different	O
aspects	O
of	O
cell	O
proliferation	O
,	O
such	O
as	O
the	O
VRK1	O
chromatin	O
-	O
kinase	O
,	O
are	O
candidates	O
to	O
be	O
targets	O
of	O
Sox2	O
.	O

Sox	O
2	O
and	O
VRK1	O
colocalize	O
in	O
nuclei	O
of	O
proliferating	O
cells	O
forming	O
a	O
stable	O
complex	O
.	O

Sox2	O
knockdown	O
abrogates	O
VRK1	O
gene	O
expression	O
.	O

Depletion	O
of	O
either	O
Sox2	O
or	O
VRK1	O
caused	O
a	O
reduction	O
of	O
cell	O
proliferation	O
.	O

Sox2	O
up	O
-	O
regulates	O
VRK1	O
expression	O
and	O
both	O
proteins	O
cooperate	O
in	O
the	O
activation	O
of	O
CCND1	O
.	O

The	O
accumulation	O
of	O
VRK1	O
protein	O
downregulates	O
SOX2	O
expression	O
and	O
both	O
proteins	O
are	O
lost	O
in	O
terminally	O
differentiated	O
cells	O
.	O

Induction	O
of	O
neural	O
differentiation	O
with	O
retinoic	O
acid	O
resulted	O
in	O
downregulation	O
of	O
Sox2	O
and	O
VRK1	O
that	O
inversely	O
correlated	O
with	O
the	O
expression	O
of	O
differentiation	O
markers	O
such	O
as	O
N	O
-	O
cadherin	O
,	O
Pax6	O
,	O
mH2A1	O
.	O
2	O
and	O
mH2A2	O
.	O

Differentiation	O
-	O
associated	O
macro	O
histones	O
mH2A1	O
.	O
2and	O
mH2A2	O
inhibit	O
CCND1	O
and	O
VRK1	O
expression	O
and	O
also	O
block	O
the	O
activation	O
of	O
the	O
VRK1	O
promoter	O
by	O
Sox2	O
.	O

VRK1	O
is	O
a	O
downstream	O
target	O
of	O
Sox2	O
and	O
both	O
form	O
an	O
autoregulatory	O
loop	O
in	O
epithelial	O
cell	O
differentiation	O
.	O

A	O
novel	O
ER	O
-	O
microtubule	O
-	O
binding	O
protein	O
,	O
ERLIN2	O
,	O
stabilizes	O
Cyclin	O
B1	O
and	O
regulates	O
cell	O
cycle	O
progression	O
.	O

The	O
gene	O
encoding	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
lipid	O
raft	O
-	O
associated	O
protein	O
2	O
(	O
ERLIN2	O
)	O
is	O
amplified	O
in	O
human	O
breast	O
cancers	O
.	O

ERLIN2	O
gene	O
mutations	O
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
human	O
childhood	O
progressive	O
motor	O
neuron	O
diseases	O
.	O

Yet	O
,	O
an	O
understanding	O
of	O
the	O
physiological	O
function	O
and	O
mechanism	O
for	O
ERLIN2	O
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
reveal	O
that	O
ERLIN2	O
is	O
a	O
spatially	O
and	O
temporally	O
regulated	O
ER	O
-	O
microtubule	O
-	O
binding	O
protein	O
that	O
has	O
an	O
important	O
role	O
in	O
cell	O
cycle	O
progression	O
by	O
interacting	O
with	O
and	O
stabilizing	O
the	O
mitosis	O
-	O
promoting	O
factors	O
.	O

Whereas	O
ERLIN2	O
is	O
highly	O
expressed	O
in	O
aggressive	O
human	O
breast	O
cancers	O
,	O
during	O
normal	O
development	O
ERLIN2	O
is	O
expressed	O
at	O
the	O
postnatal	O
stage	O
and	O
becomes	O
undetectable	O
in	O
adulthood	O
.	O

ERLIN2	O
interacts	O
with	O
the	O
microtubule	O
component	O
alpha	O
-	O
tubulin	O
,	O
and	O
this	O
interaction	O
is	O
maximal	O
during	O
the	O
cell	O
cycle	O
G2	O
/	O
M	O
phase	O
where	O
ERLIN2	O
simultaneously	O
interacts	O
with	O
the	O
mitosis	O
-	O
promoting	O
complex	O
Cyclin	O
B1	O
/	O
Cdk1	O
.	O

ERLIN2	O
facilitates	O
K63	O
-	O
linked	O
ubiquitination	O
and	O
stabilization	O
of	O
Cyclin	O
B1	O
protein	O
in	O
G2	O
/	O
M	O
phase	O
.	O

Downregulation	O
of	O
ERLIN2	O
results	O
in	O
cell	O
cycle	O
arrest	O
,	O
represses	O
breast	O
cancer	O
proliferation	O
and	O
malignancy	O
and	O
increases	O
sensitivity	O
of	O
breast	O
cancer	O
cells	O
to	O
anticancer	O
drugs	O
.	O

In	O
summary	O
,	O
our	O
study	O
revealed	O
a	O
novel	O
ER	O
-	O
microtubule	O
-	O
binding	O
protein	O
,	O
ERLIN2	O
,	O
which	O
interacts	O
with	O
and	O
stabilizes	O
mitosis	O
-	O
promoting	O
factors	O
to	O
regulate	O
cell	O
cycle	O
progression	O
associated	O
with	O
human	O
breast	O
cancer	O
malignancy	O
.	O

Studies	O
have	O
indicated	O
that	O
the	O
AAA	O
+	O
-	O
type	O
ATPase	O
Pch2	O
suppresses	O
intersister	O
repair	O
to	O
some	O
extent	O
,	O
and	O
helps	O
to	O
prevent	O
meiotic	O
progression	O
when	O
unrepaired	O
DSBs	O
accumulate	O
.	O

We	O
found	O
that	O
deletion	O
of	O
PCH2	O
relieved	O
the	O
dmc1increment	O
-	O
dependent	O
inhibition	O
of	O
DNA	O
rereplication	O
in	O
our	O
SIC1incrementPHA	O
system	O
(	O
Figure	O
S3	O
)	O
,	O
indicating	O
that	O
PCH2	O
aided	O
in	O
preventing	O
DNA	O
rereplication	O
.	O

In	O
this	O
case	O
,	O
as	O
in	O
certain	O
other	O
mutants	O
analyzed	O
(	O
see	O
below	O
)	O
,	O
few	O
cells	O
with	O
DNA	O
content	O
>	O
~	O
8C	O
were	O
observed	O
.	O

Extensive	O
DNA	O
rereplication	O
was	O
detected	O
with	O
SIC1incrementPHApch2increment	O
cells	O
(	O
Figure	O
S1	O
and	O
Figure	O
S3	O
)	O
,	O
indicating	O
that	O
PCH2	O
itself	O
was	O
not	O
required	O
for	O
the	O
DNA	O
rereplication	O
phenotype	O
in	O
SIC1incrementPHA	O
cells	O
.	O

To	O
test	O
if	O
Cbr1	O
could	O
reduce	O
Dph3	O
in	O
vitro	O
,	O
we	O
cloned	O
,	O
expressed	O
and	O
purified	O
the	O
recombinant	O
Cbr1	O
.	O

We	O
first	O
monitored	O
the	O
reduction	O
of	O
Dph3	O
by	O
detecting	O
the	O
488	O
nm	O
absorption	O
of	O
oxidized	O
Dph3	O
as	O
previously	O
described	O
.	O

Upon	O
addition	O
of	O
NADH	O
to	O
initiate	O
the	O
reaction	O
,	O
Dph3	O
was	O
rapidly	O
reduced	O
by	O
Cbr1	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
NADPH	O
did	O
not	O
lead	O
to	O
reduction	O
of	O
Dph3	O
,	O
suggesting	O
that	O
Cbr1	O
is	O
an	O
NADH	O
-	O
specific	O
enzyme	O
(	O
Supplementary	O
Fig	O
.	O
3	O
)	O
.	O

To	O
confirm	O
Cbr1	O
'	O
s	O
role	O
as	O
a	O
Dph3	O
reductase	O
,	O
we	O
tested	O
if	O
this	O
reduction	O
system	O
can	O
be	O
used	O
to	O
reduce	O
Dph1	O
-	O
Dph2	O
and	O
reconstitute	O
the	O
first	O
step	O
of	O
diphthamide	O
biosynthesis	O
in	O
vitro	O
.	O

Using	O
C	O
-	O
SAM	O
,	O
the	O
substrate	O
eEF2	O
was	O
radioactively	O
labeled	O
in	O
the	O
presence	O
of	O
Dph1	O
-	O
Dph2	O
,	O
Dph3	O
,	O
Cbr1	O
and	O
NADH	O
(	O
Fig	O
.	O
1c	O
,	O
and	O
Supplementary	O
Fig	O
.	O
7	O
,	O
lane3	O
)	O
.	O

The	O
Cbr1	O
/	O
NADH	O
/	O
Dph3	O
reduction	O
system	O
was	O
able	O
to	O
reduce	O
Dph1	O
-	O
Dph2	O
similarly	O
to	O
dithionite	O
,	O
a	O
chemical	O
reductant	O
for	O
Fe	O
-	O
S	O
clusters	O
(	O
Fig	O
.	O
1c	O
,	O
and	O
Supplementary	O
Fig	O
.	O
7	O
,	O
lane	O
1	O
)	O
.	O

These	O
results	O
demonstrated	O
that	O
Cbr1	O
can	O
reduce	O
Dph3	O
using	O
NADH	O
in	O
vitro	O
.	O

We	O
found	O
that	O
KLHL12	O
can	O
differentially	O
interact	O
with	O
KHSRP	O
and	O
promote	O
KHSRP	O
ubiquitination	O
.	O

We	O
then	O
sought	O
to	O
elucidate	O
how	O
KLHL12	O
-	O
mediated	O
KHSRP	O
ubiquitination	O
affects	O
IRES	O
-	O
driven	O
translation	O
.	O

This	O
led	O
us	O
to	O
identify	O
a	O
hitherto	O
undescribed	O
regulatory	O
mechanism	O
of	O
IRES	O
-	O
driven	O
translation	O
involving	O
ubiquitination	O
-	O
-	O
namely	O
,	O
the	O
regulation	O
of	O
IRES	O
-	O
dependent	O
translation	O
via	O
ubiquitin	O
modulation	O
of	O
ITAFs	O
.	O

Our	O
findings	O
are	O
expected	O
to	O
have	O
important	O
implications	O
for	O
future	O
research	O
regarding	O
viral	O
-	O
host	O
interactions	O
,	O
and	O
may	O
also	O
help	O
to	O
identify	O
novel	O
drug	O
targets	O
for	O
anti	O
-	O
viral	O
therapies	O
.	O

Characterization	O
of	O
the	O
interaction	O
between	O
Trm11	O
and	O
Trm112	O
.	O

(	O
A	O
)	O
ITC	O
of	O
Trm112	O
binding	O
to	O
Trm11	O
.	O

Upper	O
panel	O
:	O
ITC	O
data	O
obtained	O
by	O
injecting	O
Trm112	O
into	O
Trm11	O
.	O

Lower	O
panel	O
shows	O
the	O
fit	O
to	O
the	O
binding	O
curve	O
with	O
resulting	O
affinity	O
(	O
Kd	O
)	O
and	O
stoichiometry	O
(	O
N	O
)	O
.	O

(	O
B	O
)	O
Hydrogen	O
-	O
Deuterium	O
exchange	O
monitored	O
on	O
the	O
doubly	O
charged	O
peptide	O
202	O
-	O
213	O
from	O
Trm11	O
,	O
alone	O
(	O
left	O
,	O
black	O
)	O
or	O
in	O
the	O
presence	O
of	O
Trm112	O
(	O
right	O
,	O
gray	O
)	O
at	O
0	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
5	O
,	O
10	O
and	O
30	O
min	O
(	O
bottom	O
to	O
the	O
top	O
)	O
.	O

(	O
C	O
)	O
HDX	O
kinetics	O
of	O
three	O
representative	O
peptides	O
from	O
Trm11	O
(	O
top	O
and	O
middle	O
)	O
and	O
Trm112	O
(	O
bottom	O
)	O
.	O

Black	O
circles	O
and	O
gray	O
boxes	O
correspond	O
to	O
data	O
extracted	O
from	O
isolated	O
and	O
complexed	O
forms	O
,	O
respectively	O
.	O

The	O
error	O
bars	O
represent	O
standard	O
deviations	O
from	O
the	O
mean	O
of	O
three	O
replicates	O
.	O

(	O
D	O
)	O
Differential	O
HDX	O
heat	O
map	O
for	O
free	O
Trm11	O
compared	O
to	O
Trm11	O
bound	O
to	O
Trm112	O
.	O

Colored	O
from	O
0	O
%	O
(	O
blue	O
)	O
to	O
40	O
%	O
(	O
red	O
)	O
difference	O
of	O
deuterium	O
uptake	O
after	O
5	O
min	O
(	O
Left	O
)	O
.	O

Secondary	O
structure	O
elements	O
as	O
observed	O
in	O
our	O
model	O
of	O
the	O
Trm11	O
protein	O
structure	O
are	O
shown	O
above	O
the	O
sequence	O
.	O

(	O
Right	O
)	O
Mapping	O
of	O
differential	O
heat	O
map	O
at	O
the	O
surface	O
of	O
the	O
Trm11	O
model	O
structure	O
using	O
the	O
same	O
color	O
code	O
.	O

Residues	O
in	O
gray	O
were	O
not	O
covered	O
by	O
peptide	O
mapping	O
.	O

(	O
E	O
)	O
Differential	O
HDX	O
heat	O
map	O
for	O
free	O
Trm112	O
compared	O
to	O
Trm112	O
bound	O
to	O
Trm11	O
.	O

Colored	O
from	O
0	O
%	O
(	O
blue	O
)	O
to	O
40	O
%	O
(	O
red	O
)	O
difference	O
of	O
deuterium	O
uptake	O
after	O
5	O
min	O
.	O

Trm112	O
secondary	O
structure	O
elements	O
as	O
observed	O
in	O
Saccharomyces	O
cerevisiae	O
Bud23	O
-	O
Trm112	O
crystal	O
structure	O
are	O
shown	O
above	O
the	O
sequence	O
.	O

Trm112	O
residues	O
that	O
are	O
involved	O
in	O
the	O
interaction	O
with	O
Bud23	O
MTase	O
are	O
identified	O
by	O
black	O
stars	O
below	O
the	O
sequence	O
.	O

Residues	O
not	O
covered	O
by	O
peptide	O
mapping	O
are	O
shown	O
in	O
gray	O
.	O

(	O
F	O
)	O
Mapping	O
of	O
the	O
distribution	O
of	O
residues	O
at	O
the	O
surface	O
of	O
the	O
model	O
of	O
Trm11	O
structure	O
.	O

Residues	O
color	O
code	O
:	O
hydrophobic	O
aromatic	O
and	O
aliphatic	O
(	O
G	O
,	O
A	O
,	O
V	O
,	O
L	O
,	O
I	O
,	O
F	O
,	O
Y	O
,	O
W	O
,	O
M	O
and	O
P	O
)	O
in	O
white	O
,	O
positively	O
charged	O
(	O
K	O
and	O
R	O
)	O
in	O
blue	O
,	O
negatively	O
charged	O
(	O
D	O
and	O
E	O
)	O
in	O
red	O
,	O
polar	O
(	O
N	O
,	O
Q	O
,	O
H	O
,	O
S	O
and	O
T	O
)	O
in	O
cyan	O
.	O

Same	O
orientation	O
as	O
panel	O
D	O
.	O

The	O
hydrophobic	O
patch	O
is	O
delineated	O
by	O
black	O
dotted	O
lines	O
.	O

(	O
G	O
)	O
Ribbon	O
representation	O
of	O
the	O
model	O
of	O
the	O
Trm11	O
-	O
Trm112	O
complex	O
,	O
considering	O
that	O
Trm11	O
interacts	O
with	O
Trm112	O
in	O
a	O
similar	O
way	O
as	O
Bud23	O
.	O

Trm112	O
is	O
colored	O
purple	O
while	O
Trm11	O
THUMP	O
and	O
MTase	O
domains	O
are	O
colored	O
light	O
brown	O
and	O
green	O
,	O
respectively	O
.	O

The	O
zinc	O
atom	O
bound	O
to	O
Trm112	O
is	O
shown	O
as	O
a	O
cyan	O
sphere	O
.	O

A	O
SAM	O
molecule	O
bound	O
to	O
the	O
Trm11	O
MTase	O
domain	O
is	O
shown	O
as	O
yellow	O
sticks	O
.	O

Side	O
chains	O
from	O
Trm11	O
Asp286	O
and	O
Trm112	O
Arg53	O
are	O
shown	O
as	O
ball	O
and	O
sticks	O
.	O

(	O
H	O
)	O
Mapping	O
of	O
differential	O
HDX	O
heat	O
map	O
(	O
after	O
5	O
min	O
)	O
on	O
the	O
ribbon	O
representation	O
of	O
the	O
Trm11	O
-	O
Trm112	O
complex	O
.	O

Colored	O
from	O
0	O
%	O
(	O
blue	O
)	O
to	O
40	O
%	O
(	O
red	O
)	O
difference	O
of	O
deuterium	O
uptake	O
.	O

Same	O
orientation	O
as	O
panel	O
G	O
.	O

Residues	O
not	O
covered	O
by	O
peptide	O
mapping	O
are	O
shown	O
in	O
gray	O
.	O

Targeting	O
the	O
Genome	O
-	O
Stability	O
Hub	O
Ctf4	O
by	O
Stapled	O
-	O
Peptide	O
Design	O
.	O

The	O
exploitation	O
of	O
synthetic	O
lethality	O
by	O
small	O
-	O
molecule	O
targeting	O
of	O
pathways	O
that	O
maintain	O
genomic	O
stability	O
is	O
an	O
attractive	O
chemotherapeutic	O
approach	O
.	O

The	O
Ctf4	O
/	O
AND	O
-	O
1	O
protein	O
hub	O
,	O
which	O
links	O
DNA	O
replication	O
,	O
repair	O
,	O
and	O
chromosome	O
segregation	O
,	O
represents	O
a	O
novel	O
target	O
for	O
the	O
synthetic	O
lethality	O
approach	O
.	O

Herein	O
,	O
we	O
report	O
the	O
design	O
,	O
optimization	O
,	O
and	O
validation	O
of	O
double	O
-	O
click	O
stapled	O
peptides	O
encoding	O
the	O
Ctf4	O
-	O
interacting	O
peptide	O
(	O
CIP	O
)	O
of	O
the	O
replicative	O
helicase	O
subunit	O
Sld5	O
.	O

By	O
screening	O
stapling	O
positions	O
in	O
the	O
Sld5	O
CIP	O
,	O
we	O
identified	O
an	O
unorthodox	O
i	O
,	O
i	O
+	O
6	O
stapled	O
peptide	O
with	O
improved	O
,	O
submicromolar	O
binding	O
to	O
Ctf4	O
.	O

The	O
mode	O
of	O
interaction	O
with	O
Ctf4	O
was	O
confirmed	O
by	O
a	O
crystal	O
structure	O
of	O
the	O
stapled	O
Sld5	O
peptide	O
bound	O
to	O
Ctf4	O
.	O

The	O
stapled	O
Sld5	O
peptide	O
was	O
able	O
to	O
displace	O
the	O
Ctf4	O
partner	O
DNA	B-Complex
polymerase	I-Complex
alpha	I-Complex
from	O
the	O
replisome	O
in	O
yeast	O
extracts	O
.	O

Our	O
study	O
provides	O
proof	O
-	O
of	O
-	O
principle	O
evidence	O
for	O
the	O
development	O
of	O
small	O
-	O
molecule	O
inhibitors	O
of	O
the	O
human	O
CTF4	O
orthologue	O
AND	O
-	O
1	O
.	O

To	O
date	O
,	O
animal	O
models	O
of	O
Dup15q	O
focused	O
on	O
neuronal	O
overexpression	O
of	O
UBE3A	O
have	O
failed	O
to	O
recapitulate	O
the	O
seizure	O
phenotypes	O
observed	O
in	O
Dup15q	O
.	O

Our	O
fly	O
model	O
of	O
Dup15q	O
with	O
elevated	O
levels	O
of	O
Dube3a	O
in	O
glia	O
,	O
but	O
not	O
neurons	O
,	O
displays	O
a	O
robust	O
seizure	O
phenotype	O
,	O
highlighting	O
the	O
previously	O
unappreciated	O
role	O
that	O
glial	O
play	O
in	O
Dup15q	O
pathophysiology	O
.	O

Our	O
lab	O
previously	O
demonstrated	O
that	O
Dube3a	O
is	O
biallelically	O
expressed	O
in	O
the	O
Drosophila	O
brain	O
,	O
and	O
here	O
we	O
demonstrate	O
that	O
Drosophila	O
glia	O
endogenously	O
express	O
Dube3a	O
in	O
addition	O
to	O
expression	O
in	O
neurons	O
.	O

Studies	O
in	O
mammalian	O
systems	O
have	O
indicated	O
biallelic	O
expression	O
of	O
Ube3a	O
/	O
UBE3A	O
in	O
glial	O
cells	O
,	O
yet	O
until	O
now	O
the	O
functional	O
consequence	O
of	O
overexpression	O
of	O
Ube3a	O
/	O
Dube3a	O
in	O
glial	O
cells	O
has	O
been	O
largely	O
unexplored	O
.	O

Increased	O
dosage	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
UBE3A	O
is	O
thought	O
to	O
be	O
the	O
underlying	O
cause	O
of	O
at	O
least	O
the	O
autistic	O
features	O
of	O
Dup15q	O
syndrome	O
,	O
and	O
evidence	O
presented	O
here	O
suggests	O
that	O
elevated	O
UBE3A	O
contributes	O
to	O
epilepsy	O
in	O
Dup15q	O
as	O
well	O
.	O

The	O
zinc	O
-	O
finger	O
transcription	O
factor	O
Hindsight	O
regulates	O
ovulation	O
competency	O
of	O
<	O
i	O
>	O
Drosophila	O
<	O
/	O
i	O
>	O
follicles	O
.	O

Follicle	O
rupture	O
,	O
the	O
final	O
step	O
in	O
ovulation	O
,	O
utilizes	O
conserved	O
molecular	O
mechanisms	O
including	O
matrix	O
metalloproteinases	O
(	O
Mmps	O
)	O
,	O
steroid	O
signaling	O
,	O
and	O
adrenergic	O
signaling	O
.	O

It	O
is	O
still	O
unknown	O
how	O
follicles	O
become	O
competent	O
for	O
follicle	O
rupture	O
/	O
ovulation	O
.	O

Here	O
,	O
we	O
identify	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
Hindsight	O
(	O
Hnt	O
)	O
as	O
the	O
first	O
transcription	O
factor	O
regulating	O
follicle	O
'	O
s	O
competency	O
for	O
ovulation	O
in	O
<	O
i	O
>	O
Drosophila	O
<	O
/	O
i	O
>	O
.	O

Hnt	O
is	O
not	O
expressed	O
in	O
immature	O
stage	O
-	O
13	O
follicle	O
cells	O
but	O
is	O
upregulated	O
in	O
mature	O
stage	O
-	O
14	O
follicle	O
cells	O
,	O
which	O
is	O
essential	O
for	O
follicle	O
rupture	O
/	O
ovulation	O
.	O

Hnt	O
upregulates	O
Mmp2	O
expression	O
in	O
posterior	O
follicle	O
cells	O
(	O
essential	O
for	O
the	O
breakdown	O
of	O
the	O
follicle	O
wall	O
)	O
and	O
Oamb	O
expression	O
in	O
all	O
follicle	O
cells	O
(	O
the	O
receptor	O
for	O
receiving	O
adrenergic	O
signaling	O
and	O
inducing	O
Mmp2	O
activation	O
)	O
.	O

Hnt	O
'	O
s	O
role	O
in	O
regulating	O
Mmp2	O
and	O
Oamb	O
can	O
be	O
replaced	O
by	O
its	O
human	O
homolog	O
Ras	O
-	O
responsive	O
element	O
-	O
binding	O
protein	O
1	O
(	O
RREB	O
-	O
1	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
Hnt	O
/	O
RREB	O
-	O
1	O
plays	O
conserved	O
role	O
in	O
regulating	O
follicle	O
maturation	O
and	O
competency	O
for	O
ovulation	O
.	O

In	O
the	O
germline	O
and	O
somatic	O
cells	O
of	O
developing	O
egg	O
chambers	O
,	O
Rbfox1	O
protein	O
has	O
a	O
very	O
distinctive	O
expression	O
pattern	O
that	O
depends	O
on	O
the	O
developmental	O
stage	O
(	O
Fig	O
.	O
1f	O
)	O
.	O

This	O
is	O
especially	O
evident	O
in	O
the	O
follicular	O
epithelium	O
,	O
which	O
undergoes	O
major	O
transitions	O
in	O
cell	O
cycle	O
mode	O
during	O
differentiation	O
(	O
Fig	O
.	O
1a	O
,	O
f	O
)	O
.	O

In	O
miR	O
-	O
980	O
mutants	O
,	O
elevated	O
Rbfox1	O
levels	O
were	O
detected	O
at	O
all	O
developmental	O
stages	O
(	O
Fig	O
.	O
1g	O
)	O
,	O
demonstrating	O
that	O
miR	O
-	O
980	O
is	O
responsible	O
for	O
the	O
control	O
of	O
the	O
highly	O
dynamic	O
Rbfox1	O
expression	O
during	O
the	O
entire	O
process	O
of	O
oogenesis	O
.	O

Neural	O
Control	O
of	O
Startle	O
-	O
Induced	O
Locomotion	O
by	O
the	O
Mushroom	O
Bodies	O
and	O
Associated	O
Neurons	O
in	O
<	O
i	O
>	O
Drosophila	O
<	O
/	O
i	O
>	O
.	O

Startle	O
-	O
induced	O
locomotion	O
is	O
commonly	O
used	O
in	O
<	O
i	O
>	O
Drosophila	O
<	O
/	O
i	O
>	O
research	O
to	O
monitor	O
locomotor	O
reactivity	O
and	O
its	O
progressive	O
decline	O
with	O
age	O
or	O
under	O
various	O
neuropathological	O
conditions	O
.	O

A	O
widely	O
used	O
paradigm	O
is	O
startle	O
-	O
induced	O
negative	O
geotaxis	O
(	O
SING	O
)	O
,	O
in	O
which	O
flies	O
entrapped	O
in	O
a	O
narrow	O
column	O
react	O
to	O
a	O
gentle	O
mechanical	O
shock	O
by	O
climbing	O
rapidly	O
upwards	O
.	O

Here	O
we	O
combined	O
<	O
i	O
>	O
in	O
vivo	O
<	O
/	O
i	O
>	O
manipulation	O
of	O
neuronal	O
activity	O
and	O
splitGFP	O
reconstitution	O
across	O
cells	O
to	O
search	O
for	O
brain	O
neurons	O
and	O
putative	O
circuits	O
that	O
regulate	O
this	O
behavior	O
.	O

We	O
show	O
that	O
the	O
activity	O
of	O
specific	O
clusters	O
of	O
dopaminergic	O
neurons	O
(	O
DANs	O
)	O
afferent	O
to	O
the	O
mushroom	O
bodies	O
(	O
MBs	O
)	O
modulates	O
SING	O
,	O
and	O
that	O
DAN	O
-	O
mediated	O
SING	O
regulation	O
requires	O
expression	O
of	O
the	O
DA	O
receptor	O
Dop1R1	O
/	O
Dumb	O
,	O
but	O
not	O
Dop1R2	O
/	O
Damb	O
,	O
in	O
intrinsic	O
MB	O
Kenyon	O
cells	O
(	O
KCs	O
)	O
.	O

We	O
confirmed	O
our	O
previous	O
observation	O
that	O
activating	O
the	O
MB	O
Alfa	O
'	O
Beta	O
'	O
,	O
but	O
not	O
AlfaBeta	O
,	O
KCs	O
decreased	O
the	O
SING	O
response	O
,	O
and	O
we	O
identified	O
further	O
MB	O
neurons	O
implicated	O
in	O
SING	O
control	O
,	O
including	O
KCs	O
of	O
the	O
Gamma	O
lobe	O
and	O
two	O
subtypes	O
of	O
MB	O
output	O
neurons	O
(	O
MBONs	O
)	O
.	O

We	O
also	O
observed	O
that	O
co	O
-	O
activating	O
the	O
AlfaBeta	O
KCs	O
antagonizes	O
Alfa	O
'	O
Beta	O
'	O
and	O
Gamma	O
KC	O
-	O
mediated	O
SING	O
modulation	O
,	O
suggesting	O
the	O
existence	O
of	O
subtle	O
regulation	O
mechanisms	O
between	O
the	O
different	O
MB	O
lobes	O
in	O
locomotion	O
control	O
.	O

Overall	O
,	O
this	O
study	O
contributes	O
to	O
an	O
emerging	O
picture	O
of	O
the	O
brain	O
circuits	O
modulating	O
locomotor	O
reactivity	O
in	O
<	O
i	O
>	O
Drosophila	O
<	O
/	O
i	O
>	O
that	O
appear	O
both	O
to	O
overlap	O
and	O
differ	O
from	O
those	O
underlying	O
associative	O
learning	O
and	O
memory	O
,	O
sleep	O
/	O
wake	O
state	O
and	O
stress	O
-	O
induced	O
hyperactivity	O
.	O

In	O
a	O
previous	O
large	O
-	O
scale	O
screening	O
of	O
a	O
yeast	O
deletion	O
array	O
,	O
it	O
was	O
found	O
that	O
deleting	O
NEM1	O
or	O
SPO7	O
significantly	O
enhanced	O
BMV	O
replication	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
PAH1	O
facilitates	O
robust	O
RNA	O
replication	O
of	O
tomato	O
bushy	O
stunt	O
virus	O
(	O
TBSV	O
)	O
.	O

TBSV	O
normally	O
replicates	O
in	O
peroxisomes	O
but	O
assemble	O
their	O
VRCs	O
at	O
expanded	O
ER	O
membranes	O
in	O
pah1Delta	O
cells	O
.	O

In	O
addition	O
,	O
TBSV	O
VRCs	O
in	O
pah1Delta	O
cells	O
are	O
more	O
active	O
than	O
those	O
in	O
wt	O
cells	O
.	O

Budding	O
yeast	O
cells	O
employ	O
amyloid	O
-	O
like	O
structures	O
to	O
control	O
translation	O
during	O
meiosis	O
.	O

At	O
the	O
core	O
of	O
these	O
structures	O
is	O
the	O
RNA	O
-	O
binding	O
protein	O
Rim4	O
.	O

Rim4	O
is	O
essential	O
for	O
meiosis	O
and	O
contains	O
three	O
N	O
-	O
terminal	O
RNA	O
-	O
recognition	O
motifs	O
(	O
RRMs	O
)	O
and	O
two	O
intrinsically	O
disordered	O
regions	O
(	O
IDRs	O
)	O
.	O

Rim4	O
also	O
harbors	O
a	O
prion	O
-	O
like	O
domain	O
within	O
its	O
asparagine	O
and	O
proline	O
-	O
rich	O
C	O
-	O
terminal	O
IDR	O
which	O
is	O
algorithmically	O
-	O
defined	O
based	O
on	O
disorder	O
and	O
sequence	O
similarity	O
to	O
yeast	O
prions	O
.	O

During	O
pre	O
-	O
meiotic	O
G1	O
,	O
Rim4	O
aggregates	O
into	O
heterogeneously	O
-	O
sized	O
multimeric	O
structures	O
that	O
are	O
resistant	O
to	O
the	O
harsh	O
detergent	O
SDS	O
,	O
a	O
hallmark	O
property	O
of	O
amyloids	O
.	O

Based	O
on	O
this	O
property	O
we	O
have	O
defined	O
Rim4	O
assemblies	O
as	O
amyloid	O
-	O
like	O
.	O

In	O
vitro	O
,	O
Rim4	O
forms	O
fibrils	O
that	O
bind	O
thioflavin	O
-	O
T	O
and	O
contain	O
beta	O
-	O
sheets	O
.	O

Formation	O
and	O
clearance	O
of	O
amyloid	O
-	O
like	O
Rim4	O
is	O
a	O
developmentally	O
regulated	O
process	O
.	O

When	O
Rim4	O
is	O
ectopically	O
expressed	O
in	O
nutrient	O
-	O
rich	O
conditions	O
,	O
it	O
does	O
not	O
form	O
SDS	O
-	O
resistant	O
multimers	O
and	O
is	O
non	O
-	O
functional	O
.	O

Starvation	O
induces	O
conversion	O
of	O
Rim4	O
monomers	O
into	O
its	O
SDS	O
-	O
resistant	O
form	O
(	O
termed	O
assembly	O
)	O
.	O

After	O
completion	O
of	O
the	O
first	O
meiotic	O
division	O
,	O
Rim4	O
is	O
rapidly	O
degraded	O
by	O
an	O
unknown	O
mechanism	O
(	O
termed	O
clearance	O
)	O
.	O

The	O
amyloid	O
-	O
like	O
form	O
of	O
Rim4	O
is	O
the	O
translationally	O
repressive	O
form	O
of	O
the	O
protein	O
.	O

rim4	O
truncation	O
mutants	O
that	O
cannot	O
form	O
amyloid	O
-	O
like	O
assemblies	O
are	O
defective	O
for	O
translational	O
repression	O
but	O
retain	O
the	O
ability	O
to	O
bind	O
RNA	O
.	O

Beyond	O
yeast	O
,	O
amyloid	O
-	O
like	O
assemblies	O
are	O
also	O
critical	O
features	O
of	O
mouse	O
and	O
frog	O
meiosis	O
highlighting	O
the	O
conserved	O
use	O
of	O
these	O
structures	O
in	O
sexual	O
reproduction	O
.	O

Purification	O
and	O
characterization	O
of	O
a	O
smooth	B-Complex
muscle	I-Complex
myosin	I-Complex
phosphatase	I-Complex
from	O
turkey	O
gizzards	O
.	O

A	O
phosphoprotein	O
phosphatase	O
that	O
dephosphorylates	O
smooth	O
muscle	O
myosin	O
has	O
been	O
purified	O
to	O
apparent	O
homogeneity	O
from	O
turkey	O
gizzards	O
.	O

Smooth	B-Complex
muscle	I-Complex
phosphatase	I-Complex
(	I-Complex
SMP	I-Complex
)	I-Complex
IV	I-Complex
has	O
a	O
molecular	O
weight	O
of	O
150	O
,	O
000	O
as	O
determined	O
by	O
gel	O
filtration	O
on	O
a	O
Sephadex	O
G	O
-	O
200	O
column	O
and	O
is	O
composed	O
of	O
two	O
subunits	O
(	O
Mr	O
=	O
58	O
,	O
000	O
and	O
40	O
,	O
000	O
)	O
.	O

Although	O
it	O
is	O
active	O
toward	O
a	O
number	O
of	O
proteins	O
,	O
its	O
activities	O
toward	O
the	O
contractile	O
proteins	O
,	O
intact	O
myosin	O
,	O
heavy	O
meromyosin	O
,	O
and	O
isolated	O
myosin	O
light	O
chains	O
are	O
higher	O
than	O
its	O
activities	O
toward	O
phosphorylase	O
alpha	O
,	O
histone	O
IIA	O
,	O
and	O
phosphorylase	B-OOS
kinase	I-OOS
.	O

SMP	B-Complex
-	I-Complex
IV	I-Complex
preferentially	O
dephosphorylates	O
the	O
beta	O
-	O
subunit	O
of	O
phosphorylase	B-OOS
kinase	I-OOS
.	O

The	O
properties	O
of	O
the	O
enzyme	O
have	O
been	O
studied	O
using	O
heavy	O
meromyosin	O
,	O
a	O
soluble	O
chymotryptic	O
fragment	O
of	O
myosin	O
,	O
and	O
isolated	O
myosin	O
light	O
chains	O
as	O
substrates	O
.	O

SMP	B-Complex
-	I-Complex
IV	I-Complex
has	O
high	O
affinity	O
for	O
both	O
substrates	O
and	O
is	O
optimally	O
active	O
at	O
neutral	O
pH	O
.	O

Divalent	O
cations	O
,	O
Ca2	O
+	O
and	O
Mg2	O
+	O
,	O
activate	O
the	O
dephosphorylation	O
of	O
heavy	O
meromyosin	O
but	O
inhibit	O
the	O
activity	O
toward	O
myosin	O
light	O
chains	O
.	O

Low	O
concentrations	O
of	O
ATP	O
(	O
1	O
-	O
5	O
mM	O
)	O
activate	O
SMP	B-Complex
-	I-Complex
IV	I-Complex
but	O
concentrations	O
higher	O
than	O
5	O
mM	O
are	O
inhibitory	O
.	O

Inhibition	O
of	O
50	O
%	O
of	O
the	O
activity	O
of	O
the	O
enzyme	O
by	O
NaF	O
and	O
PPi	O
requires	O
concentrations	O
higher	O
than	O
10	O
mM	O
.	O

Rabbit	O
skeletal	O
muscle	O
heat	O
stable	O
inhibitor	O
-	O
2	O
has	O
no	O
effect	O
on	O
the	O
activity	O
of	O
SMP	B-Complex
-	I-Complex
IV	I-Complex
toward	O
heavy	O
meromyosin	O
,	O
myosin	O
light	O
chains	O
,	O
and	O
phosphorylase	O
alpha	O
.	O

The	O
effects	O
of	O
processing	O
inhibitors	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
the	O
intracellular	O
migration	O
of	O
glycoprotein	O
E2	O
of	O
mouse	O
hepatitis	O
virus	O
and	O
the	O
maturation	O
of	O
coronavirus	O
particles	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
tunicamycin	O
and	O
inhibitors	O
of	O
the	O
processing	O
of	O
N	O
-	O
linked	O
glycans	O
including	O
N	O
-	O
methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
,	O
castanospermine	O
,	O
mannodeoxynojirimycin	O
,	O
and	O
swainsonine	O
on	O
the	O
transport	O
of	O
glycoprotein	O
E2	O
and	O
the	O
intracellular	O
maturation	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Indirect	O
immunofluorescence	O
staining	O
with	O
monoclonal	O
antibodies	O
revealed	O
that	O
glycoprotein	O
E2	O
exhibits	O
different	O
antigenic	O
properties	O
depending	O
on	O
the	O
presence	O
and	O
on	O
the	O
structure	O
of	O
the	O
N	O
-	O
linked	O
oligosaccharides	O
and	O
that	O
efficient	O
transport	O
of	O
glycoprotein	O
E2	O
to	O
the	O
plasma	O
membrane	O
requires	O
the	O
removal	O
of	O
glucose	O
residues	O
.	O

In	O
the	O
presence	O
of	O
tunicamycin	O
in	O
the	O
nonglycosylated	O
E2	O
apoprotein	O
was	O
synthesized	O
in	O
normal	O
amounts	O
and	O
readily	O
acylated	O
throughout	O
the	O
infectious	O
cycle	O
.	O

This	O
E2	O
-	O
species	O
could	O
not	O
be	O
detected	O
on	O
the	O
surface	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
-	O
infected	O
cells	O
with	O
indirect	O
immunofluorescence	O
staining	O
or	O
lactoperoxidase	O
labeling	O
.	O

N	O
-	O
Methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
and	O
castanospermine	O
,	O
both	O
of	O
which	O
selectively	O
inhibited	O
the	O
processing	O
glucosidases	O
,	O
caused	O
a	O
drop	O
in	O
virion	O
formation	O
by	O
two	O
log	O
steps	O
and	O
a	O
drastic	O
delay	O
in	O
the	O
surface	O
expression	O
of	O
glycoprotein	O
E2	O
.	O

The	O
E2	O
species	O
synthesized	O
under	O
such	O
conditions	O
was	O
acylated	O
but	O
accumulated	O
intracellularly	O
in	O
a	O
compartment	O
distinct	O
from	O
the	O
Golgi	O
.	O

Concomitantly	O
,	O
synthesis	O
of	O
the	O
matrix	O
glycoprotein	O
E1	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
was	O
drastically	O
impaired	O
.	O

Mannodeoxynojirimycin	O
and	O
swainsonine	O
,	O
which	O
block	O
later	O
stages	O
of	O
the	O
processing	O
pathway	O
,	O
had	O
less	O
or	O
no	O
effect	O
on	O
the	O
transport	O
of	O
glycoprotein	O
E2	O
and	O
the	O
formation	O
of	O
virus	O
particles	O
.	O

A	O
Novel	O
Reciprocal	O
Crosstalk	O
between	O
RNF168	O
and	O
PARP1	O
to	O
Regulate	O
DNA	O
Repair	O
Processes	O
.	O

Emerging	O
evidence	O
has	O
suggested	O
that	O
cellular	O
crosstalk	O
between	O
RNF168	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
1	O
(	O
PARP1	O
)	O
contributes	O
to	O
the	O
precise	O
control	O
of	O
the	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
.	O

However	O
,	O
the	O
direct	O
and	O
reciprocal	O
functional	O
link	O
between	O
them	O
remains	O
unclear	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
that	O
RNF168	O
ubiquitinates	O
PARP1	O
via	O
direct	O
interaction	O
and	O
accelerates	O
PARP1	O
degradation	O
in	O
the	O
presence	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
(	O
PAR	O
)	O
chains	O
,	O
metabolites	O
of	O
activated	O
PARP1	O
.	O

Through	O
mass	O
spectrometric	O
analysis	O
,	O
we	O
revealed	O
that	O
RNF168	O
ubiquitinated	O
multiple	O
lysine	O
residues	O
on	O
PARP1	O
via	O
K48	O
-	O
linked	O
ubiquitin	O
chain	O
formation	O
.	O

Consistent	O
with	O
this	O
,	O
micro	O
-	O
irradiation	O
-	O
induced	O
PARP1	O
accumulation	O
at	O
damaged	O
chromatin	O
was	O
significantly	O
increased	O
by	O
knockdown	O
of	O
endogenous	O
RNF168	O
.	O

In	O
addition	O
,	O
it	O
was	O
confirmed	O
that	O
abnormal	O
changes	O
of	O
HR	O
and	O
HNEJ	O
due	O
to	O
knockdown	O
of	O
RNF168	O
were	O
restored	O
by	O
overexpression	O
of	O
WT	O
RNF168	O
but	O
not	O
by	O
reintroduction	O
of	O
mutants	O
lacking	O
E3	O
ligase	O
activity	O
or	O
PAR	O
binding	O
ability	O
.	O

The	O
comet	O
assay	O
also	O
revealed	O
that	O
both	O
PAR	O
-	O
binding	O
and	O
ubiquitin	O
-	O
conjugation	O
activities	O
are	O
indispensable	O
for	O
the	O
RNF168	O
-	O
mediated	O
DNA	O
repair	O
process	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
RNF168	O
acts	O
as	O
a	O
counterpart	O
of	O
PARP1	O
in	O
DDR	O
and	O
regulates	O
the	O
HR	O
/	O
NHEJ	O
repair	O
processes	O
through	O
the	O
ubiquitination	O
of	O
PARP1	O
.	O

We	O
used	O
fluorescence	O
polarization	O
experiments	O
to	O
examine	O
RNA	O
binding	O
and	O
found	O
that	O
S	O
.	O
pombe	O
Puf3PUM	O
binds	O
to	O
both	O
the	O
ScPuf3	O
target	O
and	O
the	O
ScPuf5	O
target	O
with	O
high	O
affinity	O
(	O
Figure	O
4A	O
,	O
bottom	O
)	O
.	O

The	O
affinity	O
for	O
the	O
ScPuf3	O
motif	O
is	O
~	O
2	O
fold	O
higher	O
than	O
for	O
the	O
ScPuf5	O
motif	O
,	O
but	O
the	O
binding	O
affinity	O
in	O
both	O
cases	O
is	O
in	O
the	O
picomolar	O
range	O
.	O

Surprisingly	O
,	O
in	O
deadenylation	O
activity	O
assays	O
with	O
100	O
nM	O
Puf3	O
,	O
we	O
found	O
that	O
the	O
ScPuf3	O
target	O
was	O
selectively	O
deadenylated	O
in	O
preference	O
to	O
the	O
ScPuf5	O
target	O
(	O
Figure	O
4B	O
)	O
.	O

Thus	O
,	O
Puf3	O
can	O
distinguish	O
between	O
very	O
similar	O
RNAs	O
and	O
selectively	O
target	O
them	O
for	O
deadenylation	O
by	O
Ccr4	O
-	O
Not	O
.	O

ETS1	O
transactivates	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
,	O
AP	B-Complex
-	I-Complex
1	I-Complex
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	O
and	O
ELF1	O
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-	O
47	O
to	O
-	O
40	O
upstream	O
of	O
the	O
GM	O
-	O
CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	O
,	O
but	O
not	O
ELF1	O
,	O
can	O
transactivate	O
GM	O
-	O
CSF	O
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-	O
GGAA	O
-	O
to	O
-	O
GGAT	O
-	O
prevents	O
the	O
binding	O
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	O
of	O
ETS1	O
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	O
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	O
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	O
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	O
-	O
CSF	O
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	O
Factor	O
VII	O
/	O
VIIa	O
to	O
the	O
tissue	O
factor	O
(	O
TF	O
)	O
receptor	O
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	O
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	O
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
kappa	B-Complex
B	I-Complex
site	O
in	O
the	O
TF	O
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	O
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	O
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Rapid	O
activation	O
of	O
the	O
STAT3	O
transcription	O
factor	O
by	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
is	O
a	O
glycoprotein	O
that	O
stimulates	O
proliferation	O
and	O
differentiation	O
of	O
progenitor	O
cells	O
of	O
neutrophils	O
by	O
signaling	O
through	O
its	O
receptor	O
(	O
G	O
-	O
CSFR	O
)	O
.	O

Although	O
the	O
G	O
-	O
CSFR	O
belongs	O
to	O
the	O
cytokine	O
receptor	O
superfamily	O
,	O
which	O
lacks	O
an	O
intracellular	O
kinase	O
domain	O
,	O
G	O
-	O
CSF	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
is	O
critical	O
for	O
its	O
biologic	O
activities	O
.	O

We	O
report	O
here	O
that	O
JAK1	O
and	O
JAK2	O
tyrosine	O
kinases	O
are	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
G	O
-	O
CSF	O
induction	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
DNA	O
-	O
binding	O
protein	O
STAT3	O
(	O
also	O
called	O
the	O
acute	O
-	O
phase	O
response	O
factor	O
[	O
APRF	O
]	O
,	O
activated	O
by	O
interleukin	O
-	O
6	O
)	O
is	O
an	O
early	O
target	O
of	O
G	O
-	O
CSF	O
-	O
induced	O
tyrosine	O
phosphorylation	O
.	O

G	O
-	O
CSF	O
induces	O
two	O
DNA	O
-	O
binding	O
complexes	O
;	O
the	O
major	O
complex	O
contains	O
tyrosine	O
phosphorylated	O
STAT3	O
protein	O
and	O
the	O
minor	O
complex	O
appears	O
to	O
be	O
a	O
heterodimer	O
of	O
the	O
STAT1	O
(	O
previously	O
p91	O
,	O
a	O
component	O
of	O
DNA	O
-	O
binding	O
complexes	O
activated	O
by	O
interferons	O
)	O
and	O
STAT3	O
proteins	O
.	O

Antiphosphotyrosine	O
antibody	O
interferes	O
with	O
the	O
DNA	O
binding	O
activity	O
of	O
activated	O
STAT3	O
,	O
indicating	O
that	O
tyrosine	O
phosphorylation	O
of	O
STAT3	O
is	O
important	O
for	O
the	O
DNA	O
binding	O
activity	O
.	O

These	O
results	O
identify	O
a	O
signal	O
transduction	O
pathway	O
activated	O
in	O
response	O
to	O
G	O
-	O
CSF	O
and	O
provide	O
a	O
mechanism	O
for	O
the	O
rapid	O
modulation	O
of	O
gene	O
expression	O
by	O
G	O
-	O
CSF	O
.	O

Posttranslational	O
processing	O
of	O
human	O
alpha	O
2	O
-	O
HS	O
glycoprotein	O
(	O
human	O
fetuin	O
)	O
.	O

Evidence	O
for	O
the	O
production	O
of	O
a	O
phosphorylated	O
single	O
-	O
chain	O
form	O
by	O
hepatoma	O
cells	O
.	O

alpha	O
2	O
-	O
HS	O
glycoprotein	O
(	O
alpha	O
2	O
-	O
HS	O
)	O
is	O
a	O
major	O
protein	O
occurring	O
in	O
human	O
blood	O
and	O
calciferous	O
tissues	O
.	O

Due	O
to	O
extensive	O
sequence	O
identity	O
,	O
alpha	O
2	O
-	O
HS	O
has	O
been	O
grouped	O
with	O
the	O
fetuins	O
,	O
a	O
family	O
of	O
proteins	O
that	O
occur	O
in	O
fetal	O
plasma	O
in	O
high	O
concentrations	O
.	O

Native	O
alpha	O
2	O
-	O
HS	O
undergoes	O
a	O
series	O
of	O
posttranslational	O
modifications	O
including	O
proteolytic	O
processing	O
,	O
multiple	O
N	O
-	O
glycosylations	O
and	O
O	O
-	O
glycosylations	O
,	O
and	O
sulfation	O
of	O
the	O
carbohydrate	O
side	O
chains	O
.	O

Various	O
two	O
-	O
chain	O
forms	O
of	O
alpha	O
2	O
-	O
HS	O
have	O
been	O
prepared	O
from	O
human	O
plasma	O
,	O
however	O
,	O
the	O
single	O
-	O
chain	O
precursor	O
has	O
not	O
yet	O
been	O
isolated	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
biosynthesis	O
of	O
alpha	O
2	O
-	O
HS	O
by	O
a	O
human	O
hepatoma	O
cell	O
line	O
,	O
HepG2	O
.	O

We	O
demonstrate	O
that	O
a	O
single	O
-	O
chain	O
form	O
and	O
the	O
two	O
-	O
chain	O
form	O
of	O
alpha	O
2	O
-	O
HS	O
are	O
secreted	O
by	O
this	O
cell	O
line	O
.	O

The	O
alpha	O
2	O
-	O
HS	O
forms	O
are	O
further	O
modified	O
by	O
phosphorylation	O
on	O
multiple	O
serine	O
residues	O
.	O

Mapping	O
studies	O
indicate	O
that	O
the	O
connecting	O
peptide	O
region	O
releasable	O
from	O
the	O
heavy	O
chain	O
of	O
alpha	O
2	O
-	O
HS	O
contains	O
at	O
least	O
one	O
such	O
phosphorylation	O
site	O
.	O

Our	O
results	O
identify	O
proteolytic	O
trimming	O
and	O
/	O
or	O
phosphorylation	O
as	O
modifications	O
possibly	O
regulating	O
the	O
biological	O
effects	O
of	O
alpha	O
2	O
-	O
HS	O
and	O
the	O
homologous	O
fetuins	O
.	O

Monocyte	O
tethering	O
by	O
P	O
-	O
selectin	O
regulates	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
secretion	O
.	O

Signal	O
integration	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	O
monocytes	O
to	O
P	O
-	O
selectin	O
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	O
tethering	O
factor	O
,	O
increased	O
the	O
secretion	O
of	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
MCP	O
-	O
1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet	O
-	O
activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti	O
-	O
P	O
-	O
selectin	O
mAb	O
that	O
prevents	O
P	O
-	O
selectin	O
from	O
binding	O
to	O
its	O
ligand	O
(	O
P	O
-	O
selectin	O
glycoprotein	O
ligand	O
-	O
1	O
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P	O
-	O
selectin	O
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
)	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
MCP	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O

These	O
results	O
demonstrate	O
that	O
P	O
-	O
selectin	O
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

The	O
products	O
of	O
the	O
SUP45	O
(	O
eRF1	O
)	O
and	O
SUP35	O
genes	O
interact	O
to	O
mediate	O
translation	O
termination	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
product	O
of	O
the	O
yeast	O
SUP45	O
gene	O
(	O
Sup45p	O
)	O
is	O
highly	O
homologous	O
to	O
the	O
Xenopus	O
eukaryote	O
release	O
factor	O
1	O
(	O
eRF1	O
)	O
,	O
which	O
has	O
release	B-Complex
factor	I-Complex
activity	O
in	O
vitro	O
.	O

We	O
show	O
,	O
using	O
the	O
two	O
-	O
hybrid	O
system	O
,	O
that	O
in	O
Saccharomyces	O
cerevisiae	O
Sup45p	O
and	O
the	O
product	O
of	O
the	O
SUP35	O
gene	O
(	O
Sup35p	O
)	O
interact	O
in	O
vivo	O
.	O

The	O
ability	O
of	O
Sup45p	O
C	O
-	O
terminally	O
tagged	O
with	O
(	O
His	O
)	O
6	O
to	O
specifically	O
precipitate	O
Sup35p	O
from	O
a	O
cell	O
lysate	O
was	O
used	O
to	O
confirm	O
this	O
interaction	O
in	O
vitro	O
.	O

Although	O
overexpression	O
of	O
either	O
the	O
SUP45	O
or	O
SUP35	O
genes	O
alone	O
did	O
not	O
reduce	O
the	O
efficiency	O
of	O
codon	O
-	O
specific	O
tRNA	O
nonsense	O
suppression	O
,	O
the	O
simultaneous	O
overexpression	O
of	O
both	O
the	O
SUP35	O
and	O
SUP45	O
genes	O
in	O
nonsense	O
suppressor	O
tRNA	O
-	O
containing	O
strains	O
produced	O
an	O
antisuppressor	O
phenotype	O
.	O

These	O
data	O
are	O
consistent	O
with	O
Sup35p	O
and	O
Sup45p	O
forming	O
a	O
complex	O
with	O
release	B-Complex
factor	I-Complex
properties	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
either	O
Xenopus	O
or	O
human	O
eRF1	O
(	O
SUP45	O
)	O
genes	O
also	O
resulted	O
in	O
anti	O
-	O
suppression	O
only	O
if	O
that	O
strain	O
was	O
also	O
overexpressing	O
the	O
yeast	O
SUP35	O
gene	O
.	O

Antisuppression	O
is	O
a	O
characteristic	O
phenotype	O
associated	O
with	O
overexpression	O
of	O
both	O
prokaryote	O
and	O
mitochondrial	O
release	O
factors	O
.	O

We	O
propose	O
that	O
Sup45p	O
and	O
Sup35p	O
interact	O
to	O
form	O
a	O
release	B-Complex
factor	I-Complex
complex	O
in	O
yeast	O
and	O
that	O
Sup35p	O
,	O
which	O
has	O
GTP	O
binding	O
sequence	O
motifs	O
in	O
its	O
C	O
-	O
terminal	O
domain	O
,	O
provides	O
the	O
GTP	O
hydrolytic	O
activity	O
which	O
is	O
a	O
demonstrated	O
requirement	O
of	O
the	O
eukaryote	O
translation	O
termination	O
reaction	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoter	O
activity	O
by	O
AML1	O
-	O
related	O
transcription	O
factor	O
,	O
PEBP2	B-Complex
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B-Complex
enhancer	I-Complex
binding	I-Complex
-	I-Complex
protein	I-Complex
2	I-Complex
(	O
PEBP2	B-Complex
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O
alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	O
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	O
A1	O
(	O
an	O
alpha	O
A	O
-	O
gene	O
product	O
)	O
and	O
alpha	O
B1	O
and	O
alpha	O
B2	O
(	O
two	O
alpha	O
B	O
-	O
encoded	O
isomers	O
)	O
for	O
their	O
effects	O
on	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
,	O
alpha	O
B1	O
,	O
and	O
alpha	O
B2	O
proteins	O
bound	O
the	O
PEBP2	B-Complex
site	O
within	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
and	O
alpha	O
B1	O
enhanced	O
the	O
expression	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
/	O
phytohemagglutinin	O
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	O
B2	O
.	O

Coexpression	O
of	O
alpha	O
B1	O
and	O
alpha	O
B2	O
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	O
B1	O
/	O
alpha	O
B2	O
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B-Complex
site	O
-	O
binding	O
protein	O
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	O
alpha	O
A1	O
antibodies	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B-Complex
alpha	O
A	O
,	O
alpha	O
B	O
(	O
AML1	O
)	O
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-Complex
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-Complex
isoforms	O
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

Properties	O
of	O
type	O
II	O
inositol	O
polyphosphate	O
5	O
-	O
phosphatase	O
.	O

We	O
have	O
isolated	O
additional	O
cDNA	O
clones	O
encoding	O
type	O
II	O
inositol	O
polyphosphate	O
5	O
-	O
phosphatase	O
(	O
5	O
-	O
phosphatase	O
II	O
)	O
resulting	O
in	O
a	O
combined	O
cDNA	O
of	O
3076	O
nucleotides	O
encoding	O
a	O
protein	O
of	O
942	O
amino	O
acids	O
.	O

The	O
5	O
-	O
phosphatase	O
II	O
hydrolyzed	O
both	O
Ins	O
(	O
1	O
,	O
4	O
,	O
5	O
)	O
P3	O
to	O
Ins	O
(	O
1	O
,	O
4	O
)	O
P2	O
and	O
the	O
phospholipid	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
to	O
PtdIns	O
(	O
4	O
)	O
P	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

There	O
are	O
two	O
motifs	O
highly	O
conserved	O
between	O
types	O
I	O
and	O
II	O
5	O
-	O
phosphatase	O
and	O
several	O
other	O
proteins	O
presumed	O
to	O
be	O
inositol	O
phosphatases	O
suggesting	O
a	O
possible	O
role	O
in	O
catalysis	O
.	O

The	O
type	O
II	O
5	O
-	O
phosphatase	O
also	O
contains	O
homology	O
to	O
several	O
GTPase	O
activating	O
proteins	O
although	O
no	O
such	O
activity	O
for	O
5	O
-	O
phosphatase	O
II	O
was	O
found	O
.	O

The	O
predicted	O
protein	O
ends	O
with	O
the	O
sequence	O
CNPL	O
,	O
suggesting	O
that	O
it	O
is	O
isoprenylated	O
as	O
a	O
mechanism	O
for	O
membrane	O
attachment	O
.	O

We	O
found	O
evidence	O
for	O
isoprenylation	O
by	O
demonstrating	O
incorporation	O
of	O
[	O
3H	O
]	O
mevalonate	O
into	O
native	O
but	O
not	O
C939S	O
mutant	O
5	O
-	O
phosphatase	O
II	O
expressed	O
in	O
Sf9	O
insect	O
cells	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
membrane	O
localization	O
and	O
the	O
activity	O
of	O
5	O
-	O
phosphatase	O
II	O
toward	O
its	O
lipid	O
substrate	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
is	O
reduced	O
by	O
eliminating	O
5	O
-	O
phosphatase	O
II	O
isoprenylation	O
in	O
the	O
mutant	O
C939S	O
relative	O
to	O
the	O
native	O
enzyme	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	O
protein	O
.	O

The	O
IE2	O
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	O
)	O
dramatically	O
suppressed	O
this	O
IE2	O
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	O
,	O
Rb	O
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	O
specifically	O
interacts	O
with	O
IE2	O
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	O
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	O
.	O

Our	O
results	O
suggest	O
that	O
Rb	O
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Induction	O
of	O
Sp1	O
phosphorylation	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	O
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	O
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	O
and	O
interleukin	O
2	O
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	B-Complex
B	I-Complex
elements	O
to	O
HIV	O
Tat	O
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	O
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	B-Complex
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	O
,	O
and	O
Sp1	O
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Ligand	O
-	O
dependent	O
repression	O
of	O
the	O
erythroid	O
transcription	O
factor	O
GATA	O
-	O
1	O
by	O
the	O
estrogen	O
receptor	O
.	O

High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha	O
-	O
and	O
beta	O
-	O
globin	O
,	O
band	O
3	O
,	O
band	O
4	O
.	O
1	O
,	O
and	O
the	O
erythroid	O
cell	O
-	O
specific	O
histone	O
H5	O
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA	O
-	O
1	O
,	O
an	O
erythroid	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA	O
-	O
1	O
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4	O
-	O
hydroxytamoxifen	O
.	O

ER	O
-	O
mediated	O
repression	O
of	O
GATA	O
-	O
1	O
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA	O
-	O
1	O
.	O

GATA	O
-	O
1	O
and	O
ER	O
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	O
-	O
1	O
and	O
ER	O
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA	O
-	O
1	O
and	O
the	O
ER	O
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
of	O
GATA	O
-	O
1	O
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA	O
-	O
1	O
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
ER	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mismatch	O
correction	O
acts	O
as	O
a	O
barrier	O
to	O
homeologous	O
recombination	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
homeologous	O
mitotic	O
recombination	O
assay	O
was	O
used	O
to	O
test	O
the	O
role	O
of	O
Saccharomyces	O
cerevisiae	O
mismatch	O
repair	O
genes	O
PMS1	O
,	O
MSH2	O
and	O
MSH3	O
on	O
recombination	O
fidelity	O
.	O

A	O
homeologous	O
gene	O
pair	O
consisting	O
of	O
S	O
.	O
cerevisiae	O
SPT15	O
and	O
its	O
S	O
.	O
pombe	O
homolog	O
were	O
present	O
as	O
a	O
direct	O
repeat	O
on	O
chromosome	O
V	O
,	O
with	O
the	O
exogenous	O
S	O
.	O
pombe	O
sequences	O
inserted	O
either	O
upstream	O
or	O
downstream	O
of	O
the	O
endogenous	O
S	O
.	O
cerevisiae	O
gene	O
.	O

Each	O
gene	O
carried	O
a	O
different	O
inactivating	O
mutation	O
,	O
rendering	O
the	O
starting	O
strain	O
Spt15	O
-	O
.	O

Recombinants	O
that	O
regenerated	O
SPT15	O
function	O
were	O
scored	O
after	O
nonselective	O
growth	O
of	O
the	O
cells	O
.	O

In	O
strains	O
wild	O
type	O
for	O
mismatch	O
repair	O
,	O
homeologous	O
recombination	O
was	O
depressed	O
150	O
-	O
to	O
180	O
-	O
fold	O
relative	O
to	O
homologous	O
controls	O
,	O
indicating	O
that	O
recombination	O
between	O
diverged	O
sequences	O
is	O
inhibited	O
.	O

In	O
one	O
orientation	O
of	O
the	O
homeologous	O
gene	O
pair	O
,	O
msh2	O
or	O
msh3	O
mutations	O
resulted	O
in	O
17	O
-	O
and	O
9	O
.	O
6	O
-	O
fold	O
elevations	O
in	O
recombination	O
and	O
the	O
msh2	O
msh3	O
double	O
mutant	O
exhibited	O
an	O
43	O
-	O
fold	O
increase	O
,	O
implying	O
that	O
each	O
MSH	O
gene	O
can	O
function	O
independently	O
in	O
trans	O
to	O
prevent	O
homeologous	O
recombination	O
.	O

Homologous	O
recombination	O
was	O
not	O
significantly	O
affected	O
by	O
the	O
msh	O
mutations	O
.	O

In	O
the	O
other	O
orientation	O
,	O
only	O
msh2	O
strains	O
were	O
elevated	O
(	O
12	O
-	O
fold	O
)	O
for	O
homeologous	O
recombination	O
.	O

A	O
mutation	O
in	O
MSH3	O
did	O
not	O
affect	O
the	O
rate	O
of	O
recombination	O
in	O
this	O
orientation	O
.	O

Surprisingly	O
,	O
a	O
pms1	O
deletion	O
mutant	O
did	O
not	O
exhibit	O
elevated	O
homeologous	O
recombination	O
.	O

A	O
kinase	O
-	O
cyclin	O
pair	O
in	O
the	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
holoenzyme	O
.	O

The	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
holoenzyme	O
consists	O
of	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
,	O
a	O
subset	O
of	O
general	O
transcription	O
factors	O
,	O
and	O
regulatory	O
proteins	O
known	O
as	O
SRB	O
proteins	O
.	O

The	O
genes	O
encoding	O
SRB	O
proteins	O
were	O
isolated	O
as	O
suppressors	O
of	O
mutations	O
in	O
the	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
carboxy	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
.	O

The	O
CTD	O
and	O
SRB	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
response	O
to	O
transcriptional	O
regulators	O
.	O

We	O
report	O
here	O
the	O
isolation	O
of	O
two	O
new	O
SRB	O
genes	O
,	O
SRB10	O
and	O
SRB11	O
,	O
which	O
encode	O
kinase	O
-	O
and	O
cyclin	O
-	O
like	O
proteins	O
,	O
respectively	O
.	O

Genetic	O
and	O
biochemical	O
evidence	O
indicates	O
that	O
the	O
SRB10	O
and	O
SRB11	O
proteins	O
form	O
a	O
kinase	O
-	O
cyclin	O
pair	O
in	O
the	O
holoenzyme	O
.	O

The	O
SRB10	O
/	O
11	O
kinase	O
is	O
essential	O
for	O
a	O
normal	O
transcriptional	O
response	O
to	O
galactose	O
induction	O
in	O
vivo	O
.	O

Holoenzymes	O
lacking	O
SRB10	O
/	O
11	O
kinase	O
function	O
are	O
strikingly	O
deficient	O
in	O
CTD	O
phosphorylation	O
.	O

Although	O
defects	O
in	O
the	O
kinase	O
substantially	O
affect	O
transcription	O
in	O
vivo	O
,	O
purified	O
holoenzymes	O
lacking	O
SRB10	O
/	O
11	O
kinase	O
function	O
do	O
not	O
show	O
defects	O
in	O
defined	O
in	O
vitro	O
transcription	O
systems	O
,	O
suggesting	O
that	O
the	O
factors	O
necessary	O
to	O
elicit	O
the	O
regulatory	O
role	O
of	O
the	O
SRB10	O
/	O
11	O
kinase	O
are	O
missing	O
in	O
these	O
systems	O
.	O

These	O
results	O
indicate	O
that	O
the	O
SRB10	O
/	O
11	O
kinase	O
is	O
involved	O
in	O
CTD	O
phosphorylation	O
and	O
suggest	O
that	O
this	O
modification	O
has	O
a	O
role	O
in	O
the	O
response	O
to	O
transcriptional	O
regulators	O
in	O
vivo	O
.	O

Evolution	O
of	O
the	O
Glx	O
-	O
tRNA	O
synthetase	O
family	O
:	O
the	O
glutaminyl	O
enzyme	O
as	O
a	O
case	O
of	O
horizontal	O
gene	O
transfer	O
.	O

An	O
important	O
step	O
ensuring	O
the	O
fidelity	O
in	O
protein	O
biosynthesis	O
is	O
the	O
aminoacylation	O
of	O
tRNAs	O
by	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
.	O

The	O
accuracy	O
of	O
this	O
process	O
rests	O
on	O
a	O
family	O
of	O
20	O
enzymes	O
,	O
one	O
for	O
each	O
amino	O
acid	O
.	O

One	O
exception	O
is	O
the	O
formation	O
of	O
Gln	O
-	O
tRNA	O
(	O
Gln	O
)	O
that	O
can	O
be	O
accomplished	O
by	O
two	O
different	O
pathways	O
:	O
aminoacylation	O
of	O
tRNA	O
(	O
Gln	O
)	O
with	O
Gln	O
by	O
glutaminyl	O
-	O
tRNA	O
synthetase	O
(	O
GlnRS	O
;	O
EC	O
6	O
.	O
1	O
.	O
1	O
.	O
18	O
)	O
or	O
transamidation	O
of	O
Glu	O
from	O
Glu	O
-	O
tRNA	O
(	O
Gln	O
)	O
mischarged	O
by	O
glutamyl	O
-	O
tRNA	O
synthetase	O
(	O
GluRS	O
;	O
EC	O
6	O
.	O
1	O
.	O
1	O
.	O
17	O
)	O
.	O

The	O
latter	O
pathway	O
is	O
widespread	O
among	O
bacteria	O
and	O
organelles	O
that	O
,	O
accordingly	O
,	O
lack	O
GlnRS	O
.	O

However	O
,	O
some	O
bacterial	O
species	O
,	O
such	O
as	O
Escherichia	O
coli	O
,	O
do	O
possess	O
a	O
GlnRS	O
activity	O
,	O
which	O
is	O
responsible	O
for	O
Gln	O
-	O
tRNA	O
(	O
Gln	O
)	O
formation	O
.	O

In	O
the	O
cytoplasm	O
of	O
eukaryotic	O
cells	O
,	O
both	O
GluRS	O
and	O
GlnRS	O
activities	O
can	O
be	O
detected	O
.	O

To	O
gain	O
more	O
insight	O
into	O
the	O
evolutionary	O
relationship	O
between	O
GluRS	O
and	O
GlnRS	O
enzyme	O
species	O
,	O
we	O
have	O
now	O
isolated	O
and	O
characterized	O
a	O
human	O
cDNA	O
encoding	O
GlnRS	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
shows	O
a	O
strong	O
similarity	O
with	O
other	O
known	O
GlnRSs	O
and	O
with	O
eukaryotic	O
GluRSs	O
.	O

A	O
molecular	O
phylogenetic	O
analysis	O
was	O
conducted	O
on	O
the	O
14	O
GlxRS	O
(	O
GluRS	O
or	O
GlnRS	O
)	O
sequences	O
available	O
to	O
date	O
.	O

Our	O
data	O
suggest	O
that	O
bacterial	O
GlnRS	O
has	O
a	O
eukaryotic	O
origin	O
and	O
was	O
acquired	O
by	O
a	O
mechanism	O
of	O
horizontal	O
gene	O
transfer	O
.	O

NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
controls	O
expression	O
of	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
.	O

Phorbol	O
ester	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
induction	O
of	O
nuclear	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	O
kappa	O
B	O
alpha	O
and	O
the	O
activation	O
of	O
I	O
kappa	O
B	O
alpha	O
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65	O
-	O
kilodalton	O
transactivating	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
with	O
p65	O
restores	O
intracellular	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
controls	O
the	O
expression	O
of	O
I	O
kappa	O
B	O
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	O
plus	O
CD28	O
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O

Long	O
-	O
lasting	O
IL	O
-	O
2	O
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL	O
-	O
2	O
receptor	O
alpha	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	O
of	O
IL	O
-	O
2R	O
alpha	O
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
binding	O
to	O
a	O
radiolabeled	O
IL	O
-	O
2R	O
alpha	O
kappa	B-Complex
B	I-Complex
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	O
+	O
CD28	O
activation	O
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	O
/	O
p50	O
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	B-Complex
B	I-Complex
-	O
specific	O
complexes	O
were	O
identified	O
as	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
-	O
p65	O
heterodimer	O
and	O
putative	O
c	O
-	O
Rel	O
homodimer	O
or	O
c	O
-	O
Rel	O
-	O
p65	O
heterodimer	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	O
+	O
CD28	O
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL	O
-	O
2	O
secretion	O
,	O
IL	O
-	O
2R	O
alpha	O
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	O
+	O
CD28	O
.	O

Overproduction	O
of	O
NFKB2	O
(	O
lyt	O
-	O
10	O
)	O
and	O
c	O
-	O
Rel	O
:	O
a	O
mechanism	O
for	O
HTLV	O
-	O
I	O
Tax	O
-	O
mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	O
protein	O
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
2R	O
alpha	O
and	O
IL	O
-	O
2	O
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	O
(	O
lyt	O
-	O
10	O
)	O
and	O
c	O
-	O
Rel	O
are	O
overexpressed	O
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	O
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	O
-	O
dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	O
(	O
p100	O
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	O
(	O
p52	O
)	O
form	O
,	O
induction	O
of	O
c	O
-	O
Rel	O
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	O
precursor	O
is	O
physically	O
associated	O
with	O
c	O
-	O
Rel	O
and	O
with	O
Tax	O
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	O
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c	O
-	O
Rel	O
,	O
NFKB2	O
alters	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

Autoregulation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
transactivator	O
RelA	O
(	O
p65	O
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O

RelA	O
(	O
p65	O
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50	O
-	O
p65	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
complex	O
and	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

After	O
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	O
kappa	O
B	O
alpha	O
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	O
is	O
stably	O
associated	O
not	O
only	O
with	O
I	O
kappa	O
B	O
alpha	O
but	O
also	O
with	O
other	O
ankyrin	O
motif	O
-	O
rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF	O
-	O
kappa	O
B2	O
(	O
p100	O
)	O
and	O
NF	O
-	O
kappa	O
B1	O
(	O
p105	O
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	O
-	O
I	O
kappa	O
B	O
alpha	O
,	O
RelA	O
-	O
p100	O
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	O
necrosis	O
factor	O
alpha	O
activation	O
;	O
(	O
iii	O
)	O
p100	O
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	O
-	O
mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	O
and	O
p100	O
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	O
localization	O
signal	O
of	O
RelA	O
,	O
which	O
is	O
required	O
for	O
I	O
kappa	O
B	O
alpha	O
binding	O
;	O
(	O
v	O
)	O
p100	O
inhibition	O
of	O
RelA	O
function	O
requires	O
the	O
C	O
-	O
terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	O
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	O
kappa	O
B	O
alpha	O
,	O
nuclear	O
RelA	O
stimulates	O
p100	O
mRNA	O
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Calcineurin	B-Complex
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	O
kappa	O
B	O
/	O
MAD3	O
,	O
an	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

The	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
(	O
TcR	B-Complex
)	O
responsive	O
elements	O
.	O

The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK	O
-	O
506	O
)	O
.	O

Calcineurin	B-Complex
,	O
a	O
Ca2	B-Complex
+	I-Complex
/	I-Complex
calmodulin	I-Complex
-	I-Complex
dependent	I-Complex
protein	I-Complex
phosphatase	I-Complex
,	O
is	O
the	O
FK	O
-	O
506	O
-	O
and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	O
for	O
TcR	B-Complex
mediated	O
activation	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-Complex
partially	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	O
the	O
IL	O
-	O
2	O
promoter	O
elements	O
IL	O
-	O
2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	O
and	O
Oct	O
-	O
1	O
)	O
and	O
IL	O
-	O
2E	O
(	O
which	O
binds	O
NF	O
-	O
AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
dependent	O
element	O
.	O

Calcineurin	B-Complex
stimulates	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
element	O
by	O
enhancing	O
inactivation	O
of	O
I	O
kappa	O
B	O
/	O
MAD3	O
,	O
an	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK	O
-	O
506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	B-Complex
-	O
dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O

Posttranslational	O
modification	O
of	O
nitrogenase	O
.	O

Differences	O
between	O
the	O
purple	O
bacterium	O
Rhodospirillum	O
rubrum	O
and	O
the	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

In	O
the	O
photosynthetic	O
bacteria	O
Rhodospirillum	O
rubrum	O
and	O
Rhodopseudomonas	O
capsulatus	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
is	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
the	O
Fe	B-OOS
-	I-OOS
protein	I-OOS
,	O
the	O
dinitrogenase	O
reductase	O
[	O
Burris	O
,	O
R	O
.	O
H	O
.	O
(	O
1991	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
266	O
,	O
9339	O
-	O
9342	O
]	O
.	O

This	O
mechanism	O
has	O
been	O
assumed	O
to	O
be	O
responsible	O
for	O
nitrogenase	O
modification	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
ADP	O
-	O
ribosylation	O
holds	O
true	O
for	O
the	O
filamentous	O
cyanobacterium	O
Anabaena	O
variabilis	O
.	O

Genes	O
coding	O
for	O
the	O
nitrogenase	O
-	O
modifying	O
enzymes	O
dinitrogenase	O
reductase	O
-	O
activating	O
glycohydrolase	O
(	O
DRAG	O
)	O
and	O
dinitrogenase	O
reductase	O
ADP	O
-	O
ribosyl	O
transferase	O
(	O
DRAT	O
)	O
from	O
R	O
.	O
rubrum	O
have	O
been	O
subcloned	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

After	O
isolation	O
under	O
anaerobic	O
conditions	O
,	O
both	O
proteins	O
were	O
functional	O
as	O
determined	O
by	O
in	O
-	O
vitro	O
assays	O
using	O
nitrogenase	O
from	O
R	O
.	O
rubrum	O
as	O
substrate	O
.	O

In	O
contrast	O
to	O
the	O
R	O
.	O
rubrum	O
enzyme	O
,	O
nitrogenase	O
from	O
A	O
.	O
variabilis	O
was	O
not	O
affected	O
by	O
DRAG	O
or	O
DRAT	O
.	O

Neither	O
could	O
inactive	O
nitrogenase	O
be	O
restored	O
by	O
DRAG	O
,	O
nor	O
nitrogenase	O
activity	O
suppressed	O
by	O
DRAT	O
.	O

Using	O
specific	O
antibodies	O
against	O
arginine	O
-	O
bound	O
ADP	O
-	O
ribose	O
[	O
Meyer	O
,	O
T	O
.	O
&	O
Hilz	O
,	O
H	O
.	O
(	O
1986	O
)	O
Eur	O
.	O
J	O
.	O
Biochem	O
.	O
155	O
,	O
157	O
-	O
165	O
]	O
,	O
immunoblotting	O
of	O
the	O
inactive	O
,	O
modified	O
form	O
of	O
the	O
Fe	B-OOS
-	I-OOS
protein	I-OOS
from	O
R	O
.	O
rubrum	O
but	O
not	O
that	O
from	O
A	O
.	O
variabilis	O
showed	O
a	O
strong	O
cross	O
reaction	O
.	O

Furthermore	O
,	O
differently	O
to	O
R	O
.	O
rubrum	O
no	O
ADP	O
-	O
ribosylated	O
proteins	O
could	O
be	O
detected	O
at	O
all	O
,	O
indicating	O
the	O
absence	O
of	O
this	O
posttranslational	O
modification	O
in	O
A	O
.	O
variabilis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
an	O
isoprenylated	O
67	O
kDa	O
protein	O
.	O

The	O
cDNA	O
coding	O
for	O
a	O
67	O
kDa	O
protein	O
(	O
p67	O
)	O
was	O
isolated	O
from	O
a	O
rat	O
Schwann	O
cell	O
library	O
.	O

A	O
recombinant	O
form	O
of	O
p67	O
expressed	O
in	O
bacteria	O
was	O
used	O
to	O
produce	O
polyclonal	O
anti	O
-	O
p67	O
antibodies	O
.	O

By	O
immunoblot	O
analysis	O
p67	O
was	O
found	O
to	O
be	O
expressed	O
in	O
most	O
tissues	O
and	O
cell	O
lines	O
examined	O
.	O

Inspection	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
revealed	O
a	O
COOH	O
-	O
terminal	O
consensus	O
sequence	O
for	O
isoprenylation	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
p67	O
was	O
a	O
substrate	O
for	O
isoprenylation	O
in	O
vitro	O
by	O
geranylgeranylpyrophosphate	O
.	O

p67	O
was	O
associated	O
predominantly	O
with	O
the	O
particulate	O
fraction	O
of	O
rat	O
smooth	O
muscle	O
cells	O
.	O

The	O
rat	O
p67	O
sequence	O
was	O
highly	O
homologous	O
to	O
a	O
family	O
of	O
recently	O
described	O
human	O
and	O
mouse	O
gamma	O
-	O
interferon	O
inducible	O
,	O
guanine	O
nucleotide	O
binding	O
proteins	O
.	O

Cyclin	O
E	O
controls	O
S	O
phase	O
progression	O
and	O
its	O
down	O
-	O
regulation	O
during	O
Drosophila	O
embryogenesis	O
is	O
required	O
for	O
the	O
arrest	O
of	O
cell	O
proliferation	O
.	O

Most	O
cells	O
of	O
the	O
dorsal	O
epidermis	O
exit	O
from	O
the	O
mitotic	O
cycle	O
after	O
division	O
16	O
in	O
Drosophila	O
embryogenesis	O
.	O

This	O
exit	O
is	O
dependent	O
on	O
the	O
down	O
-	O
regulation	O
of	O
Drosophila	O
cyclin	O
E	O
(	O
DmcycE	O
)	O
during	O
the	O
final	O
mitotic	O
cycle	O
.	O

Ectopic	O
expression	O
of	O
DmcycE	O
after	O
the	O
final	O
mitosis	O
induces	O
entry	O
into	O
S	O
phase	O
and	O
reaccumulation	O
of	O
G2	O
cyclins	O
and	O
results	O
in	O
progression	O
through	O
a	O
complete	O
additional	O
cell	O
cycle	O
.	O

Conversely	O
,	O
analyses	O
in	O
DmcycE	O
mutant	O
embryos	O
indicate	O
that	O
cyclin	O
E	O
is	O
required	O
for	O
progression	O
through	O
S	O
phase	O
of	O
the	O
mitotic	O
cycle	O
.	O

Moreover	O
,	O
endoreplication	O
,	O
which	O
occurs	O
in	O
late	O
wild	O
-	O
type	O
embryos	O
in	O
the	O
same	O
pattern	O
as	O
DmcycE	O
expression	O
,	O
is	O
not	O
observed	O
in	O
the	O
mutant	O
embryos	O
.	O

Therefore	O
,	O
Drosophila	O
cyclin	O
E	O
,	O
which	O
forms	O
a	O
complex	O
with	O
the	O
Dmcdc2c	O
kinase	O
,	O
controls	O
progression	O
through	O
S	O
phase	O
and	O
its	O
down	O
-	O
regulation	O
limits	O
embryonic	O
proliferation	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Schizosaccharomyces	O
pombe	O
YPT5	O
protein	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
analysis	O
of	O
processing	O
mutants	O
.	O

SpYPT5p	O
is	O
a	O
member	O
of	O
the	O
rab	O
/	O
YPT	O
small	O
GTP	O
-	O
binding	O
protein	O
family	O
,	O
which	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
intracellular	O
trafficking	O
.	O

The	O
protein	O
sequence	O
terminates	O
with	O
a	O
CXC	O
motif	O
,	O
and	O
in	O
our	O
previous	O
report	O
(	O
Newman	O
,	O
C	O
.	O
M	O
.	O
H	O
.	O
,	O
Giannakouros	O
,	O
T	O
.	O
,	O
Hancock	O
,	O
J	O
.	O
F	O
.	O
,	O
Fawell	O
,	O
E	O
.	O
H	O
.	O
,	O
Armstrong	O
,	O
J	O
.	O
,	O
and	O
Magee	O
,	O
A	O
.	O
I	O
.	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
11329	O
-	O
11336	O
)	O
we	O
have	O
shown	O
that	O
SpYPT5p	O
is	O
prenylated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
where	O
geranylgeranylation	O
was	O
confirmed	O
,	O
and	O
carboxyl	O
-	O
methylated	O
.	O

In	O
order	O
to	O
dissect	O
the	O
role	O
of	O
prenylation	O
of	O
each	O
cysteine	O
,	O
we	O
have	O
generated	O
C	O
-	O
terminal	O
mutants	O
where	O
either	O
one	O
or	O
both	O
cysteine	O
(	O
s	O
)	O
were	O
replaced	O
by	O
serine	O
and	O
expressed	O
them	O
in	O
vitro	O
in	O
reticulocyte	O
lysates	O
and	O
in	O
vivo	O
in	O
transfected	O
COS	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
both	O
cysteines	O
of	O
the	O
CXC	O
motif	O
are	O
prenylated	O
but	O
that	O
the	O
rate	O
of	O
prenylation	O
of	O
the	O
two	O
cysteines	O
is	O
different	O
.	O

The	O
upstream	O
cysteine	O
was	O
found	O
to	O
be	O
preferentially	O
prenylated	O
in	O
reticulocyte	O
lysates	O
unless	O
cytosol	O
from	O
COS	O
cells	O
was	O
added	O
.	O

A	O
separate	O
activity	O
could	O
therefore	O
be	O
required	O
for	O
prenylation	O
of	O
the	O
second	O
cysteine	O
,	O
or	O
the	O
presence	O
of	O
an	O
additional	O
factor	O
is	O
needed	O
to	O
allow	O
accumulation	O
of	O
doubly	O
prenylated	O
SpYPT5p	O
.	O

However	O
,	O
the	O
modification	O
of	O
the	O
upstream	O
cysteine	O
is	O
not	O
a	O
prerequisite	O
for	O
the	O
prenylation	O
of	O
the	O
other	O
.	O

Furthermore	O
,	O
gene	O
replacement	O
in	O
Schizosaccharomyces	O
pombe	O
revealed	O
that	O
each	O
cysteine	O
of	O
the	O
CXC	O
motif	O
can	O
individually	O
support	O
function	O
.	O

Carboxyl	O
methylation	O
occurred	O
only	O
on	O
protein	O
which	O
had	O
been	O
prenylated	O
on	O
the	O
C	O
-	O
terminal	O
cysteine	O
and	O
was	O
required	O
for	O
efficient	O
membrane	O
binding	O
in	O
vitro	O
.	O

The	O
31	O
-	O
kDa	O
precursor	O
of	O
interleukin	O
1	O
alpha	O
is	O
myristoylated	O
on	O
specific	O
lysines	O
within	O
the	O
16	O
-	O
kDa	O
N	O
-	O
terminal	O
propiece	O
.	O

The	O
cytokine	O
interleukin	O
1	O
alpha	O
(	O
IL	O
-	O
1	O
alpha	O
)	O
is	O
a	O
critical	O
mediator	O
of	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

A	O
unique	O
determinant	O
of	O
its	O
activity	O
as	O
compared	O
with	O
IL	O
-	O
1	O
beta	O
may	O
be	O
its	O
association	O
with	O
the	O
plasma	O
membrane	O
.	O

While	O
the	O
biologic	O
activity	O
of	O
"	O
membrane	O
IL	O
-	O
1	O
"	O
has	O
been	O
extensively	O
reported	O
,	O
the	O
mechanism	O
of	O
membrane	O
binding	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
the	O
N	O
terminus	O
of	O
the	O
31	O
-	O
kDa	O
IL	O
-	O
1	O
alpha	O
precursor	O
is	O
myristoylated	O
on	O
specific	O
internal	O
lysine	O
residues	O
.	O

Immunoprecipitation	O
of	O
[	O
3H	O
]	O
myristic	O
acid	O
-	O
radiolabeled	O
human	O
monocyte	O
lysates	O
with	O
IgG	B-Complex
antibodies	O
to	O
the	O
31	O
-	O
kDa	O
IL	O
-	O
1	O
alpha	O
precursor	O
recovered	O
a	O
protein	O
with	O
the	O
physicochemical	O
properties	O
of	O
the	O
IL	O
-	O
1	O
alpha	O
N	O
-	O
terminal	O
propiece	O
(	O
16	O
kDa	O
,	O
pI	O
4	O
.	O
45	O
)	O
.	O

Glycyl	O
N	O
-	O
myristoylation	O
of	O
this	O
protein	O
is	O
precluded	O
by	O
the	O
absence	O
of	O
a	O
glycine	O
residue	O
at	O
position	O
2	O
,	O
suggesting	O
that	O
the	O
propiece	O
is	O
myristoylated	O
on	O
epsilon	O
-	O
amino	O
groups	O
of	O
lysine	O
.	O

To	O
determine	O
which	O
lysine	O
(	O
s	O
)	O
are	O
acylated	O
,	O
a	O
series	O
of	O
synthetic	O
peptides	O
containing	O
all	O
lysines	O
found	O
in	O
the	O
IL	O
-	O
1	O
alpha	O
N	O
-	O
terminal	O
propiece	O
were	O
used	O
in	O
an	O
in	O
vitro	O
myristoylation	O
assay	O
containing	O
peptide	O
,	O
myristoyl	O
-	O
CoA	O
,	O
and	O
monocyte	O
lysate	O
as	O
enzyme	O
source	O
.	O

Analysis	O
of	O
the	O
reaction	O
products	O
by	O
reverse	O
-	O
phase	O
HPLC	O
and	O
gas	O
-	O
phase	O
sequencing	O
demonstrated	O
the	O
specific	O
myristoylation	O
of	O
Lys	O
-	O
82	O
and	O
Lys	O
-	O
83	O
,	O
yielding	O
predominantly	O
monoacylated	O
product	O
.	O

A	O
conserved	O
sequence	O
in	O
the	O
IL	O
-	O
1	O
beta	O
propiece	O
was	O
myristoylated	O
with	O
at	O
least	O
8	O
-	O
fold	O
less	O
efficiency	O
.	O

Acylation	O
of	O
the	O
IL	O
-	O
1	O
alpha	O
precursor	O
by	O
a	O
previously	O
unrecognized	O
lysyl	O
epsilon	O
-	O
amino	O
N	O
-	O
myristoyl	O
-	O
transferase	O
activity	O
may	O
facilitate	O
its	O
specific	O
membrane	O
targeting	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
and	O
demonstration	O
of	O
its	O
role	O
as	O
a	O
Rab	O
escort	O
protein	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
rat	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
confirms	O
identity	O
of	O
the	O
protein	O
with	O
the	O
human	O
choroideremia	O
gene	O
product	O
and	O
its	O
resemblance	O
to	O
Rab3A	O
guanine	O
nucleotide	O
dissociation	O
inhibitor	O
(	O
GDI	O
)	O
,	O
which	O
binds	O
prenylated	O
Rabs	O
.	O

In	O
biochemical	O
assays	O
we	O
demonstrate	O
that	O
component	O
A	O
binds	O
unprenylated	O
Rab1A	O
,	O
presents	O
it	O
to	O
the	O
catalytic	O
component	O
B	O
,	O
and	O
remains	O
bound	O
to	O
it	O
after	O
the	O
geranylgeranyl	O
transfer	O
reaction	O
.	O

In	O
the	O
absence	O
of	O
detergents	O
,	O
the	O
reaction	O
terminates	O
when	O
all	O
of	O
component	O
A	O
is	O
occupied	O
with	O
prenylated	O
Rab	O
.	O

Detergents	O
allow	O
multiple	O
rounds	O
of	O
catalysis	O
,	O
apparently	O
by	O
dissociating	O
the	O
component	O
A	O
-	O
Rab	O
complex	O
and	O
thus	O
allowing	O
recycling	O
of	O
component	O
A	O
.	O

Within	O
the	O
cell	O
,	O
component	O
A	O
may	O
be	O
regenerated	O
by	O
transferring	O
its	O
prenylated	O
Rab	O
to	O
a	O
protein	O
acceptor	O
,	O
such	O
as	O
Rab3A	O
GDI	O
.	O

In	O
view	O
of	O
its	O
function	O
in	O
escorting	O
Rab	O
proteins	O
during	O
and	O
presumably	O
after	O
the	O
prenyl	O
transfer	O
reaction	O
,	O
we	O
propose	O
to	O
rename	O
component	O
A	O
as	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
.	O

A	O
genetic	O
defect	O
in	O
REP	O
underlies	O
human	O
choroideremia	O
,	O
a	O
disease	O
of	O
retinal	O
degeneration	O
.	O

Initiation	O
binding	O
repressor	O
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	O
binding	O
repressor	O
[	O
corrected	O
]	O
(	O
IBR	O
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	O
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	O
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	O
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	O
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	O
and	O
IBF	O
.	O

IBR	O
is	O
a	O
503	O
-	O
amino	O
-	O
acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99	O
.	O
0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF	O
-	O
1	O
/	O
alpha	O
-	O
Pal	O
factor	O
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	O
and	O
erected	O
wing	O
gene	O
product	O
(	O
EWG	O
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	O
and	O
IBF	O
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	O
/	O
F	O
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	O
species	O
.	O

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR	O
/	O
F	O
harbors	O
the	O
DNA	O
-	O
binding	O
/	O
dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR	O
/	O
F	O
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	B-Complex
.	O

An	O
inhibitory	O
,	O
"	O
dominant	O
-	O
negative	O
,	O
"	O
form	O
of	O
the	O
calcineurin	B-Complex
catalytic	O
(	O
A	O
)	O
subunit	O
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	O
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	B-Complex
-	O
dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
"	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
"	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	O
B	O
subunit	O
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	O
subunit	O
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
"	O
rescued	O
"	O
by	O
overexpression	O
of	O
transfected	O
B	O
subunit	O
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	B-Complex
-	O
mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	B-Complex
A	O
and	O
B	O
subunits	O
.	O

Preassociation	O
of	O
STAT1	O
with	O
STAT2	O
and	O
STAT3	O
in	O
separate	O
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	O
or	O
STAT2	O
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	O
protein	O
.	O

Similarly	O
,	O
STAT1	O
-	O
STAT3	O
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O

STAT1	O
and	O
STAT2	O
or	O
STAT1	O
and	O
STAT3	O
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	O
-	O
STAT2	O
signaling	O
complex	O
.	O

Newly	O
translated	O
STAT1	O
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	O
and	O
STAT3	O
,	O
but	O
we	O
show	O
that	O
STAT2	O
and	O
STAT3	O
exist	O
in	O
separate	O
heterocomplexes	O
with	O
STAT1	O
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	O
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Inhibition	O
of	O
p105	O
processing	O
by	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
involves	O
proteasome	B-Complex
-	O
mediated	O
processing	O
of	O
the	O
NF	O
-	O
kappaB1	O
p105	O
precursor	O
protein	O
,	O
which	O
generates	O
the	O
p50	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

The	O
processing	O
of	O
p105	O
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	O
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	O
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	O
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	O
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	O
or	O
other	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
subunits	O
,	O
including	O
RelA	O
and	O
c	O
-	O
Rel	O
,	O
that	O
physically	O
interact	O
with	O
p105	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	O
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
subunits	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	O
undergoes	O
degradation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	O
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	O
are	O
differentially	O
regulated	O
.	O

A	O
putative	O
new	O
membrane	O
protein	O
,	O
Pho86p	O
,	O
in	O
the	O
inorganic	O
phosphate	O
uptake	O
system	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
PHO84	O
gene	O
in	O
Saccharomyces	O
cerevisiae	O
encodes	O
the	O
P	O
(	O
i	O
)	O
transporter	O
Pho84p	O
.	O

The	O
other	O
three	O
genes	O
,	O
GTR1	O
,	O
PHO86	O
and	O
PHO87	O
,	O
are	O
also	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
P	O
(	O
i	O
)	O
uptake	O
system	O
.	O

We	O
cloned	O
and	O
sequenced	O
PHO86	O
and	O
found	O
that	O
it	O
encodes	O
a	O
34	O
-	O
kDa	O
protein	O
consisting	O
of	O
311	O
amino	O
acid	O
residues	O
with	O
two	O
strongly	O
hydrophobic	O
segments	O
in	O
its	O
N	O
-	O
terminal	O
half	O
.	O

Western	O
blotting	O
analysis	O
of	O
cell	O
extracts	O
revealed	O
that	O
Pho86p	O
,	O
tagged	O
with	O
c	O
-	O
Myc	O
,	O
was	O
fractionated	O
into	O
a	O
water	O
-	O
insoluble	O
fraction	O
.	O

Disruption	O
of	O
PHO86	O
did	O
not	O
affect	O
cell	O
viability	O
even	O
in	O
combination	O
with	O
the	O
pho84	O
and	O
/	O
or	O
pho87	O
disruptions	O
.	O

The	O
triple	O
disruptants	O
showed	O
high	O
levels	O
of	O
constitutive	O
rAPase	O
synthesis	O
and	O
arsenate	O
resistance	O
similar	O
to	O
the	O
pho84	O
mutant	O
,	O
but	O
showed	O
slower	O
cell	O
growth	O
than	O
the	O
pho84	O
mutant	O
.	O

PHO86	O
has	O
two	O
putative	O
binding	O
sites	O
for	O
the	O
transcriptional	O
activator	O
,	O
Pho4p	O
,	O
at	O
nucleotide	O
positions	O
-	O
191	O
and	O
-	O
497	O
relative	O
to	O
the	O
ATG	O
start	O
codon	O
,	O
and	O
showed	O
substantial	O
levels	O
of	O
transcription	O
under	O
high	O
-	O
P	O
(	O
i	O
)	O
conditions	O
and	O
more	O
enhanced	O
levels	O
in	O
low	O
-	O
P	O
(	O
i	O
)	O
medium	O
.	O

Prenylated	O
isoforms	O
of	O
yeast	O
casein	O
kinase	O
I	O
,	O
including	O
the	O
novel	O
Yck3p	O
,	O
suppress	O
the	O
gcs1	O
blockage	O
of	O
cell	O
proliferation	O
from	O
stationary	O
phase	O
.	O

The	O
GCS1	O
gene	O
of	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
mediate	O
the	O
resumption	O
of	O
cell	O
proliferation	O
from	O
the	O
starved	O
,	O
stationary	O
-	O
phase	O
state	O
.	O

Here	O
we	O
identify	O
yeast	O
genes	O
that	O
,	O
in	O
increased	O
dosages	O
,	O
overcome	O
the	O
growth	O
defect	O
of	O
gcs1	O
delta	O
mutant	O
cells	O
.	O

Among	O
these	O
are	O
YCK1	O
(	O
CK12	O
)	O
and	O
YCK2	O
(	O
CKI1	O
)	O
,	O
encoding	O
membrane	O
-	O
associated	O
casein	O
kinase	O
I	O
,	O
and	O
YCK3	O
,	O
encoding	O
a	O
novel	O
casein	O
kinase	O
I	O
isoform	O
.	O

Some	O
Yck3p	O
gene	O
product	O
was	O
found	O
associated	O
with	O
the	O
plasma	O
membrane	O
,	O
like	O
Yck1p	O
and	O
Yck2p	O
,	O
but	O
most	O
confractionated	O
with	O
the	O
nucleus	O
,	O
like	O
another	O
yeast	O
casein	O
kinase	O
I	O
isoform	O
,	O
Hrr25p	O
.	O

Genetic	O
studies	O
showed	O
that	O
YCK3	O
and	O
HRR25	O
constitute	O
an	O
essential	O
gene	O
family	O
and	O
that	O
Yck3p	O
can	O
weakly	O
substitute	O
for	O
Yck1p	O
-	O
Yck2p	O
.	O

For	O
gcs1	O
delta	O
suppression	O
,	O
both	O
a	O
protein	O
kinase	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
prenylation	O
motif	O
were	O
shown	O
to	O
be	O
necessary	O
.	O

An	O
impairment	O
in	O
endocytosis	O
was	O
found	O
for	O
gcs1	O
delta	O
mutant	O
cells	O
,	O
which	O
was	O
alleviated	O
by	O
an	O
increased	O
YCK2	O
gene	O
dosage	O
.	O

The	O
ability	O
of	O
an	O
increased	O
casein	O
kinase	O
I	O
gene	O
dosage	O
to	O
suppress	O
the	O
effects	O
caused	O
by	O
the	O
absence	O
of	O
Gcs1p	O
suggests	O
that	O
Gcs1p	O
and	O
Yck1p	O
-	O
Yck2p	O
affect	O
parallel	O
pathways	O
.	O

Structure	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
complexed	O
with	O
human	O
PCNA	B-OOS
.	O

The	O
crystal	O
structure	O
of	O
the	O
human	O
DNA	B-Complex
polymerase	I-Complex
delta	I-Complex
processivity	O
factor	O
PCNA	B-OOS
(	O
proliferating	B-OOS
cell	I-OOS
nuclear	I-OOS
antigen	I-OOS
)	O
complexed	O
with	O
a	O
22	O
residue	O
peptide	O
derived	O
from	O
the	O
C	O
-	O
terminus	O
of	O
the	O
cell	O
-	O
cycle	O
checkpoint	O
protein	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
has	O
been	O
determined	O
at	O
2	O
.	O
6	O
angstrom	O
resolution	O
.	O

p21	O
binds	O
to	O
PCNA	B-OOS
in	O
a	O
1	O
:	O
1	O
stoichiometry	O
with	O
an	O
extensive	O
array	O
of	O
interactions	O
that	O
include	O
the	O
formation	O
of	O
a	O
beta	O
sheet	O
with	O
the	O
interdomain	O
connector	O
loop	O
of	O
PCNA	B-OOS
.	O

An	O
intact	O
trimeric	O
ring	O
is	O
maintained	O
in	O
the	O
structure	O
of	O
the	O
p21	O
-	O
PCNA	B-OOS
complex	O
,	O
with	O
a	O
central	O
hole	O
available	O
for	O
DNA	O
interaction	O
.	O

The	O
ability	O
of	O
p21	O
to	O
inhibit	O
the	O
action	O
of	O
PCNA	B-OOS
is	O
therefore	O
likely	O
to	O
be	O
due	O
to	O
its	O
masking	O
of	O
elements	O
on	O
PCNA	B-OOS
that	O
are	O
required	O
for	O
the	O
binding	O
of	O
other	O
components	O
of	O
the	O
polymerase	O
assembly	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl	O
-	O
2	O
and	O
IL	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid	O
-	O
and	O
Fas	O
-	O
mediated	O
cytotoxicity	O
.	O

Fas	O
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

Restimulation	O
of	O
T	O
cell	O
blasts	O
up	O
-	O
regulates	O
Fas	O
and	O
Fas	O
ligand	O
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl	O
-	O
2	O
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	O
-	O
mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl	O
-	O
2	O
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl	O
-	O
2	O
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl	O
-	O
2	O
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	O
-	O
mediated	O
apoptosis	O
,	O
whereas	O
etoposide	O
-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl	O
-	O
xL	O
and	O
adenovirus	O
E1B	O
19K	O
did	O
not	O
interfere	O
with	O
anti	O
-	O
Fas	O
killing	O
.	O

In	O
contrast	O
,	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	O
-	O
2	O
and	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	O
cells	O
normally	O
express	O
Bcl	O
-	O
2	O
and	O
Bcl	O
-	O
xL	O
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	O
-	O
mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

A	O
collagen	O
-	O
like	O
peptide	O
stimulates	O
tyrosine	O
phosphorylation	O
of	O
syk	O
and	O
phospholipase	O
C	O
gamma2	O
in	O
platelets	O
independent	O
of	O
the	O
integrin	O
alpha2beta1	O
.	O

Activation	O
of	O
platelets	O
by	O
collagen	B-Complex
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
that	O
is	O
associated	O
with	O
phosphorylation	O
of	O
the	O
Fc	O
receptor	O
gamma	O
chain	O
,	O
the	O
tyrosine	O
kinase	O
syk	O
,	O
and	O
phospholipase	O
C	O
gamma2	O
(	O
PLC	O
gamma2	O
)	O
.	O

We	O
recently	O
described	O
a	O
collagen	O
-	O
related	O
triple	O
-	O
helical	O
peptide	O
(	O
CRP	O
)	O
with	O
the	O
sequence	O
GCP	O
*	O
(	O
GPP	O
*	O
)	O
GCP	O
*	O
G	O
(	O
single	O
letter	O
amino	O
acid	O
code	O
:	O
P	O
*	O
=	O
hydroxyproline	O
;	O
Morton	O
et	O
al	O
,	O
Biochem	O
J306	O
:	O
337	O
,	O
1995	O
)	O
.	O

The	O
cross	O
-	O
linked	O
peptide	O
is	O
a	O
potent	O
stimulus	O
of	O
platelet	O
activation	O
but	O
,	O
unlike	O
collagen	B-Complex
,	O
does	O
not	O
support	O
alpha2beta1	O
-	O
mediated	O
,	O
Mg2	O
+	O
-	O
dependent	O
adhesion	O
,	O
suggesting	O
that	O
its	O
action	O
is	O
independent	O
of	O
the	O
integrin	O
alpha2beta1	O
.	O

This	O
finding	O
suggests	O
the	O
existence	O
of	O
a	O
platelet	O
receptor	O
other	O
than	O
alpha2beta1	O
that	O
underlies	O
activation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
CRP	O
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
same	O
pattern	O
of	O
proteins	O
in	O
platelets	O
as	O
collagen	B-Complex
,	O
including	O
syk	O
and	O
PLC	O
gamma2	O
.	O

Protein	O
tyrosine	O
phosphorylation	O
induced	O
by	O
CRP	O
is	O
not	O
altered	O
in	O
the	O
absence	O
of	O
Mg2	O
+	O
or	O
the	O
presence	O
of	O
monoclonal	O
antibodies	O
(	O
MoAbs	O
)	O
to	O
the	O
integrin	O
alpha2beta1	O
(	O
MoAb	O
6F1	O
and	O
MoAb	O
13	O
)	O
,	O
conditions	O
that	O
prevent	O
the	O
interaction	O
of	O
collagen	B-Complex
with	O
the	O
integrin	O
.	O

In	O
contrast	O
,	O
phosphorylation	O
of	O
syk	O
and	O
PLC	O
gamma2	O
by	O
collagen	B-Complex
is	O
partially	O
reduced	O
by	O
MoAb	O
6F1	O
and	O
MoAb	O
13	O
or	O
by	O
removal	O
of	O
Mg2	O
+	O
.	O

This	O
may	O
reflect	O
a	O
direct	O
role	O
of	O
alpha2beta1	O
in	O
collagen	B-Complex
-	O
induced	O
signaling	O
events	O
or	O
an	O
indirect	O
role	O
in	O
which	O
the	O
integrin	O
facilitates	O
the	O
binding	O
of	O
collagen	B-Complex
to	O
its	O
signaling	O
receptor	O
.	O

The	O
results	O
show	O
an	O
alpha2beta1	O
-	O
independent	O
pathway	O
of	O
platelet	O
activation	O
by	O
CRP	O
that	O
involves	O
phosphorylation	O
of	O
syk	O
and	O
PLC	O
gamma2	O
.	O

This	O
pathway	O
appears	O
to	O
contribute	O
to	O
platelet	O
activation	O
by	O
collagen	B-Complex
.	O

Germline	O
and	O
somatic	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	O
renal	O
carcinomas	O
.	O

Hereditary	O
papillary	O
renal	O
carcinoma	O
(	O
HPRC	O
)	O
is	O
a	O
recently	O
recognized	O
form	O
of	O
inherited	O
kidney	O
cancer	O
characterized	O
by	O
a	O
predisposition	O
to	O
develop	O
multiple	O
,	O
bilateral	O
papillary	O
renal	O
tumours	O
.	O

The	O
pattern	O
of	O
inheritance	O
of	O
HPRC	O
is	O
consistent	O
with	O
autosomal	O
dominant	O
transmission	O
with	O
reduced	O
penetrance	O
.	O

HPRC	O
is	O
histologically	O
and	O
genetically	O
distinct	O
from	O
two	O
other	O
causes	O
of	O
inherited	O
renal	O
carcinoma	O
,	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
(	O
VHL	O
)	O
and	O
the	O
chromosome	O
translocation	O
(	O
3	O
;	O
8	O
)	O
.	O

Malignant	O
papillary	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
trisomy	O
of	O
chromosomes	O
7	O
,	O
16	O
and	O
17	O
,	O
and	O
in	O
men	O
,	O
by	O
loss	O
of	O
the	O
Y	O
chromosome	O
.	O

Inherited	O
and	O
sporadic	O
clear	O
cell	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
inactivation	O
of	O
both	O
copies	O
of	O
the	O
VHL	O
gene	O
by	O
mutation	O
,	O
and	O
/	O
or	O
by	O
hypermethylation	O
.	O

We	O
found	O
that	O
the	O
HPRC	O
gene	O
was	O
located	O
at	O
chromosome	O
7q31	O
.	O
1	O
-	O
34	O
in	O
a	O
27	O
-	O
centimorgan	O
(	O
cM	O
)	O
interval	O
between	O
D7S496	O
and	O
D7S1837	O
.	O

We	O
identified	O
missense	O
mutations	O
located	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
in	O
the	O
germline	O
of	O
affected	O
members	O
of	O
HPRC	O
families	O
and	O
in	O
a	O
subset	O
of	O
sporadic	O
papillary	O
renal	O
carcinomas	O
.	O

Three	O
mutations	O
in	O
the	O
MET	O
gene	O
are	O
located	O
in	O
codons	O
that	O
are	O
homologous	O
to	O
those	O
in	O
c	O
-	O
kit	O
and	O
RET	O
,	O
proto	O
-	O
oncogenes	O
that	O
are	O
targets	O
of	O
naturally	O
-	O
occurring	O
mutations	O
.	O

The	O
results	O
suggest	O
that	O
missense	O
mutations	O
located	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
lead	O
to	O
constitutive	O
activation	O
of	O
the	O
MET	O
protein	O
and	O
papillary	O
renal	O
carcinomas	O
.	O

Homodimerization	O
of	O
the	O
human	O
interleukin	O
4	O
receptor	O
alpha	O
chain	O
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	O
2	O
receptor	O
gamma	O
chain	O
.	O

The	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
-	O
4	O
and	O
IL	O
-	O
13	O
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	B-Complex
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL	B-Complex
-	I-Complex
4	I-Complex
receptor	I-Complex
(	O
IL	B-Complex
-	I-Complex
4R	I-Complex
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL	O
-	O
4	O
-	O
binding	O
IL	O
-	O
4Ralpha	O
chain	O
,	O
which	O
is	O
shared	O
with	O
the	O
IL	O
-	O
13R	O
,	O
and	O
the	O
IL	O
-	O
2Rgamma	O
(	O
gammac	O
)	O
chain	O
,	O
which	O
is	O
shared	O
with	O
IL	O
-	O
7R	O
,	O
IL	O
-	O
9R	O
,	O
and	O
IL	O
-	O
15R	O
.	O

IL	O
-	O
4	O
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	B-Complex
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	O
chain	O
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL	O
-	O
4	O
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	O
chain	O
may	O
involve	O
signaling	O
via	O
the	O
IL	O
-	O
13R	O
.	O

Alternatively	O
,	O
the	O
IL	O
-	O
4Ralpha	O
chain	O
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	O
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL	O
-	O
4Ralpha	O
induces	O
Janus	O
kinase	O
1	O
(	O
Jak1	O
)	O
activation	O
,	O
STAT6	O
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1	O
-	O
binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL	O
-	O
4Ralpha	O
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	O
CD8alpha	O
/	O
IL	O
-	O
4Ralpha	O
receptor	O
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL	O
-	O
4Ralpha	O
chain	O
is	O
sufficient	O
to	O
transduce	O
Jak1	O
-	O
dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	B-Complex
isotype	O
switching	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	O
-	O
I	O
Tax	O
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Tax1	O
,	O
a	O
transcriptional	O
trans	O
-	O
activator	O
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB	O
/	O
ATF	O
,	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
and	O
SRF	O
.	O

This	O
Tax1	O
-	O
induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	O
-	O
inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	O
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	O
-	O
2	O
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	O
receptor	O
(	O
hMR	O
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729	O
-	O
Lys984	O
of	O
hMR	O
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	O
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	O
form	O
and	O
the	O
transformed	O
MR	O
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	O
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	O
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	O
complex	O
and	O
the	O
antibody	O
-	O
MR	O
complex	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	O
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	O
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729	O
-	O
Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J	O
.	O
Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol	O
.	O
57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729	O
-	O
Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
CIITA	O
interacts	O
with	O
the	O
TBP	O
-	O
associated	O
factor	O
TAFII32	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
(	O
CIITA	O
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	B-Complex
class	I-Complex
II	I-Complex
proteins	O
.	O

Its	O
N	O
-	O
terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha	O
-	O
helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	O
-	O
helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	O
.	O

Moreover	O
,	O
a	O
CIITA	O
protein	O
in	O
which	O
both	O
functional	O
alpha	O
-	O
helices	O
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

This	O
activation	O
domain	O
of	O
CIITA	O
interacts	O
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	B-Complex
,	O
TAFII32	O
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N	O
-	O
terminal	O
deletions	O
of	O
CIITA	O
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	O
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	O
and	O
CIITA	O
are	O
responsible	O
for	O
activation	O
of	O
class	B-Complex
II	I-Complex
genes	O
.	O

The	O
alpha	O
7	O
integrin	O
as	O
a	O
target	O
protein	O
for	O
cell	O
surface	O
mono	O
-	O
ADP	O
-	O
ribosylation	O
in	O
muscle	O
cells	O
.	O

A	O
membrane	O
-	O
associated	O
arginine	O
-	O
specific	O
mono	O
-	O
ADP	O
-	O
ribosyltransferase	O
was	O
purified	O
215	O
,	O
000	O
-	O
fold	O
from	O
rabbit	O
skeletal	O
muscle	O
and	O
its	O
gene	O
was	O
isolated	O
from	O
a	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O

The	O
enzyme	O
was	O
a	O
glycosylphosphatidyl	O
-	O
inositol	O
-	O
linked	O
protein	O
,	O
present	O
on	O
the	O
surface	O
of	O
differentiated	O
skeletal	O
muscle	O
myoblasts	O
(	O
myotubes	O
)	O
.	O

Following	O
incubation	O
of	O
cultured	O
,	O
intact	O
myotubes	O
with	O
[	O
adenylate	O
-	O
32P	O
]	O
NAD	O
and	O
analysis	O
by	O
SDS	O
-	O
PAGE	O
,	O
a	O
major	O
radiolabeled	O
protein	O
of	O
97	O
/	O
140	O
kDa	O
(	O
reduced	O
/	O
nonreduced	O
conditions	O
)	O
was	O
observed	O
.	O

It	O
was	O
identified	O
as	O
integrin	O
alpha	O
7	O
based	O
on	O
its	O
size	O
,	O
binding	O
to	O
a	O
laminin	O
affinity	O
column	O
,	O
immunoprecipitation	O
with	O
a	O
monoclonal	O
antibody	O
,	O
and	O
partial	O
amino	O
acid	O
sequencing	O
.	O

Since	O
ADP	O
-	O
ribosylarginine	O
hydrolase	O
,	O
the	O
enzyme	O
responsible	O
for	O
cleavage	O
of	O
the	O
ADP	O
-	O
ribosylarginine	O
bond	O
and	O
a	O
component	O
with	O
the	O
transferase	O
of	O
a	O
putative	O
ADP	O
-	O
ribosylation	O
cycle	O
,	O
is	O
cytosolic	O
,	O
whereas	O
the	O
transferase	O
is	O
attached	O
via	O
a	O
GPI	O
-	O
anchor	O
to	O
the	O
cell	O
surface	O
,	O
the	O
processing	O
of	O
ADP	O
-	O
ribosylated	O
integrin	O
alpha	O
7	O
was	O
investigated	O
.	O

32P	O
label	O
was	O
rapidly	O
removed	O
from	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylated	O
integrin	O
alpha	O
7	O
,	O
a	O
process	O
inhibited	O
by	O
free	O
ADP	O
-	O
ribose	O
or	O
p	O
-	O
nitrophenylthymidine	O
-	O
5	O
'	O
-	O
monophosphate	O
,	O
alternative	O
substrates	O
for	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

The	O
processed	O
integrin	O
alpha	O
7	O
was	O
not	O
susceptible	O
to	O
subsequent	O
ADP	O
-	O
ribosylation	O
,	O
although	O
the	O
amount	O
of	O
surface	O
integrin	O
alpha	O
7	O
remained	O
constant	O
.	O

During	O
the	O
processing	O
,	O
no	O
loss	O
of	O
label	O
was	O
observed	O
from	O
integrin	O
alpha	O
7	O
radiolabeled	O
with	O
[	O
14C	O
]	O
NAD	O
,	O
containing	O
14C	O
in	O
the	O
nicotinamide	O
-	O
proximal	O
ribose	O
,	O
consistent	O
with	O
a	O
degradation	O
of	O
the	O
ADP	O
-	O
ribose	O
moiety	O
by	O
a	O
cell	O
surface	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

Thus	O
,	O
cell	O
surface	O
ADP	O
-	O
ribosylation	O
,	O
in	O
contrast	O
to	O
intracellular	O
ADP	O
-	O
ribosylation	O
,	O
is	O
not	O
readily	O
reversed	O
by	O
the	O
presently	O
known	O
ADP	O
-	O
ribosylarginine	O
hydrolase	O
and	O
seems	O
to	O
operate	O
outside	O
the	O
postulated	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O

Physiological	O
regulation	O
of	O
membrane	O
protein	O
sorting	O
late	O
in	O
the	O
secretory	O
pathway	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
mammalian	O
cells	O
,	O
extracellular	O
signals	O
can	O
regulate	O
the	O
delivery	O
of	O
particular	O
proteins	O
to	O
the	O
plasma	O
membrane	O
.	O

We	O
have	O
discovered	O
a	O
novel	O
example	O
of	O
regulated	O
protein	O
sorting	O
in	O
the	O
late	O
secretory	O
pathway	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
yeast	O
cells	O
grown	O
on	O
either	O
ammonia	O
or	O
urea	O
medium	O
,	O
the	O
general	O
amino	O
acid	O
permease	O
(	O
Gap1p	O
)	O
is	O
transported	O
from	O
the	O
Golgi	O
complex	O
to	O
the	O
plasma	O
membrane	O
,	O
whereas	O
,	O
in	O
cells	O
grown	O
on	O
glutamate	O
medium	O
,	O
Gap1p	O
is	O
transported	O
from	O
the	O
Golgi	O
to	O
the	O
vacuole	O
.	O

We	O
have	O
also	O
found	O
that	O
sorting	O
of	O
Gap1p	O
in	O
the	O
Golgi	O
is	O
controlled	O
by	O
SEC13	O
,	O
a	O
gene	O
previously	O
shown	O
to	O
encode	O
a	O
component	O
of	O
the	O
COPII	B-Complex
vesicle	I-Complex
coat	I-Complex
.	O

In	O
sec13	O
mutants	O
grown	O
on	O
ammonia	O
,	O
Gap1p	O
is	O
transported	O
from	O
the	O
Golgi	O
to	O
the	O
vacuole	O
,	O
instead	O
of	O
to	O
the	O
plasma	O
membrane	O
.	O

Deletion	O
of	O
PEP12	O
,	O
a	O
gene	O
required	O
for	O
vesicular	O
transport	O
from	O
the	O
Golgi	O
to	O
the	O
prevacuolar	O
compartment	O
,	O
counteracts	O
the	O
effect	O
of	O
the	O
sec13	O
mutation	O
and	O
partially	O
restores	O
Gap1p	O
transport	O
to	O
the	O
plasma	O
membrane	O
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
both	O
a	O
nitrogen	O
-	O
sensing	O
mechanism	O
and	O
Sec13p	O
control	O
Gap1p	O
transport	O
from	O
the	O
Golgi	O
to	O
the	O
plasma	O
membrane	O
.	O

Interaction	O
of	O
CTLA	O
-	O
4	O
with	O
the	O
clathrin	B-Complex
-	O
associated	O
protein	O
AP50	O
results	O
in	O
ligand	O
-	O
independent	O
endocytosis	O
that	O
limits	O
cell	O
surface	O
expression	O
.	O

CTLA	O
-	O
4	O
is	O
a	O
lymphocyte	O
cell	O
surface	O
receptor	O
expressed	O
by	O
activated	O
T	O
cells	O
that	O
functions	O
to	O
down	O
-	O
regulate	O
T	O
cell	O
responses	O
induced	O
by	O
TCR	B-Complex
and	O
CD28	O
stimulation	O
.	O

Since	O
CTLA	O
-	O
4	O
competes	O
with	O
CD28	O
for	O
binding	O
to	O
the	O
common	O
ligands	O
B7	O
-	O
1	O
and	O
B7	O
-	O
2	O
,	O
the	O
level	O
of	O
CTLA	O
-	O
4	O
surface	O
expression	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
its	O
ability	O
to	O
inhibit	O
CD28	O
-	O
dependent	O
T	O
cell	O
activation	O
.	O

The	O
factors	O
that	O
regulate	O
these	O
levels	O
are	O
poorly	O
understood	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
following	O
T	O
cell	O
activation	O
,	O
the	O
majority	O
of	O
CTLA	O
-	O
4	O
is	O
localized	O
intracellularly	O
rather	O
than	O
on	O
the	O
cell	O
surface	O
,	O
and	O
surface	O
CTLA	O
-	O
4	O
is	O
rapidly	O
reinternalized	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
rapid	O
clearance	O
of	O
CTLA	O
-	O
4	O
from	O
the	O
cell	O
surface	O
.	O

The	O
data	O
demonstrate	O
that	O
cell	O
surface	O
CTLA	O
-	O
4	O
is	O
endocytosed	O
into	O
clathrin	B-Complex
-	O
coated	O
vesicles	O
even	O
in	O
the	O
absence	O
of	O
ligand	O
.	O

The	O
targeting	O
of	O
CTLA	O
-	O
4	O
to	O
clathrin	B-Complex
-	O
coated	O
vesicles	O
is	O
mediated	O
by	O
the	O
clathrin	B-Complex
-	I-Complex
associated	I-Complex
adaptor	I-Complex
complex	I-Complex
AP	B-Complex
-	I-Complex
2	I-Complex
.	O

The	O
cytoplasmic	O
domain	O
of	O
CTLA	O
-	O
4	O
was	O
found	O
to	O
specifically	O
bind	O
to	O
AP50	O
,	O
the	O
medium	O
chain	O
subunit	O
of	O
AP	B-Complex
-	I-Complex
2	I-Complex
in	O
both	O
yeast	O
two	O
-	O
hybrid	O
and	O
coimmunoprecipitation	O
assays	O
.	O

The	O
interaction	O
requires	O
the	O
peptide	O
sequence	O
199	O
-	O
GVYVKM	O
-	O
204	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
CTLA	O
-	O
4	O
.	O

Mutation	O
of	O
the	O
CTLA	O
-	O
4	O
amino	O
acid	O
residue	O
Y201	O
abrogates	O
the	O
interaction	O
with	O
AP50	O
,	O
resulting	O
in	O
the	O
accumulation	O
of	O
CTLA	O
-	O
4	O
at	O
the	O
cell	O
surface	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
the	O
interaction	O
of	O
CTLA	O
-	O
4	O
with	O
AP50	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
cell	O
surface	O
expression	O
of	O
CTLA	O
-	O
4	O
.	O

Cloning	O
and	O
characterization	O
of	O
APS	O
,	O
an	O
adaptor	O
molecule	O
containing	O
PH	O
and	O
SH2	O
domains	O
that	O
is	O
tyrosine	O
phosphorylated	O
upon	O
B	O
-	O
cell	O
receptor	O
stimulation	O
.	O

Stimulation	O
of	O
B	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
(	O
BCR	O
)	O
results	O
in	O
rapid	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
a	O
number	O
of	O
proteins	O
,	O
which	O
leads	O
to	O
a	O
cascade	O
of	O
biochemical	O
changes	O
that	O
initiates	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
or	O
growth	O
inhibition	O
.	O

A	O
novel	O
cDNA	O
,	O
designed	O
APS	O
,	O
encoding	O
an	O
adaptor	O
protein	O
with	O
a	O
Pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
,	O
Src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
,	O
and	O
a	O
tyrosine	O
phosphorylation	O
site	O
was	O
cloned	O
from	O
a	O
B	O
cell	O
cDNA	O
library	O
using	O
a	O
yeast	O
two	O
hybrid	O
system	O
.	O

APS	O
is	O
structurally	O
similar	O
to	O
SH2	O
-	O
B	O
,	O
an	O
SH2	O
protein	O
that	O
potentially	O
binds	O
to	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
as	O
well	O
as	O
Lnk	O
which	O
is	O
postulated	O
to	O
be	O
a	O
signal	O
transducer	O
that	O
links	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
to	O
phospholipase	O
Cgamma	O
,	O
Grb2	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
.	O

APS	O
expressed	O
only	O
in	O
human	O
Burkitt	O
'	O
s	O
lymphoma	O
cells	O
among	O
cell	O
lines	O
we	O
examined	O
and	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
BCR	O
stimulation	O
.	O

APS	O
bound	O
to	O
Shc	O
irrespective	O
of	O
stimulation	O
and	O
bound	O
to	O
Grb2	O
after	O
stimulation	O
,	O
suggesting	O
that	O
it	O
plays	O
a	O
role	O
in	O
linkage	O
from	O
BCR	O
to	O
Shc	O
/	O
Grb2	O
pathway	O
.	O

These	O
results	O
indicate	O
that	O
APS	O
,	O
SH2	O
-	O
B	O
and	O
Lnk	O
form	O
a	O
new	O
adaptor	O
family	O
that	O
links	O
immune	O
receptors	O
to	O
signaling	O
pathways	O
involved	O
in	O
tyrosine	O
-	O
phosphorylation	O
.	O

cDNA	O
cloning	O
and	O
mRNA	O
expression	O
of	O
the	O
human	O
adrenoleukodystrophy	O
related	O
protein	O
(	O
ALDRP	O
)	O
,	O
a	O
peroxisomal	O
ABC	O
transporter	O
.	O

We	O
have	O
cloned	O
the	O
cDNA	O
containing	O
the	O
complete	O
coding	O
region	O
of	O
the	O
human	O
adrenoleukodystrophy	O
related	O
(	O
ALDR	O
)	O
gene	O
.	O

The	O
2220	O
-	O
bp	O
open	O
reading	O
frame	O
encodes	O
a	O
740	O
-	O
amino	O
-	O
acid	O
polypeptide	O
with	O
a	O
predicted	O
molecular	O
weight	O
of	O
83	O
.	O
3	O
kDa	O
.	O

The	O
human	O
ALDR	O
protein	O
displays	O
high	O
similarity	O
(	O
62	O
.	O
8	O
%	O
identical	O
amino	O
acid	O
residues	O
)	O
to	O
the	O
human	O
adrenoleukodystrophy	O
(	O
ALD	O
)	O
gene	O
.	O

Analysis	O
of	O
ALDR	O
expression	O
revealed	O
the	O
presence	O
of	O
ALDR	O
mRNA	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
,	O
predominantly	O
in	O
brain	O
and	O
heart	O
.	O

This	O
expression	O
pattern	O
is	O
different	O
from	O
all	O
other	O
known	O
peroxisomal	O
ABC	O
-	O
transporters	O
.	O

Defects	O
in	O
the	O
ALD	O
gene	O
are	O
the	O
primary	O
cause	O
of	O
adrenoleukodystrophy	O
,	O
a	O
demyelinating	O
disorder	O
of	O
the	O
central	O
nervous	O
system	O
.	O

The	O
ALD	O
protein	O
(	O
ALDP	O
)	O
and	O
the	O
ALDR	O
gene	O
product	O
are	O
peroxisomal	O
membrane	O
proteins	O
belonging	O
to	O
the	O
superfamily	O
of	O
transporters	O
containing	O
an	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
-	O
transporters	O
)	O
.	O

All	O
known	O
peroxisomal	O
ABC	O
-	O
transporters	O
represent	O
only	O
one	O
-	O
half	O
of	O
a	O
functional	O
transporter	O
.	O

They	O
are	O
expected	O
to	O
form	O
dimers	O
either	O
as	O
a	O
homodimer	O
or	O
as	O
a	O
heterodimer	O
.	O

ALDRP	O
is	O
a	O
potential	O
dimerization	O
partner	O
of	O
ALDP	O
or	O
other	O
peroxisomal	O
ABC	O
-	O
transporters	O
.	O

The	O
ALDR	O
gene	O
is	O
a	O
candidate	O
for	O
a	O
modifier	O
gene	O
,	O
accounting	O
for	O
the	O
strikingly	O
varying	O
clinical	O
courses	O
of	O
ALD	O
observed	O
even	O
within	O
a	O
family	O
.	O

CD30	O
-	O
dependent	O
degradation	O
of	O
TRAF2	O
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	O
is	O
a	O
cell	O
-	O
surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

CD30	O
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	O
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	O
1	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR1	O
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	O
-	O
binding	O
sites	O
within	O
the	O
CD30	O
cytoplasmic	O
domain	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	O
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	O
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O

During	O
CD30	O
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	O
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	O
and	O
the	O
associated	O
protein	O
TRAF1	O
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	O
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	O
.	O

Depletion	O
of	O
intracellular	O
TRAF2	O
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death	O
-	O
inducing	O
receptors	O
such	O
as	O
TNFR1	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
TRAF2	O
was	O
found	O
to	O
potentiate	O
TNFR1	O
-	O
mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	O
,	O
as	O
well	O
as	O
other	O
TRAF	O
-	O
binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
product	O
latent	O
membrane	O
protein	O
1	O
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	O
is	O
a	O
constitutively	O
activated	O
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
.	O

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	O
residues	O
beyond	O
TES1	O
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	O
interacting	O
proteins	O
,	O
including	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
.	O

TRADD	O
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	O
-	O
type	O
TES2	O
and	O
not	O
with	O
isoleucine	O
-	O
mutated	O
TES2	O
.	O

TRADD	O
associated	O
with	O
wild	O
-	O
type	O
LMP1	O
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	O
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	O
constitutively	O
associated	O
with	O
LMP1	O
in	O
EBV	O
-	O
transformed	O
cells	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	O
and	O
TES2	O
synergistically	O
mediated	O
high	O
-	O
level	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	O
appropriates	O
TRADD	O
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High	O
-	O
level	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O

Molecularly	O
cloned	O
mammalian	O
glucosamine	O
-	O
6	O
-	O
phosphate	O
deaminase	O
localizes	O
to	O
transporting	O
epithelium	O
and	O
lacks	O
oscillin	O
activity	O
.	O

Glucosamine	O
-	O
6	O
-	O
phosphate	O
deaminase	O
(	O
GNPDA	O
)	O
catalyzes	O
the	O
conversion	O
of	O
glucosamine	O
-	O
6	O
-	O
phosphate	O
to	O
fructose	O
-	O
6	O
-	O
phosphate	O
,	O
a	O
reaction	O
that	O
under	O
physiological	O
conditions	O
proceeds	O
to	O
the	O
formation	O
of	O
fructose	O
-	O
6	O
-	O
phosphate	O
.	O

Though	O
first	O
identified	O
in	O
mammalian	O
tissues	O
in	O
1956	O
,	O
the	O
enzyme	O
has	O
not	O
previously	O
been	O
molecularly	O
characterized	O
in	O
mammalian	O
tissues	O
,	O
although	O
a	O
bacterial	O
GNPDA	O
has	O
been	O
cloned	O
.	O

Recently	O
,	O
a	O
protein	O
displaying	O
similarity	O
to	O
bacterial	O
GNPDA	O
was	O
purified	O
and	O
cloned	O
from	O
sperm	O
extract	O
.	O

It	O
was	O
proposed	O
that	O
this	O
protein	O
was	O
the	O
factor	O
,	O
found	O
in	O
sperm	O
extracts	O
,	O
that	O
causes	O
calcium	O
oscillations	O
in	O
cells	O
;	O
thus	O
,	O
the	O
protein	O
was	O
named	O
'	O
oscillin	O
.	O
'	O
We	O
demonstrate	O
that	O
oscillin	O
is	O
the	O
mammalian	O
form	O
of	O
glucosamine	O
6	O
-	O
phosphate	O
deaminase	O
by	O
showing	O
that	O
cloned	O
oscillin	O
has	O
a	O
robust	O
GNPDA	O
activity	O
and	O
can	O
account	O
for	O
all	O
such	O
activity	O
in	O
mammalian	O
tissues	O
extracts	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
localize	O
GNPDA	O
selectively	O
to	O
tissues	O
with	O
high	O
energy	O
requirements	O
such	O
as	O
the	O
apical	O
zone	O
of	O
transporting	O
epithelia	O
in	O
the	O
proximal	O
convoluted	O
tubules	O
of	O
the	O
kidney	O
and	O
the	O
small	O
intestine	O
;	O
to	O
neurons	O
(	O
but	O
not	O
glia	O
)	O
and	O
especially	O
to	O
nerve	O
terminals	O
in	O
the	O
brain	O
;	O
and	O
to	O
motile	O
sperm	O
.	O

Recombinant	O
GNPDA	O
and	O
GNPDA	O
purified	O
to	O
homogeneity	O
from	O
hamster	O
sperm	O
fail	O
to	O
elevate	O
intracellular	O
calcium	O
when	O
injected	O
into	O
mouse	O
eggs	O
over	O
a	O
wide	O
range	O
of	O
concentrations	O
under	O
conditions	O
in	O
which	O
sperm	O
extracts	O
elicit	O
pronounced	O
calcium	O
oscillations	O
.	O

Thus	O
,	O
the	O
calcium	O
-	O
releasing	O
or	O
oscillin	O
activity	O
of	O
sperm	O
extracts	O
is	O
due	O
to	O
a	O
substance	O
other	O
than	O
GNPDA	O
.	O

Since	O
GNPDA	O
is	O
the	O
sole	O
enzyme	O
linking	O
hexosamine	O
systems	O
with	O
glycolytic	O
pathways	O
,	O
we	O
propose	O
that	O
it	O
provides	O
a	O
source	O
of	O
energy	O
in	O
the	O
form	O
of	O
phosphosugar	O
derived	O
from	O
the	O
catabolism	O
of	O
hexosamines	O
found	O
in	O
glycoproteins	O
,	O
glycolipids	O
,	O
and	O
sialic	O
acid	O
-	O
containing	O
macromolecules	O
.	O

Evidence	O
that	O
GNPDA	O
can	O
regulate	O
hexosamine	O
stores	O
comes	O
from	O
our	O
observation	O
that	O
transfection	O
of	O
GNPDA	O
into	O
HEK	O
-	O
293	O
cells	O
reduces	O
cellular	O
levels	O
of	O
sialic	O
acid	O
.	O

A	O
second	O
mammalian	O
N	O
-	O
myristoyltransferase	O
.	O

N	O
-	O
terminal	O
myristoylation	O
is	O
a	O
cotranslational	O
lipid	O
modification	O
common	O
to	O
many	O
signaling	O
proteins	O
that	O
often	O
serves	O
an	O
integral	O
role	O
in	O
the	O
targeting	O
and	O
/	O
or	O
function	O
of	O
these	O
proteins	O
.	O

Myristoylation	O
is	O
catalyzed	O
by	O
an	O
enzyme	O
activity	O
,	O
N	O
-	O
myristoyltransferase	O
(	O
NMT	O
)	O
,	O
which	O
transfers	O
myristic	O
acid	O
from	O
myristoyl	O
coenzyme	O
A	O
to	O
the	O
amino	O
group	O
of	O
a	O
protein	O
'	O
s	O
N	O
-	O
terminal	O
glycine	O
residue	O
.	O

While	O
a	O
single	O
human	O
NMT	O
cDNA	O
has	O
been	O
isolated	O
and	O
characterized	O
(	O
hNMT	O
-	O
1	O
)	O
,	O
biochemical	O
evidence	O
has	O
indicated	O
the	O
presence	O
of	O
several	O
distinct	O
NMTs	O
in	O
vivo	O
,	O
often	O
varying	O
in	O
either	O
apparent	O
molecular	O
weight	O
and	O
/	O
or	O
subcellular	O
distribution	O
.	O

We	O
now	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
second	O
,	O
genetically	O
distinct	O
human	O
NMT	O
(	O
hNMT	O
-	O
2	O
)	O
,	O
as	O
well	O
as	O
the	O
isolation	O
of	O
the	O
respective	O
mouse	O
NMT	O
homologue	O
for	O
each	O
human	O
enzyme	O
.	O

The	O
mouse	O
and	O
human	O
versions	O
of	O
each	O
NMT	O
are	O
highly	O
homologous	O
,	O
displaying	O
greater	O
than	O
95	O
%	O
amino	O
acid	O
sequence	O
identity	O
.	O

Comparisons	O
between	O
the	O
NMT	O
-	O
1	O
and	O
NMT	O
-	O
2	O
proteins	O
revealed	O
reduced	O
levels	O
of	O
sequence	O
identity	O
(	O
76	O
-	O
77	O
%	O
)	O
,	O
indicating	O
that	O
NMT	O
-	O
1	O
and	O
NMT	O
-	O
2	O
comprise	O
two	O
distinct	O
families	O
of	O
N	O
-	O
myristoyltransferases	O
.	O

Transient	O
transfection	O
of	O
either	O
the	O
hNMT	O
-	O
1	O
or	O
hNMT	O
-	O
2	O
cDNA	O
into	O
COS	O
-	O
7	O
cells	O
resulted	O
in	O
the	O
expression	O
of	O
high	O
levels	O
of	O
NMT	O
enzyme	O
activity	O
.	O

Both	O
hNMT	O
-	O
1	O
and	O
hNMT	O
-	O
2	O
were	O
found	O
to	O
myristoylate	O
several	O
commonly	O
studied	O
peptide	O
substrates	O
with	O
similar	O
,	O
but	O
distinguishable	O
,	O
relative	O
selectivities	O
.	O

Western	O
analysis	O
revealed	O
that	O
while	O
hNMT	O
-	O
2	O
appeared	O
as	O
a	O
single	O
65	O
-	O
kDa	O
protein	O
in	O
transfected	O
COS	O
-	O
7	O
cells	O
,	O
hNMT	O
-	O
1	O
was	O
processed	O
to	O
provide	O
four	O
distinct	O
protein	O
isoforms	O
ranging	O
from	O
49	O
to	O
68	O
kDa	O
in	O
size	O
.	O

Collectively	O
,	O
these	O
studies	O
demonstrate	O
a	O
heretofore	O
unappreciated	O
level	O
of	O
genetic	O
complexity	O
underlying	O
the	O
enzymology	O
of	O
N	O
-	O
terminal	O
myristoylation	O
and	O
suggest	O
that	O
the	O
specific	O
inhibition	O
or	O
regulation	O
of	O
either	O
NMT	O
in	O
vivo	O
may	O
in	O
turn	O
allow	O
for	O
the	O
selective	O
control	O
of	O
particular	O
myristoylation	O
-	O
dependent	O
cellular	O
functions	O
.	O

Phospholipase	O
C	O
-	O
delta1	O
and	O
oxytocin	O
receptor	O
signalling	O
:	O
evidence	O
of	O
its	O
role	O
as	O
an	O
effector	O
.	O

Although	O
the	O
oxytocin	O
receptor	O
modulates	O
intracellular	O
Ca2	O
+	O
ion	O
levels	O
in	O
myometrium	O
,	O
the	O
identities	O
of	O
signal	O
molecules	O
have	O
not	O
been	O
clearly	O
clarified	O
.	O

Our	O
previous	O
studies	O
on	O
oxytocin	O
receptor	O
signalling	O
demonstrated	O
that	O
80	O
kDa	O
Ghalpha	O
is	O
a	O
signal	O
mediator	O
[	O
Baek	O
,	O
Kwon	O
,	O
Lee	O
,	O
Kim	O
,	O
Muralidhar	O
and	O
Im	O
(	O
1996	O
)	O
Biochem	O
.	O
J	O
.	O
315	O
,	O
739	O
-	O
744	O
]	O
.	O

To	O
elucidate	O
the	O
effector	O
in	O
the	O
oxytocin	O
receptor	O
signalling	O
pathway	O
,	O
we	O
evaluated	O
the	O
oxytocin	O
-	O
mediated	O
activation	O
of	O
phospholipase	O
C	O
(	O
PLC	O
)	O
by	O
using	O
solubilized	O
membranes	O
from	O
human	O
myometrium	O
and	O
a	O
three	O
-	O
component	O
preparation	O
containing	O
the	O
oxytocin	O
receptor	O
-	O
Ghalpha	O
-	O
PLC	O
-	O
delta1	O
complex	O
.	O

PLC	O
-	O
delta1	O
activity	O
in	O
the	O
three	O
-	O
component	O
preparation	O
,	O
as	O
well	O
as	O
PLC	O
activity	O
in	O
solubilized	O
membranes	O
,	O
was	O
increased	O
by	O
oxytocin	O
in	O
the	O
presence	O
of	O
Ca2	O
+	O
and	O
activated	O
Ghalpha	O
(	O
GTP	O
-	O
bound	O
Ghalpha	O
)	O
.	O

Furthermore	O
the	O
stimulated	O
PLC	O
-	O
delta1	O
activity	O
resulting	O
from	O
activation	O
of	O
Ghalpha	O
via	O
the	O
oxytocin	O
receptor	O
was	O
significantly	O
attenuated	O
by	O
the	O
selective	O
oxytocin	O
antagonist	O
desGly	O
-	O
NH2d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
,	O
Thr4	O
]	O
ornithine	O
vasotocin	O
or	O
GDP	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
co	O
-	O
immunoprecipitation	O
and	O
co	O
-	O
immunoadsorption	O
of	O
PLC	O
-	O
delta1	O
in	O
the	O
three	O
-	O
component	O
preparation	O
by	O
anti	O
-	O
Gh7alpha	O
antibody	O
resulted	O
in	O
the	O
PLC	O
-	O
delta1	O
being	O
tightly	O
coupled	O
to	O
activated	O
Ghalpha	O
on	O
stimulation	O
of	O
the	O
oxytocin	O
receptor	O
.	O

These	O
results	O
indicate	O
that	O
PLC	O
-	O
delta1	O
is	O
the	O
effector	O
for	O
Ghalpha	O
-	O
mediated	O
oxytocin	O
receptor	O
signalling	O
.	O

Modification	O
of	O
yeast	O
Cdc53p	O
by	O
the	O
ubiquitin	O
-	O
related	O
protein	O
rub1p	O
affects	O
function	O
of	O
the	O
SCFCdc4	B-Complex
complex	O
.	O

The	O
RUB1	O
/	O
NEDD	O
-	O
8	O
family	O
of	O
ubiquitin	O
-	O
related	O
genes	O
is	O
widely	O
represented	O
among	O
eukaryotes	O
.	O

Here	O
we	O
report	O
that	O
Cdc53p	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
a	O
member	O
of	O
the	O
Cullin	O
family	O
of	O
proteins	O
,	O
is	O
stably	O
modified	O
by	O
the	O
covalent	O
attachment	O
of	O
a	O
single	O
Rub1p	O
molecule	O
.	O

Two	O
genes	O
have	O
been	O
identified	O
that	O
are	O
required	O
for	O
Rub1p	O
conjugation	O
to	O
Cdc53p	O
.	O

The	O
first	O
gene	O
,	O
designated	O
ENR2	O
,	O
encodes	O
a	O
protein	O
with	O
sequence	O
similarity	O
to	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
ubiquitin	O
-	O
activating	O
enzyme	O
.	O

By	O
analogy	O
with	O
Aos1p	O
,	O
we	O
infer	O
that	O
Enr2p	O
functions	O
in	O
a	O
bipartite	O
Rub1p	O
-	O
activating	O
enzyme	O
.	O

The	O
second	O
gene	O
is	O
SKP1	O
,	O
shown	O
previously	O
to	O
be	O
required	O
for	O
some	O
ubiquitin	O
-	O
conjugation	O
events	O
.	O

A	O
deletion	O
allele	O
of	O
ENR2	O
is	O
lethal	O
with	O
temperature	O
-	O
sensitive	O
alleles	O
of	O
cdc34	O
and	O
enhances	O
the	O
phenotypes	O
of	O
cdc4	O
,	O
cdc53	O
,	O
and	O
skp1	O
,	O
strongly	O
implying	O
that	O
Rub1p	O
conjugation	O
to	O
Cdc53p	O
is	O
required	O
for	O
optimal	O
assembly	O
or	O
function	O
of	O
the	O
E3	O
complex	O
SCFCdc4	B-Complex
.	O

Consistent	O
with	O
this	O
model	O
,	O
both	O
enr2delta	O
and	O
an	O
allele	O
of	O
Cdc53p	O
that	O
is	O
not	O
Rub1p	O
modified	O
,	O
render	O
cells	O
sensitive	O
to	O
alterations	O
in	O
the	O
levels	O
of	O
Cdc4p	O
,	O
Cdc34p	O
,	O
and	O
Cdc53p	O
.	O

A	O
novel	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
,	O
cPLA2	O
-	O
gamma	O
,	O
that	O
is	O
prenylated	O
and	O
contains	O
homology	O
to	O
cPLA2	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
membrane	O
-	O
bound	O
,	O
calcium	O
-	O
independent	O
PLA2	O
,	O
named	O
cPLA2	O
-	O
gamma	O
.	O

The	O
sequence	O
encodes	O
a	O
541	O
-	O
amino	O
acid	O
protein	O
containing	O
a	O
domain	O
with	O
significant	O
homology	O
to	O
the	O
catalytic	O
domain	O
of	O
the	O
85	O
-	O
kDa	O
cPLA2	O
(	O
cPLA2	O
-	O
alpha	O
)	O
.	O

cPLA2	O
-	O
gamma	O
does	O
not	O
contain	O
the	O
regulatory	O
calcium	O
-	O
dependent	O
lipid	O
binding	O
(	O
CaLB	O
)	O
domain	O
found	O
in	O
cPLA2	O
-	O
alpha	O
.	O

However	O
,	O
cPLA2	O
-	O
gamma	O
does	O
contain	O
two	O
consensus	O
motifs	O
for	O
lipid	O
modification	O
,	O
a	O
prenylation	O
motif	O
(	O
-	O
CCLA	O
)	O
at	O
the	O
C	O
terminus	O
and	O
a	O
myristoylation	O
site	O
at	O
the	O
N	O
terminus	O
.	O

We	O
present	O
evidence	O
that	O
the	O
isoprenoid	O
precursor	O
[	O
3H	O
]	O
mevalonolactone	O
is	O
incorporated	O
into	O
the	O
prenylation	O
motif	O
of	O
cPLA2	O
-	O
gamma	O
.	O

Interestingly	O
,	O
cPLA2	O
-	O
gamma	O
demonstrates	O
a	O
preference	O
for	O
arachidonic	O
acid	O
at	O
the	O
sn	O
-	O
2	O
position	O
of	O
phosphatidylcholine	O
as	O
compared	O
with	O
palmitic	O
acid	O
.	O

cPLA2	O
-	O
gamma	O
encodes	O
a	O
3	O
-	O
kilobase	O
message	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
specific	O
role	O
in	O
these	O
tissues	O
.	O

Identification	O
of	O
cPLA2	O
-	O
gamma	O
reveals	O
a	O
newly	O
defined	O
family	O
of	O
phospholipases	O
A2	O
with	O
homology	O
to	O
cPLA2	O
-	O
alpha	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	O
T	O
-	O
cell	O
-	O
line	O
-	O
expressing	O
wild	O
-	O
type	O
and	O
mutated	O
CD4	O
receptors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
induced	O
apoptosis	O
(	O
J	O
.	O
Corbeil	O
,	O
M	O
.	O
Tremblay	O
,	O
and	O
D	O
.	O
D	O
.	O
Richman	O
,	O
J	O
.	O
Exp	O
.	O
Med	O
.	O
183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	O
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O

To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2	O
.	O
01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	O
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	O
(	O
lck	O
)	O
(	O
mutated	O
at	O
the	O
dicysteine	O
motif	O
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild	O
-	O
type	O
CD4	O
.	O

The	O
differences	O
between	O
wild	O
-	O
type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	O
(	O
lck	O
)	O
or	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

Initial	O
signaling	O
through	O
the	O
CD4	O
receptor	O
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8	O
-	O
2	O
,	O
which	O
binds	O
to	O
CD4	O
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	O
-	O
Fas	O
ligand	O
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	O
MAb	O
(	O
ZB	O
-	O
4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	O
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	O
-	O
Fas	O
ligand	O
interaction	O
,	O
does	O
not	O
require	O
p56	O
(	O
lck	O
)	O
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	O
dimerization	O
.	O

Crystal	O
structure	O
of	O
the	O
complex	O
of	O
the	O
cyclin	O
D	O
-	O
dependent	O
kinase	O
Cdk6	O
bound	O
to	O
the	O
cell	O
-	O
cycle	O
inhibitor	O
p19INK4d	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
cyclin	O
D	O
-	O
dependent	O
kinase	O
Cdk6	O
bound	O
to	O
the	O
p19	O
INK4d	O
protein	O
has	O
been	O
determined	O
at	O
1	O
.	O
9	O
A	O
resolution	O
.	O

The	O
results	O
provide	O
the	O
first	O
structural	O
information	O
for	O
a	O
cyclin	O
D	O
-	O
dependent	O
protein	O
kinase	O
and	O
show	O
how	O
the	O
INK4	O
family	O
of	O
CDK	O
inhibitors	O
bind	O
.	O

The	O
structure	O
indicates	O
that	O
the	O
conformational	O
changes	O
induced	O
by	O
p19INK4d	O
inhibit	O
both	O
productive	O
binding	O
of	O
ATP	O
and	O
the	O
cyclin	O
-	O
induced	O
rearrangement	O
of	O
the	O
kinase	O
from	O
an	O
inactive	O
to	O
an	O
active	O
conformation	O
.	O

The	O
structure	O
also	O
shows	O
how	O
binding	O
of	O
an	O
INK4	O
inhibitor	O
would	O
prevent	O
binding	O
of	O
p27Kip1	O
,	O
resulting	O
in	O
its	O
redistribution	O
to	O
other	O
CDKs	O
.	O

Identification	O
of	O
the	O
critical	O
residues	O
involved	O
in	O
the	O
interaction	O
explains	O
how	O
mutations	O
in	O
Cdk4	O
and	O
p16INK4a	O
result	O
in	O
loss	O
of	O
kinase	O
inhibition	O
and	O
cancer	O
.	O

Ligand	O
specificity	O
of	O
LOX	O
-	O
1	O
,	O
a	O
novel	O
endothelial	O
receptor	O
for	O
oxidized	O
low	B-Complex
density	I-Complex
lipoprotein	I-Complex
.	O

Endothelial	O
dysfunction	O
,	O
or	O
activation	O
,	O
elicited	O
by	O
oxidized	O
low	B-Complex
density	I-Complex
lipoprotein	I-Complex
(	O
Ox	O
-	O
LDL	B-Complex
)	O
and	O
its	O
lipid	O
constituents	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

We	O
recently	O
have	O
identified	O
a	O
novel	O
receptor	O
for	O
Ox	O
-	O
LDL	B-Complex
-	O
designated	O
lectin	O
-	O
like	O
Ox	O
-	O
LDL	O
receptor	O
(	O
LOX	O
-	O
1	O
)	O
in	O
vascular	O
endothelial	O
cells	O
.	O

To	O
examine	O
ligand	O
specificity	O
of	O
LOX	O
-	O
1	O
,	O
we	O
established	O
CHO	O
cell	O
lines	O
stably	O
expressing	O
both	O
human	O
and	O
bovine	O
LOX	O
-	O
1	O
(	O
LOX	O
-	O
1	O
-	O
CHO	O
)	O
.	O

LOX	O
-	O
1	O
-	O
CHO	O
bound	O
and	O
degraded	O
125I	O
-	O
labeled	O
Ox	O
-	O
LDL	B-Complex
but	O
did	O
not	O
significantly	O
degrade	O
125I	O
-	O
labeled	O
acetylated	O
LDL	B-Complex
(	O
Ac	O
-	O
LDL	B-Complex
)	O
.	O

Fucoidin	O
and	O
maleylated	O
BSA	O
(	O
M	O
-	O
BSA	O
)	O
,	O
which	O
inhibit	O
125I	O
-	O
Ox	O
-	O
LDL	B-Complex
binding	O
to	O
class	O
A	O
scavenger	O
receptors	O
,	O
did	O
not	O
inhibit	O
125I	O
-	O
Ox	O
-	O
LDL	B-Complex
binding	O
or	O
degradation	O
in	O
LOX	O
-	O
1	O
-	O
CHO	O
.	O

Polyinosinic	O
acid	O
and	O
carrageenan	O
,	O
in	O
contrast	O
,	O
significantly	O
reduced	O
125I	O
-	O
Ox	O
-	O
LDL	B-Complex
binding	O
to	O
LOX	O
-	O
1	O
-	O
CHO	O
by	O
62	O
%	O
and	O
60	O
%	O
,	O
respectively	O
.	O

Delipidated	O
and	O
untreated	O
125I	O
-	O
Ox	O
-	O
LDL	B-Complex
were	O
bound	O
and	O
degraded	O
equally	O
in	O
LOX	O
-	O
1	O
-	O
CHO	O
;	O
furthermore	O
,	O
excess	O
amounts	O
of	O
unlabeled	O
,	O
delipidated	O
Ox	O
-	O
LDL	B-Complex
inhibited	O
binding	O
and	O
degradation	O
of	O
untreated	O
125I	O
-	O
Ox	O
-	O
LDL	B-Complex
.	O

Taken	O
together	O
,	O
LOX	O
-	O
1	O
is	O
a	O
receptor	O
for	O
Ox	O
-	O
LDL	B-Complex
but	O
not	O
for	O
Ac	O
-	O
LDL	B-Complex
.	O

LOX	O
-	O
1	O
recognizes	O
protein	O
moiety	O
of	O
Ox	O
-	O
LDL	B-Complex
,	O
and	O
its	O
ligand	O
specificity	O
is	O
distinct	O
from	O
other	O
receptors	O
for	O
Ox	O
-	O
LDL	B-Complex
,	O
including	O
class	O
A	O
and	O
B	O
scavenger	O
receptors	O
.	O

Uncoupling	O
activation	O
-	O
dependent	O
HS1	O
phosphorylation	O
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	O
and	O
CD28	O
.	O

CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	O
,	O
Cbl	O
,	O
p85	O
phosphoinositide	O
3	O
-	O
kinase	O
,	O
and	O
the	O
Src	O
family	O
kinases	O
Lck	O
and	O
Fyn	O
.	O

Ligation	O
of	O
CD3	O
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
,	O
a	O
75	O
-	O
kDa	O
hematopoietic	O
cell	O
-	O
specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O

We	O
have	O
examined	O
changes	O
in	O
HS1	O
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti	O
-	O
CD28	O
mAb	O
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	O
ligands	O
CD80	O
or	O
CD86	O
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
in	O
Jurkat	O
T	O
cells	O
.	O

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
was	O
induced	O
by	O
mitogenic	O
pairs	O
of	O
anti	O
-	O
CD2	O
mAbs	O
capable	O
of	O
activating	O
the	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
.	O

Costimulation	O
through	O
CD28	O
and	O
/	O
or	O
CD2	O
did	O
not	O
modulate	O
the	O
CD3	O
-	O
dependent	O
phosphorylation	O
of	O
HS1	O
.	O

In	O
vivo	O
studies	O
indicated	O
that	O
CD3	O
-	O
induced	O
HSI	O
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	O
family	O
tyrosine	O
kinase	O
Lck	O
and	O
the	O
tyrosine	O
phosphatase	O
CD45	O
,	O
did	O
not	O
require	O
MEK1	O
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	O
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	O
.	O

Furthermore	O
,	O
activation	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
was	O
not	O
required	O
for	O
NFAT	O
transcriptional	O
activation	O
.	O

Transcriptional	O
regulation	O
of	O
lysosomal	O
acid	O
lipase	O
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	O
factors	O
Sp1	O
and	O
AP	B-OOS
-	I-OOS
2	I-OOS
.	O

Human	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	O
-	O
mRNA	O
is	O
induced	O
.	O

This	O
induction	O
is	O
dependent	O
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O

The	O
cell	O
type	O
-	O
specific	O
increase	O
in	O
LAL	O
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O

In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-	O
182	O
bp	O
and	O
-	O
107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	O
and	O
AP	B-OOS
-	I-OOS
2	I-OOS
to	O
the	O
LAL	O
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	O
and	O
AP	B-OOS
-	I-OOS
2	I-OOS
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	O
LAL	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
expression	O
in	O
THP	O
-	O
1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	O
and	O
AP	B-OOS
-	I-OOS
2	I-OOS
.	O

DNA	O
end	O
-	O
joining	O
catalyzed	O
by	O
human	O
cell	O
-	O
free	O
extracts	O
.	O

Mammalian	O
cells	O
defective	O
in	O
DNA	O
end	O
-	O
joining	O
are	O
highly	O
sensitive	O
to	O
ionizing	O
radiation	O
and	O
are	O
immunodeficient	O
because	O
of	O
a	O
failure	O
to	O
complete	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O

By	O
using	O
cell	O
-	O
free	O
extracts	O
prepared	O
from	O
human	O
lymphoblastoid	O
cell	O
lines	O
,	O
an	O
in	O
vitro	O
system	O
for	O
end	O
-	O
joining	O
has	O
been	O
developed	O
.	O

Intermolecular	O
ligation	O
was	O
found	O
to	O
be	O
accurate	O
and	O
to	O
depend	O
on	O
DNA	O
ligase	O
IV	O
/	O
Xrcc4	O
and	O
requires	O
Ku70	O
,	O
Ku86	O
,	O
and	O
DNA	O
-	O
PKcs	O
,	O
the	O
three	O
subunits	O
of	O
the	O
DNA	B-OOS
-	I-OOS
activated	I-OOS
protein	I-OOS
kinase	I-OOS
DNA	B-OOS
-	I-OOS
PK	I-OOS
.	O

Because	O
these	O
activities	O
are	O
involved	O
in	O
the	O
cellular	O
resistance	O
to	O
x	O
-	O
irradiation	O
and	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
the	O
development	O
of	O
this	O
in	O
vitro	O
system	O
provides	O
an	O
important	O
advance	O
in	O
the	O
study	O
of	O
the	O
mechanism	O
of	O
DNA	O
end	O
-	O
joining	O
in	O
human	O
cells	O
.	O

Sec61p	O
serves	O
multiple	O
roles	O
in	O
secretory	O
precursor	O
binding	O
and	O
translocation	O
into	O
the	O
endoplasmic	O
reticulum	O
membrane	O
.	O

The	O
evolutionarily	O
conserved	O
Sec61	B-Complex
protein	O
complex	O
mediates	O
the	O
translocation	O
of	O
secretory	O
proteins	O
into	O
the	O
endoplasmic	O
reticulum	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Sec61p	O
,	O
which	O
is	O
the	O
main	O
subunit	O
of	O
this	O
complex	O
,	O
we	O
generated	O
recessive	O
,	O
cold	O
-	O
sensitive	O
alleles	O
of	O
sec61	O
that	O
encode	O
stably	O
expressed	O
proteins	O
with	O
strong	O
defects	O
in	O
translocation	O
.	O

The	O
stage	O
at	O
which	O
posttranslational	O
translocation	O
was	O
blocked	O
was	O
probed	O
by	O
chemical	O
crosslinking	O
of	O
radiolabeled	O
secretory	O
precursors	O
added	O
to	O
membranes	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
mutant	O
strains	O
.	O

Two	O
classes	O
of	O
sec61	O
mutants	O
were	O
distinguished	O
.	O

The	O
first	O
class	O
of	O
mutants	O
was	O
defective	O
in	O
preprotein	O
docking	O
onto	O
a	O
receptor	O
site	O
of	O
the	O
translocon	O
that	O
included	O
Sec61p	O
itself	O
.	O

The	O
second	O
class	O
of	O
mutants	O
allowed	O
docking	O
of	O
precursors	O
onto	O
the	O
translocon	O
but	O
was	O
defective	O
in	O
the	O
ATP	O
-	O
dependent	O
release	O
of	O
precursors	O
from	O
this	O
site	O
that	O
in	O
wild	O
-	O
type	O
membranes	O
leads	O
to	O
pore	O
insertion	O
and	O
full	O
translocation	O
.	O

Only	O
mutants	O
of	O
the	O
second	O
class	O
were	O
partially	O
suppressed	O
by	O
overexpression	O
of	O
SEC63	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
the	O
Sec61	B-Complex
holoenzyme	O
complex	O
responsible	O
for	O
positioning	O
Kar2p	O
(	O
yeast	O
BiP	O
)	O
at	O
the	O
translocation	O
channel	O
.	O

These	O
mutants	O
thus	O
define	O
two	O
early	O
stages	O
of	O
translocation	O
that	O
require	O
SEC61	O
function	O
before	O
precursor	O
protein	O
transfer	O
across	O
the	O
endoplasmic	O
reticulum	O
membrane	O
.	O

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-	O
associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O

Receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
(	O
RANK	O
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O

Its	O
cognate	O
ligand	O
(	O
RANKL	O
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	O
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	O
/	O
RANK	O
interaction	O
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	O
cytoplasmic	O
tail	O
.	O

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	O
-	O
dependent	O
induction	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
activities	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O

In	O
particular	O
,	O
TRAF6	O
interacted	O
with	O
membrane	O
-	O
proximal	O
determinants	O
distinct	O
from	O
those	O
binding	O
TRAFs	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
.	O

When	O
this	O
membrane	O
-	O
proximal	O
TRAF6	O
interaction	O
domain	O
was	O
deleted	O
,	O
RANK	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
was	O
completely	O
inhibited	O
while	O
c	O
-	O
Jun	O
NH2	O
-	O
terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2	O
-	O
terminal	O
truncation	O
mutant	O
of	O
TRAF6	O
inhibited	O
RANKL	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	O
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O

The	O
dynamic	O
role	O
of	O
GRP78	O
/	O
BiP	O
in	O
the	O
coordination	O
of	O
mRNA	O
translation	O
with	O
protein	O
processing	O
.	O

The	O
role	O
of	O
GRP78	O
/	O
BiP	O
in	O
coordinating	O
endoplasmic	O
reticular	O
(	O
ER	O
)	O
protein	O
processing	O
with	O
mRNA	O
translation	O
was	O
examined	O
in	O
GH3	O
pituitary	O
cells	O
.	O

ADP	O
-	O
ribosylation	O
of	O
GRP78	O
and	O
eukaryotic	O
initiation	O
factor	O
(	O
eIF	O
)	O
-	O
2alpha	O
phosphorylation	O
were	O
assessed	O
,	O
respectively	O
,	O
as	O
indices	O
of	O
chaperone	O
inactivation	O
and	O
the	O
inhibition	O
of	O
translational	O
initiation	O
.	O

Inhibition	O
of	O
protein	O
processing	O
by	O
ER	O
stress	O
(	O
ionomycin	O
and	O
dithiothreitol	O
)	O
resulted	O
in	O
GRP78	O
deribosylation	O
and	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
.	O

Suppression	O
of	O
translation	O
relative	O
to	O
ER	O
protein	O
processing	O
(	O
cycloheximide	O
)	O
produced	O
approximately	O
50	O
%	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	O
within	O
90	O
min	O
without	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
.	O

ADP	O
-	O
ribosylation	O
was	O
reversed	O
in	O
90	O
min	O
by	O
cycloheximide	O
removal	O
in	O
a	O
manner	O
accelerated	O
by	O
ER	O
stressors	O
.	O

Cycloheximide	O
sharply	O
reduced	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
for	O
about	O
30	O
min	O
;	O
sensitivity	O
returned	O
as	O
GRP78	O
became	O
increasingly	O
ADP	O
-	O
ribosylated	O
.	O

Reduced	O
sensitivity	O
of	O
eIF	B-Complex
-	I-Complex
2	I-Complex
to	O
phosphorylation	O
appeared	O
to	O
derive	O
from	O
the	O
accumulation	O
of	O
free	O
,	O
unmodified	O
chaperone	O
as	O
proteins	O
completed	O
processing	O
without	O
replacements	O
.	O

Prolonged	O
(	O
24	O
h	O
)	O
incubations	O
with	O
cycloheximide	O
resulted	O
in	O
the	O
selective	O
loss	O
of	O
the	O
ADP	O
-	O
ribosylated	O
form	O
of	O
GRP78	O
and	O
increased	O
sensitivity	O
of	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
in	O
response	O
to	O
ER	O
stressors	O
.	O

Brefeldin	O
A	O
decreased	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	O
in	O
parallel	O
with	O
increased	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
.	O

The	O
cytoplasmic	O
stressor	O
,	O
arsenite	O
,	O
which	O
inhibits	O
translational	O
initiation	O
through	O
eIF	B-Complex
-	I-Complex
2	I-Complex
phosphorylation	O
without	O
affecting	O
the	O
ER	O
,	O
also	O
produced	O
ADP	O
-	O
ribosylation	O
of	O
GRP78	O
.	O

Functional	O
association	O
of	O
Nmi	O
with	O
Stat5	O
and	O
Stat1	O
in	O
IL	O
-	O
2	O
-	O
and	O
IFNgamma	O
-	O
mediated	O
signaling	O
.	O

Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	O
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	O
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	O
-	O
Myc	O
interactor	O
.	O

We	O
further	O
show	O
that	O
Nmi	O
interacts	O
with	O
all	O
STATs	O
except	O
Stat2	O
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL	O
-	O
2	O
and	O
IFNgamma	O
,	O
and	O
demonstrate	O
that	O
Nmi	O
augments	O
STAT	O
-	O
mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O

Interestingly	O
,	O
Nmi	O
lacks	O
an	O
intrinsic	O
transcriptional	O
activation	O
domain	O
;	O
instead	O
,	O
Nmi	O
enhances	O
the	O
association	O
of	O
CBP	O
/	O
p300	O
coactivator	O
proteins	O
with	O
Stat1	O
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP	O
/	O
p300	O
can	O
augment	O
IL	O
-	O
2	O
-	O
and	O
IFNgamma	O
-	O
dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	O
can	O
potentiate	O
STAT	O
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	O
-	O
specific	O
transcription	O
factors	O
.	O

Prototypic	O
G	O
protein	O
-	O
coupled	O
receptor	O
for	O
the	O
intestinotrophic	O
factor	O
glucagon	O
-	O
like	O
peptide	O
2	O
.	O

Glucagon	O
-	O
like	O
peptide	O
2	O
(	O
GLP	O
-	O
2	O
)	O
is	O
a	O
33	O
-	O
aa	O
proglucagon	O
-	O
derived	O
peptide	O
produced	O
by	O
intestinal	O
enteroendocrine	O
cells	O
.	O

GLP	O
-	O
2	O
stimulates	O
intestinal	O
growth	O
and	O
up	O
-	O
regulates	O
villus	O
height	O
in	O
the	O
small	O
intestine	O
,	O
concomitant	O
with	O
increased	O
crypt	O
cell	O
proliferation	O
and	O
decreased	O
enterocyte	O
apoptosis	O
.	O

Moreover	O
,	O
GLP	O
-	O
2	O
prevents	O
intestinal	O
hypoplasia	O
resulting	O
from	O
total	O
parenteral	O
nutrition	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
these	O
actions	O
has	O
remained	O
unclear	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
cDNAs	O
encoding	O
rat	O
and	O
human	O
GLP	O
-	O
2	O
receptors	O
(	O
GLP	O
-	O
2R	O
)	O
,	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
superfamily	O
member	O
expressed	O
in	O
the	O
gut	O
and	O
closely	O
related	O
to	O
the	O
glucagon	O
and	O
GLP	O
-	O
1	O
receptors	O
.	O

The	O
human	O
GLP	O
-	O
2R	O
gene	O
maps	O
to	O
chromosome	O
17p13	O
.	O
3	O
.	O

Cells	O
expressing	O
the	O
GLP	O
-	O
2R	O
responded	O
to	O
GLP	O
-	O
2	O
,	O
but	O
not	O
GLP	O
-	O
1	O
or	O
related	O
peptides	O
,	O
with	O
increased	O
cAMP	O
production	O
(	O
EC50	O
=	O
0	O
.	O
58	O
nM	O
)	O
and	O
displayed	O
saturable	O
high	O
-	O
affinity	O
radioligand	O
binding	O
(	O
Kd	O
=	O
0	O
.	O
57	O
nM	O
)	O
,	O
which	O
could	O
be	O
displaced	O
by	O
synthetic	O
rat	O
GLP	O
-	O
2	O
(	O
Ki	O
=	O
0	O
.	O
06	O
nM	O
)	O
.	O

GLP	O
-	O
2	O
analogs	O
that	O
activated	O
GLP	O
-	O
2R	O
signal	O
transduction	O
in	O
vitro	O
displayed	O
intestinotrophic	O
activity	O
in	O
vivo	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
GLP	O
-	O
2	O
,	O
like	O
glucagon	O
and	O
GLP	O
-	O
1	O
,	O
exerts	O
its	O
actions	O
through	O
a	O
distinct	O
and	O
specific	O
novel	O
receptor	O
expressed	O
in	O
its	O
principal	O
target	O
tissue	O
,	O
the	O
gastrointestinal	O
tract	O
.	O

